<SEC-DOCUMENT>0001558370-24-003949.txt : 20240326
<SEC-HEADER>0001558370-24-003949.hdr.sgml : 20240326
<ACCEPTANCE-DATETIME>20240326161612
ACCESSION NUMBER:		0001558370-24-003949
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240326
DATE AS OF CHANGE:		20240326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COGNITION THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001455365
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40886
		FILM NUMBER:		24783734

	BUSINESS ADDRESS:	
		STREET 1:		2403 SIDNEY STREET
		STREET 2:		SUITE 261
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		412-481-2210

	MAIL ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COGNITION THERAPUTICS INC
		DATE OF NAME CHANGE:	20090204
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cgtx-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.5.0.8 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/25/2024 2:25:42 PM -->
<!-- iXBRL Library version: 1.0.8703.18788 -->
<!-- iXBRL Service Job ID: 321986f8-1321-4444-8310-0f4c9a3942fd -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cgtx="http://www.cogrx.com/20231231"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" xs:nil="true" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_e7x5gOaUTkO7iSYDksxQhQ"/><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" xs:nil="true" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_u5U8is6XH0uIv9RGk6BAnw"/><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityCentralIndexKey" id="Tc_bvYulE0s_k6M5tHg_TPnUg_2_1">0001455365</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:DocumentFiscalYearFocus" id="Tc_Cjcx_bcnp0SBp6Yu-feEWQ_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:DocumentFiscalPeriodFocus" id="Tc_uis9W9wjnEev87DmC6EBtw_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:AmendmentFlag" id="Tc_RmTfk1QR-0SQTGvWnWpfyQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_fCMcc30VrEuBtpYtIUMoog">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_g32P2O2i-kWhjcBmZYKsXA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_3dmFxBspikeQpVonqzl1-A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_LPJj1PySJE23Xx8l-XIWEQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VWGUaJ66V0y4SA962FOAsA" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_FMlYcx_LLUigdn_0wCQu8A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XYSO_78oUkSochkQvqlMkA" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_68HRszMgH0iikEmClqgPAg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Hidden_uaCaWxtaRUyygHCR2IjWgw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Hidden_DpqAOV6-W0KIuqygKL-oAw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" xs:nil="true" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" name="us-gaap:PreferredStockValue" id="Hidden_bNPKjeMogkiRwabi4DnToA"/><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" xs:nil="true" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" name="us-gaap:PreferredStockValue" id="Hidden_x_0-tty1qkCdgZ8MygWwoA"/><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_crfbz-8nX0uPcYlZLZkBoA">32165478</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_z0-6MhzaqEi07JiIaYImxA">28991548</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VVVdi6pD1kGcMpi2IuK05A" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_mQJYQs2rZkWuRg8O_Rotqw">P5Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_EgdiPbStcUqDXdhNU2tjcQ" decimals="-3" name="us-gaap:RepaymentsOfDebtMaturingInMoreThanThreeMonths" id="Hidden__XyZb69CXEGjsKwFBnsFpA">634000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_ePTF4GwkoU2wTSik52QcmQ">28991548</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_Qj7kaN5TikGnEe3obL6iig">32165478</ix:nonFraction><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_GoVENcIHxUC0xotmdahUqw" name="ecd:Rule10b51ArrAdoptedFlag" id="Hidden_EhWfKhNhJ0mxDKk9K-W3pw">true</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cgtx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_XUZrCkEwDEyMKEMstcPgZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__0_YbKxmOU2r78jXkEEzlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_bkEmqGmAXk2V435yqi4NaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_bz4gK_i3F0uQC7rL-HFYWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_UveeLV5jg0Gs7n8IWxBGxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_LshqVKz1-k65X8p9RQ7mDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_uhpLOBdKk0WZcXfNyIcT2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_glCHD9EtbESXtKFFuEPfMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_mjbf_mTu8EG-1PNbRNcxEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fxo-cpkpfUGMsbMoJHuOAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_6UVH8Rgk6cL-CiQ1IpeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_X48c3Sa37UK9EHex0j44hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jO4Ihl3vbUygM5jjvQg_Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y4ykLegMm0ecV5xUeC4XMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MGbOgarFTEaIN0_BlZV7RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9Bca2RtZUSaAp6SOKJZeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mjQQQJ2EckyysDZdzZQoXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ga2Znj6Iy0yqPXctu2LwwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_RHH5Gs9baU-2LKRDJ3NO3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_x_Z7jkOkrUCdh_AMcj9ldw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_onxTRXE0sU2j9FuXL78qkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cRBLgf-FmkW2y3hxofLyXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ygnTJ3cZlkyoT6PpTTP3JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_8bYcitqYY0y77znhmkKzNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_QC7xgFr49EmCFLiMsbsf_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_gQpvyXpSRE-aqnPz6O907Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_tRoSIxX58UuuBcSM22cTJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_yDEeKMfAzkS-KSBkUEc6qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_LRobkF0nj0SY3xdEzUjMVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_rrHi5dcFDE-G4d-8RUX0Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_uguCNEEtGkiIZdHpBUsd8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:AmendedAndRestatedEquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_WLXjwrWnP0CgsWctD9xbtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_fSE3Go7PW0eAeiIVxPMeeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_cgCekGBDeU-iow6w5GkUWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_oU9CqFmCiUKDm0PxrYz0zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kQSwmvFsp0mgTkQQwG0VHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_efBKw3qAME6ZmwdlSdK_6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_-Aambe7M-Ei21IEK190qVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cgtx:NonEmployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_EmployeeDirectorMember_Ln6Hn2FojEa8itKVr-awUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cgtx:EmployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_nrintSTwQECLB58C0p_EaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_EgdiPbStcUqDXdhNU2tjcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JA-tMjbxgkOcxeZ-D5dbbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VVVdi6pD1kGcMpi2IuK05A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-558bBZDIUKyf-5W-hEnOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_d7jEg2zHjU29ZRjFt5YiYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_Cb1fCNb9LEq93fXulA-3xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_lCt9u7t8z0W44yS58i4_kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_YVGucSObRUi_kS5-NUT2_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HMKbTdzF40CY46TtwizjkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pLCQK7N8yEeOO-emzO9KTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_7LajySWg40OL9NM2rgbwrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_q3DH0WMQa0CmwYFvp51zwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QXLq1_nOvk2P7yx3QDOUOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTU5BrA1tEmz30aajDlz6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_c7z7ZQ_fFUeLePhaNsuU1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OdAlZTCHTkKTcjg6k-b-og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_ZB35Xclq7k6gaWDy5dCb0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_YK8t0UGtpEeESc004CPSVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_YqDdVDtS20ecG70OxtdrqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_vQQHg-kY3kaNtOqhbYQgyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_ecCutZaSMkeuO8iQOXjXGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_60EfJYivGUOdbqzJUjaoug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Ao_-LDEYrUuIE9YczdQENA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_cRq6e-5OZ0Ke_a61Ul0DuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LxxS8eZ15U26cdY_7vD36w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_zimJT2kt9UiSyyAiSWSK6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XYSO_78oUkSochkQvqlMkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_ENLs-VXh8kmNzn1_ZzoFlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VWGUaJ66V0y4SA962FOAsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_9tl_WCDNBE6HpfXJYxxGQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_S_oPesVvSUGLXTpCrxhISg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_zQZdkP6aak6WFLzryRsnUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_iifjj9nFxUWWEEoGkB7y3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Tcs3Fe77zk-E5SHgaFWR2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pRPh5Rg4yk2qvio_UPRCJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_MrwJ0AbrfEahvl8J7zIwLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T29Qjyz35U2p3fWGxDsVjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W7FO-pbJEUO0d761WgliwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tqAFWsRuSEOU2TS77Gr5vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_70PXE3i9G0SgTEnVDcJbMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tuVKl_ZuvU2ErvU1ol886A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_GoVENcIHxUC0xotmdahUqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">cgtx:AaronFletcherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_JlzDcywjoU2rtXry2sZxig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_22_2024_Z7oTilaLYUqLKorj8N32wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mUz7VNnd5EuqjwdONSKJpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_fYz-UjM3pkmim-rRGGRZzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-15</xbrli:startDate><xbrli:endDate>2022-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_V21-ck426EKj_jaNHfEcpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_CljcQCdgAUmy0i-o6OBaKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_23_2022_vzbl8zprq0ijwIokKFM6sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_JzSuP6-isUqGYxI89s2DJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_pZh55Gbcxkm9kdN4Koe6yQ"><xbrli:measure>cgtx:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_5qxERgMtAE2JatGJwvNkAQ"><xbrli:measure>cgtx:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:0pt;padding-top:1pt;text-align:center;text-indent:0pt;border-top:2.25pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_89dde844_4dd5_4d2b_83b3_815b09367866"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:DocumentType" id="Narr_5JWUffvmYEWUYBSqKIB03Q"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:DocumentAnnualReport" id="Narr_oAc1CkJNNUqJ3UOR6b2GRw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">For the fiscal&#160;year ended</span><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:DocumentPeriodEndDate" id="Narr_29cybrsRkUmEHjUyY2FohQ"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:CurrentFiscalYearEndDate" id="Narr_44tc0W4bDEiClQnyrxKjQA"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:DocumentTransitionReport" id="Narr_9QVtmySu5U-brjaIERJctQ"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">For The Transition Period From&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityFileNumber" id="Narr_EisK1kYjHku6RtMJ8oMqjw"><b style="font-size:8pt;font-weight:bold;">001-40886</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityRegistrantName" id="Narr_wFcRdo-CW0aGDdQyhnVXpQ"><b style="font-weight:bold;">COGNITION THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_0bd4c4e5_d908_49c7_81ef_291d7e378540"></a><a id="Tc_NCBRN3vEJ0y27SECwlDIdg_2_0"></a><a id="Tc_PFtqcaty8UGoWLGvnHpoPw_2_1"></a><a id="Tc_e15QFXYUZ0WlzvQNScqT4g_5_0"></a><a id="Tc_-zjHW9RVbEGAMY7VK2ISHw_6_0"></a><a id="Tc_zjoLmXE7sk2Fm4Rk-_k_ZA_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityIncorporationStateCountryCode" id="Tc_gixG949HjEKve9CtMfIxZQ_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityTaxIdentificationNumber" id="Tc_Yd7OMcnjM0C7klfvr2Kulw_1_1"><b style="font-size:8pt;font-weight:bold;">13-4365359</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityAddressAddressLine1" id="Tc_dCW03ZOvw0yfKu0_jhQR1A_4_0"><b style="font-size:8pt;font-weight:bold;">2500 Westchester Ave.</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityAddressCityOrTown" id="Narr_AWssRxUS7Uqt_QDyXeiEUQ"><b style="font-size:8pt;font-weight:bold;">Purchase</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityAddressStateOrProvince" id="Narr_2FJvCDOow0KTtj6BRVBnuQ"><b style="font-size:8pt;font-weight:bold;">NY</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityAddressPostalZipCode" id="Tc_zdEwLRxD8UiAjR-h4n1-JA_5_1"><b style="font-size:8pt;font-weight:bold;">10577</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code:</span><b style="font-size:8pt;font-weight:bold;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:CityAreaCode" id="Narr_LQeYhIpyXEuHT6_pQzY9YQ"><b style="font-size:8pt;font-weight:bold;">412</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:LocalPhoneNumber" id="Narr_AX3lyVT3vUerFnTxNqwYLQ"><b style="font-size:8pt;font-weight:bold;">481-2210</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_6a81bc1b_1939_4c30_9a32_7126c7b10385"></a><a id="Tc_u6K9Zs-XokaDGplE4QTSwA_1_4"></a><a id="Tc_4LieNA2ejUabvkohKB52RA_2_0"></a><a id="Tc_uWBQB3JWxE-zfUh4DPSAxA_2_2"></a><a id="Tc_wpwW-ATmY0WTNnrN8qQvdQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">On Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:Security12bTitle" id="Tc_zFi0jcVjdEe5NFGnji4OXw_3_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, par value $0.001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:TradingSymbol" id="Tc_hlu-lYKR_0W-bbr25rWWkQ_3_2"><b style="font-size:8pt;font-weight:bold;">CGTX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:SecurityExchangeName" id="Tc_6quRf6ZFjkO19wbJhLt2Jw_3_4"><b style="font-size:8pt;font-weight:bold;">The Nasdaq Stock Market LLC</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;<span style="white-space:pre-wrap;">of the Act:  </span><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">  </span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_sfnTavekaEuE4D8pjjDkOA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityVoluntaryFilers" id="Narr_T6WMLRz8zUa_dj0FUVmDtg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityCurrentReportingStatus" id="Narr_5T-kAMZzekmz_ZyonreCCg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.0405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityInteractiveDataCurrent" id="Narr_47LrTjoh60q-lRtwLHEwrw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityFilerCategory" id="Narr__5m0RGpwvUqKUJdVSnZaRA"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntitySmallBusiness" id="Narr_qulyBhyOwUKdZdmzEbhQlA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityEmergingGrowthCompany" id="Narr_Xn4nd4vCwUy6_1I135RDpw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityExTransitionPeriod" id="Narr_UgRRCwblZk23tMvKp5rTfQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C.&#160;7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_fw4YROLLl0GwSOlD8V8ExA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:EntityShellCompany" id="Narr_V6-SGj6C5USjfPCc-rNt1A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">The aggregate market value of the Registrant&#8217;s Common Stock held by non-affiliates, as of June 30, 2023, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2023_JlzDcywjoU2rtXry2sZxig" decimals="0" name="dei:EntityPublicFloat" id="Narr_eYrSw5rPBkSYIzJNb0dEwg">43,124,364</ix:nonFraction>. Shares of Common Stock held by each executive officer and director and by each stockholder affiliated with a director or an executive officer have been excluded from this calculation because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">The number of outstanding shares of the Registrant&#8217;s Common Stock as of March 22, 2024, was <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_22_2024_Z7oTilaLYUqLKorj8N32wg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_G0RWPU8nZk6i5Rg3RlWBHw">39,000,152</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5dce0578_0c4a_4bcf_80c3_5e7777be47c2"></a><a id="Tc_-tS5mO9cak6ZScP9DQ0rlA_1_0"></a><a id="Tc_h0jgud-fKkitwhY2BPm_dg_1_2"></a><a id="Tc_a5m7Yqci_UaNgJia7wJSDw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Firm ID:</p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:AuditorFirmId" id="Tc_Szyx76JM7U2L-y-OWZSX8A_1_1"><span style="font-size:8pt;">42</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Name:</p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:AuditorName" id="Tc_9-yJft1UAky0hGeD7m3pKg_1_3"><span style="font-size:8pt;">Ernst &amp; Young LLP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Location:</p></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="dei:AuditorLocation" id="Tc_qumr7aEcMkydz5LyzrjSEQ_1_5"><span style="font-size:8pt;">Philadelphia, PA</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:2.25pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_03d2f828_40ed_4783_92a5_75cf094b8569"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PARTI_883693"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1Business_571021"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;1. Business</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">7</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1ARiskFactors_361684"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">49</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1BUnresolvedStaffComments_685711"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">102</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1CCybersecurity_492794"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item 1C. Cybersecurity</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">102</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item2Properties_347022"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;2. Properties</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item3LegalProceedings_272268"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item4MineSafetyDisclosures_494562"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PARTII_331600"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item6SelectedFinancialData_500456"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;6. [Reserved]</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">105</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">116</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">117</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">139</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9AControlsandProcedures_434960"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">139</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9BOtherInformation_878908"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;9B. Other Information</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">140</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9CDisclosureRegardingForeign"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">140</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PARTIII_479695"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item11ExecutiveCompensation_635596"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item14PrincipalAccountantsFeesandService"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;14. Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">141</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PartIV_346291"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item15ExhibitsandFinancialStatementSched"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">142</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item16Form10KSummary_806161"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;16. Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">145</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47605478_9473_4d7f_8d3c_72baa2dacc22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, or Annual Report, contains forward-looking statements concerning our business, operations and financial performance, as well as our plans, objectives and expectations for our business operations and financial performance and condition. All statements other than statements of historical or current facts included in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements including &#8220;we believe&#8221; or similar phrases reflect our beliefs and opinions on the relevant subject. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed in, or implied by these, forward-looking statements and therefore, you should not unduly rely on such statements. These risks and uncertainties include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical nature of our business and our ability to successfully and in a timely manner advance our current and future product candidates through our ongoing and future clinical trials, preclinical studies and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected uses of our existing cash and cash equivalents and the sufficiency of such resources to fund our planned operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which health epidemics and other outbreaks of communicable diseases, including the COVID-19 pandemic, geopolitical turmoil, including the ongoing global and regional conflicts or increased trade restrictions between the United States, Russia, China, and other countries, social unrest, political instability, terrorism, or other acts of war could ultimately impact our business, including our ongoing and future clinical trials, preclinical studies and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our dependence on the success of CT1812, our lead product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the novelty of our approach to targeting the &#963;-2 (sigma-2) receptor (&#8220;S2R&#8221;) complex to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competing therapies that are or become available; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, success, cost, and timing of our ongoing and future clinical trials, preclinical studies and development activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory clearance of CT1812 for clinical trials under investigational new drug, or IND, applications and any future IND applications for any of our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments and approval pathways in the United States and foreign countries for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential scope and value of our intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic uncertainty resulting from actual or perceived inflation or banking stability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risk and uncertainties, including those described in Item 1A &#8220;Risk Factors&#8221; in this Annual Report.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#8220;Risk Factors&#8221; set forth in Part I, Item 1A of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_43f04c59_c822_47f6_bc5e_ae3dfcd9bc03"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SUMMARY OF RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our future prospects, and/or cause the price of our common stock to decline. These are not all the risks we face, and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur. Additional detail about these risks is included in Part I, Item 1A &#8220;Risk Factors.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-size:9.5pt;">Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs; Discovery, Development and Regulatory Approval of Our Product Candidates; and Business and Industry</span><span style="color:#ff0000;font-size:9.5pt;font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We are conducting Phase&#160;2 clinical trials and have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of CT1812 and any future product candidates that we may develop or acquire.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for CT1812 or by in-licensing or acquiring additional product candidates for other diseases.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#8203;&#160;</span><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Our Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, CT1812, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We may not be able to protect our intellectual property rights throughout the world.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, CT1812, for an adequate amount of time.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, CT1812.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">The market opportunities for CT1812, if approved, may be smaller than we anticipate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We rely on third parties in the conduct of all our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and for which we receive approval and ultimately harm our financial condition.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Relating to Government Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales or affected products. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Relating to Our Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">The market price and trading volume of our common stock have been and may continue to be volatile, which could result in rapid and substantial losses for our stockholders.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Concentration of our capital stock ownership with our directors and their affiliated entities and our executive officers will limit stockholders&#8217; abilities to influence certain corporate matters.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_84b1d0d6_480d_4bd1_9da0_3c6146932566"></a><a id="PARTI_883693_0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_571021"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the &#963;-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. We have initially focused on the development of CT1812 for the treatment of Alzheimer&#8217;s disease, or AD, by targeting &#946;-amyloid, or A&#946; oligomers, which have been linked to the disease. We believe our evidence demonstrates that by binding to the S2R complex, CT1812 displaces A&#946; oligomers from their neuronal receptors. Based on this mechanism, we believe CT1812 has the potential to slow the loss of synapses and cognitive decline observed in AD. CT1812 is the first S2R selective ligand modulator to reach clinical trials and is currently in Phase 2 development for the treatment of AD. The direct healthcare costs to care for patients with AD and other dementias in the United States is estimated to exceed $300 billion. Approximately 6.5 million people in the United States have been diagnosed with AD, and the World Health Organization estimates that AD affects as many as 35 million people globally. Among people with AD, approximately 50% have mild disease, 30% have moderate disease and 20% have severe disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are continuing to enroll patients in the Phase 2 COG1201 (SHIMMER) study of CT1812 in mild-to-moderate dementia with Lewy bodies, or DLB. Enrollment concluded in the Phase 2 COG0201 (SHINE) study of CT1812 in mild-to-moderate AD. Preliminary results from an interim analysis of the first 24 patients demonstrated a statistically significant decline in the presence of A&#946; monomers and a positive trend on cognitive function as measured by the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate top-line results in mid-2024 after the last participants have completed six months of treatment. As of November 21, 2023, approximately 278 subjects with dementia have received CT1812 in our clinical trials, including subjects with AD and DLB. CT1812 has continued to be well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, for AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our clinical trials have been funded by approximately $171 million in cumulative grants awarded primarily by the National Institute of Aging, or NIA, a division of the National Institutes of Health, or NIH. Our awards include a grant award of approximately $81 million from the NIA to fund our Phase 2 START (COG0203) study of CT1812 in patients with early-stage AD. &#160;We received clearance from the FDA to proceed with the START clinical trial and recruitment has commenced. We intend to enroll 540 adults with mild cognitive impairment, or MCI, due to AD or mild AD who have elevated levels of A&#946; as determined by a clinical diagnosis of AD confirmed with amyloid biomarkers positron emission tomography, or PET, imaging and/or cerebrospinal fluid, or CSF, biomarkers. Participants are being randomized to receive CT1812 or a placebo for 18 months. In addition to cognitive and functional measures, such as the Clinical Dementia Rating Scale, or CDR, Sum of Boxes, or SB, and ADAS-Cog, we intend to use a variety of biomarkers to measure target and/or pathway engagement and assess changes in neurodegeneration and disease progression. We are conducting this clinical trial in collaboration with the Alzheimer&#8217;s Clinical Trial Consortium, or ACTC, an NIA-funded clinical trials network designed to accelerate studies for therapeutics for AD and related dementias.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">We expanded our CT1812 pipeline to include geographic atrophy, or GA, secondary to dry age-related macular degeneration, or dry AMD as an additional indication. GA is an advanced form of dry AMD, an eye disease that results in the deterioration of the macula, causing distortion, loss of central vision and eventual blindness. The S2R complex is expressed in the retina in several cell types including the retinal pigment epithelial cells, or RPE, photoreceptors and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:189.71pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">retinal ganglion cells. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We submitted an Investigational New Drug, or IND, application to the FDA at the end of 2022 and we announced dosing of the first patient in our Phase 2 COG2201 (MAGNIFY) study in July 2023. We intend to enroll up to 246 adults in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, we are developing other product candidates in the area of synucleinopathies. Synucleinopathies are a group of degenerative diseases characterized by the abnormal accumulation of the &#945;-synuclein protein in neural cell bodies, including Parkinson&#8217;s disease, or PD, and DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are developing a pipeline of innovative, small molecule product candidates that are designed to target the S2R complex, a key regulator of the cellular damage response for diseases such as AD, dry AMD, geographic atrophy (an advanced form of dry AMD), or GA, and other conditions for which there is significant unmet medical need. Our current pipeline is summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k001.jpg" alt="Graphic" style="display:inline-block;height:189.71pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:473.36pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mild-to-Moderate AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Phase 2 COG0201 (SHINE) clinical trial, is designed to evaluate safety, dosing and potential efficacy for CT1812 as a treatment for mild-to moderate AD and enrolled 158 adults with mild-to-moderate (MMSE 18-26) AD. In SHINE, the largest of our trials, we are assessing CT1812&#8217;s ability to alter disease progression and cognition. Top-line results are expected in mid-2024 after the last participants have completed six months of treatment. In addition, we completed the Phase 2 COG0202 (SEQUEL) study and presented complete results in October 2023 at the Clinical Trials on Alzheimer&#8217;s Disease (CTAD) conference. The SEQUEL trial included evaluations of CT1812&#8217;s ability to engage with the S2R complex enabling the restoration of synaptic function as measured by quantitative EEG, or qEEG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Early-stage AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We received clearance from the FDA to proceed with our Phase 2 START (COG0203) clinical trial to evaluate CT1812 in up to 540 adult patients, which is designed to investigate the potential for CT1812&#8217;s use at an earlier stage of AD. In addition to cognitive and functional measures, such as CDR-SB (Clinical Dementia Rating Sum of Boxes), ADAS-Cog and volumetric magnetic resonance imaging, or vMRI, we intend to use a variety of biomarkers to measure target and/or pathway engagement and assess changes in neurodegeneration and disease progression. This trial has been funded by a grant of approximately $81 million from the NIA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">DLB</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are evaluating CT1812 in a 120-patient Phase 2 COG1201 SHIMMER clinical trial to investigate the potential for CT1812&#8217;s use as a disease-modifying agent in adults with mild-to-moderate DLB. We are assessing cognitive and functional measures such as Montreal Cognitive Assessment (MoCA), Cognitive Drug Research Battery (CDR), Clinician Assessment of Fluctuation (CAF), Epworth Sleepiness Scale (ESS), Unified Parkinson&#8217;s Disease Rating Scale &#8212; Part III (MDS-UPDRS3), Clinical Global Impression of Change (ADCS-CGIC), ADCS-Activities of Daily Living (ADCS-ADL) and Neuropsychiatric Inventory (NPI). We are currently recruiting patients in the United States. The trial has been funded by a grant of approximately $30 million from the NIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Geographic Atrophy Secondary to Dry AMD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are also evaluating the use of CT1812 to treat GA secondary to dry AMD in Phase 2 COG2201 (MAGNIFY) study. We are assessing the change in GA lesion size over the treatment duration, as measured by fundus autofluorescence (FAF) imaging, as well as CT1812&#8217;s safety and tolerability. We believe that human genetic and proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the S2R complex and dry AMD. Preclinical data suggest that modulating the S2R complex can alter the biological processes that contribute to dry AMD. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We submitted an Investigational New Drug, or IND, application to the FDA at the end of 2022; the IND was cleared at the end of January 2023; and we announced the initiation of dosing in July 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Discovery Initiatives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are pursuing a number of early-stage discovery programs which are built upon our identification of five structurally distinct chemical series. We believe we have identified several structurally distinct compounds that possess advantages for specific disease indications and patient populations. A few of these next-generation S2R modulators have been identified for synucleinopathies and dry AMD and are being assessed as potential IND candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For example, one of our next-generation S2R modulators has shown activity in cell-based dry AMD assays, suggesting the potential to maintain homeostatic functions of RPEs, ameliorate lysosomal dysfunction, and prevent RPE cell death. It has further demonstrated retinal exposures above 80% receptor occupancy with oral administration and favorable PK properties, including high degree of bioavailability and high retina-to-plasma ratio, which we believe may provide us with a suitable next-generation molecule to advance for this indication. Therefore, we believe S2R modulators may present a novel therapeutic approach for these indications and intend to pursue development as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our objectives are to develop and advance our portfolio, beginning with our lead product candidate, CT1812, through clinical development for the treatment of age-related degenerative diseases and disorders of the CNS and retina and to leverage our understanding of the S2R complex and its regulation of pathways to pursue indications in other degenerative disorders. The key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance clinical development of our lead product candidate, CT1812, in mild-to-moderate AD and earlier stages of the disease</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Our lead product candidate, CT1812, has progressed through Phase 1 and into Phase 2 clinical trials. Funding of the Phase 1 and Phase 2 trials has come primarily from the NIA. We are evaluating CT1812 in earlier symptomatic stages of AD and MCI, which is a slight and noticeable measurable decline in cognitive abilities due to AD. Our START (COG0203) clinical trial in patients with mild dementia associated with early-stage AD has been funded by a grant of approximately $81 million awarded from the NIA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance clinical development of CT1812 for GA secondary to dry AMD</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We are evaluating CT1812 as a potential therapy for GA secondary to dry AMD. GA is an advanced form of dry AMD. Dry AMD is an eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. We are currently evaluating CT1812 in a 246-patient Phase 2 study of CT1812 in patients with GA.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Leverage our understanding of the S2R complex to develop product candidates for other CNS and degenerative diseases, including synucleinopathies. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We intend to develop and advance other product candidates to treat other conditions, potentially including the synucleinopathies, which include PD and DLB. We are evaluating CT1812 in a 120-patient Phase 2 COG1201 study of CT1812 in patients with DLB, which is funded primarily through the NIA and are currently recruiting patients. Preclinical data published in February 2021 showed that the S2R complex may play an integral role in the pathology of PD and we believe these results merit further study.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand our pipeline through internal development, in-licensing and acquisitions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;We intend to leverage our expertise in drug development and business development to evaluate additional product candidates as well as bring forward novel chemical matter using libraries generated with our Novel Improved Conditioned Extraction, or NICE, screening platform as well as other molecule generation and screening strategies. To achieve this objective, we may supplement our internal development initiatives through selective in-licensing arrangements, as well as investments in strategic collaborations, and partnerships which complement our initiatives.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Optimize the value of CT1812 and other product candidates in major markets. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We currently retain all worldwide rights to CT1812 for all indications. We plan to develop and pursue approval of CT1812 and other future product candidates in major markets. Where appropriate, we may use strategic collaborations or partnerships to accelerate development and maximize the commercial potential of our programs. We and our key opinion leaders believe CT1812 also can be used in combination with other therapeutics and thus may have many partnering opportunities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to pursue non-dilutive funding opportunities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The majority of our research and clinical efforts have been funded by approximately $171 million in cumulative grants awarded primarily by the NIA. This includes awards totaling $11 million in support of preclinical studies and $160 million for clinical development, the largest of which was the 2020 award of $81 million supporting our upcoming Phase 2 START (COG0203) study of CT1812 in early-stage AD. These grants are non-dilutive and allow us to collaborate with research institutions in pursuing the development of our product candidates for age-related degenerative diseases. We intend to continue our work with these research institutions and plan to seek additional non-dilutive funding for our clinical development when possible.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Team and Collaborators</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have assembled a management team with extensive experience with CNS and degenerative diseases, significant expertise in the S2R biology domain, as well as drug discovery, clinical development, general management and business development. Collectively, our management team has a track record of managing drug development programs that have received regulatory approval and been successfully commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, our management team has built companies that have initiated innovative technologies and investigational new drug programs. We augment the strengths of our management team with an experienced board of directors and scientific and medical advisory boards. We believe our team, with its deep scientific and drug development background, positions us to become a leader in the development of therapies for age-related degenerative diseases and disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have collaborated and worked closely with key healthcare organizations and thought leading institutions in the field of degenerative diseases to develop and advance our therapeutic candidates. To date, we have received approximately $171 million in cumulative grants awarded primarily from the NIA to support our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Approach to Treating Age-Related Degenerative Diseases of the CNS and Retina</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Age-related degenerative diseases are defined by an age-related decline of cellular function often resulting in cell death. Neurodegenerative diseases, perhaps the most prominent of these degenerative disorders, are a variety of conditions defined by progressive degeneration of nerve cells, or neurons, which often leads to neuronal death, causing decline in cognition or other functions, resulting in decreased quality of life and shorter life span. The two most common neurodegenerative diseases are AD and PD.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To our knowledge, no other biopharmaceutical company has focused solely on stopping the synaptic binding of soluble A&#946; oligomers through the use of small molecule receptor modulators, such as CT1812. We believe our deep expertise in oligomer and synaptic biology provides us with a competitive advantage and led to the creation of (1) proprietary assays that target the critical molecular step causing memory loss and (2) proprietary chemical libraries yielding highly brain penetrant small molecule drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Based on this expertise, we are able to discover and optimize small molecule receptor modulators like CT1812 that we believe represent a functionally distinct and promising approach to synaptorestorative AD therapeutics where neurons remain viable and functional. These molecules were designed to displace A&#946; oligomers bound to neuronal receptors at synapses and clearing A&#946; oligomers from the brain into the CSF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to neurodegenerative diseases, other degenerative diseases include AMD. AMD is a common eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. An estimated 18 million adults in the United States have some form of AMD, which is the leading cause of vision loss in people over 60 years of age. We believe that human genetic and proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the S2R complex and dry AMD. Preclinical data suggest that modulation of the S2R complex can alter the biological processes that contribute to dry AMD. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in dry AMD. We submitted an IND application to the FDA at the end of 2022; it was cleared by the FDA at the end of January 2023; and we reported that the first participant was dosed in the Phase 2 COG2201 (MAGNIFY) study in July 2023. We intend to enroll approximately 246 adult patients who will be randomized to receive once-daily oral CT1812 or placebo for 24 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sigma-2 Receptor Complex</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The S2R complex is comprised of transmembrane protein 97, or TMEM97, a four-domain transmembrane protein that forms a complex with progesterone receptor membrane component 1, or PGRMC1. The S2R complex is expressed in the CNS, the retina, as well as peripheral organs, including the pancreas, liver and kidney. Within the brain, the S2R complex is found in several areas, including the cerebellum, cortex, hippocampus and substantia nigra, and is enriched in neurons as compared to glial cells in the adult brain. In the retina, the S2R complex is expressed in several cell types including the RPE cells, photoreceptors and retinal ganglion cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:241.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The sigma-2 receptor (S2R) complex</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k002.jpg" alt="Graphic" style="display:inline-block;height:241.5pt;width:271.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Internal and third-party studies suggest that the role of PGRMC1 and TMEM97, the protein components of the S2R complex, regulate cell damage response processes, including cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. In addition, the S2R complex regulates autophagy, the cellular process by which altered cellular proteins are degraded and removed. The aberrant activity of these processes, believed to be triggered by cellular stresses, is a hallmark of the dysfunction related to degenerative diseases. The S2R complex is a key regulator of processes that have been implicated in several age-related degenerative diseases and disorders including AD, retinal diseases, such as dry AMD, and synucleinopathies, such as PD and DLB. S2R affects diverse regulatory functions through specific interactions with the oligomer receptors and other membrane proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe the array of degenerative disorders which involve protein components of the S2R complex allows for the potential therapeutic use of proprietary S2R modulators in numerous indications. While a fuller understanding of the molecular mechanisms involving the S2R complex remains to be elucidated, evidence suggests that targeting the S2R complex may provide therapeutic benefit to a wide range of age- related degenerative diseases and disorders. We believe modulating the S2R complex to normalize cellular function may provide a restoration of normal cellular processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Biomarker and Imaging-Driven Evidence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Biomarkers have become increasingly important in the development of treatments for neurodegenerative diseases for a number of reasons, including monitoring drug activity in patients, assessing changes in disease pathology during treatment and identifying responder populations for clinical trials. Given that biomarker-enabled therapeutics have a higher rate of success at gaining product approval, we elected to employ biomarkers in our programs to mitigate clinical development risk. To that end, in addition to a number of cognitive tests, our clinical trials use a variety of biomarkers to measure target and/or pathway engagement and assess changes in disease progression. For example, in AD, changes in cerebrospinal fluid, or CSF, concentrations of neurogranin and synaptotagmin-1 can be indicative of damage to synapses. In PD and other synucleinopathies, changes in markers such as &#945;-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain can indicate dysfunction in membrane trafficking and autophagy processes. Quantitative EEG and PET imaging agents as well as vMRI may have utility in several neurodegenerative disorders to measure synaptic function, synaptic density and brain atrophy, respectively.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:213pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Novel, Improved Conditioned Extracts (NICE) Screening Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Chemical structures that we are currently evaluating as potential therapeutics for degenerative diseases originate from our NICE screening platform. The NICE screening platform allowed us to generate proprietary small molecule libraries derived from natural chemical scaffolds through a proprietary process which we refer to as conditioned extraction. Conditioned extraction, a process pioneered by a cofounder, allows us to eliminate undesirable properties of well characterized, biologically active compounds sourced from natural products, while retaining their biological activity. The resulting molecular configurations are then subjected to proprietary functional <i style="font-style:italic;">in vitro</i> screening assays designed to replicate the mature brain and its intricate connections and patterns of electrical signaling. Unlike most other screening assays, such as cells lines derived from immortalized neuronal tumor cells, our use of mature primary neuronal cultures provides us with information-rich measurements more indicative of normal brain function and predicative of functional benefit. We have utilized our NICE screening platform in conjunction with these mature primary neuronal cultures to develop product candidates for our proprietary Early Alzheimer&#8217;s Screening System, or EASSY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The candidate library produced by the NICE screening platform is predisposed to compounds with attractive drug-like properties such as low molecular weight, low number of reactive hydrogen bonds, lipophilicity and relatively neutral chemistry properties. These characteristics reduce the reactivity of the molecules and related toxicities, while also enhancing their ability to cross the blood-brain and blood-retina barriers. As a result, the NICE screening platform was designed to accelerate drug development time while reducing development risk. We believe this platform provides us with differentiated libraries which may lead to development candidates beyond CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are leveraging our expertise in the biology of the S2R complex, synaptic function and plasticity, and our understanding of the role of toxic age-related soluble proteins, to construct a pipeline of innovative, differentiated small molecule product candidates that are intended to restore normal cellular damage responses. We intend to develop therapeutics with the potential to overcome diseases associated with age-related toxic protein buildups that disrupt key cellular processes. Our initial product candidates target diseases characterized by dysfunction or dysregulation of the S2R complex that leads to cellular degeneration, as observed in age-related degenerative diseases and disorders, such as AD, GA secondary to dry AMD, PD and DLB as depicted in the illustration below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k003.jpg" alt="Graphic" style="display:inline-block;height:212.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:411.98pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Lead Product Candidate: CT1812</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the S2R complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. CT1812 originated from our initial efforts with our NICE screening platform which enables the generation of innovative leads. Leads identified through NICE were then evaluated using proprietary <i style="font-style:italic;">in vitro</i> assays designed to better emulate <i style="font-style:italic;">in vitro</i> synaptic activity. We believe the use of these assays allows us to identify functionally active structures which may impact neuronal behavior significantly faster than alternate screening approaches. We currently retain worldwide rights to CT1812 for all indications and are developing CT1812 as a potential treatment for a range of diseases including AD, GA secondary to dry AMD and synucleinopathies, such as DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CT1812 for the Treatment of Alzheimer&#8217;s Disease (AD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">CT1812 was designed to selectively target and displace A&#946; oligomers bound to neuronal receptors at synapses by a new and differentiated mechanism of action. CT1812 binds to S2R which interacts directly with components of the oligomer receptor, resulting in displacement of bound oligomers, which are then cleared from synapses. In our preclinical studies, CT1812 has demonstrated the potential to protect synapses, facilitate their restoration and improve cognitive performance. These preclinical results are currently being evaluated through our ongoing Phase 2 clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview of the Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">AD is a progressive neurodegenerative disorder characterized by cognitive dysfunction, memory loss, dementia and the impairment of daily living activities, along with numerous behavioral and neuropsychiatric symptoms. In the advanced stages of the disease, an AD patient is unable to recognize faces, use or understand language and displays a lack of awareness for their surroundings. Continued functional decline ultimately results in the patient&#8217;s death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Due to the size of the affected population, we believe that AD is one of the most significant unmet medical needs of our time. Nearly six million Americans have been diagnosed with AD and disease prevalence is expected to more than double by 2050. The direct healthcare costs to care for patients with AD and other dementias in the United States is currently estimated to exceed $300 billion and projected to increase to $1 trillion by 2050. Absent the development of meaningful intervention in the course of the disease, the number of people diagnosed with, and dying from, AD is anticipated to escalate appreciably as lifespans lengthen, since prevalence increases significantly with age. The Centers for Disease Control listed AD as the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older. The disease is equally devastating worldwide, with the World Health Organization estimating that AD affects as many as 35 million people globally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Currently Approved AD Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Only two disease-modifying therapeutic options have been approved by the FDA: Biogen&#8217;s Aduhelm, which received accelerated approval on June 7, 2021 and Eisai&#8217;s Leqembi, which received complete approval in July 2023. &#160;Aduhelm and Leqembi are monoclonal antibodies administered via infusion reported to reduce A&#946; plaques and protofibrils, and representing approaches that are distinct from our small molecule approach to modulate the S2R, thereby blocking A&#946; oligomers from binding to synapses. Other therapies approved for AD are indicated to treat the symptoms of AD: acetylcholinesterase inhibitors, or AChEIs, antipsychotics, glutamatergic modulators and an orexin receptor antagonist. AChEIs are designed to slow the degradation of the neurotransmitter acetylcholine, helping to preserve neuronal communication and function temporarily. Glutamatergic modulators are designed to block sustained, low-level activation of the N-methyl-D-aspartate, or NMDA, receptor without inhibiting the normal function of the receptor in memory and cognition. Namenda (memantine), an NMDA receptor antagonist was approved in the United States in 2003. These therapeutic products do not modify or alter the progression of the underlying disease and provide only modest efficacy in treating the symptoms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Therapeutic Approaches in Development to Treat the Underlying Disease Have Shown Little Success</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Numerous therapeutic approaches have been evaluated to remedy the causes of AD. Those focused on reducing the aberrant production, or removal, of intraneuronal neurofibrillary tangles of tau protein have yielded limited clinical benefit. Development initiatives intended to inhibit hyperphosphorylation of the tau protein and related kinase activity, enhance microtubule stability or block tau aggregation have largely been discontinued due to toxicity or a lack of efficacy. Microglial activation and its role in AD-induced neuroinflammation has emerged as another potential target for therapeutic development as has the proper functioning of processes dictating synaptic plasticity, believed to be of central importance to neuronal activity and continued viability. These efforts have also not yielded meaningful clinical advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Among the more prevalent and targeted mechanisms implicated in AD is the accumulation of A&#946; aggregates in the neuronal synapse where disease progression leads to synaptic dysfunction and dysregulation. The accompanying deterioration in neuronal activity ultimately results in neuronal death. As a result, the reduction in the levels of A&#946; aggregates at the synapse has been a prominent objective of a significant number of therapeutic candidates, including active and passive immunotherapies, designed specifically to target A&#946; aggregates. Several therapeutics in this class have recently been approved by the FDA, including Aduhelm and Leqembi, which are monoclonal antibodies designed to reduce A&#946; plaques and protofibrils, approaches that are distinct from but potentially complementary to our small molecule approach of targeting the S2R to prevent A&#946; oligomer toxicity at the synapse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe a common issue with therapeutic interventions intended to limit A&#946; aggregate concentrations in the brain is that they fail to discriminate between different forms of A&#946; aggregates: fibrils, plaques and oligomers. Such efforts may demonstrate success clearing fibrils and the largely inert plaques but fail to address the specific neurotoxic effects of A&#946; oligomers. Conversely, as exemplified by Leqembi&#8217;s clinical results, we believe that preferentially targeting A&#946; protofibrils/oligomers has the potential to prevent synaptotoxicity. Our strategy of targeting the S2R to prevent A&#946; oligomer toxicity at the synapse is distinct from these immunotherapeutic approaches, but we believe may be complementary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Role of A&#946; Oligomers on Synapses and the Downstream Impact to Brain Function and AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synapses are specialized points of contact between neurons, where electrical signaling and communication takes place. It is well established that synapses are routinely sprouted and resorbed as part of the normal process of learning and memory. Each neuron is covered with an estimated 10,000 synapses and these synapses participate in a complex electrical circuit with other neurons. Neurons do not divide or reproduce as part of normal physiological function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Emerging scientific evidence suggests that A&#946; oligomers, formed over time through the buildup of A&#946; and its aggregates, bind to specific parts of the synaptic structure and interfere with the normal process of memory formation. This ligand-like activity confers to A&#946; oligomers potent synaptotoxic activity. In response, the neuron dismantles and resorbs the synaptic structure to prevent its abnormal function from interfering with what remains of the normal circuit behavior. If a large enough number of synapses are lost, the neuron dies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synaptic loss, however, is not necessarily permanent and synapses can be regained or sprout again once the oligomers are removed. We have observed this process in our research involving preclinical AD models. This observation leads us to believe that displacement of synaptotoxic A&#946; oligomers may enable synapses to recover and potentially slow cognitive decline. We are further encouraged by the numerous precedents which exist that demonstrate the therapeutic utility of blocking ligand-receptor interactions in the brain with small molecule drugs capable of crossing the blood-brain barrier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CT1812 Uses a Differentiated Mechanism of Action to Selectively Target A&#946; Oligomers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our proprietary CT1812 product candidate employs a novel and fundamentally different mechanism which through alteration of S2R activity selectively facilitates removal of neurotoxic A&#946; oligomers. Experimental evidence suggests that A&#946; oligomers likely occupy binding sites contiguous to the S2R complex. Binding at these locations is believed to produce structural distortions which inhibit the proper functioning of the S2R complex including its role in regulating critical signaling pathways. The preferential binding of CT1812 to the S2R complex produces changes that alters the binding affinity of A&#946; oligomers to their targets. CT1812 binding to the S2R complex likely modulates the conformation of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">S2R complex, which in turn allosterically alters the conformation of the oligomer binding pocket on the oligomer receptors. Binding pocket destabilization leads to displacement of A&#946; oligomers from the neurons and neuronal synapse. Once displaced, A&#946; oligomers are unable to rebind as long as threshold concentrations of CT1812 are present, and are then rapidly removed from the synapse. Based on our preclinical studies, we believe that CT1812 not only prevents binding of A&#946; oligomers, displacing them from the S2R complex sites at neuronal synapses, but also slows A&#946; oligomer-induced loss of synapses and restores synaptic activity, which may reverse downstream alterations related to membrane trafficking.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Use of an S2R Targeted Approach is Supported by the A673T Mutation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe the benefit of the mechanism by which CT1812 stops the toxic impact of A&#946; oligomers on cellular function is further supported by an analysis of the A&#946; sequence variant, A673T, which is commonly referred to as the &#8220;Icelandic&#8221; mutation. The A673T mutation is the first variant associated with a mutation in the protein structure of A&#946;, first identified through a genomic analysis of the Icelandic population. Importantly, carriers of the mutation are four-fold less likely to develop AD. The A673T mutation, which involves the substitution of the amino acid alanine for threonine at position 673 of the precursor molecule, not only produces fewer A&#946; monomers, but our research indicated that the toxic A&#946; oligomers generated have four-fold lower affinity for brain cell synapses. This reduced binding is evidenced in the results of <i style="font-style:italic;">in vitro</i> experiments, which are presented below. Whereas wildtype A&#946; oligomer binding is pronounced, the binding of the A673T variant is much lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Binding affinities of wildtype versus mutant A&#946; oligomers to synapses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(intensity in arbitrary fluorescent&#160;units)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Kd&#160;</span><b style="font-weight:bold;">(nM)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">B&#160;max</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">wt A&#946; (1&#8201;&#8211;&#8201;42) oligomers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Site 1:442 &#177; 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.98 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup> &#177; 0.29 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A673T mutant A&#946; (1&#8201;&#8211;&#8201;42) oligomers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Site 1:1,955 &#177; 502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.98 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup> &#177; 0.50 &#215; 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Kd is a constant used to evaluate and rank the strengths of interactions for ligands and their receptors. The smaller the Kd value, the greater the binding affinity. Bmax refers to the maximum amount of a ligand that can bind specifically to a receptor. Intensity is measured in arbitrary fluorescent units.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k004.jpg" alt="Graphic" style="display:inline-block;height:219.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:365.83pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that CT1812 is the only drug candidate currently in clinical trials that mimics the effects of the A673T mutation. As the images presented below suggest, both CT1812 and the A673T mutation similarly reduced the binding of toxic A&#946; oligomers to synapses. We believe that drug candidates like CT1812 that mimic the protective effects of the A673T mutation are more likely to succeed in the clinical setting in patients with mild-to-moderate AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k005.jpg" alt="Graphic" style="display:inline-block;height:236.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:394.16pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CT1812 Clinical Results in AD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have completed multiple clinical trial evaluations of CT1812, in both healthy volunteers and patients with mild-to-moderate AD, with two clinical trials ongoing (SHINE, which has concluded enrollment, and START, which is currently recruiting). The clinical trials we have conducted to date have enabled us to evaluate the safety profile of CT1812, as well as validate its mechanism through proof-of-concept trials and to conduct initial assessments of its therapeutic potential. The following is the status of our completed and ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of our completed, ongoing and planned clinical studies of CT1812 for AD and dementia</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k006.jpg" alt="Graphic" style="display:inline-block;height:166.91pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:408.92pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:151.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">COG0201&#8201;&#8212;&#8201;Phase&#160;2 (SHINE) Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our ongoing COG0201 SHINE study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety and potential efficacy of CT1812. A total of 153 adult participants were enrolled and divided in two CT1812 dose groups (100 mg or 300 mg) and one placebo group, dosed daily for six months. Endpoints include safety and biomarker evidence of disease modification as well as cognitive function, as measured by the ADAS-Cog 11-item version, or ADAS-Cog 11. ADAS-Cog 11 is a globally recognized cognitive scale that is used to assess cognition in patients with AD. Top-line results are expected in mid-2024 after the last participants have completed six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Preliminary data from an interim analysis of the first 24 patients from the COG0201 study demonstrated that CT1812 continued to be generally well tolerated. There were four serious adverse events, or SAEs, which were not drug-related and occurred in a single placebo patient. The patient was discontinued due to one of the SAEs. Treatment emergent adverse events, or TEAEs, were well balanced across all treatment groups. We observed mild and transient elevations of liver enzymes in three patients without any other indications of liver injury. These data were consistent with findings from earlier clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preliminary data also demonstrated a significant decline in the presence of A&#946; monomers and a three-point mean improvement in the rate of cognitive decline as measured by ADAS-Cog 11, in patients receiving CT1812 when compared to placebo. These results were observed in patients receiving CT1812 or placebo in addition to background therapies they may have already been receiving for AD. We believe these preliminary data provide promising evidence of CT1812&#8217;s potential cognitive and biological impact. These data also indicate that patients treated with CT1812 showed relative stability on a measure of cognitive performance compared to the placebo group. A mean difference in the rate of decline of approximately three points was observed between the CT1812 dose groups receiving either 100 mg or 300 mg versus the placebo group based on the ADAS-Cog 11 measurements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preliminary data showed a three-point improvement in cognitive decline in CT1812-treated patients.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:151.53pt;width:396.35pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Proteomic measurements were also performed of CSF and plasma from these patients, from which we have comprehensive datasets of whole proteome changes observed in AD patients given CT1812 versus placebo for six months. From this, we identified product candidate pharmacodynamic biomarkers that could reflect processes of target engagement, pathway engagement and/or early disease modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The interim analysis of the SHINE trial (SHINE A) was not powered to detect statistically significant treatment differences. Nevertheless, p-values were calculated at the time of the interim analysis with respect to the clinical and biomarker outcomes to help inform on the potential importance of observed numerical treatment differences. For these interim analyses, p-values&lt;0.05 were considered &#8220;significant&#8221; while p values&gt;0.05 were considered &#8220;non-significant.&#8221; The approximately three-point treatment difference relative to placebo observed for the pooled dose groups that was observed on the ADAS-Cog 11 was non-significant (p&gt;0.05; p=0.1295), while the treatment difference relative to placebo that observed for the reduction in CSF A&#946; 42 protein at the 300 mg dose was significant (p&lt;0.05; p=0.0178).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">COG0203&#8201;&#8212; Phase&#160;2 START Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0203 study, referred to as START, is a randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to enroll 540 patients with early-stage AD and powered to show a change in the rate of cognitive and functional decline. We are currently recruiting patients with MCI due to AD or mild AD who have elevated levels of A&#946; as determined by PET imaging or as measured in CSF. The trial is being conducted in collaboration with the ACTC and will utilize approximately 50-60 sites including research sites associated with the consortium, as well as other qualified sites that are not part of the consortium. Patients will be randomized to receive CT1812 or placebo for 18 months. In addition to a battery of cognitive measures, we intend to use a variety of biomarkers to measure target engagement and assess changes in neurodegeneration and disease progression. We have received a grant of approximately $81 million from the NIA to fund this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Completed Proof-of-Concept Clinical Trials for the Mechanism of CT1812</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have conducted a series of clinical proof-of-concept trials intended to assess target engagement and the impact of CT1812 on synaptic activity. These proof-of-concept trials are presented in more detail below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">COG0202&#8201;&#8212;&#8201;Phase&#160;2 SEQUEL Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0202 SEQUEL study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of 16 patients with mild-to-moderate AD to evaluate the potential efficacy of CT1812 in restoring synaptic function in patients through qEEG measurement, as reflected by relative theta power. The trial is a two-arm crossover trial, in which half of the participants received 300 mg of CT1812 daily for 29 days. After a 14-day wash out period, these participants received placebo for an additional 29 days. The other half of the participants received placebo daily for 29 days. After a 14-day wash out period, these participants received CT1812 treatment for an additional 29 days. CSF and qEEG evaluations were taken periodically throughout the duration of the trial. We completed enrollment in the first quarter of 2023 and presented results in October 2023. Results showed that CT1812-treated participants exhibited a statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters, reflecting improved synaptic function after just a matter of weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">COG0105&#8201;&#8212;&#8201;Phase&#160;1 SPARC Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The COG0105 SPARC study is a randomized, double-blind, placebo-controlled Phase 1 clinical trial of 23 patients with mild-to-moderate AD. The primary objectives of the study were to evaluate CT1812 for safety and tolerability. The secondary objectives were to evaluate potential effects of CT1812 on biologically relevant endpoints using various imaging modalities, including PET imaging and vMRI as well as CSF biomarkers, and cognitive and clinical endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Participants were randomized to receive treatment with 100 mg or 300 mg of CT1812 or placebo once daily for 24 weeks. A preliminary analysis has been made of safety, clinical laboratory measurements, PET imaging, functional MRI and vMRI, CSF biomarkers and clinical outcomes in patients treated with CT1812 compared to those in patients receiving placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Seventeen patients completed the study protocol, eleven in the CT1812 arm (six in the 100 mg cohort; five in the 300 mg cohort) and six in the placebo arm. CT1812 was well tolerated with similar adverse event rates across treatment arms. Most adverse events were mild-to-moderate in severity with no deaths and no treatment-related SAEs reported. We observed mild and transient elevations of liver enzymes without any other indications of liver injury in two patients in the 300 mg group. The patients were discontinued from the study and the liver enzyme levels returned to normal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Top-line results from the analyses of secondary endpoints demonstrated that after 24-weeks of treatment, there were no significant treatment differences on the ADAS-Cog 11 change from baseline. In addition, there were no significant treatment differences on SV2A signal change compared to baseline. However, vMRI showed a trend (p=0.0641) towards a significant reduction in the loss of composite brain volume in CT1812- treated patients (pooled) compared to placebo. A statistically significant (p&lt;0.05) reduction in loss of brain volume was also observed in three brain regions </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.78pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(hippocampus, prefrontal cortex and pericentral cortex) in treated patients (pooled) compared to placebo, as shown in the table below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">LS Mean Change from Baseline in vMRI (composite) over Time by Treatment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k008.jpg" alt="Graphic" style="display:inline-block;height:205.78pt;width:313.57pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k009.jpg" alt="Graphic" style="display:inline-block;height:106.8pt;width:288pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">COG0104&#8201;&#8212;&#8201;Phase&#160;1 SNAP Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0104 SNAP study was a randomized, double-blind, placebo-controlled Phase 1 clinical trial that enrolled three patients with mild-to-moderate AD to measure the effects of CT1812 on displacement of A&#946; oligomers. Patients were randomized 2:1 to receive a single dose of CT1812 or placebo. Patients enrolled in the trial had an indwelling catheter placed in the lumbar CSF space. CSF samples were collected hourly over a 28-hour period. Five CSF samples were collected before and 24 samples collected after administration of a single 560 mg oral dose of CT1812 or placebo. CSF samples from each trial participant were analyzed to measure the concentration of A&#946; oligomers over the trial period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Results of this clinical trial revealed an increase in A&#946; oligomer levels in the CSF over the 24-hour period following treatment with CT1812, but not in the patient administered placebo. These findings were measured using two independent methods, microimmunoelectrodes and western blots. This effect of CT1812 was specific to A&#946; oligomers, as no CT1812-related increase in A&#946; 1-40 or 1-42 monomer was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe these results provide the early proof of principle of CT1812 target engagement in AD patients. Further, we believe that they corroborate our mechanism of action previously demonstrated in preclinical studies, providing the first evidence that our preclinical studies translate to patients with AD.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:356pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">First evidence of target engagement in humans, which mirrors that found preclinically; and we believe this reinforces that our mechanism of action extends to patients with AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k010.jpg" alt="Graphic" style="display:inline-block;height:356pt;width:356pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">COG0102&#8201;&#8212;&#8201;Phase&#160;1 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0102 study was a randomized, double-blind, placebo-controlled, Phase 1 clinical trial of 19 patients with mild-to-moderate AD. Participants were administered one of three oral doses of CT1812, either 90 mg, 280 mg or 560 mg, once daily for 28 days. The primary endpoint of the trial was safety with a secondary objective of establishing the pharmacokinetic, or PK, profile of CT1812. Also included as exploratory endpoints were measurement of CT1812 in CSF, and protein expression changes in CSF and plasma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In order to gauge the impact of CT1812 on synaptic damage due to AD, we measured concentrations of synaptic proteins, neurogranin and synaptotagmin-1, in CSF samples from these patients using clinically validated standardized assays. Our evaluation of AD protein biomarkers in the CSF revealed that neurogranin levels, shown in the left graph below, in patients treated with CT1812 for 28 days was significantly decreased compared to levels measured in patients administered placebo (p =0.05, analysis of covariance). Neurogranin is a synaptic damage marker that increases in the CSF of AD patients reflecting its decrease in the brain. The lowering of synaptic damage markers in the CSF is consistent with CT1812&#8217;s mechanism of action as observed in our preclinical studies and demonstrates the potential of the CT1812 to slow A&#946; oligomer- induced synapse loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Another synaptic damage biomarker that is elevated in the CSF of AD patients is synaptotagmin-1. CSF levels of synaptotagmin-1 were similar at baseline and end of study in patients treated with CT1812, whereas its levels in the placebo group displayed a marked increase over the same time period. This analysis of CT1812&#8217;s impact on synaptotagmin-1 levels </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.86pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">is presented in the right graph below. Consistent with our belief that targeting the S2R has the potential to prevent A&#946; oligomer toxicity, we observed a reduction in neurogranin and synaptotagmin in CSF, which are measures of synaptic damage, suggesting that CT1812 may have the ability to protect synapses in AD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Treatment with CT1812 was associated with lower levels of neurogranin and</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">synaptotagmin-1 compared to placebo</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k011.jpg" alt="Graphic" style="display:inline-block;height:205.86pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:308.8pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">CT1812 was well tolerated in the COG0102 study. All AEs were mild to moderate. Some of the participants in the highest dose group experienced lymphocytopenia or elevated liver enzymes. These laboratory abnormalities resolved in most patients with continued dosing of CT1812. One trial participant was discontinued from CT1812 prior to study completion because of elevated liver enzymes with subsequent resolution of this abnormality. Lymphocytopenia or elevated liver enzymes were not observed in either the 90 mg or 280 mg dosing cohorts. There were no SAEs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Phase&#160;1 Safety Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to Phase 1 clinical trials conducted in our targeted patient population, we also conducted a series of Phase 1 clinical trials in healthy volunteers designed to evaluate the safety profile of CT1812, as well as determine potential drug-food or drug-drug interactions. These trials and their results, which are summarized below, indicated that CT1812 was generally well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COG0101 &#8212; First in human phase 1 clinical trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0101 study was a randomized, double-blind, placebo-controlled ascending dose Phase 1 multi-cohort clinical trial of 93 healthy volunteers to assess the safety and potential drug-food interactions of CT1812. The trial was conducted in two segments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The first segment was structured as an ascending single dose trial, in which participants received one dose of CT1812 with increasing doses given to each of six cohorts. In this segment of the trial, eight participants were enrolled per dosing cohort with six participants receiving CT1812 and two receiving placebo. The doses evaluated were 10 mg, 30 mg, 90 mg, 180 mg, 450 mg and 1,120 mg. A seventh cohort of six patients received a single 90 mg dose after receiving a standardized meal. All doses were administered as scheduled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The second segment was configured as a multiple ascending dose trial, that enrolled 39 healthy volunteers, divided in three cohorts of ten participants, with one additional cohort consisting of nine healthy elderly volunteers. Each </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">participant in this segment of the trial received a single dose of CT1812 each day for 14 days. The doses evaluated in this second segment were 280 mg, 560 mg and 840 mg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 CSF concentrations correlated to a &gt;80% S2R predicted receptor occupancy in brain</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k012.jpg" alt="Graphic" style="display:inline-block;height:205.41pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:251.96pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following completion of each trial cohort, bioanalytical evaluation of plasma CT1812 PK was conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">This trial demonstrated that administration of CT1812 in single doses of up to 1,120 mg, administered once, as well as up to 840 mg of CT1812 dosed for 14 consecutive days was well tolerated. Significantly, CT1812 concentrations detected in the CSF correlated to an estimated receptor occupancy in the brain of greater than 80%. There was one SAE in the multiple-dose portion of the study that was deemed unrelated to study drug. There were no SAEs related to the product candidate or TEAEs leading to withdrawal from the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COG0103 &#8212; Phase 1 Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0103 study was a Phase 1 clinical trial of 15 healthy volunteers designed to evaluate the potential effects of CT1812 on select CYP isoenzymes: CYP2C19, CYP2C9, CYP2D6 and CYP3A4. This was accomplished by assessing its effects on substrates of these isoenzymes: 20 mg omeprazole, 500 mg tolbutamide, 50 mg dextromethorphan and 4 mg midazolam. The 15 healthy volunteers who participated in the trial received the substrates of these isoenzymes two days prior to the initial dose of CT1812 and PK assessments were performed. A dose of 560 mg of CT1812 was administered to each of the trial participants for the following six consecutive days. The day 6 dose of CT1812 was administered concomitantly with the four-substrate cocktail and PK assessments were repeated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">A weak drug interaction was observed between CT1812 and midazolam and dextromethorphan. A lack of any clinically meaningful interaction was observed with coadministration of omeprazole or tolbutamide. Based on the small magnitude of change in PK parameters of the probe drugs observed in this study for the isoenzymes CYP2D6 and CYP3A4, clinically meaningful interactions are unlikely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In all blinded and unblinded clinical trials, several patients experienced asymptomatic, reversible elevations in serum liver chemistries prompting harmonization of monitoring, increasing frequency where appropriate, across our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:328.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to entering clinical trials, the therapeutic potential of CT1812 was observed in numerous preclinical studies. As is demonstrated in the images below, the addition of A&#946; oligomers to neuronal cell cultures resulted in synaptotoxicity as illustrated by the reduced expression of synaptic markers neurogranin, synaptotagmin and SV2A. The lack of immunoreactivity of these three synaptic proteins can be seen in the middle column of the image below. However, the presence of CT1812 blocked the A&#946; oligomer-induced loss of synapses, as reflected by the presence of synaptic protein expression displayed in the right-hand column below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 prevented A&#946; oligomer-mediated synaptic damage</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k013.jpg" alt="Graphic" style="display:inline-block;height:328.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:328.45pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Results showed that CT1812 also slowed the loss of synapses that is triggered by A&#946; oligomers. A higher resolution image of the cell culture exposed to A&#946; oligomer is shown below, before the addition of CT1812, which is presented on the left, and after the addition of CT1812, which is presented on the right. A&#946; oligomers shown in red bind to synaptic receptors and reduce numbers of synapses shown in green. The addition of CT1812 displaces A&#946; oligomer binding and appears to block the effects induced by the A&#946; oligomers, with the synapse numbers remaining at levels similar to normal.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:192.28pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812&#160;slowed loss of synapse numbers in the presence of A&#946; oligomers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k014.jpg" alt="Graphic" style="display:inline-block;height:75.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:347.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The protective benefits of CT1812 observed in these <i style="font-style:italic;">in vitro</i> assays are supported by functional <i style="font-style:italic;">in vivo</i> assessments of CT1812. In one such preclinical study, the memory of mice was tested based on the subject&#8217;s ability to recall fear-inducing triggers and its performance in a maze. The mice exhibiting symptoms of AD, depicted by the red bars in the image below, performed significantly worse in both the fear and maze tests when compared to normal, non-transgenic mice, represented by the blue bars. However, after administration of CT1812, the AD mice, represented by the solid green bars, were seen to perform at a level similar to that achieved by normal mice. We believe these results are illustrative of CT1812&#8217;s ability to restore synaptic proteins and numbers to normal levels and with it, the animal&#8217;s functional capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 restored functional capabilities in a mouse model of AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k015.jpg" alt="Graphic" style="display:inline-block;height:192.28pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:371.79pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CT1812 for the Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (Dry AMD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that several lines of evidence suggest that modulation of the S2R complex may provide significant therapeutic utility for the treatment of GA secondary to dry AMD. Human genetics points to TMEM97 as a promising therapeutic target for GA secondary to dry AMD, as indicated via several large- scale, independent genome-wide association, or GWA, studies. In addition, unbiased pathway analysis of AD patient proteomic data obtained during our clinical trials provides independent evidence of a relationship between the S2R complex and GA secondary to dry AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Early proof-of-concept studies with CT1812 indicate a role of S2R modulators in rescuing key aspects of dry AMD including maintaining homeostatic functions of RPEs, ameliorating lysosomal dysfunction and preventing RPE cell death. PK assessment indicates that we can achieve therapeutic levels (&gt;80% receptor occupancy) of CT1812 in retinal tissue through oral administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We submitted an IND application to the FDA at the end of 2022 to initiate a Phase 2 clinical trial of CT1812 in this indication; it was cleared by the FDA at the end of January 2023; and we announced in July 2023 that participant dosing had commenced in the Phase 2 COG2201 (MAGNIFY) study. CT1812 will be given orally, once daily for 24 months to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:238.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">determine if it can slow disease progression. Approximately 246 patients will be randomized to receive once-daily oral CT1812 or placebo for 24 months. We are assessing the change in GA lesion size over the treatment duration, as measured by fundus autofluorescence (FAF) imaging, as well as CT1812&#8217;s safety and tolerability. We believe that well-characterized clinical endpoints and a defined regulatory path make dry AMD an attractive indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview of the Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">AMD is the leading cause of blindness in people over 50 years of age in the United States, afflicting approximately 11 million people in the United States, including an estimated 12% of all U.S. adults over 80 years of age. Dry AMD is a progressive condition and accounts for up to 90% of all AMD cases. Advanced dry AMD, or GA, affects approximately two million people in the United States. There are currently two approved therapeutics for dry AMD, both of which are intravitreal injections designed to regulate the complement system. Other treatments in development are primarily invasive, including intravitreal injections, stem cell replacement and gene therapy approaches. We believe the limited treatment options available for patients with dry AMD, coupled with newly implicated biochemical pathways, make GA secondary to dry AMD an attractive target for the development of therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">There are two types of AMD, the first of which is neovascular, or wet AMD, and non-neovascular, or dry AMD. Dry AMD, which accounts for approximately 90% of all AMD cases, is a progressive condition that involves a dysregulation of cellular processes, among which is the accumulation of lipid deposits, known as drusen, that causes a thickening of the Bruch&#8217;s membrane. This thickening disrupts the cytoarchitecture of the RPE, and this disruption, coupled with oxidative stress and inflammation, leads to the diminished health and function of RPE and photoreceptor cells, with accumulated damage resulting in cell death and visual impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The anatomy of the eye and the regions impacted by AMD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k016.jpg" alt="Graphic" style="display:inline-block;height:238pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:357pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Limitations of Current Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There are currently two FDA-approved therapeutics for dry AMD: Apellis Pharmaceuticals&#8217; SYFOVRE and Astellas Pharma&#8217;s Izervay, both of which are designed to inhibit complement factors. In addition, there is considerable development activity ongoing involving numerous targets. Beyond complement inhibitors, other areas of ongoing interest include cell and gene therapy approaches to regenerate RPE cells and rescue the loss of photoreceptors. Small molecule visual cycle </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">modulators are also under evaluation to maintain retinal integrity. Most of these approaches require invasive administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rationale for S2R Mechanism of Action</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Indications of S2R Involvement in Geographic Atrophy Secondary to Dry AMD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that several lines of evidence suggest that modulation of the S2R complex may provide significant therapeutic utility for the treatment of GA secondary to dry AMD. First, human genetics point to TMEM97 as a promising therapeutic target, as indicated via several large-scale, independent GWA studies. These studies indicate a genetic mutation known as a single nucleotide polymorphism, or SNP, in the TMEM-VTN locus confers decreased risk for dry AMD. It remains unknown if this mutation confers a change in TMEM97 expression levels. However, knockdown of TMEM97 in <i style="font-style:italic;">in vitro</i> models of the disease partially rescues RPE cells from oxidative stress-induced cell death. Further investigation of the role of the S2R complex in dry AMD is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unbiased Analysis of Clinical Trial Sample Proteomics Data: Top Disease Ontologies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Unbiased pathway analysis of AD patient proteomic data obtained during the COG0102 and SHINE Part-A clinical trials provides independent evidence of the relationship between the S2R complex and dry AMD. Analyses of CSF were performed to ascertain which predesignated functional disease ontologies may be affected by the administration of CT1812. These analyses identified GA and macular degeneration as two of the top indications affected, with GA presenting the most significant relationship. Subsequent analyses identified several subsets of proteins altered by CT1812 that are involved in dry AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In subsequent analyses examining the overlap of proteins altered in CSF and plasma biofluids of AD patients treated with CT1812 versus placebo, we identified a set of proteins, altered by CT1812 that have been previously shown by other groups to be disrupted in dry AMD or GA, compared to age-matched controls. Subsequent analysis identified several pathways in which these proteins are involved, many of which have known genetic or biological links to processes disrupted in dry AMD. We believe the collective insights provided by these analyses provide early proof of concept that an S2R modulator may be capable of altering AMD relevant proteins and pathways in an aged patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Support for Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We believe that proof-of-concept studies indicate a clear role of S2R modulators in rescuing key aspects of dry AMD. Pathway analysis of transcriptomic data suggests a key role of S2R modulators in regulating pathways involved in cell survival and inflammation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:329.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Mechanistic Studies Indicate CT1812 Plays a Role in Cell Survival</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">and Inflammatory Pathways in RPE Cells</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k017.jpg" alt="Graphic" style="display:inline-block;height:329.2pt;width:395.05pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Additional functional studies indicate S2R modulators may ameliorate disruptions in homeostatic functions of RPEs, including ameliorating lysosomal dysfunction and salvaging the ability of RPE cells to recycle photoreceptor outer segments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:325.55pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Working Hypothesis of Mechanism of Action in Dry AMD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k018.jpg" alt="Graphic" style="display:inline-block;height:325.55pt;width:293pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe preclinical studies provide further evidence supporting a clinical trial for CT1812 as a potential treatment for GA secondary to dry AMD. PK assessment indicates that we can achieve therapeutic levels (&gt;80% receptor occupancy) of CT1812 in retinal tissue through oral administration. Moreover, as is illustrated in the graph below, CT1812 levels recorded in the retina were similar to those in the brain, suggesting that the doses used to achieve potential therapeutic levels in the retina needed to achieve efficacy will be similar to the doses for AD.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:256.62pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Similarities in CT1812 concentrations following oral administration in the brain and retina</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k019.jpg" alt="Graphic" style="display:inline-block;height:256.62pt;width:414.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Additional studies have been conducted to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD.&#160;<i style="font-style:italic;">In vivo</i>&#160;preclinical studies are evaluating the utility of CT1812 to impede the death of retinal ganglion cells. Not only is it anticipated that these proof-of-concept studies will allow us to further elucidate the mechanism by which the S2R complex modulators act upon the various disease pathologies, but the learnings from this may also inform appropriate patient selection, time of intervention and clinical outcome measurements to enable a successful clinical trial design. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COG2201 &#8212; Phase 2 MAGNIFY Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that an S2R antagonist, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We submitted an IND application to the FDA at the end of 2022 to initiate a Phase 2 clinical trial of CT1812 in this indication; it was cleared by the FDA, and we announced that the first participant was dosed in July 2023 in the Phase 2 COG2201 (MAGNIFY) study. CT1812 will be given orally, once daily for 24 months to determine if it can slow disease progression. Approximately 246 patients will be randomized to receive once-daily oral CT1812 or placebo for 24 months. We are assessing the change in GA lesion size over the treatment duration, as measured by fundus autofluorescence (FAF) imaging, as well as CT1812&#8217;s safety and tolerability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">S2R Modulators for the Treatment of Synucleinopathies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Substantial cellular and clinical biomarker evidence demonstrate that our S2R modulators, including our clinical drug candidate CT1812, have a beneficial impact on the pathways impaired in synucleinopathies, namely the localization of &#945;-synuclein aggregates in Lewy bodies, which is a chief hallmark of PD and other synucleinopathies. More recently, human genetic evidence has linked SNCA, the gene encoding &#945;-synuclein, to the pathology of synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have conducted preclinical studies of S2R ligands in our library, including CT1812, to explore the potential of S2R antagonists to rescue the biological processes that are impaired in synucleinopathies. Subject to discussion with the FDA, we intend to conduct clinical studies in DLB, PD and potentially other synucleinopathies as outlined below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">An Overview of Synucleinopathies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synucleinopathies are a group of neurodegenerative disorders in which the protein &#945;-synuclein accumulates &#160;abnormally to form inclusions in the cell bodies or axons of neurons or oligodendrocytes. Two of the primary synucleinopathies are PD and DLB, which each involve motor and cognitive dysfunction. While the cell types and brain structures that are affected in PD and DLB vary markedly between the disorders, synucleinopathies share a characteristic accumulation of &#945;-synuclein aggregates into fibrils, the major constituent of the Lewy bodies that occur inside brain neurons in these diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Increasing evidence suggests that &#945;-synuclein also aggregates into oligomers, and that oligomers are more toxic than fibrils. <span style="letter-spacing:0.2pt;">&#945;</span>-synuclein oligomers contribute to neurodegeneration through a variety of mechanisms including disrupting normal autophagy and inducing synaptic dysfunction and loss. Synaptic dysfunction and loss contribute to the cognitive and motor symptoms of these diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synucleinopathies are second only to AD in terms of neurodegenerative disease prevalence. In the United States, as many as 1 million people suffer from PD and an estimated 1.4&#160;million from DLB. According to the Parkinson&#8217;s Foundation and the Lewy Body Dementia Association, the direct healthcare costs for patients with PD and DLB are estimated to be approximately $25 billion and $31&#160;billion per&#160;year, respectively. For PD, these direct medical costs include an estimated $2 billion for medications annually in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Limitations of Current Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Most approved therapeutic products treat the symptoms of the diseases and modulate dopamine. While some existing products provide meaningful symptomatic relief, they have significant side effect risks, fail to address the progression of the disease, and over time gradually lose their effectiveness in treating the symptoms of the disease. There are no currently approved disease-modifying therapeutics for PD or other synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rationale for S2R Mechanism of Action for Synucleinopathies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">&#945;-synuclein is a protein primarily found in neural tissue that plays a role in neurotransmission. In synucleinopathies such as DLB and PD, &#945;-synuclein builds up in brain cells and forms oligomers that saturably bind to neurons where they impair critical cellular processes, causing synaptic dysfunction and eventual loss. Our decision to pursue the treatment of synucleinopathies with S2R compounds is based on internal and third-party data, indicating that the S2R components PGRMC1 and TMEM97 regulate cell pathways known to be impaired in synucleinopathies, such as autophagy, vesicle trafficking and lipid synthesis; &#945;-synuclein oligomers bind directly to PGRMC1; and synucleinopathies share certain mechanistic similarities with AD, including pathologies related to aberrant oligomeric protein formations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As summarized below, we believe our preclinical studies provide compelling evidence supporting the use of CT1812 and our next-generation S2R modulators as potential therapeutics to treat synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As with oligomers of the A&#946; protein in AD, oligomers of &#945;-synuclein are highly toxic when bound to brains cells and internalized. This binding causes cellular stress, including three major pathway disruptions: upregulation of the autophagy receptor LAMP2A, dysregulation of lipid metabolism and a reduction in membrane trafficking. The S2R complex components, PGRMC1 and TMEM97, directly regulate these processes and activities which are compromised by the binding and internalization of &#945;-synuclein oligomers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Compounds that bind to S2R and block &#945;-synuclein binding and/or internalization are therefore expected to be disease-modifying.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Study Support for Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The results of <i style="font-style:italic;">in vitro</i> studies suggest that S2R modulator, such as CT1812, may have disease modifying effect on the synucleinopathies by reversing pathway disruption and dysregulation caused by &#945;-synuclein oligomers. In work funded by grants from the Michael J. Fox Foundation, &#945;-synuclein oligomers were found to bind to brain cells in culture and are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:169.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">internalized as indicated by the red dots in the image to the left below. With the addition of S2R modulator CT1812, the binding and thus internalization of the &#945;-synuclein oligomers is inhibited as indicated in the image to the right below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT1812 blocked the binding and internalization of &#945;-synuclein oligomers in the neuronal synapses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k020.jpg" alt="Graphic" style="display:inline-block;height:169.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:350.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The potential for S2R modulators to reverse the deleterious cellular effects of &#945;-synuclein oligomers is also reflected in the <i style="font-style:italic;">in vitro</i> analysis of LAMP2A expression presented below. LAMP2A is a critical component of chaperone-mediated autophagy, one of several processes that eliminate damaged cellular proteins. Its expression, noted in orange, is upregulated in the presence of the toxic &#945;-synuclein oligomer, likely a compensatory mechanism in response to the cellular insult. S2R modulators, which block membrane trafficking deficits caused by &#945;-synuclein oligomers, are observed to inhibit the upregulation of LAMP2A, as evidenced by the dark and light gray in the below chart. As these antagonists are selective for the S2R complex, their ability to reverse the effects of &#945;-synuclein on LAMP2A expression provides compelling evidence of the S2R complex&#8217;s importance in the regulation of this autophagy pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In vitro</i> analysis further illustrates &#945;-synuclein oligomers&#8217; dose-dependent inhibition of membrane trafficking. Importantly, oligomer-related inhibition was noted to be four-fold higher than that observed with high concentrations of monomeric &#945;-synuclein, illustrative of the significantly greater toxicity of &#945;-synuclein oligomers. The addition of CT1812 was observed to reverse the membrane trafficking deficit related to the presence of &#945;-synuclein oligomer, while having no effect on membrane activity when dosed in its absence.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">S2R antagonists reversed the effects of &#945;-synuclein oligomers on LAMP2A expression and trafficking</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20231231x10k021.jpg" alt="Graphic" style="display:inline-block;height:237.3pt;width:444.93pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COG1201 &#8212; </i>Phase&#160;2 SHIMMER Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are actively enrolling participants in our Phase 2, SHIMMER (COG1201) clinical trial, which is studying the use of CT1812 to treat adults with mild-to-moderate DLB. The design of this trial is a double-blind, randomized, six-month trial involving three dose groups, two active treatment cohorts and a placebo group. We intend to enroll approximately 120 patients with equal participant numbers in each of the three dose groups, with daily (QD) dosing. Eligibility requirements include individuals between 50 and 80 years of age that have received a diagnosis of DLB and have a mini-mental state exam, or MMSE, score of between 18 and 27. Clinical endpoints of the trial include safety and physical activity measurements, cognitive assessments, and PK and pharmacodynamic biomarker analyses compared to baseline measurements recorded at the beginning of the trial. In addition, CSF will be collected and analyzed for &#945;-synuclein content and established patterns of differential protein expression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Many degenerative disorders are likely to involve a dysfunctional cellular damage response mechanism and significant evidence is emerging which highlights the importance of the S2R complex and its components in regulating this response. The complex likely contains a number of relevant binding sites that may allow for multiple disease intervention approaches, making it an attractive therapeutic target. Accordingly, we are actively engaged in a number of earlier-stage discovery programs which are built upon our identification of five structurally distinct chemical series. From these series we have multiple leads which will be optimized from each of our lead series. Each of these leads has demonstrated favorable potency with variable selectivity in early preclinical testing and each of the molecular series possesses distinct bioavailability and PK properties, including differences in half-life and blood-brain and blood-retina permeability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Proposed Synucleinopathies Clinical Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Subject to additional funding, we plan to study several next-generation S2R modulators derived from chemically distinct series to measure their ability to rescue cell death in synucleinopathies such as PD and DLB. We would also study &#945;-synuclein pathology and motor deficits in two mechanistically distinct <i style="font-style:italic;">in vivo </i>models of synucleinopathies. In parallel, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">these studies will elucidate the mechanism of action by which S2R modulators are efficacious in PD and DLB and provide essential data to support potential biomarker nomination for PD and DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Funding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Historically, we have sought grant funding to strategically advance our programs. To date, we have secured non-dilutive funds from the NIA, the Michael J. Fox Foundation and other groups to pursue our commonly aligned interests of developing therapeutics for neurodegenerative disorders. Taken together, the company has been awarded approximately $171 million in cumulative grants for the advancement of our pipeline programs. Of this, approximately $81 million in cumulative non-dilutive grants have been awarded by the NIA to fund development of CT1812 for the treatment of AD. As of December 31, 2023, we had approximately $67 million available from NIA funds for applicable expenses to be incurred in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Funding Org</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Project</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0101 Ph1b first-in-patient trial for CT1812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,410,669</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0102 Ph1b/2a Clinical Trial for CT1812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,410,669</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0104 Ph1 SNAP Study: CSF Catheter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,527,271</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0105 Ph1 SPARC Study: SV2a PET</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,795,774</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0201 Ph2 SHINE Study</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,848,329</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0202 Ph2 SEQUEL Study: qEEG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,445,051</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0203 Ph2 Study with ACTC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,974,766</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0108 Study: hAME</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,642,783</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0201 Ph2 SHINE Amendment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,634,548</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG1201: Study: DLB</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,498,048</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NIH and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2010&#8209;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ten Preclinical Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,859,971</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 171,047,879</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Each of the grants awarded to us relates to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to CROs, research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for our eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIA grants do not contain claw back provisions, the NIA or other government agency may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. To date, we have not been found to have breached the terms of any NIA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We seek to protect and enhance our proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, in the United States and internationally, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company Owned Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of March 1, 2024, our intellectual property portfolio contained ten issued U.S. patents, forty five issued foreign patents as well as five pending U.S. provisional applications, three pending U.S. patent applications, one pending Patent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cooperation Treaty applications and forty five foreign pending patent applications directed to the composition of matter of, pharmaceutical compositions of, methods of use of, and methods for selecting subsets of patients for treatment with our chemical structures, including our lead CT1812. Our current issued patents relating to CT1812 are projected to begin to expire no earlier than 2035, with the composition of matter patent covering CT1812 set to naturally expire in 2035, subject to adjustment or extension of patent term available in a particular jurisdiction. We will likely be awarded Patent Term Extension, or PTE, when CT1812 is approved as a New Chemical Entity, or NCE, that will extend the term of the CT1812 composition of matter patent by up to five years, and we anticipate pursuing additional patents to further protect CT1812 and to further extend the patent term associated with CT1812. We expect to file additional patent applications in support of current and new product candidates as well as new platform and core technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are the exclusive owner of eight patent families that include several granted U.S. patents and pending U.S. patent applications, as well as granted patents and pending patent applications in numerous foreign jurisdictions, relating to compositions of matter and pharmaceutical compositions of CT1812, analogs of CT1812, and the use of CT1812 for the treatment in certain diseases, disorders and conditions including AD, GA secondary to dry AMD, PD, and synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The first of these patent families is directed to compositions of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD, and we are the exclusive owner of this patent family in the United States and certain foreign jurisdictions, including Australia, Brazil, Canada, China, the European Union, Hong Kong, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, and South Africa. As of March 1, 2024, this patent family includes granted patents claiming composition of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD in the United States (three patents), Australia, Brazil, China, the European Union, Hong Kong, India, Israel, Japan, New Zealand, Mexico, South Korea, Russia and South Africa. This patent family also includes a pending U.S. patent application and pending application in certain foreign jurisdictions including India and the European Union. This patent family has a natural expiration date in 2035 subject to any adjustment or extension of patent term that may be available in in a particular jurisdiction such as PTE following approval of the New Drug Application, or NDA, in the United States or extension of patent term via a Supplementary Protection Certificate, or SPC, following EMEA marketing authorization. Upon approval of the NDA for CT1812 in the United States, the patents in this family claiming compositions of matter of CT1812, pharmaceutical compositions of CT1812, and methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD will be eligible to be listed in the FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. These patents complement the regulatory exclusivity by providing the basis for an additional waiting period prior to the FDA&#8217;s &#160; approval of an abbreviated new drug application, or ANDA, or 505(b)(2) applicant. If &#160;an ANDA or 505(b)(2) applicant were to file its application referencing the NDA for CT1812 before expiration of our composition of matter, pharmaceutical composition, and method of use patents and the applicant asserted that our patents identified on the Orange Book to be invalid or not be infringed, it may be subject to additional waiting periods prior to the FDA&#8217;s approval (including a statutory 30-month stay if we sue for infringement, or a shorter period if the patent expires or there are certain settlements or judicial decisions in the patent litigation, starting at the end of the five-year NCE regulatory exclusivity period).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to patent exclusivity, under the provisions of the Hatch-Waxman Act, upon any approval in the United States, we believe that CT1812 will be eligible for five-year NCE regulatory exclusivity, during which time no 505(b)(2) NDA or ANDA can be approved that contains the same active moiety as the chemical entity in the CT1812 NDA. When approved in Europe, CT1812 will also be eligible for 10 years of data and market exclusivity which is extendible for an additional year upon market authorization for one or more new indications during the first eight years of the data and market exclusivity period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>We also own seven families of pending patent applications directed to methods for selecting subsets of patients with AD for treatment with CT1812, methods of modulating amyloid beta monomer and oligomer levels using CT812, methods of treating GA secondary to dry AMD with CT1812 and methods of treating various neurologic diseases including PD and synucleinopathies with CT1812, as well as a pending provisional application directed to treating certain subsets of AD patients with CT1812 and treating Niemann-Pick disease. Any of these applications, if issued, will have a natural </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expiration between 2038 and 2044, subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are the exclusive owner of four patent families that include several pending U.S. patent applications, as well as pending patent applications in numerous foreign jurisdictions directed to additional product candidates. These patent families have expirations no earlier than 2038 subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturing Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We oversee and manage third party contract manufacturing organizations to support development and manufacture of product candidates for our clinical trials, and, if we receive marketing approval, we will rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products. Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the drug substance for CT1812 and with a single third-party contract manufacturer to manufacture clinical trial supplies of CT1812, and we expect to enter into commercial supply agreements with such manufacturers prior to any potential approval of CT1812. We continue to develop a commercial route for CT1812 API and to meet all requirements for our planned clinical trials. The current API manufacturer is able to supply all of our needs for the planned clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">CT1812 drug product is manufactured via conventional pharmaceutical processing procedures, employing commercially available excipients and packaging materials. The procedure and equipment employed for manufacture and analysis are consistent with standard pharmaceutical production, and are transferable to a range of manufacturing facilities, if needed. We have selected a larger third-party drug product manufacturer and will be executing technology transfer of drug product manufacture to a larger manufacturer. We will also maintain the current drug substance and product manufacturer as part of our supply chain strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Commercialization Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may seek third-party support from established pharmaceutical and biotechnology companies for those products that would benefit from the promotional support of a large sales and marketing force. In these cases, we might seek to promote our products in collaboration with marketing partners or rely on relationships with one or more companies with large established sales forces and distribution systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may elect to establish our own sales force to market and sell a product for which we obtain regulatory approval if we expect that the geographic market for a product we develop on our own is limited or that the prescriptions for the product will be written principally by a relatively small number of physicians. If we decide to market and sell any products ourselves, we do not expect to establish direct sales capability until shortly before the products are approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We face substantial competition from multiple sources, including large and specialty biotechnology and pharmaceutical companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">established companies to (i) obtain support for their research, development and commercialization of products or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to the current standard of care treatments for patients with neurodegenerative diseases, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess technologies and product candidates in the CNS field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the biopharmaceutical sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retain qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Currently available therapies for these diseases are limited, with two approved disease-modifying treatments each for Alzheimer&#8217;s disease and geographic atrophy (GA) secondary to dry AMD but no approved treatments for dementia with Lewy bodies. However, our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Employees and Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of March 1, 2024, we had 28 employees, 25 of whom were full-time and 17 of whom were engaged in research and development activities. Seven of our employees hold Ph.D. or M.D. degrees. None of our employees are represented by a labor union. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are dedicated to conducting business with the highest standards of corporate responsibility. Our goal is to build a culture of diverse and passionate people striving to positively impact patients, our communities, and broader society. Our human capital resource priorities include attracting, recruiting, retaining, incentivizing and integrating our existing and new employees. We believe that a diverse, equitable, and inclusive workplace allows our company to best fulfill our mission. We are committed to continuing our efforts to increase diversity throughout our company and foster an inclusive work environment that supports our employees and the communities we serve. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. During 2023, the Company has taken proactive steps to enhance and improve our policies related to employee welfare and engagement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Government authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, nonclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, and export and import of products such as those we are developing. Generally, before a new drug can be marketed, considerable data must be generated, which demonstrate the drug&#8217;s quality, safety, and efficacy. Such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">U.S. Drug Development Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, the approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of nonclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s good laboratory requirements and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, or ethics committee, either centralized or with respect to each clinical site, before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA after completion of all pivotal trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination by the FDA within 60 days of its receipt of an NDA to accept the filing for substantive review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practices, or cGMP, requirements to ensure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity, and of selected clinical investigation sites to assess compliance with GCPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including potential requirements to conduct any post-approval studies required by the FDA or the potential requirement to implement a risk evaluation and mitigation strategy, or REMS; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with the Pediatric Research Equity Act, or PREA, which requires either exemption from the requirements or may require conducting clinical research in a pediatric population.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and <i style="font-style:italic;">in vitro</i> studies assessing the toxicology, PK, pharmacology, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial or drug candidate. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, or DSMB, which may review data and endpoints at designated check points, make recommendations and/or halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the registration of ongoing clinical studies and posting of clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;One</i>:&#160;&#160;&#160;The product candidate is initially introduced into a limited number of healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism, and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;Two</i>:&#160;&#160;&#160;The product candidate is administered to a limited patient population with the target disease or condition to evaluate the preliminary efficacy, optimal dosages, and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning Phase 3 trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;Three</i>:&#160;&#160;&#160;The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk relative to potential benefit and generate the data used by FDA and other regulatory agencies to evaluate suitability for marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Post-approval clinical trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Sponsor may voluntarily pause or stop a clinical trial, or the FDA may place a trial on full or partial clinical hold at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or concerns related to chemistry, manufacturing and controls. A clinical hold is an order issued by the FDA to delay or suspend an investigation Following the issuance of a clinical hold or a partial clinical hold, a clinical trial may only proceed after FDA has notified the sponsor that any deficiencies have been corrected and FDA is authorizing the trial to proceed. In addition, an IRB representing each institution participating in the clinical trial must review and approve the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. Finally, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a clinical trial may move &#160; forward at designated check points based on access to certain data from the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested by the sponsor. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach alignment on plans for the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 clinical trials to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug candidate and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <i style="font-style:italic;">in vitro </i>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NDA Review and Approval Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development nonclinical and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product candidate. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for product candidates designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process, or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with and approved drug and to enable patients to have continued access to such drug by managing their safe use. It could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may offer conditional approval subject to, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission to and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. As with new NDAs, the review process is often significantly extended by the FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing new drug candidates that meet certain criteria. Specifically, new drug candidates are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the drug candidate and the specific indication for which it is being studied. The sponsor of a fast track designated product has opportunities for more frequent interactions with the applicable FDA review team during product development. With regard to a fast track </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">designated product, the FDA may also consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Any drug candidate submitted to the FDA for approval, including a drug candidate with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A drug candidate is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug candidate designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, a drug candidate may be eligible for accelerated approval. Drug candidates intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the drug candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA generally requires that the sponsor perform adequate and well-controlled post-marketing confirmatory clinical trials which must be conducted with due diligence to verify and describe the predicted clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA may require, as appropriate, that such confirmatory trials be underway prior to approval or within a specific time period after the date accelerated approval is granted. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct the required confirmatory trials or if such studies fail to verify the predicted clinical benefit. &#160;In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive Breakthrough Therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;Breakthrough Therapy&#8221; if the drug candidate is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a drug candidate is designated as Breakthrough Therapy, the FDA will work to expedite the development and review of such drug candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Fast Track designation, priority review, accelerated approval, and Breakthrough Therapy designation do not change the standards for approval, but may expedite the development, review or approval process. Even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our drug candidates as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There are continuing, annual program fees for any marketed products. Drug manufacturers </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, untitled letters, Form 483s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds on post-approval or Phase&#160;4 clinical studies, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under PREA, an NDA must contain data to assess the safety and efficacy of the applicant product for indications in applicable pediatric populations. It must also contain information to support dose administration for pediatric populations where the drug may be utilized. FDA has the ability to grant complete waivers, partial waivers, or deferrals for compliance with PREA. PREA requirements may be waived for applications for approval of drug candidates intended to treat, mitigate, prevent, diagnose or cure diseases and other conditions that do not occur in pediatric populations. Generally PREA does not apply for drug candidates which have obtained an orphan designation, unless otherwise regulated by the FDA. Despite this, separate PREA compliance or waivers may still be required for each product indication. Although noncompliance with PREA will generally not be considered for withdrawal of an approval it may be considered by the FDA as the sole basis for enforcement action such as injunction or seizure as non-compliance and may render the drug misbranded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the same active ingredient. The FDCA provides a five- year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. The FDCA also permits patent term restoration of up to five years as compensation for a patent term lost during product development and FDA regulatory review process to the first applicant to obtain approval of an NDA for an NCE in the United States. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. During the NCE exclusivity period, the FDA may not approve or even accept for review an ANDA or an NDA submitted under Section 505(b)(2), or a (505(b)(2) NDA), submitted by another company for another &#160;drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book. These products may be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. Any competitor who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must make patent certifications to the FDA that (1) no patent information on the drug or method of use that is the subject of the application has been submitted to the FDA; (2) the patent has expired; (3) the date on which the patent has expired and approval will not be sought until after the patent expiration; or (4) the patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not &#160; approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval, the 30-month stay is extended so that it expires 7 1&#8725;2 years after approval of the innovator drug, unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">conduct or obtain a right of reference to any nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. The indications the Company is currently pursuing for its product candidates will not be eligible for pediatric exclusivity because they are age-related degenerative diseases and disorders that do not occur in the pediatric population. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities &#160;from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments made in the preceding calendar year and other transfers of value provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; applicable manufacturers also are required to report such information regarding payments and transfers &#160;of value provided, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Foreign Corrupt Practices Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Foreign Corrupt Practices Act, or the FCPA, generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our industry is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Enforcement actions may be brought by the Department of Justice or the SEC, and recent enacted legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims such as those under the FCPA from five years to ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific details, information on cost-effectiveness, and clinical support for the use of a product to each payor separately. This can be a time- consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and related services. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not &#160; &#160;to cover a product could reduce physician usage and patient demand for the product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The Inflation Reduction Act of 2022, for example, contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. The Inflation Reduction Act of 2022 also caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. Additional drug pricing proposals could appear in future federal legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the state level, there are also new laws and ongoing ballot initiatives that create additional pressure on drug pricing and may affect how pharmaceutical products are covered and reimbursed. A number of states have adopted or are considering various pricing actions, such as those requiring pharmaceutical manufacturers to publicly report proprietary pricing information, limit price increases or to place a maximum price ceiling or cap on certain products. Existing and proposed state pricing laws have added complexity to the pricing of pharmaceutical drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. There have been significant ongoing efforts to modify or eliminate the Affordable Care Act. The Tax Act, enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code, commonly referred to as the individual mandate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress that include aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which remain in effect through 2031. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. &#160;The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Affordable Care Act has also been subject to challenges in the courts. &#160;In the most recent challenge, in June 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;text-indent:19.95pt;margin:8.44pt 30.65pt 12pt 0pt;"><span style="color:#231f20;">We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:justify;text-indent:0pt;margin:8.44pt 30.65pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:justify;text-indent:22.5pt;margin:8.44pt 30.65pt 12pt 0pt;">We were incorporated under the laws of the State of Delaware on August 21, 2007. Our principal corporate office is located at 2500 Westchester Avenue Purchase, NY 10577, and our telephone number is (412) 481- 2210. Our website address is www.cogrx.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9c1a1fe5_3a36_4c01_bcc4_09338ee2742a"></a><a id="Item1ARiskFactors_361684"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. We have listed below (not necessarily in order of importance or probability of occurrence) what we believe to be the most significant risk factors applicable to us. The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. Some of the statements in the following risk factors constitute forward-looking statements. &#160;Please see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Capital Needs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses over the foreseeable future and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Since our inception, we have incurred significant net losses, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses were $25.8 million and $21.4 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $141.2 million. Our clinical trials have been funded by approximately $171.0 million in cumulative nondilutive grants, awarded primarily by the National Institute of Aging, or NIA, a division of the National Institutes of Health. On October 13, 2021, we completed our initial public offering, or IPO, whereby we received net proceeds of $37.9 million. On November 12, 2021, we received an additional $6.3 million in net proceeds resulting from the exercise of the overallotment option held by the underwriters in our IPO. On November 15, 2022, we completed a follow-on public offering whereby we received net proceeds of $5.2 million. On March 14, 2024, we completed a follow-on public offering whereby we received net proceeds of approximately $10.4 million. We have no products approved for commercialization and have never generated any revenue from product sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have devoted substantially all of our financial resources and efforts to the development of our product candidates, including conducting preclinical studies and clinical trials. We expect to continue to incur significant expenses and operating losses over the next several years. We expect that it could be several years, if ever, before we have a commercialized product. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially for the foreseeable future as we:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">conduct our ongoing and planned clinical trials of CT1812, as well as initiate and complete additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">pursue regulatory approval of CT1812 for the treatment of mild-to-moderate Alzheimer&#8217;s disease, or AD, dry age-related macular degeneration, or GA secondary to dry AMD, and Parkinson&#8217;s disease, or PD, and dementia with Lewy bodies, or DLB, and other age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">seek to discover and develop additional clinical and preclinical product candidates from libraries generated using Novel Improved Conditioned Extraction, or NICE, screening platform, as well as other molecule generating and screening strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">hire and retain additional clinical, manufacturing and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">incur additional legal, accounting and other expenses in operating as a public company;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">scale up our clinical and regulatory capabilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">establish a commercialization infrastructure and scale up external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval, including CT1812. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with therapeutic development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of our candidates or any future therapeutic candidates, our expenses could increase beyond our current expectations and revenue could be further delayed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Even if we or any future collaborators do generate sales, we may never achieve, sustain or increase profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our stock and could impair our ability to raise capital, expand our business, diversify our therapeutic offerings or continue our operations. If we continue to suffer losses, investors may not receive any return on their investment and may lose their entire investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are conducting Phase 2 clinical trials and have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We commenced operations in 2007, and our operations to date have been largely focused on developing our clinical and preclinical product candidates and our NICE screening platform. We have limited experience conducting and completing clinical trials and not yet demonstrated our ability to successfully complete pivotal clinical trials, obtain regulatory approvals, manufacture a product on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We may also need to transition from a company with a research focus to a company capable of supporting commercial activities. Our inability to adequately address these risks and difficulties or successfully make such a transition could adversely affect our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our operations have required substantial amounts of capital since inception, and we expect our expenses to increase significantly in the foreseeable future. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect to continue to incur significant expenses and operating losses over the next several years as we complete our ongoing clinical trials of our product candidates, initiate future clinical trials of our product candidates, seek marketing approval for CT1812 for the treatment of age-related degenerative diseases and disorders of the CNS and retina, such as AD, GA secondary to dry AMD, PD and DLB, and advance any of our other product candidates we may develop or otherwise acquire. In addition, our product candidates, if approved, may not achieve commercial success. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for the foreseeable future, if at all. If we obtain marketing approval for CT1812 or any other product candidates that we develop or otherwise acquire, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. We also expect an increase in our expenses associated with creating additional infrastructure to support operations as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had $29.9 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, income from our non-dilutive grants, and net proceeds received from our March 2024 follow-on public offering will be sufficient for us to fund our operating expenses and capital expenditures requirements through May of 2025. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including, but not limited to<span style="letter-spacing:0.2pt;">:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scope, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">progress, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs and results of our ongoing and planned clinical trials of CT1812, as well as the associated costs, including </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs we </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur as a result of preclinical study or clinical trial delays due to supply chain disruptions or other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the extent to which we develop, in-license or acquire other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs we advance them through preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability, timing and receipt of any future non-dilutive grants from the NIA, or NIA Grants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the number and development requirements of other product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to establish collaborations to commercialize CT1812 or any of our other product candidates outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">macroeconomic factors such as inflationary pressures, rising interest rates, liquidity constraints, failures and instability in U.S. and international financial banking systems, supply disruptions due to political unrest, conflict and war or other factors, and pandemics such as the COVID-19 pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We believe our existing cash and cash equivalents and income from our non-dilutive grants will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of C1812 and our product candidates. If we receive regulatory approval for any of these product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. In addition to our existing cash and cash equivalents and income from our non-dilutive grans, in March 2023, we entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, providing for the sale of up to $35 million worth of shares of our common stock. In addition, in December 2022, we entered into a sales </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by us of up to $40 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings, or the ATM Facility. There can be no assurance that we will be able to sell all of the shares under the equity line with Lincoln Park or the ATM Facility. Amounts available under the equity line with Lincoln Park have a strong and direct correlation to the Company&#8217;s publicly traded price per share and volumes. There can be no assurances of our traded price per share and volumes being at sufficient levels to provide adequate funding from the equity line with Lincoln Park or the ATM Facility. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by recent volatility in the equity markets in the United States and worldwide. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The economic environment may make it difficult to raise capital on acceptable terms or at all. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our ability to raise additional funds when needed and on acceptable terms or at all will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. For example, the continued challenging capital markets environment, lower prices for many securities and concerns about potential recessionary factors may affect our ability to raise additional funding through sales of our securities or issuance of indebtedness, which may harm our liquidity, force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization planning efforts or cause us to grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or our product candidates or any future therapeutic candidate, or we may be unable to take advantage of future business opportunities. Market volatility, liquidity constraints, failures and instability in United States and international financial banking systems, geopolitical tensions resulting from the ongoing conflicts between Ukraine and Russia and Israel and Hamas, heightened or fluctuating inflation and interest rates and the related impact on U.S. and global economies or other economic or other factors could also adversely impact our ability to access capital as and when needed or increase our costs in order to raise capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that future financing will be available in sufficient amounts, or on commercially reasonable terms, or at all. Current capital market conditions, including the impact of inflation, have increased borrowing rates and can be expected to significantly increase our cost of capital as compared to prior periods. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our stock to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to our product candidates or any future therapeutics candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To date, we have partially relied on the availability of NIA Grants. Although we have applied for and currently anticipate receiving additional NIA Grants, we cannot be certain that our grant applications will be successful, that additional NIA Grants will be made available to support our clinical trials or that we will continue to satisfy the award criteria of prior NIA Grants that have already been awarded to us. If we fail to continue to receive NIA Grants, our ability to continue our clinical programs for CT1812 may be impaired and delayed, and we may otherwise need to seek additional financing through dilutive methods, such as through equity or debt financings. Such dilutive financings could have an adverse effect on the price of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We could be subject to audit and repayment of our non-dilutive NIA Grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, in connection with the NIA Grants, we may be subject to routine audits by certain government agencies. As part of an audit, these agencies may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA Grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA Grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. Any audit by the NIA could require significant financial and management resources and may result in a material adjustment to our results of operations and financial condition and harm our ability to operate in accordance with our business plan. Additionally, negative results in any of our ongoing and planned clinical trials of CT1812 that are funded with NIA Grants may result in our failure to receive additional NIA Grants to fund future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are currently focused on developing product candidates to address age-related degenerative diseases and disorders of the CNS and retina. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between aggressively advancing our lead product candidate, CT1812, in identified indications and exploring additional indications or mechanisms as well as developing future product candidates. However, due to the significant resources required for the development of our product candidates, we must focus on specific diseases and disease pathways and decide which product candidates to pursue from time to time and the amount of time and resources to allocate to each such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate with third parties with respect to certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the market of age-related degenerative diseases and disorders of the CNS and retina or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to our product candidates, which may change from time to time;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and status of enrollment for our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability, timing, and receipt of any future NIA grants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">future accounting pronouncements or changes in our accounting policies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States and internationally;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the level of demand for our product candidates, if approved, which may vary significantly over time.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Discovery, Development and Regulatory Approval of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of CT1812 and any future product candidates that we may develop or acquire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">currently have no products approved for sale, and our lead product candidate is in early stages of clinical development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of CT1812, currently our only clinical-stage product candidate. However, given our stage of development, it may be many years, if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The clinical and commercial success of CT1812 and any future product candidates that we may develop or acquire will depend on a number of factors, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to raise any additional required capital on acceptable terms, or at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to complete an investigational new drug application, or IND, enabling studies and successfully submit INDs or comparable applications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">delays or difficulties in enrolling and retaining patients in our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">whether we are required by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates, if approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the convenience of our treatment or dosing regimen;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or any future product candidates, if approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or &#160;in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient demand for our product candidates, if approved, including patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:12.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, the FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions. We have not yet conducted an end of Phase 2 meeting with the FDA to discuss the registration pathway for CT1812, and our current clinical development plans for CT1812 in mild-to-moderate AD may change as a result of future interactions with the FDA. For example, the FDA may not accept the results of the ongoing CT1812 clinical trials and may require that we conduct additional trials, including more than one pivotal trial, in order to gain approval in AD. Furthermore, any approval of CT1812 for AD may be limited to CT1812 in combination with the existing standard of care.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for CT1812 or by in-licensing or acquiring additional product candidates for other diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">A key element of our strategy is to build and expand our pipeline of product candidates, including by developing CT1812 for the treatment of GA secondary to dry AMD and age-related degenerative diseases and disorders of the CNS beyond indications in AD, and by identifying other product candidates from libraries created using our NICE platform as well as new molecule and screening strategies. In addition, we may in-license or acquire additional product candidates for other diseases. We may not be able to identify or develop additional product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify, in-license or acquire may not be suitable for clinical development. For example, our research methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side effects or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We have devoted significant resources to discovery efforts through our proprietary NICE platform, and we cannot guarantee that we will be successful in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license new and valuable product candidates from other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development of pharmaceuticals is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are at an early stage of clinical development of our only clinical stage product candidate, CT1812. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our product candidates may not successfully complete preclinical studies or clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and we may never succeed in developing marketable products or generating product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be successful in our efforts to further develop our current and future product candidates. Each of our product candidates will require significant clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not be acceptable to the FDA or other regulatory authorities or demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, to obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on collaborators or partners to conduct the required activities to support an application for regulatory approval and to seek approval for one or more of our product candidates. We cannot be sure that any such collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we or any future collaborators or partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may encounter substantial delays in our preclinical studies and clinical trials or may not be able to conduct or complete our preclinical studies or clinical trials on the timelines we expect, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:18pt;margin:0pt;">Clinical <span style="letter-spacing:0.2pt;">trials are expensive and can take many years to complete, and the outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage and our future clinical trials may not be successful. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">delays in obtaining, or failure to obtain, regulatory authorization to commence a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">imposition of a temporary or permanent clinical hold by the FDA or comparable foreign regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">identifying, recruiting and training suitable clinical investigators;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtaining institutional review board, or IRB, approval at each trial site;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">new safety findings that present unreasonable risk to clinical trial participants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a negative finding from an inspection of our clinical trial operations or study sites;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">recruiting an adequate number of suitable patients to participate in a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">having subjects complete a trial or return for post-treatment follow-up;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">addressing subject safety concerns that arise during the course of a trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtaining sufficient supply of product candidates for use in preclinical studies or clinical trials from third-party suppliers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials or require that we submit additional data or information before allowing a clinical trial to be initiated or continue;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">clinical studies of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulators may revise the requirements for approving our product candidates or such requirements may not be as we anticipate; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">any future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval in some countries and not in others;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be subject to additional post-marketing testing requirements; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">have the product removed from the market after obtaining marketing approval</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">available </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapies, including </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new drugs that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the indications we are investigating; the severity and difficulty of diagnosing the disease under investigation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the patient eligibility and exclusion criteria defined in the protocol;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the proximity of patients to trial sites;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">competition with other companies for clinical trial sites or patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the design of the trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the existing body of safety and efficacy data with respect to the study drug and safety concerns;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">patient referral practices of physicians;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">risk that enrolled subjects will drop out before completion of the trial, including as a result of contracting health conditions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">ability to monitor patients adequately during and after treatment;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">availability </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and efficacy of </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medications or therapies, or other clinical </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">trials, for </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the disease or condition under</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investigation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to obtain and maintain patient consents.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause undesirable and unforeseen side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Adverse <span style="letter-spacing:0.2pt;">events or other undesirable side effects caused by our product candidates or related to procedures conducted as part of the clinical trials could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the data safety monitoring board, or DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, early clinical trials may only include a limited number of subjects and limited duration of exposure to our product candidates. In particular, we are pursuing a new approach to inhibiting the synaptic binding and signaling of soluble A&#946; oligomers through the use of small molecule receptor antagonists, like CT1812. As a result, our product candidates may cause unforeseen safety events when evaluated in larger patient populations. Further, clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable and unforeseen side effects caused by such product, a number of potentially significant negative consequences could result, including but not limited to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to conduct additional clinical trials or post-approval studies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be subject to fines, injunctions or the imposition of criminal penalties;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the product may become less competitive; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">Preclinical <span style="letter-spacing:0.2pt;">and clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim, top-line, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain Phase 2 clinical trials of CT1812 targeting mild-to-moderate AD, we do not know whether CT1812 will perform in future clinical trials as it has performed in these prior trials. The positive results we have observed for CT1812 in past clinical trials may not be predictive of our ongoing and future clinical trials in humans. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. In addition, changes to the design of our current or future clinical trials may be necessary if there are new developments in the field of Alzheimer&#8217;s research. A number of companies in the biopharmaceutical, pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additionally, some of our past clinical trials have utilized an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates when studied in a controlled environment with a placebo or active control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">For all of the foregoing reasons, we cannot be certain that any of our ongoing and planned preclinical studies or clinical trials will be successful or acceptable to the FDA or other regulatory authorities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interim &#8220;top-line&#8221; and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;">From <span style="letter-spacing:0.2pt;">time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have initially concentrated our research and development efforts on the treatment of AD, a disease that has seen limited success in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Efforts <span style="letter-spacing:0.2pt;">by biopharmaceutical and pharmaceutical companies in treating AD have seen limited success in drug development. Only two disease-modifying therapeutic options have been approved by the FDA. Specifically, Biogen&#8217;s Aduhelm received accelerated approval on June 7, 2021 and the FDA granted accelerated approval to Eisai&#8217;s Leqembi on January 6, 2023. &#160;Aduhelm and Leqembi are monoclonal antibodies administered via infusion reported to reduce A&#946; plaques and protofibrils. We cannot be certain that our oral, small-molecule approach will lead to the development of approvable or marketable products. With the exception of Aduhelm and Leqembi, the only drugs approved by the FDA to treat patients with AD address the symptoms of the disease. As a result, the FDA has a limited set of products to rely on in evaluating CT1812. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of CT1812 for the treatment of AD</span><span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We will need to successfully initiate and complete pivotal clinical trials in order to obtain the approval of the FDA, the European Medicines Agency, or EMA, or other regulatory agencies to market CT1812 or any future product candidate. Carrying out pivotal clinical trials is a complicated process that requires significant financial resources. As an organization, we have not previously initiated nor conducted any later stage or pivotal clinical trials. In order to do so, we will need to expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to NDA submission and approval of CT1812 or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We<span style="letter-spacing:0.2pt;"> may seek a &#8220;Breakthrough Therapy&#8221; designation for our product candidates if the clinical data support such a designation for one or more product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">A Fast Track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA granted CT1812 Fast Track designation in October 2017 for the treatment of mild-to- moderate AD, and, in the future, we may seek Fast Track designation for other of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Fast Track designation may not result in a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many small molecule product candidates that have received Fast Track designation have failed to obtain marketing approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. In addition, government funding of other agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have conducted, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">have conducted clinical trials of our product candidates outside the United States, and plan to continue to do so in the future. For example, we initially conducted our Phase 1b SNAP clinical trial of CT1812 in collaboration with the Karolinska Institute in Sweden. In addition, the Phase 1 single and multiple ascending dose studies of CT1812 in healthy volunteers (COG0101) as well as the first-in-patient study (COG0102) were conducted in Australia. We opened additional clinical trial site in the Netherlands, Czech Republic and Spain for our SHINE study. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, any comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the data are applicable to the U.S. population and U.S. medical practice;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the trials were performed by clinical investigators of recognized competence, or GCP, requirements; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many foreign regulatory authorities have similar requirements. In addition, foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are not successful in identifying, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Although <span style="letter-spacing:0.2pt;">a substantial amount of our effort will focus on the continued development and potential approval of our current product candidates, a key element of our strategy is to identify, develop and commercialize a portfolio of products that help restore normal cellular damage responses in age-related degenerative diseases and disorders of the CNS and retina. A component of our strategy is to evaluate our product candidates in multiple indications based, in part, on our evaluation of certain biomarkers in a disease area. For example, we intend to evaluate CT1812 and other product candidates discovered through our NICE platform in other diseases beyond indications in AD, such as GA secondary to dry AMD, and synucleinopathies, including PD and DLB. However, we may find that while we have seen promising results in one neurodegenerative disease, that effect is not replicated across other indications with promising similarities. Even if we successfully identify additional product candidates, we may still fail to yield additional product candidates for development and commercialization for many reasons, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the research methodology used may not be successful in identifying potential product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be unable to identify viable product candidates through our NICE platform and other molecule generating and screening strategies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">competitors may develop alternatives that render our additional product candidates obsolete;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">additional product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may not be accepted as safe and effective by physicians and patients.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We therefore cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunities may be limited</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if the product candidates that we develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for our product candidates and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or any future collaborators&#8217; ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the European Union, or EU, and many other jurisdictions, we and any future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or any future collaborators fail to comply with the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are heavily dependent on the success of CT1812, our lead product candidate, which is still under clinical development, and if CT1812 does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of CT1812, currently our only clinical-stage product candidate. To date, we have invested a significant portion of our efforts and financial resources in the development of CT1812 for the treatment of AD. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for and successfully commercialize CT1812, which may never occur. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to CT1812, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Furthermore, while inhibition of A&#946; oligomers has been validated as a therapeutic approach, the use of small molecule receptor antagonists, such as CT1812, to inhibit the synaptic binding and signaling of soluble A&#946; oligomers is an innovative therapeutic approach, which exposes us to certain risks. For example, we may discover unforeseen safety events or that CT1812 does not possess certain properties required for therapeutic effectiveness. Even if found to be effective in one type of disease, CT1812, or the associated therapeutic approach, may not be effective in other diseases. In addition, given our therapeutic approach, designing preclinical studies and clinical trials to demonstrate its effect is complex and exposes us to risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market CT1812 in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities for CT1812 and may not be in a position to do so for several years, if ever. If we are unable to obtain the necessary regulatory approvals for CT1812, we will not be able to commercialize CT1812 in AD, GA secondary to dry AMD, PD and DLB or other age-related degenerative diseases and disorders of the CNS and retina, and our financial position will be materially adversely affected and we may not be able to generate sufficient revenue to continue our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">of March 1, 2024, we had 25 full-time and 3 part-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize CT1812, our lead product candidate, or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth and we expect will lead to increasing costs. Our need to effectively execute our growth strategy requires that we:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">manage our clinical trials effectively;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">identify, recruit, retain, incentivize and integrate additional employees, including personnel focused on research and development and, if our product candidates receive marketing approval, sales;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Our future financial performance and our ability to develop, manufacture and commercialize CT1812 and our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize CT1812, if approved, and our product candidates and, accordingly, may not achieve our research, development and commercialization goals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, particularly our President and Chief Executive Officer, Lisa Ricciardi, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth or raise funds to support our growth could delay the execution of our business plans or disrupt our operations. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our current or future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">injury to our reputation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">withdrawal of clinical trial participants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">costs to defend the related litigation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">diversion of management&#8217;s time and our resources;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">substantial monetary awards to trial participants or patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">loss of revenue; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the inability to commercialize our current or any future product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may explore strategic collaborations that may never materialize or may fail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may attempt to broaden the global reach of our platform by selectively collaborating with leading therapeutic companies and other organizations. As a result, we may periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. In the event we do form such collaborations, we intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may seek to grow our business through acquisitions of complementary businesses, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could harm our financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">From <span style="letter-spacing:0.2pt;">time to time, we may consider opportunities to acquire other companies, products or technologies that may enhance our manufacturing capabilities, expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous risks, including: problems assimilating the acquired service offerings, products or technologies; issues maintaining uniform standards, procedures, quality control and policies; unanticipated costs associated with acquisitions; diversion of management&#8217;s attention from our existing business; risks associated with entering new markets in which we have limited or no experience; increased legal and accounting costs relating to the acquisitions or compliance with regulatory matters; and unanticipated or undisclosed liabilities of any target.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired service offerings, products or technologies. Our potential inability to integrate any business, products or technologies effectively may adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant disruptions of information technology systems and infrastructure, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems and infrastructure to prevent a data compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and infrastructure and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may have access to our confidential information. Our internal information technology systems and infrastructure, and those of any future collaborators and our contractors, consultants, vendors and other &#160;third parties on which we rely, are vulnerable to damage, disruption, security compromise or incident, or other unauthorized access or use resulting from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, denial or degradation of service attacks, ransomware, hacking, phishing schemes intended to cause an unauthorized transfer of funds and other social engineering attacks, attachments to emails, persons inside our organization or persons with access to systems and data inside our organization. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The risk of a security compromise, incident, breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The prevalent use of mobile devices that access confidential information also increases the risk of lost or stolen devices, security incidents and data security compromises or breaches, which could lead to the loss of confidential information, including intellectual property, proprietary business information and personal information. We may face increased risks of a security compromise, incident, breach or disruption due to our reliance on internet technology and the number of our employees who work on a hybrid basis, at home and in the office. &#160;This may create additional opportunities for cybercriminals to exploit vulnerabilities. The costs to us to investigate, mitigate and remediate security incidents, compromises, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have in the past experienced threats related to our data and systems, including phishing attacks, and we may in the future experience other threats, compromises or breaches affecting confidential information. While we have implemented security measures designed to protect our data security and information technology systems and infrastructure, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss or misappropriation of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, if a computer security compromise or breach affects our systems or infrastructure or results in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information or clinical trial data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws, and our reputation could be materially damaged. &#160;We would also be exposed to a risk of loss, governmental investigations or enforcement, &#160;litigation, fines, penalties, and other potential legal and financial exposure and liability, which could materially adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are subject to or affected by federal, state and foreign data protection laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, or HITECH, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section 5 of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of any future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative, civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Further, various states have implemented similar privacy laws and regulations. For example, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA also provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA went into effect on January 1, 2020 and grants the California Attorney General the power to bring enforcement actions for violations beginning July 1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and as a result may increase our compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Foreign data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information data subjects in the European Union or the United Kingdom. The GDPR went into effect on May 25, 2018. Companies that must comply with the GDPR face increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential fines for noncompliance of up to &#8364;20 million or 4% of annual global revenue of the noncompliance company, whichever is greater. The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal information of European Union or United Kingdom data subjects, including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border transfers of personal information, and honoring and providing for the rights of European Union or United Kingdom individuals in relation to their personal information, including the right to access, correct and delete their data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, other sanctions, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, CT1812, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our current and future drug development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our technology and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future drug development programs and product candidates, successfully defend our intellectual property rights against third-party challenges and successfully enforce our intellectual property rights to prevent third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may choose not to seek patent protection for certain innovations or products and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, some of our product candidates are not, and in the future may not be, protected by patents. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. The patent applications that we own may fail to result in issued patents with claims that cover any of our product candidates in the United </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">States or in other foreign countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated or held unenforceable, and vice versa that may affect the regulatory approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The patents and patent applications that we own may fail to result in issued patents with claims that protect any of our product candidates in the United States or in other foreign countries. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may obtain. Even if patents do successfully issue based on our patent applications, and even if such patents cover our product candidates, uses of our product candidates, or other aspects related to our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for our products and technologies. Other companies may also design around technologies we have patented or developed. Any successful opposition to these patents or any other patents owned by us in the future could deprive us of rights necessary for the successful commercialization of any of our product candidates, if approved. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our products, and if we do not own or have exclusive rights to other enforceable patents protecting our products or other technologies, competitors and other third parties could market products and use processes that are substantially similar to, or superior to, ours and our business would suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If the patent applications we hold with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for any of our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any such outcome could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September 16, 2011 and includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, and derivation proceedings. After March 15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, post-grant review or interference proceedings challenging our owned patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">Filing, <span style="letter-spacing:0.2pt;">prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, CT1812, for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">Patents <span style="letter-spacing:0.2pt;">have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, one or more of our U.S. patents may be eligible for limited patent term extension, or PTE, under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we do not obtain protection under the Hatch-Waxman Amendments by obtaining data exclusivity, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">commercial success will largely depend on our ability to obtain market exclusivity in the United States and other countries with respect to our drug candidates and their target indications. Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, certain of our product candidates may be eligible for marketing exclusivity. The Food, Drug and Cosmetic Act, or FDCA, provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. If market exclusivity is granted for an NCE, during the exclusivity period, the FDA may not accept for review or approve an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, dosage forms or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and prohibits the FDA from approving an ANDA or a 505(b)(2) NDA submitted by another company with overlapping conditions associated with the new clinical investigations for the three-year period. Clinical investigation exclusivity does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of an NDA for the same drug. However, an applicant submitting an NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are unable to obtain such marketing exclusivity for our product candidates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products and launch their product earlier than might otherwise be the case</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates including our lead product candidate CT1812 can be challenged by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">If <span style="letter-spacing:0.2pt;">one of our product candidates is approved by the FDA, one or more third parties may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non- infringement. For example, if a third party files an application under Section 505(b)(2) or an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1) there is no patent information listed in the Orange Book with respect to our NDA for the applicable approved drug candidate; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved drug candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">file a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, a third party may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our drug candidates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Periodic <span style="letter-spacing:0.2pt;">maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering any of &#160; our product candidates, our competitors might be able to enter the market earlier than anticipated, which would harm our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">issuance of a patent does not give us the right to practice the patented invention. A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. Third parties may also have blocking patents that could prevent us from marketing our products or practicing our own patented technology. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms. Such a license may not be available, or it may not be available on commercially reasonable terms, in which case our business would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The risks described elsewhere pertaining to our intellectual property rights also apply to any intellectual property rights that we may in-license, and any failure by us or our potential licensors to obtain, maintain, defend and enforce these rights could harm our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we may license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our potential licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. However, while certain research, development and commercialization activities may be protected by the safe harbor provision of the Hatch Waxman Act, other activities may subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent was to be held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our common shares. If securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. The occurrence of any of these events may harm our business, results of operation, financial condition or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside &#160; the United States remain confidential until patents issue. Therefore, patent applications covering our products could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our products that are held to be infringing. We might, if possible, also be forced to redesign products or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce our patents or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Competitors <span style="letter-spacing:0.2pt;">may infringe or otherwise violate our patents or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">patents do not cover the technology in question. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of written description or statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as </span><i style="font-style:italic;letter-spacing:0.2pt;">ex parte</i><span style="letter-spacing:0.2pt;"> reexaminations, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, or post- grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be able to detect or prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could harm the price of our common shares</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because <span style="letter-spacing:0.2pt;">of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protects our product including our lead product candidate, CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">United States has recently enacted and implemented wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain &#160; patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. The United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Filing, <span style="letter-spacing:0.2pt;">prosecuting and defending patents covering any of our product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. We do not have patent rights in certain foreign countries in which a market may exist. Moreover, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Because <span style="letter-spacing:0.2pt;">we expect to rely on third parties to manufacture our product candidates and expect to continue to collaborate with third parties on the development of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may harm our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants, independent contractors or we have wrongfully used or disclosed confidential information of their former employers or other third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We do and may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and to not use the confidential information of their former employer, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or product candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Even <span style="letter-spacing:0.2pt;">if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials and internal research programs. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our product candidates, if approved</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In <span style="letter-spacing:0.2pt;">addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed</span>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">expect to rely on trademarks as one means to distinguish any of our drug candidates that are approved for marketing from the products of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Certain <span style="letter-spacing:0.2pt;">provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. For example, the NIA has provided grants to fund certain of our preclinical activities and clinical trials. If the United States or another jurisdiction decides that the NIA grant bestows rights to our patent applications, that could affect our ability to obtain valid and enforceable patent claims protecting our rights as they relate to our lead product candidate, CT1812, our other product candidates and our NICE platform. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries. Such a loss of patent protection could harm our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">Once <span style="letter-spacing:0.2pt;">granted, patents may remain open to invalidity challenges including opposition, interference, re- examination, post-grant review, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">others may be able to make product that is similar to product candidates we intend to commercialize that is not covered by the patents that we own;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we, or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we or any collaborators might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">issued patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the patents of others may harm our business.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Should any of these events occur, they could significantly harm our business and results of operations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Even <span style="letter-spacing:0.2pt;">if one or more of our product candidates receive FDA or other regulatory approvals, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the safety and efficacy of our product as compared to other available therapies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability of coverage and adequate reimbursement from governmental healthcare plans or third party payors for any of our product candidates that may be approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">proper training and administration of our product candidates by physicians and medical staff;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">public misperception regarding the use of our therapies, if approved for commercial sale;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the revenue and profitability that our products may offer a physician as compared to alternative therapies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">limitations or warnings contained in the FDA-approved labeling for our products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">any FDA requirement to undertake a REMS;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the effectiveness of our sales, marketing and distribution efforts;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adverse publicity about our products or favorable publicity about competitive products; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">potential product liability claims.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians, patients, healthcare payors and others in the medical community. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be more effective than other commercially available alternatives or successfully commercialized. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our reputation, ability to raise additional capital, financial condition, results of operations and business prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market opportunities for CT1812, if approved, may be smaller than we anticipate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">expect to initially seek approval for CT1812 for AD, GA secondary to dry AMD, PD and DLB and other age-related degenerative diseases and disorders of the CNS and retina. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and market research and may prove to be incorrect. Even if we obtain significant market share for CT1812 after FDA approval, the potential target populations may be too small to consistently generate revenue, and we may never achieve profitability without obtaining marketing approval for additional indications</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">do not currently have nor do we plan to build or acquire the infrastructure or capability internally to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing processes of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which we may not be able to do on reasonable terms, if at all,, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new manufacturer maintains facilities </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We currently rely on third parties at key stages in our supply chain. For instance, the supply chains for our lead product candidate involves several manufacturers that specialize in specific operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a result, the supply chain for the manufacturing of our product candidates is complicated, and we expect the logistical challenges associated with our supply chain to grow more complex as our product candidates are further developed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers. We generally do not begin preclinical or clinical trials unless we believe we have access to a sufficient supply of a product candidate to complete such study. In addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have not yet engaged any manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, if approved, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party manufacturers&#8217; or suppliers&#8217; relevant operations, or if we are unable to enter into arrangements for the commercial supply of our product candidates, if approved, we will have no other means of producing our product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, to manufacture our product candidates in the quantities we believe would be required to meet anticipated market demand, our third-party manufacturers would likely need to increase manufacturing capacity and we may need to secure alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals. In addition, the development of commercial- scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels or in adequate quantities, if at all, the commercial launch of our product candidates, if approved, would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0.2pt;">product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our third-party manufacturers will be successful in establishing a larger-scale commercial manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition, there is no assurance that our third-party manufacturers will be able to manufacture our product candidates to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of such products or to meet potential future demand. Our failure to properly or adequately scale up manufacturing for commercial scale would adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third parties in the conduct of all of our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">currently do not have the ability to independently conduct clinical trials that comply with the regulatory requirements known as good laboratory practice, or GLP, requirements or GCP requirements, respectively. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting preclinical studies, clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result we may not be able to obtain regulatory approval in a timely fashion, or at all, for &#160; the applicable product candidate, our business, financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of product candidates for the treatment of the diseases and disorders for which we have research programs, including AD, dry AMD, PD and DLB. Companies developing therapeutics for similar indications include large companies with significant financial resources, such as AbbVie, AstraZeneca, Biogen, Celgene, Eli Lilly, GlaxoSmithKline, Johnson &amp; Johnson, Novartis, Pfizer, Roche, Sanofi and Takeda. In addition to competition from other companies targeting neurodegenerative indications, any products we may develop may also face competition from other types of therapies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early- stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of age-related degenerative diseases and disorders, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products &#160; that we may develop and commercialize. See &#8220;Risks Related to Our Intellectual Property.&#8221; The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates, if approved. Even if we obtain coverage for our product candidates, if approved, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates, if approved, or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved, and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly- approved products. In the United States, third-party payors, and governmental healthcare plans, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs &#160; and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially- reasonable revenue and profits.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad &#160; &#160;to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">currently do not have a marketing or sales organization. In order to commercialize our product candidates, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our product candidates or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">If <span style="letter-spacing:0.2pt;">our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We will have to comply with requirements concerning advertising and promotion for any future products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. We may not promote products for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">issue warning letters, untitled letters, or Form 483s;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">impose civil or criminal penalties;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">suspend or withdraw regulatory approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">suspend any of our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">refuse to approve pending applications or supplements to approved applications submitted by us;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">seize or detain products, or require a product recall.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from any future products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. The Centers for Medicare &amp; Medicaid Services, or CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. There have been significant ongoing efforts to modify or eliminate the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Affordable Care Act. For example, the Tax Act, enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code or the individual mandate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress that include aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which remain went into through 2031. &#160;The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The Inflation Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The Affordable Care Act, or ACA, has also been subject to challenges in the courts. In the most recent such challenge in June, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Under <span style="letter-spacing:0.2pt;">the Hatch-Waxman Act, a pharmaceutical manufacturer may file an ANDA seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA, under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#8217;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the Orange Book. If there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications a paragraph IV certification, challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. &#160;Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Accordingly, if we choose to develop a small molecule product candidate, and the product is approved, competitors could file ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">False </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Claims Act (which can be enforced through &#8220;qui </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">tam,&#8221; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or whistleblower actions, by private citizens on behalf of the federal government), prohibits </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">person from, among other </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">things, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly presenting, or causing to be presented false or fraudulent claims </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of government funds or knowingly making, using </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or causing to be made or used, a false record or statement material to an obligation to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">pay </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">money to the government or knowingly and improperly </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">avoiding, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreasing or concealing an obligation to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">pay </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">money to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">HIPAA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which imposes criminal liability and amends provisions on the reporting, investigation, enforcement,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">penalizing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;">for,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">among</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">things,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">willfully</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">executing, or attempting to execute, a scheme to defraud </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare benefit program, or knowingly and willfully</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">falsifying,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">concealing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">covering</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fact</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">materially</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statement, in connection with the delivery of, or payment </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare benefits, items or services by a healthcare benefit program, which includes both government and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">privately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funded benefits programs; similar to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal Anti-Kickback Statute, a person or entity does not need to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">have </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual knowledge of the statute or specific intent to violate it in order to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">have </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">committed a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">violation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations, including state anti-kickback and false claims </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">laws, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">apply to our business practices, including but not limited </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">to, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">payer, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including private insurers; state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government, or otherwise restrict payments that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be made to healthcare providers and other potential referral sources; and state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provided to healthcare professionals and entities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicare,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicaid,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Children&#8217;s</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Health</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Insurance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Program to report </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">annually </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to CMS information related to certain payments made in the preceding calendar year and other transfers of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; applicable manufacturers are also required to report such information regarding payments and transfers &#160;of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nurse-midwives</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">similar </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data protection and healthcare </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governing the privacy and security of personal data, including the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the European Union and European Economic Area (including with regard to health data</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">).</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical products. Further, defending against any such actions can be costly and </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">New <span style="letter-spacing:0.2pt;">income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions and results of operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti- &#160;money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our stock price may be volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">trading price of our common stock could be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. Since our common stock began trading on the Nasdaq Global Market on October 8, 2021, our stock has traded at prices as low as $0.90 per share and as high as $13.80 per share through March 22, 2024. In particular, the trading prices for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment, or results of our current and future preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and foreign countries;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems, especially in light of current reforms to the United States healthcare system;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success or failure of our efforts to acquire, license, or develop additional product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">innovations or new products developed by us or our competitors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, or capital commitments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, supply or distribution delays or shortages;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our relationship with manufacturers, suppliers, licensors, future collaborators, or other strategic partners;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achievement of expected product sales and profitability;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to obtain additional funding;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our stock by insiders and stockholders;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, product liability, or other litigation against us; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, including with respect to the financial markets in the United States and worldwide resulting from inflation, the COVID-19 pandemic and ongoing global and regional conflicts.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, the stock markets in general, and the markets for biopharmaceutical stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to comply with the auditor attestation requirements in the assessment of our internal control </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">over </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to comply with </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirement that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be adopted by the Public Company Accounting</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Oversight</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regarding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">firm</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rotation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supplement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">auditor&#8217;s report</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">about</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">reduced </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosure obligations regarding executive compensation in our periodic reports,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">proxy </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements and registration statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to hold a nonbinding advisory vote on executive compensation and stockholder </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">approval </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">golden parachute payments not previously</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="letter-spacing:0.2pt;">, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Under Section 107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we sell shares of our common stock in future financings, stockholders may experience dilution and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because we expect our expenses to increase significantly in the foreseeable future and because, based on our current business plans, we believe that our cash, cash equivalents, income from our non-dilutive grants, and net proceeds received from our March 2024 follow-on public offering will be sufficient for us to fund our operating and capital expenditures through May of 2025. As a result, we may from time to time issue additional shares of common stock or other securities to raise capital. These issuances may be at a discount from the current trading price of our common stock. Our stockholders would experience dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders will experience additional dilution and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">As of March 22, 2024, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates beneficially owned approximately 30% of our outstanding common stock. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions<span style="letter-spacing:0.2pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Sales <span style="letter-spacing:0.2pt;">of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. Sales of significant number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We have also registered or intend to register all shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be available for sale in the public market subject to vesting arrangements and exercise of options, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates may in the future establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">In December 2022, we filed a registration statement on Form S-3 relating to the registration of our common stock, preferred stock, debt securities, warrants, units and subscription rights or any combination thereof. Concurrently with the filing of such registration statement, we entered into an "at-the-market" offering program, or ATM, which provides for the offering, issuance and sale by us of up shares of our common stock from time to time for aggregate gross proceeds of up to $40 million in sales deemed to be &#8220;at-the-market&#8221; as defined by the Securities Act of 1933, as amended. For the period ended December 31, 2023, we sold 2,859,074 shares of its common stock pursuant to the ATM for gross proceeds of approximately $5.3 million. For the period ended December 31, 2023, the Company sold 125,000 shares of common stock to Lincoln Park for proceeds of $0.2 million, as part of the equity line financing arrangement. As of December 31, 2023, $34.8 million was available to draw pursuant to the Purchase Agreement. Any additional sale or issuance of securities pursuant to this registration statement or otherwise may result in dilution to our stockholders and may cause the market price of our stock to decline. Furthermore, new investors purchasing securities that we may issue and sell in the future could obtain rights superior to the rights of our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We are also authorized to grant stock options and other equity-based awards to our employees, directors and consultants pursuant to our 2021 Equity Incentive Plan. The number of shares available for future grant under the 2021 will automatically increase each year by up to 5% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors or compensation committee to take action to reduce the size of the increase in any given year. Currently, we plan to register any increase in the number of shares available for issuance under the 2021 Plan promptly following the effectiveness of any such increase. If our board of directors elects to increase the number of shares available for future grant under the 2021 Plan, our stockholders may experience additional dilution, and our stock price may fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">of December 31, 2023, we had federal net operating loss, or NOL, carryforwards of approximately $29.8 million and state NOL carryforwards of approximately $12.1 million available to offset future taxable income. Of the federal NOL carryforwards, $11.5 million begin to expire in 2035, and $18.3 million can be carried forward indefinitely. State NOL carryforwards will begin to expire in 2028. As of December 31, 2023, we also had $2.9 million of federal research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2029, if not utilized. Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the &#8220;ownership change&#8221; provisions under Sections 382 and 383 of the Code. An &#8220;ownership change&#8221; is generally defined as a cumulative change in the ownership interest of significant stockholders over a rolling three-year period in excess of 50 percentage points. Similar provisions under state tax law may also apply. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or credits if we undergo a future ownership change. We may experience an ownership change in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. Such ownership changes could result in the expiration of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">our NOL carryforwards and other tax attributes before they can be utilized and, if we are profitable, our future cash flows could be adversely affected due to our increased tax liability. In 2023 we completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $0.6 million of federal net operating loss carryforwards expiring unutilized. We updated the analysis through December 31, 2023 and determined that it is more-likely-than-not that our existing net operating loss and research and development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additionally, under the Tax Cuts and Jobs Act, or the TCJA, NOL carryforwards arising in tax years beginning after December 31, 2017 are limited to 80% of taxable income, and may be carried forward indefinitely and are prohibited from being carried back. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, allowed federal NOL carryforwards arising in tax years beginning after December 31, 2017 and before January 1, 2021 to be carried back to each of the five tax years preceding the tax year of such loss and temporarily suspends the 80% limitation mentioned above for this period. The changes in the carryforward and carryback periods as well as the limitation on use of NOL carryforwards may significantly impact our ability to use NOL carryforwards, particularly for tax years beginning after December 31, 2023, as well as the timing of any such use, and could adversely affect our results of operations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">third amended and restated certificate of incorporation and second amended and restated bylaws each contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the exclusive right of our board of directors to elect a director to fill a vacancy, however occurring, including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of our board of directors to alter our second amended and restated bylaws without obtaining stockholder approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the required approval of at least </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;">6</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">2</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8725;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;">3</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">%</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">of the shares entitled to vote at an election of directors to adopt, amend or repeal our second amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law, or the DGCL. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our third amended and restated certificate of incorporation and second amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">third amended and restated certificate of incorporation and second amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our third amended and restated certificate of incorporation or our second amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our third amended and restated certificate of incorporation and second amended and restated bylaws, however, provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. The Supreme Court of Delaware has held that this type of exclusive federal forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce this provision, if applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision contained in our third amended and restated certificate of incorporation and second amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it</span>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic or political conditions has in the past and could in the future adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0.2pt;">business is susceptible to general conditions in the global economy and in the global financial markets. Further, the impacts of political unrest, including as a result geopolitical tension, such as a deterioration in the relationship between the United States and China or the conflicts between Russia and Ukraine and Israel and Hamas, including any additional sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries against governmental or other entities in, for example, Russia, also has in the past and could in the future lead to disruption, instability and volatility in the global markets, which may have an adverse impact on our business or ability to access the capital markets. A severe or prolonged economic downturn, including rises in interest rates, liquidity constraints, failures and instability in the United States and international financial banking systems, inflation, recession or depression, or political disruption has and could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Key national economies, including the United States, have been affected from time to time by economic downturns or recessions, supply chain constraints, heightened and fluctuating inflation and interest rates, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies and overall uncertainty with respect to the economy. In particular, in relation to uncertainty around inflation and the U.S. Federal Reserve&#8217;s measures to slow inflation, the stock market has been exceptionally volatile. &#160;In addition, U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the United States. The impact of this or any further downgrades to the U.S. government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"><span style="background:#ffffff;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. &#160;In March 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. &#160;Similarly, in March 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Since then, additional financial institutions have experienced similar failures and have been placed into receivership. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. &#160;These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. &#160;Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. &#160;Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The <span style="letter-spacing:0.2pt;">trading market for our common stock may be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred, and will continue to incur, significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, which could result in sanctions or other penalties that could materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">have incurred, and will continue to incur, significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We are subject to Section 404 and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are deemed to be a large accelerated filer or an accelerated filer, we will be required to include an attestation report on internal control over financial reporting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we identify any material weaknesses, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could materially and adversely affect our business, financial condition, results of operations and prospects, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs and other third parties to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Market or other adverse consequences that would materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred, and will continue to incur, increased costs and demands upon management as a result of being a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">a public company listed in the United States, we incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and The Nasdaq Stock Market LLC, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b9f119e6_4311_4c3e_9a19_b76bca4cf40a"></a><a id="Item1BUnresolvedStaffComments_685711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0d248ac9_e969_495d_b08d_49b4c88c7995"></a><a id="Item1CCybersecurity_492794"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1C. Cybersecurity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cyber Risk Management and Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. has implemented and maintains an enterprise risk management program that includes processes designed to identify, assess, and mitigate cybersecurity risks. &#160;These processes include the deployment of third-party security solutions and tools designed to monitor, identify, and address cybersecurity risks. &#160;We engage a third-party information technology advisor to support our cyber risk management efforts and, periodically, we engage additional third-party consultants for penetration testing and threat simulation exercises. &#160;We also maintain processes to assess and review the cybersecurity practices of third-party vendors and service providers prior to onboarding, including through review of System and Organization Controls (SOC) reports provided by potential vendors and inclusion of security requirements in contracts, as appropriate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk160105269"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. &#160;Although such risks have not materially affected, and we do not believe they are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats related to our data and systems, including phishing attacks. &#160;For more information about risks from cybersecurity threats, see the risk factor entitled &#8220;Significant disruptions of information technology systems and infrastructure, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition&#8221; included in Item 1A &#8220;Risk Factors.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Governance Related to Cybersecurity Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our cyber risk management program and related operations and processes are managed by the Chief Financial Officer in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Corporate Controller reports to and meets with the Chief Financial Officer periodically to discuss and review risk management processes related to cybersecurity and potential cybersecurity risks, with input from the Company&#8217;s third-party information technology advisor as appropriate. &#160;The Chief Financial Officer reports on a quarterly basis to the audit committee, which oversees cybersecurity risks pursuant to the audit committee charter. The audit committee is responsible for discussing cybersecurity-related risks with management, including the steps management has taken to monitor and control such risks, including our risk assessment and risk management policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Chief Financial Officer and the audit committee periodically report on cybersecurity risk management to the board of directors. The board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the board of directors has the responsibility to confirm that the risk management processes designed and implemented by management are appropriate and functioning as designed.</p><a id="_a5b4859a_e175_4808_96f3_3fedc661c3a2"></a><a id="Item2Properties_347022"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. We lease approximately 6,686 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9ade5d1e_a074_4bd7_939d_8f20c2446774"></a><a id="Item3LegalProceedings_272268"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We are not aware of any pending legal actions that would, if determined aversely to us, have a material adverse effect on our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We may, from time to time, become involved in disputes and proceedings arising in the ordinary course of business. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations, and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b5594b92_a8fc_4224_94d5_2f9e6df51610"></a><a id="Item4MineSafetyDisclosures_494562"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_331600"></a><a id="_29e07427_fe31_4a46_adda_59f648082019"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our common stock began trading on the Nasdaq Global Market under the symbol &#8220;CGTX&#8221; on October 8, 2021. Prior to that time, there was no public market for our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of March 22, 2024, there were approximately 39,000,152 shares of our common stock outstanding held by approximately 277 holders of record. The actual number of holders of our common stock is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We have never declared or paid any cash dividends on our common stock, and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Our future ability to pay cash dividends on our common stock may be limited by any future debt instruments or preferred securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Information about our equity compensation plans is incorporated herein by reference to Item 12, <i style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i>, of this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">There were no unregistered sales of our equity securities during the fiscal year ended December 31, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer or Affiliated Purchaser</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">We did not purchase any of our registered equity securities during the fiscal year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On October 13, 2021, we completed our IPO. Our registration statements on Form S-1 (File Nos. 333-257999 and 333-260128), each relating to the IPO were declared effective by the SEC on October 7, 2021. We issued 3,768,116 shares of our common stock at a price of $12.00 per share for aggregate net cash proceeds of $37.9 million, after deducting underwriting discounts and commissions and other offering related costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On November 10, 2021, the Representative provided notice to us that it had elected to exercise its over-allotment option in full to purchase 565,217 shares of our common stock. The Representative&#8217;s exercise of the over-allotment option closed on November 12, 2021, resulting in net proceeds of $6.3 million to us, after deducting underwriting discounts and commissions and other offering related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus dated October 7, 2021, filed with the SEC pursuant to Rule 424(b) under the Securities Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a1f0643c_d2da_46f5_9872_c25685bad995"></a><a id="Item6SelectedFinancialData_500456"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;6. [Reserved].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47c94969_c53a_4ac6_adb5_dcf01bcbaafb"></a><a id="_643054"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under Item 1A, Risk factors, in this Annual Report on Form 10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. Currently available therapies for these diseases are limited, with few Alzheimer&#8217;s disease (&#8220;AD&#8221;) treatments, two approved treatments for geographic atrophy (GA) secondary to dry age-related macular degeneration (&#8220;dAMD&#8221;) and no approved treatments for dementia with Lewy bodies. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the &#963;-2 (sigma-2) receptor (&#8220;S2R&#8221;), which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. Recent clinical results support this hypothesis. In the SNAP study, results of which were published in May 2023 in the journal, Translational Neurodegeneration and showed that a single oral dose of CT1812 rapidly displaces A&#946; oligomers from synapses of individuals with AD. In the SEQUEL study, top-line results showed that four weeks of treatment with CT1812 improved synapse activity and connectivity of brain regions as measured via quantitative electroencephalogram (&#8220;qEEG&#8221;). Together, these findings provide evidence that the displacement of oligomers from synapses via CT1812 engagement with the S2R results in improved synapse function. In blinded and unblinded clinical trials, several patients experienced asymptomatic, reversible elevations in serum liver chemistries prompting harmonization of monitoring, increasing frequency where appropriate, across our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2007, we have incurred significant operating losses and devoted substantially all of our time and resources to developing our lead product candidate, CT1812, building our intellectual property portfolio, raising capital and recruiting management and technical staff to support these operations. As of December 31, 2023, we had an accumulated deficit of $141.2 million. We incurred net losses of $25.8 million and $21.4 million for the years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the National Institute of Aging (the &#8220;NIA&#8221;), a division of the National Institutes of Health (the &#8220;NIH&#8221;), and proceeds from our initial public offering (the &#8220;IPO&#8221;), completed in October 2021, proceeds from our follow-on public offerings in November 2022 and March 2024, sales of our common stock through our ATM (as defined below), sales of our convertible promissory notes, convertible preferred stock, simple agreements for future equity (&#8220;SAFE&#8221;) and stock option exercises. Since our inception, we have received approximately $171.0 million in cumulative grant awards to fund our clinical trials, primarily from the NIA, and we have raised approximately $124.5 million in net proceeds from sales of our equity securities, convertible notes, SAFE, stock option exercises, IPO, follow-on public offerings, ATM, and equity line financing with Lincoln Park. As of December 31, 2023, we had cash and cash equivalents of $29.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 13, 2021, we completed our IPO, pursuant to which we issued and sold 3,768,116 shares of our common stock at a public offering price of $12.00 per share. Additionally, on November 12, 2021, the underwriters exercise of their over-allotment option in full to purchase 565,217 shares of our common stock closed. In connection with the IPO, we received net proceeds of approximately $44.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us, which includes net proceeds of approximately $6.3 million from the exercise of the over-allotment option.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 15, 2022, we completed our follow-on public offering, pursuant to which we issued and sold 5,000,000 shares of our common stock at a public offering price of $1.20 per share. In connection with the follow-on public offering, we received net proceeds of approximately $5.2 million, after deducting underwriting discounts and commissions and other offering related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2022, we entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by us of up to $40 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings (the &#8220;ATM&#8221;). For the period ended December 31, 2023, we sold 2,859,074 shares of its common stock pursuant to the ATM for gross proceeds of approximately $5.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2023, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Lincoln Park Purchase Agreement&#8221;). The Lincoln Park Purchase Agreement provides that, subject to the terms and conditions set forth therein, we have the right, but not the obligation, to direct Lincoln Park to purchase up to $35 million of shares of common stock at our sole discretion, over a 36-month period commencing on March 10, 2023. We filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that are issued under the Lincoln Park Purchase Agreement. During the year end December 31, 2023, we sold 125,000 shares of common stock to Lincoln Park for proceeds of $0.2 million, as part of the equity line financing arrangement. As of December 31, 2023, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On March 14, 2024, we completed our follow-on public offering, pursuant to which we issued and sold 6,571,428 shares of our common stock at a public offering price of $1.75 per share. In connection with the follow-on public offering, we received net proceeds of approximately $10.4 million, after deducting underwriting discounts and commissions and other offering related expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We do not own or operate manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of CT1812 for preclinical studies and clinical trials, as well as for commercial manufacture if CT1812 obtains </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">marketing approval. We also rely, and expect to continue to rely, on third parties to manufacture, package, label, store, and distribute CT1812, if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of CT1812.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Impact of COVID-19 on Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">Our business has been and could be adversely affected by the effects of the COVID-19 pandemic or other national health issues. For example, our ongoing and/or planned clinical trials may be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory authorities. Additionally, we have made certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA and may need to make further adjustments in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">While the potential further economic impact brought by the COVID-19 pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. As a result, we may face difficulties raising capital through future sales of our common stock or such sales may be on unfavorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of direct and indirect costs incurred for our research activities, including development of our drug discovery efforts and the development of our product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities, and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. Product candidates in later stages of development generally have higher development costs than those in earlier stages. We expect that our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, as we expand our product pipeline, as we maintain, expand, protect and enforce our intellectual property portfolio, and as we incur expenses associated with hiring additional personnel to support our research and development efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, finance and accounting, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase for the foreseeable future as we increase our headcount to support our continued research activities and development of our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Grant income relates to the grants awarded from governmental bodies that are conditional cost reimbursement grants and are recognized as grant income as allowable costs are incurred and the right to payment is realized. The grants awarded relate to agreed upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and /or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. As of December 31, 2023, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension. Our clinical trials have been funded by approximately $171.0 million in cumulative grants awarded primarily by the NIA, which includes an approximately $81.0 million grant from the NIA to fund our Phase 2 (COG0203) study of CT1812 in patients with early-stage AD, an approximately $30.5 million grant from the NIA to fund our Phase 2 (COG0201) study of CT1812 in patients with mild-to-moderate AD, and an approximately $29.5 million grant from the NIA to fund our Phase 2 (COG1201) study of CT1812 in patients with dementia with Lewy bodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Interest expense for the years ended December 31, 2023 and 2022 consisted of interest expense related to the insurance premium financing arrangement with a lender.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Income (Expense), Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists primarily of interest income from money market funds, other fees such as offering costs incurred to establish our equity line financing, as well as foreign currency transaction gains or losses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Years Ended December 31, 2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our results of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations Data: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,196</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,872</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,528</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,227</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 301</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,551</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,173</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (50,724)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (43,551)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,173)</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,805</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,217</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,588</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 158</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 193</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,936</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,154</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,782</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,788)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (21,397)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,391)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our research and development expenses (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,398</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,481</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,712</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,503</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,178</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,325</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,890</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,661</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,771)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 430</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 222</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 208</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total research &amp; development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,196</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,872</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $37.2 million for the year ended December 31, 2023, compared to $30.3 million for the year ended December 31, 2022. The increase of $6.9 million was primarily due to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $5.4 million in clinical programs primarily related to increased Phase 2 trial activities with contract research organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $1.7 million in personnel costs associated with expanded research and development activities, and equity-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $1.5 million in preclinical programs, and other expense primarily due to increased research spend; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $1.7 million in manufacturing related to lower costs with contract manufacturing organizations for the production of pre-clinical and future clinical trial supply.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $13.5 million for the year ended December 31, 2023, compared to $13.2 million for the year ended December 31, 2022. The increase of $0.3 million was primarily due to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.6 million in equity-based compensation from stock option grants and restricted stock unit (&#8220;RSU&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.3 million in compensation and employee benefits driven by increased headcount;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.2 million in professional fees driven by decreased audit, tax, and legal services; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.4 million in Director &amp; Officer liability insurance and other expenses. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Grant income was $24.8 million for the year ended December 31, 2023, compared to $22.2 million for the year ended December 31, 2022. The change in grant income is correlated with the increase in eligible reimbursable costs related to clinical trials incurred during 2023 as compared to 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Income (Expense), Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other income, net was $0.2 million for the year ended December 31, 2023, compared to other expense, net of less than $0.1 million for the year ended December 31, 2022. The change in other income (expense), net was driven primarily by interest earned on money market funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Interest expense was less than $0.1 million for the year ended December 31, 2023, compared to interest expense of less than $0.1 million for the year ended December 31, 2022. Interest expense was not significant in either period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the NIA, and proceeds from the sales of our convertible promissory notes, convertible preferred stock, SAFE, stock option exercises, follow-on equity offerings, sales under our ATM and equity line financing, and our IPO. Since our inception, we have received grant awards primarily from the NIA in the aggregate amount of approximately $171.0 million and have raised approximately $124.5 million in net proceeds from sales of our equity securities, convertible notes and SAFE, stock option exercises, our ATM, our equity line financing with Lincoln Park, our IPO and our follow-on public offerings. The net proceeds from our IPO, which closed on October 13, 2021, were approximately $44.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On November 15, 2022, we closed our follow-on public offering, selling 5,000,000 shares of our common stock at a public offering price of $1.20 per share. The net proceeds were approximately $5.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On December 23, 2022, we entered into a sales agreement with the Sales Agents, providing for the offering, issuance and sale by us of up to $40 million of our common stock from time to time in ATM offerings. As of December 31, 2023, we sold 2,859,074 shares of common stock under the ATM for gross proceeds of approximately $5.3 million. As of December 31, 2023, there was $34.7 million of common stock remaining available for sale under the ATM. In addition, in March 2023, we entered into the Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, giving the Company the right, but not the obligation to sell to Lincoln Park up to $35 million worth of shares </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">of our common stock. During the year ended December 31, 2023, we sold 125,000 shares of common stock to Lincoln Park for proceeds of $0.2 million, as part of the equity line financing arrangement. As of December 31, 2023, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement. On March 14, 2024, we closed our follow-on public offering, selling 6,571,428 shares of our common stock at a public offering price of $1.75 per share. The net proceeds were approximately $10.4 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">As of December 31, 2023, we had $29.9 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, income from non-dilutive grants, and net proceeds from our March 2024 follow-on public offering will be sufficient for us to fund our operating expenses and capital expenditures requirements through May of 2025, which assumes no usage from the remaining ATM nor the Lincoln Park Purchase Agreement. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company. We anticipate that we will need to raise additional funding in the future to fund our operations, including the commercialization of any approved product candidates. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 20.15pt;">Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, costs and results of our ongoing and planned clinical trials of CT1812, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to a pandemic, such as the COVID-19 pandemic, or other diseases, macroeconomic conditions, global or political instability, such as the ongoing global and regional conflicts, inflation, or other delays;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we develop, in-license or acquire other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, timing, and receipt of any future NIA grants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations to commercialize CT1812 or any of our other product candidates outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Until such time as we can generate significant revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the effects of the COVID-19 pandemic or other diseases, the ongoing global and regional conflicts, inflation, liquidity constraints, failures and instability in U.S. and international financial banking systems, and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our cash flows for the periods indicated (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,018)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18,533)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (147)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (171)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,521</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,546</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,640)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,159)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Net cash used in operating activities for the year ended December 31, 2023 was $16.0 million, which consisted primarily of our net loss of $25.8 million partially offset by net non-cash charges of $5.0 million and a net change of $4.8 million in our operating assets and liabilities. The non-cash charges primarily consisted of $0.3 million of other expense related to the Lincoln Park Purchase Agreement, amortization of right-of-use assets and other depreciation and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">amortization of $0.3 million, and equity-based compensation of $4.4 million. The net change in our operating assets and liabilities was primarily due to an increase in grant receivables of $2.4 million, an increase in prepaid expenses and other assets of $1.8 million, an increase in accounts payable and accrued expenses of $2.4 million, partially offset by a decrease in deferred grant income and other liabilities of $1.6 million, and a decrease of $0.1 million of operating lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2022 was $18.5 million, which consisted primarily of our net loss of $21.4 million partially offset by net non-cash charges of $3.8 million and a net change of $0.9 million in our operating assets and liabilities. The non-cash charges primarily consisted of depreciation and amortization of less than $0.1 million, amortization of right-of-use assets of $0.2 million, and equity-based compensation of $3.6 million. The net change in our operating assets and liabilities was primarily due to an increase in grant receivables of $1.9 million, an increase in other assets of $1.7 million, a decrease in accounts payable of $1.1 million, partially offset by an increase in deferred grant income and other liabilities of $2.6 million, and a decrease of $0.9 million of prepaid expenses, other current assets, and other receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2023 and 2022, we used $0.1 and $0.2 million of cash, respectively, for investing activities related to purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $4.5 million and $5.5 million for the years ended December 31, 2023 and 2022, respectively. The change in net cash provided by financing activities is primarily related to net proceeds from the issuance of common stock under the ATM program and sale of common stock pursuant to the Lincoln Park Purchase Agreement during the year ended December 31, 2023 as compared to the proceeds from the issuance of common stock in our November 2022 follow-on public offering in the amount of $5.3 million during the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Contractual Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our contractual obligations as of December&#160;31, 2023 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less&#160;than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3&#160;to&#160;5</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More&#160;than&#160;5</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 221</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 377</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 810</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 221</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 377</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 810</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we entered into an insurance premium financing arrangement with a lender. Under the agreement, we financed $0.8 million of certain premiums at a 6.85% annual interest rate. Payments of less than $0.1 million are due monthly from October 2022 through September 2023. As of December 31, 2023, there was no remaining outstanding principal on the loan. In October 2023, we entered into an insurance premium financing arrangement with the same lender whereby we financed $0.7 million of certain premiums at a 8.65% annual interest rate. Payments of less than $0.1 million are due monthly from October 2023 through September 2024. As of December 31, 2023, the outstanding principal of the loan was $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have entered into operating leases for office and laboratory facilities under agreements that run through May 31, 2029. The amounts reflected in the table above consist of the future minimum lease payments under the non-cancelable lease arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, we entered into an agreement to lease 2,980 square feet of office space in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. The annual base rent under the lease is less than $0.1 million throughout the term of the lease. Total payments due over the term of the lease are $0.2 million. Additionally, on August 31, 2022, we modified one of our existing lease agreements with the landlord for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On July&#160;1, 2021, we entered into an agreement to lease 2,864 square feet of office space in Purchase, New York. The lease has a term of 89 months and commenced on December 9, 2021. The annual base rent under the lease is less than $0.1 million for the first lease year and is subject to annual increases of between 1.82% and 2.04%. We provided a security deposit in the form of a Letter of Credit in the amount of less than $0.1 million pursuant to the terms of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development and other services and products for operating purposes. These contracts typically do not contain minimum purchase commitments and generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable advance payments for research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We maintain an equity-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for stock options subject to time-based vesting on a straight-line basis over the requisite service period and account for forfeitures as they occur. To the extent any stock option grants are made subject to the achievement of a performance condition, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Term. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The expected term represents the period that the stock-based awards are expected to be outstanding. As we do not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk-Free Interest Rate. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Volatility. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Dividend Yield. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The expected dividend yield is zero as we have not paid and do not anticipate paying any dividends in the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Fair Value of Common Stock. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors has determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">See Note&#160;9 to our audited financial statements for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the total unrecognized compensation expense related to unvested time-based vesting awards was $4.3&#160;million, which is expected to be recognized over weighted-average remaining vesting period of approximately 1.6&#160;years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">For a description of recent accounting pronouncements, see Note&#160;2 of the notes to our audited consolidated financial statements for the&#160;year ended December&#160;31, 2023 included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in annual revenue; (2) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our IPO.</p><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As a &#8220;smaller reporting company,&#8221; as that term is defined in Rule 229.10(f)(1), we are not required to provide the information required by this Item. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a52e1a1e_a274_47ee_8af2_a68ca40863eb"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk130366833"></a><a id="_73c32d2d_474a_4e8d_9c73_10f8d1552bdf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Index to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">As of and for the years ended December 31, 2023 and 2022</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentAccountingFirm"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID 42)</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">120</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofStockholdersEquity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">121</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">122</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_63e13730_5e25_4186_ad84_27467de8dea7"></a><a id="ReportofIndependentAccountingFirm"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">To the Shareholders and the Board of Directors of Cognition Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Cognition Therapeutics, Inc. and subsidiary (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">March 26, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d9ceaa26_9653_479b_a25f_e3fb4a036d93"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="ConsolidatedBalanceSheets"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_54f3b420_0b09_47cd_9448_1231a4edc769"></a><a id="Tc_Dx0ytB2Su0yLv6s_JSHSMg_2_2"></a><a id="Tc_AIPMCOp1U0ip29QXKvcm7w_3_2"></a><a id="Tc_NLxkBRC3BEaVY2cV5-Exrw_3_5"></a><a id="Tc_PDU7yrRoB0WZxkGjz0ZREw_4_0"></a><a id="Tc_E2hM-L0XbUqavGX_548zlA_5_0"></a><a id="Tc_udDhLDi-R0WZkgzedjUK_A_6_0"></a><a id="Tc_YWzwnkfP8kqJfT2TwU3h5g_6_2"></a><a id="Tc_gkj_nZgN2kOkGryBYMo8fw_6_5"></a><a id="Tc_Pyv7CJt4skuBPEVY0WZ3sg_7_0"></a><a id="Tc_6Pe3amNkN0iGeFaMtFEqTQ_8_0"></a><a id="Tc_FjlVBU65pUWJ1uOgSoH1dg_9_0"></a><a id="Tc_fasLPbYDRkaWr1S05azhRQ_10_0"></a><a id="Tc_KhpcVYPI-EebDh0I1Mot7A_11_0"></a><a id="Tc_N4TAj8wN00auEFOT11Sj-w_12_0"></a><a id="Tc_BJJBjGRlXU6kO-iivWWK8A_12_3"></a><a id="Tc_1cvz-rfl9UW0jovWuSM3vw_13_0"></a><a id="Tc_4CviwJ0AS0C1dPILo7W00Q_13_2"></a><a id="Tc_DNTmN3gDK0Klw-i2MbmSlg_13_5"></a><a id="Tc_OIauR8iZbkmyqY4vSYDQbw_14_0"></a><a id="Tc_QlOPtHqitEuivx2bXnOjCw_15_0"></a><a id="Tc_pCxdvx9Py0qK4fVfNtFH7g_16_0"></a><a id="Tc_ysK8KNeDME6RYdg74RxydA_17_0"></a><a id="Tc_JuruSQ4COEmILlrgZUG8pg_18_0"></a><a id="Tc_Hf35wZE2WEqwPGpS29_kew_19_0"></a><a id="Tc_GCN3BOA9CUK2KvN5lowbrw_20_0"></a><a id="Tc_7_9KwGpbY0mY6797Wpe8mQ_21_0"></a><a id="Tc_gI_Tcn-XnkypwSjB4pdk8w_22_0"></a><a id="Tc_6AULSjjtyk6HRh9kKbYMCw_23_0"></a><a id="Tc_DwnWpn8Q6UepjMpcmREroQ_23_3"></a><a id="Tc_ae2QdoKpTUeDEFikNzwQFA_24_0"></a><a id="Tc__axRrMLsp0O_OpNSG36WsA_25_0"></a><a id="Tc_Bswc-Umgu06sAtmmyAmeyA_26_0"></a><a id="Tc_5eHvLsQ7A0ysTKONHtRZJw_27_0"></a><a id="_145dec51_a9c8_448e_a961_684cfd97c27a"></a><a id="_145dec51_a9c8_448e_a961_684cfd97c27a_2"></a><a id="_145dec51_a9c8_448e_a961_684cfd97c27a_3"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682_2"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682_3"></a><a id="Tc_MZxKq7Wi1UybZTkwHLFIGw_28_0"></a><a id="Tc_ui1X82mv7ESCDPx9nnGyHw_29_0"></a><a id="Tc_kDLkiO2FPUe1Qg6ULrkmnw_30_0"></a><a id="Tc_P1YGGlgH3kqkz5qeN3Jz_Q_31_0"></a><a id="Tc_PRzZ460ddECsg8H-QCqJ8w_32_0"></a><a id="Tc_hoM-FyyqCkORayxpySguKA_33_0"></a><a id="Tc_aX1D_nLh5kCERK6VarHJgw_33_2"></a><a id="Tc_H3xPazqczEmfQcFm9fkVGg_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_MOcDkXnBxkqfMhvJDBNQTg_6_3">29,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_IWOlK7-ypUWbfyv87A4kGQ_6_6">41,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Grant receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="3" id="Tc_E9dmQ0EEWkSDnK8fE5MTVw_7_3">1,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="3" id="Tc_dw90dcTthEK_mDpaPiLYnA_7_6">3,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_dARMVzMfBUyaHNoScPpo0g_8_3">3,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_LonoXukVh0OsRHIn8Yn5Ow_8_6">2,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_cqSllIZrlk-UPaTEYf8q8Q_9_3">34,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_b1UPSTMRQkyL4pAWr54m3w_9_6">47,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_uXvQ99vzskCWqhNTeYBidA_10_3">284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_LG0cryLF_U6RplTW_XBXkg_10_6">233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_fMENXkkZU0G8tn8lphm8jA_11_3">657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_IHq4W_fHSkehfDvzapBrvA_11_6">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="3" id="Tc_EF6nB8BRUEK_1IvVh1ih1w_12_6">1,732</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_siRN156ewU2dkx3JGGm99g_13_3">35,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Xcsz2J-9aEOtYxg7Hq5r9w_13_6">50,425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_54UG9MiwMUemkQFuJznzSw_16_3">3,695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_VG33qMofNEeUQdv2p8GS-Q_16_6">3,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_kVDGjV02zka7WFPH0kDGBQ_17_3">4,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_u7AjXRer7Uy5NLc1LDTzNA_17_6">2,094</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Deferred grant income, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Tc_uTzy5mns70C3whMxSYRpgg_18_3">1,701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Tc_KZess_vOIUuuGPF7IO6YaQ_18_6">1,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ACMlXgnA_EuYYQUGz8o0JQ_19_3">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_kIXkIi0zXEmwpgp8p6og-g_19_6">149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_nSjazw9B2kW6EmGtQR0gRA_20_3">544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_fpl9UEOfbE-kZd8NfFz4Xw_20_6">634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_R37irfA3QUO3ZWD406MyAw_21_3">10,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_REHBo4NAQkKoNc5BTuMonA_21_6">7,795</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_K6h04P_fAESd_9p3fqjlNg_22_3">520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_PxVKbY7saU29JMF4Kwx5bQ_22_6">695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Deferred grant income and other liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_DiEk4gsQYk6qd4VOPWQV1g_23_6">1,686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_xYw2CKaC5kil-puoe_8ZhA_24_3">10,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Gni-uHJQCEaQiIldLoZH1A_24_6">10,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_tV_uk0LW4EqTfCgSy3AXIA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_R7Q4kBy1O0yJSaklxHLXkg">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_VJh_hDPTb0uzTVMzUZj1ug"><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_IDluKXgQ5EaH2aWjd5a2Ag">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; no shares issued and outstanding at December&#160;31,&#160;2023 and December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_bNPKjeMogkiRwabi4DnToA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_x_0-tty1qkCdgZ8MygWwoA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9pt;">Common stock, </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_0SBDRX_atEGLrSA2qH0JmA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_tBBoEXIKk0Gnhg6bn-A5Ew">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> par value, </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_kJ3c7pJMTkKfbZ1MUwWOyQ"><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_tO5kEOr0zkeyJ7tQuMdCZg">250,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_NrrQ2BzquEypUnJnfcf-jQ">32,165,478</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_heGMF26E2k2f7mpxmkAjoQ">28,991,548</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_crfbz-8nX0uPcYlZLZkBoA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_z0-6MhzaqEi07JiIaYImxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_JA7gicFC3UqJ1utnWEg6tw_28_3">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_NA--BCdb0E2pr08GYMY5MQ_28_6">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_impE8gmj5UWtZrQ55NDidA_29_3">165,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Gy30Ahk_jU6I1C6erql5wA_29_6">155,820</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_mpSeZ5BxFkqYPanELEEQgA_30_3">141,189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_cBTwBWEpOE2DLHKQP787lw_30_6">115,401</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_IIk3kWQFkESyS9KrhmfJpw_31_3">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_dXuOM9_gqEWaQ9JBQeAxhw_31_6">199</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OfNub9GHYEqjcab0E4gSfg_32_3">24,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wd4JmzjkQkSMJA4fm6ssFQ_32_6">40,249</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_XkwUxpBSXUSyr4W4MVKuQw_33_3">35,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_DGIbykuXkU-Z54ovQ7DLHg_33_6">50,425</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb76aa09_bcae_433f_9cf5_b4b970357d3b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="StatementsofOperations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_cbd2e53e_0778_4387_a69a_47f92c968321"></a><a id="Tc_X9da8UqcOkCRQtploPG9iw_1_3"></a><a id="Tc_CcSP5IqIcEWZ3QFWvDuWuA_2_3"></a><a id="Tc_Id6C_0BfEESn0zYVAO1cEQ_3_3"></a><a id="Tc_DihYxjVar0SqPLGLYJpEow_3_6"></a><a id="Tc_mrI3_IVgD02vDBKCGopfHw_4_0"></a><a id="Tc_kmybVFMm40etzo3gOl3hwA_5_0"></a><a id="Tc_cGz-B5zlqUaRL2KSQmzjOw_5_3"></a><a id="Tc_8FwZUeqda0Ks8SaRx6aR0A_5_6"></a><a id="Tc_S3HnKCB6gU2V2Npu94Dx-g_6_0"></a><a id="Tc_KSjRujSTpUyyHZIKJoI7Dw_7_0"></a><a id="Tc_DISXJjpUSU6zAcctJ7cw_w_8_0"></a><a id="Tc_YbCG4rb25UGBckITi7MDEQ_9_0"></a><a id="Tc_ACqSwYl6AEG6MkIDvE6WiQ_10_0"></a><a id="Tc_Z1B0fBLPW0ywXulelc5pGQ_11_0"></a><a id="Tc_ojbJyAbLmkOZ2anASzVIfw_12_0"></a><a id="Tc_2g2lP_tKoEiQL75a633UMA_13_0"></a><a id="Tc_8OO1BQb5xU60VBCsWK5Lzg_14_0"></a><a id="Tc_dJx9OCXgJkulP_jePAXoOg_15_0"></a><a id="Tc_0joStuk6b0KF-to5OnSCaw_16_0"></a><a id="Tc_1pV2QNN5fkqgStwn7hciuw_16_3"></a><a id="Tc__PbyrZqDfkGwDsAWAwIENQ_16_6"></a><a id="Tc_NUCPSGOAL0aDo0g-N6r5Iw_17_0"></a><a id="Tc_yNPYPpJank28ylIO70XfLA_18_0"></a><a id="Tc_XV1wP88NEUq9aGFZwC1A1A_18_3"></a><a id="Tc_K2I0sxvizUqSp_v2rqwvDw_18_6"></a><a id="Tc_XKVbPt_yEEGD6gjmX7WqmA_19_0"></a><a id="Tc_cOnnhRLvJkOG9Wz37Ixp8A_19_3"></a><a id="Tc_P071oDFDMkm9ma5_se-WJQ_19_6"></a><a id="Tc_IDXkzL-F8UOFXkzQknMkfw_20_0"></a><a id="Tc_4j8QiVlSC0Or8B46aYwsJw_21_0"></a><a id="Tc_-IFXcpk-z0yRwX3_xph86Q_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the&#160;Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_5Uwg0j81O0-F43HcHeoH0g_5_4">37,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_dpbr-_hX-UuR_U1fNfUrYQ_5_7">30,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Jz3NNYNBaEC_FNpsUrApGw_6_4">13,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_z7m4Stbt_ku125bnu5-_mw_6_7">13,227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_u4EOaW11CEyFw5_99k8lyw_7_4">50,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_ShpadbYV5E240hpJR1q6yg_7_7">43,551</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_X1q-IrAfMUaTYtO6K7UhIg_8_4">50,724</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_CYOVA9tYVEqrd4dImVaYzg_8_7">43,551</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Tc_6ZTsdvGRfEG2FV3b7FUFAQ_10_4">24,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Tc_LA-ZHOM-E0SqFPf7AhgGdQ_10_7">22,217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Tc__WlRBoRwpU2vpopLr9HUtg_11_4">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_CgRZ2DkQAU6j4LDqLCATqA_11_7">35</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" sign="-" scale="3" id="Tc_ccGIXjmcRUuYMORyHrxqOQ_12_4">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" sign="-" scale="3" id="Tc_SxRWsrBgT0OnSSieKNnOrw_12_7">28</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_hJJSNCX6e0CTy2W381zRmw_13_4">24,936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_-rIbUBhFuEmcKnBhEDUcug_13_7">22,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ToJDp1mYL06FLOyQ18QiLQ_14_4">25,788</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eZWTlsucz0GFCa0igR25bA_14_7">21,397</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized gain (loss) on foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_q-_bNE9PPkyx29Ne-pI2qQ_15_4">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_h9fU9Rsv5k6DfpCzphQlFg_15_7">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_fl6x4SPEb0CqO_Ye7w3o9w_16_4">25,784</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_xU1QKS4pmUqDwC75kTznyA_16_7">21,398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_tt7ejucBVEOL3XAel-wMJg_18_4">0.86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_h-oy4MpnuEKG9U8gisrfDA_18_7">0.91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_5okWLioRMUe-rn54YqJC9A_19_4">0.86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Bo6VYqxgXEymp8uX2ORf8A_19_7">0.91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_fdy-6uNESESyCFF3b_DOqA_21_4">30,029,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_NKfcgaFf8EapxuVdfMlufw_21_7">23,640,199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_QxNBJs4TMkaqUfOAKINmkQ_22_4">30,029,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_4JaXdF-RQ0yfossGh-N_JQ_22_7">23,640,199</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d5d89a37_6e7f_4149_8838_9165fe55b004"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="StatementsofStockholdersEquity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f1d84c4c_1bc3_480b_881e_038b6f5c88aa"></a><a id="Tc_BxlwOX9K-U6lA5F5D9MddA_1_12"></a><a id="Tc_kkB0UTZS7EyBZgdh_eIXWA_2_6"></a><a id="Tc_lGu32DiBjU6Pw6FaYHq0uQ_2_12"></a><a id="Tc_Idhp4M1QlkWY02gPMsjLFg_2_15"></a><a id="Tc_X1VhWsZlE0mFrj6kQfInrQ_3_1"></a><a id="Tc_vUcjUgFpCE2AhmvdSJEbiA_3_6"></a><a id="Tc_171dogtg9kyiCezg4PPNJw_3_9"></a><a id="Tc_lAFFsJY6ikqK8kobbbdrpw_3_12"></a><a id="Tc_w6erCHWu5U-uEalaLWTDSw_3_15"></a><a id="Tc_fBp8lxysHUiHXhCJ23j3pw_4_1"></a><a id="Tc_gX6zpq8nVEui0-l8EHoabQ_4_3"></a><a id="Tc_5wtrD4qsLk-DNbvTjl-RXA_4_6"></a><a id="Tc_T7tUoduFrEy1kKOtdah8-g_4_9"></a><a id="Tc_CDoQqHjSSEu18CPqFbvLPQ_4_12"></a><a id="Tc_HoU0KEBp9UCJjDPwFU9PKg_4_15"></a><a id="Tc_N5iaXIwhR0OZwSlFb9i_oQ_5_0"></a><a id="Tc_WEwi_S7y2Eeom6v5NhoHEw_5_3"></a><a id="Tc_uFOsYQnVvkSOrz-UlvV40g_5_6"></a><a id="Tc_V1bxdO7bbESs8q7SZANxBQ_5_9"></a><a id="Tc_MtBPohoY2kCv2_pOP9xEdw_5_12"></a><a id="Tc__T_pUmYNQUqB9kvuqfFOAQ_5_15"></a><a id="Tc_fA1bhixz-02pb7bik9x2vg_6_0"></a><a id="Tc_ySjwmnyJWUWRUmQmRu9dZw_6_10"></a><a id="Tc_4h5HmyZdLUup66StM4I_bA_6_13"></a><a id="Tc_e-d_edRKm0G-j-c6mXWvQw_7_0"></a><a id="Tc_ZHCBSd_zkUuJ9jzxu7yntw_7_10"></a><a id="Tc_Usg__IbpuECJrBrJtuWdEg_7_13"></a><a id="Tc_VvDOEMVezU22pKMXuXUmvg_8_0"></a><a id="Tc_CbmjNydH2k-0SNzgg_QRpQ_8_1"></a><a id="Tc_1H6zbbeJNUSpIrBok_i0Yw_8_4"></a><a id="Tc_1IHy6dO5YUCeCbIwvhXOsw_8_10"></a><a id="Tc_qTL3dgSX40WDQaYf2MYRjg_8_13"></a><a id="Tc__OM9WW07sk6tfSGfBkwmZQ_9_0"></a><a id="Tc_6n5JwThpoEm3IU7lCWVwVA_9_1"></a><a id="Tc_RXT0dNZbiUKtBgaOeqQFUw_9_4"></a><a id="Tc_gLn2YlqTTEaJ2f2QJPQxqw_9_7"></a><a id="Tc_3FMihxf_EEunCg_DcJNLmA_9_10"></a><a id="Tc_SnXRPlrIIECjmst7LClmtw_10_0"></a><a id="Tc_PRehnGqfdEKgkGLqgYjWaA_10_1"></a><a id="Tc_BLOQOwAy_Eaam3PijOweKA_10_4"></a><a id="Tc_bjINhloVeEeCTf_JgznXKQ_10_7"></a><a id="Tc_jSjrzQNZ30qsG57we4QJxw_10_13"></a><a id="Tc_NqSLvmIlkUuCIsJag-BYIA_11_0"></a><a id="Tc_sSN5p-F_mkWkgT16hijibg_11_3"></a><a id="Tc_UGUEBjFfikSka2tngOYJmw_11_6"></a><a id="Tc_qimoJgzXLUusyPgBNPfe6g_11_9"></a><a id="Tc_pLUfy5UL8UOkCuB3bpnHvQ_11_12"></a><a id="Tc__-_b31khbkSQtXJB1Wi0Tg_11_15"></a><a id="Tc_477WORbs-kqXtju3JF6ikw_12_0"></a><a id="Tc_NWg7-RiY8Um5hzvdSDvq2A_12_10"></a><a id="Tc__DVlAqdYpUOWPm_ULYqb4w_12_13"></a><a id="Tc_HAov-H8Ntkq1ORiGQajfig_13_0"></a><a id="Tc_N8gfj5AxhkuydC7oJMYAcw_13_4"></a><a id="Tc_nl-9W_GHGkGz3yKKxsH9Ag_13_10"></a><a id="Tc_Xd7B1WPmVkW3ckoMgUvOmA_13_13"></a><a id="Tc_1qyvOpw7wkmMiOIQzUO-og_14_0"></a><a id="Tc_PEmKLig-jkKqi70vVfoAEQ_14_4"></a><a id="Tc_t4WkDacAdkm8iFEvqTf-JQ_14_10"></a><a id="Tc_4nnxNRnBXEe6-_PbnoYn3A_14_13"></a><a id="Tc_ZDD5f37KxUqonuZ0UBKRKw_15_0"></a><a id="Tc_r3whJkKwskmsYLC4iO54rA_15_1"></a><a id="Tc_ll6-77CFfkiOVKS9kOD7dg_15_4"></a><a id="Tc_gM0-IYcMyE6LBxLlWnZR-A_15_10"></a><a id="Tc_Nj1gawvyBkSAW63OdR3bxw_15_13"></a><a id="Tc_Ui16OfyiQEivS4HTgBkS3Q_16_0"></a><a id="Tc_FwXGIenKNkixe_J6EPkuxQ_16_1"></a><a id="Tc_LKlvQcNpAEm67Tt4ODja_w_16_4"></a><a id="Tc_w9vPQohuDkqJyez-nWyLxw_16_7"></a><a id="Tc_GZ1iEMNqCUOpZ6p9aPjRnw_16_10"></a><a id="Tc_esgCJAtj7kCEQz4kbBjD_A_17_0"></a><a id="Tc_jeUE2R_G1kuSClvildYoLQ_17_1"></a><a id="Tc_gqHiT-5-ykG7KBI9APRlUQ_17_4"></a><a id="Tc_0gNRCn8bok6UmaIupydZUA_17_7"></a><a id="Tc_psZLD69MJ0avYwFWbiG6qQ_17_13"></a><a id="Tc_53tqoNkxqka_XgOPQ79-hg_18_0"></a><a id="Tc_jtQA-voKBEOA3r8P7heotw_18_3"></a><a id="Tc_rhaudUwX60eQFAVH6-5GxQ_18_6"></a><a id="Tc_xyHF26Engka5vHqOQs9Quw_18_9"></a><a id="Tc_SjwEVAwTQEaA1_NMweHRdg_18_12"></a><a id="Tc_9nyMOhaaDEy81K2CHP_uKw_18_15"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.2893448%;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_JuSGa05TOU-bdrbuvrH9yQ_5_1">22,230,032</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yMnY-MxI2ECzztyLZp0DGA_5_4">22</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mjQQQJ2EckyysDZdzZQoXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EIwzD6zsu0Gm5QHZyxNThg_5_7">145,453</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9Bca2RtZUSaAp6SOKJZeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_MeelY2xwxUi8Uu4_VgVk2Q_5_10">94,004</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ga2Znj6Iy0yqPXctu2LwwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IxIuopnt1USourhfjufQAQ_5_13">198</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2021_60EfJYivGUOdbqzJUjaoug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OS6UI2ZPWEGEsGO-SJv5lw_5_16">51,273</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Exercise of common stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_y4K8NDdD1kGx51ew-0f2JA_6_1">1,761,516</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_WQOdAcvFiEaHCtjxDOek9w_6_4">2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Pzhj-iwHNEGwtvlqLAlOsw_6_7">1,616</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_awNS-vtXl0yM4s14Uj6_4A_6_16">1,618</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock in follow-on public offering, net of discounts and issuance costs of </span><span style="font-size:8.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_CiK7Vv_AhEOPuxzv4-HzHQ">816</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_b0Rl-lHW20GK0_U0cobwBg_7_1">5,000,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_3NCHsJ18K0iXp92vxX_Hmw_7_4">5</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_P6Usi-mPd0izIaAmErCTVA_7_7">5,179</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_udQNwswumUeKtCCY94n1HA_7_16">5,184</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Equity-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_l4qJtdN2P06o5-r856wRFg_8_7">3,572</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_RSh1YK1qO0ybvsQGLgASDw_8_16">3,572</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Other comprehensive loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pLCQK7N8yEeOO-emzO9KTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_fn4166FIxUKfSeCLAF9P2w_9_13">1</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_JTaNcqijnkidgmtvsV2U2w_9_16">1</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTU5BrA1tEmz30aajDlz6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_CZIShyFm7kqI3s5GIX29UQ_10_10">21,397</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mjdfSAW1PUyT1eeKty6VOQ_10_16">21,397</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cRBLgf-FmkW2y3hxofLyXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_OvAb7gvW1EaP3EpbcGuJ7A_11_1">28,991,548</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cRBLgf-FmkW2y3hxofLyXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4LLEbeWFeUKXpNQEvXlzLA_11_4">29</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y4ykLegMm0ecV5xUeC4XMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_y6DdEND_wkuT3exLtosZTA_11_7">155,820</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jO4Ihl3vbUygM5jjvQg_Lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Dg1VR0JF2kiShTIeiOqGPg_11_10">115,401</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MGbOgarFTEaIN0_BlZV7RQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SXqAMpcd40-90STM88d9sA_11_13">199</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1p3edK3kskSjkvZFcbj6ew_11_16">40,249</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock under the at-the-market (ATM) sales agreement, net of commissions and allocated fees of </span><span style="font-size:8.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_V0-T4I0f90W2FUVY_B22ag">159</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_mjbf_mTu8EG-1PNbRNcxEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_abJkFXLCP0OuNg5KVfYRJg_12_1">2,859,074</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_mjbf_mTu8EG-1PNbRNcxEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_49LIPWGBn0GcDf5ANgB_pQ_12_4">3</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_UveeLV5jg0Gs7n8IWxBGxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_WUq2gXr8QEiTWPagyiJbPw_12_7">5,124</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_X5X45Xj0K0i7hUutC9Nc-g_12_16">5,127</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock as commitment shares for equity line financing (Note 8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_glCHD9EtbESXtKFFuEPfMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_HSkeuldY2kaBHgNE4QsJmg_13_1">189,856</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_bz4gK_i3F0uQC7rL-HFYWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_GdYQ67PPG0adoe1OpDmhNg_13_7">318</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_LshqVKz1-k65X8p9RQ7mDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_0rcUv8N0Bk2ckwYbSCt39A_13_16">318</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock related to the equity line financing</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_uhpLOBdKk0WZcXfNyIcT2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_4xfhPk4Lv0aMkfWC7imdog_14_1">125,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_bkEmqGmAXk2V435yqi4NaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_V7o7ae7Cr0euohHezXtkhw_14_7">210</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_YVGucSObRUi_kS5-NUT2_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_sEUNdmCCmEe7BshejfQe_g_14_16">210</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Equity-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tuVKl_ZuvU2ErvU1ol886A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Y5AJixYYN0yLqUieVUaGGA_15_7">4,354</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kHCO7bR21EyBjTp5HZeA6w_15_16">4,354</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Other comprehensive gain</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HMKbTdzF40CY46TtwizjkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_eggd28qfaEqi-duWzbUw0A_16_13">4</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_cak_Bh0uTUC6MPd7Of3c0g_16_16">4</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QXLq1_nOvk2P7yx3QDOUOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_beRgeWh5Q0aianNvSeokjw_17_10">25,788</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_iQoRlvRx1ECgrabO5i9XWQ_17_16">25,788</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_onxTRXE0sU2j9FuXL78qkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_MwROsHeBYEu0vdJnELMniw_18_1">32,165,478</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_onxTRXE0sU2j9FuXL78qkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-IAbb7Vw50io_UjzMwX_3Q_18_4">32</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_6UVH8Rgk6cL-CiQ1IpeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kA4Kg-EgcUeFn3Tqz-U_Vw_18_7">165,826</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fxo-cpkpfUGMsbMoJHuOAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PUP3nrr7zkeJtYrCp1U9ug_18_10">141,189</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_X48c3Sa37UK9EHex0j44hQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_qz19R5rWIEaDo3H0CIvpOQ_18_13">195</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7OwUeE0pxkWUmHBS1se8TQ_18_16">24,474</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a06e62f9_8d95_4cb3_9c72_4c51fefbb292"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY</p><a id="StatementsofCashFlows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bb87a9fc_583a_4719_a1bb_e1fbd8ec0021"></a><a id="Tc_m2kLOyC5t0SWBmWER-D8Ng_1_2"></a><a id="Tc_J1-QPEWhFEivaD5depsZvw_2_2"></a><a id="Tc_AWifcmtal0q5GuMTZ1Kyyw_2_5"></a><a id="Tc_rymQK-De_EmSskpG28ar1w_3_0"></a><a id="Tc_MllQeGIm5EmnB4bZXZNiOQ_4_0"></a><a id="Tc_8BU6WHlEUEa0hRZVSWdJkQ_4_2"></a><a id="Tc_zY7D1-PM2EiA0ZyBB7SUvw_4_5"></a><a id="Tc_l4bLHDG0f0ymeXAndF0V7A_5_0"></a><a id="Tc_9ARsgDMGok-D2ifGGpPaMw_6_0"></a><a id="Tc_pd8XgoY1bUih0w4FyjZ7FQ_7_0"></a><a id="Tc_3QRHyJl6wU-IkuglYcK2Nw_8_0"></a><a id="Tc_D0xGTWFiOkud96_JsNodHg_9_0"></a><a id="Tc_eFB5778CrUehsvWOZZqzRA_9_6"></a><a id="Tc_hfbZrdZxH02xHuyZkFMaww_10_0"></a><a id="Tc_KGV0zXfNuUeSzABDqrtxog_11_0"></a><a id="Tc_K7mH0xscZUuxprRswoJL9w_12_0"></a><a id="Tc_hrLwB3PGB0G56Cv5CKuhRA_13_0"></a><a id="Tc_QU_0Q4-7mEuMB90gNh5QKA_13_3"></a><a id="Tc_IwIQqnxMoEK2ScwtrelOuw_14_0"></a><a id="Tc_dtVMsbqqE0mECUMDnNluZA_15_0"></a><a id="Tc_QprAgVjGSkKMCMIlQLvPzw_16_0"></a><a id="Tc_oMK6TaSPc0q0dEXlG0R4JQ_17_0"></a><a id="Tc_XQ0JtZI5K0GT-jwmEzyTLw_18_0"></a><a id="Tc_dqWObx5Mr0uSJZnjPkcRgg_19_0"></a><a id="Tc_t7TS6ZyEvk2D1e24KgJ_jA_20_0"></a><a id="Tc_t9tQf_jsXkSzu4x0K3SRvA_21_0"></a><a id="Tc_ffh6k6AS306YJSnBwYpAHQ_22_0"></a><a id="Tc_WXNv446O10eKI-B7MhMJxg_22_6"></a><a id="Tc_zByonAJSTkCVsKH0xAvzyQ_23_0"></a><a id="Tc_u2IUbd9x2EmmB_ydvgjiHg_23_6"></a><a id="Tc_Unt3e9pz3ki-IThV-HbSOg_24_0"></a><a id="Tc_6z27ANXTgkaWhNKFv1dEPQ_24_3"></a><a id="Tc_1f0QOKLaYUS2lmdyyntlOQ_25_0"></a><a id="Tc_vYwdNpGHiEqFW2qLxjYJOg_25_3"></a><a id="Tc_rBeeHkCPuEqPEUwX-2XUNA_26_0"></a><a id="Tc_nsiegznvCk2Mtort5i0Dig_27_0"></a><a id="Tc_6sMeYZQMLUOwpprOFmAZLw_28_0"></a><a id="Tc_Q_g0G2Cz3kmTHYGzndDo6g_29_0"></a><a id="Tc_VRNs7n9ABk-WspVMqZ20Yw_30_0"></a><a id="Tc_NaNrctKtEkiL94Sr3NeutQ_31_0"></a><a id="Tc_IRPlEEKu2Ue6m1w-D5Lg1A_32_0"></a><a id="Tc_qxDkRfZXvUGbwax9qdYH_g_32_2"></a><a id="Tc_JCXMpLya0UG8H6RUnBIVzA_32_5"></a><a id="Tc_ad6LVOVhk0SZchJCS_TEWA_33_0"></a><a id="Tc_45BC_aeIVE-_XB1D5DEMwQ_34_0"></a><a id="Tc_HHVNeiVHnkGq9CNQs7mUUg_34_2"></a><a id="Tc_WBVeYWB8k0GtYiIeKKRsHg_34_5"></a><a id="Tc_Tf9kwXaKuEKEVwTqj8T8cQ_35_0"></a><a id="Tc_YiZ5OpxYNk-LfWAQNt0mlA_35_2"></a><a id="Tc_ewp6xpRuvU-4Gl8PxXJKMQ_35_3"></a><a id="Tc_xUq47BwNk0qK6MGxl_JX5w_35_5"></a><a id="Tc_0Gx_GguBQUaEu9nyz-qaSg_36_0"></a><a id="Tc_7gxwfTBKE0OM488tKE00Lw_36_2"></a><a id="Tc_1LcincSdEkmVR6_oGDBjlg_36_3"></a><a id="Tc_xbhDMKETN0C5qtXi1EIbGQ_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Q2N2qMFxp02RpBCEJ_Goww_4_3">25,788</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fXKNlAiJIkucZmVSvH0b2g_4_6">21,397</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_JgW_uHvslEiwU49TGoLBoA_6_3">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_e9vJ5myMckqSRNVqp-5qpA_6_6">83</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_yfIG5ux3zEKLQBkq6GNbDw_7_3">4,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_abrRsm2tY0ubXEEu4Aes7Q_7_6">3,572</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_c1VP1-d8N0CMLIcfhORFaw_8_3">156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_C1RvbWdmgUubKdXzjGieow_8_6">152</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Issuance of common stock as commitment shares for equity line financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" scale="3" id="Tc_6wUezDz9l0CEOXAXVg51sw_9_3">318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Grant receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInGrantReceivables" sign="-" scale="3" id="Tc_hM2g4rQRCEmSMSXMOAvT0A_11_3">2,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInGrantReceivables" scale="3" id="Tc_RFaktXF_xkOr7nu5jkbjRg_11_6">1,873</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_jhBIN1_qqkmRwlKseVIpdQ_12_3">1,852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_ba6q--EtsEqVanTqbHVFtw_12_6">1,302</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" sign="-" scale="3" id="Tc_LHbVC6d7-EmlHLgdHdffig_13_6">467</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc__D6DtQpnU0aRNvHnJttoTQ_14_3">2,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_8ykt_abAFUuY52eJJwSJlA_14_6">749</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Deferred grant income and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent" sign="-" scale="3" id="Tc_CSy6NTamMEuXrvQDIYuW3Q_15_3">1,687</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent" scale="3" id="Tc_r3SiB8d_e0ueC3SP54GTSA_15_6">2,635</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_P6Y9o1I8YUuan2-UoYKDSg_16_3">150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc__mxGN6s_b0yGHsoeXOfMnw_16_6">121</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_rRn1OpHemEa_ZkdaFt_8OA_17_3">16,018</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_mMCqNkQj_ke5_ZUOEigJuA_17_6">18,533</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payments for property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ASyqXYmXFUSwDOdfdPKHBg_19_3">147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_gXJy9HQ0F0ChwR-IRW-kww_19_6">171</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_abFJJs6H-kq_oOUzrQQ5KQ_20_3">147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_ubsmFnOv7UerhHHiv_3z_g_20_6">171</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock under the ATM sales agreement, net of commissions and allocated fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_dUGZ1aBTQUCOFY1duEo02A_22_3">5,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from sale of common stock related to the equity line financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_YVGucSObRUi_kS5-NUT2_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_r6Sfol9bF0qZI4N7KtGpHg_23_3">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock in follow-on public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_x4Y607WBOUmNXRkBvpFKIg_24_6">5,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from the exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_8m6RmWZ7xUym940GPf90-Q_25_6">1,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payments on loan payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="Tc_likratsYfkO8kBaA8j2KgQ_26_3">811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="Tc_wNvo150mYEGFNfT_IIKzrA_26_6">1,396</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_iqCe-AbTC0iKoDNyuM1RMQ_27_3">4,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_FW0r_VRaS0iVgLUpHfCFhA_27_6">5,546</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_3VLDUEaSqkKtCKyYYGuwzg_28_3">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc__nXDgW5aA06mYSyxHsJrrg_28_6">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_ay1Kose620iSW1UvALMe7Q_29_3">11,640</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_Rr4aFg_J2UK2vdAPms7R9g_29_6">13,159</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents&#8201;&#8211;&#8201;beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_0ooJLVmuO0OoRozOHB7Sag_31_3">41,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2021_60EfJYivGUOdbqzJUjaoug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ovGOepxS-kqijUmxZL0ulA_31_6">54,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents&#8201;&#8211;&#8201;end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_DjESLnFDVk-zE4WSJOYU5g_32_3">29,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RQoCXwJ8iUam7iHaAb7Inw_32_6">41,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosures of non-cash financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Prepayment of insurance through third-party financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing" scale="3" id="Tc_u6DLmE9yTEiW04aNqgFR1w_34_3">721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing" scale="3" id="Tc_UlCmxpNvDUmssqEv3Ihtjg_34_6">838</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Remeasurement of right-of-use asset and operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_c3J9trJ70Umh1uIGPil9zA_35_6">349</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Deferred offering costs included in Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredOfferingCostsIncludedInAccountsPayable" scale="3" id="Tc_El2H_e2al0a3Fn6LUo_c4w_36_6">140</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a327eaf6_2c76_471d_afba_d585f6189857"></a><a id="NotestoConsolidatedFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">COGNITION THERAPEUTICS,&#160;INC. AND SUBSIDIARY<br/>NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS<br/>(in thousands, except share and per share amounts)</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_Jkns-F2hD02Q8rPHUWfhPg" continuedAt="Tb_Jkns-F2hD02Q8rPHUWfhPg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">1. Description of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease-modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. The Company&#8217;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2015, the Company formed Cognition Therapeutics PTY LTD, as its wholly owned subsidiary (the &#8220;Subsidiary&#8221;), primarily for the purpose of conducting research and development efforts at facilities located in Australia. Assets and liabilities of the Subsidiary, which uses the Australian dollar as its local functional currency, are translated to United States (U.S.) dollars at year-end exchange rates. Income statement accounts are translated using the average exchange rates prevailing during the month in which income and expenses are generated. Translation adjustments are recorded to accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) within stockholders&#8217; equity. Gains and losses from foreign currency transactions are included in net loss as a part of other income, net. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 15, 2022, the Company closed its follow-on public offering of <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_gwx2-sVA70-hKsPrEr4SgA">5,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ygnTJ3cZlkyoT6PpTTP3JA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Nep-z7KtuEWgXGeyloUuzQ">1.20</ix:nonFraction> per share (&#8220;November 2022 Offering&#8221;). The gross proceeds from the November 2022 Offering were $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="Narr_PnGAyHbiE0K--npcbGpPEw">6,000</ix:nonFraction> and the net proceeds were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Narr_dTJ_q7LloUGAuGmLDcybjg">5,184</ix:nonFraction>, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_23_2022_vzbl8zprq0ijwIokKFM6sA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumAggregateOfferingPrice" scale="3" id="Narr_9cck9cmQXkWJlFFZTs_siA">200,000</ix:nonFraction> in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (the &#8220;Sales Agents&#8221;) providing for the offering, issuance and sale by the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_V21-ck426EKj_jaNHfEcpQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_2pFFVlxzgEaCxOPqscGtrA">40,000</ix:nonFraction> of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). During the year ended December 31, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_zpBErroONk-5VAXD1yo9jw">2,859,074</ix:nonFraction> shares of its common stock pursuant to the ATM for net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_1P3NpSFKyEyHrDfN1K3yyw">5,127</ix:nonFraction>. Please refer to Note 8 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Purchase Agreement&#8221;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_9V862H9a40S32sFVbIZRJQ">35,000</ix:nonFraction></span><span style="background:#ffffff;">&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;</span><ix:nonNumeric contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q" format="ixt-sec:durwordsen" name="cgtx:PurchaseAgreementTerm" id="Narr_XNFoqh75dUCYX7xo8DuJJQ"><span style="background:#ffffff;">36-month</span></ix:nonNumeric><span style="background:#ffffff;">&#160;period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_MGpDgmMJK0WujMumG22DeA">189,856</ix:nonFraction></span><span style="background:#ffffff;"> shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement. During the year ended December 31, 2023, the Company sold&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Her4KWZ5Okab6Hwi8TmttA">125,000</ix:nonFraction></span><span style="background:#ffffff;">&#160;shares of common stock to Lincoln Park for proceeds of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_b1KXo4r2XU6PN1ZmNheGbQ">205</ix:nonFraction></span><span style="background:#ffffff;">, as part of the equity line financing arrangement. As of December 31, 2023, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:RemainingValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_eDPIJjXb3EG9yBvOxTWfIg">34,795</ix:nonFraction></span><span style="background:#ffffff;">&#160;was available to draw pursuant to the Purchase Agreement. Please refer to Note 8 for further details.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company held cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_iwzAGfTy_E6-cOajw0zcpg">29,922</ix:nonFraction> at December 31, 2023, and received net proceeds from a follow on public offering of common stock of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_Cb1fCNb9LEq93fXulA-3xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_qEUe9pcvS0e-cTTwOwbzcw">10,363</ix:nonFraction> in March of 2024 (Note 13). The Company expects that its cash and cash equivalents, including the net proceeds from its IPO, its follow-on public offerings, and its ATM will enable it to fund its operating expenses and capital expenditure requirements through at least the one year period subsequent to the filing date of this Annual Report on Form 10-K. However, additional funding will be necessary to fund future preclinical </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jkns-F2hD02Q8rPHUWfhPg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">and clinical activities. The Company expects to finance its future cash needs through a combination of grant awards, equity or debt financings, collaboration agreements, strategic alliances, and licensing arrangements. Please refer to Note 13 for further details. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_Hlk161736969"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_p_cQVa88oEyjcgbAg6-BTQ" continuedAt="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_iqpurcQAv0aWQF1pjBKaYA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:UseOfEstimates" id="Tb_aiQw-GO67U-ZDzHsfp9EjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_5uPg20GEjUe8YXlNtBNCqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ReceivablesPolicyTextBlock" id="Tb_TupW2OW2dE-vmK43-cqB4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt-sec:numwordsen" name="cgtx:AllowanceForCreditLossGrantsReceivableCurrent" scale="3" id="Narr_gk5mU1iqxUyfAnLWndiRig">no</ix:nonFraction> allowance for doubtful accounts required on these grant receivables. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="cgtx:GrantIncomePolicyPolicyTextBlock" id="Tb_5bswnzyv2kONB0vm0wlX8w" continuedAt="Tb_5bswnzyv2kONB0vm0wlX8w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2023 and 2022, the Company generated grant income of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Narr_v1hm5MNco0mObpPLpbFt_w">24,805</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:GrantIncome" scale="3" id="Narr_HDGzxBFe3UWR7rR0W-OQPA">22,217</ix:nonFraction>, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Narr_5Y8yH03cqkq1HaeW4mURoQ">1,701</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Narr_9RA1iPuGBkmGc0eTSjPl6Q">0</ix:nonFraction>, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2022 of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Narr_TN0YCOZacECXeNQCKV9i9A">1,702</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Narr_WCtl7YrBLE-8l1JL2hiWow">1,686</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont1" continuedAt="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont2"><ix:continuation id="Tb_5bswnzyv2kONB0vm0wlX8w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2023, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_8OIeXhtMU0aNt2Ub7pexkg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of proceeds generated as a result of the offering. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_HvLtL5DtBES-ELSeuxITaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be <span style="-sec-ix-hidden:Hidden_mQJYQs2rZkWuRg8O_Rotqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> and <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JA-tMjbxgkOcxeZ-D5dbbw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_V6AXHsECHEmN9OPqeIirOQ">6&#160;years</ix:nonNumeric> for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2023 or 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_gI1YWgjC90yXzrjGnp76mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#8217;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_VXRoCZZ-AEmR8prB3_ZRyw" continuedAt="Tb_VXRoCZZ-AEmR8prB3_ZRyw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_L-vtdCCFQUKjemCEMLJY4A_1_1"></a><a id="Tc_i4Ze355cDEuQnpjX_kup7g_1_4"></a><a id="Tc_t8BFXi-qFkmr25qrhcMZ7w_2_1"></a><a id="Tc_0kmEwOEcokqXBRHLZy8fDw_2_4"></a><a id="Tc_ZfLh5O-GJEWC-XKQ1MDhKw_3_1"></a><a id="Tc_uqGAHv_fAU6qEz2PpOHyYA_3_4"></a><a id="Tc_-dqVBK66wEu8uFMLAEITgA_3_7"></a><a id="Tc_bxbDLirbf0GYuG54uzccMA_4_0"></a><a id="Tc_2wOxT9cggkmRgxrARG-oew_4_1"></a><a id="Tc_Z5UcaIHqLkim4iawoMG7MQ_4_2"></a><a id="Tc_30h2YgKfXkum_3Kah6b-VQ_4_4"></a><a id="Tc_V3IKPP5TIEWsce-cHuWHCA_4_7"></a><a id="Tc_pTy6eWCHgkCPM9uQsgdCXw_5_0"></a><a id="Tc_w2rLJqegykK6Di1ciAVwiA_5_1"></a><a id="Tc_38z2pSN1W0efJmHTBAZq-w_5_4"></a><a id="Tc_0JCp8mTpQkaM9Uki3ZQWyg_5_7"></a><a id="Tc_pp8cGtMDR0q8ZBcv1MZtKQ_5_8"></a><a id="Tc_qc5neUv3WkyfmJuiyIISEg_6_0"></a><a id="Tc_82Jp2r_U4keb9JPmJc0lPA_6_1"></a><a id="Tc_py2QT1RFPUiISuRX-11w1g_6_2"></a><a id="Tc_ayellsbti0-oRDq7NxeZ9w_6_4"></a><a id="Tc_aq2OxxPVf02R7NOd_l-QAw_6_7"></a><a id="Tc_D6M1l3kUOkGrTdDbbL6Cig_7_0"></a><a id="Tc_jE2JOvWsbE-WayLtYsfB7Q_7_1"></a><a id="Tc_-1oE-K4FQ0mu0aJ8TbYtnw_7_2"></a><a id="Tc_Q--Yh5aD40m5O1A89edZFw_7_4"></a><a id="Tc_7IlHvBwvm0mUoko7cuLd8Q_7_7"></a><a id="Tc_sAlG6JZ8A0yAflpu8kIYJQ_9_0"></a><a id="Tc_wDwSxeHOJ0mEqP0LcWiOfg_10_0"></a><a id="Tc__n3zfyDXcECQz3OBqRyrnQ_11_0"></a><ix:continuation id="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont2" continuedAt="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont3"><ix:continuation id="Tb_VXRoCZZ-AEmR8prB3_ZRyw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Narr_RixqnmmuOkSMnlbasrFeHw">616</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> and corresponding current and noncurrent operating lease liabilities of </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Narr_R56Wh79QXEeYHc2tXheO8w">130</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> and </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Narr_gmCPIrIlEEC3xJzD19vRRw">486</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;">, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impact of Adoption of ASC 842 on the Consolidated Financial Statements</i></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="Tb_SSSQwjvtyUWafdevGOuhLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_1s8FOlKuwU6NANTyjtzPOw_4_5">616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_0QnhszhLB0-vVvA5ovgnLw_4_8">616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OdAlZTCHTkKTcjg6k-b-og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCredit" scale="3" id="Tc_in9m0JJLLEiH4n2U90xmvg_5_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCredit" sign="-" scale="3" id="Tc_v6oPQLtH40GYAm4gwwRJ4w_5_5">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_FihJ5lsDT0eOXsRHRANqYg_6_5">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_mSsnJjkhh0-BYHmr1ZIwmQ_6_8">130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ZIIsrs-hRkGasBsX87FTRQ_7_5">486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_S7civEQvxEadJ2g8AFG2Gg_7_8">486</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_EMnPNq-KSkuwePj_99MMSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_9cD8KYWEA06NTzxtEdQnXA"><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_JR9TGs4VpUCBlEeyc-lekg">no</ix:nonFraction></ix:nonFraction> uncertainties as of December&#160;31, 2023 and 2022 that met the recognition threshold.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_r8GE4JExgkOcMJITST9ojw" continuedAt="Tb_r8GE4JExgkOcMJITST9ojw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont3" continuedAt="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont4"><ix:continuation id="Tb_r8GE4JExgkOcMJITST9ojw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_6pjLU3LyN0KpX0ApnsXWJQ">zero</ix:nonFraction> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;<i style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</i>, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_xfX1UwU1WUmCspQTxba6zA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_npfWObElV0a3x_ViurXG1w" continuedAt="Tb_npfWObElV0a3x_ViurXG1w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont4" continuedAt="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont5"><ix:continuation id="Tb_npfWObElV0a3x_ViurXG1w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_U2aNd-RMYEKwXG7dkvjzIQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Narr_M-yQyd85y0qpi3z8INw0iA">4</ix:nonFraction> in other comprehensive gain and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Narr_eX7xYlX_L0ifOXTUGUtZrQ">1</ix:nonFraction> in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2023 and 2022, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_ATBa66RcmkukpqY6I9U89g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_Q0QpPzh2xEC7IF7w6epi8Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages <ix:nonFraction unitRef="Unit_Standard_segment_5qxERgMtAE2JatGJwvNkAQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_KAeI9f4IfECu3IId9_57VQ">one</ix:nonFraction> operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="cgtx:EmergingGrowthCompanyPolicyTextBlock" id="Tb_xlRmcrMcuE2zus2uHly22Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_tJUGHDxSzkiBM4Cn2zsLoA" continuedAt="Tb_tJUGHDxSzkiBM4Cn2zsLoA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_p_cQVa88oEyjcgbAg6-BTQ_cont5"><ix:continuation id="Tb_tJUGHDxSzkiBM4Cn2zsLoA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Not Yet Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements</i> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</p></ix:continuation></ix:continuation><a id="_d11d9ff2_a834_4232_af98_d34c9aa23701"></a><a id="Tc_ntgI9RX8L0yOHQP4YWgUcg_1_2"></a><a id="Tc_D99zpnHcrkmRh-JCbGZk7g_2_8"></a><a id="Tc_8les4jRfzEWF5w3uQf0E_A_3_2"></a><a id="Tc_qSTRGS3wOEiJWC-6b1bMtw_3_5"></a><a id="Tc_FHzp6ZRMW0isPjSCqox36g_3_8"></a><a id="Tc_ILNE6tT530aMXFKIkFlExQ_4_2"></a><a id="Tc_bu1J2zvywEKsQWQVtuMRXQ_4_5"></a><a id="Tc_wYBYScK_kkaU7IOhaP4c-Q_4_8"></a><a id="Tc_-HWpGjF70EWk4IaXCDRiNw_5_2"></a><a id="Tc_mSYSA3nH402E_N6dbbWYcA_5_5"></a><a id="Tc_7N7K_wfitUmI1CpSc42Dzg_5_8"></a><a id="Tc_He5ehoBnr06JWnLa61vSVg_5_11"></a><a id="Tc_OiUWrC6cf0K4lceBg6m22w_6_0"></a><a id="Tc_uR8yxwiHZUKvT7J5-UCjKw_7_0"></a><a id="Tc_Ufx91eLZYkGboMV58lT3qQ_7_2"></a><a id="Tc_3OGNBvtx4UWIFQWCLGkXEg_7_5"></a><a id="Tc_dMeLhLqrfUS1SVEmPeVbOw_7_6"></a><a id="Tc_j8l9qheGNkOpRzbX0GLzsg_7_8"></a><a id="Tc_CKrl0-4Dt02BdP9e3LpOcg_7_9"></a><a id="Tc_WDmfLNx2SEmbIBBJxC0xig_7_11"></a><a id="Tc_ECySeHT0EUCxqlTpF_6-Sg_8_0"></a><a id="Tc_YA1JzrInVUCE3446ruk1GQ_8_2"></a><a id="Tc_sEohWf2DeUOotqgb0HMxNA_8_5"></a><a id="Tc_e37GdHSXAUaHgC_nBxJrgQ_8_6"></a><a id="Tc_3QXHPrMx-E-bQ3H4OK9mog_8_8"></a><a id="Tc_Yyl55Vh0A0C1hx2ObrVpVg_8_9"></a><a id="Tc_2yPPdDgunkKbTLaGnXUevg_8_11"></a><a id="_69c15f46_951c_49d5_976e_9ebc5ba4826b"></a><a id="Tc_PFhXQrtAhEqfDMZKJ0348g_1_2"></a><a id="Tc_r25CWdz6WUS_mJg3fRZs3w_2_8"></a><a id="Tc_SLqwqCUqIUWw9tZ8V0e8aA_3_2"></a><a id="Tc__7LQ8q8E80at8jKj-5G9ww_3_5"></a><a id="Tc_CsqH_XKErEW9srKfpcF8wA_3_8"></a><a id="Tc_bCT6Cg77ukG-yI1r-JnxXQ_4_2"></a><a id="Tc_EA7ZK-7uKkiG6NlBCMNtGA_4_5"></a><a id="Tc_RjoqZPKz5U-uyc_bJ9mxSw_4_8"></a><a id="Tc_NOW9NkPMeEemq0JkEY_9dA_5_2"></a><a id="Tc_x7R28I-SxkmH-ou7QF-yig_5_5"></a><a id="Tc_IU8L1rwBI0ygoek6O40CIw_5_8"></a><a id="Tc_wlWWBbqAQEmxzS6mkKkd7g_5_11"></a><a id="Tc_Jvod8DWFjEO3aOoANNC0KA_6_0"></a><a id="Tc_FxNSiic5n0CkpbJ7T7NrOA_7_0"></a><a id="Tc__hmF5KXyyEWW6XfmqHtSvw_7_2"></a><a id="Tc_DLruJiqQMUCMLe-CSRt9RA_7_5"></a><a id="Tc_VBVIIv7JeEatF5FKfjwa8A_7_6"></a><a id="Tc_O6rvgrKMSES7hmF0X70jHQ_7_8"></a><a id="Tc_5LGqrb-_8EG_6sx5SSGLCg_7_9"></a><a id="Tc_7NzVCyR_SkqFtD9jBMM5nQ_7_11"></a><a id="Tc_c6XsGAMI4Uaa0RwX9QfIUQ_8_0"></a><a id="Tc_nTjMKo88tk6yAKVbT5geHw_8_2"></a><a id="Tc_iuW3jjC3rUyi1F5H5ivnww_8_5"></a><a id="Tc_wFJdnn25MUO9bPhHgO4gAQ_8_6"></a><a id="Tc_Nar95DTm9kScvqxb1D9Dwg_8_8"></a><a id="Tc_HK_DT-CkikS3YNhqwTRPdg_8_9"></a><a id="Tc_bek7WCd1P0CKdUCBVGOpOg_8_11"></a><a id="_7f7d12c5_7677_443c_9f6a_4cfa0835ba05"></a><a id="_7f7d12c5_7677_443c_9f6a_4cfa0835ba05_2"></a><a id="_7f7d12c5_7677_443c_9f6a_4cfa0835ba05_3"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_MtLgR3W_gEGc8IrAqzV2qw" continuedAt="Tb_MtLgR3W_gEGc8IrAqzV2qw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">3. Financial Instruments and Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Financial assets and liabilities measured at fair value are summarized below:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Tb_AYkqJd_1i0udIFZ7G8Q28w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Ao_-LDEYrUuIE9YczdQENA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_-AC-omu4CU-GZ9cmCK-CvQ_7_3">29,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_cRq6e-5OZ0Ke_a61Ul0DuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ZBY8ypBPKE6YVMX5-UFMvw_7_12">29,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_ENLs-VXh8kmNzn1_ZzoFlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_NSrLKKAb2k-qaagduyMJxQ_8_3">29,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_9VXbVQBkpUSKW-Z92UtMuw_8_12">29,391</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LxxS8eZ15U26cdY_7vD36w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_QPkje6MqvUCxetjSfRmLaw_7_3">37,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_zimJT2kt9UiSyyAiSWSK6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_KzNjJt09CkOgB_Zwe_PUxA_7_12">37,479</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_9tl_WCDNBE6HpfXJYxxGQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_qqfsFeJvsUy5feutZn4h-g_8_3">37,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_WYYmep5vFkughzsuOxnpCA_8_12">37,479</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There were no Level 3 financial instruments during the year ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_MtLgR3W_gEGc8IrAqzV2qw_cont1"></ix:continuation><a id="Tc_7LiWnmpGEUeRwxY50av4Mg_1_2"></a><a id="Tc_P6YUP7Dquk-iPIwPA5GipQ_2_2"></a><a id="Tc_WMRT0UQXGUel_Hml3Tetrg_2_5"></a><a id="Tc_fo4jP_gszUij6jtbzIHE7g_3_0"></a><a id="Tc_hjytDHGz2Eit5yEz568X8A_3_2"></a><a id="Tc_e88OIlRZK02S8VU16qRtWg_3_5"></a><a id="Tc_y7zsRCN0S0epWFABPESQ5Q_4_0"></a><a id="Tc_MFOvrKlXqk6en68KDBuv7w_5_2"></a><a id="Tc_HcSeH3xQfUSB-RFf5M1srw_5_5"></a><a id="Tc_BVR1h0UkkUGhcibQTnzu3g_6_0"></a><a id="Tc_TmAopoxBMkKRoqeObkUu5Q_7_0"></a><a id="Tc_ZlWRkySJLEyEKZ-dII9EGg_7_2"></a><a id="Tc_974rIj_YIkqARBoEJ3ihYQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_anp_eYq1VESHXuMvSlOFlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Property and equipment, net, consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_njYsLHeh-0eY04SRfRmO8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VVVdi6pD1kGcMpi2IuK05A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_aQkVLZcWqU-j6E8AjVQtlA_3_3">1,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_d7jEg2zHjU29ZRjFt5YiYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_b9pWCzAewkK0Po4Ib2Ko-A_3_6">1,057</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JA-tMjbxgkOcxeZ-D5dbbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_O8ChhQikhUSeh12OUMJ7GQ_4_3">140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-558bBZDIUKyf-5W-hEnOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_GPp8nrEo3k69OJysBqxTyg_4_6">129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_2YF4u85SuEGY9WiMvygtFQ_5_3">1,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sBg8kB_45kuxMhwKNRPowg_5_6">1,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_cai3e1SbAkGcBs4N35L1DA_6_3">1,049</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_HoI_EN0JuUi8IWJQ0QX-ng_6_6">953</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_gK6QmaiookyIxRQIbbmRIg_7_3">284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_CSmYeOaz2k-3abdYYOow9A_7_6">233</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Narr_rhrTqAHeEUyjYvP9MvBDAg">96</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Narr_3Ne4GUpd7EeytWy9GbVUZQ">83</ix:nonFraction>, respectively, which includes amortization expense of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="3" id="Narr_URZz0zoZXk2U65ep12aB1g">2</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="3" id="Narr_ccCD494NwkSsUw1koZi-RA">2</ix:nonFraction> for the&#160;years ended December&#160;31, 2023 and 2022, respectively. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_Ae1qqzaeGUWcYF2SxLZ-4Q_1_2"></a><a id="Tc_S1OsRQbrY0eimH39QdHpKw_2_2"></a><a id="Tc_b6BRZ4XGZ0SVdPrQ6JIVLw_2_5"></a><a id="Tc_c0Ap4G6pfEGBo9pYYv-8vQ_3_0"></a><a id="Tc_rLQ7hmZ6JkSlysWMjt-6mg_3_2"></a><a id="Tc_LFZXlebRMUOzAsoTh8OE8Q_3_5"></a><a id="Tc_CZIvRrsosESSvky7CmdAwg_4_0"></a><a id="Tc_CPzztPzeLUOw9WElyHhBYA_5_0"></a><a id="Tc_iz1Hzd_DqE6H2IStOmAacQ_6_0"></a><a id="Tc_HX_PuhJxoU6P0E73BQijfA_6_2"></a><a id="Tc_2N05tyLjGkquHo8H4_qovg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_ELKTzSZUskmdhnrBEs4NIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Accrued expense consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_ks0jtr5QmkiaPwVbjhxv1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_EHOC1FnUr0yvCoHEMUNjxA_3_3">1,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_KxXqZnewjEGSni9cpVuRbw_3_6">870</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_x2kHTS7qLECTEF-LfiqQLQ_4_3">2,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_mJLJFCExY0Khj7_IRplcYA_4_6">900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent" scale="3" id="Tc_BIakJ9o5KkSAIdblZRJ_Hw_5_3">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent" scale="3" id="Tc_HmlQCVNPfUCtpQXOMsbRVw_5_6">324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_pkkUWTk3H0S2m-3egAD81w_6_3">4,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_EqdF7IW-9kaWBkDEegd3Xg_6_6">2,094</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4f46743a_2fca_447f_9e94_15b037d3899d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="cgtx:OtherCurrentLiabilitiesTextBlock" id="Tb_VtxdrzrLek23KUMIQst7zg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">6. Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In October 2022, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_vQQHg-kY3kaNtOqhbYQgyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_MqugpkDn9kWt5-Rpha6v6w">841</ix:nonFraction> of certain premiums at a <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_vQQHg-kY3kaNtOqhbYQgyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_vZGm38_UCEuH-Cyj63lW1g">6.85</ix:nonFraction>% annual interest rate. Total payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_YK8t0UGtpEeESc004CPSVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="Narr_Yuq_XG4J3EiFHuVn1dSpBw">72</ix:nonFraction>, including interest and principal, are due monthly from November 2022 through October 2023. As of December 31, 2022, the outstanding principal of the loan was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_x_Z7jkOkrUCdh_AMcj9ldw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Narr_PgAk_mQwlkCFjdNDkR7F3g">634</ix:nonFraction> and the amount was paid off in <span style="-sec-ix-hidden:Hidden__XyZb69CXEGjsKwFBnsFpA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023</span></span>. In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_YqDdVDtS20ecG70OxtdrqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_wJH75imWJEqs4S3xjEuhNw">721</ix:nonFraction> of certain premiums at a <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_YqDdVDtS20ecG70OxtdrqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_vL7-_sfTJ0m4OCvx7qMSyg">8.65</ix:nonFraction>% annual interest rate. Total payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_ZB35Xclq7k6gaWDy5dCb0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="Narr_7_MmvnV0SkS7DNo0hwXfig">62</ix:nonFraction>, including interest and principal, are due monthly from November 2023 through October 2024. As of December 31, 2023, the outstanding principal of the loan was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_RHH5Gs9baU-2LKRDJ3NO3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Narr_7It1_ZgulkqAOG_5QlHhMQ">544</ix:nonFraction>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_lUSEPBEQJkW6HbDhTau80A" continuedAt="Tb_lUSEPBEQJkW6HbDhTau80A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">7. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal executive offices are located in Purchase, New York where we currently occupy <ix:nonFraction unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_S_oPesVvSUGLXTpCrxhISg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_3Sq05Jq4YUyIEfUlIN8hnA">2,864</ix:nonFraction> square feet of office space under a lease that expires in May of 2029. The Company also leases approximately <ix:nonFraction unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_zQZdkP6aak6WFLzryRsnUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_sAiF3IsgVESA6stWZ4SSSg">6,068</ix:nonFraction> square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_iifjj9nFxUWWEEoGkB7y3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_PhVTRRRShkalOjUYEDrcCQ">2,980</ix:nonFraction> square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of <ix:nonNumeric contextRef="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_c7z7ZQ_fFUeLePhaNsuU1w" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_q5AMWSvJLkusv7PgGt0DPA">45 months</ix:nonNumeric> and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified <ix:nonFraction unitRef="Unit_Standard_lease_pZh55Gbcxkm9kdN4Koe6yQ" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_JzSuP6-isUqGYxI89s2DJA" decimals="INF" format="ixt-sec:numwordsen" name="cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" scale="0" id="Narr_2AQaGVj30Um38sLxMqTxuA">one</ix:nonFraction> of its existing lease agreements for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_JzSuP6-isUqGYxI89s2DJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_syiz1maXmEqc_6rBobd78w">3,706</ix:nonFraction> square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_cheIDCxlPEChTvhsfcB5pA_1_1"></a><a id="Tc_sXpXhsGVhkC0JysMBYnZ2g_2_1"></a><a id="Tc_3qcFwB7s0kepsWN6h4-RLg_2_4"></a><a id="Tc_AdlpL9HUn0ubkoD6FYDCLQ_3_0"></a><a id="Tc_E-edf4-p20ipDefXeC-6bQ_4_0"></a><a id="Tc_oX9drXwThEeS0fi_pBP84g_4_1"></a><a id="Tc_o_Qx26KEf0KEBEfpY7tqAw_4_4"></a><a id="Tc_JmjkJ8Ry2UW9pUb2Vc6PNQ_5_0"></a><a id="Tc_CaGRnKAsL0G5q73WZ74sJg_5_1"></a><a id="Tc_STK61Rmlo0SvJ76BXdvAPQ_5_4"></a><a id="Tc_SwTCWe3fxEqrNnQy5E6KSg_6_0"></a><a id="Tc_olBj5asSiUquXMwl2o1EjA_7_0"></a><a id="Tc_i9aCDv32Tku4wUnbnkC6GQ_8_0"></a><a id="Tc_uKkdr3Wc9k-qiJdP7dedjw_8_1"></a><a id="Tc_y4oj9u8hK0mdhwI2Xu0x7Q_8_4"></a><a id="Tc_CLIPZSxQIkKlcOSMVGBy5Q_9_0"></a><a id="Tc_6C8-3CIQ6E2G9ICobc01QA_10_0"></a><a id="Tc_PLTGGCf8CUOFaLj277-Ezw_11_0"></a><a id="Tc_mnjgNwDnH0KzrnRahvyDEA_11_1"></a><a id="Tc_rbn2c-pMwU2UzAPU-0Lt5A_11_4"></a><a id="_922b3997_28c5_4b68_9e9c_0737a2d9c5b8"></a><a id="Tc_lh6r21TXKE6rrq4Sxg-zyw_1_0"></a><a id="Tc_Gg9hDC7xLkCogPDEHsh78A_1_2"></a><a id="Tc_8w77qJq0M0qVvU4LctWkkw_2_0"></a><a id="Tc_45BcRpVTMUSDn_JPqY9o8A_2_2"></a><a id="Tc_XyvrvszafEG3fe_U-NE5HA_3_0"></a><a id="Tc_4FqUqbuyoUG5zBGDo5ExAg_4_0"></a><a id="Tc_y8BcAf25JkmLN3i8dzLh6w_5_0"></a><a id="Tc_fYH4XxC3SEadSTYRrIzC7g_6_0"></a><a id="Tc_XQv6DiMu4UKttW25CruHvQ_7_0"></a><a id="Tc_23MKY6l_20SbaH1KaO_JDA_8_0"></a><a id="Tc_Zsz-S1jIJkCX3AmIqgPstg_8_2"></a><a id="Tc_wNSkkyYBY0afvzvyuBkrdQ_9_0"></a><a id="Tc_1v4EXCNu4U6QlCZHTV9uMA_10_0"></a><a id="Tc_DX9SDbFnM0KhlyjEr21nJQ_10_2"></a><a id="_5cd29646_248f_4e6d_8182_c84b5c23c9bf"></a><a id="Tc_YZkzRi91YUKge9KayxIExg_1_1"></a><a id="Tc_nGQQjAfb6UeuzmKzexQ_YA_2_1"></a><a id="Tc_DX1dAYqCrku2Gn1fjYeGiA_2_3"></a><a id="Tc_vX08l0drs06rHFBCVl9_Rw_3_0"></a><a id="Tc_y2fNw5xcfUyTZBFtmYkfWA_4_0"></a><a id="Tc_2BCaDwA8oUq50DHxxCgU6Q_5_0"></a><a id="Tc_dzlzgeky30uZSZeCPNesUg_6_0"></a><ix:continuation id="Tb_lUSEPBEQJkW6HbDhTau80A_cont1" continuedAt="Tb_lUSEPBEQJkW6HbDhTau80A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2023 and 2022 were as follows, in thousands:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:LeaseCostTableTextBlock" id="Group_HOKUznt9bEyYW3XjmAUP5A" continuedAt="Group_HOKUznt9bEyYW3XjmAUP5A_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:OperatingLeaseAssets" scale="3" id="Tc_pOq-GBzPekGr27RmZeqbaw_4_2">657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:OperatingLeaseAssets" scale="3" id="Tc_edXoWiNNIkiABJPulKwZ6A_4_5">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Js-khG4nMU2lwR7Xu47QMg_5_2">657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Z0D44kfuq06H8xjbRD2ubA_5_5">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ZNw_FuoCZ0aBXs2wvTbdfg_8_2">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_cF6wNDqkVUCkMqzE_ixIcQ_8_5">149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_apuVRwxrvkatv8YJa5iTTQ_10_2">520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_L8xixJTJOEqUcLqdxVCvhw_10_5">695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_VSoce4qdBEWOQ6YuHDw4rg_11_2">694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_-itJ-xWdS0GYgdRzm5uhew_11_5">844</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease costs for the year ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_AXkyTSE7hkSp5vd2bisTRw">215</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_FZhLo3CaFk6oCzs_g0TATw">203</ix:nonFraction>, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_tyG0w-hPv0iGu9i8VTN8Ug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_Z9Iu-QfCYEajfYLzEeoDvQ_2_3">221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_1xlMO9jcukecLLP4Oh8ZTw_3_3">222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_dnTXfIWhtkG68xhi9zzsgw_4_3">155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_lEeIxHsPS0SEMVyP8qLN2A_5_3">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_LAUUc3b5BEusE_6i0T7LSA_6_3">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_9IWyobFkY0KQ8VG-sd2npw_7_3">37</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_cSArPD9vwUe22jj4-vJBIg_8_3">810</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_ysWtITW5AEyYh-tkpjvgOw_9_3">116</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_7mViDVx34UmcLIfOVFgu_A_10_3">694</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:continuation id="Group_HOKUznt9bEyYW3XjmAUP5A_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2023 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_K2cAzOCeb0mL76ddZslLBw_4_1"> 4.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_ESsZiKRku0ivQgkpGTBuVw_4_3"> 5.0</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_PLyCCfzTJUKiPBWTx5b4qg_6_1">8.1</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_mUbmT12Sfkq-caatSawsUQ_6_3">8.1</ix:nonFraction>%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating cash flows used for operating leases for the year ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Narr_7rjfD7AffEyZHvtsMdPB2w">209</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Narr_fWHu8dDpHUC9hal41oG2uQ">172</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lUSEPBEQJkW6HbDhTau80A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of December&#160;31, 2023 and 2022, there was no litigation or contingency with at least a reasonable possibility of a material loss.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_rWCi4C4fFkS3Kf3nHtH6Iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">8. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common and Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue up to <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_1PR33-7VA0-z6p6UYzsQOA">250,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_zNZrS7M6A0eGeC04DHU2zw">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_T0TWRmD_F0G56M2Rd2QSLQ">10,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_AKYpwlXQb0WQ21a9MH1mBg">0.001</ix:nonFraction> per share. As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_c0k-F3jjZk2qDPnSItzQJQ">32,165,478</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_tUqJAS3ETUqiJmDQiHcmdA">28,991,548</ix:nonFraction> shares of common stock <span style="-sec-ix-hidden:Hidden_ePTF4GwkoU2wTSik52QcmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_Qj7kaN5TikGnEe3obL6iig;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2023, <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="3" id="Narr_DuJ5rhNKHUqrguipAXIQew">no</ix:nonFraction> dividends on common stock had been declared by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">ATM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_CljcQCdgAUmy0i-o6OBaKQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumAggregateOfferingPrice" scale="3" id="Narr_5wDfm78JEE-PmAs7DqECRw">200,000</ix:nonFraction>&#160;in aggregate (the &#8220;Shelf&#8221;). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_V21-ck426EKj_jaNHfEcpQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_GCH0Kw4aekuBHVzu--qO7A">40,000</ix:nonFraction>&#160;of its common stock from time to time in ATM offerings under the Shelf. &#160;The Company sold&#160;<ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_lCt9u7t8z0W44yS58i4_kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_o2cGyANHG0-zKAjZIGtfRQ">2,859,074</ix:nonFraction>&#160;shares of common stock pursuant to the ATM during the year ended December 31, 2023 for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_lCt9u7t8z0W44yS58i4_kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_ABAkIHi4G0qIjb6GgR0bKg">5,286</ix:nonFraction>. As of December 31, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_fYz-UjM3pkmim-rRGGRZzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:SharesOfferingAgreementRemainingValueOfStockToBeIssued" scale="3" id="Narr_scETmmzTQ0Sz4vVwe0NGdg">34,714</ix:nonFraction>&#160;remaining of common stock available for sale under the ATM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lincoln Park Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q" decimals="-3" format="ixt:numdotdecimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_JZ75MUzIgU-NrkV0ePXOoQ">35,000</ix:nonFraction>&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;<ix:nonNumeric contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q" format="ixt-sec:durwordsen" name="cgtx:PurchaseAgreementTerm" id="Narr_eSFYaIEkqU6kgekBO6XP_A">36-month</ix:nonNumeric>&#160;period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued&#160;<ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YvS0pJtz_UuLsHhUjVXDDw">189,856</ix:nonFraction>&#160;shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement (the &#8220;Commitment Shares&#8221;). The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Narr_ZvXtX5umEUyhl0Q3f9Oczg">318</ix:nonFraction>&#160;to other expense, net in connection with the issuance of the Commitment Shares. During the year ended December 31, 2023, the Company sold&#160;<ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-qpRdZ5AQUSFDAkLzfKPIw">125,000</ix:nonFraction>&#160;shares of common stock to Lincoln Park for proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_Pi-Rnx7T7kOCCIn5_PqMUQ">205</ix:nonFraction>, as part of the equity line financing arrangement. As of December 31, 2023, $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA" decimals="-3" format="ixt:numdotdecimal" name="cgtx:RemainingValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_fyStsB1Y8UeV76DgbV75gQ">34,795</ix:nonFraction>&#160;was available to draw pursuant to the Purchase Agreement.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Jdz4dhFWpkaWYo3Hdkj-7w" continuedAt="Tb_Jdz4dhFWpkaWYo3Hdkj-7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">9. Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 7, 2021, the date upon which the Company&#8217;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of December 31, 2023, the aggregate number of shares of common stock of the Company that may be issued under the Plan is <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_MjcyCtAoAkaWUPrkciHZmg">2,954,570</ix:nonFraction>. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2023 pursuant to an evergreen provision therein by <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_ecCutZaSMkeuO8iQOXjXGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr__4yj_RIPvEKLhwGf70JQHQ">1,449,577</ix:nonFraction> shares, representing <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_LRobkF0nj0SY3xdEzUjMVQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_iFj1VrHuz0axxS3hYYuycA">5</ix:nonFraction>% of total common shares </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jdz4dhFWpkaWYo3Hdkj-7w_cont1" continuedAt="Tb_Jdz4dhFWpkaWYo3Hdkj-7w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">outstanding at December 31, 2022. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_yDEeKMfAzkS-KSBkUEc6qg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_tz7SKPw_Dka6yEXlL518jA">5</ix:nonFraction>% of the Company&#8217;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#8217;s board of directors or the compensation committee. No more than <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_W9SysfqFDkaTNepYjUi24g">7,543,185</ix:nonFraction> shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the &#8220;2007 Plan&#8221; and collectively with the 2017 Plan, the &#8220;Prior Plans&#8221;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw" decimals="INF" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" scale="0" id="Narr_0bL5NFAbjk-b9uDcNWzY8w">4,334,131</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2017, the Company&#8217;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_uguCNEEtGkiIZdHpBUsd8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Mrdo76deGE6dHSmTU01-zg">4,334,131</ix:nonFraction> (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#8217;s common stock at a discounted purchase price. As of December 31, 2023, a total of <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_rrHi5dcFDE-G4d-8RUX0Kw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_2s9uDvrjnUOhWX2F1C0wGg">209,532</ix:nonFraction> shares of common stock was authorized and reserved for issuance under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_WLXjwrWnP0CgsWctD9xbtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_jrEmeV7VfUmxseN2AV1o1A">1,000,000</ix:nonFraction> shares of our common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_WLXjwrWnP0CgsWctD9xbtg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_3WYaxQtmWU2KsWkmg5FaIQ">1</ix:nonFraction>% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Nh3zoO3GB0Gdo6Pfc80ZmQ_1_2"></a><a id="Tc_GWTVqt4vZ0Crwid83Fnl_A_2_2"></a><a id="Tc_kxeuBBsH30ec-wkcLEDAsg_2_4"></a><a id="Tc_jW5gqmuf8EOsARFhWxEA1g_3_0"></a><a id="Tc_WLpgFXdhak2AgXonrfPmzA_3_2"></a><a id="Tc_nSIv3-TpJ0i_NVz99sBjGA_3_4"></a><a id="Tc_PmVJn2dmAkunmS787J87QQ_4_0"></a><a id="Tc_ksOuGEgd8ECGScejjxSalQ_4_2"></a><a id="Tc_5FrJzV7JukCXWUElpJEg-A_4_4"></a><a id="Tc_0YGdJGaK20yDkPuxlDLf2g_5_0"></a><a id="Tc_19YpAxVmhUmrigAY3M0pzA_5_2"></a><a id="Tc_Z9XgQzx5fE6Q1dt9cCO8ag_5_4"></a><a id="Tc_kvjHKsBTqkeFpCmmr6l3Mg_6_0"></a><a id="Tc_iYFrcIK2J0SCFuszO3oNrg_7_0"></a><a id="Tc_p3lfJNqFdEykLJ10gyN4RQ_7_2"></a><a id="Tc_0kdQkPNZmkaOVBtIhLqV9w_7_4"></a><a id="Tc_jjdgejDWKEmNuSk3lRk5VA_1_2"></a><a id="Tc_8U4JsabGPUqsb0fLzUTxqQ_2_10"></a><a id="Tc_EbogcC91QkivvHLwhSWgMA_3_4"></a><a id="Tc_BS1cDSxgGE2QrhU5XpUObg_3_7"></a><a id="Tc_MMQc0_GhLkyUJORFAARHNw_3_10"></a><a id="Tc_31m_5UhP-0W7bbA5CQMOpg_4_4"></a><a id="Tc_8_1TVn5jykifRPwLEBCJ5Q_4_7"></a><a id="Tc_DTk_Nn2OEEKpdMMrf5a5eg_4_10"></a><a id="Tc_OlnhfWQazE2wQl8Pu2KimQ_5_2"></a><a id="Tc_LT4tIygpckWKVjISzqAbhg_5_4"></a><a id="Tc_Fm5JvhXKckyjT-bDyBgRDQ_5_7"></a><a id="Tc_dZb5Z83dR0GXtw4KaFYikA_5_10"></a><a id="Tc_fDAYY1sDpk6yGe1uL5zRBg_6_2"></a><a id="Tc_axBaborAJE6ZaXOoteddfw_6_4"></a><a id="Tc_6Th7Dz6wr0CykZmQMo3fkw_6_7"></a><a id="Tc_oSUAqtHb1UCqsT3y4aOFBQ_6_10"></a><a id="Tc_iT8xxKTQO06xsOhFazsQPw_7_0"></a><a id="Tc__SDIK8d9h06CLv75SN1Hfg_7_4"></a><a id="Tc_VSDF8o3V0k6UfyGRuvWofA_7_7"></a><a id="Tc_hyabt3dKNUq26gKRoTVzgQ_8_0"></a><a id="Tc_51j1ppKQ506J1SqATYghgg_9_0"></a><a id="Tc_k7Pjq7EkHkmRGDoIgzd9wQ_9_2"></a><a id="Tc_dncSToykSUCKKvzptgg05w_9_5"></a><a id="Tc_BC_2SyTw-0ShJaTpA8hvOg_10_0"></a><a id="Tc_wK_WLPOYDESpLLPDDBvOxA_11_0"></a><a id="Tc_V5GPEK-G0kOEIpH5mhCecQ_12_0"></a><a id="Tc_UyfOr7D-VUCBNqX5jAXrng_12_4"></a><a id="Tc_-5utmZs9XEOLCv8BsnrWGw_12_7"></a><a id="Tc_iYonR5yHkESTvV5kGae6rQ_13_0"></a><a id="Tc_IABDJc19VECPVuQsaq6Dvw_13_4"></a><a id="Tc_2PaCd_TuEEuoKIf3wrelaw_13_7"></a><ix:continuation id="Tb_Jdz4dhFWpkaWYo3Hdkj-7w_cont2" continuedAt="Tb_Jdz4dhFWpkaWYo3Hdkj-7w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_lCc_NntOXU632R-UmDKjbw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_8bYcitqYY0y77znhmkKzNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_dsNJ7EWwDU-ZOuZay9k9rw">1.20</ix:nonFraction> &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_QC7xgFr49EmCFLiMsbsf_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_VkDgsYhuxESH_DxNRJixqA">2.99</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_gQpvyXpSRE-aqnPz6O907Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_PRi2CVkoBkifdcK_tA7Dmg">1.72</ix:nonFraction> &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_tRoSIxX58UuuBcSM22cTJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_8a9NbZFmJEGkivuOmBhLmw">3.05</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_Wiu3HBJ0zUK0tMpjKAH-0w">91.47</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_2ZMboJSULE-er7UuVGP48g">92.68</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_g6Y57BrWuUSzhKQ5HEHSFA">91.09</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_Oexg0kFvF0qKyvqU4P7yZA">92.73</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_EZK4TpjkMkCAbcSxp_4apA">3.46</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_aFd80g3nwEaEkOvuAnig1w">4.71</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_coMRkL3ghUmdpsAyYO2JgQ">1.87</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_TzpKaBkolEuXcuYSsG17kA">4.22</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_SQiE4B5HMUq0idTNHar0bw_6_2">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_SFe3RC31-0mrkVyDMTfVKw_6_4">0.00</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_cgCekGBDeU-iow6w5GkUWw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr__08FV_c69Eu5cFxwh3gmKg">6.18</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_fSE3Go7PW0eAeiIVxPMeeA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_SidjY7dQNkWAxEaefCUwEQ">6.37</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_oU9CqFmCiUKDm0PxrYz0zw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_I8MPUxWL9Um9d29yBGPs5w">5.50</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kQSwmvFsp0mgTkQQwG0VHA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_ATdhbz-HpkCIwmk55kqDsw">6.40</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8201;&#8212;&#8201;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8201;&#8212;&#8201;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8201;&#8212;&#8201;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividend Yield</i>&#8201;&#8212;&#8201;The expected dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_uTLP1UfrOUmiIRQVJrXajw">zero</ix:nonFraction> as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Common Stock</i>&#8201;&#8212;&#8201;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Activity for options was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb__-V7QHAhmE2uHEa4nnVeww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_49ZFCHa-MEqGR5YaDXlTAg_7_2">3,679,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_607trlmcWUSVR9POlXaEnw_7_5">5.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_fJjKhZ9cYEi2hq3OX83daw_7_8">2,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_yJkAcrcT90CHrnketNRIBw_7_10"> 6.7</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_OKRL5RK--E2zZQKLAAtwgQ_8_2">628,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_bGKhFOMhckC75YTyIoVH0A_8_5">2.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_vEyxrGOAxUeu4Xi_tXUCwQ_10_2">83,931</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_lKicsDrKhU64CcDDYFXLvA_10_5">1.98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_4DvehEQhK0-ZIW7ErugS4g_11_2">10,901</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_LlzrwQVTK06bM8tnPIFPEw_11_5">2.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_3KEwZj0J5UKjcYGeiIUVqA_12_2">4,213,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_cYkSviN4GUqTsf0rcBiL5g_12_5">4.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_Di7Yd7lxyEyfsHhdk2lOkA_12_8">1,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_T7NHuDjgk06AwhUzIi5UeA_12_10"> 6.5</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_A5rw1sXCD0K6xo43Mq_z_Q_13_2">3,012,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_mXZ9GXAgQkekXcgL5JaFsw_13_5">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_CcgdfVWSeU-WW766rXNtPw_13_8">1,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_WPRDdvmKdkih5VjleqOHaA_13_10"> 5.7</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_x2inZENANUmIG1Tzeo2UJQ_1_2"></a><a id="Tc_0UZRvyAK60yLtzH22xcRIg_1_4"></a><a id="Tc_U80yBLrltUOZzYaftyKwXQ_2_2"></a><a id="Tc_erhMisiJvEu5nHvFu4dyZg_2_4"></a><a id="Tc_gqMZXdJXfEyPE1YpyyNvIQ_3_0"></a><a id="Tc_ObGncfJDUEW-jeZhli1ukQ_3_2"></a><a id="Tc_7xjoyw4D2EKNxbpQ-614dA_3_4"></a><a id="Tc_QQRy4050EkC_lVrfhDIN5Q_3_5"></a><a id="Tc_P6T4hRUrLEmdPWr5VwFI6g_4_0"></a><a id="Tc_Ldm8y8Lp-0Ouuj7KQQ-6kQ_4_4"></a><a id="Tc_3AypLmXMC0GXxZJ2f-rZhA_5_0"></a><a id="Tc_Sco18dfqCk-HcCQG63NiQQ_5_2"></a><a id="Tc_2QdHvzdcp0ST7Wz2rtzAXg_5_4"></a><a id="Tc_Lcv6Kp28wk2KParuh2Nq1w_5_5"></a><a id="Tc_c1BQJD6pQEe4RYtjOZKUqA_6_0"></a><a id="Tc_WUREYrwmx0OCnSawzto8QQ_6_4"></a><a id="Tc_-UodqAw5_keE-jMHZgJifQ_7_0"></a><a id="Tc_bBeGHxrbmkGey8EQq9s6RA_7_4"></a><a id="Tc_P02pJCkDH0W5G3DWkYR5Sg_1_3"></a><a id="Tc_TzqfpF6cEEWsMFp1I2N4fg_2_3"></a><a id="Tc_T9VAw_zqCUmDpZ5ojWCx2Q_2_6"></a><a id="Tc_5m11-LtKjUKdvbo0lL_i-g_3_0"></a><a id="Tc_TADGxrp-okKUv2SARsbLcQ_3_3"></a><a id="Tc_09UBXnQlgU6MEDBV1aQO9g_3_6"></a><a id="Tc_qcoiy5H0VEmPqhlGl7jyqA_4_0"></a><a id="Tc_Vw9CyOP7-E--31BZfG_rkg_5_0"></a><a id="Tc_Y0x18NS7o0OC5JQEVjnOJQ_5_3"></a><a id="Tc_b4D95nE14E2HSCQQZzge8Q_5_6"></a><ix:continuation id="Tb_Jdz4dhFWpkaWYo3Hdkj-7w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_qsomFLyJ7EaR2VRpzuL_YA">1.56</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Qr-6TQdbO0SzBjCPPXu7YA">1.83</ix:nonFraction> during the years ended December 31, 2023 and 2022, respectively. There were <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_4m6vXzo__UueeJmoqpBv3w">628,769</ix:nonFraction> stock options granted at an aggregate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" scale="3" id="Narr_wBBGo-db9k-Jh7QuwftIMA">983</ix:nonFraction> for the year ended December 31, 2023 and <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Zng5DFSd1USvWQCUxmgh_A">524,370</ix:nonFraction> stock options granted at an aggregate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" scale="3" id="Narr_NQNJs37eLkeMRavxO1nffw">943</ix:nonFraction> for the year ended December 31, 2022. During the year ended December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_BGOhK0xlS0a-8dIGkCUnKQ">0</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_KusW01TmK0aODINZ2VRdUA">1,761,516</ix:nonFraction> stock options exercised, respectively, with an aggregate grant date fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" scale="3" id="Narr_d13bBAgy_UOjMG7YMaM5AA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" scale="3" id="Narr_7HksVzh7YUyFfkhRyYcBjw">1,325</ix:nonFraction>, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_jKpLbpc8H0e-bhNAqncxeA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_ZC_YQaLF3kWlgfaBiCQmwQ">2,738</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The fair values of RSUs are based on the fair market value of the Company&#8217;s common stock on the date of grant. Each RSU represents a contingent right to receive <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA" decimals="INF" format="ixt-sec:numwordsen" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" scale="0" id="Narr_Mhqb7goV3EasTAPNRBkyng">one</ix:nonFraction> share of the Company&#8217;s common stock upon vesting. RSUs for employees vest annually over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_EmployeeDirectorMember_Ln6Hn2FojEa8itKVr-awUw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_CvzP3d_PNU-KuIMwhkqsrA">three years</ix:nonNumeric> on each anniversary of the Grant Date and RSUs for non-employee directors vest on the <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_-Aambe7M-Ei21IEK190qVg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_qC6xtXN6kUmfiTvCnlJ8Mg">one-year</ix:nonNumeric> anniversary of the Grant Date. The following table summarizes the Company&#8217;s RSU activity for the year ended December 31, 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_vJO_rntdGEaGTcxuT8t-kg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_qEJErd_t7EW3FCR-Vkul-Q_4_2">542,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_4M1rxkTRxU23kcefUZYFjA_4_5">2.07</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_rCQfRJhx0kWECo_U2wwFZA_6_2">20,264</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_nSMvWy4MmkaqWEgBFHElAQ_6_5">1.97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_efBKw3qAME6ZmwdlSdK_6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_rcBi7LE9vEK1qC_YwOpGdg_7_2">522,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_efBKw3qAME6ZmwdlSdK_6Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_BkqRYuhO6kq_wgYvP6ntQQ_7_5">2.07</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity-based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_SOh8lixfnkqTUX5R0ENPyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T29Qjyz35U2p3fWGxDsVjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2sFslSw9WEO1zfe88KLyyA_3_4">670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tqAFWsRuSEOU2TS77Gr5vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_SVIQWYNALkyzDUqw94VZjw_3_7">528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W7FO-pbJEUO0d761WgliwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ylEXh0PGkUORdhD1tKsi9Q_4_4">3,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_70PXE3i9G0SgTEnVDcJbMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DuQJX9LSvUKMXMUdZ_9EvQ_4_7">3,044</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HuWzX14kkkq-ftOEclyOSg_5_4">4,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_KGlEwqPmzUaLZw_-eRyPqA_5_7">3,572</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, total future compensation expense related to unvested awards yet to be recognized by the Company was $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_ZatDqmN11UCsfphGjJSs9A">4,258</ix:nonFraction>. Total future compensation expense related to unvested awards yet to be recognized by the Company is expected to be recognized over a weighted-average remaining vesting period of approximately <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_KdpFLT3eLUO4tON21nvyfQ">1.6</ix:nonNumeric> years.</p></ix:continuation><a id="Tc_dtIKnriTbU-9aCmbn6mRFg_1_2"></a><a id="Tc_UPNzs8kh-EegxYR8oAjx0w_2_2"></a><a id="Tc_vllXUbeg-0WWJ0gg5jmc_g_2_4"></a><a id="Tc_wOr0h3U5xUOukrX4wJwL1A_3_0"></a><a id="Tc_OM9kLksOLkiUumWL-w5HpQ_4_0"></a><a id="Tc_m-BaMG_AN0ajDv3lI6slxw_4_4"></a><a id="Tc_88xEt3Ir60OIwNV9eIBLnQ_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:EarningsPerShareTextBlock" id="Tb_53AmBpHPy0W9vNrGbXiH5w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">10. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_6oAtPgffMUaWlGegNoKFEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Tcs3Fe77zk-E5SHgaFWR2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sW3P_Qk13k6K4AOi16Qfrw_3_2">4,213,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_MrwJ0AbrfEahvl8J7zIwLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_a9IivEU32UeyrveDjtR-_A_3_4">3,679,468</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pRPh5Rg4yk2qvio_UPRCJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Qf2gFWZLI0-XiACEY6dMnQ_4_2">522,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Bs1SHCj0nUWSYrmDEdDc1Q_5_2">4,735,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_iUYBP8IQvUiw8ayy2IBhzw_5_4">3,679,468</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;font-style:normal;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_Vj42ovN4KkO01c9psGPBdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">11. Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_gAsVVV23AEe1d5nUNNFK-w">6</ix:nonFraction>% of the employees&#8217; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="Narr_Vk7a0LByN0ORcV80NcuqyQ">199</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="Narr_53n8F3Zh8kC2FDhdQSq-Qg">156</ix:nonFraction> for the&#160;year ended December&#160;31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_aY0gHpUhpUKue6x8vQgnXw_1_2"></a><a id="Tc_27apCDdl7kmiD2fArf8l5g_2_2"></a><a id="Tc_onlyYagqw0ieb3XjF0ek9w_2_5"></a><a id="Tc_rDUtjPxnWEyDfSu-kiVJxA_3_0"></a><a id="Tc_9xC5WOadxEupBvhg0lizGQ_3_2"></a><a id="Tc_YT6UqPu-3keCr3-HGRHfrA_3_5"></a><a id="Tc_Zd8bxolyGE2zMEQUGjK9fg_4_0"></a><a id="Tc_3K3JYf1tFE6xceEtSY9Vbg_5_0"></a><a id="Tc_G_r86SXlLUC8oQ2VX1BZ6A_5_2"></a><a id="Tc_Uhv_WlyQXEG-wjcjk7b5cg_5_5"></a><a id="_cd8b0f8b_295f_4eb4_aa76_0b43912ce55d"></a><a id="_cd8b0f8b_295f_4eb4_aa76_0b43912ce55d_2"></a><a id="_cd8b0f8b_295f_4eb4_aa76_0b43912ce55d_3"></a><a id="Tc_7E5ENcljk0i7fxo9RfLqFw_1_2"></a><a id="Tc_5mZ_IkByNkaiUGqvpRRtNw_2_2"></a><a id="Tc_oHe3yUXpAUephQq259wcLA_2_4"></a><a id="Tc_nd_7EX2_okmjeES6lhBV_A_3_0"></a><a id="Tc_RQMjhcui106IhUuBdEFYcw_3_3"></a><a id="Tc_7HmpHSnD1UKq6CGsTXRbVw_3_5"></a><a id="Tc_8Xu1KlyA2UC-X25Dy6RQvg_4_0"></a><a id="Tc_--u3j8HTp0y_naL570pIJg_4_3"></a><a id="Tc_GW6dng6lgkivjCeL7nMj0Q_4_5"></a><a id="Tc_gADCBMfD30GZ9WI-UtNAbw_5_0"></a><a id="Tc_tnULu99ZBEqAKyFS1l6SXA_5_3"></a><a id="Tc_6GTKclY1MkKm34lez5q_kg_5_5"></a><a id="Tc_OMkwRKjf7UWsYxXZ2Dvw2w_6_0"></a><a id="Tc_D9IUkJEkzkGFQEowgs770A_6_3"></a><a id="Tc_CjzGmcgqA0aaZ1g4lOj-rg_6_5"></a><a id="Tc_QmM8ZKyYOESz98pspVVjmA_7_0"></a><a id="Tc_f2vV3UTqvkWq4FaXtLufXg_7_3"></a><a id="Tc_o4ZCc5sXt0SepNen6nfq9w_7_5"></a><a id="Tc_bNlA0oDMBEugHYp7l9nBJQ_8_0"></a><a id="Tc_3oCpP77A_EmRYmMxINQRsg_8_3"></a><a id="Tc_oJpxFDWXqkudsujH0wOOTA_8_5"></a><a id="Tc_ns0ImRnvQkKzUIVtFOh_QQ_9_0"></a><a id="Tc_l6KQDBXOoEmapAAuhFYYFg_9_2"></a><a id="Tc_fbl4J0VEM06uSrli9d0BDw_9_3"></a><a id="Tc_2jKxsxLWvE2jwV3AIErIOg_9_4"></a><a id="Tc_eNsP57JIk0acfXLZcsdFdw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_QGZ2yMwYX06_G2oZwz0Epg" continuedAt="Tb_QGZ2yMwYX06_G2oZwz0Epg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The net loss consists of the following components:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_VUTNk6oW0ECcGZieKVnLbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_JW_MkLDbeU-yFGxMZfN6iQ_3_3">25,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_9o4mZqSAfkmlpJh-5j71iw_3_6">21,384</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_rm2iFqqnlEKNLv8eFfd4Kg_4_3">21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_kweX1_9NukmE0_mVLwMgrw_4_6">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VKSxQP7oykKXE86_w59gXQ_5_3">25,788</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Lz085U7Bh0GxxTkchzXelA_5_6">21,397</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2023 and 2022, the Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_ZhTk3OYq0ku8piZMu8bDDg"><ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_8grkNmBg0kW4l7O9027i_Q">no</ix:nonFraction></ix:nonFraction> current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) is the excess of a U.S shareholders total net foreign income over a deemed return on tangible assets. In January 2018, in response to inquiries by companies, the FASB issued guidance that allows companies to elect as an accounting policy whether to treat the GILTI tax as a period cost or to recognize deferred tax assets and liabilities when basis differences exist that are expected to affect the amount of GILTI inclusion upon reversal. The Company has elected to treat GILTI as a period expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;D expense over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside of the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_LE6zMQ4QPUGUuRoXO3tW4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_YMWXOlAXO0-HQ2BUj5Jctg_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_HK_u68IwMECzCS_17Mm6Xg_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_1titDZdpCEO6fthGTIzijA_4_2">0.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_7_t2JEXNREivplzBuUp1kg_4_4">15.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_81X1DVa-J0CAN07Wg9mewA_5_2">22.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_y-0cWRywsEKHecNRA-l0hA_5_4">12.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_D364VKehuUmgy9VqphlsIA_6_2">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" sign="-" scale="-2" id="Tc_W8StB5ptxE6s5vccSq4TvQ_6_4">15.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc_bf8Jyec7wUiREFjOOArnJw_7_2">3.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc__6a4AspilEOE6UqyjUYFqQ_7_4">1.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_bmQtAKukpUmJ2d8Hn14t7Q_8_2">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_yo95y-600kCvRF579y0Xmg_8_4">0.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IaRy7QVwrkym_xK37VrTog_1_2"></a><a id="Tc_1ipdcBRKVU6-quvBCH3SWQ_2_2"></a><a id="Tc_2XbIwDiyRky66iAXMNmG0A_2_5"></a><a id="Tc_qkdkKKctzEK4zIyKbuS0SA_3_0"></a><a id="Tc_g_u4e19tYE2Fu6nX74xr4A_4_0"></a><a id="Tc_y_QaaqS-fUaiJU4Ga0noDw_4_2"></a><a id="Tc_h90uMnVcCEW7tXBJo8Hy6A_4_5"></a><a id="Tc_tVg3KhY420iox9NCqBKcDQ_5_0"></a><a id="Tc_85xzj_ubxkOBRGQgGSS2fQ_6_0"></a><a id="Tc_YZE6Y-QMW0WcONqye4sjwA_7_0"></a><a id="Tc_-_eZqkZcgEezzgNANHDAUg_8_0"></a><a id="Tc_5Su2poe1V0SVOp0cSWeSgw_9_0"></a><a id="Tc_Qb-BMlKHEUetKYrahmKstA_10_0"></a><a id="Tc_eAjb9cvmgUC2ArnuGt_9Cg_11_0"></a><a id="Tc_Wpy1ua-F9UOXoTJH54Q2zA_12_0"></a><a id="Tc_n6q5bOkL_0CEQfqQ8gEE3w_13_0"></a><a id="Tc_KtRfaKAwT0OFOS4Pjfwz8A_15_0"></a><a id="Tc_0ckjNs2YY0CIjm69caAPqg_16_0"></a><a id="Tc_fEyajgrlZEeb-0mvnPI3uw_17_0"></a><a id="Tc_e8JmfsMJxEav56tJTM-O1A_18_0"></a><a id="Tc_ny6BjAcIr0a_3qTneLFEOA_19_0"></a><a id="Tc_RQ4unpHarUOvfofPZyR2zw_19_2"></a><a id="Tc_HSXpWCIlvEW05BLq4q6zag_19_3"></a><a id="Tc_67OddoyITkS-aRXRO66JjA_19_5"></a><a id="Tc_lryiY_-VAUK8u8HpHhXAsg_19_6"></a><ix:continuation id="Tb_QGZ2yMwYX06_G2oZwz0Epg_cont1" continuedAt="Tb_QGZ2yMwYX06_G2oZwz0Epg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The Company&#8217;s deferred tax assets and liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_nrXNmUhPfESqWWU_lGkqzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_JtcbNRX33kygrFD0EaaFNg_4_3">6,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_0Y_gykuKL0KrkemQdPCxKg_4_6">8,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_Dz249aUTDkqfem9h3q35-w_5_3">3,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_5cH_McsMAkuow0z22rwUMA_5_6">1,728</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_e3xAO_0HyUalyJiLlqigwQ_6_3">407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_W9UpSXGuV0OTbieji3TV4w_6_6">307</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_SGUMa9vsSUydl6yNwTQlNg_7_3">148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_A9ka3CiI0k-C8wyBu06F0Q_7_6">178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_u_oK3NHbjE2gv3jviH3V5g_8_3">11,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_-w1VlLax0keqqSNAkyziDQ_8_6">5,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_QU3OMbPzaEqds8yeja5sgA_9_3">223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_ojpA7UobAU-6vBuh0B7rpQ_9_6">354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_D2yDPNRm6E2Yz7mEwg2Z1w_10_3">246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_UNtOdPI36UOSIhSqMANmYQ_10_6">165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_CQsDAsXXYk-EeRyT7ZQ5pA_11_3">22,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_k7t6ElvOTU6n2FiW3MAlkA_11_6">16,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_ovGji26-60iRk1JZNy0aug_12_3">22,207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_cbQbNyA5t0KWYbzwu740IA_12_6">16,435</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Z1vZEWzFPE2PegHPWjfXDg_13_3">147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Pf1iKT_anEyaWl-0rZMTQQ_13_6">178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_O5BOQM-RkUu_2IOJcBOvzA_16_3">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_7pwxauSfxkGSi3e6g7rB_w_16_6">7</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_OCQROXhbvEmsIUO6b_ZdFA_17_3">139</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc__xUXYSZnokuJDzaIQonMfQ_17_6">171</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_KdmHyoCtYkGF3GwBYWMQ9w_18_3">147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_2OrxfUmglUqATTmeyhxLPA_18_6">178</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2023 and 2022. Management has considered the Company&#8217;s history of cumulative net losses and has concluded as of December 31, 2023 and 2022, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2023 and 2022. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_eC1pUsoftEWXM4Tyrae3oA">5,772</ix:nonFraction> and decreased by $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Narr_sk_cb8VwhEmiNmv4pv59SQ">2,610</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively. The increase in valuation allowance in 2023 was primarily a result of an increase to capitalized research expenditures, while the decrease in valuation allowance in 2022 was primarily a result of a reduction in operating losses and tax credits, offset partially by the capitalized research expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company incurred net operating losses (&#8220;NOL&#8221;) since inception through December 31, 2021. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;D expenses, the Company was in a taxable position as of December 31, 2023 and 2022, and has utilized NOL generated in prior years to fully offset their income tax expense. As of December 31, 2023, the Company had federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_huPDgo3JRUCGo3dkA69tCg">29,843</ix:nonFraction>, net of Section 382 limited amounts. Included in federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_GoGOptgaDE6_M-lvMqRENg">29,843</ix:nonFraction> is $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:OperatingLossCarryForwardsSubjectToExpiration" scale="3" id="Narr_IwgbhB0ebUm5EL0xBmO_Tg">11,501</ix:nonFraction> that begin to expire in 2035 and $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:OperatingLossCarryForwardsNotSubjectToExpiration" scale="3" id="Narr_ERCogLQ-iU2-7K_6WSpnjQ">18,342</ix:nonFraction> that can be carried forward indefinitely. As of December 31, 2023, the Company had state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_7LajySWg40OL9NM2rgbwrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_jY3T5h3Bd0aBBp1b19lk_w">12,060</ix:nonFraction>, available to reduce future state taxable income, which will begin to expire in 2028. As of December 31, 2023, the Company had foreign net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_q3DH0WMQa0CmwYFvp51zwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_kIsJb0NiakyN9ShR_b-Qog">349</ix:nonFraction> and foreign research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__0_YbKxmOU2r78jXkEEzlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Narr_VZ0sLAzYnEOc0a5ycfOPrg">268</ix:nonFraction> that can be carried forward indefinitely. As of December 31, 2023, the Company had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:ResearchAndDevelopmentTaxCreditCarryForwards" scale="3" id="Narr_1xZymyxE10KcNPa1ghrsOA">2,851</ix:nonFraction>, net of Section 382 limited amounts, available to reduce future federal tax liabilities, which will begin to expire in 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Utilization of the Company&#8217;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The amount of the limitation is determined based on the value of the Company immediately prior to the ownership change and could be subject to additional adjustments as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. In 2023 the Company completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_QGZ2yMwYX06_G2oZwz0Epg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_XUZrCkEwDEyMKEMstcPgZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="Narr_fEY-QTOJg06DVDHm9gXT0Q">589</ix:nonFraction> of federal net operating loss carryforwards expiring unutilized. &#160;The Company updated the analysis through December 31, 2023 and determined that it is more-likely-than-not that the Company&#8217;s existing net operating loss and research and development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively, due to the conclusion that an ownership change did not occur in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue for tax years beginning on or after January 1, 2020; however, carryforward attributes that were generated prior to January 1, 2020 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww" name="us-gaap:SubsequentEventsTextBlock" id="Tb_tabj-x9Bi02BZuX6xPKdvw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">13. Subsequent Events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale by the Company of <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mUz7VNnd5EuqjwdONSKJpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ZbtK4NLsoUuHBGiMQE8i0w">6,571,428</ix:nonFraction> shares of its common stock, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_nrintSTwQECLB58C0p_EaA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_Fi7QNIrvLky5VbPlFzvniQ">1.75</ix:nonFraction> per share before deducting the underwriters&#8217; discount. The underwriters were granted an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mUz7VNnd5EuqjwdONSKJpQ" decimals="INF" format="ixt:numdotdecimal" name="cgtx:UnderwritersOptionToPurchaseAdditionalShares" scale="0" id="Narr_rA_NjmvUL0SAOBfk0SPDTw">985,714</ix:nonFraction> additional shares of common stock, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA" contextRef="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_nrintSTwQECLB58C0p_EaA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_b0OKv_3JoUSgmEqNyIdzfA">1.75</ix:nonFraction> per share before deducting the underwriters&#8217; discount. This offering was made pursuant to the Company&#8217;s Shelf Registration Statement, and a related prospectus supplement dated March 11, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On March 14, 2024, the Company closed the offering, excluding the underwriters&#8217; option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ" decimals="INF" format="ixt:numdotdecimal" name="cgtx:UnderwritersOptionToPurchaseAdditionalShares" scale="0" id="Narr_bZi5oi_TiUmm9kmhYvBv0Q">985,714</ix:nonFraction> additional shares of common stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_6MAQvDB-PUW0vEavRnXsMQ">10,361</ix:nonFraction>, after deducting $<ix:nonFraction unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ" decimals="-3" format="ixt:numdotdecimal" name="cgtx:UnderwritingDiscountsCommissionsAndOfferingExpenses" scale="3" id="Narr_HTmoFMSys020LLwcxg6CLQ">1,139</ix:nonFraction> of underwriting discounts and commissions and estimated offering expenses payable by the Company.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_38cb8e29_a7fd_4682_8568_a4afe39009d0"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_80069763_767a_4f32_9627_d823df350228"></a><a id="Item9AControlsandProcedures_434960"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our President and Chief Executive Officer and our Chief Financial Officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer, to allow for timely decisions regarding required disclosures, and recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Controls over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Changes in Internal Control</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our management, including our President and Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the system are met and cannot detect all deviations. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or deviations, if any, within the company have been detected. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a17b7672_2d1e_4db0_867f_75f4e054d83b"></a><a id="Item9BOtherInformation_878908"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Rule 10b5-1 Trading Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_slyfpVK_VEW68Boop4OX0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">During the three months ended December 31, 2023, the following directors or officers (as defined in Rule&#160;16a-1(f)&#160;of the&#160;Exchange Act) adopted&#160;or terminated a &#8220;Rule <span style="-sec-ix-hidden:Hidden_EhWfKhNhJ0mxDKk9K-W3pw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span>b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item&#160;408(c)&#160;of&#160;Regulation S-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100.09%;"><tr style="height:1pt;"><td style="vertical-align:top;width:19.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.81%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:19.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name and Title</p></td><td style="vertical-align:middle;width:13.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Action</p></td><td style="vertical-align:middle;width:12.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td><td style="vertical-align:middle;width:13.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan</p></td><td style="vertical-align:middle;width:22.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aggregate Number of securities to be sold</p></td><td style="vertical-align:middle;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan Expiration Date</p></td></tr><tr><td style="vertical-align:middle;width:19.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw" name="ecd:TrdArrIndName" id="Narr_oYW6j5bUnEG_KH5QuF_k6Q">Aaron Fletcher</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw" name="ecd:TrdArrIndTitle" id="Narr_t9NOD0pxQk6c52VQknRFRg">Director</ix:nonNumeric><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:middle;width:13.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;width:12.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 29, 2023</p></td><td style="vertical-align:middle;width:13.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;width:22.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2,000,000</p></td><td style="vertical-align:middle;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 28, 2025</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(1) The plan was adopted by BIOS Equity Partners, LP. BIOS Capital Management, LP is the general partner of BIOS Equity Partners, LP. <span style="letter-spacing:0.2pt;">Bios Advisors GP, LLC, an entity controlled by Dr. Aaron Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to shares directly or indirectly held by the</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">BIOS Equity Partners LP.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0a4758d4_8b4a_44d1_9721_30659c0b4649"></a><a id="Item9CDisclosureRegardingForeign"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5d469cda_de5c_4dda_9025_cbe54f0743f1"></a><a id="PARTIII_479695"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our definitive proxy statement related to the 2024 Annual Meeting of Stockholders, or the Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><a id="_bd683f1a_e5f5_49d7_9665_39b68c5fe35a"></a><a id="Item11ExecutiveCompensation_635596"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4cf3ee16_839a_46f4_b626_976ec7e1db17"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_df000952_393c_4ea8_8723_1726b057846e"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2e38f99e_de02_45dc_9d75_3aeb2547e965"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountant&#8217;s Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PartIV_346291"></a><a id="_1623df11_7d93_4ca1_a693_c38d24c226fe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">(a)(1) Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Index to Consolidated Financial Statements</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentAccountingFirm"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID 42) </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">120</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofStockholdersEquity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">121</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">122</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">(a)(2) Financial Statement Schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">(a)(3) Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The following is a list of exhibits filed or incorporated by reference as part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e34cbe8d_ca70_49ed_81e0_2ec0b4dd8aae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT&#160;INDEX</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.39%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.17%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Certificate of Incorporation of Cognition Therapeutics, Inc.</span></a>&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/14/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837023008117/cgtx-20230331xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of Cognition Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2023</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837022004672/cgtx-20211231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/30/2022</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922129904/tm2233311d2_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indenture</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268992</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/2022</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Investors&#8217; Rights Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Third Amended and Restated Investors&#8217; Rights Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Office Lease Agreement between RJ Equities LP and Cognition Therapeutics, Inc., dated July 1, 2017</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Office Lease Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement between 2500/2700 Westchester Avenue Owner SPE LLC and Cognition Therapeutics, Inc., dated July 1, 2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2007 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/04/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2021 Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/04/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Award Agreement under the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of&#160;Stock Option Grant Notice and Award Agreement under the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated June 1, 2020, between Cognition Therapeutics, Inc. and Lisa Ricciardi</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/tm2314004d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated April 17, 2023, between Cognition Therapeutics, Inc. and John Doyle</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/01/2023</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922115489/tm2226999d4_ex10-29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Office Lease Agreement, dated August 31, 2022</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268228</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.29</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/07/2022</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employee Restrictive Covenant Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/29/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Board of Directors of Cognition Therapeutics, Inc. Nomination Letter of Mr. Brett Monia, Ph.D.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/29/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 08/14/2016</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.39%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.17%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 09/08/2018</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 08/28/2020</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 02/03/2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 05/06/2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 05/10/2021</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922129904/tm2233311d2_ex1-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Controlled Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:5.62pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;Sales Agreement, dated December 23, 2022, by and among the registrant, Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268992</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/2022</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923030852/tm239035d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase Agreement, dated as of March 10, 2023, by and between Cognition Therapeutics, Inc. and Lincoln Park Capital Fund, LLC</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2023</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923030852/tm239035d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of March 10, 2023, by and between Cognition Therapeutics, Inc. and Lincoln Park Capital Fund, LLC</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2023</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465924025580/tm246515d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Performance Restricted Stock Unit Award Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/20/2024</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20231231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Cognition Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP, independent registered public accountant</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20231231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc.&#8217;s Compensation Recovery Policy</span></a></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.39%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:43.15%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.17%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.82%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.54%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_59961f14_4451_4f2d_9818_cccd9dd5d5aa"></a><a id="Item16Form10KSummary_806161"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3f83037f_a01f_4ad5_afc8_c5bb30f22fcb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 26, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Lisa Ricciardi</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer) </i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 26, 2024 by the following persons on behalf of the registrant and in the capacities indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1.1pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.05pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Lisa Ricciardi</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer, President and Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 26, 2024</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lisa Ricciardi</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ John Doyle</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 26, 2024</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">John Doyle</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Jack A. Khattar </p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director (Chairman of the Board)</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 26, 2024</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Jack A. Khattar</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Aaron G. L. Fletcher, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 26, 2024</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aaron G. L. Fletcher, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Brett P. Monia, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 26, 2024</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Brett P. Monia, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Ellen B. Richstone</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 26, 2024</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Ellen B. Richstone</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Peggy Wallace</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 26, 2024</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Peggy Wallace</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>cgtx-20231231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/25/2024 02:25:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:39.12%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.18%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:14.83%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:41.8%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:39.12%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:2.18%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:14.83%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:41.8%;margin:0pt;padding:0.75pt;"></td></tr><tr style="height:8pt;"><td style="vertical-align:bottom;width:39.12%;border-bottom:1px solid #000000;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Subsidiary</b></p></td><td style="vertical-align:bottom;width:2.18%;border-bottom:1px solid transparent;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ownership percentage</b></p></td><td style="vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.8%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction of incorporation or organization</b></p></td></tr><tr style="height:10pt;"><td style="vertical-align:top;width:39.12%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Cognition Therapeutics PTY LTD</p></td><td style="vertical-align:top;width:2.18%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:14.83%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">100%</p></td><td style="vertical-align:top;width:2.05%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.8%;background:#cff0fc;margin:0pt;padding:0.69pt 0.69pt 0.75pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Australia</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cgtx-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/25/2024 02:25:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We consent to the incorporation by reference in the Registration Statements: </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-260686) pertaining to the Cognition Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan, the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan, as Amended, the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan and the Cognition Therapeutics, Inc. 2021 Employee Stock Purchase Plan, </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-263968) pertaining to the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-270784) pertaining to the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-268992) of Cognition Therapeutics, Inc.,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-276316) of Cognition Therapeutics, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of our report dated March 26, 2024, with respect to the consolidated financial statements of Cognition Therapeutics, Inc. and subsidiary included in this Annual Report (Form 10-K) of Cognition Therapeutics, Inc. for the year ended December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 26, 2024</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cgtx-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/25/2024 02:25:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Lisa Ricciardi, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of Cognition Therapeutics, Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:38.8pt;text-indent:-38.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:40.5pt;text-indent:-40.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 27.8pt 0pt 0pt;">Date: &#160;March 26, 2024</p></td><td style="vertical-align:top;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">/s/ Lisa Ricciardi </p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cgtx-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/25/2024 02:25:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, John Doyle, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of Cognition Therapeutics, Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">. JK</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 26, 2024</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">/s/ John Doyle </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">John Doyle</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Chief Financial Officer </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cgtx-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/25/2024 02:26:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 26, 2024</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Lisa Ricciardi</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lisa Ricciardi</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to Cognition Therapeutics, Inc. and will be retained by Cognition Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>cgtx-20231231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/25/2024 02:26:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 26, 2024</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John Doyle</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer<br>(Principal Financial Officer and Principal </p></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Doyle</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting Officer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to Cognition Therapeutics, Inc. and will be retained by Cognition Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>cgtx-20231231xex97d1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/25/2024 02:25:59 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;97.</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font><b style="font-weight:bold;">1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_Hlk121482929"></a><b style="font-family:'Times New Roman Bold';font-weight:bold;text-transform:uppercase;">Cognition THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPENSATION RECOVERY POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Adopted as of November 13, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Cognition Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), has adopted a Compensation Recovery Policy (this &#8220;Policy&#8221;) as described below.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with rules issued by the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Nasdaq Stock Market.    Capitalized terms used and not otherwise defined herein shall have the meanings given in Section 3 below. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Compensation Recovery Requirement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Definitions</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Applicable Recovery Period&#8221; means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Applicable Rules&#8221; means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Board&#8221; means the Board of Directors of the Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Committee&#8221; means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Covered Person&#8221; means any Executive Officer. A person&#8217;s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person&#8217;s current role or status with the Company (e.g., if a person began service as an Executive Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">f.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Effective Date&#8221; means October 2, 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">g.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Erroneously Awarded Compensation&#8221; means the amount of any Incentive-Based Compensation received by a Covered Person on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_Hlk121482897"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">or after the Effective Date </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules. Incentive-Based Compensation is deemed received, earned or vested when the Financial Reporting Measure is attained, not when the actual payment, grant or vesting occurs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">h.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8220;Exchange&#8221; means the Nasdaq Stock Market LLC.  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">An &#8220;Executive Officer&#8221; means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive-Based Compensation and received Incentive-Based Compensation after beginning service in any such role (regardless of whether such Incentive-Based Compensation was received during or after such person&#8217;s service in such role): the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy making function or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">j.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8220;Financial Reporting Measures&#8221; mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, any measures that are derived wholly or in part from such measures (including, for example, a non-GAAP financial measure), and stock price and total shareholder return.  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">k.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Incentive-Based Compensation&#8221; means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure. </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">l.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">A &#8220;Financial Restatement&#8221; means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">m.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;Restatement Date&#8221; means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Exception to Compensation Recovery Requirement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">Tax Considerations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">Method of Compensation Recovery</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">requiring reimbursement of cash Incentive-Based Compensation previously paid;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">adjusting or withholding from unpaid compensation or other set-off;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">cancelling or offsetting against planned future grants of equity-based awards; and/or </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">f.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">any other method permitted by applicable law or contract.</font></td></tr></table><div style="margin-top:12pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person&#8217;s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">8. </b></font><b style="font-weight:bold;">Policy Interpretation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">Policy Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">This Policy shall be administered by the Committee; provided, however, that the Board shall have exclusive authority to authorize the Company to prepare a Financial Restatement. In doing so, the Board may rely on a recommendation of the Audit Committee of the Board. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy.  The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding and conclusive.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">Compensation Recovery Repayments not Subject to Indemnification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk121482930"></a>Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy<a name="_Hlk129762974"></a>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cgtx-20231231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %\ [,# 2(  A$! Q$!_\0
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M_P#&"^%]+'AO7M+U"QT72_L<?V6RU"*.Y6X,4>,*8OLC.,?=\U,8XK\]#UH
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M8KROXR_#ZU\ _"+PI9R65M'K,&MZK9W5ZD2K+<+&8_++,.67!R,GC=0!]/\
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MK1^#_BR^O/"OBS3;_4M:GUG1I&22+7DA^UVNZ+<BF6+Y)1U(? /;'3/I&I^
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MZ>7;AT8[$R3M//S*"3PV0,TNK_ 'P!KFN'5[WPO9SZD2A^T9=3\@ 3A6 X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOX;U>+5(=,?2KU=2F56CLS;N)I 02I5,9((&1QTJ?J]!;Q1+R_!)V=-'M?\
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M%?\ Z".E?^"M?_BJ\"HH^JT?Y4/^S<'_ ,^U]Q[[_P -P_%;_H(Z5_X+%_\
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M4?5:/\J#^S<'_P ^U]Q[Y_PW#\5_^@CI7_@K7_XJE_X;A^*__01TK_P5K_\
M%5X%11]5H_RH/[-P?_/M?<>^_P##</Q7_P"@CI7_ (+%_P#BJ/\ AN'XK_\
M01TK_P %B_\ Q5>!44?5:/\ *@_LW!_\^U]Q[[_PW#\5_P#H(Z5_X*U_^*I/
M^&X?BO\ ]!'2O_!6O_Q5>!T4?5:/\J#^S<'_ ,^U]Q[[_P -P_%?_H(Z5_X*
MU_\ BJ/^&X?BO_T$=*_\%B__ !5>!44?5:/\J#^S<'_S[7W'OO\ PW#\5_\
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M1TGSPV/CLURIX9^UHZP_(]UHI <T5YA\T+1110 4444 %%%% !1110 4444
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M/$7@KQ%X*\-VFM>'/ =IKFE7^I7NO>)$,]MO@CC(LHB)(QO?S"=^[.U,JI-
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M,;L8QQG%;5?#OQ4_9#UKQ]\;?%/BR?PE;:A'?>//#UY!?27T:2-HL5G%#J
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M=/CUXR6^T_6)KP72>8]M?11QD^1'C"M$Q'&.I-?I8W]*_+7]JO\ Y.'\;_\
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M@W_H%:]_X,H/_C%<S11RC]FN[.F^U^#?^@5KW_@R@_\ C%'VOP;_ - K7O\
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M_P# ZP_^-UYSSZ4=*/9+NP^JK^>7WGH_VGX/_P#0-\>_^!UA_P#&Z/M/P?\
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M7<,?6OFW: <X%&Q?0#/M25)J]F3'!R@FHRWO^)Z=XV&LVWPRTNT\7RW3Z_\
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M(^$?^'=WB7_H<M)_\ 9?_BJ/^'=WB7_H<M)_\ 9?_BJ^[J*/KM?^8/[9QO\
M/^"_R/A'_AW?XE_Z'+2?_ &7_P"*H_X=W>)?^ARTG_P!E_\ BJ^[J*/KM?\
MF#^VL=_/^"/A'_AW=XE_Z'+2?_ &7_XJC_AW=XE_Z'+2O_ &7_XJONZBCZ[7
M_F#^VL=_/^"/A'_AW=XE_P"ARTG_ , 9?_BJ/^'=WB7_ *'+2?\ P!E_^*K[
MNHH^NU_Y@_MK&_S_ (+_ "/A'_AW=XE_Z'+2O_ &7_XJC_AW=XE_Z'+2O_ &
M7_XJONZBCZ[7_F#^V<=_/^"/A'_AW=XE_P"ARTK_ , 9?_BJ/^'=WB7_ *'+
M2O\ P!E_^*K[NHH^NU_Y@_MK'?S_ ((^$?\ AW=XE_Z'+2O_  !E_P#BJ/\
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M Z5WQ QZU2EU>Q@D:.2\@CD7JC2 $'WYH-J,I0J1G%7::?W'S5X^TK4/'O\
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M )_[?_OZO^- >SG_ "LO9HS5'^WM._Y_[?\ [^K_ (TG]N::3_Q_VW_?U?\
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M+>:,U4_M>Q_Y_8/^_J_XT?VM8_\ /[!_W]7_ !H#EEV+>:,U4_M:Q_Y_8/\
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M?^?V#_OZO^-']KV/_/[!_P!_5_QH#EEV+>:,U4_M>Q_Y_(/^_J_XT?VO8_\
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M_P">B?\ ?0HLPYX]Q]%,\V/_ )ZI_P!]"CS8_P#GHG_?0HLPYX]Q]%,\V/\
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MQN5@),9>-L%ESS@\'!KMJZXR4ES(\RHJE*;A)ZHR/^$3T/\ Z!%A_P" L?\
M\31_PB>A_P#0(L/_  %C_P#B:UZ*HSYY=S(_X1/0_P#H$6'_ ("Q_P#Q-'_"
M)Z'_ - BP_\  6/_ .)K7HH#GEW,C_A$]#_Z!%A_X"Q__$T?\(GH?_0(L/\
MP%C_ /B:UZ* YY=S(_X1/0_^@18?^ L?_P 31_PB>A_] BP_\!8__B:UZ* Y
MY=S(_P"$3T/_ *!%A_X"Q_\ Q-'_  B>A_\ 0(L/_ 6/_P")K7HH#GEW,C_A
M$]#_ .@18?\ @+'_ /$T?\(GH?\ T"+#_P !8_\ XFM>B@.>7<R/^$3T/_H$
M6'_@+'_\31_PB>A_] BP_P# 6/\ ^)K7HH#GEW,C_A$]#_Z!%A_X"Q__ !-)
M_P (IHG_ $"+#_P%C_PK8HH#GEW*$6BV%O;/;165O%;/]^%(E"-]5 P:K_\
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M_ 6/_P")K7HH#GEW,C_A$]#_ .@18?\ @+'_ /$T?\(GH?\ T"+#_P !8_\
MXFM>B@.>7<R/^$3T/_H$6'_@+'_\31_PB>A_] BP_P# 6/\ ^)K7HH#GEW,C
M_A$]#_Z!%A_X"Q__ !-'_")Z'_T"+#_P%C_^)K7HH#GEW,C_ (1/0_\ H$6'
M_@+'_P#$T?\ ")Z'_P! BP_\!8__ (FM>B@.>7<R/^$3T/\ Z!%A_P" L?\
M\31_PB>A_P#0(L/_  %C_P#B:UZ* YY=S(_X1/0_^@18?^ L?_Q-'_")Z'_T
M"+#_ ,!8_P#XFM>B@.>7<R/^$3T/_H$6'_@+'_\ $T?\(GH?_0(L/_ 6/_XF
MM>B@.>7<R/\ A$]#_P"@18?^ L?_ ,31_P (GH?_ $"+#_P%C_\ B:UZ* YY
M=S(_X1/0_P#H$6'_ ("Q_P#Q-'_")Z'_ - BP_\  6/_ .)K7HH#GEW,@^$]
M$'_,(L/_  %C_P *THXEC0*BJJ@8 48 J6B@3DY;L8.#3Z**"0HHHH ****
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ML9V!(>5R[#@#C)./ZUQ=U^S?X-OK>\-Q:S2ZI=3O<MK#2 WBR,^_<K8P-IP
M"IP!7CO_  W#J'_0H6O_ (,&_P#C='_#<.H?]"A:_P#@P;_XW0\?@6E%RT7D
MPCP_GL).<:;3?FO\SV\_ OP_)J6GWTLMY/<66HRZHAD=#NED W!OE^[E00/4
M=:KR? ?38UTHV&OZ[I,VG02V\4]E<1J[))(9&#$QG/)[8Z"O&/\ AN'4/^A0
MM?\ P8-_\;H_X;@U _\ ,H6O_@P;_P"-U/UW =)?@S3^PL_>\']Z_P _-GTQ
MX2\(:?X+T:'2]-200(S2-)*^^261CEG=CU8GDFM[FODG_AN"_P#^A0M?_!@W
M_P ;H_X;BU#_ *%"U_\ !@W_ ,;K99GA$DE+\&<DN&,YG)RE1NWYK_,^M>:.
M:^2O^&XM0_Z%"U_\&#?_ !NC_AN'4/\ H4+7_P &#?\ QNG_ &IA/Y_P9/\
MJMF__/G\5_F?6O-'-?)7_#<.H?\ 0H6W_@P;_P"-T?\ #<.H?]"A;?\ @P;_
M .-T?VIA/Y_P8?ZK9O\ \^?Q7^9]:\T<U\E?\-PZA_T*%K_X,&_^-TO_  W#
MJ/\ T*-K_P"#!O\ XW1_:F$_G_!A_JMF_P#SY_&/^9]:<T<U\E_\-PZA_P!"
MC;?^#!O_ (W1_P -PZA_T*%M_P"#!O\ XW1_:F$_G_!A_JMF_P#SY_&/^9]:
M<T<U\E?\-PZA_P!"C;?^#!O_ (W2_P##<.H?]"A;?^#!O_C=']J83^?\&/\
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M/^##_5;-_P#GS^*_S/K7FCFODK_AN'4?^A0M?_!@W_QNE_X;AU'_ *%"U_\
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M_P!"A:_^#!O_ (W1_:F$_G_!A_JMF_\ SY_%?YGUKS1S7R5_PW%J'_0H6O\
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MF1ZT;AZT +12;AZTM !1110 4444 %%%% !1110!&0<#M7YZ_M$?\EK\6_\
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M CQ'=OL-X#%;WTOF7#O@[FCZD)ZG(!RN,GITVH1:>WA9O!\5W(=5L+47B0B
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M_)K7C_ZS?^BUKYN-?2/PE_Y-9\??6;_T6M?-S=:];&ZTJ/\ A/D,B_WG'?\
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MGI^T.1_PNOQ;_P!?2_\ HJ.OT*VY7 KYP^)/[)U_X[\<ZQK\7B&WM([^591
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M7\0_UHR?_GY_Y*_\CYD(![9HP#U _*OIS_AB'4_^AIM/_ 1O_BJ3_AB'4O\
MH:;3_P !&_\ BJ7]F8O^7\2O]:<G_P"?OX/_ "/F0X/7FDP/05].?\,0ZG_T
M--I_X"/_ /%4H_8AU/\ Z&JT_P# 1O\ XJC^R\7_ "_B#XIR=_\ +W\'_D?,
M0 '0 ?2EP,8P,>F*^G/^&(=3_P"AJM/_  $;_P"*H_X8AU/_ *&JU_\  1O_
M (JC^S,7_+^(+BG*%_R]_!_Y'S'@9/O1@>@_*OIO_AB'4_\ H:K7_P !&_\
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M_P#T,^F?^ LO_P 51_PQ'K__ $,^F?\ @+)_\51_9V-WY?Q0EQ+DB5E45O\
M"_\ (^<I;N>X&)9Y91G=B20MSZ\GK3!*XC,>]Q&3DH&.TGUQ7T?_ ,,1:_\
M]#/IG_@++_\ %4?\,1:__P!#/IG_ ("R_P#Q5+^S<8]X?BBEQ/DR5E5_\E?^
M1\W9%%?2/_#$6O\ _0SZ9_X"R_\ Q5'_  Q%K_\ T,^F?^ LO_Q5']F8O^3\
M47_K5E'_ #^_"7^1\W45](_\,1:__P!#/IG_ ("R_P#Q5'_#$6O_ /0SZ9_X
M"R__ !5']F8O^3\4'^M.4?\ /[\)?Y'S=17TC_PQ%K__ $,^F?\ @++_ /%4
M?\,1:_\ ]#/IG_@++_\ %4?V9B_Y/Q0?ZTY1_P _OPE_D?-U%?2/_#$6O_\
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MCE>*D[.-C.IQ9E4(.4:MVNEGK^!Q/[/G[/<WCFXAU[786BT*-MT4#C!NB/\
MV3^=?:%I:16<$<$$2Q0QJ%5%& H'0 4ZSM([*!(((UBAC4*B(,!0.@%3A37V
M&%PD,+#ECN?BV;9M7S:O[6KHNB["C@4M%%=QXH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% "'H:^#O&7P*^)%WX6^*_B.PB\6-XCO\ QS<0+:IJD[/-X8^TQ221
MV5O]HCC!?#$8:-V 9 Z@U]Y4F!SQUH _/RY^&'Q#L/AUX&75]!^)?BOP)%JN
MKSW_ (6M+];+6H$DB5=/QY=V7\B.02,$>=F3S 6W  #3U+X!?$+QE8?%_5+O
M3O%UEXBA\)Z=:^$;2]\3321K>-IK1W7SQR+'-.&"*TK*!NY'.6K[PV@C&!CT
MHP/2@#X+_P"$=^*_CSXC:AK?_")^-- T.]\3^"W6TU&Y\EQ9P)<)J#%(YV"H
M"5WC/S J2#7%^%?@=\2O"'P\;PWH/A'Q;HMQ8Z7X[M;G;>/Y-U=7$:?V=)"?
M/.X,/E1B 0ZN>"2Q_2@*H[#\J-H]!^5 'YW>-_AQXU^&.@^(H&?Q)9^!KF/P
MG<:E:7?B*6.?4G#R#4X+>XGG!29QY0*+)'NP #DU[;^P%?OJ/@[XCRQ/JATE
M?&M]%ID6KZB;Z:"V6& )%YIDD#;>1@.P!R,D@U]*:WX>TWQ+IUQIVK:?::II
MUPNR:TO8%FBD7KAD8$$<#@CM1H/A_3O#&F6^FZ186FEZ=;@K%9V,"PPQC).%
M10 .2>@H T:*** "BBB@ HHHH **** &-\B$CMZUYAXJ_:A^$G@7Q!>:%XC^
M)7A;1-:LF"7-A?:K%%-"2H8!D8Y&00?H17J#C*D5X1X^_8<^"'Q4\8ZGXI\5
M?#^RU;7]1=9+J]ENKE&E8(J D)*%X55' '2@#1_X;.^!/_17_!?_ (.X/_BJ
M/^&SO@3_ -%?\%_^#N#_ .*KCO\ AVW^S?\ ]$NT[_P.O/\ X]1_P[;_ &;_
M /HE^G?^!UY_\>H ['_AL[X$_P#17_!?_@[@_P#BJ/\ AL[X$_\ 17_!?_@[
M@_\ BJX[_AVW^S?_ -$OT[_P.O/_ (]1_P .V_V;_P#HE^G?^!UY_P#'J .Q
M_P"&SO@3_P!%?\%_^#N#_P"*H_X;.^!/_17_  7_ .#N#_XJN._X=M_LW_\
M1+M._P# Z\_^/4?\.W/V;O\ HE^G?^!UY_\ 'J .Q_X;.^!/_17_  7_ .#N
M#_XJC_AL[X$_]%?\%_\ @[@_^*KCO^';?[-__1+]._\  Z\_^/4?\.V_V;_^
MB7Z=_P"!UY_\>H ['_AL[X$_]%?\%_\ @[@_^*H_X;.^!/\ T5_P7_X.X/\
MXJN._P"';?[-_P#T2[3_ /P-O/\ X]1_P[;_ &;_ /HEVG?^!UY_\>H ['_A
ML[X$_P#17_!?_@[@_P#BJ/\ AL[X$_\ 17_!?_@[@_\ BJX[_AVW^S?_ -$N
MT_\ \#KS_P"/4?\ #MO]F_\ Z)=I_P#X'7G_ ,>H ['_ (;.^!/_ $5_P7_X
M.X/_ (JC_AL[X$_]%?\ !?\ X.X/_BJX[_AVW^S?_P!$NT__ ,#KS_X]1_P[
M;_9O_P"B7Z=_X'7G_P >H ['_AL[X$_]%?\ !?\ X.X/_BJ/^&SO@3_T5_P7
M_P"#N#_XJN._X=M_LW_]$NT[_P #KS_X]1_P[;_9O/\ S2_3O_ Z\_\ CU '
M8_\ #9WP)_Z*_P""_P#P=P?_ !5'_#9WP)_Z*_X+_P#!W!_\57'?\.VOV;_^
MB7:?_P"!MY_\>H_X=M?LW_\ 1+M/_P# V\_^/4 =C_PV=\"?^BO^"_\ P=P?
M_%4?\-G? G_HK_@O_P '<'_Q5<=_P[:_9O\ ^B7:?_X&WG_QZC_AVU^S?_T2
M[3__  -O/_CU '8_\-G? G_HK_@O_P '<'_Q5'_#9WP)_P"BO^"__!W!_P#%
M5QW_  [:_9O_ .B7:?\ ^!MY_P#'J/\ AVU^S?\ ]$NT_P#\#;S_ ./4 =C_
M ,-G? G_ **_X+_\'<'_ ,51_P -F_ C_HK_ (+_ /!W!_\ %5QW_#MK]F__
M *)=I_\ X&WG_P >H_X=M?LW_P#1+M/_ / V\_\ CU '8_\ #9OP(_Z*_P""
M_P#P=P?_ !5)_P -F? C_HK_ (+_ /!W!_\ %5Q__#MK]F__ *)=I_\ X&WG
M_P >H_X=M?LW_P#1+M/_ / V\_\ CU '8_\ #9OP(_Z*_P""_P#P=P?_ !5+
M_P -G_ G_HK_ (+_ /!W!_\ %5QO_#MK]F__ *)=I_\ X&WG_P >H_X=M?LW
M_P#1+M/_ / V\_\ CU '9?\ #9_P)_Z*_P""_P#P=P?_ !5'_#9_P)_Z*_X+
M_P#!W!_\57&_\.VOV;_^B7:?_P"!MY_\>H_X=M?LW_\ 1+M/_P# V\_^/4 =
ME_PV?\"?^BO^"_\ P=P?_%4?\-G_  )_Z*_X+_\ !W!_\57&_P##MK]F_P#Z
M)=I__@;>?_'J/^';7[-__1+M/_\  V\_^/4 =E_PV?\  G_HK_@O_P '<'_Q
M5'_#9_P)_P"BO^"__!W!_P#%5QO_  [:_9O_ .B7:?\ ^!MY_P#'J/\ AVU^
MS?\ ]$NT_P#\#;S_ ./4 =E_PV?\"?\ HK_@O_P=P?\ Q5'_  V?\"?^BO\
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M\"?^BO\ @O\ \'<'_P 51_PV?\"?^BO^"_\ P=P?_%5QO_#MK]F__HEVG_\
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MW_\ 1+M/_P# V\_^/4 =E_PV?\"?^BO^"_\ P=P?_%4?\-G_  )_Z*_X+_\
M!W!_\57&_P##MK]F_P#Z)=I__@;>?_'J/^';7[-__1+M/_\  V\_^/4 =E_P
MV?\  G_HK_@O_P '<'_Q5'_#9_P)_P"BO^"__!W!_P#%5QO_  [:_9O_ .B7
M:?\ ^!MY_P#'J/\ AVU^S?\ ]$NT_P#\#;S_ ./4 =E_PV?\"?\ HK_@O_P=
MP?\ Q5'_  V?\"?^BO\ @O\ \'<'_P 57&_\.VOV;_\ HEVG_P#@;>?_ !ZC
M_AVU^S?_ -$NT_\ \#;S_P"/4 =E_P -G_ G_HK_ (+_ /!W!_\ %4?\-G_
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M3_T5_P %_P#@[@_^*KC?^';7[-__ $2[3_\ P-O/_CU'_#MK]F__ *)=I_\
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M_P"&S_@3_P!%?\%_^#N#_P"*H_X;/^!/_17_  7_ .#N#_XJN-_X=M?LW_\
M1+M/_P# V\_^/4?\.VOV;_\ HEVG_P#@;>?_ !Z@#LO^&S_@3_T5_P %_P#@
M[@_^*H_X;/\ @3_T5_P7_P"#N#_XJN-_X=M?LW_]$NT__P #;S_X]1_P[:_9
MO_Z)=I__ (&WG_QZ@#LO^&S_ ($_]%?\%_\ @[@_^*H_X;/^!/\ T5_P7_X.
MX/\ XJN-_P"';7[-_P#T2[3_ /P-O/\ X]1_P[:_9O\ ^B7:?_X&WG_QZ@#L
MO^&S_@3_ -%?\%_^#N#_ .*H_P"&S_@3_P!%?\%_^#N#_P"*KC?^';7[-_\
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MX;/^!/\ T5_P7_X.X/\ XJN-_P"';7[-_P#T2[3_ /P-O/\ X]1_P[:_9O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^L=X]:-X]:^3?MUS_P _$W_?P_XT?;KG_GXF_P"_A_QH^JON/^SI?S'UEO\
M>C?[U\F_;KG_ )^)O^_A_P :7[=<_P#/Q-_W\;_&CZJ^XO[/E_,?6._WHW^]
M?)OVZY_Y^)O^_A_QH^W7/_/Q-_W\/^-'U5]P_LZ7\Q]9;_>C?[U\F_;KG_GX
MF_[^'_&E^W7/_/Q-_P!_#_C1]5?</[.E_,?6._W%+O [BODW[=<_\_$W_?QO
M\:/MUS_S\3?]_#1]5?</[.E_,?6(D!I=XKY;N+VY_L:S/VB7_72_\M#Z)[U1
M^W7/_/Q+_P!_&_QI+#/N)9>W]H^L2X]:-_O7R=]NN?\ GXF_[^-_C1]NN?\
MGXF_[^-_C3^JON/^SI?S'UCO]Z-_O7R=]NN?^?B;_OX?\:3[=<_\_$W_ '\/
M^-'U5]P_LZ7\Q]9;_>C?[U\F_;KG_GXF_P"_A_QI?MMS_P _$W_?P_XT?57W
M#^SI?S'UCO\ >C?[U\G?;KG_ )^)O^_C?XT?;KG_ )^)O^_A_P :/JK[A_9[
M_F/K'?[T;_>OD[[;<_\ /Q-_W\/^-)]NN?\ GXF_[^'_ !H^JON/^SI?S'UE
MO]Z-_O7R;]NN?^?B;_OX?\:7[=<_\_$W_?QO\:/JK[B_LZ7\Q]8[_>C?[U\G
M?;;G_GXF_P"_A_QH^VW/_/Q-_P!_#_C1]5?<?]G2_F/K'?[T;_>ODW[=<_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #"<9KYN^)8/\
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M (2#5/\ H(W7_?UO\: ]XH;3Z&C:WH:O_P#"0:I_T$;K_OZW^-'_  D&J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 QN]?-GQ,=1X\UD%@/WJ]3_L+7TDXR#7SW\1-9OK7QMJT4-RR1
MK(H"@+Q\B^HKIP_QGHX&_M-.QQ7F+_>7\Z/,7^\OYUI?\)#J7_/V_P#WRO\
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M?,7^\OYT>8O]Y?SK2_X2'4O^?M_^^5_PH_X2'4O^?M_^^5_PHU"\NQF^8O\
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M'2O^NW]#7TT.M>;B?B1X&8?Q$.HHHKD/+"BBB@ HHHH **** "BBB@ HHHH
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M._\ 0$L/^_"_X4?\()X<_P"@)8?]^%_PI_6H]@_M&/\ *?,5%?3O_"">'/\
MH"6'_?A?\*/^$$\.?] 2P_[\+_A2^M1[!_:,?Y3YBHQ7T[_P@GAS_H"6'_?A
M?\*/^$$\.?\ 0$L/^_"_X4?6H]@_M&/\I\Q45]._\()X<_Z EA_WX7_"C_A!
M/#G_ $!+#_OPO^%'UJ/8/[1C_*?,5%?3O_"">'/^@)8?]^%_PH_X03PY_P!
M2P_[\+_A1]:CV#^T8_RGS%BC%?3O_"">'/\ H"6'_?A?\*3_ (07PZ#_ ,@2
MP_[\+_A1]:CT0?VC'^4^<KG_ ) UF/\ IM+_ "2J%?3P\$Z T:QG1K(HI)53
M N 3C/;V%)_P@GAS_H"6'_?A?\*2Q,5T)CF$4OA/F*C%?3O_  @GAS_H"6'_
M 'X7_"C_ (03PY_T!+#_ +\+_A3^M1[%?VC'^4^8J,5]._\ "">'/^@)8?\
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cgtx-20231231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'D B$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO8GHJF^L6$<'G-?6RP[_ "_,,RA=W]W.>O'2I[>YAO(5E@E2>)NCQL&4_B*
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M1=,UVXOKF:"5<K801,BJW5P_F!MX!8Y4<$#%?;7@P:;_ ,(U8-I(46+Q*\>
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MI:>//#-GJMJR?O5(=$<-M8'!Y'^>:_)[QW=W^H^([NSU"66"WMDG,=TI9TN
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYGR(^?\ Q?\ "S7M6U'6]*U66_\ $<6IOI'DZR=BM';PWH:6-D5%1'CWM(K
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M%+FG3<8M];[K3J:<C2YFC4HHHK@$%%%% !1110 4444 %%%% !1110 4444
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MDO;%,I!>E+8M!@J" ^>0C-$W&>/FXK[SV%+&.+JP6D8WT:<M?^'M9.]VCO\
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M<HN$G&6Z/)V"BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK&C2FWAN!L)/S#9.G/KGTK9M]2M+N>2""ZAFFC +QQR!F4'H2!TS0!9HHHH
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M_'Z5\KA\15NZ:?Q'T5:A3LIM;'SW\6OASKESK][J-IIHNY=S1M]FC+_+T
MSD;CQQQBN1^#_@C4/#WBI-1U!Y[.RLANG\TE6C)R-I'7+<\>@-?:_P 6_#.C
MZ-&)M2NVTV$QRR"^A.TJJ#+;_;&,U7U3PYX8\': ^MZE:1VMBL7GFX?YO/*(
M3NQC).T$_K6\LKQ,:DH6VZ]#*.8T)04K[FS\+]#N]1B']I%I%8&:'> 6@5D
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ML^(!;G^UVT2RLC<&1S^Y\^Y?9MSM W#/3/7U-=C0,**YOQ=XRM/#=O(KR@7
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M#82C1IJ,4?IWX1^(UM=Z5%=W;-;VCQ[P9<DH.W/7\#7GOQ8^.T'AR&9VRKH
ML=O))Y9,C#*J?3"\GJ?I7/> KW55TJ")9UNK>U@Q=-)\_P"\"@X&.A&W\S7F
MO[0O@G4?$>M">UM%O5C'F18;EB<9)'K\O4^@KIJYEB*F'5-R_P""84\!0A7<
MTCG/%WBZP^+,=I%K\5K-)@@K'/YI"G."-P."02,<CGKFO/\ XG?!BXUG7+7[
M.(4T6WTRV2V:$10RRD)&0'&_[RL@7&3N*@94Y88FB>!=>NO%$3>7<VQEF#O
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M,GN%'2O2Q=>E0KM59632_KY:?>SAPU&I6I)TXW:?]??^AS_[(/CRU\.>,Y]
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MP:;N[OK\[_F?3?Q<OAH&A/9V5PZ6.F10VT<;/D>6%5CD]V8%1D_W<U\+:_\
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MWTUDMO'#/>V(0K\L@R P/"G(8?4,.U2:SHGACX>R6+20I:,+NW2&"<;WW32
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MTQ2(4.22=S')YJX1D8-+179&$8+EBK(YI2<W>3NQ  !Q2T451(4444 %%%%
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M-/G6KZ'AU\RK5X\CT1'*I? '2GJ-J@>E+17M'E!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_1JU]JU^Y^'G^ZXC_$OR/R?C/\ WBCZ/\PHHHK]:/SH**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9?W<CJQ568'[H.S\;_V+K;XKW\B:5K.B^&=%?PZOAR.P/A6TN9;&$2%B]K<
MI)&=IVA&+H,LP7<01ZW<? ?X>W?BJS\2S^$=,FURS\LPWLD.YU:,!8W.>&=0
MH"N06 X!H ^>/!O[;'BO6=1\"76J>%=)@T+Q/?\ B2Q46ES*]S'_ &5#<2[^
M1M_>>2%VXXY.3D 8.I_M_>+M)^#^K^,W\"QS2)H6F:S9)+9:A9VZO=7L-NUO
M)+-$JR868,LL)97*MT Y^M;+X2>"=-_LK[+X4T>W_LF:ZN+#R[*-?LLER&%P
M\?'RF0.X<C[VXYZU@Z=^S1\*M*LM6L[;P!H*VFJK$EY ]FLD<J1R+)%'M;("
M(ZJZH,*K#( - '@WQX_;+\8? &RO7U?1_#>JZGHVDV^JZOI&D+J5S+")KQHD
M5IE@\BW4Q $/*X+." F"I.7/\8_'-QKWCB'7]7EGT_3/B[IWA[3$TFY>RDAM
MFBMW,3L@_>18D!*MDL2^3C&/IKQM\ _AS\2=:;5_%/@S1]?U![<6DDU_:K+Y
ML2L65'!X<*22NX';DXQDU97X*^!%U[5-:_X133&U34[R#4;RX> ,9KJ'_53D
M'@2+V<#/ YX% 'SIJ'[;/B+3M$T/QB_AK2G\%^(=<U+0--M1=2#5XI;>.<Q2
MSQ$;55FMG\Q0=T89/O9X[#X&_M*>+/B/XU\!:3XA\/:3I-KXO\#?\)E;?8+F
M2:2W >V01N6 !WBXW\ %>%.X@L?3D_9[^&L?BR[\3#P1HIUZZ:=YKUK12[-,
MK+.V#P&D#L'8 %@?F)XKHM*^'WAG0KW2KS3M!TZQNM)TT:/836]LB/:V64/V
M>,@?+'^[C^0<?(OI0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cgtx-20231231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &K SH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR:*+(#6_X2K5/^?K_P AI_A1_P )5JG_ #]?^0T_PK)HHL@-;_A*M4_Y^O\
MR&G^%'_"5:I_S]?^0T_PK)HHL@-;_A*M4_Y^O_(:?X4?\)5JG_/U_P"0T_PK
M)HHL@-;_ (2K5/\ GZ_\AI_A1_PE6J?\_7_D-/\ "LFBBR UO^$JU3_GZ_\
M(:?X4?\ "5:I_P _7_D-/\*R:*+(#6_X2K5/^?K_ ,AI_A1_PE6J?\_7_D-/
M\*R:*+(#6_X2K5/^?K_R&G^%'_"5:I_S]?\ D-/\*R:*+(#6_P"$JU3_ )^O
M_(:?X4?\)5JG_/U_Y#3_  K)HHL@-;_A*M4_Y^O_ "&G^%'_  E6J?\ /U_Y
M#3_"LFBBR UO^$JU3_GZ_P#(:?X5M^%=9O-2O)DN9O,58]P&T#G(]!7'5TG@
M;_D(7'_7+^HI-: SI=<N9+/2KB:%MDB $-@''(]:XS_A*M4_Y^O_ "&G^%==
MXF_Y =W_ +H_F*\[I(2-;_A*M4_Y^O\ R&G^%'_"5:I_S]?^0T_PK)HJK(9K
M?\)5JG_/U_Y#3_"C_A*M4_Y^O_(:?X5DT460&M_PE6J?\_7_ )#3_"C_ (2K
M5/\ GZ_\AI_A63119 :W_"5:I_S]?^0T_P */^$JU3_GZ_\ (:?X5DT460&M
M_P )5JG_ #]?^0T_PH_X2K5/^?K_ ,AI_A7+>*/$=CX/\-:MKVJ2-#INE6DU
M]=2(A<K%$A=R%')(53P*7PWX@LO%GAW2]<TV1I=.U.UBO;:1E*EHI$#H2#R,
MAAP:+(#J/^$JU3_GZ_\ (:?X4?\ "5:I_P _7_D-/\*Y34_$EMI6M:-I<L%[
M)/JKRQPRP6LDD,9CC,A,LB@K$"%(!<C<< 9)Q6K19 :W_"5:I_S]?^0T_P *
M/^$JU3_GZ_\ (:?X5DU%=7,=E:S7$IVQ1(9'(&< #)HL@-O_ (2K5/\ GZ_\
MAI_A1_PE6J?\_7_D-/\ "O//"'Q.T7QS;^'[G1Q?7-GKFE_VQ9W9LI5@,&4
M#R%=J.?,4A&(8@,0,*:ZVBR UO\ A*M4_P"?K_R&G^%'_"5:I_S]?^0T_P *
MR:*+(#6_X2K5/^?K_P AI_A1_P )5JG_ #]?^0T_PK)HHL@-;_A*M4_Y^O\
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M[0GB9_&_BG1_"7AG1-4L_#,T=K>OK.OII]Q=7!B29H[9"C*V$D4!I'0;\@D
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MYXEN=:^#'BKX2:EHWB?Q!J=YXHT/6Y=6_MK4I;R*YEBTMKR.00N?+C83(/\
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M4RF'.WS F<[<\;L8S0!>HJA<Z]IEGJMKIEQJ-I!J5TK-;V<DZK-,%^\40G+
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M =1110!Z?IO_ "#K7_KDG\A7,>.O]?:?[K?S%=/IO_(.M?\ KDG\A7,>.O\
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MX3T&\DU7P[JGCO1/$.JZTC7]M*VFW\-[([2VTBG+Q*V8R"!(4,:XW@<_3]%
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MI+X8?%_2?BC#>10:?JWA[6[#8;[0-?M/LM]:!\F-G3+*5<#(9&8=B0P(&?\
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M3BYT^WDNYI;>P+*RN;>%W*1$JS E ."1WKT.B@ HHHH **** "BBB@ HHHH
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MG ]A2>'/%%KKNDZ;<O+!;W5Y;I/]E\T%EW ''J>H[5MU<8T,0XUTDWT=M?\
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MI84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_*I:CN?^/>7_ '3_ "H \KHKM(O!-D\:,9KC) /#+_\ $T[_ (0>Q_Y[7/\
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M>C_A!%_Y_3_W[_\ KT707.2HKK?^$$7_ )_3_P!^_P#Z]'_""+_S^G_OW_\
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MI_[]_P#UZ/\ A!%_Y_3_ -^__KT707.2HKK?^$$7_G]/_?O_ .O1_P ((O\
MS^G_ +]__7HN@N<E176_\((O_/Z?^_?_ ->C_A!%_P"?T_\ ?O\ ^O1=!<Y*
MBNM_X01?^?T_]^__ *]'_""+_P _I_[]_P#UZ+H+G)45UO\ P@B_\_I_[]__
M %Z/^$$7_G]/_?O_ .O1=!<Y*BNM_P"$$7_G]/\ W[_^O1_P@B_\_I_[]_\
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M_$C3]7\0W.BSE++4!,8[6%I-S7*K;P32,.!C:)U!'X]\"CIOQBT34=7U"%)
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MSG_A!/%]E(VEZ7XILK#PV]T;DM_9[OJ,2M-YCPI*9MF#EE#&/*@]">:P-)^
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MHHH *0D*"2< =2:6J&O:+:^)-#U'2;Z/SK&_MY+6>/<5W1NI5AD$$9!/((-
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MZR;,UB/K$JZDT[K67K:UK)-[J^RZE7X:_M;^&_BEXFATK2M%UJ.WD9XSJ5Q
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MV$>6;NW'=[ZMWE=+M:+ZW:V/:****] ^/"BBB@ HHHH **** "BBB@ HHHH
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M;=0C6_S?NB,8*?,WR]/F/K3[_P +:-JBW2WFEV=TMTZR3B6%6\UU4*K-D<D
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MZYK_ "I__+Z/^N?]:9I?_(.MO^N:_P J?_R^C_KG_6@">BBB@!.M"J$4!0%
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M=];WW_K?8WITX4TJ5KKJ?7'P^_:L\-^,]:L='OK.YT+4M06W>RCG_>+-YJ9
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M77<%7'S!OXN,\<<]!BO::_ ,7AJF#KSP]7XHNS/G)P<).,MPHHHKD("BBB@
MHHHH *JR?\A2W_ZXR?\ H25:JK)_R%+?_KC)_P"A)0 FI_\ 'LG_ %VA_P#1
MBU;JIJ?_ ![)_P!=H?\ T8M6Z "BBB@ HHHH **** "BBB@ HHHH YCXF>*+
M7P9X"US6;U9WM;6U=G%L@:3&,< \=^_%?E[;:E);3G5]+@,=S-?0W42:I;&<
M3I*7S(KN ,DJ1A>/W;D9VC;]X_MGZ@^F?!>]ERT]N[^3+8H_EFX!!(PW4$$<
M##9)'!.*^$G^Q:-/9:3X?:!KE8//BNS?L7)5,RQLH"*Y5OD4!EP.N2=P_>.
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MQQPA1110 4444 %%%% %?4/^/&?_ '#5BJ^H?\>,_P#N&K% !1110 5'<?\
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M3_D*6_\ UQD_]"2K559/^0I;_P#7&3_T)*W,A-3_ ./9/^NT/_HQ:MU4U/\
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MJNC2?:/#MS+HUM97L,K:-:I(!+"W[MEE((#'?Y2[A\Q# ;3@*F9<0WUI9QW
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MR;?+;31QY=.Y]SC\T^O4,$XJTHS5W\35FK-W];GJFN^*O%VI?!R&6PEEBO\
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MUZYZX.!DUY1\.?VBC\7--U?3>8I498SYCY).<E4.U<G"\<<_CQH_#[P.VI^
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MP><IDG@D=< _*Q!!R17R/XG\,S^$_%FO75Q?6M@L#F32+A95>7"DDRQA,$$
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M2'&23YZH<M_ 3@\!:P/%_P /-3@D\2V,]]:65R^H07MG:VTYC@)SO<0AE&"
MQ&[&,S.#DC)I_"?]FG5_"OCF?4(+^81L/+968HT2Y!X4$CLO)QU)(Z9R?CQ\
M)?&?B#QJMQIMU/ \J+&(B\A"[0-W(!')7//7&>37+]>Q4</S3I]=':R.CZGA
MY5N6$^FJN=-\39;ZR\-?"F31[2'3_%%K9?V?$(HE6,W$+P111J&R-A<G:#QM
MD&<9KK?AQ8W6F^)OB/8ZK]IL;>YAGN[6;[RJT<DA>=>H/R2VJ@<_ZE@>^?,_
MBW:>(] \*^$YD#V^J11R+:-,BJ%*F#DH#M!XS^(!Z58_9N\=>-+?4M036DGE
MCA^6,7,A9]@'SE@<DX&TD$_3V^EQV:-4L![:'Q0=_P#P9-;?B<BP"=.HJ4OA
M>GX/<M7OQ0U^SC\/RP6$=E9PWLD<]T(-T<Y\BX7RW4CY"2%D_P"!J#R16GXA
M\+>%;;XP>)XM7F6Z=8(IK*$QDM(PA5CAD4X/"]U!+5Q?C/X\P:-XPU;PW#I9
M:QU:]Q>1,SNMQ*RQQE]P;(PL:+P!RN<]ZT]5\2Z'%\5-1\1:S-']AM(XHX[=
MV=?M#>2B!1C'93R021G& 2:RR[%8.MA<;!K14XWTMI[6G?;SL:2PV*IRC)/5
MWZ];/O\ ,[UX-#^('PCFU-],F32[*Y:TD  DC,"ME+A06R1Y;KN_B/..F2GP
MKT/P?X<\6:+H>FV]S<QZU:R2I+#@1QLJ,Q+X(96PN/490=SBU\/SI5]\-/%T
M.B:X++3+J0W=FP+(MO*J LA;&#%N1#\JCC<,8KF?!_B#PK)X^\)6NC:VD>IZ
M&5@4+$SBY7!CFW@8P?*)4')P54D5YG+E\9TJ[:UMZ:>1G?&N%2DD]+_CYFGJ
MN@^%])UGQ?)>6<4.M:(X:*"0L5:-S&(Y-RCH3*A(R<*PZ$D#I/B7K5ZO@KX?
M>*](D73[2=K:3[#/ SROYR"78P4X(P#N4#C'!QD'D?BGX]\)_#_Q3XB>[DEN
M?[?C1F$J;Q"@929,R-UWA=N. $C 'RBD\3^+-0D^!.BV_A2222.UMUCM-ZJ9
M%APRQ@'(^Y&8UW=>1UR:GZS@L(JL:2U\NNO?[BO88K$^SE4V\_3M]YL_!J\U
M"P^*'CJ36])N([75M/M9W2XPR6T?F7#1QMGALM/+&5'W3&O4/D><6]UX&\0Z
MM-H<5XTFJ-J(DBF=,VZCS)9&@15PVS$TD;$X^7(&#5W]G7Q)XVUUM1TK6TGD
M,K*D)GE.0HR?G)!/)V@DYZ\9Q6O9?LE-#X\&KQR/#)#+YD)DS(.2<Y';'U.3
M@\=*YJF-Q6*A!X:&BO?2^IO#"8?#RDJ\]7;R/ISP?-Y_AVT;=NP74_,6P0[#
M&3SQC'X5LU0T+3!HNCVEB&WB! @)J_7W-%2C2BI[V5SY&JXNI)QVNRKI?_(.
MMO\ KFO\J?\ \OH_ZY_UIFE_\@ZV_P"N:_RI_P#R^C_KG_6MC(GHHHH Q?%W
MBNQ\&Z+-J5^^R&,?KT'ZXKQOPU^TMI?Q(OK_ $6P7]\R$QY48V\8)*LW!Z<@
M'GI76?%F-/%%\?"DC,!=6J.H1L,2[2+E<<\; 3R.,^AKQ/P#^S79>%/&ETZW
MT$&J- TKVLSYD$ 8#?D@8&=HS@X'&>>/C<QQ>,GB/989/E6FG5]3ZC!8;#0H
M^TKOWGK\CC]5_9TUB[^($.IV%W,T*72SE=P1&#?,OS!N1P!C&1D8R*]<U'Q=
MI&A6-WHVO0!]9L+F$K<76WRUC<J#.0<$K"S9<#G85))SQK:!XOLOB)J=IX*\
M3Z?<Z!K5@@-KJ5O,83<31D\1L "I*>7)M#')#@9$>X\9XD^'MKX-UO6]8\:V
M:W^CPL\L%R6Q<7#*RN)F*_=QEU4+MQOD"X%32R^C@H.O)\R>]UHO7?6^A53&
MU,5-48KE:VMN_0[6YTF_UZ*WTFR@M],\9Z'+%K%E-:39MKV(-V*A>'&4(( 9
M78;@2P3G?$SZU+JDNM+I$T7BFPU"V74-(L[MI+;R6'FJ[CIAEA*''&)@Q ;<
MM5/V>?CGX:U'4+K2=.M6CN(HV*"9TDDAAW96$-PVT,S,$Z#<0#T \Z^.7Q3\
M;Z3XRD:PLGFAWHV4@^^^W!W$J>BE<>Y'H!2JYIAZ5&+H:Z[;6\]M_P ];CIY
M?6J59*MIIOO?R_K8]!U30-&TC3=*\00ZN;;PS?I+J,=U*@2[LMTB2-#CDL78
MS$_+\I$N"-X6NC^ ,?A*#4[V6RU&'4+:S1?L4DPD,]N64B8.[!0P8!#@J,-Y
MAZ-QAZ[X<O?C+\,HX[E95\M8Y)7!5P) /FQVX)/H-RGD=:J_ 3]G;4?!]W>$
MWTPMKKF9@Y4YP1@J,@<,QZGG&,<FL(8_$U,3!T:?NNVEOEN;3P="%"2JSU5]
M?^ 8OB_QKX!TG4_$WAV<+YNN:C'=23V\*9M=B1QQPJ"00 $9ONG'FGD'&/0_
MBQJ_A>#P?X9UC4W9;C27A ,8*+(H4X0*"%4,X4^H*J!Q7'^.OV35\2>,?[0D
M+@F7S2P5F5FSG& .F,X)/MBO0_$_P#.M>"ETV4K<2GYG124!D"X#<=![#IQ]
M*F%7,Y>T7)T[;>G]>94J> 7LWS?COZG+?"7Q?X;^(?B[7-8@DDTZ#4K&2SU2
MTMY!L9Y&0JQ=&)5DQ,,C@>:YR!BN;\1KX)T?3=1\+OJ,-I>RZA)<6LD1D=K=
M7VH%#%>OR;\,PPQ!'  KL_A#^S*O@4SRPS_9VF =E92=LNW Y.-P7)QP,YSZ
M5YK\0OV6;WQ!XX?41)+ SW G9.%!YR!N')/4="#ZUG.KF-/#QYH=7K;7O^>I
M4*>!G6?++HM+Z'JOQ,TF]\8:YX0U@W:PPLBVTZP1LOEY93)(SYZ+D.JD<[2"
M1N(K,^'?@LZ!X7^(OARXMO[=LKBW\ZUEM5;%UO:4A.@.X%AN[]6[UC_&CPAX
MHTCP):V6GS.+HJKSDRDKLR<J-P/'4<]G]ZP?V:;?QKX?AOFU%':4OYBL58 1
M@8&/X>_& 1@'TKH6:58XA0JT]7OO?:VQB\OIRHN5.>G3MOW*OC#7/'&K:#9Z
MMJ<FHW5KIE]/$)[.!;:]2 0MYV=@ 20C8J]"KD]@377_ !AU*#1/V@?#.IV1
MBU,:C;0,(99<(3)OB4(1TW +M'=F]#QY)XN^(WCO3_B0D4=A-]ADN1 "(_+B
M1 W)R00#]_OP!^75?&#QV?#WB;PGXC\D2_8[13!&@'RX<B,]1D L&!XX(]*^
M@R'-(5ZN)A./_+JHUUV@_P!#.ME\J3IRC+K;MN>B?";7M2\;>#?&-IJ$\4US
MIS27-O%=J0(BT]P71B.=H"JF#G& 0,$5RDOQ%\/Z)'I4NBZ UQ=2WS6-S#=G
M8XE,<K;!+N.5W1RIGJ-N<8ZS_ +XJ:-\0KW7)-0TZ.,7J_8KHA7C>X4@DY5>
M,D+U!SVSQ69XDUSX>Q2:AX,F8SEYVD@ND7)MC(@144;LG')').'QG&:\&6*P
M5:G&M-*^VN^CO^7^1<</BJ4Y4H-VW_#_ #,SQ'\(;#QY\==<T74I!,UL#(FW
MY3*?DR ,CGGUXKT!_"WA[Q3\+;VSL]2!M[1RMZ% #H/-,22E1T1O*89]!GL:
MXEK"36OC[!?7EZA2REMKN^OMFQ6$:QL\FW/RYV=B=I8=0,UZA\(?#%YH5QXX
MT6R6WU&SU&S\RSNY5_T>1@&4*_&<%9$!7&/D<C[U?49W@\)7QL$GK.E32UZ*
MG&SMOT.:.*Q-&FG;2+N].O74\Y^&?P6T;X:ZO9WMWK-O';:W,( \C$[SM=P
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MSN3G@<4O$_B#Q%X]OC>Z=87#:K/;-:&/3HF@N+:)XY1)'<+(VT[98U 8':2
MP)&",O4?&_@[6=6TS1)+Z>&^TS$-E?VK$^2YE9H]BGJR,4.3_='/4&3]I+QS
MXET^XBO-!M"RS*4N6CB^<HI/E@D#H3ELXXW>AKG_ +0PN'HM45?79:?.]O\
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M.EZ+9Z-9+:V4"6\*C 6,8%70,  4M%>K&*@E&*LD>?*3D[R>H44451(4444
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M>0_&?_D=O"/_ %Y:C_Z':5Z]7D/QG_Y';PC_ ->6H_\ H=I7IY;_ +U'T?\
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M %%%% %72_\ D'6W_7-?Y4__ )?1_P!<_P"M,TO_ )!UM_US7^5/_P"7T?\
M7/\ K0!/1110 E+110 4444 %%%% !1110 4444 %%%% '!_&O\ Y$=?^PGI
MW_I9#7&UV7QK_P"1'7_L)Z=_Z60UQM?18'_=_F_R1\5FW^^?]NK\Y%/6O^0/
M?_\ 7"3_ -!->K_#?_DG?A;_ +!5K_Z)6O*-:_Y ]_\ ]<)/_037J_PW_P"2
M=^%O^P5:_P#HE:C,/X,?7]#7)_\ >)?X?U.CHHHKP#[ **** "BBB@ HHHH
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MPS7FWCKQMK4WQ)L-3&HRQ3:GX;TZ.2:XMXPEBKWL\4DJQH77&4R&+NN7!+%
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M%=.V6!;<N "'PM\'_$EI\0[?Q+J=S9B)-7;46A^VR74NPZ:UIM+F) 6W;6Z
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MN]&%5J*].I"-6/)-:?Y'@T:M3#U/:4WK9K77>S^_0Z__ (7)IO\ T"-:_P#
M5?\ XJJFI?&&5X2ND>';V>X885[]TMX5/JQ!9L>P7\JYNBN98.@G?E_$[I9E
MBY*W-;T2_P""4[:VNIKZ?4]4NS?ZM<J%EGQM1%&2(XUYVH"3QR222235RBJF
MIZG%I5MYL@>1V8)%!$-TDSGA40=R37;OHCRV[7;8"Q7Q%XFT30@HD$TXO+E,
M9 MX65F)]B_EK[[J]YKBOAIX,G\.6MUJ.J+'_;FHD-.$.X01KG9"K=PN22>[
M,3Z5VM?/8VLJL^6.R_IGV>5X:5"DY35I2U]%T7Z_,****\\]D**** "OE?\
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MT]8^J@97@8KSL7@%5O4HJTNW1^G9GOY9G<L/:ABW>'275>O=>>ZZWW7O])D
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MSGQ'\)6\7>--:O\ 4-5O+;0M1TRTT^?3[&8(+Q$DG:6.?*$A")5 *,K8,@R
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cgtx-20231231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &X MT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ )ZFL&3_@G?J]U^Q1)\"9_&-E]KAU8:G::Q'9OY?^LW%'C+9[L,@^E?<-%
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MP@\2_#*WT_4'\'Z_=+?W5G->%V2Y 4":-R,JWR)ZCY1QUR ?#?[27A;6=/\
MAA^Q991^+=0O=2U#4-*FLM1U"WMW;33)%9B..-(XT5XXC@@.&8]&8U]0?\$_
MOC5XX^(7B[XW>#_&?B*?Q6O@[Q$;/3]3O(8H[AH2\R;7$2*I_P!2#TZL>V /
M1+_]AGX;ZIHG@K3+V?Q#=Q>#Y4N-'FGU>1Y8)4V"-]Q!Y411JH^Z @ %=?\
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M=FS ,Y,<+*<D$=>*T3I6G6^BQS"5EOP )8E^0NQ/ 'K]: /MW5/^"Q/CC1C
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MI!>1N@\I#GY=C=^* /T8A_X+3:%<,53X3ZN2 3_R%X?_ (W3F_X+1Z$L8?\
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M@32QJBD7K6%O("P<)O\ *XZ''7TK%O[AO*'D@ -EF(]:D-Q$44>6&^7#-G%
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MM;^T\,Z*=1U1H[B2>UM$,@BB"G#>G7IS7FXUW4='N$$L#F2%PGE7,?)(XP:
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M">Q,KQZ7?,JW050S% >U5+K&K7-[<[4MR6+K"G0 GHOL*FM_^)-;EY0'F)P
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M_P"PK<_S% 'V_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5^*W_!5]9'_;1B6,X)\,6F?IOFK]J:_%C_ (*MR/%^VG$T:;R/#%ID
M>V^:@#YI\+Z!?^-=0@T737ADGF5I/W["+:%&3\QP*KZGHIT&\ELI721D?:6A
M<,N>_/>NKOOA];Z;\+]*\6QZ_937%_?-;OHT3_Z3"JC.YAV4UE6%C#J!N+>V
MLRTKC]R2<E3W% #? 'B;4_#/BK3=8LKVZMI=/E\V&2!\/&<\E.P->B_%_0-.
MM)+?6K+7)M?OM50WUSYZ%Y%W'/[QN@.<U'X*^'R7UY>I:W#0W'V3_1U=-X>4
MXRIQTXS7HGC/X)ZIX:^&?AMI[QHFU)Y(IXC P\E@P"[FQ]TT >'2^$I_L-K=
MB;<MPOVB0VYW/;QCNP7IS5[7)]'TK2M-@\+:U>W&IS08U*==\7+=8L@_,O R
M:[[XI>#+WX RQZ1I6O6FMS7VG*-4%@N8X2X!\LO_ !8&*\<TNTOM2U&RT>QB
M*SZG(L$8' 9BP"C/UH RY82EV&C!\Z(_P]FSVKUC7/$.K0_"N"2\"ZC>37(M
M[J:[G\R9T*_*@7[R@>M=/X0^"%KX&\>OIWCFYDT>ZTPLEU/)$'MH+@KN0.W<
M,,$?6O-O%_BF#5[#;;6YMY+6ZE#WD:DI<?,=I/OCI0!/XJ^&+Z=X:L]3TNWF
M%L+83SFX78^[.#@=P"1^=95OX4UG2-+D'V><BZ"AHE5C&P/S+N/0_2J%KXKO
M[YH8[V_NFC "L/,Y9<@[<?4"MJ#XR^)X;B&WFO9Y]-1@?(8 #@\'..30!Z_^
MSG^S/K_Q\T35O[*5=.?1XS(Q:41.TW8%3VP#7C/Q%\-SZ;XON;*\24ZDF5F"
M?,I*Y!Y]>*^I/AMXM\%^"--U;Q0^N^)M)DUFS<?V=IH\S;-Q@2,.S')Q7R=X
MP\27^NZY<:J\D]QNE8,&7:%7L/K0!VWP>\:>(O@OJ>F^)]-O[[1M-O'>,7*1
ME8GPI5_]\C/2NO\ #'ASPC\2/B4^F6>K7^M7ETAFAN+E%MX X!?+Y[=:\I@\
M:W7B?P=%X0UO4KEK/2F>ZTFU10425B-VX]<$9KZ+_9]\/:1X.\$^)?&BW5C(
MT5N+:.&[0[)9,_,5/7\O6@#Y^\;W&O\ C;5VTRZNHYK'04D1=TP5(QDYY/6N
M*\,BWFN)[>23;MB8Q29P5<#(-.U^*;6]7U6^6)HH_,>::*(G"Y;@?2CPW'"E
MM<WK"-A&FV5'.& .0-OO0!DW6J316X@R<Y)8'D?45T_P_P#%L?@FY;57T2RU
MEQLVM>QEO*(8'('OC'XURK1Q3#S8P1\^ &/\/O72^'[%M?OK32;54>\F/E)Y
M9^4YZ?C0!]">+?%MXGA#P]K^FZGH]G=Z['?[X(-@^SVKG)@ (^4YX KRWQS\
M--=\#)X;\07+VS+J$27-BUC,DK+@\;U&=K#T->IW_P /O#%A^SMI?B%K^5_$
M5I=_9I]-EA!6, $DXZ[21C=[UX=<>+[O6[FZNI!Y,$B^6EM$P\N+CL.M &+X
MDUC6-2UB=M0FFN&\UG,+$'YVY8@#U]JRK<Q72BVDFD%IM:01QKDAZK2SS6MR
MDL<C"16PI)YS6A:P>67O-VPH-NQ1G+$T 6+:67P[83V_VAHGF4 K"W&T^I_I
M3M-U2X\-:_'J6GA9G@!PTJY[?>(K/DG:V\TJ&>-W^5)5Z^M/U% @,EM"]O&X
M!VR]=HZT ?0/A_XY6D7P[\2-JNGPZQXAU + DL\0*P@_Q@]F'&*\$U_5KJ="
MEU,7!D\P(W\3>I_"JEI<S"RNF21UY#+&/NGUS4*E-1<?:)/WI7: QX_&@ FM
M([:*&ZEDB9;@9,<+ M'SW'8U#-$\6987(0KE26PQ'3FHXH)(KM8A#EBVT <Y
M-:MII]NEW)%>+NE0?+%GY2?<^E %6WGN;5Q( @0Q["S<_4CWJK,\L@*CYH';
M"NXP:EN<&&1U. LG$9/3// ]*K&7:64'._@ _P /O0!TGPUM6B\>^&[B-]F-
M4ME)!P?]:M?T@)]Q?I7\W7P]#S?$#PP$. -3M5^N)5K^D5/N+]* '4444 %%
M%% !7BO[:W_)I'Q>_P"Q9OO_ $4U>U5XI^VO_P FC_%[_L6;[_T4U 'X$Z;J
MFGZ1I[[;47%W)&/+EE'" CK]:HQ3L]JT<TF^-FZ!N23_ $JA*S-;VZLN!L X
M[BEMX]LORNN%Y);I0 Z2SFCO?),9@. <,/X?7Z5)-<-9E[9)UECSSL^ZU17=
MW<W<JRSR^9(JA%;/\/85#"RI*I*Y /*T :D#7.BW8N5=#, K*Z'('M5Z\TXZ
MI!-J487SU8>; O.!ZCVK)O)8[NZ>6UA%M;L1B'=G!JYI.MS>'[]IK=U8%2K*
M1E6!'(- $UC!F*1ELFN$VE>"2%/8_A7IMUIF@:?X?TQFLYIX619+F92//QCH
M!Z9[US?PZRNHC6]DPL[9_-FCC3>@8<J"O]TD8JG!XKO==\637B>59"=762%!
MA-ISD =J 'Z]_9M[]D?39)[.1796>Z88V]CQ6)=N[V%G-&5\Z.1E\U3RQ!X-
M6;FWGTQ?-DAS;2$A2PR!4GA'P7>>*=:A2P :WW@,YY$>>A;VH EU!)[.W5TE
MDF2Y4-<QR')9NQQ4VH^';PZ?;WT.GS_9$41O,(R$4GU;I5B+3[?PYJ>-5<32
MQNR&"-LG /.:[#4=8F\9Z3%X;T.ZNK729'#BVN9 J;\=S0!YQI^AZ5%.T-Q=
MO]N8X408*'ZM4\SZ7<K):3W4T,@(2)3'N!.>Y["J^G>'I%OI(Y491$&R4&3D
M=Z9'HUQ?RB>.WD:-'$995R230!M>&;7PG:17L>NO?&\2-UA^R8V;_P"#)/;-
M<IJ-C<7+A]K.&.%+'YN.E;.OQ6RZ1'$ELZS6[F.2X (!.>C>XK$;4)6V2&0R
MB(!?3(H ]>_94^#_ (>^,WQ-/ASQ9XF@\*Z:]J\C7,KJI=EZ*"W'_P"JO+?'
M^@6WAGQCK.D:=J*:K:V5W+!'=Q?=F16(##Z@5DWPEMRQ; =_FR&Y JK'*4RQ
M^8G@G/- $L<"20!MQ:7G(/0"D: Q(NXAL],=JE$;BV+A,!NA]JJLYDCZG<O?
MUH GV[PV0N,8Z]ZWU\'7]GX8_P"$@EV16@=4C.\;I">/E'7CO6&BHMNAVEF/
M)],5L#Q')'H#Z8J+);&19073+ @=CVH Y^<$X=5YSR34+EL$D8SU*UL:C:-;
M0VLOFPRI<)YFR-MQ3GO[UFM'Y<@<<\\+0!#OC69=H9D Y]S6A;V<NH2V\*N&
M>9@B[S@ DX&?05 RJ,C'S'IZ4/&T2QN9%;<<%0<$4 :>N^%[WPOKESH]T\+W
M<+88P2"1.F>"..].UG0+C0+BVCGN87::)95:&0,H#= Q'0^U5',<8S [.[$?
M.W!'J*+ZR$4$?SQEI?F(W9((/0T +-8W%N!$JQR\[]R') K-$<TLY"*[2$\*
MHR:NZ=(L5ZAFW_9PP$FSKCVJS?:E':ZAY]F6@C4GRSCYR/4^] $>C&WM;@B^
M+(C*5.P9(X/6OV4_X)#@+^RD@4Y U:YQ^8K\I[7X'7FN:1)?6^IH@:U2\S<K
ML5T;.<-W(/:OU:_X)%1>3^RJ(]P;;J]RNX=#@B@#[<HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *_'W_ (*3ZWI>E?MKW%OJEGY\
M=[X4LH%N5^_;?O9LNH[G&>*_8*OQ8_X*M/L_;4A/?_A&+3&?]^:@#Q_7?"WA
MRQNM6.BRWVJVHD0VM]( JA2/F# ?Q9K2^%O@L^)O$UE9VIDCNI7VHQ.,DG K
MSG2_$-\KK9PDK;3, T"#[QKZF^ 7Q1\'?!;2O%UGKV@7.I>+KB&)])DNH OV
M?(R2<G*X.#QUH _0/]F#]E#2_A5H_P!OU[3[:[U^8Y.] PB'M[FO>M=\'Z+X
MFTR33]3TNUO;-UVF*6($#Z>E<=^S_P#$B'XF_#32=2-Y'=:@L*K=^6>CX_J*
M])H _*K]L3PB_P ![F^\(6NC6%UH.M3"^M]3G3]_$H_Y9;O0&OF"X^)'A^#P
MKIMA8^'+>S\4V^8/[7A=FW#<&60*>DF1C([5^EG_  4&L/#&OZ+I%M>%Y-=A
MD/DQJN5VGJ#ZGVKX"\5?$+P_)K4+R>!-"L-2LT: 3*&$4IVA59D'\0(W9]:
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MW<FH:K#+INGV3I-'=RDQ!GZD =23VK<^)WQQTSQ1<@Z?H</A]#$!NB.)9FP
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M\5Z']MOC:>3IUK>6ZMB8@C>0W( R/KFOE[Q%J&M>*]434+AW:2Z8F,KP!D]
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M:K-IPTT%7OKEG98QG.-HXV@CI0!2\00Z+86FJ:-IFG0:_+#<K,NM1S,N4/\
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M+2_#FGV\\C3RSDSI+%]W8WMV(/:@#D[/4(+2^L[6>>:*Q282N\0RP/J!ZU]
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M#P/9Z]\+]7U6YSYT,!9'V\*1T!^M7?"&N:+\19K7PYK%W)<7(ACBANI?E1$
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MCGID]JP/):\,>G65X5MT/RI)P-WK6I;:/XBT[1;R1_.GTH/^]6%_EW@<'\J
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M9([EU/RMD$C@5JW,NDZ9IT,MNTMW.ZXE5U 4-Z#VK"U?6Y]2=$<>0B@(L<?
MQ0!J>*-$EL;Y&G?]]+^\)49'/(Y'M6;I^FRWM]Y,CD,. 1T%>^:A^T'X9\0_
M #3_ (>+X%T\>(;=4C77X5Q-A7+9/&6)W>O:O'9=+CLA?F2:0W"*&CDC&X8/
MKZ4 9_B*YM6-O!;P2I-"@%Q),^XR2?WAZ#&.*SK$6TEP!<LR0L?F=1EE'? [
MTR9C<!W+Y;/W2>34?V8$HBABXZY/2@#J8_'&H6=DVG:1</IFGLOEOY)VM= '
M(:0>M:_PN\8RV_C;3K;6;_RM&N)U6\ED8[1&>N<<XKF='\'WFJ:G:FXQIUE-
M(%^U2*3%']2*U)_#,UW?7#V^F-<6D#[6, /[P#N._- 'H_Q,T!8;:?Q?X>83
MZ0ES-90G?O\ /C4G&5ZA<8K]*O\ @D._F?LIHVT+G5KDX'0<BORSCN]3L;2V
MMDM6M[?:6%@23G(.=P^E?J=_P2+_ .35N%V#^U[KY1VY'% 'VW1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^,O_  5+E6W_ &SI
M9#G</"=H%YXYDFK]FJ_([_@H%!X3N/V]POC1KQ=$'A"V9Q8Q[I"P>; ZC H
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MR  ?*:\6\4^%?^$=UZZT3[0U_  ABV X$C*&V#MD9P:J7FDM-)8PZC/]FM$
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M>[FWU_6M?FTW4;&Q>ZLX&3:C,7)P"#R *U;/Q;X9T+5?$&DVT8F\*FU6UO\
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MY3S/+&/X&Y J_80PSVIBEA>.X(_UN>,#T% &VGABTUVTBO1&VG6>,;GY3?\
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M3XBL;S[639Q.<[EEQQRO;UKSC0OB=KVKLGA^*ZN-;AU6)T@T^69W>T<] O\
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M5-KH6&"1FI8;=Y%1&4*K'A\\_A0!;T769-'9D+,]O,1YL6>' -=<-!AU6/\
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M>&HY-LTH8LR,^W.4[ =N/6L?5+S49[J;1+(2"!7\Y;"U0N6.WKQU..M6-?\
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MK)RK75LT-L\6'"AN"&)Z@\\U]R:C^S[X8\56,.CF_O=/N87:*U\I\I&"N64
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M'3H0UM)--*("R%8ANY/KG':LZ2Q+RLQ8JBC=D\#\* -FSN(;RRE-Z'DN4'(
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MXB:C+I-B8[=-*>[99)$(..!RRC'>O++O5I+YF\T;59MQ(')-6E\ >+A,K_\
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MC_H%V7_@.G^%:5% &;_PC>D?] NR_P# =/\ "C_A&](_Z!=E_P" Z?X5I44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cgtx-20231231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ': Q8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M =_X@^&$:6_C;Q$?$%]%X7\0G2[JSN9A-/:6_P ]C(KQ16SF(KM0(P.Q?F+
M _6NBOQW^+T&D'_@I!^S;J6CZ3'HUOJNF>&+^2$2>;(69V ,LQ :9PBHAD?Y
MF"#-=U^V_P#M/G]I?X*_&C0M(^&]B_A[X>ZS:V4GB;5-47[9'<F<Q%[>U$#
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M4"'C_P"//BGX6>-?A]<?#C6=%LYKU3/JBZ@\B1+YCAUBB"QD1?,0'?GY1DT
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M=TGXA?"WX8Z-X$TX_$[QKIJZA<V.JZ^!8:*3&T@BEF@AD>1BL;](U&"A&02
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG73Y>H13@$.+=(F>-1C')+9_AQR?H_XQ_LN_%_Q%\:/@/\1O#=GX3EU'P1I
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M+3K'2Q%'I]G9PJS*R1Q0Q*LKO-(&;:25BB&<* /HBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S-_X*1?M;_&CX#_'_
M $70/ OBV7P[X8N]&MIGCBT>SO&>Y::X#%3-$Q)*H@V[@/3')KY:T/\ X*=_
MM&7][%9/X^A2ZV21R/>6&EQ1%^BL#]E4+C!R&8@Y[5VG_!8^69/VH=*5;42[
MO"EJR2[<E-MS<ESQUP,=>!DG&>1\'136]K<IDEF9@9)(V#'&Y2"A/1N#G/K0
M!]N^&/\ @H'^T?K>N6=G??%+^S8+C:QF;0],VI'U+\VW3 /)QSC/I63\0_\
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MS1A45!$ZR(2)&+9!.>.,<?G6IH=];Z'JL=R\,<WDKDPRR,1(?16CP5/OG\:
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M;WY8&0YPK-ECOX'#54\,O?\ A_7+.^L%L92XWQ7%W((UB)..&$@((/(&<^U
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M_P %0?VGXI2LOQ)="#@@^'],!'_DK7S-K7BC4O$>J_VAJEP;VYV+%\P"*$4
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M'=.^22^1C/H0<^AH ^HF_P""GW[3FP;?B=EL9(/A_3!_[;5"O_!43]IXD?\
M%S/_ "@Z7_\ (U?.5Y+HUS;Z6;07%G,(]EV9/G&\?Q)CL?SX-1:A;7=E#+ H
MM[VVW^;]KME#]L?? R!_LG'TH ^I;G_@I=^TW!IQN/\ A:2!P1F,Z%I>[\!]
MFK*_X>C?M._]%,_\H&E__(U?+#S-)C<2?K3=O&??&.] 'U3_ ,/1_P!IW_HI
MO_E TO\ ^1J/^'H_[3O_ $4W_P H&E__ "-7RN4/.01CKQ3>] 'U6W_!4?\
M:=/_ #4O'';0-,_^1J3_ (>C_M._]%,_\H&F?_(U?*V.,^M)F@#ZUE_X*D?M
M*2%V'Q*6/<A9%AT'3B$;=]T[K;H!]>W/6O</V%/V^/CO\9/VJ? O@_QAXZ_M
MCPYJ<EVMW9?V180>8$LYY%^>*!7&'13P1TYXK\V\XQBOJ3_@F7&8_P!N;X89
M4J#)?D ^ATZY- '] =%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?!NDP>);/4=+ALGEG:W^T"Z,;2-;LG)(VD *1P=P/7/4"@#DR8C(?*RBX/\
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MX[6W8D*9F4.1TR$R6([<"M&_L_#-CIT5Q%J3ZK<7 YM([9H'@PW)+DE>1G&
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MR,S.!GDG+''<UU.N>"M0O/ ^CZW#!ILBK</8^18RC[0 I)WR1C^$DX\PD@G
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M0?8TW98$D[^&<9!'\6WCID4 6+'6+?6_#-UI]U92F>VMF%I<J2^?WA8C:5.
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MZU]8_P#!,C2UA_;.^%U[)=6X:6?45CME?=+\NGW&2RC[HY.,]<&@#]]J***
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M4 @T_P#8R\*Q^&/V_P#X8QQ!41I;_"]#_P @^YYQ0!^W%%%% !1110 4444
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M][IE[I<&NI>Z#!)]ICLHY6%NS$;3+'%)SNQU*@D=R!7(WUE-'';WJV4MG;W
M(C>13L=EP&V,1S@]N<>M 'Z/_P#!$V&-/BA\19(W)5]$M\J[ L#Y_/3M]<?2
MOUVK\A/^")))^*WQ)W* W]BVY)!Z_OZ_7N@ HHHH **** "OB7_@K]_R9W=?
M]AVQ_F]?;5?%?_!7:-)?V/;Q7#<ZW9;2#C!R_7VH _#!H&"*WRG<,@*V2/J*
MC4 L-Q(7/) R0*T=(O?L<=XJQL998BJ2+U3U.>U4;>)IY0BXR<]?SH :Y&2
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M/_30;B%Y*YZ@'G6JZ#=Z9<M8A97DRI\B2/$H)0,<J"V.OKTQTZ"C97/EL5W
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MQY4F<KSUW9YX%:>O>.]4G\-V5H0(GFG>[N-34S&>^E)SND=V(;!)^Z!U.<T
M4?B1%)I_BF\TJ20R0Z9*]I&$F62-55CPC#@C_)J/1/$"V,49FC218Y49#L!7
M@?=;*UL6?AVX\=:>UY;V]DC0[8IKJXNDMPK $DD,P&".YYS^53G0/# ^RZ=%
MKNH!))%$Y$*M"CD8WXW@C'^Z2<]1TH W?"?C#29M0NII;7[.9F+;"4*^P'R@
M<UD_$[48M;",B1HL8 VQG[I[GC@UF7.DZ%8:FJ1:VI1':.YWP,K*0V 5!)W
MCG@U;C\$7OC3Q&VD>$;EM?2"W:X:6.!U"HHRY*@$\?2@#@&BVKTZGCMCZUU.
M@ZFO@G5H+B*:WN8IX7BDD1H[J)P1@[H'4$ 9Z.!R,BL>^TMTU$I-<QR'=MDF
MV.(UQQZ _I5*6QGCD;]T65<9902H!Z'- 'ZD?\$=/"PT'XD>.;R*6.6TO]$@
MDA)>,RD"?!)522JYZ @9K]5J_(/_ ((C.Q^*GQ*4]!HUOV_Z;U^OE !1110
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MW%)'(@3#+@X/S#J:1]\A\QB3D]30!'WI5;:0<9ISIM/!R,4J@@@NA)/3/\Z
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M7E002,JX<#^+UH GCM?MLS1VD3LH8[0V"WMD\=A^A-)9R>3)MDCCD#$ )*<
M^G/8>O(IT%Y<_9A:+(!&&9U3@?,0 3GZ 8_^O4,4)"^82%4'!+'K^'7_ !H
M62,)(0[!<'DKS^1KZA_X)GS*W[<GPP523^]OQD^G]GW7_P!:OEJ6-T?#(4.
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M0H+_ $#2 5L8K>8V[1!CEP"0ZH&_V5 &!C'.0#R_3X]:\+:3%JR%+:RU+?;
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M_9]NH-(\4^(O$]__ &C/-I-E-<A+***18V(PCO(QPIWE0-@W9/&"* /-M?\
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M'';Q2DMN#*,<#!R1S71^']/UOQ9XDFOM)EGMI-1G:TD6ZN6N))+CGAC( Q)
M//(_E4,7[7D5EK&G7UIX2L].BM("EJ;:..,POWE78JGS">K[MQQSQQ7(>.?C
M#IGCCPMI,1A31+M&:*>>U WR!6#*S1K@*>2,\DX]A@ ]'U#6?!'@S6=2\/\
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MO5?3]/?4+A;6"V>XN7&(TC;!SUY'?Z<4M]/JFE:G)%=O<VU_;D1.LA(DC*<
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M-^6 V\C@<\C!KQ_0_ ">-=*N!I%G-=:G?7362VTDRP7$AD'[MTA4G(4YS\[
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MCW4K1"[CM'DVL,9+JH+(#N&"P&>V:3XR_%SQMXQU>]L?$>J$:5;W<LUO8:3
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MT!4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ'I,6LW"(EG:RARQBC17WKNC0MND5B27PH)#  Y+X'^-?LNKQ:IXE,6I:3"
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M;NOZ5A^)=%^&'C6[\.KX9U-],U/45C_M"&ZMUM[:TF+$.%R1E NW'/)SSVH
MU;C2M:^('[*+:E8WEQ#H?A._5[^SNY]T<TTIVJ\0QG< >1GIFO2OV./V[/%G
MP'TC_A'TO$GT)YBPM)H%DVG'522"/^^JYKX9Z0?@Q\3)?"_B&_M?&'P_U6W:
MROH= MDO&GCDY3?&S(8I02IW;B5/3=W\@^/OPC'P=^(VL:1IUY+J^B03;;74
M3$4." WER=A*N=K =P: /U0?]JW3/VKO %SI-Y;1VR;S#<VQ?;'*P].N5_/Z
MUY!XG\$>!?A1X5FU=K;1[-YC);VI:$QR3SJA("8&" >.IY[=Z^#OA#\5_$?P
MTN+J70-6?33=QM;S80/N##'W33_$FM!##+<7HN+XG>9&E,OWC]X#HOY@^U %
M36O$$EO>7U_<:=,CWI58KN4L"A1_F";"JD8P/F5N_2O>/!OBKX?0^"K.[M%:
MTU&%0LDP8ISZ-@&O(_$VC:%XG\0VL&C:[$EE(T,<5RL-PV;AD&_"K'N.&R,*
MGT)ZG&\,_#I%\1WEEXP\5#P+I<$NV[N+VVGDN)!N*L8K=1ND8$'ABON10!O>
M-/&<>H_;)DO3<Q1RA5E'S @GH!_]:O.YM;U2;4?/LKF7YB0BH=N0>HVBNZN9
MOAWHFJI%X;M=<U_2;C;&\^M*EM*)%;[T0B<C##LV=N<<D9JY)JOPQT/5+::S
M\*:O?7(F!N+/5-906S,<DQKY4 8H#CDMGM[T <UX:\1ZX8Y]/FN!'N7*L@Q<
M+@_<C*@D$],=/6N^\/:;IUC>36DOAKQ#KOB+455[&V64;K!MV#)-\C>;D<!1
MLZ]17M&L?%&QM8]/US1]'\,_#N9]/<7<'ANT5G & '/GNS+P!@(5SR<5X/XN
M_:>\;F>XL/#WCSQ+;:.T9B$3791958Y=613@*3S@YZ"@"]J_@/QWJFJ6$%Q+
MJ&G7TDK>0=5T\6L5OL;(6-W^Z1@9"X'3DYKC-*^%_CGQ;+>ZS:VL-PR3/)/=
M7-Y#;B9Q\Q"EV7<3Z+S^-<N=7U*RU87-MJ(N+F&(-).^' /?[_4\UT'B+Q)'
MXF\$:5-)J135]*E^ROY9(\V$\K)@#JIR,Y[]* -*]U*RTV\1KX):ZM=0B,M8
M/YAT_'# 9<_,WUXR:IZGX(?3/#-EJT=K;374K"/[(DV^=@Q^5WCR2I-<.;8Q
MP&?S(Y3YF1(P;+'\177Q^(]NI1ZK%#;7JNB"[M/+\J$%2 "45N1^7- 'WO\
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M2W"!V*Q@C+*,X'K73ZU=2ZY>2WKZFVJ79C19);R1WFE./F+%L\# Y)';&><
M%./46L8+81D.3(9GPH STP..F!6[;ZAJ&JR/>V>ZQ6WB)DGC)&!T/3ZU@FY&
MH7:->SD0YVA+*, 9 XP,!?RJ>\LY;"R$WVVYDTECM"QR;<S; 2N/8-R2.AQW
MH ?XNUY=0%K;Q_99+6*&,));VIA+$* S-P"S<<DDY.2.M1:1J>FVNG:C$UK;
M27(*RV]Q=)(9N,@HFTE!G<"0ZL#MX*GK7@FCO;""WNV-M;667VEW+2AFYV@D
MJ&^@'OFLZ2XM9)KAQ&Z1X(ABZD>FX\=O:@!VK7MQJ-VUW<001/.2_P#H]ND$
M9_W510H&>P%1/#/=S>7&7N7$>\A<M@ 9/X 4+?NE@;;AE9MP+#)3_=],]_7B
MH(4$L\:LVT,P!8]N>M #XK=MJS21N;?=@D<;L8R <8S@_K5DM<7\1MK97,"L
MTB6JDL1QRW [!1DU-X@U;^T;K;'&(;>)5CCB&/E4#'4 9)]<5G6UU/93+-;S
M202KT>-BK#\10!:T36KOPYJUKJ5C*\%[:R++#(/X74@C((Y''([U/XHN[34-
M9GN[*(6\%QB7R$SMB8C+*N23@'(&2:S[B\ENYO-F;?+QE^A/U]_>K"RVSZ1*
MD@(O%E#1D9^9"#N![<$#\Z *6W J1PL978<Y49R >:C)].:<I"D,#D@\C':@
M!7CD@.UT*%E#8=<9!&0?Q'-/O&5KA]B.B [521][*.P)P,_D*1IDEE5I$^3(
M+*AVDCT!YQ5NXU B[M;A8(XY8D0;60%#M^Z=N,'C&<YSR3G- #-(U&XTF^BO
M+68P3Q;MDBH&(X(Z'CH:Z*\N=/\ %&GWVK7^IQ6VK(8U%D(&,MVQ#;Y<JBQA
M<@9RV[YA@-@XYRXB>RD5DN5;S(@^Z D !ER5[<C)!'3@]15:$[94.Y5Y')R1
M^.* .JT2+^W?#6KQ2V\3OIMGYMN69E8?ODW%>0"0';@@C!)QD9KZ<_X)O:1,
MW[7GP?U:?5;:YDN9=3'V4W8>>-4L)E&Z/.5SGY<]0#CH<?+*Z)*^KM):1"VT
M]LW%N=0.T20AN#S]_P!PN>A]*^D?^"<&HRWW[=WPS+W+7<:/>Q1&1B=D8TZY
MVJH.,   8 P* /WSHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#\9O^"OE_>3_M9^']*2Z2WM)/#5F[;F6, FXN@27/
M; [FOCK2/ASXJ\4:-?ZEIWAO5?$%M'($N9H+6:62WSC82RC^(D ;AC(]Q7W'
M_P %:_$UYX6_:3T:73_#6GW%_/X;MQ%K5[:M<,JK-<AXD5R83PX))0L,C!%?
M*?B'Q#XHUWPU:^(/%GBZ6PC8MIUK8BX431@QAEQ:JR^7"=H&\+@@ =0 0#/\
M(_LG>._$OB*'3=?M8?AY;FW>Y;4/%VZPCV@L,!6&YW+*RA54DD$=C7LVB_ '
M3OA1>R7-E\;[&(G99+)IEG+<6TKR$$0SW&?LJG"N^T2L0$R<'@>4:/\ $+1+
M:SD?QE<ZCXRO9?LHMQ)/-;Q0Q1$*BH^< A<\NI&,\$G(Y_XM?%>W^(/C3[7H
MUC)HFF/%&'TN9UFACN"H\UHQC)5F&X;LGU)XH [SQW9>$K7PXNOIK]R9TN)+
M*QTJ6#>9+A)6\R>W$3%$C56B.'9MS,W+=:^COV1?VG]*T'P1K?AKQZD]S9:A
M,+NUOIOE\B5L[QY>"-I+<XX''3MXEHNKZMX>^!FEZ]#X9TZ34? %U]ML]:03
M"4-<2*OS*6\IU5A&W*Y!4+GYN*_PWM?$7Q9\*^,_BCK=QI^C:9X?MQ;>9>(T
M%I.TP*/'&V3NE().WDGGV! /5O''Q5M;#3];LM,OY]0MI5,L<UK,LD83<0@=
M5(*<@_?Y _7YM^,?PYU?3+O1-9O;.2%-?A-Y;N[;E89P<-SG!/J>HJA!XNGD
M3QE?V%WIJAHA8QHD6\2PYV^9$'0&/@?>PK?-R 2:[?X/?&*S\:6]I\/?B'KL
MUEX8E BM=2BCC=K*5<^629.$3<?F8=!S@]* .,3P?-:3Z=>:+?V,7F!8Y+">
M_B,_FA>20=I120>3P,@9KJ?$NG:M_;EOIU_I^E>(VFL9(UBAO!(('9,(T1AN
M%W-D9W'*\#((X)XWTCP_\"_'5]#:^+[#QQJ,3".&6RM9H87A)&<.P*OG+<@,
MI X/:L?P_KDGB?Q]I]M%/<^#8;II)(2+4W$?ER$EY,*%XP-N$7@+Q0!%JO[&
MWQ=TBW@N-3\)/HNE A6U34IH[:V4D!OFDD8 G!& N<_P@U3MO@U!]JDTV+5+
M%'> Q-J5[=JNGE^3Y@EV\ +R!C.>.#Q7IM[\0_$=[>ZGIOC;QWJUIX=\5?O+
MSQ#I"O>V\R!2D7F6SXWE=N%(8,F"1DX->??$S]FG6? _AS3M?D\:Z)KGAN\8
MPZ9=V=S(WG1A0S85E C;Y_\ 5.5?G)7'- '3>"?V2H+FTTYO&'C_ $CPI;7;
MF>R9H'NEN$5]A=75@@CR#\Q8<@<<UM_'#PWH'Q#\-:;=)XATW3]2L)(].A>W
MTYK>SF@C3&]WW.YD;!/W<95N>F?GW3=3USPQ8V]UIFLJ_D%C'' 6WPN5.Y@I
M (P,_,!@>M=IX,\/3>.;>W%W=AK&T14FO8E5/+7!8+L.&=QDXX.0,#- $WAS
MX,>$QI-Y?>)?%\>EVP@WQ/:0/-+YG)$>UQ'EB%/*@@9')-<Q#%X1@\6K(^K:
MA<Z;;-F!+BU!GE(.$4XX Z$^@S@$UT>D^--8\,:X^@WVISZOHUU=NB*R^0Y/
M #['3Y 0?NGMTQ7.>(8_#5X)XI)KI=6M)3;+;>89!(=YR58 C:!_.@#3M/#O
MAKQMX@FLM4U/5=+\07SR7(GO+8M"!MS%"%&YSN) #<!0!USQFV/@_P )/?PQ
M:GXJU6SNHQF:T&E;Y-V<;$;S,'I]XXQZ&O4;_P .Z//<:!JOA\W3ZI:6ZPAY
MIDDE9XU+9CB5@Q4=-V .,=:Y'Q/KE]XGOX+BZT!-!U6SAWP)'8E3<(S9+.<G
MD'=@X).>2>, !'X6T;5/"D<MGXIGMI3<LUO8MIS/NP" \L[%(E'.."3SR*]"
MT;]DV"[\,:9?6_B:/4/%>I0/+96=I'NMRP(P?M19ER,'*D*1QC(->-V]OKFH
MI;:1J*N^DS3":*?[.P5B^0=I(P3UY/0CJ*]2UF+P]\(&-JWB&_GTZZA*+IEM
MJ&R>UD^ZQ9E1AG!)P 1SUZT >2>.Q-X3\9- ->F/B"R(^U:A;2G_ %X/12H'
M*_WLG/:NW^#W[1&N^#/%@L-<>W\7>'+F?S+Z&^TZWU)9&.<RA;E"I8$YRW3D
MYK$\1:_X:TC0=7M="TQ;ZRUF**.>]UAOM=S;2+)O\V%Q&@0D+L.,G!/->I_
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M*Z?%&H>-1;M*\SD@;01T '))/;@9->J>&?$2R[XU?[5*H\I8[B,H\:CU..U
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M0_M8Z?;Z@\^FZM>VDL>E6\$;2VT\BP2&4/ELH^P,ZN<J )%P"RX /W(HHHH
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MC2$]1M/3H!P._P!*]=C^(WB+19=+\-VFF:C9)-;L+S38RS+>JYP@=  5"C
M^E=I::+9?%RTMO&5[?65CI-G-#%*)YO,N)KC'!P$)"X7.,] ?I5+XS>(?#_A
M_P :^'?$FCZ/++#%.OF7S%H?M2*5W$A7XYR >,CMV !\^ZJ\6A?Z+ );77$,
MBW;QR%?+(;H"O\7!!':L'9!J%E;Q6UC(E_$S>?*)=RR XVX3&5(YSR<YZ#%=
MWXW\86OB+Q+K&IPVMCI'G7DC[-/#0B6&0E@H0' "@XZ#/?FL6]T2*RBT?^R)
M'?4+L[CY2DNCDX6/M@XYXSG(H R[OPAJL>D/JKZ>4TP-Y8N4?,6\#[N[)YQS
MCOSBLM?.ACCD\TD2*0 'S\OH15WQ$;VWUB>WO(9DOK>1EGCG7G<."",=L'K4
MDVJ0:AIL$+I+;O!D?*Y**"<L0/X<\# H 9X?NYX=9L(RZ10^>C%7'R'# \CN
M/K7<?&/3=4O/%>IZPWE/"[^:IA "A>,;0 ,J/;@5S7P^T"76M<C*;8;6-MTC
MR#)V]=O3!)_"NK^,'CB3Q[XBDM%U6.?2=)M_L]EFU$.0IR5P@^8YXW,22 .:
M -FUT?4?$G@C3-276+::>:(6K6;H2X1"2%7&>N>G%<#>):6]W<7=G$\LD,P)
MB:%6B _BW$?[708Q@UV/ACQ(GB:PTW2X[R:P*!8+EXVV1QPANZ*OSYR>^?4T
MWQRVB>!]?N3X'?4/[#O%>&1M9C^SR2IC$B;58@KNSC!S0!W'PGU*[_:,OX?!
MLT8.J+&TK;(DBB:UAC9L97#DKVB3 /7J!7%^*_C -=TBU\)R:1!H>G6#2VOV
MB$3,51R,Y61G"\J"2H#'OG K)^ 6I:AHGQN\)7.FF6&_74D,4H#="W)(P21C
M.>/6NB^(/C?P99_&#Q4$T>6_T1-4F:W$%ZSK-\Y!).XC'7:0,XQF@#"TGX56
M5_;7D<&O07]ZJ_Z,$1O*"XR69CT^F/RKD_\ A6OB$W#0?V9*0,XG)"Q?]]'C
MH#QG->\Z=?>'_%?@!M%^'WB[_A#-5UC4#;ZAH5\XB@G@'S1DW#9QAO[S*O'4
MDUF>']+\36&D7?A/Q+KNEOH=XRR[HYX;J59%Z&*7.1R,'#=#Z4 >=_#[P-X9
M3Q)IO_"6^)6TZR\TFYBT^V$TZ*!PP\PK&0?K7>^(O@MX9U+0+G6O#M_J>M)!
M(@=;VVCLB$D?:LC/N9"I;@'</IBDUW0])L? .M1:_P"&XIK\1NUGK^FSR>?"
MZC"13+N*%&)],^AQ7A-DY2VE5IR2^ (5+!C[],4 >LZC\-=2\#:#I/BG6?!-
MN--W.T,MUJ*RPW@0\C;&^2HR!D8'O7G@\:7::U_:>GZ?8V)C<O':+;B:%5SG
M;MDW;@/]K-:/ASQ3H]MHKZ-K>CO=P2R[UOTN)!-$,$!57=LVYP3@ G'WL<5D
M7-K_ ,(]JL]I<3V^IJ(?W4ME.LBG<,CYESSZKVZ4 =A%XEU[53J7BC3(]-AU
M-XREY;BSA7=$PV[TB*;,=1\HR.OO7G!+1VZ+L1O-YSL!88]#6IH.IQP17<$B
MV\4A@=5><,<>PQW^O%=1IOBZYNI;2#1M12UNBBF5I[&WL[:-@.,;"V?]X[<]
MQWH ^Z?^")EI-:_%'XD>8F$.C6^UP,JW[_L>]?KO7Y(_\$8TO!\:OBB]_*DU
MW)H]N\CQS+*"3/\ WE)%?K=0 4444 %%%% !7Q+_ ,%?O^3.KK_L.V/\WK[:
MKXE_X*_?\F=77_8=L?YO0!^&UN$,R;VVH#DGFK]W$MW+=2/<JLZ8VQ-SN'H"
M../PK+K6T'0_^$@O!;QSQV[!<EI6P#0!FJ9(7W+N1AW'!K6MID.FBWF%V)I)
M%,+JX6&,9^8E<$L3[$8]Z2\@CM+B2![A%-ME59<YE].@('XT@U>Y2Q$(D0Q]
MOW:;L8_O8R/IF@#6U&2"/0([6X1H[])]_FRIM8KMXQ\Q^7_@/XTB^/KF#0AI
M]M$(-[8N) P83KG(4J00!G\ZYVXEN-6O6ED8//*W+$XR:DDLUMK8K<LT-P&.
M$*Y.!Z^E %V\URWNK4Q)9QQ.""'" ;QWW $ ?@*?<:E'J6II-9:;#IP<@"&T
M:0@'U&]F;WZU1DLH#:"YCG(0ML\EN9,XSGH!CWJ;1-6GT/6[.[M;JYT]HI5;
MS[9R)$7/)!!&>,T 6]0N[;5;BX:6"1IQC#I+]P = N!Q6O<>?8:2=6TEE6&6
M,07$UOG&YN2K*<X' QTSC-<IJN(]4NRLAE!D8B0\%LGJ:TM$UVXT&UN5MS#O
ME (9@2T?N#V__50!Z=\!--5?'VG3ZGJ"+NB*)"T@RP."!CJ!TZ\5]U6_C"'3
M)K:-H5>,((Y)HW.T9&,*.AXK\T_#?C2_TK6YM4D*7-W(A4W$XRRD_P 6?7_"
MOH+PM^T@NE:)"OB"&UU"5(EDCDM'*ECP,%6P,]>G'% 'K/[2.B^'K/PC?:VP
M35%B@W"(Q, '/R@;NV,@Y_6O@Z:S>5HKN.U2*V<\;BVQB.HR3FO9/BC\:;[X
MD6BZ(FG&RCN)?,6./<9"N/E8\ 8QSQ]:]Z_8M_96\._M ZA=Q:[]FM=/LF"*
MUM,L@=L<X/3Z^E 'Q''H%]>NB0VDAG<LPB QP%W'&>>@)KJO"OA.Z@<:GKB7
MUKH*@^;>6LPC9BP("[F!X.#G@\ \$X!^O/V^OV8=*_9NN=/UW0]5-TG%O;6Y
MVH]N2.",#!&,^^><U\H:1J=EXGL#I<]G';W.I7 ,^JEI9)P!R25#A, 9(7;S
MGEA0!S'B6ZTV]O84TZ6201 1"9D50RJ %. JD^Y(R>]5M=FM;:;RK.<W4$,Q
M*%6;[.WNJN W/?(%6-4NHY_%%O::'&8X(G2V@-HDB/<-PAD*%V.]^I .,G
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MTSPC93O%8W,%UO1;HQ*9D! _=["2$ QN4@#AB>^*QO#OBI_"EM<10BVU.VO
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MI5@]Y-:3701_+P"P191M)(QA5(8D\5Y/XUEM_$_B^_U'3YS]ENV>6#SX?+;
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M]IO/*>1[VR@CAED8+QN"A0Q)Y+')/J:R_'OA<^''TYDCCCBN;.*;,=Q'(&+
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MWDA< +SGC Q@>U0G5Y[N5O.;_16<L;= 0F3Z =_2J&T3,/I]T=!5J),E%P<
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M/CCQB?\ @=I_\9K]$:* /SM'_!$[X5#_ )GCQC_WW:__ !FI6_X(J?"IL?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cgtx-20231231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %. S(# 2(  A$! Q$!_\0
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M681=I)+Y'Z7?\/.?AM_T+_BC_P !H?\ X[1_P\X^&W_0O^*/_ :'_P".U^:
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MY?<?IA_P\X^&Q_YE_P 4?^ T/_QRNP^&W[>WPO\ B/K=OI/VB_\ #U]<R"*
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M=L'U-*>&JMJTNOGV]1T\702;<>GEO=>1W/QGL;*S^%/@1=%TRQ?2(KS5[?\
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M^WN/0_E1QZ'\J/[1Q?\ S\8?V-E__/I?C_F?$'_#K3PY_P!#]K'_ (!04?\
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M%!7V_P >A_*CCT/Y4?VCB_\ GXP_L7+_ /GTOQ_S/B#_ (=:>'/^A^UG_P
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M/_\ %5Z'XG_9G3PEX^\8:%>>(FDT[PQ9V$]S?16H#S27<D<<:+'NX :3DY.
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M:*U\D<M?ZM0MSP6NFR/,O^%[?$K'_)0_%/\ X.;C_P"*H_X7M\2_^BA>*?\
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MO+Y\/1%VLP&<'@'IS50JT)M*,-_)&M.OA:DHQA3O?R1Y1_PO?XE?]%"\4_\
M@XN/_BJ/^%[_ !*_Z*%XI_\ !Q<?_%5PU%=WL:?\J^Y'I?5Z/\B^X[G_ (7O
M\2O^BA>*?_!Q<?\ Q5'_  O?XE?]%"\4_P#@XN/_ (JN&HH]C3_E7W(/J]'^
M1?<=S_PO?XE?]%"\4_\ @XN/_BJ/^%[_ !*_Z*%XI_\ !Q<?_%5PU%'L:?\
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M1X^\C;@0RMQUZ$"O1-=_:.BUC0/B/#;:;J>D:KXOU2#41=6-\L26WDC:J':
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M?]A.3^0K]/&^Z?I7YA_'S_DM/C;_ +"<G\A7VW"G^]3_ ,/ZH_*/$3_<*/\
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M^B5JSX^_Y$;7_P#KQG_]%FJWPK_Y)GX2_P"P3:?^B5JSX^_Y$;7_ /KQG_\
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MK>GZ4;6]/THY5V%R1ZHT=5U^ZU>STVTE\N.TT^$PV\$2[57)RS'U9CR3[ =
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M .*K"HH^KT^P?6ZW\QN_\)4O_0O^'_\ P7#_ .*H_P"$K7_H7_#_ /X+A_\
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M%'^5D/3*D$YXS?AY\<)OB)H%EJ<&D6>E->:A>6L%AJ6J*ES+#!N'FJ@0[F)
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MR%SDJ&92<9SC)[UZI10XIFBDUL>??\*A_P"IX\;?^#P__&Z/^%0_]3QXV_\
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M0_\ 4\>-O_!X?_C='_"H?^IX\;?^#P__ !NO0:*.1!SR[GGW_"H?^IX\;?\
M@\/_ ,;H_P"%0_\ 4\>-O_!X?_C=>@T4<B#VDNYY]_PJ'_J>/&W_ (/#_P#&
MZ/\ A4/_ %/'C;_P>'_XW7H-%'(@]I+N>6>(/@';^)=,:PNO'?CV.!G1V-OX
MA>-CM8-C<J @'&#@]*]%T+2O[#TFVL/MEYJ @39]IU";SIY/=WP-Q]ZO44U%
M(ER;W"BBBJ)-"V_U:_2GMT:F6W^K7Z4]NC5QO<])?"9A^]^%%!^]^%%=BV/-
M>X5#=W<5A:37-Q(L4$*-))(YP%4#))/IBIJRO$_ARV\6:%>:3=S7,-K=+LE:
MTE\J0KD9 8<@'&#[$T,$>0_#?XXWGQ#A^).F/=V-OJVC(+_3)].=)U_L^>$M
M;2,,LID#)(&4GKCL16]IOQGMH?#/@^VU);Y_$NOV,!MQ!9Y$TIM4FEG"@X$*
M;LLQPH)QR<"NAN/@_P"&9?%<7B&VLCIFH+I\^ERC3ML$5Q;RE24D15PVUE#*
M>H.?4TS0?@_H7AV^N;NWEU&6>73;?2$:XO&?[/:0J%6*+@; Q 9B.6(&3P ,
MK2-KQ/(_@?\ M76VJ?!W0=:\?K?66LOI\5W<:@UDD=M>>9=?9U:$(QP-[1@Y
M"XSFMC4_VKO"5O=6FK0S^(I-*32]5OVLX-)79=)9NBS.&<A\J&#)M^5U?/.,
M#HK/]F3P;IOA'3O#UG)K%G;:=8I86=U;ZBR7-N$N%N4D60#_ %BRJI#$8XP0
M14VO_LY>&O%<4!UO4=>U6\CTN^TAK^ZU$F>2&["B8L0H&["*%V@!<<#DT-,+
MQ*"_M1>%XKNRCU#2=>TB"YOK2P^V7MK&(8WNE#6S.5D)"/G (!P?O #FJTG[
M77@*9+IM+&JZ_' D,GF:9:;U<27'V<;69E&0Y7(S]U@PR*Z'5OV>O!^M6\,-
MU!>/'%=Z=>A1<GF2R $&<CE<#YA_%5?2?V>=!TGPS<^&SK'B"\\/O=17-MIE
MU?AHK'RYA,L<.$!5-PQM).% 48%'O![A:UKQU=>#;@>+O$NH/HO@RZM[6S&D
M7UI&D]A>23[/.FF5RH0AE!YPN,YY->@Z?>#4+&WNA&\0FC60)(5+*",C)4D?
MD2*J^(M#A\2:5/I]PS+;S\2H$5UD7/*,K AE/0@]0:K>"O!^E^ /"NF^'=%A
M:WTO3XO)MXF<N57)/4^Y/'0=   !5I-&;L]C:HHHJB0HHHH X7XS>.=7\!>!
M;[4/#FEP:WXB*D6.G7$WE),P!9LMV 56/8< $C.:IQ?%:/6H/ASJFBJESHOB
ME'F/R%YA&+.2=0F#]X,@4CZUT=WX2:_\:VNO7&I236MK926L>EM#&80[E=T^
M[&[?M7:.V&;UK@/#O[/<GA73M-LM,\8ZC!#IFIWVI6 -E;L+8722JT*@C[BF
M9V7.3GOCBLG<U7+;4P_B'^TE<:7JNA6V@Z9>(8_$UEHVL07-B)I&692QB@*2
M$>;@*2#T##.,BNRF_:$\*Q:%IFK&/59+.[:);@16+/+IV^5H5^TQC+)^]1T^
M4-RI/W1FN8T+]F$:5I_ARPG\9ZA>6>AZO%K<$:Z=:P^=<JS.\DS*N7:1FRS9
MSZ5I^'_V?;CPKKEAJNE>/-=L9EBDMM0BBB@$5_"UQ).H9"I$;JTL@$B8.UB#
M2U*]TK6/[2>@6'VF"[FU/7[PZKJ=E"NEZ*\>P6BAY4;+D?*O'F$@.1P!70P_
M'_PM/<WMI&NH-?0Q6<]M:M;;)+]+I2;=H,D ABK+\Q7!'.*Y[3OV9;#3=1DN
MHO$FHL9+S5KTHUO#@27Z!'YQT0#Y1WS\V:CN?V8X)KJ+4$\7ZK;:S:V.F6EG
M?PVUN&MWLF8QRA2I5BP8AE;@@\8IW8K0.DL_CQH.KZSHVD:;I^NWM[JL#3HT
M6E2-%: 2&)OM#' CVR J<\=P2.:N>$OB)<3:Q8>$]<B\SQ;]A^W7ZV,2I;VR
M,[B(LID+#<%/W=P!!!(R,SZ#\.IM%\9CQ#+X@O=1D.F?V>]O<Q1X=C+YC2[Q
M\P); "#Y5' %5O%/PAL?%WQ T/Q3>7LD<^BO'+9QV]O''+&ZEMP%P )-C@@/
M&258#IS1J)\IW]%%%:F04444 %%%% !0:*.._(H \!3XM^/M7G^*MUI2Z ]O
MX*U;[-%IUS;2*][ MNDSJ9Q)A'.X@-M(&!D&MGX,_'B?XN^.]=LK>TAM] BT
M+2M9L'*D7!%V)"RR'./EV <#UIK_ +.+MK'C)QXVUBWT+Q;?&^U32[6W@B9B
M8EC*)< >8BE4 ..>3R,U+#^SY+X?\<ZIXB\)^+;OPM%J-A9Z;+IMOIUM/#'!
M;!A$L9<;EX8C/T]*QU.CW+6//OB%^U!XB\'^(_B59P2Z"#X8U'3[33=+N;>4
M3:D)XPQ0R[PL;9. Q&!WKZAC9FC4NNQB 2N<[3CD9]J\2U3]F4:EJ_C-QXVU
M>#1?&'D+K&F"TMW,R1Q"+:L[*77<N<M@G))&*]FTO3;;1M,L]/LX_)L[2%+>
M&/<6V(BA5&3R< #D\U4;W(FU;0LT445H9!1110!/:?ZP_2KPZ51M/]8?I5X=
M*Y9_$=]+X1:***@V"BBB@!&^Z?I7YB?'S_DM/C;_ +"<G\A7Z=M]T_2OS%^/
M:/\ \+I\:_(X_P")G)_ 3V7VK[3A9I8J;?\ +^J/RKQ#BY8"CRK[?Z,X TE.
M\M_[C_\ ?!_PH\I_[DG_ '[;_"OU'GCW/P+V4_Y6-HQ3_*?_ )YR?]^V_P *
M/*?_ )YR?]^V_P *.>/<7LI_RL913_*?_GG)_P!^V_PI/*?^Y)_W[;_"CGCW
M#V4_Y6-HIWE/_<D_[]M_A1Y3_P!R3_OVW^%'/'N'LI_RL;5_0?\ D.:;_P!?
M4/\ Z,6J7E/_ ,\Y/^_;?X5>T.)SKFF_))_Q]0_P-_?7VK*K./LY:]#HP]*?
MMH:/=?F?JL?O-]:2CN>W-+BOPM,_K9(2BEQ1BBX[,2BEQ1BG<+,2BEHQ2N%F
M)12XHQ1<+,2BEQ1BG<+,2BEQ1BBX68E%+1BE<+,2BEQ1BG<+,2BEQ1BBX68E
M%+BC%*X68E%+1BBX68E%+BC%.X68E%+BC%%PLQ**7%&*5PLQ**6C%%PLQ**7
M%&*=PLQ**7%&*+A9B44N*,4KA9B44M&*+A9B44N*,4[A9B448HQ2N%F:%M_J
MDI[]&IEO_JD^E/?[K?2N1ZL]%:1,P]?PHHI:ZTSSVF)12XHQ3N*S$HI<44KA
M9B44N*,47"S$(S28IV*,47#E8E%+BC%%PLQ**7%%%PLQ**7%&*+A9B4=:7%&
M*+AROL)12XHQ1<+,2BEQ11<+/L)1BEQ1BG<+,2BEQ1BBX68E%+1BE<+,2BEQ
M1BBX68E%+BC%%PLQ**7%&* LQ**6C%%PLQ**7%&*=PLQ**7%)BBX69/9_P"L
M/TJ\.E4;,?O3VXJ\.E<L_B.ZE\(M%%%0;!1110 C?=/TK\VOCGXPUZS^,7C&
MWM]:U"""/4I%2*.Y9548'  -?I*WW3]*_,/X]_\ ):O&W_83D_D*^SX6BI8J
M:DK^[^J/ROQ"E*& I.+M[WZ,YW_A.O$G_0?U/_P+?_&C_A._$G_0P:G_ .!;
M_P"-8=%?J#HT_P"5?<?@7MZO\S^\W/\ A._$G_0P:G_X%O\ XT?\)WXD_P"A
M@U/_ ,"W_P :PZ*7L:?\J^X/;U?YG]YN?\)WXD_Z&#4__ M_\:/^$[\2?]#!
MJ?\ X%O_ (UAT4>QI_RK[@]O5_F?WFY_PG?B3_H8-3_\"W_QH_X3OQ)_T,&I
M_P#@6_\ C6'11[&G_*ON#V]7^9_>;G_"=^)/^A@U/_P+?_&KVB>./$<FLZ<K
M:_J14W40(-T_(WK[URM7M#_Y#6F_]?</_HQ:SJTJ:IR]U;=CHP]>JZT%S/==
M?,_6E%RH/%.V#V_*DC_U8J*]O[;3;5[F[N(K:W3&Z69PB+DX&2>!R17X"?V.
MMD3;![?E1L'M4-EJ%MJ5M'<6EQ%<P2#<DL+AU8>H(.#4^1ZT#LA-@]J-@]J4
ML,5!#?V]S-/%%/%++ P65$<,T9(R P'0D$'F@+(FV#VHV#VI0P/>H+W4+;3K
M9KBZN(K:!<;I9G"(,G R3QU.* LB;8/:C8/:E4[AD<CVI: LANP>U&P>U*6Q
M35D5ER""/4'(H"R%V#VHV#VI<CUHR#WH"R$V#VHV#VIK7$:2*A=0[ E5+#)
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M_;DC!MH]I4;6?/WFW9 QR :NM>PI&9#-&$!P7+# /3&: +-%,5MQ_P#K4^@
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M&NEZG9S:?J-EX;T^VN;2X39)#(ENBLC*>A!!!'M7I%-48[TZ@ HHHH ****
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MZS+?VM[-IBZ?=7<;QQY>XB4#]X'#)N(!*HO& *]3*Y[TH7&: %HHHH ****
M"BBB@ HHHH **** .5^*?@H_$7X=>(O#277V&35+*6U2Y*;Q$S*0K%<C< <'
M&>:\O\<?"CQ/\58OAI::]::?:Q^'+G^UM2G2576XN8X'A2*./;PCF3>6R-J@
MK@DYKWJB@#XE\8_!36/AIX;N=49+/P_9/X;T32YY+?4RB2:I#>(?,FRNTQX
M!9\;E8J2HYK6^&_PFU;6'N6MM#L[FSN3K<6O+>W8:.:]OECD6YMGCRCQC:8B
MO+('."><_7\]M'<QO'*BR1.-K(Z@@CN"#U%$%O';1)%$BQQH JH@ 50.@ '2
M@#XOU#]COQ9=7UNES_9>L1)_PB:SW5Y/F2Z^P._VQW!7EFC95&?O@8-.^(?@
M.3PK/8^$H[;2_P#2H=;672GU%+:$Z;<W*N! LB",S<+T)*<_*0<C[2Q4-S8P
M79C,T,<QB<21^8@;8PZ,,]#[B@"AX66*/P[I20VK6$2VD02T?&Z!=@PAV\9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>VD7OMB>_P"5)]L3W_*J5%'LT+VTB[]L3W_*C[8GO^54J*/9H?MI%W[:GO\
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MJB@459F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0*)%5B23NV+G).2 >M;E%*R'=G%:A\$_!.IF%KCP_$3"]ZZ&.66,_P"EG==
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M8ND9^;#A68LN_.TG(Q3!\ /AX=-;3F\*6,EB=.DTG[/*9'06KS><T0#,<#S
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M8'?/''KS]>:0V<+$'[/&2K^8/W8X;^]TZ^_6OD;4]:\3Z9X5-_9W7BW3]#U
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MVE:EIA@"E+EF+)O$@=F+_O<F,J2,U[U5IW,Y1L%%%%42%%%% !1110 4444
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MO-H\@N]/:32K^QN8K:2TFTX%[3;Y?E+<&[>-O,9PRAMI Q@JZ+Y7M<]L\(_
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MMCSGN%%&:,T" C--CB2%=J(J+G.$  ]^E.S1FBP!11FC- !11FC- !11FC-
M!11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11F
MC- !11FC- !11FC- !11FC- !11FC- !11FB@"6U_P!<M: Z5GVW^N6M =*Y
MJFYVT?A%HHHK,Z HHHH 0C((KYQ\;?L9:/XW\7ZOK\WB34K:74KAKEX8XHRJ
M$@< D9QQWKZ/IN.]=6'Q5;"R<Z$N5GFX[+\+F,%3Q<%-+6S[GRN/V"-"/7Q7
MJG_?F+_"E_X8(T+_ *&S5/\ OQ%_A7U.M.KO_MK,/^?K/&_U6R;_ *!U^/\
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@X>SCV*\=J(W#!B2*L#I0?I12;;W*45%60M%%%(H__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cgtx-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $P QD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "F4^F4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HI*6@ HHHH **** "BBB@ HHHH ***3- "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 44E+0 44E&: %HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F4^F4 /HHHH
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M?>"H-2N=<3[#H^IWVH:K-&;R.[^T2SS#R@71F^>)8V5^<9( )Q7UY0 4444
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MQCS$5AP&QQGZ5U->._L??\FP?#3_ + D'\J]BH **** "BBB@ HHHH ****
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M,=I<L"ZH?NDX]1S^-?)OQB^,FM?#7]IG5K+6=<\2#2KDV<VC^'+;PF-7@U!
M&$ZQ38)A.< X([&N[_8N^+FG?$K_ (2R6W\5:SJE_+>W5V='U6)U_L^W\[;
M%#*/*^7CRP3ZT =O\1_A_P#&+XB:WJ]MIOQ&LOASX5,2QV;Z1IPN]2=OXG>2
M0A8_8+GWJK\&KWX@Z7K"V-UXWTOXN^%D<V$^KV\$5I?Z=<)]X3*C%)!TSC#
M]L5XGJ/[:'QST37]:TS3_@%KGC73[._G@MM:L87CBN8U<@$ +VZ9[XKZ#_9@
M\>^+/B/X)U#6/&'PZ;X::D^H2*FERQ%))8\+B5\@9).1GVH ]CHHHH ****
M/*_VI_\ DW3XB?\ 8%N/_0:I?L@?\FQ_#;_L#0_RKS_]N_Q!\5=+^%6O6O@G
MPGHFN>&;C2;@:S?:C?F">U7'6-,C?QDUZ!^R!_R;'\-O^P-#_*@#V&BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KS/XM_L[^"OC5<Z;<^)+&9KJQ;Y;B
MSG,$DT6<M!(R\O$W=3^E=GXA\8:-X4$)U;48+ 39$?G$C=CKBO!-1\8?$+XJ
M:M?:CX9\:VW@OPE%*8=+GL--BU"744'#32>=@1C=D!1SQS5*C[?W+7#VSH-5
M%*S75;GT5I>EV>BZ?;V%A;16EG;QB*&"%0J1J!@  =!5JO$/A3\=)435?#GQ
M&U/2K+Q;I$XC=[3<L=U;OS!/C&%9UY*CH>*]M1UD0,IRI&01WI-.+LQ)IJZ/
M'?C5\!+GXP>._!VIGQ!?Z%I>CP7L5T=(NWM;R;SUC 59 #\F$.X?3%-O_P!D
MKX>7?A_4M&AL[W3;*]L[*RQ8WC1- MI*98'C;^&0.Q8MR2>M)^U1\1?&WPS^
M&TNL>#+"R9X983>:E?2 K:Q&:-"%BZN[!R!V&"3VKD?BU\3O''_"9>+;3P[K
M\/A^Q\%^'(O$$\7V&.X;57=9&\ER_P#JD'DXRG/SGT%(9TC?L>^ I(=0DDFU
MV76;V:VNWUZ359#J"74"E([A)?X9-K%20,$=JNWO[*_A*>WTMK/4O$6CZQ9"
M57UW3-5>'4+Q96WRK<2@?O [@,01UY&*\OU+XV_$7Q3H/B7X@Z'JUIH?A?P;
M%;O>:-]C2=M598DFO4\QOFBPK[8V'!/)KUWXA?'I/!"^!X;/PSJ7B+4?%YDB
MT^SL60%95@\U1(S'"(1P7Z+U/% #/$O[,?@OQ-JNF7DW]JV<5G8QZ9)966H/
M';WUI&Q=(+A>3(@8DX)!.3DU)X@_9I\'>(O$\FK3_P!HV]G<2Q7%]H5K=F/3
M-0FCVB.6X@ P[+LCQR/]6O'%<KH7[6UIJ/B+3;34?"E]H^CW<&HA]7ENXI$A
MN[!<W=N8U^8["& <</CBM/P!^TPOC7QOX<\.7'@_5=&_X2+3KC6=+U">2-[>
MXLD\O8^5/RR.) 3$?F0=>M &AX[\-:E9_'OX?^+;.RFU&R-G>Z!=I O_ !Z+
M-LF6X8_W0;<)CUD%9NE_LM:1:>%/ASX?O-6N-1T_P@UYN26%5_M!+B*6-TDP
M?E $QY7G@5U'CSXAZCIWQ'\'>"M#C@DU#5C+?7\D^1]GTZ$ 221GHSF1X4VG
ML['^&N5\(?MB> /&FHI962:[!/<VES>:=]LTB:$:JD#$3"T)'[YEVD[5Y(&:
M .B\'?LU_#KX<ZP-9\*^&;71=92%X8KR.260H&&#\K.0:J>&?"%S^SY\$M3M
M+:[O/%FK0->7_G"T_>75W<2O)@0QYVJ9),8'0<U;\(?M">'O&6KBP@TOQ'IA
M\B2X:YU?19[2W1$7<Q:1P%''K7#?#?\ :.\0?%?5/B9%8>'A8:7H<,=SX?N4
M;S;C5H"I/FA#\H60J?+/=6!H ]'^ G@6Y^'7PF\/Z-?J8]4$3W=_'N#".ZG=
MIID4C@JLDC 8[ 5Z#7,_#;QY8?$WP-HWB;3ODM]1MUE,)<,T$G22)B.-R.&1
MO=3734 %,I],H ?1110 4444 %%%% %+67OH])O'TR.*;45A<V\<[%8VDP=H
M8CH,XS7YF_&/]GOXQ_&7QU<:]X_^%?POU;Q"EDNY/^$MO86CMT)^81)(,+R>
M<8K]/Z\(^+?P=^(&O>*;S5?A_P"(_"_A*YO[46MQJ]_H1O-3A7)W>3,7 VXQ
MB,C&<F@#H/V5])ET/]G_ ,%V$V@VWAF2"S*'2K.=IX8/WC<([,2P/7))/->K
MUQ_PD^'</PH^'6B>%8+^XU0:="5>^NL>9/(S%W<XX&69C@=.E?)WQ&\:?M=>
M"OB%XH@TX^!K?P*MX9M,UWQ&66,12,%C@9H^5*GJ6  !Y:@#[AHKYY_9#@^*
MLMOXTU7XJW.G7FH:E?PS6$^AW7GZ:]N(@/\ 1^3@9!SZFOH:@ KR7]K+_DVW
MXC_]@2Y_] -8GQF^/WBOX3>)X5/@2"[\(&:SMFUVYUF.W>66>39LA@*$N5X)
MY&<\56_:T^)G@^/X#?$C1Y/%FAQZL-'N8OL#ZE")]^PX79NW9]L9H W/V/O^
M38/AI_V!(/Y5[%7CO['W_)L'PT_[ D'\J]BH **** "BBH;R62"UFDBB,\J(
M66('!<@<#/O0!SGQ$\0>(_#>@F\\,^&8_%-\K?-9RZBED G=M[*PX],5Q'P(
M^,OBSXPV2ZIJ7P_3PMH<BR"&[.MQ7CO(CE"IC1!CD'G-5/#OQM\1^*_$E]X?
MN? -UIAMD87MP]]&XM@5.TD <Y]JF_9'_P"2(:5_U\W?_H]Z /9:*** "BBB
M@ KP[Q[\$_!VH_$'19+C22[ZK-.]V?/D'F$*".AX_"O<:\6^+'QE\"^"?BQX
M$T;7O%>E:5JMS-*L5G<W"K(2R@+D?PY[%L9H ]>TK3+;1=-MK"TC\JUMT$<:
M9)VJ.@R:MTU'610RD,I&01T(IU !1110 4444 %%%% !1110!GZSH&F^(K5;
M;5+&WU"W5@XBN(PZAAT.#WKP_P 6?#'Q9\.O$%[J'PZT#2]=T#4V$L_AMKE=
M.:VN3]^XCF*L"'P-R$9S@@XKZ KQGQA^V'\(? /BG4?#>O>,(]/UO3V"75FU
MC<NT9/(R5C((/8@X-:4Y3C*\-R)QC*-I[!\.?@W<ZE=7OB3XBZ;I5YK=XBQ6
MNFI$L\>E6W7R%E(S(2V69L $] !7L%I:06%K%;6T2001*$2.,855'0 >E>=_
M"S]H[X=_&K4]0T[P7XC36[S3XUDNHDM9XO)5ON[BZ*,GTZUZ54R<G)N6XXI)
M)1V,'Q[X<D\8>!_$.@Q3K:R:IIUQ8K.R[A&9(V0,1WQNSBO+[WX*:_H$W@76
M?#FH6-UKWAS0&\.R1:@C"VGB=8\RC:<JRO$K8SRNX=2#7J/C/QOHGP^T&;6-
M?OTT^PB(!<JSLQ/14106=O90367KGQ?\&>'/"MGXDU'Q%96^BWNW[-=;RPFS
M_=5<L<=3@?* 2<8-24>*^$_V:_&GPM\._8_"7B/3EU'4?#JZ-J=W/;-M^UJS
M>5>(A)^6-'D3R^^5)/%=[K7P MY/AU\/?"&CWJ6-CX3U73;]3/&9?.CM6R4Z
M\%LGDYQ75:_\9?!7AF'19M0\1V,<&L,HL9HG\V.53TDW)D+'_P!-&PHR,FNR
M5U= RL&4C((/!H \&US]FJ\UCQ;J6K'788X+SQM8>*S"(&W"*WLQ;M!N#?>;
M&X/VKP_X<Z?XAO\ XA?#+X?Z9J%IJ^F>"O$M]J=_;G0[BRN].M@+A8A/*Y,9
M8F88VY,@^;CFONJCB@#QW]J_2+K4?@[=75O&94TB_L=9N44$N;>UN8YY=B@9
M9]B-A>YP*\N^('@#7O&.D?M$W^F^';J\3Q1I6F'1&,*[[S%H0RIGG*D@$'&#
M7U#XG\0Z9X2\.ZEK6LW*6>DZ?;O<W=Q("5CB12S,<=@ :IZ5XRTBZTG1;J2X
MATI=6"BQM;V1(I)2R[E15SRQ7G:,G% '!ZM\)O%FM:Q9ZG9?$G5_#UDL-N#H
MMOIME+$NQ%#+ODB9_FP<\\9XKP[QI\)/&6J^*+BRF\-WNI?$>774U#3OB/:R
M_9[6STT2 B)GSE"L8:,VX&')WYYK[+KQC6/VJ/#&B?$D^$[K2M:6%-4BT6?Q
M ;=%TV"\DC$B1/*7!!*E>=N,L!GF@"/X7Q_VW^T+\4_$-F5ETN.&PT5I.C"Z
M@$CR)CT"S1\^]>V5SOA'Q%X?UZYUV/0V@::PU!K341#%L(N0BLP;@;CM9.?I
M714 %%%% !1110!^?G[7?Q'TRP^-6HZ7XB^*GQ6\-06UM";/3? 6BD6\08'>
MTD^T^8Q..F-N*^S?@N]E<_"[PQ<V%YJ>I6\MA$R7VM1[+Z=<</., [SWKX__
M &O?&G[0UG\5M:M? NK>(_#_ (<TS3XKR'^Q?#L=_#<P\^?(TK'/F*=H6,#)
MS7UK\ -8US7O@KX.U'Q&]S+KUSIL4MX][#Y,S2$<ETP-I/ICB@#PW]MR\U*_
MUWP'X8L/$?Q TF'47N)9K'X;VN[4)@B@^8TF1A$SRO?->C_LFZ#)X=^&TUK+
MJGQ U5_MLC&;XC1E-1' X /_ "S]/QKRK]IGP9%\3-;T>X\?6WCWP%;Z&+ET
M\1^!+P26ZP.<#SI$'FAB "45&QGJ:]B_9>\(^'?!_P -$@\,^,]?\<:;<7#S
MC4/$EX]Q=(3@%#O560#'W6 //O0!Z_12,P12S$*H&22>!7F^@?M"^!O%/Q!U
MWP?H^LQ:EJ6AV(O]0FM2)+>!-V-ID!(W=R!TH ])HKP/X;?MK?#GXG>(-0TN
MQ?5=.2W@GNK:_P!3L6AM=1AA)$LEO)D[PN#D<'':KWP5_:[\#_'7Q%+HVA0Z
MO9W#0-=V,NJ6)@BU&W5BK36[Y(901WP?:@#:_:G_ .3=/B)_V!;C_P!!JE^R
M!_R;'\-O^P-#_*KW[4PS^SK\1,?] 6X_]!JC^R!_R;'\-O\ L#0_RH ]AHHH
MH **Q/$GB27P\L;)H^H:HK EC8HK; /7<PK,\+?$'_A*Y(&@T'5[:TF4LMW=
M0HL?'T8G]*Y)8JC&K[%OWNUG_D=L<'7G2==+W>]U_G<ZZBBBNLX@HHHH **S
M];U231[!KF.PNM18$#R+-0TA]P"0/UKF=$^)HUS5I;"+PYK<,D,HBGDF@0)"
MQ&?F._T]* .VHHHH **** &/$DN-Z*V.F1FO$?&/P;\:Z=XCO]2^'OB#1[&T
MU24W%YI_B.SENHHINA>W\MU*!NZG(R.,9->X$@=:^9M7_;O\.Z3XDUK1/^$!
M\=7=WI%X]C=-;:;$R"5>P/FC(((/XUO1A5G.U%-OR5V8U94HQO5:2\]#V3X8
M_#.'X>Z'+!<7\VNZM=S-<WVIW@'F3RMUP ,*@Z*HX KMJ\N^!'Q^TKX_:3JN
MHZ1H6N:-;Z==M8R?VU;)"SRK]]5"NV=IX/O7J-924DVI;FD6FDX['*_%#X>V
M?Q4\"ZGX7U"YGM+2_P#+WS6I D79*D@QD$=4 ^AKC_B)^S];>-KS7+NPU^_\
M.7.O:0-%U26T2.0W%NN0N-X(1@&D7([.>X%;WQ/^,6C_  M;3X+RTU#5=1OO
M,DBT_2X!+.88\&:8@D#9&&!;G/(P#6%XM_:9\&^%[73+F%[S7H+NR_M6631X
M//6RL/XKN?D;(Q_WUP< X-248NI?LKZ?=/JMI9^)]6T[P_K$%C;ZEH\(C\JX
M6V 4\[<@RJ LA_B KT'7OA?INN^*?!>MF:>TD\*O.]I;P8$;B6'RBKC&<!>F
M,5S>L_M*^#M'\1VNF>;=7=JT5O->ZM;Q;K33EN /LWVAR04\W/RD @=\5ZD9
MXQ#YID41;=V\D;<>N?2@#Q:;]E[0;>TMREW?W[6=QK5[':RR(JSOJ(;S$8[>
M I;Y3VXSFO,?V??A3XVA^*_AC5-5N/% \->#M#N=&BA\6PVL<GGR&(;;<P*#
M+&JQ ><W#<8'6OK5+R"281+-&TI02! P+;2<!L>GO2P74-R9!#*DIC<QOL8'
M:PZJ<=#[4 >*_$9&\-_M)?#KQ)>@KI-[IM_X=CE0%BEW,T4T>_LJ%;>0;B?O
M%1_$*X_PO^SKXG@\%_!'1-3$$1\,3:C_ &S)9WK))''/!<1H8)% ;=F5>001
MSZ5[5\0?&VG:#J/AS0;C3CK%_KU\+>WM @=8P@,C3R==J+L^]C[Q0<$BM&P^
M)7A'5'OTLO%6B7;V$;37BP:C"YMD4X9Y,-\@!ZDX H \SO?V3/#DN@ZUIUIX
MF\96TFIV$NGFXG\175WY2R  NL<SLA88X)![UR/@+X/^*_@/XV\;^-=;\;7G
MB'PS!HL45K8SPVEL)_)C(5#L11'MP%3& =W->PZA\>/A[8Z1J6HQ^,=&U&+3
M[66]GATR^CNYQ%&NYV$<;,S8'H*\VT[]H8^.O#GB.WU3P3;L\6AP^*K'3[R[
M26"^TJ1SY<DK;"(Y?W;$QX;! ^;G@ [+]F#PQ=>%?@CX<@O<K=7JS:J\)0HT
M!NIGN/*8'^)/-VD]RI->J5D>$?$UEXU\*Z/X@T[>;#5;.*]M_,7:WER('7([
M'!%:] !3*?3* 'T444 %%%% !1110 5\'_ME?&J3PW\8CX>NOV@M4^#4%KID
M5W!:6/ATWR7N]F!8RJ"<@IC!  SWK[PKX?\ VN?B3\6/"_Q7>T\+7WA?3M%A
MTS[;/_:?AF;4+A+6//G7'F*I#A25'E)EAG.,&@#Z!_9)\6:GXX_9W\%ZWK&K
MRZ_J%W;2-)JDZ!'N@)759"N!C*@'':O*O%G['/B+XR^+/$6H?%KXGZSJ?@M[
MV673?">C7'V.U@M^ !/(!F0%=P93QSUKV[]G?5+C7/@IX1U"ZNY[^XNK(3/=
M7%@+%I=Q)W"  "-3_"/[N,\U\W>./VG-9^%_BO5_#GA?X._%">UM]=EN[Z^M
MM&2^MM35B/,6)G?*(W&".GI0![I^S?IEGX>TS7]%\,:?I%G\.K"Z2/PY+H]T
M+B.:,IF<EM[<B7(P<5ZUJ>G0:OI]S972E[>XC:*158J2I&#@C!'U%?,_[%?C
M%?'FM_%?68O">J>!K>?5[;9H&KVPMI[<BW&6,8^50QYXZ]Z^H: /DWQ]^S'\
M07^+W@34?!M]X7_X5_X6B5;71?$D=Q>20RLY,DZ$L=TNWA68G;S76_M:?"?P
M3+\"OB1KDGA#0I-:;2+F8Z@VG1&?>$.&\S;NS[YS7T+7DO[67_)MOQ'_ .P)
M<_\ H!H K_L??\FP?#3_ + D'\J]BKQW]C[_ )-@^&G_ &!(/Y5[%0 4444
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M<LD,R!/W00)&8LD,Z\\]OLUM,LWD,C6D!<RB8L8UR9 ,!\X^\!QGK7DG@O\
M95\'^"?&4?B.*]UW5;B"ZGO;6TU;43<6UK/*S%I44@'< [JI8MM5B!@4 0_M
M<+.?@^'C\S[-'K.ER7A3.T6RWD1F,G;RP@;=GC;G/%>)_&_X3P^-[K]H/69O
M#MYJU[9Z?I,GABYB65O*=("X>RVG 8.!EH^>Q..*^Q]?T#3_ !3H=_H^K6D=
M]IE] ]M<VLPRDL;##*1Z$$BF>&]!A\+Z#8Z3;37%Q;V<2P1R74GF2%1P 6[X
M''X4 ?.GQ ^".M^+_B%;:['\/- UN!X[0OJFH>*M0LKDE47<3;Q*8P5P<<\X
MYKPC5]$UG6/B3XEDNV\30_$MO&L>IV'@JZTIG\/W<482..8RA"CY@&_>TB[7
M &W(%?HK2$9H \2^'!,O[3'Q1DM"SZ8-/TR)GA.81<@S&13CCS I3=WP5SVK
MVZL?P[X1TCPH=1;2[*.TDU&Z:^O)$'S3SL ID8]VPJCZ 5L4 %%%% !4=Q+Y
M$$DNUGV*6VJ,DX'0>]244 ?F+\:?BMH?Q@^(-_JOB/PW^T?;V=N1;6.G>&K%
MK"UMMI(=AMR9"Y .X] />OT'^#2VJ_"OPL+*'6;>T%A%Y47B%B=05<<"<GG?
MZU\^?&32_CYX+^-NM^)_ /@ZW^(FD:OI:6%M'>>(S8Q:6 <N! Q"LS-M.\<X
M&.*]]^"&B^(_#WPI\-6'BV2.3Q%#:*+T18VI(>2@()W;<XSGG&: /$/VRF\0
M:'XE\$^(=-7XA-IL"W-I/_PKQ8Y+@2R@"(RH^04R.N./45QGPA\87.J_M.7%
MYK?A#XA>&]3G@L],@:\L]D-PT<;&::Z:,M 5;Y,L#NSP#Q6C^W_'>7NJ^![*
M\\._$'Q3X2D%R][IOP_E:*<S #RFD9?X1SQFF_LE?'%]'N]'^&]C\)OB[H^C
MR2/Y.J^-$\^*T7&=K2DY"YS@<]: /LB>".Z@DAE4/%(I1U/<$8(KYTT_X.0>
M&?C?XAL_#'AR#1-!N?![V4,EM (X#.TN<,P'+<Y).37T?10!^8?PO^"'C[7C
MX1^'5UX5UO0M0^'2:I<7NJ31JMC?M.KB&.WEW?.'W#/IWKT/]D'0?&6L^,/
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MR6XNWNKVUCE?<5M9KF26WQ@\#RGCPO88':O8J9##';0I%$BQ1(H540 *H'0
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MY<2.FYIKF<$EW)[GG%?2]?)W[!&D?V##\2K";X>'X87\>K0-<^'AJ?V]8B8
M0XER<[ASC)KZQH 2O)OVLO\ DVWXC_\ 8$N?_0#7K5>2_M9?\FV_$?\ [ ES
M_P"@&@"O^Q]_R;!\-/\ L"0?RKV*O'?V/O\ DV#X:?\ 8$@_E7L5 &#K/A.W
MU"Z-_:.VGZJ%VK=P\$^SCHP^OX8JE;>*KG0Y(;3Q+$EO)(VV._MU/V>0]L]2
MA]CQ[UU=1S01W,3Q2HLD;C#(XR"/0BN25"TG.B^5_@_5?KN=L,3>*IUUS1Z=
MUZ/MY/0>K!U#*0RD9!'0BAF"*68A5'))/ KE)/#M_P"&0\OAUA+"S[WTV[D/
ME^_EMR4/MR/I5_3?$6G^)%GT^53#>!-MQ87 VR $8/\ O#W&11"O[RIU5RR_
M!^CZ^F_D*>&]UU*3YH_BO5=/7;S/F3QMX5\._$?XI>(]*U>*'4;&\U"TB813
ME'9-IW!70A@/7!KUKX4?LG_"[X)^*+OQ%X/\-#2]:NHC!->-=S3.Z9Z'S'-4
MO%/PF\(^"-<\+W^A:%;Z=>/J:(TT18L0<Y')->U5RX>,5BZ[2_E_([,5.;P6
M'C*3:][KYBT445ZIXX5S'C/X;^'O'HMGUC3HY[RT;?:WR?)<VS=<QR##+[@'
M![UT]% 'D2:QXX^%$MR_B _\)GX2C^9-2LX-NHVJ9_Y;1CB4 <ED ('\)KHY
MOBS8:AX:M]<\,6DWBVPE)WMIK*&A &3O5R"I_P!D@'VKNJ\?^,WP"TSQSX?U
MB72-4OO!NJW$#>?>Z,_EK<J#N*S(.'!(Y(PWO6%=2=.7)+E??3]=#HP[@JL7
M4CS*^VOZ69R?PHU@>+/VF_%NNM;RZ8]QX?LE2PN?];L#MB3CC!_.OHROQ-\.
M> [CQ-\5]*MO#MQXZN/'*:L7U/2+'5-DJV,#ALA)60;'XV@MC!-?J)8?';Q<
MHAMS\$?'"(JA?,DEL#T'4_Z16E*C4HT:?M9J;E%2NK=5>VB6PL14IU,145*'
M)&,G&VO1VOJV]3VZBN"T+XCZUJT2O<^ -?THD@%;IK<D?]\RFNG'B#8 9[&[
M@!]8]V/RS5F!K45Q&J?&+PYHY<7+:D"G7R]*N9/_ $%#7+W_ .U5X!TW'G2:
M]S_<\-Z@_P#*&@#T76O"MKJ\GVB.273]0'W;VT;;(.,#/9ACLP-8XU[7?"S[
M=;M!J>GC/_$RT]#N0>LD7)P!W4G)[5PG_#87PX_YZ^(__"6U+_XQ2C]L'X<M
MTD\1?^$OJ7_QB@#V+3M4M-7MEN+.X2XB/&Y#T/H1V/L:M5\_7'[1'PVU"[-Q
MIMQXBTO46_Y;P^&=057Y)PZF## D\]"?6NE\-_'[3[JY^RW]GJ3P@$C58M)N
M8X" !]]70,C'DXY ]: .DUK_ )*SX?\ ^P==?^AQUY+\!?\ DZ?]H+_KYTS_
M -)S7F/Q[_;D\,:5XKOCX)FO[ZZTG3;BV_X2J+29+S1;2\.UU@G=2.NT*2#A
M2XSWKQS]G3XT?%+Q)\;/#VL^'M<T'5=1^)<T-[K=I+HLD<=I9VR;9'1TD;8>
M"@W9RQ%=%.A4J0E.*TBKO5>GS^1C.M"G*,);RT7Y_+YGZAT4@S@9ZTM<YL%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\:_'CXH3>"_CY?7GC;3
M8SX2TO27_LW3;;PFVI7.O^:A62$7(#>6%;;E"%R#SFOHSX&^(KKQ9\(/#6KW
M7AV+PE)=V2R+HT2[%M4/W5VX&WC'RXXZ5\5?M9_%7Q[H'Q]US3-$^(WQ#L]-
M@M;<II/@+PRNII9LP.3<.X 5FZ@ G@'I7V[\'KV\U3X3>&+K4+K4KZ^FTZ-Y
MKC5[46UY(Q7DRQ#A'/<4 ?//P?\ V<_A%\0/B#XG\4^(,?$?QQ8ZI,99M4,]
MQ;6"%B$@B651&RJ.PW8.:^EO!>J17O\ :MI!<VLT&GW7V6."UM'MQ;*$7$9W
M<,1GJO';M7Q'XN^#7[1_BPM-IUSX T_PAI&L7.H:9'K[WEO<QIYC',YB9593
MR<'C&*^L?V==2\>ZQ\/DO?B#J_A36]4FF9K>]\',S63P<!<,Q.3G.<<4 >HT
M444 %)7,_$[4KK1OAYXDOK*9K>[MM/GEBE3JCJA((^AKX<_8UU;5M%\0_"O5
MK;6=7\077CK0KZ\UZ"ZOWEA>>*0[)PCD[#_"=N![4 ?6W[4__)NGQ$_[ MQ_
MZ#5+]D#_ )-C^&W_ &!H?Y5\W_M%_'G]H.]^&/CW2K[]G=K+P^]E<P/K/_"2
M6[[(.1YWECD\<[>M>Y?LMZQK-C\!/@W9V.B'4--N])1;V_$ZI]C 0E3M/+9/
M''2@#W^BN4M_$7B*23Q2)/#1C73SC2V^U*?[2&S.?^F?S?+S]:A_X2?Q/_9W
MA:8^%'^U:C*B:G +M/\ B6J5RS$_\M,'C"T :WB3P?IOBH1#4!<,(\[1!<R0
M]?78PS^-4/#WPST'PM=Q7&FPW,#1@A$:\E= #_LLQ'Z5&?%FO)J_B2!O"=V;
M#38%DL;E+B,MJ3E<E$7/RX/&6Q6>/'_B9=!\,7C^ -2-]JDPCO;%+J MI:'J
M\K;L,!Z)FN66$P\JGMI4TY=[*_WG9'&XF%+V$:C4.UW;[COJ*Y&+Q=KDGB+Q
M!II\(WT=I86XFLM3:>+R=0<@GRT&[<I!XRPQS6?;^._%-QX;\/:C_P ('?0W
MU]=+#?Z9+=P^;81G.92P8JX'' .>:ZCC.^HKGK?6]:D\4ZM82:"T6DVUM'+:
M:G]H4BZD(.Z/9U7;QR>N:QE\7>+CX+TS4CX,8:Y/=1Q7.D?;4S;Q%R&D\SHV
MU?FP.M '<GI7%>!O^1K\9_\ 7\G_ *+6K&NZ]XJA\12Z?I/AR&ZL19B=-3NK
MP1QM-O(,.T L#MP<XQS7FVF>(OB=X>M]3UY?ANEY/J>I(LFE1:J@N(8\A#+D
MC85P-V,YQVH ]WHKE_\ A*=8_P"$WAT4>%KW^RFLOM,FN&:+R$ESQ %W;RWO
MC%8)^(_BH^";[65^'&K#5;>\^SQZ&;NW\^XBW[?.1MVS&/FP2#0!Z-17+GQ-
MK(\8Z?I@\,W1T>YL3<2ZOY\>VVFS_J'3.XDCG(R*S?\ A+_%I\&:SJ0\%R#7
M+6Y>*TTAKV/-W&)0JR"3HN4R^#SQB@#NJ*YRZUS7(O%&C6,.@&;2;JVEEO-2
M^T*/LDB[=D>SJV[+<CIM]ZSV\5>*$T7Q;=?\(D[7NFSRII5FMVF=415!1PW2
M/<21ANF* .SHKDI_%/B"+5?"UHGA2>6#4D=]2NUN8Q'IA"9"L,Y<EOE^4>]4
M5\>^(C9^+[@^!-3!T>0IIMO]H@\S6 %!W1?-A 2<#>1TH [NBN)D\;^((YO"
M*CP1J+QZP#_:++<0_P#$G.P,/-!;YQG*_)GD5H^&_$>KZMX@\0V&H^&[G2+/
M3[A8[+4)9HWBU",J#O0*=RX.00P'2@#I:*** "BBB@ HHHH **** "BBB@ I
ME/IE #Z*** "BBB@!#7YK?&KPA'X3^.&I?VA\0/AOX*M/B#?/I5Q<V5O=3:G
M<Q+<B02.O*13I@1^:2%SCH17Z4GI7PUI>H?LYV_Q/^(&O^._$^B:-\1KS4;K
M1Y%F\0&XN8+=9=L?DHP_<.PQE5''3/6@#[4U"]&A>'Y[M(9]0%I;&188!NEF
MVKG"CNQQQ]:^/M;_ &\[G7=)NK&^_9K^*EU:3QE7CN-$C9",=P6K[*,"3V'D
MQR.D;1[5D1L,!C@@^OO7S_XMN?VDO!FIV6F>$]+\'>/-$DF,?]JZS=RV=Y;1
M$C!G1?EDP"1E.3MR1DT ;W[&5X^H?LT^"KETN(C-#.XANV9I8E-Q)B-RW.5&
M%_"OG']J']G+X4Z#\2+;4=5G\3_VCXEOS=7]U=^,&TK3K.#(\V1&<;691R(5
MR3]!7V9\-]%\3Z/HLH\5ZI87^HSRF7R-*M?(M;0'_EG'GYF&>=S\Y)KPK]MR
MWU;4-#TZ"W^&,_Q.@0E[72&TF&_M9;H_*OGEOG@102Q=>N,=Z %_89T;X?\
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M+9.-[:=[WE?SV/;K5*+P]"56EJ^:[4K7U[6:C;RW.4_X6SI'_/CK?_@IG_\
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MX3U2<7(T^/9\WE3[F,BNWS<XVGBOHJ@ KR7]K+_DVWXC_P#8$N?_ $ UD_M
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MG<T<BAHR>X)//UKZ*^"6I>,M6\.PS>)O!>G?#ZT2%$L]!M+I;F2%?]MD543
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M(^!O@WXD\0ZKK$$5@EL]NJH=TLD[KA(53J9"2!MQFMKX(?$7P]\4_ACH.O\
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M'"N0"0#T)% 'R[X'_;9U_6O#+^(/%'PNU'PGH&HK+)H.ORW*W&GW**&*&Y=
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M,)=7=8(B"$6 *NW:5) H ^SO@GXQTWQY\,-"UC2+$Z;ILD;P06NU%"+%(T7
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MDREHW5P#C*G/- 'R-_PA_P"VK_T4#X7?^"JX_P#B:/\ A#_VU?\ HH'PN_\
M!5<?_$U];Q74,RNT<J.J$ABK A2.H-'VJ$,%\U-QY W#)H ^2/\ A#_VU?\
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MXR^'VH^%$D8W]KI.G3QW,B;3@1LP !W;>O;-?2F1ZTM !1110 4444 %%%%
M!1110 4444 %,I],H ?1110 4444 %%%% $%\+DV4XLS$+K8?*,P)0/CC<!S
MC/I7PQX[\#?&KXM:_J&B_&?Q_<?#3P9M*QP^ K)Q:W0+>6GF7K[F!DW',)'3
M'-?=U-=%D1E8!E88(/>@#SK]G?PEX<\!_!GPQX=\)ZTWB'P_ID#VMKJ3LK-,
M%D8-DJ ,AMPX':O1ZSO#_A[3?"NDP:9I-G%8:?!N,=O",*NYBQP/<DG\:T:
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M]JT8ZA]HCU"Q$.FZ6LK H]O,H'GM+R26)P!QBOOFBB@ HHHH **** "BBB@
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M /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I#2T4 ?*/Q3^,'Q9O?VB=?^'O@/5/#>DV^E>'5UI&UG3I+@W#Y.8RR
MR+L''7!H\(_MY:7=?!O1?&.K^$]?NYBLPU<Z/9B2VL?)?RY9FD9@-F[H 2Q'
M:I/C!^S?\5=9^/MY\0_AUXQ\.^'TU'2$TB[AUG3WNG\L$Y* 8&>?6O./'O\
MP3CU:[\(Z-X6\.>(=+O-(73;BVOWU]9]RW4LAD-U D3! VXXPV<"@#W*/]M#
MP9)X;N]873-<=(=5MM*BM8[57GN6N &BE1%8GRRISDX/!XKWR&3SHDDVLNX
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M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
; %HI,T9H 6BDS1F@!:*3-&: %IE.S3: /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cgtx-20231231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #\ 8 # 2(  A$! Q$!_\0
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M'0?$#PCJGAV\N[RRL]1B\B>?3YS#.$)&X(XY7(R,CGFNCHH _-'1?!>D6O[
MWCGPQ<ZG-X1\.IX]GMGO38/>K;VZW\>/,0<E, !F/&,Y[UZ[^R=J?BW6OAC\
M2=#\ 7OA9I-)U\6^C>,(-&%M8:O&41I':&(@,RC*;E..!Z5]@-HFGFQN+(V%
ML;*X+&:W\E?+DW?>W+C!SWS3M*T>RT*SCL].L[?3[./[EO:Q+'&N3DX50 *
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M@VR_:#U95\7WG_"/:SX@NH=<M(-($MQ;R+<6LMP_V@](5F6% W\)+ 5^FO\
M$: %HHHH *PO&'B[2O GAC4O$&M78L]*TZ%I[B<@ML4>PY)Z#'O6[56]L;?4
M(&@NH8[B%L;HY5#*<'(R#[T ?.>C_MN>'M:^ -]\4H-"U/[*NMMH.GZ20!=7
MMR9EBB4 _=W%@>>@SFO0_@7\=+/XT^'M7NI-+N/#6M:'J4FD:QH]^RE[.Y0
ME"PX8$,I!'K7S7<?LU^/H/V<M2TVVTJ.7Q1I?Q#D\6V.FM,%%W;K=+)L#= S
M)NQ[XKT#X'_ #4_%7@_XI7/Q'TNYT"3X@>)GUPZ1:W96>RB58UB1I$_B_=Y.
M/6@ _:2GBF_:N_9=\N5) -4UG.U@?^7$5]3U\*^/?@+X7^"_[6O[-\_AXZB9
M-0U'5HYC?7LEP,+99&T,>.O:ONJ@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHKE/BGXMD\!?#;Q1XDAB$\VDZ9<7L<3=&:.-F /MD"@#\XOBSKVC:?
M\>_'=Y:>"5;2[S7A9WMYJ&LM$)'M[ZW-RL4..DDDD;LHY=5SVK]1ESGFORZU
MKXJ^(=:N)]9\0:WX%UN;PI)H?B$VZVD9;59M0*ADZY#PJ, CDD+FOTR\0>)-
M+\):3<:IK-_!IFGP#,ES<N$1?J30!JT5XYH_[7/PDUS5$T^U\:67VB1ML;2J
M\:.?9F4 UZ]'*DR!T8.C#<K*<@CU% $M%%% "8]Z,"O$_P!L7XD^)?A3\!M9
MUWPA!-/XB-Q:VEKY%N9V0RSHC/L'7:I)_"N+_9]_:!6W^$/B;Q)XY\6W/B&?
M1M5^QWJC2F@N;%B$"Q/"!G.3G/HU #/VEO\ DZ_]ES_L*:S_ .D0KZDKX:^(
M?QT\)?&/]K7]FV#PW<7<TMCJ.K23"YM)(,*UE@8+ 9Y':ON6@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX[5QY?2I4<-&G1222V1VYG6KXC%3J8AMR;ZCJ***],\P**** "BBB@ HHHH
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MHZ1ZIK!=EF4A<V0QDYXR:^GO^$GT?_H*V7_@0G^- &I165_PE&C_ /05L_\
MO^O^-'_"4:/_ -!6S_[_ *_XT :M%97_  E&C_\ 05L_^_Z_XT?\)1H__05L
M_P#O^O\ C0!JT5E?\)1H_P#T%;/_ +_K_C1_PE&C_P#05L_^_P"O^- &K165
M_P )1HX_YBME_P!_U_QI?^$GT?\ Z"ME_P"!"?XT :E%97_"4:/_ -!6S_[_
M *_XT?\ "4:/_P!!6S_[_K_C0!JT5E?\)1H__05L_P#O^O\ C1_PE&C_ /05
ML_\ O^O^- &K165_PE&C_P#05L_^_P"O^-'_  E&C_\ 05L_^_Z_XT :M%97
M_"4:/_T%;/\ [_K_ (T?\)1H_P#T%;+_ ,"%_P : -6BLK_A*-'_ .@K9_\
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MIOAOX[^+-UX7TA9HM9N7N+6WU66T,<.I/:G$T<4I'SE#GCZXH 9_PPU\'_\
MH7KC_P #YO\ XJC_ (8:^#__ $+UQ_X'S?\ Q5>]CI2T >!_\,-?!_\ Z%ZX
M_P# ^;_XJC_AAKX/_P#0O7'_ ('S?_%5[Y10!X'_ ,,-?!__ *%ZX_\  ^;_
M .*H_P"&&O@__P!"]<?^!\W_ ,57OE% '@7_  PW\'^/^*>N/_ ^;_XJO$O@
M3^RE\.O$WQ8^-VF:IH]Y-I^BZ_;VNG0O?3A88FM4=@OS="Q)KZ<^-WQ^\+_
M6PT:X\1B]EDUBZ:SLK;3[9IYI9 A=@%49X4$UPWBK]K_ .'7P]T70]:N;#5(
MI_$EM+JCVMOIK_:H[6([9+F= ,JJ\<F@"W_PPU\'_P#H7KC_ ,#YO_BJ/^&&
MO@__ -"]<?\ @?-_\57M>AZW9>)='LM6TVX2[T^]@2XMYXSE9(W 96'U!K1H
M \#_ .&&O@__ -"]<?\ @?-_\51_PPU\'_\ H7KC_P #YO\ XJO?** / _\
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M /H7KC_P/F_^*KWRN8^(GC[1OA=X+U?Q5K\[6VCZ7#Y]Q*B%V R% "CDDD@
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cgtx-20231231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "S > # 2(  A$! Q$!_\0
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MHWQ$\26%EX@N;:TMKZ2*&%43"*#P!QTKFO\ A?GQ!_Z&B[_[X3_XFL_XO?\
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MV)AV 5QNP#CIFG?&VOS/[_\ @A_M-KW?WA_POSX@_P#0SW?_ 'PG_P 32_\
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MK?X:?]"K!_WS_P#7H_X5O\-/^A5@_P"^?_KT?V%5_G7XA_9LOYD?%%%?:_\
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M^CM9O[+>.*&&]U.:ZFFN)"L?ERP-$T9(!*DAOO#H><5])_\ "M_AI_T*L/\
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M:S-9ZA";>S2T6XBO0)FVR,^6^7:0P8C!'88Q7T%_PK?X:=O"D/\ WR/\:/\
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MW3?B)X9U?Q+<^'K'7;*ZUNV+B6QCDS(I7&X>A*Y&0.F>:?*NP<J-'_A'[?\
MY^)/^^11_P (];_\_$G_ 'R*77_$.E^%=+DU/6+^#3=/B9$>YN7"H&9@JKGU
M+$ #WK-UKXA^&/#OB&TT/4]<LK'5[O;Y-G-)AVW'"?3)! SC)I\J[#Y%V-'_
M (1^W_Y^)/\ OD4?\(_;_P#/Q)_WR*FU75K+0K![S4;F.SM490TLQP Q;:!]
M22 /4FLAOB)X97Q9_P (N=<LAX@Z?V?YG[P';N ]-VWG;UQVHY5V#E78T?\
MA'[?_GXD_P"^:/\ A'[?_GXD_P"^:DUG6]/\.:9/J6J7L.G:?;@&6YN'"HF2
M ,D_4?C2:MKFGZ!;P3ZE>PV,4\T=M$\[A1)+(P5$7/5F)X HY5V#E0S_ (1^
MW_Y^)/\ OFC_ (1^W_Y^)/\ OFIK35;/4+J^M[>YCFGL)!#=1*?FA<J& 8=L
M@@CUS5NCE787*C-_X1^V_P"?B3_OD59CT.%+"Y03OM9D).WD8)QC\ZLU,G_'
MI-_O+_,TN5%<J,C_ (1^W_Y^)/\ OFC_ (1^W_Y^)/\ OFM&BCE78GE1G?\
M"/6__/Q)_P!\BC_A'K?_ )^)/^^16C11RH?*C-_X1^V_Y^)/^^:7_A'[?_GX
MD_[Y%9VN?$7PQX:URST;5=<LK#5+S;Y%K-)AG#-M7Z9/ )QD]*O>)/%&D^#M
M+;4=;U"#3+%75#-.V 78X"CN2?0<T^5=@Y5V'_\ "/V__/Q)_P!\BC_A'[?_
M )^)/^^14$/B_0[GPNWB2/5;5] 6!KIM1$@\E8E!+,6[ ;3G/3%/N_%6CZ?H
MMKJ]SJ5M;Z7<^5Y%W)(%CE,A41;2>N[<N![BCDCV#E78D_X1^#_GN_\ WR*/
M^$?@_P"?B3_OFLS7_B1X6\*:S;Z3K&O66G:E/M*6T\FUOF.%+?W<G@9QFNDZ
M4<J[!RHSO^$>M_\ GXD_[Y%'_"/6_P#S\2?]\BM&BIY4+E1G?\(];_\ /Q)_
MWR*UO#.E166H.\<K.?+(P1@=145:&A?\?;_[G]:N,5<J,5<K7O\ Q^S_ .^:
M^-#H/CR_T;]I6Y\.^*-,TG0UU[5Q/8W6F^=)(181%R),\97VXK[*OO\ C]G_
M -\UFII%C''>1I96ZQWK,]RJQ@"=F&&+C^(D  YZBJZEGQRGQ7\1>'_^$7T&
MS\20>%]*DC\'Z>^H/;([00W.G7#2@D]26CCP3POTK87XO^*;CXF:7X)D^(D-
MIH0\0WVF#Q6MO'F^C2PAN%A!/R!TD=DWCCC'6OH3QE\(O#_C670&N;.&W32-
M1@U#RH[="MR(8I(HX9 1S&%E; [8J/7/@QX9US6?"MW)IUK#8>'?M?D:5';)
M]FE-Q&$;>F,<;00>N:8KG@O@[XQ^*?&^O3>'=5\>0>%=+TV#4WM?%:6R*-<,
M%T8$D7?\H")\S!?O'IQ3?"WQK\6>/=.N+S7_ !I;_#:73/#MCJD2-:*4U-Y3
M(9+@J_)C_=H B\C?ZD5].7W@KP]J6F6>GW>@Z;<V%F?]&MI;1&CA_P!Q<8'O
MBI=4\)Z'K<]I-J.C:??36@ MY+BV21H0#D;<C@9 X]JFY1\L7_[0WB+_ (6C
MHKZ;KT]]HVH^))=#DM)+:.&W2-8),[%8^9O5T!WD8.<4G@'Q'\5/%B_#:&Y^
M)$T1\8>$KO7[J2/3H]UK+!Y6Q8?9O-^;/7''6OJ-_!/AV34Y-2?0=-;49)!*
M]V;5/-9QT8MC.?>KEOH6G6?V7R-/MH?LD)M[?RX0/)B.,HF!P#@<#C@4[DW/
ME+0/C5XF\=WFDG4/B';^!T?X>V/B,H+="L]ZTLZR-\_\'[M24')R,5&?VH/$
M0^"_Q(UO5M3M] \66VDZ/?:1I\J!'C>XM(FD*(W+J9&?'IG':OH-_@KX6F\<
M7'B.YTRUNQ)I=KI,6G36J-;V\<,DLB,@(X.92#CC %='J?@KP]KEXEYJ.@Z;
MJ%XD7DK/<VB2.(^RY(Z#THT"YX'X?^+/B:W^/T>DZOKOVO1K_7KO1[2TT]8Y
M;=0L6Z*.11^\BE7:Q9R-I_$5]*UEQ>%-%AUI]9CTBQCU=P5>_6W43'(P1OQG
MH,5J5(@HHHH **** "II?^/6'ZM_2H:FE_X]8?JW]* (:*** .'\:>)?$=MJ
MD^B:7X3OKVSN[";&O0SQK%;2F-PH*$[B0P7I_>%> _"'4_#\+_LWMIDMK#>Z
M5X9U!]=DCPAM8EM(UF^TGJ,W _BYW*QKZVZ5D0^#] MWU)XM#T^-M25DO2EJ
M@^U*WWEDP/F!R<@]<T ?+GQ9O]#,?[3$>K/!/J6JZ9I;Z$#AIKF)K)5M_LQZ
MG_2=Q^7^(YKG_'UEJVGVOB3PSI=YHM_JMYX[TW4?/EW#5X;QYK:1H%3&2JJK
M,)0=HCW#M7V)/X1T*[NM.N9]%L)KC3D5+.5[9"ULJ_="$CY0.P'2I6\-Z0^N
M+K3:59MJZ)L&H&W7S]N,8WXSC'%5<=SS_P >R&__ &D/A1IER =*CM]7U6,'
M[KWD21)$/JL<LS"O#/AU<:<OA;X(Z<IA'C>S\=:A+JL:@"ZA"M?&[>;OL*,F
M2>#E/:OJ3Q3X,M/%-YH%])+)::AH=^+ZSN8,;E.TI)&?5'C8JP]P>U78O#&C
M0:O<ZI%I-C%J=RI2>[6W432+@ JS8R<@#/THN,^?O'.O>%7^+GQ#U/Q#=6%S
MH6H?#B$:5<S,KQ7$8EN_M*PL>"Q+0Y"\D[?2O$]7M;V3P%XO&K7MOI$UCX8\
M-1ZGH>I1[K[7&CM8GQ Y^:,G/DC;GYU).#7W+-X'\.7-EI]G/H&F2VFG'-G
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M,Q*=._:MN[>S;$.J>$!=ZC&O3S8+SRX)#_M%))4]PGM7J=8&D>#;72O%VO\
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M=<-D _PMZ&CFD'-(]7_X2*W_ .?9O^^Q1_PD4'_/LW_?8KROQS\8?#?P^O\
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M[S38M+@\B%9?M-PMI$Y,:$/&KL2-^!QU)^R_7WHS2N!\H0?!J;PM\1;&YC\
MSWGA;1OB1)>:=:6MHLR6FGS:8B>?#&3E81=$LVW[K MCBLO3O@C>>$?@[H!3
MX=#4/$.I>([J?Q#)/:O?7$< N+I[>1[595-S&-T8$1;8N\,0<5]A^GM1FBX'
MRE^R_P##GQCX6\::#<>(- O]+LK'3-?M5-U"L2P+-J<4UK$$5W"*8LE44D *
M1GBO2_B'8:YX*^-6C?$73?#NH>+-)DT&;P]J-EHZI)>VI^T"XBG2)F!D0MN1
M@IR/E."*]BH]?>D!\W^-8_&?Q%U#PMXC\5_#R]NO 5AK%PY\((HFU*:!K8)!
M=7=N'VOMFWL(@255E8@D<<WX"_9_N-;^(/@V?Q3X-N4\&69U^^TW1=3<RII$
M<MS;-9V\JAB XV2NL>2$R ,%17UI13N!\:^*/@]X@6#Q!9:5X/O;+2[;X@W.
MLZG#9:7%.FL:?+"_V=HXBZK<I%*P9HF((YX)&##??!3QSJGPWTG2/"NEZWHW
MB)M8U+5=/U34A'8+HU@T6R:T"1,_E"Z/RK!R8RQD^7:!7VA1Z>W2G<#G?AQ'
M;P?#_P .0VF@7'A6VBL88TT2[7;+8A5 ,3<G)4@Y()SU[UT5'?-%22%32_\
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ME6#ZW<^&--2XB\1Z@L:M)"T@==MLCJNX*!YC CA1@_6$3^9%')Y9CW(&\M@
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M\T44 'V&W_YXI_WS1]AM_P#GBG_?-%% !]AM_P#GBG_?-'V&W_YXI_WS110
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*Z9 Q111U)ZG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cgtx-20231231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +( L@# 2(  A$! Q$!_\0
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MB)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\  >Y_^+H\OXB?\_'AC_P'N?\
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MN)\OXB?\_'AC_P ![G_XNCR_B)_S\>&/_ >Y_P#BZ .VHKB?+^(G_/QX8_\
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MB@#BO&EK_87B#1?%%N!&ZSQ:9?DN%66UF<*N<]TE9&!ZX+C^(UV@Z5PGQO\
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M18M2;3-4NK&+4%'43QPR*LF1PV1\W?->XVUG!96<5K;1);VT2"*.*)=JHH&
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M4C4(K<DGOT )Z D 'F]C^P_\+;-O#)DM_$=\/#+EM&6\\4ZC*M@-NW9$#/\
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M"7AJ'Q/I^CV.J:5?0MJ,=H;8W*ILF?>/FC&TYV MV Y% &;??'SXV>(?B/\
M$[P7X+\">%+S5/!M[IH\S4=7F2"YM;F)I>'"#$Q0I\N J;6R7RHJ/QO^UCXE
MF\/^*O$?@33=(U"R\.7MQ9QZ-J%O=O>ZXUK(\=T+=X1M@_>(T<>]9"Y4L0@*
M@]9\'/!GC/0?VE/C7XBUOPZMAX>\4?V4^FZBE]#+YC6EMY$@:)6+H&)W+D=
M=V#@5YGX)TSX]_LW>./%WA'0_ D'Q.\$>(-:O=:T#61K$=@ND/<RF:6"[5PQ
M$2R.[9C!)^8J"6VJ >FS_'?QAXJU'P@OA_PS_P (AX<U7PT?$FH^*?&5I)]F
MTUB0B6#QK)'MGRP9BTB@*IP&)X\-^,'[3WCOXG_\$_\ Q3\0?"QTGPUJ5LUW
MI>L7$,DDVZ..<6TDEBV/E,FX%6DR44G&3AAW_BWP1\5[3XZ>"[W7/#47Q=\)
M0^'ELQ_I<%E:Z=K/F%Y;Z:WER'4JJJC .T:\*"Q8MYIX>_9U^+NH_L2_%CX5
MZEX1LM,\0:A?W\^FG^UXY5U!IKY9\H< 1Q[5(!D(9C@D** /?M=^-VK^ _\
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MX7_%S5_V*O!_P\?X>);>)-"ET*U%F^MVV9$T^XBEEG9\[%23R $4%F^;+8%
M'JN@_'3Q[H?[1^A?#OQ[H?A^ST[Q7I%WJ>B2Z'<SSSVLML4,UO<M(%5_D8D2
M(JC(QM/6KW[=/Q.U?X/_ +*7Q"\3Z!,UMK,%DEM:W"J28'GE2'S!CHRK(S G
M@,!FJ7Q#^&_BOQ#^UU\(O&]EH;2>&O#^DZK:ZC>-=P*T4ET@" 1E]S;2GS$
MCYAC/./3_C7\)])^.?PJ\3>!-<:2/3=<LVMGEA^_"V0T<B]BR.J, >"5P>*
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M7A/X&VC^'_"7]K>,[73(+>WT.ZOX84\\(J?O)@Y38I!8[220,#D\ 'D_Q_\
MAKIGCK]I;X$Q^';(6'BSPQ?/K=_K-C"%:TT6.-T^RRLN/EN)BL:*>R7!7@,#
M]1#@5\I?##5/CKX:CALI/A%'_;NLW\4VN>+]=\56=POS,JR2BV@ ;RXX\K%
MC *H W$EF;ZM&<<T +1110 4444 %%%% !1110 4444 %%%% '!_&_\ Y)W<
M_P#7_IW_ *705W8Z5PGQO_Y)W<_]?^G?^ET%=V.E "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '!_![_D :S_V,&K?^ELM=Y7!_![_ ) &L_\
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M .#^#W_( UG_ +&#5O\ TMEKO*X/X/?\@#6?^Q@U;_TMEKO* "BBB@ HHHH
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MN=L_*IP:=X<^-OP_\8>*#X<T+QIH.M:X+8W9L-/U&*>7R@VTMA&.<'KW&1G
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MX 3G@RL#SF@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q/&WB[3?
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MS_U_Z=_Z705W8Z5PGQO_ .2=W/\ U_Z=_P"ET%=V.E "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '!_![_ ) &L_\ 8P:M_P"ELM=Y7!_![_D
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M=U-/->>%;<S7]K96L>]Y(_F0#,[VD9RPRLCCD$XY+PI\4_'?Q%\8_LZ>(?\
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M4-V\ED64F)A/;P.I8N%\M0H"\5'%^QAX!BOM#O/M&N/<6,OG7[OJ&3KCB_\
M[04W_P G[_%T6D&-H^8K]WY:[\_'?X=B_P#$]D?&NAK<^&8C-K,9OHP;%!PS
M2<\!3P?0D X) IL'QZ^'-PGA1H_&^A.OBIBNB$7\?_$P;.W$7/S'=\F/[Y"_
M>.* /.;?]B'X>V=IJ\-M=:_;O=7-M<V,Z:E^\T8P7TE]"EF2A\M%N)7?#!\Y
M )( QC?M%?#?0OA)^QO+X2T&*2/2](ETFUM3=2F69A_:=L69G/)9B68^Y. !
MQ7K\WQZ^'4%KXJN'\:Z((O"S^5K1%ZA-B_0+( <@ELH ,Y<%1E@0/+?VT[/P
MYX[_ &:WU](]/UR*TU#2=2TC44VS+&[7UN@FA<9&3'(XW#LQ]: /HY>GXFEI
M%Z?B:6@!*Y[P%!);^'MDJRHWVN[.)K%+-L&YE(_=KQC!&&ZN,.>6-=#7,_#G
MRAX9_=/:.GVV]YLI99(\_:YL\R_-NSG<.@;<%^4+0!T]%%% !1110 4444 %
M%%% !1110 5P7B34M:UCQTWAS2M?MO#ZVNFQZ@[BW2>XG+RR( %?Y1&OE_,1
MDDNO*XY[VL+Q1X$\.^-4@77M%L=7$&[ROMD"R% PPP!(X!'!'?O433:T,JD9
M2C:/^7XHY_2_B9!IOPBNO&GB*ZM/LNEV=U=W]Y89\AX[<R"26/<<A6$98 GC
M(Y/6OF+X%_MK>+OC'\"?BIK%@OA6_P#'GABT358(K:25+"&TN+;[1&LHY=Y8
M-LT4BC :2+:&&2U?8.N^#M#\3>&9O#NJ:39WV@S1+!)IL\*M;O&I!"%.A7Y1
M\O3BJVH?#SPQJNK76J7F@:=<ZC=:8^C3W<ELAEEL6.YK9FQDQ$\[#Q5)-))E
MQ344F]3Q?P3\:_'6N^.?@K:7]IH\/ASQCX2DU:YGBWM=RWB6MM,^$^[#$IFP
M!N<MG^$+SI^/?VN?#OPY^(U_X-UC2=1CU.T9;HLNPK)IHL;B[FOD&=SQQ?99
M8W4 MO* 9W<>M6G@7P]82Z#);Z+8P2:#;-9Z4T<"@V,#(B-'%_<4K&BD#LH]
M*DNO!VA7WB.+Q!<:/8S:Y%9R:>FHO;J9Q;.RL\._&=A95)7ID9IE'S$O[97B
M3Q;:^"G\-^!I['4-4\2V6G2V.J3!8;RTNM+O+N/RKK:%616MU$F%<*054ON5
MJMZ+^VLGB35-$;1-"N]2N/%&DZ1+HOA^X\JU*W=S-J22B:[+,H5!ITA/R<A!
ML\QI @]T\/?!'P%X4BLX](\(Z1IZV5W'?VWDVB@PSQPM!&Z'JI2)WC7'"JQ
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M7\'_ !/I>OZAI^O7DMKH=D+^^9M+N%,<)ECB# %/F.^5!@<\YZ UIZ7^V?\
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MOQZ_:2T?X@?L06/BC5K.ZT:]UY--O3:06=Q=11M'JD"R*)DCV DQMM5BK-D
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M<V_Y9"6SNW;CT9LE?E(KJ*Y[P&YD\/[C-)/_ *7=C?)?B]/%S*,>8.PZ!/X
M G\- '14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ^);K4]/TJWL$#M/J:NT1).%3"$,69B ,9Y/0UXA\2?VLO#GASX8>"_%LOQ
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 <'\;_P#DG=S_ -?^G?\
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MF*QIA5+$@ FKNF?"7P9I'AC_ (1RV\+:2-",QN6T^2T22%I2>9&5P<MTY//
M]*A0Q;6LDM/QOZ=O^&9"IXYI)S2TZ=[^:[?=V9YW<?M7Z%!X;T/6(_#VM7T-
M]HA\0W:6:PL=/LUD$;R.6D7?AB>(]Q(4G'2O< <C-<IXD^$_@WQ@NDKK/AG2
M]132L?84GM5*VX&,*HQ@+P/EZ<#BNLKHI1K1;]K)-:6_4ZJ$:\7+VTDUI:WX
M_P!:A11172=9P?QO_P"2=W/_ %_Z=_Z705W8Z5PGQO\ ^2=W/_7_ *=_Z705
MW8Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 <'\'O^0!K/\
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MI_\ X0=M_P#)- 'O]%?+?@[P7^T7XCO_ !3!J'Q@M=&BTG5FT^SFF\!P8U"
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M,<=W#+("Z L"4C< CG)'(Z@ ]+5QCH>OH:7>/?\ (UX)_P ,+?!G_H7=4_\
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MEVLXC_I"_,D!C0\'E3\S=2GQ4_8&\#:IX+GM_ ^GWFD^(S=V3QW5UXHU;RQ
MMU$UTG^O?E[<3(/EZL.5^\ #ZHWCW_(T;Q[_ )&O!!^PM\&N_AS5/_"HU;_Y
M*KF8/V"/ "_$J]O)-,O6\'-I,$5O8#Q1JWFI?":8RR'_ $C[K1-"H^8\H>!U
M(!]0[Q[_ )&C>/?\C7@G_#"WP9_Z%W5/_"HU;_Y*K#\"_L&?#:Q\&Z+;^)M(
MO[_Q#%:1I?W4'BC5O+EG"C>R_P"DKP3D]!]!0!]+A@3W_(TZOG27]C?POX.\
M9>!_$7P_M+G1[W2=;2ZU%[SQ!J,XFLO)F5XUCEFD1F+O&<$#[IY'?Z* P!0
MM%%% '!_&_\ Y)W<_P#7_IW_ *705W8Z5PGQO_Y)W<_]?^G?^ET%=V.E "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '!_![_D :S_V,&K?^ELM
M=Y7!_![_ ) &L_\ 8P:M_P"ELM=Y0 4444 %%%% !1110 5Y3^T'\=+7X+>"
MK[4;=+'4-8C-N!:W=YY,5I%-,L/VRZVAY$M8RVZ21$8@ \=2/53TKX[^,GPB
M\5>*?B=-J_PU\#+!X@@\6*^H^*/%WEFUN+:?19;2<0H3YTMI%NMF,'^KDEW
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M&P+'SKB"U/$SI\I93_RS\P@%@H.?^SQ\>#\2/A;K>OZY?:5J!\.WEQ976O:
M3)IVI1Q1),+JW +%08Y 'C)+)(DB<[03[41FJ=[HMCJ&DW.F7%K%)87,3PS6
MY7".C@AU('8@G/UH ^._BW^UIXB\*^*[3QEX?\3:)=?#2[TBWU+P_;S6F;3Q
M,N6^V6RWV0UOJ*X_=0,-K\*1NW[/>OC-^T'X?^$FB6@O;Q+/6M5M9)K!+ZVG
M-M;8"JL]\\:L;:V666%'E? 4OZYQK>"_@EX>^'GBW7=7\/>?I>G:QY4UQX>@
MV#35NTX-W'%M_=S.H16*$*VP,06^:LW]H;X'6?QM^&WBG1H/LFG^(M3T6XTF
MTUB:'>T"2,DA0XY\MGBC+ >E 'D?[*G[1'BGQ;XV/@7QCJL.OZV^ERZC<J^F
MKINI:'=0RQQ7%E>VRLR["95:"=.)%5^NT,6_'W]J827EMI7P^\9P:*FE:FT7
MB753H<E_)96X,L2SQPR!%N+5;F%XKB6%F:+;G@!F'T'\+O UWX \(66F:IXC
MU'Q?K"AI+W7-5(,]U*[L[D*.(XPS,$B7Y47"CI7$^/OV;])\9_$'P9X@M$TC
M0(/#]\-2DDT_1XTU*>59C,L:7@8&*&1WD\Z,(WFAV!(W$D 9\-_VB;37/V>+
MKXF^)$MH+;28;UM2GT,M>6DXM))(Y+BT8<RPR>67C/7:P!Y!KPB/]L/Q#I?Q
ME-Y+XDT;6_ ^LZG80:#HEM9A/[3TN[,445[I]YG=-<Q3,XN+610557*X"@G[
M&\2^&+7Q-X3U3P_+FWLM0LIK%S  I1)(V0[1T& QQ7EW[.O[+>@?L[VNKR66
MJZAK^L:V\-SJM]J B59[I/,S/'$B@1%A*00IQA5_B+,P ?M!_'0^!=)UKPUX
M7N[)OB/)H<^I:=!?LJ6L&,I"TTCLJ(99 T<2L?WCJ1PJLPY/]DO]H>_^*&I:
MWX6U75X?%5UI=E;:E'KD=A_9]RJ3O(C6>H6>2+:\B>)@57Y70HXZG/>_&S]G
MCP[\8'M]6DTO0AXMM+9[&SU;6M*&HQ16TI F1[<R(LN4,@3>2$:1B!\S!NV\
M >"K3X?>"]#\.6D]Q>0Z586]@MY>-ON)UAB6-7E?^)R%&30!\H_&7]K+7K_6
M?#NK^ /$UGX:\%H;J.XU/Q#HK?9KB[5H6M3=F0K+;Z;<(946^C7:),9(&,^L
MS_M@^#M#^ ?A/XG^(K;4-(B\1VD=Q9Z###]IU"5RNZ1(HEP9 BAG+C "#<<9
M K(\#?L4>'/AY\4H?$^BZQ<V^BVU]<:A;Z&;6)FB::V^SO;_ &L@S&SQAQ;$
M[ ZH?X% ]UU_P=HGBFR:TU;2K/4(#;S6NV>%6*Q2IY<J*<94.A*G!&1Q0!\E
M> ?VG/'OAG]H./P3X^N[34IM<UV?2XM AT\6MSI\#&:6QU"SD4D7UC) @69R
M0\$HP>#@]]^TI^TJ/#%AJ7A3P-J,Y\>Q3PQE;?2S=-M4PSWEO:^9M@GOULY#
M,EJ7W,"O!+ 'V'X6_#]OAQX#T'PW<:M<>(GT6W-E;ZG?QHMPUNI(B5RHP66,
M(A88W%-Q )Q7C_Q\_8J\-?&;Q:/$EE+9>'M7O89+/6+E]+2[:[B98PD\6YE\
MB]B\E!%=+ED4N,-D8 '?LU?M/VWC[P#XQOO$VMZ9J%KX+*_;/&6GQM!I^H6K
M6XG6X:-N;>=(^)[<Y,4@(Z$ >3_&+]M35]%^(5UJ_A+Q+I\7@W1[*+.F:WI3
MVD6H:@HEEN-/NKB4+-8W$EN(I+1FC\J9E=<L1BOLW4_".D:WX9O_  _J-C%?
MZ1J%O):7EK<#<MQ'(I60/W;<"<D\G->1?##]E;2_AC\7-<\96NIRWEM=Z7'I
M5M9W?G75T44PL7N[N>622Y93"JQ?=$2$J 22U '2^,OVB/"'@#PAH>N^(;F\
MT5=8L#J,-I/I\\MS;P+&CS2SQ1*S1)")8_-<C"%@"<D5X/\ LM?M0>,?$OQ"
MTSP5XXU2P\0ZOJ]E-=SP65DMM=Z'<Q(DC*ZQL\<^G31R(]M>JV'W!&)9AC2\
M9_"'XF:_\0K6/Q%?7E[IUWKU[J'ACQ5H(C:_\&R9<)!,K@)<V-Q;J%=64[6<
MQL&!1U]'M?@=KOP[_9^7P-X!UR/3/$"2E8-;BM8K86:37YN)C#"%9 D:R2B.
M#[I"JI89W4 <O^T+^T2]O!K&B> ?%*Z=K/A35;9?&4UOI(U&\T;3I8&<7:6C
MD>?$)&MQ(T>XK&9"/F6NC^$?[2UCK_P+OO'?C*ZTRSBT:[FTZ^U717>XTS49
M(Y%C2>P?&Z:.9GC5%7<PD8Q99E-4? ?P@@\;:M#XB\6^$6\#_$OP[KQNKGQ!
MX>D$46M-Y42O+'(=S26MQ#'$DD,@RA3;G=&'JQ\;?#_Q M?$D6M:%I&G^+O
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M526."2:[3X7? K0OA+J+7FD75_/(?#^D^',7<BL/L^GK,L#<*/G83ON/0X&
M* /,-&_:<\2>&-4^($WQ)TS0M*\/^#=1L]%NKCPZ][J%S<WMW%:26XBA\D%E
M/VM$/\6X<#'-=/I_[7W@.\\5IX>N(];TR_,823[9I<@6*^^R_:VTYMNX_:U@
M^<Q@$'[JLS_+6UKO[.OAWQ!/XKEN+S44;Q'XBTOQ+=>7(@V7-@+00JGR\(?L
M46X').YL$<8P?$7['G@7Q+XP\3Z]/+JEK_PD:7/]H6-G-'%%)-/:?99)@XC\
MT-Y8&%\S8'&\+N)) ,;2OVWO"/B6_P##UCHNB:[=7NH>)?\ A&[^TGLS'/I<
MGV6:Z6255W@AHX20H.0 Y;:8V6FV7[>OPPU&]M(K>/Q)):W8L)X=0.A3K;-:
M7DWV>"[WD#$)N/W.3AM^<*5!86/"W[%'A+PC,ESI_B#Q#%?)K-EKBW2-:1L)
M[:SEL@H1+=4"/!/(K*%')W @\U%I?[#?@;2?#EIHT.IZX;:VT;2=$1VGB+^3
MI^I-J$#']WC>96*L<8*\  \T :LG[:GPNM9O$IO=3OK"RT-)YFOY]/E\B]B@
MN5M;F2V*@F58IW$;< ]P&7YJ9I?[7>@:_P".O!OAC3?#VO"\US6M1T.]74+)
M[6329[2U^TD31D'/F(\3K@XV2;B1@BJ-]^P[X!N].\6Z?'>:S::?XA29&M+>
M6%$LQ+=B[E\HB+<Q:4'F5I"JG8NU0 .J7]F?PY%\1H_&L.HZK!K,?B.;Q(OE
MRQ^7YLUA%8RPE2AS$T4*<?>#9(89Q0!G>)OVH]$\'>/?$NC:K9W2:;I%WINB
MPW%I;R7-Q?ZO>123I:111J>D:Q?,2/FE . ,GF+;]NKP+XE\//>Z'_:.GRO:
M6E_:R^(M)NK:WN89-0@L9@A1&9FBGG6)L#;O8$,R!F'0:C^S5'K7Q@U?Q%>W
MSC0;G6=(\56\%M($ECU6RADMV#J4(:*2(PDG<&W(1P,&LE/V&O J:'H^EC4]
M=\C2],&E0M]HCW-$-6@U3+'R^6\^W1<]-A(QGD %O7?VOO"US<Z_HWAFRO\
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M.>5XK_Y^-'_[\3?_ !='E>*_^?C1_P#OQ-_\70!T=%<YY7BO_GXT?_OQ-_\
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M_P#/QH__ 'XF_P#BZ .CHKG/*\5_\_&C_P#?B;_XNCRO%?\ S\:/_P!^)O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "OFO\ ;;_Y%CPU_P!?LO\
MZ*KZ4KYK_;;_ .18\-?]?LO_ **KZ3AS_D:T?5_DSXKC3_D08KT7_I2/D.BB
MBOZ!/X_"BBB@ HHHH **** "BBB@#L/@Y_R5;P?_ -A:V_\ 1@K]'QTK\X/@
MY_R5;P?_ -A:V_\ 1@K]'QTK\AXV_P!YH_X7^9_1GA?_ +CB/\:_(6BBBOS@
M_:0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***YSQOX@UCPUI8O-(\/2^(V0GS;:WN%BE"^JA@=_?@'/H#6E.G*K-0C
MN^[2_%V1C6K1H4W5G>R[)M_<DV_DCHZ*^9IOVV+.WE>*7PA>Q2(=K(]VJLI]
M""G!IG_#;VG_ /0IW?\ X&I_\37T7^K6:O\ Y<_C'_,^-?&W#ZT>)7_@,_\
MY$^G**^8_P#AM[3_ /H4[O\ \#4_^)H_X;>T_P#Z%.[_ / U/_B:/]6LV_Y\
M_C'_ #%_KOP__P!!*_\  9?_ ")].5\U_MM_\BQX:_Z_9?\ T55?_AM[3_\
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MMLO_ (U1_P (7XK_ .BA:C_X+;+_ .-4 =Q17#_\(7XK_P"BA:C_ ."VR_\
MC5'_  A?BO\ Z*%J/_@MLO\ XU0!W%%</_PA?BO_ **%J/\ X+;+_P"-4?\
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M_DU?J<]X*\ Z%\/M*73]"T^.RAX,C@9DE8#&YV/+'Z_ABNAKD/$'Q)M_#OQ
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M?*QVXQSUH ]-UWP-:>(_%.AZQJ4TES'HLC7-C8,J>3%=,CQ_:#QN+K'(Z+R
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MR^.4$>E>(/#'A^/Q-IVO)>Z%\1K:]V3Z=8+>"9!Y:HLIG$(\DQ@F-FP^\'H
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MM+C*A+>.VV[$G"#RQ(Q*H.?WA4;OKP4 +1110 4444 %%%% !1110!P?QO\
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M[_TN@KNQTKA/C?\ \D[N?^O_ $[_ -+H*[L=* %HHHH **** "BBB@ HHHH
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MS9Y806R6E&851 3([J2"(LI]@6LZ7-O'-&28Y%#J64J<'D9!Y'7H: ):***
M"BBB@ HHHH **** "BBB@ HHHH *Y+XJZGXET7P#K-_X073YO$5M;M+9VVJ1
MN\%Q*!\L3%70KN; W9XSG!KK:YOQ_I>MZUX;FM/#]QI]KJ$CI^]U*&26((&!
M;Y8W5L\<'/'O0!\I^,OV\=:LOV/])^*^@>'+"3Q.9EM=8T?43(L6G2QW<=I<
MJ5!#Y$LT.T$CY9 2<X!]0O/C'XTM/VJ;7X2B;0VL9O!<GB@ZD=.E$OFI<_9O
M*V_:,;"QWYZX^7_:KC_BM^PG8^*? /Q2T#PIJ]OH-S\1->M=;U*YO+:2XCM3
M"\4QC@C61>'FC=R2?^6S#^%<=I=_ KQA<_M)VWQ:_MS0A+%X0?PO_99LIRI+
M2_:#-YGFC_EJ -N/N9YW<@ XW]EO]I_QG^T)H.@:B9O":ZDU[/\ VWX?M()E
MGM=/2:>W2Y21IF 9I8AA77Y@'QTS6_\ M8?M'^)OV<-6\(:M;Z?I>H^")Y0_
MB.2>*7[5I]H+FV@>>(H^UN;M,AEXP.3NP,[]G3]EOQE\!_#>A>'4\3^'[JSL
M[Z6XO=6M-)FAU"ZMWN'N6M58S,J(96 )(;Y-X !;</3/BS\'KCXLZM)::C/I
MY\*W?AW4=!O;62!VN6^UF$F1&W;!L-O&0"IZGD8% '!>(_VF=?@_:\\$?"O2
M=/TIO"NMZ?=WEQK4PDDG>2W1GD2$!E3;]Q=YW?-O'5"*[S3?VGOAOJ>GW]\G
MB.&"VM8;:Z22Z1H!=6]Q-Y%M<0;P/-AEF!C61?E+#K@@GRVP_8SO]$^*WPJ\
M06/B:UET'P+X;D\-_8KRUE:[OXY8FCGF:82X5R6+ !2!Z],5_!O[&FO^ _@E
MJ/@?1?%7AS3M9"VUC9>*;/PP(+V6PBN5E,-XR3!IF9 8]R-'C.[[W- 'K.G_
M +37@/4[?0VMK^\>[U>]O=.ATXZ?.+M+BS!-Y')"5W*T.T[AC/INS5B[_:3^
M'5AXDDT&X\1)#JL>OV_A=[=K:7Y=2GC,D%OG;C+HK,&SMXY(KP_Q!^PG<:[\
M+[CP=-K>C[_^$EU7Q!I^KV^G3VMWH\EW*)8GM6CG!5XB7&TDHXV @;0:G\4?
ML2ZWJGQ2F\4Z?XTLH[-_'6D>.#:7FF.\S36=JUNT)D651A]Q;<%R">0<4 >O
M3?M3_#.VU?6-.F\1B&71C?KJDLMI.L-@UFJ-<+-*4V(0)$*@GY\_+NHN_P!J
M+X>Z;#:_;M3O+2]N-6DT)=-?3+E[L7Z1+*;9H41F#F-E=>,,K @D&N U7]D"
M;Q;\*/C=X%U_7[9K3XAZ_<Z];W=C:.DEA(YA:)7!D/FA&MXCP5#?,, &J<_[
M)/B"6;X8WT6K^$M.U'PMX@_X2"_&C^&S86^H2K +=<)'+D,4W%G<OSM"A4&V
M@#T'P3^UO\+O'XT]])\1D6]_HT^O6UW>V<]K;R6L#;+DB61%0M"?]8@.4')X
MJ=_VK/AE!X>NM:N?$)M;&UN+*WF\VSF\U#>+NLV,00N%F4AD..0><'('AGA7
M]@75M.\.>!?#FL>,K&\T;0/#WB+PY>/9Z=)%<7<&K&0R/&6E98WCW+C(8'!S
MU&-<?L4:O_PIG3/!0UGPG::G::GI%S<:[IGAIK2;4(=/??&;DK,6EG<@ N6V
MC+%5!:@#O=;_ &R/!5OIO@^[T:/4=;_X2'Q0WA7R8[&:.:QNXBWVA+B)DWQR
M(JDB,J&;((&,D>\AP5!YY]J^3_#W[&&O:3/;WLWB_36OK?XH7'Q'01Z9+Y1^
MT(R2VA!FSP'.V3/894U[YXZ^#/@_XF:OX>U7Q-HT>JZAH$WVC3IVFEC\B3<C
M%@$< \QH<,#T^M 'GO[1/QQU_P"$GCSX7:/ITVBV^F>+]6DTJYN]6@=OL>V%
MI?.#":-2. -IQZY[5PGPJ_;&\0^/M4^$QU3P[8:#I7BRXU^UO9Y6D*E-.A\Q
M+NUD8KF&09^^O&#@D#)]#^/OP%U?XP>.OAKK=IJ6D6UEX/U-]4:RU.QDN1>.
MT9C*'#J%7:<YP3D#M5_XJ_!;6O'7Q1^'7BK2=<LM'@\)1:G'Y$EFTLDK7=M]
MGW(0X5=@PP!5@2,<"@"SI/[4?PVU;3M>OQXA6VLM&M+34+BXN;>6-)+2[Q]D
MGA.W]\DQ.U-F6+?+C=Q59?VL?ALVA-J?]LS@PW-[:75B;&;[79O9;3?>=!MW
MHMN'1I&Q@!EP3N7/C^G?L(:O<>$_&FFZY\0([G5?$V@:3I\NLV&E&":.^T^Z
M>XBO"&E?>68Q[E)&=IV[1M5>F\>?LI^(OB/X@\">*]=USPCJ/BC0EO+34H+O
MPLT^E:E:W(C# VSW!9)5,082;SDL0P*C% $>@?MI:58_&3XI>&_%UQ967A+P
MY>:'!I7B*QM9Y+>1-1M3-&]U,I>.-"S1(DA*JV\'OQZSI_[0?@/5/'A\(6VN
MQ2ZP;^?24 1O)EOH(O.GM4DQM:6.,JS+GC=C.X$#Q3QC^PNGBS7OB*C^(K:'
MPSX]N] DU/3XK Q26EOI*0K%%;%'"KYGEL&)7"*R[5^7G<TO]CS[#\7],\32
M>)/-T'2_%>J>,[2Q%KBY^VWT866)Y=VTPJ_F.N%#?,JD_+D@'TK12 8 'I2T
M %%%% !1110 4444 %%%% '!_&__ ))W<_\ 7_IW_I=!7=CI7"?&_P#Y)W<_
M]?\ IW_I=!7=CI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P
M?P>_Y &L_P#8P:M_Z6RUWE<'\'O^0!K/_8P:M_Z6RUWE !1110 4444 4]6T
MBPU_3;G3M3LK?4=/N8S%/:7<2RQ2H>JLC A@?0BLV[\!^&;_ ,/_ -@W/AW2
MKC0Q#';_ -F2V,36WE1G,:>45V[5/(&,#M6Z>E?GP?BSXHD/BVSU6XU6SUVZ
MU4#7KRWUJ;RM,TM?$2VLB20X"VC?9&#1R*06AWL3QNH ^TA\$?ATK:>P\ ^&
M VGC%F1HUMFV&XM^[^3Y/F)/RXY.:BB^ OPS@N#/'\._"D<YE$YE70[4,9 V
MX/GR\[@W.>N>:^,?#_Q+\97'B+PFC^(=5DEMY=/C\+Q-=.1JML_B&YM[AV7I
M<XL$ARS9PFV3C=N/T;\4OVC/&/PI\1*-2^$M[-X/DU>STF+Q+'KUGM?[3-'#
M')]GR90-\@&",\9Z4 >R:YX/T'Q-=:?<ZQHFG:K<:=)YUG-?6D<SVTG!WQE@
M2C?*.5P>!Z51\2?#+P?XQO+:[U_PIHFMW5J,03ZEIT-P\0R6^5G4E>23QW-=
M*#FEH PF\!^&GU74]3;P]I3:EJEO]DO[PV,7G7<'3RI7VYD3_98D>U5T^&?@
M^*PN[%/"NB+97B0QW-N-.A$<Z1#;$KKMPP0<*#]T=,5TA. 3C/M7EGQ2U36;
MK6OAOIUEK.H^%$UK5+BWO5M3;&8HFGW4X3<Z2J"'A0Y7L#SB@#L-?^&WA+Q7
MY/\ ;?A?1M8\F VL7V_3X9]D)()C7>IPA*K\HXX''%3:-X"\,^'-7N=5TGP[
MI.F:G=1)#/>V=C%#-+&H 5&=5#,H"J "<# ]*\-\)_M(:S:6&LVFIV,&MR:%
MJ5RC:KYZ6QU33$N_LRW4$:A@\BR$HZ_*I:(E=OF(HT+W]IO48]8U?1;7PW9O
MKUE=3B/3+_4S822V\*QLQ\R>-8O-99D>,*[1NNX^8-CA0#T^7X-^ 9],O-.D
M\$>')-/O+O[?<VCZ3;F*>YQCSG39AI,$C>03SUI+;X+_  ^LWB:#P+X:A:*Z
M%]&8](MU*7 Z3#"<2#^_U]ZY#XN_M"0_";Q7IMA<Z;%?::\<4E[-#=$W4"RB
MY\MD@5&WY:U9<$J6+_(&*,*X[1OVBM?BT_6]3>ST_5C=ZFK6-C_:2I'96O\
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MI?!F>;[3/I;P3Z%IVGRQZ=&Z;[NWENS).VX#=OCGA7)^;]WCH%KVV@ HHHH
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MH$;F+4-18,/+FO)%.88\ D6R')W#S6ZQ#U2BB@ HHHH **** "BBB@ HHHH
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M:^WH*KS0<5=M<LGM-6W:[/06DQ2U%=74-C;37-S,EO;PH9))96"JB@9))/
M'>MCS4FW9$M%>%?%_P#:X\,?##1O#6JZ?;/XPT_6KM[9+G2)U:./9C?\W(9_
MF&$X)]17N%M.+JWBF5659%#A74JP!&>0>A]JPIUZ564H0E=JU_GL>IBLJQN!
MH4L3B:3C"HY*+?5Q=I*VZL]-4B6BBBMSR@HHHH **** "BBB@ HHHH ^/OVR
M-,O--\7:=K%U-IFG:1>)#96]S??$;5= >>YR_P"Z2WM$97X8'=UYYP *]O\
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MUB$17! F< %0!\H'"''*!3SG-;U !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <'\;_ /DG=S_U_P"G?^ET%=V.E<)\;_\
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MEW4*+Y4DJ28EDC6-L'T8Y[9K[%'2O /VNQA?@QR>?B9HG?WEKW\=* %HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%8_@N*6#PKID<T.HVTJP -%J]P)[I3Z2R!F#-[@GZT ;=%%% !1110 4444
M%%%5=2U*UT>QFO+V=+:UA7=)+(<!1_GC'>DW;5E1BY-1BKMEAW6-2S$*H&22
M< 5R,NIWOC=WM]&G:RT,$I-JR<27&.J6_MV,O3^[D_,///CE\+_%'[1'@:32
M]/UJ3P98&=)8HIHF,EXHSGSP""B\Y5.N0"V.@]8\$^'Y_"GA#1M&N=0EU6>P
MM(K9[V<8><HH4N1[XKE4YU:CARVA;?OY=T>_/#X;!82&(592KN33A9^XDE:3
M?PR;VM?3K=[7]*TFST.PBLK&W2VMHQA8T'YD]R2>23R3UJY7D7[2?P=\0?&?
MPA8:5X>\52^%[BWO%N)'4N$G4 C#%"&RI.X=LCGL1Z;H&G3:1H6G6-S>2:C<
M6UM'#)>3##SLJ@%V]V(R?K6D92]HX<EHJUGW^7D<=>A0^J4\4L0I59N7-"SO
M&UK-R>CYK]/^&T****W/*"BBB@ HHHH **** "BBB@ HHHH **** /D#]N7X
M@:!J&K>%?ASJKZ3!9W<CZAJ=_K'@RY\0I9(J'R#'$B[ SL'4ONRH X^;->O?
MLD^)I_%?P#\,W<^G6.EB(3V<-OIVF2:9 889GCB=;5QF#>BJ_E\A=V 36;^U
M'\)_'GQ7TS1[7P7XMU#PNMHMW+.--U673GN)_+4VP>2,%FBW*ZLH(_UH;G9B
MNG_9S\&>(_ /PETG2/%ERUUKJR7$\[RZC+J,JB29W1)+F0!IG5&52^%!*Y
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M0Z9YS&AC*^(RZA&E"I%PY'^\45)).SDKW=KI[J]EH%%%%=I\R%%%% !1110
M4444 %%%% !1110 4444 %%%% 'R=^WMJ,&F:?X,N1X;U37=0LVO[Z*XT[Q)
M/HGV.**%#.QDA5GD;8Q(C ^ZDA_AKTK]D'75\2_ ;0M00RF.2>[5&EU2?4]R
MI<R(&6[F :=#MRKX ((P,5P7[66M^.=1\8>%] T#PY\4)?#-NLMYJNI?#V2S
MMY9V9=L,:S32!AL8,70* 0Z_,<8KUW]GNWN;3X4Z1%=VWB^TF4RCR?'4\4VJ
MJ/,; E:(E,8^Z >%Q0!Z/1110!X!^UY]WX+_ /93-$_G+7OPZ5X#^UY]WX+_
M /93-$_G+7OPZ4 +1110!@^"5=?#T8D354;S[CY=:</<X\Y\9()&TCE/1-N:
MWJPO!5H]CX?CADL;S3F$]PWV>_O/M4HS,Y#&3<V0V=P&?E5@N!C W: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X/XW_\
MD[N?^O\ T[_TN@KNQTKA/C?_ ,D[N?\ K_T[_P!+H*[L=* %HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .#^#W_ " -9_[&#5O_ $MEKO*X/X/?
M\@#6?^Q@U;_TMEKO* "BBB@ KQ/]H;4?&7AWQ)\/=?T2P\2:UX2TN^N)M?TG
MPGL:^N28@+7=&Q4RPJ^_>BL"<H>0"*]LKD?B#\3]%^&5O:76O+>PV%P7!O8+
M.2:"!E ($KH"(]V< M@9!Y% '#_LOIXV;PMXBNO%R:W;V%YKEQ<^'[3Q/(CZ
MK;Z<P0HEP5)P?,\W:I)94*@GBO9J\_\ @W\7(/C'X?GUBTT>\TNR615AFN)(
MI([@%0V49&(.W.UO0@X)'->@4 %?/_[;?_)(=(_[&_P[_P"G2WKW^O /VV_^
M20Z1_P!C?X=_].EO0![^O3\32TB]/Q-+0 R7_5OC=T/W>OX5D>#5D3POIBRI
MJ22"%=RZPZO=@_\ 35E)!;UP:KP^/O#>H^(=2\.VVMV-QKEA#YMUIR7"^=$A
M'5AGCMGTR,XR*YW1_B%X5\">#O"L.LZG9>'!J"K;6=M=ZK]L+/G&P3DGS,$C
M+DXY&36?M()7YE;U.U8+%2FJ<:4G)JZ5G=IJZ:5MK:^FIT'Q&\?:9\+_  3J
MWBC6/._L[38A)*($WNV6"JJCU+,!SP,\\5B_#3XT^'OB=\-K?QK922V&E2;U
MD%ZH1XG5MK*<9!.>!C.<C'/%>:Z3\:?%6N?%SQKX-\7> "O@Z%7@L)OLS.U\
M<@*F&^282*2W& @'S''-=_H^DZ#X3GT.'79]'T*9G\O1?#\4D<-O;-Z1)QYL
MO/+@<$X4#))X8XB56IS4W[JNFFK:WWOV[+J?4U\HHX'"JCBZ;=>3C.,H34DZ
M;C?E45?WD]92;M%='HGL1Z?>^.W$NK02:?H(.8]+<XENO1KC^ZOI%W_C_NCD
MOBG^S/X;^+'C_P *^+-3O-0M;O02@CM[20+',J/YB \97#=U(R.*S_@_\!-?
M^''Q7\:^*]2\:7.NV&NNS0Z?(&^3+[@SY8C<B_(NT#@GZ5[;5PI+$4[8B'79
MZ[/1Z?D<N(QT\GQJEE&*NE&RE%.-N>/O1M+5O6SEULFK627G_P =]-\;ZK\,
M=6MOAY>1V/BA]A@E=@I*[@75&;A6*Y )_3K6G\)[+Q3IWP[T*V\:W<-]XHCM
MP+Z>'&UGR<9(P"0, D<$@FN(^"'[2=E\:_%OBW0K?P_J&COH,NSSKL@B5=[)
M\PP#&^5SM.>._%>PM/$DJ1-(BR/G:A8 MCK@=ZJBZ=>7UFG)M-6\M'V[F.8P
MQN64?[&QE",)1DJE[)S]Z*LN9-^[;6W?<YWXB?#CP_\ %3PQ/X?\2V U#3)F
M5S'O9&5U^ZRLI!!'/(]:U/#GAS3?".A6.C:/9QV&F640AM[:(?*B#H/?ZGDU
MI45U<D5+GMKM?J>&\57E06%=1^S3YE&[Y4WHW;:]NH44459RA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?-GQE\"^.['XW2>-=)\&M\4/#]]X9
M;P\NAKKRZ:VFNTCM/(%D(CD6=6C4N/G3RN.#7H?[-'@'Q%\,O@KX<\.>*;P7
M>KV:2[D%RUR+6)I7>*V$S_-*(HV2/>W+;,U'\8OCU;?"".[%WX=U6_=;3[3:
MW$48^R3OD@Q-(NYHB,9+.FW'?K71?"7Q_-\3/!5MK\VG0Z:MQ)(L26]]'=QR
MQJV%D5TZ!ASM(#+T(H [*BBH7O($NH[9IXUN)%+)$7 =@.I ZD#(H \&_:\^
M[\%_^RF:)_.6O?ATKP']KS[OP7_[*9HG\Y:]^'2@!::[JBEF(51R23@"JFIZ
MUI^BHCZA?VUBKDA&N9EC#$=<;B,U\H>+7^.'Q ^-'B;P<\=U;_"[5H;NR@U
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MC_A$X!.@AUVX)UK-OY^RQ_T']XW_ "SP<?/Q[U;O?BO\5[.X\'Q#X7Z7<?\
M"1R^6SQ:]<%=+_T=IMUW_H/R#Y?+XS\Y KO_ (L_$[2_@_X#U/Q5K$=Q/9V0
M4>3:INDD=F"JH[#)(Y/ I_PJ^)&F_%SP%I/BO28KB"ROT9EANEVR1LK%64XX
M."#R.#5>UI^T]E?WK7MY&?\ 9^*^I_VA[-^QYN3FZ<UKV];:GF>F_$[XGK;>
M.KV#X1Z1:2:#=31NG]M3I+K31VZ2^;;8L?WH;=Y:D\EE([5XQ\9/#'C[Q%^U
M3\&M4O-,TS3]1OX;F2VLK?Q'<>4OV-5G8,QLP8R_FA6 5MVW'%?;SN(T9CG
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M+]X]>/SK9\5^(?VC_P#A?NF0Z4;.X\,3+'.DEH"=&>)47S#)*09%&YQGG/\
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MN?\ K_T[_P!+H*[L=*X3XW_\D[N?^O\ T[_TN@KNQTH 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH X/X/?\@#6?^Q@U;_TMEKO*X/X/?\ ( UG
M_L8-6_\ 2V6N\H **** "BBB@ HHHH *CF@CN%"RHLB@AL.H(R.0>:DHH **
M** .2^*GPZL?BMX&U#PU?SRVL5RT,T=S"%+P30RI-#( W!VR1H<'J 1WI/A=
M\/(?AIX7;2UOIM4N[B]NM2O;Z=0C7%U<3--,^T<("[G"CH !SUKKJ* "BBB@
M"MJ.FVFL6,]E?6L-[9SJ4EM[B,21R+Z,IX(^M&G:=:Z18P65C;0V=G @2*WM
MXPD<:CH%4< ?2K-%*RO<OGER\E]-[=+]Q",C%>':O^RU8W[:Y=VWB&[LM8O/
M%W_"8V-\+:.3[#=&U6U*!#Q(AC#CG!RV>U>Y4AX%,@Y[X=^!M-^&7@70/">C
M^;_9FBV,-A;&9MSE(U"@L>Y.,GW-=%7QW\4?VW]1^'7A[XS7'EZ!)KG@C7[;
M2M.TJX,JMJ$,@MBTC$-D,!<-TXS'[U[Q=_'_ ,)Z5XV3PC<7L]QJXO8](>:"
MT8V_]H/;/=):;\X$K0QM)MY !4$@L 0#TRBO!]-_;1^'&K^"M3\4VL^JRZ3I
M_A^+Q/,_]FN'^P/<36XD"GDD/;S97J A/(Q71:-^TEX5UOQ1HWAZ*WUFUU?5
M86NH;34=-DM)EMQ<&W69HI=LFQG'#!3\K*QPIS0!ZM7D7QW^ DGQNU/PA+/X
MA:QTOP_>G46T6>R6ZLM0N ,0O<1EUWB(Y95)QN()!Q7KM% 'C_@C]F_2_!GQ
M/NO&*ZK<W9:;4+NUT]XU2.VN+]X7O9 P^9@[0*54\(&8<Y&/8*** "BBB@ H
MHHH \(\1_LMCQAK]_P"(-;\7WU_KZM9MI%\;.&,6!M;W[9 SQJ L[!\)E@/W
M8V\$ECZ7\*_AU8?"?P%I7A;39IKFVLA(S7%P1OFEDD>65SC@;I)'.!P,X'2N
MLHH **** "BBB@ HHHH **** "BBB@!KQJ^-RAL'(R,X/K3J** "N8^)WP_T
M[XJ_#WQ%X/U9I4TW6[&6QG>$X=%=2-RGU'!'TKIZ* //_@]\*G^%^GZX][J[
M:_KFNZB=3U+4?LPMDEE\F*! D09@BB*&,8R<D$]\#T"BB@ HHHH **** /,/
M'_P*T_XB?$&T\1ZEJ$HM(_#NI>')]-2(8GAO#'O?S,Y4@1X P<[O:H_@5\#5
M^#5IJC7&NS>(=3U!+.WDO)+9;=1;VENMO;H$4D9"+EFS\S,3A1@#U.OGSQQ\
M8?&6G?M6Z+\--,NM)M=!O_"=UX@>>XTV2>Y66&;R@@83HNTY#?=SQC/.0 ?0
M=%?)_P"S]^V<OB+]G_PMXY^(TD*:SKFEZMX@DL_#VERB&ST_3YO*N)6W2.2%
MS&2<Y)DP%P":]4L_VHO >H>.Y?"=O>7<VJ1ZQ::&62T<PFYN;.2\A ?H5:&%
MVW#@8 [B@#URD(R,'I7A'AW]M/X:^)-$L-8@N-7M-*U&]&F6-_J&E36MM=79
M:X7R$FD CWYM7&"PY>,9RX%>ZPRB:%) K*'4-M88(R.XH H0>'['3H[@Z99V
MFFW$J%?.@MT4YYP2 !NP3G!KYL\'?L6:AX8\,26MSX[AU3Q-'XAB\5V_B>;0
M5%Y)J:^8IEN<SD3IY4SQK&-@0'BOJ6BDDEHA)):(Y3X5?#G3OA)\.] \'Z5)
M--8Z1:K;1S3G,DF,EG;'&2Q)P.!FNKHHIC"BBB@ K"\::/J^N>'Y[30M;'A[
M4V9&CO6LTNT # LCQ.0&5@"IP5.#P0>:W:* /F8_L0Z28=!B/B:[\N*V6TUO
M%H@.IQ+J?]IJJ88"V N"P 4,!&VP= U?3 &*6B@ HHHH X/XW_\ ).[G_K_T
M[_TN@KNQTKA/C?\ \D[N?^O_ $[_ -+H*[L=* %HHHH **** "BBB@ HHHH
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M_P (E<?]#'K/_?V+_P"-UT5% '._\(E<?]#'K/\ W]B_^-T?\(E<?]#'K/\
MW]B_^-UT5% '._\ ")7'_0QZS_W]B_\ C='_  B5Q_T,>L_]_8O_ (W7144
M<[_PB5Q_T,>L_P#?V+_XW1_PB5Q_T,>L_P#?V+_XW7144 <[_P (E<?]#'K/
M_?V+_P"-T?\ ")7'_0QZS_W]B_\ C==%10!SO_")7'_0QZS_ -_8O_C='_")
M7'_0QZS_ -_8O_C==%10!SO_  B5Q_T,>L_]_8O_ (W1_P (E<?]#'K/_?V+
M_P"-UT5% '._\(E<?]#'K/\ W]B_^-T?\(E<?]#'K/\ W]B_^-UT5% '._\
M")7'_0QZS_W]B_\ C='_  B5Q_T,>L_]_8O_ (W7144 <[_PB5Q_T,>L_P#?
MV+_XW1_PB5Q_T,>L_P#?V+_XW7144 <[_P (E<?]#'K/_?V+_P"-T?\ ")7'
M_0QZS_W]B_\ C==%10!SO_")7'_0QZS_ -_8O_C='_")7'_0QZS_ -_8O_C=
M=%10!SO_  B5Q_T,>L_]_8O_ (W1_P (E<?]#'K/_?V+_P"-UT5% '._\(E<
M?]#'K/\ W]B_^-T?\(E<?]#'K/\ W]B_^-UT5% '._\ ")7'_0QZS_W]B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cgtx-20231231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &= FL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y#_A)-4\3ZA<VOAU((+"TE,-QJ]V"RLXR'2",8
MWE2 "S,%!R &P<:/CFYN+;PIJ'V24V]S,JV\<ZDAHFD81AQCNN[(^E:>E:7:
MZ)IEII]E%Y%G:1+!#'N+;44  9))/ ZDYH R?[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\
M\D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_
M *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\
M\D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_
M *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\
M\D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_
M *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\
MH8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#G
MO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :Z&B@#GO[%U[_ *&/_P D8_\
M&C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R1C_QH_L77O\ H8__ "1C_P :
MZ&B@#GO[%U[_ *&/_P D8_\ &C^Q=>_Z&/\ \D8_\:Z&B@#GO[%U[_H8_P#R
M1C_QJK?7/B3PTC7;^7XBTZ-"T\,$(BO%]XQG9)CJ5.T]<%CA3U=% %;3=1M]
M7L+>]M)!-;3H)(W (W*>G!JS7+^%X9-)\2^(])W!K/?%J5LH)_=+/O#Q\_\
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MKX*_\%$OCM\//#8U6^\'67AV'5K?0IK^YOI6N%M+28B-IG=R[O<2]23\P X
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MJL7D9G.9#NKS#X)0>#?VI_C5X9_:#TG09M.N=)\-OI<[7,JLWVR63<D)4?\
M+2"$N6;&#]KB4',3A?K2B@#P_P"/'[)'A?\ :'^('@'Q9XDUWQ#:7'@FY%YI
M5AIDMM';&;S8Y6>3? \C;C#$I < !. "6)H>&OV,/"/AOX^>,_BV/$'B6_\
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M3QS:4/"/_"S-$$T+0R_;S=[IMC*^[RQ%LWY!7=N*X( (/UE7S3^VY][X _\
M96M!_E<5]+4 %%%% !1110 4444 %%%% !1110!Y=\))8/"NJ>,/#.J)%;>(
M(=3?5KB]9@#JUO<EO(O"<G# 1-;LO&TVORJL9BR[P]=1^+?C;JVN:(1_9.E:
M8-$U#4(\&+4;H2^:D*D'YOLH:4%N@>[= =R2!>^UCPYI/B*-8]5TNRU.-<@)
M>6Z2@9ZX# T_1M#T[PYIT=AI.GVNEV$1)2ULH5AB0DDG"J !DDD^Y- 'AVH0
MW_PD_:5\6^.-:TW6_$'AGQ5H>FZ?9WVCZ5/J4NCRVCW)DMF@MXWF$4OGB4.%
M*[PX;;\A.E\=?$3CX665T/#6O![GQ%ILR6>F:/<W]R8HK^*9YY(K:-VC'EQ,
MYW $<*?F(6O;:* /)/C%X@MA#X CMM)UN[?4?$%C>K]AT&]G$$:2(7DN3'"?
ML^ ZY\[8>&_N-CSG7/!>K)^TM'KNFV>LV-T^LVTEQI#:9+<:%J=F(1&^H-<8
M,4%[%N(4[T8K"%\N3?N/U#10!XII/CZ/0_&/QAUQ?#OBB\ATY;39#%X=O5>_
M>*-XV6TW1 7/S+C=%N&"&!*D$O\ V;]=MO%I\8^(G\->(= U[5]0BN=3?7M!
MGTH2,MND44<"S@/)'''$BES]YR[ (&"+[110 4444 <]8_\ )0=:_P"P78?^
MC;NNAKGK'_DH.M?]@NP_]&W==#0!SWCS_D6I?^OBV_\ 2B.NAKGO'G_(M2_]
M?%M_Z41UT- !1110!\;?M9?%SX>?$+P]'_9OQW'PHU'P/XK>PO->MM+FNI8+
M[[-<1/:A1MZJTV6!(^0CG((W/V%_$MKXAC\7&U^/UW\>(XFMP;FZTQ[+^SB0
M_P @W,=V_&>V-OO7)_M2ZK^T+\,_$VM>,;#XL_#7P#\.I+R*#3!XCLF>Z1VC
M5"I9;9RS,4<C!)V#G 4X];_9<C^+D4_B./XM^,?"_BW45CM9+(^&[9H##!(K
M,#(&AC+!_P"$C(RKC(((H [[XO\ Q[\ _ /3=/U#Q]XDM_#=E?S-;VTUQ%(X
MDD"[BHV*QZ<\U\Z>//VN?@1\3_%'@K_A#/B.+WQV_B70[*PAT^6]@\^*34X$
MGB9"JQNK0RS@AQW]0*^H?'WP_P#"7C>SAG\5^&=,\3Q:8LD]O!JEHERB,5^8
MJC@KN(&,XKX;\.^.=7\1>)/!4\7[$FC^"M"O/$6C2P^+S<V:O8Q-?VYCN D5
MNCAL%2%$G4@'<,@@'Z'4444 %%%>3_M0:QX[T/X,^(;OX?2V%CK,-I<33:IJ
M!)%A;QV\LKRQQ@?O)245%4D &3<20I4@'K%%?(L'Q6\4^+? '[*/@]/$E_I.
MN_$C2(-2UCQ%:I&UP\-MI275PBY&$DFD>,;P/E&_CD5D:Y\7/''A[7=6^$MG
MK^H7D[?$?2O"L7BFZDB.HP:=>:<VHRE2(PADC$<D2LRD[6!^\H- 'VC7BGA_
M_D\;QK_V)6C_ /I9?UE>"OB,?A-\0?B=X1\8^+[W6-!\.:3;>*X-8UB-3+8V
M,QG66&65.90CV[LK; 0C!3N*[CA_ OXP^#?C;^U'X[U[P-K]MXCT>'PGI5G)
M=VH8*LRW5ZS)\P!R%=#^- 'TY1110 5\Z?\ !1#_ ),M^*O_ &#$_P#1\5?1
M=?.G_!1#_DRWXJ_]@Q/_ $?%0!]%T444 %%%% !1110 4444 %%%% !1110
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MI\.KZKH#:/ -+MY)%C2UC+.LD8E,N7#$@D A3G/3_M_OH=_\/]#T34OA5?\
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M *^=/^"B'_)EOQ5_[!B?^CXJ^BZ^=/\ @HA_R9;\5?\ L&)_Z/BH ^BZ***
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M* "BBB@#GK'_ )*#K7_8+L/_ $;=UT-<]8_\E!UK_L%V'_HV[KH: .>\>?\
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M1S7TK7S]^R[^RU!\%HKSQ1XGGMO$/Q.UF-5U'5T4F*TB'(M+3<,I"IZG ,A
M+=%"_0-=>"6(6&IK%M.I9<UMK];'+BW0=>;PJ:IW=K[V\PHHHKM.0*:[K$C.
M[!$49+,< #U-.IDT,=Q"\4J++%(I5T<95@>""#U% '*?\+?\!_\ 0[>'?_!M
M!_\ %UNZ%XDTGQ1:/=:-JEEJUJCF)I[&X29%< $J64D X(./<>M?)/QN_9P^
M$ND_'S]GS3['X7>"[.PU36]4BO[6W\/VD<5VB:3<R(LJ"/#A756 8'!4$<BO
MJ?P5\/?"OPUTJ73/"'AG1_"NFRS&YDL]$L(K.%Y2JJ9"D:J"Q5$&[&<*!V%
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M0O\ @HJMOJ?AOX?Z!=77CN]MM6UB6*;PM\/H6-_K$:6[2$^8%8*("JR[2#O
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M&/P8\867A;Q?X@N=,UR]@CN8+:+1[ZZ5HW=D0^9#"Z#+(PP6!&,D $4 <O\
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M;8MN>]@MI)&CD:/&51%!! QBOKJ]M_M=G/!N"^;&R;BNX#(QT[_2OCKX=_\
M!/RYT'QO%XW\4>+-,USQ?:ZCI3:;=6NCO;0:3IUC,K_9;2%9PL9G1 CMR%#R
M *^XD@'V71110 4444 %><_'/X1#XO\ AC2H+745T;Q%H.KVNOZ'JDD33):7
ML!.UGB#J)$:-Y8V4G&)"1\P4CT:B@#S+X3?#'7/#.O>(O%WC+6;'7/&6OI:P
MW#:59-:V-G;P(5C@MU=Y)-I=I9&+N<M(<!0,5@^'_P#D\;QK_P!B5H__ *67
M]>UUXIX?_P"3QO&O_8E:/_Z67] 'M=%%% !7SI_P40_Y,M^*O_8,3_T?%7T7
M7SI_P40_Y,M^*O\ V#$_]'Q4 ?1=%%% !1110 445G>)/$.G^$O#VIZYJURE
MEI>F6LMY=W,I 6**-"[L2>@"@G\* /#OC]_R<=^S3_V']7_],UU7T%7Q/X:^
M _Q+_:A;1_BYXC^)NN_#^X-_<:IX3T#3K.%O[)LI83!$9/,0-YKQ,[,.G[P=
M#G'M7[+GQ6U;QGHFO^#?&,LC_$;P+>#2==>2+R_M88%K:]0!0H2>,;P!T(8<
MC#, >W4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[7EAH&L>!
M/#VFZQ\/[7XF:E>:XD6B>'M0NUMK22]%K<L9)Y&.T(ENMRW(;D+M4MMQQ?[)
M7A&U\'>//$EK/\$_#/PFU>33HG2Z\,ZW#>Q:A!YARK1J$92C8^8ICYL!NU:W
M[?/B+PEX?^"FG+X[MM!O/!]_K]G9ZK;ZY;7$KO;$2-+]C,!#1W:JC-&Y(7Y6
M!ZBL7]B:[_9FTRY\0Z#^S^T,]P8TOM4G"73RA2=B*TMR-Q&02%!P.3U- 'U4
MZAT92 01@@]#7YE^ ?'7C;PM\;H?ACX=_:K^'UOIL6N,4\(66C0QJ\<MSO:Q
MAN_LWE^<WF&,(DNX.=H *X'Z97,(N;>6%F9%D4H60X(R,9!]:_.>T\*V9\1I
MX'O_ (X_ >;P_P#V@;"2_L+:S'C*6#?L$",C;5NVXC\U5\Q7.\9<8(!^CE%%
M% !1110!\\?M(?%_P[\/O%VG:!:3^'-%^(7B/2Y+9/$?B>2&WLM,TT2?/)))
M*RB;YV^2V0DNPRP5%9AZ_P#"S0M*\+?#'PAHV@ZD-9T/3M'L[.PU$21R"ZMX
MX42*7=& C;E"ME0%.>.*ZBB@#X=_:I\ ?$30_B=\'=<U[XJ2>)O"5Y\6M(^P
M>%6\/VMJNG[Y)FBQ=1_O)/+0%/F^]NR>17W%7S3^VY][X _]E:T'^5Q7TM0
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MP07#N0T:R@E9%8$$8Y7:0V2V% /4M4U73[6XL]/O9DCEU-GM[>.0$"9PC.R
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M4UR?A_\ Y/&\:_\ 8E:/_P"EE_7M=>*>'_\ D\;QK_V)6C_^EE_0![71110
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M** "BN2^)WC_ /X5QX8&I1:->^(M1N+F&QL-'TYXDGO+B5PJ(K2NB*.K,S,
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M444 %%%% !1110!SUC_R4'6O^P78?^C;NNAKGK'_ )*#K7_8+L/_ $;=UT-
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M6P?RU#,@&_.T_>SS7O=%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!SUC_ ,E!UK_L%V'_ *-NZZ&N>L?^2@ZU_P!@NP_]&W==
M#0!SWCS_ )%J7_KXMO\ THCKH:Y[QY_R+4O_ %\6W_I1'70T %%%% !1110
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M !H TJ*S?^$DTC_H*67_ ($)_C1_PDFD?]!2R_\  A/\: -*BLW_ (232/\
MH*67_@0G^-'_  DFD?\ 04LO_ A/\: -*BLW_A)-(_Z"EE_X$)_C1_PDFD?]
M!2R_\"$_QH TJ*S?^$DTC_H*67_@0G^-'_"2:1_T%++_ ,"$_P : -*BLW_A
M)-(_Z"EE_P"!"?XT?\))I'_04LO_  (3_&@#2HK-_P"$DTC_ *"EE_X$)_C1
M_P ))I'_ $%++_P(3_&@#2HK-_X232/^@I9?^!"?XT?\))I'_04LO_ A/\:
M-*BLW_A)-(_Z"EE_X$)_C1_PDFD?]!2R_P# A/\ &@#2HK-_X232/^@I9?\
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MB@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\
MWX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!
MMG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/
M_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_
M  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_W
MX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$
M?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_
MX1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"
MM"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_
M *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2
M_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@
M#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!M
MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H
M&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\
M^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX
M7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_
M 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?T
MO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C
M_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7
M_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&
MV?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"C_A']
M+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\ WX7_  H_X1_2_P#H&V?_ 'X7_"M"
MB@#/_P"$?TO_ *!MG_WX7_"C_A']+_Z!MG_WX7_"M"B@#/\ ^$?TO_H&V?\
MWX7_  H_X1_2_P#H&V?_ 'X7_"M"B@#/_P"$?TO_ *!MG_WX7_"K=M:PV<7E
MP0QP1YSLC4*/R%2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cgtx-20231231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &; ?@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JOJ&H6NDV-Q>WMQ%:6EO&TLT\SA$C0#)9B>  .YJQ7C_
M .UQ\,-<^,G[.OCGPAX;N!!K6IZ>\=L&?8LK AO*)R,!\;23Q\W- '-_#O\
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M7]I&3L@NRORSX.0/ER3QR10!]O7%_;6L:R37$42,P56=PH)/0 GO4QD4'!8
M]<$U\"_&/24\,?M)IH'B/]UX'TWX=7W]AV]XP%HUTL1\UT#?*9@<$$_,.V*\
MLM_$/B'2_A)^R7XD\>7MWIRP^()4FU/6)C$5LRI\GSI&(X(QC>>: /U,\U,
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M-6.\6G]Q^7WPW\">*-9^(>F:=I>FWUOJEM=QLY:%T-KM899R0-H'O7Z?H"%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/OPP:WN0!)!(IP\;8X)![C@UZ+0 4444 %%%% !1110 4444 %%%% !1110
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MWQ#\,?#V*?X=_#NQ^(VH2S-'=V5]=1P+;P>4Y,P+L 2" , YYH \O_X)4?\
M)F'A/_KZO?\ T>U?7M?(7_!*C_DS#PG_ -?5[_Z/:OKV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D.*I:WK>G^&])N]4U6\@T_3K2-IKBZN9 D<2 9+,QX KXF\4?M ?$7]M#6[
MWP9\ 3+X;\ 12&VUGXEWD13>.C1V*G!+$?Q=?]T<T >@_M _MF/X;\6K\,/A
M%HX^(?Q8N@4-G;MFSTD?\];J0<#;UVY^N.E+^S[^QA_PB_BMOB;\6M8_X6+\
M6;K#G4+D9M-+_P"F5K&> %Z;L?0"O3_V?/V:O!7[-OA4Z3X5L2UW<8?4-8NS
MYEY?R]WED/)YR0.@KU:@!#P.*_-[X[_$?Q;K'Q2UD7VHW]@UA<M#;6D,[QK
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M+:;KUP9!IVG^(?#%M9?VD4SGR) KHW^[G<!_#Q77_!#X?_L]?M&V'BB+P_\
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MV./"%MJ/A;1SXK77_"WP_P!5FU+2?#PAA\VRN),LJ7$RL2Z)N8JI5#R-Q;%
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MA[_P36U#XS_VU\1_B3\06T_QMJ6K#4FL-)ECO[;2W1]S0SEV(D=5PN,X0>M
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MU8)<112JSPL1D!P#E3CG!I--UBPUF.22PO;>^CBD:)VMI5D"N#AE)4G!'<4
M7**** "BBB@ HHHH **** "BBB@ KB?C3\*=*^-_PM\2>!M:DF@T[6K1K62>
MW.)(CD%77/!*L%;!X.,'BNVKD_BMX!T[XH_#CQ'X4U5_*L-6L9;628,5,6Y3
MB0$$8*G# YZJ* .8T#X%:%=?!CP[X"\7:1I.K0:38PV:O96QMT1X@ L\'.^"
M3*JX*-N5N0QP#7'?LK_L[VW[._B+XH6-KXGD\21:[K2:UF];=?0F5&W"=@ &
M);<0PQD=1GK\X:+_ ,$SO@3!X"M=>UGXL^)GMX(DCO\ 5X/$]HEB)PHWX<QE
M5&X\*6)&1UKZ1_9$_9V\+? '1?$/_"$>)KGQ5X6UZXAO;6^N[V.\<LD9C<":
M,!67(&...10!]!444A&10!%)=P0SPPO-&DLV1&C, SX&3@=\#GBIJ^!]5T2/
M0?\ @K/X0@AN]0NH[CP?<7;+?WTMR$D9;E3Y8D8B,81?E7 ZG')KZH_:?\:Z
MC\.?V>?B)XFTB3RM4TO0KNZM9/[DBQ,5;\#@T >A66N:=J-Y=VEI?6US=6A"
MW$,,RN\)/0.H.5S[XJ'Q1_R+6J_]>LO_ * :_,WP9XBN/AYJ?[#FL:/_ *+J
M'B5+VSUFXC4M+J*7$L7F>>>LIW2,X+9PQR*^KOC;^VOX2^&>O>(_!VH>$O'F
MH:A9P^4]YI7AZ2XLW+PAP4E# , ' )[$$=J .)_X)E>'M-\6?L)Z'HNL6<6H
M:5J#ZA:W5I.N4FB>5E9&'<$$BOI[5_A%X/U[X=1> ]0T"TNO",5O#:II,@/D
MK%%M\M1SGY=JXYSQ7SE_P2H_Y,P\)_\ 7U>_^CVKZ]H Y;Q=\+_"?CVQTFS\
M0^'['5[72;J*]L8;J(,MO-']QU'8@<>F.#Q4NO\ PX\,^*?$V@>(=6T2TO\
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M$<<42A510,!0!P !V%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'/B/6M5U&.Z@@\0O9MKFFV\JI;ZLUL^Z#SLJ6!!P#L9=P #9%>Q+Y< CC&U
M?E11QT'0#Z"@#XL\*_!#Q#\ =>LTM/$%GJ?C_6_#=IX-T>.TMY!!:VEL2\VH
MSAR3\@(.T<9VJ"2XKL_@7^TQX!T[4/#?P_T/2M6M=%O=0OM%TO7KTQL-1OK8
M[KEY #O!D=F8.1\[;LA>,^\:7\/-*TWQYK7BJ2::^UK5+>.U!NF1A:VT?/DP
M@*"J,YWMDDLV,G"J!Y]X1_9(\ ^#OB!;>)K'^T)7T^]N]4T_2)[A6LM/NKH
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M]@0*@M/V^?%-K\,=&^,>IW%C;^$;WQI-H-QH;V8_T?3U4!91*I+^<,[CU4]
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M'(->B>,?V"OAWX[U#QM=7>M>*;=/%=_!J-_:V>JJL$=U#C9(BF,X88'WMP]
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M9O'J'BW4=6C>2UFWKCS58JQR 3F,8'0+7N_A_1K/POHFFZ/9(L-I96Z6T$?
MPB*% _(4 :5%-WKOV;ANQG;GG% =69E# LO49Y% #J*:KJ^=I!P<'!Z&D$J-
M'O# IUW \4 /HIAE01^864)C.XGC\Z5G5<98#)P,GK0 ZBFM(JLJE@"W0$]:
M/,7?LW#?C.W/.* '44T2*6*A@6'49Y%"NK$@$$@X.#TH =13%E1U+*P*CN#Q
M1YJ>7OWKLQG=GC\Z 'T4UI%5=Q8!?4GBAI%0J&8 L<#)ZF@!U%-,BAPA8!CR
M!GDT;UWE-PW 9QGG% #J*:'5F90P)7J >E"2+("58, <'!SS0 ZBBB@ HHHH
M **** "BBB@ HHHH *\G_:KNKNP_9^\:75M93:E#;V7G7MG;X\R>R61&NXP#
MU+0"48[YP*]8KCOBY\1]'^$GP]U?Q9X@5CH>FHDEZRH7*0EU1WV@$MM#%MH!
M)Q@=: ,+PC^T7\)_$?A;3]4T7Q[X8.D30*\'_$S@A\M,<*8V8%"O0J0",8QQ
M7+?LZ?$?PY\4?'7Q4UCP7>#4O"RZG:6XU"V.;2[O5MA]HDA/1A@P*6'!*9YZ
MG\]_'OAS_@G=XV\8R:[%X[UWPW'/*9;C2]&TZ^CM&)'.Q7M&,8SSA2!V  KZ
MH^%G[='[+'PR\):+X#^%VM!T26.TTW1;?2[Z$SRRR!?FFEAQN9FR7=N?6@#[
M7HI <BEH **** "O'?VG_%?Q-\)^ 5G^&/@JQ\;ZC-*T5[:WU^+58+8QOND!
M++N((48SWKV*N5^)7B[0O"'A.^GU[6M.T2">&2&*74KN.W1W*'"AG8 GKQ0!
M\K_\$T_#&G>-?V"]'T#5X&N=+U,ZC:74*R-&7B>5E8!E(*Y!/((-?2VN?!#P
MAXB^$\'PWOM/FE\(P6L%FEFMY,CB*';Y8\T,'.-B\[LGO7S]_P $J/\ DS#P
MG_U]7O\ Z/:OKV@#C/'7P@\*_$C3=#L-?T^2\M=%O8-0L8TNIHO+FB_U;$HP
M+ >C9![U+XG^%7AKQAXP\,>*-5L'N-:\-R2RZ9<+<RQB%I%VOE%8*^1C[P.*
MZZB@#E)?A?X=F^)%OX\>RD/B:#3VTQ+K[3(%%NS!BOE[MA.1U(S[TFC?"WPY
MH'CW7?&5E921^(=;AAM[ZY:YE=9$BSL C+%%QGJH&:ZRB@#C_!OPE\+> +WQ
M-=Z'ISVD_B.\-_J;-<RR^=,5VD@.QV#&>%P.:K^$_@OX2\$> [WP;H^G26OA
MZ\:X>:U:[FD9C,29,.S%AG)Z'CM7<44 <#<? SP==?"1/AI+ILS>#TM!9"R^
MVS!_*!R!YN_S.O?=4WC3X+>$/B#X3TGPWKNF/=Z/I4MO/:6ZW<T11H,>5ET<
M,V-HZDY[UW%9WB#Q%IGA31KO5M9O[?2],M(S-<7=W((XHD'5F8\ 4 8?B[X6
M^&_&_B+PUKNL64ESJ?AVZ-YILR7,L8BE*E22JL XP>C BOE/]HC]H'0Y?CGI
M>B?!SPVWQ'^/5A:SZ?#-!<R'3=%AE($KW95A&2..#R.Y&<',U[XR?$K]NG7;
MKPI\&9KOP/\ "6&1K?5OB+/"4GOP#AHK%3@\C^+@\\E>_P!/_ ;]G7P1^SEX
M130?!VEBVWG?>:A.?,N[V3O)-(>6/MT'8"@#RO\ 9W_8PA\#^*9/B7\3]8;X
MB_%R^^>75KP;K;3L]([2,C"!>@; ]@O.?</!_P )/"_@37_%.LZ+I[VNH>)K
ME;K5)&N99!-(J[00K,0G'90!78T4 <5X+^#WA7X?>%]5\/:'82VNDZI<W%W=
M0/=RREY)SF4AG8LH.>@( [8JE;? ;P7:?!W_ (5?%ILZ^"_LCV7V$WTYD\IB
M25\[?YG4GG=FO0J* ."\6_ WP;XX^'VF^"=8TN2X\.:?]F^S6J7DT3)Y!!B_
M>*X<XVCJ3GOFKOC/X3^&?']_X8O=;L)+FY\-WRZCICQW4L7DSJI4,0C#>,$_
M*V1[5V%% '):U\+?#GB#Q_H'C2^LY9?$.APS06%R+F54C248<&,,$;..K D=
MJ2#X5^&K?XE7'CU+*3_A*+BQ739+LW,I0P!MP41EM@.>X7/O7744 <AX6^%'
MAGP9XN\3>)M(L'MM9\1R1S:E.US+()F1=JD(S%4X[*!3/!7PB\+_  ]TG6],
MT*PEM+/6;N>^O4>ZEE,DTW^L8%V)7/HN .U=E10!P6D_ _P=HGPMF^'=IITT
M?A2:&6![0WLS.4D)+CS2^_DD\[J37?@7X+\2?#*S^']_I4DOA6T6%(;-;R9&
M41$&/]XKAS@CNW/>N^HH X[QE\)?"_CV'P_%K5A)<IH-W'>Z>$NI8O*EC&%)
M*,"P [-D&IO$/PO\.^*?&/A[Q1J5G)/K6@F0V$ZW,B+%O&&RBL%;C^\#75T4
M <B_PJ\,R?$F+QXU@[>*([(Z>EY]IEVB G)7R]VS/OMS1X?^%7AKPMXU\0^+
M--L'M]=UX1C4+@W,KK+L&%PC,57_ ("!7744 <CX-^%/AKP#_P )!_8ME+:_
MV[=O?7^^ZEE\R5AAB-S'8,=EP*I^'O@GX0\+?#R^\$:=ILL/AN]\_P ^U:[F
M=F\XDR?O&8N,DGH>.U=U10!Y_?\ P(\%ZE\*+?X;W&ER-X0MX$MX[(7DP=40
MY4>:'\S.>^[-7/&?P@\+>/\ 0M&T?6[&6YL-(N8+NSC2[EB:.2''EDLK MC'
M0D@]\UVE% ')>*OA9X;\:^)_#'B#5[*2YU7PW</=:9,MS)&(9&7:255@K\=F
M!%-O/A1X9O\ XEV'CZ:P=O%%C9/I\%V+F4*L+G++Y8;83[E<UU]% '(Z1\*O
M#6A?$+6O&UE8R0^(]9@BMKVY-U*R2)']P",ML4CU !/>CP;\*_#?@#5?$^HZ
M)92VMWXDO3J&I.]U+*)9MNW<H=B$&!T7 KKJ* .$\)_!+PAX)\#ZKX1TC39;
M?0M4DN9;NWDO)I6D:<DRGS&<N,Y/0C';%5S\ O!)^#Q^%YTJ4^"S:BS^P_;9
M]_E!MP'G;_,SD==V:]#HH XCQ=\&O"GCGP=I7A;6;":YT73)[:XM8$NYHV1X
M"#$2ZL&;&.A)![YJSXQ^%?AOQ[JOAK4=;LI+JZ\.W9O=.9;F6,12[=NXJK /
MQV;(KKJ* .0U7X3^&-;^(NC^.;RP>7Q+I-K)9VEV+F55CB<Y8&,-L;GN033K
M/X6>&[#XCZEX[@L9$\3:A9QV%S=FYE*O#']Q?++; 1GJ!FNMHH Y3PK\,/#O
M@OQ'XDUW2;.2WU+Q%<K=ZC*]S)()9 H4$*S$)P.B@"D^'GPM\-_"RQU"T\-V
M,EE!?WDM_<"2YDG+S2'+-F1B1SV' KK** "BBB@ HHHH **** "BBB@ HHHH
M *BN;6&]@>"XB2>%QAHY%#*P]P>#4M% &/\ \(?H7_0%T[_P$C_^)IT?A/1(
MG5TT>P1U(966UC!!'0CBM:B@ HHHH **** "O,/V@_@9X&^.O@:33?'6@1Z_
M9:>7OK6*2XFA\N81LH<&-U)X8C!..:]/K+\4 GPYJ@ ))M90 !G^ T ?*W_!
M*C_DS#PG_P!?5[_Z/:OKVOD+_@E1_P F8>$_^OJ]_P#1[5]>T %%%% !1110
M 445\Q?M$_MG6W@#Q+%\./AKHS_$;XN7PV0:)8G,%CG_ ):W<@X11UVY!QUV
MCF@#TSX__M'^"?V;O")USQ=J/EO*2EEIEL!)>7TO:.&/.6.<9/0=R*^9M ^"
M'Q,_;BU:R\5_'!;CP7\+8Y!<Z3\-[25HYKL Y22_;@\C!V\'T"]3WW[/_P"Q
MK=Z;XO7XJ?&G6%^(7Q7N%#Q-,H:PT49R(K6,\97/W\<'IS\Q^J^E &?X>\/:
M9X3T6ST?1K"WTO2[.,0V]G:1".*)!T55' %:-%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)+'3?O:9H*]1'!']UF7^]C (R-Q^:OKBOE/_ (><? ;_ *#FN?\ A-W_ /\
M&JC7_@J%\ 'G>%?$.LM,@!:,>';XL!ZD>5F@#ZQHKY2_X><? ;_H.:Y_X3=_
M_P#&J/\ AYQ\!O\ H.:Y_P"$W?\ _P :H ^K:*^3?^'H?[/_ -I%O_PD.L^?
MMW>7_P ([?;L>N/*SBI?^'G'P&_Z#FN?^$W?_P#QJ@#ZMHKY,G_X*B?L_6SQ
MI-XBUB)Y#M17\.WRECZ#,7-3?\/./@-_T'-<_P#";O\ _P"-4 ?5M%?)J?\
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M_P""H7P N6D$7B'69#&=KA/#M\=I]#B+B@#ZRHKY2_X><? ;_H.:Y_X3=_\
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MUZI10 @&!CK]:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_9;\*_%.#P0OB74=<OY_"-VM[8W"WJQ/(ZC $H1 K#&.BJ??K0!^?E[-=S>
MOVZGNR_VG[:@^9B3@*VWD\],5^A_[*DMU-^SC\.GO"[7!T2VW&0DG[G'7VQ6
M3XY_9'\%>//$6OZI<W&KZ?!XC,!U[3--NUAM=6\HY0SC86SC@E&7<.#FO9K&
MQ@TRR@M+6)(+:"-8HHHQA411@*!V   H GHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^&_V[T5?VB_V:2% )\129P.ORTWXV37I_X*9?!:.7(LAHER8<
M$X)W'=QTS7OWQ>_99\/_ !I\9^'_ !-KGB#Q';7_ (?G^TZ7'IUW##%:R]V
M,+%B?]HD5T'Q%^!.B?$B[\/:G>7^IZ;XCT$L;#7]-ECCO(PR[74[D9&5AU!3
M /(P: /G/_@F1+>/X:^+"3M*;5/&5Y]G#YV %CNV_CUK[4KD/A9\*_#WP<\(
M6_ASPU;/;V$<CS.\TADEGE=MSRR.?O,Q.2:Z^@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/B9^T
MQX+^$GC'0O"_B(ZO#K.O2B#2H;72+BX6]E) \N-T4J6!9>"1UKI/ 7Q?\)?$
MJ]U2PT+5X[C5M*=8]1TJ='@O+)F&0)H) '3.>"1@]B:^4OVXUS^U5^RCQ_S-
M#9X_Z:05QGQ*U77M$_X*6ZWXC\%VTE]%H'@*:;7HK8;D=Q#.T,4FT$[B_D$
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M',?QA^)/B'XEZ_\ M,Z%K/B*\L--\(^%(UTS2K27R87\V%7EGE0\2DEMGS9
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MN;F<JI9BL48+$*H))Q@5O>#_ !=I7CSPQIOB#1+DW>E:C"MQ;3-&T99#TRK
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MP,F%2_KQ0!]N?%SXX^$O@?IVF:AXNN[FQL=1O$L(;B"REN$$SD!%<QJ=N2<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.$\:_ [P/\1=>TW6O$GAZWUC5=,<26-U<O(7M'R#NBPP\ML@<K@\#TK=\+^
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M+O$$GBO7])T=-%T^ZF4@I'UEF<G[TLC=3C@ #GK7LM% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cgtx-20231231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *1 I$# 2(  A$! Q$!_\0
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M+Z!1P!6'/\-O#=UX8\0>'I],2?1O$#73:G:2R.ZW7VG/G[B6SA@Q& 0 .!@
M4 ?+'[0?B6+XB_'K]D;4] -GJNEZY_;NI64&H;C:7&[25>!I$P>@<\[25R<8
MYK?_ &%?%VB>#?V+;-HIM0OE\&#5+;5HY5$DJW%O-++/'#CAX_F_=@?PE >0
M<:7CO]CNVO/&WP-7P8\?ACP1X!?6?/M+74KF&\C6[MMD?V60;B"LF6(9U '
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M4 %%%% !1110 4444 %%)N'J/SI-Z_WA^= #J*;O7^\/SHWK_>'YT .KRO\
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M7]9^ _A7XK66B^-K>;6?&>N7FN66HR:5A-,EG7"@Q^<?.V'!ZJ#CD5H_LU?
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M>#_V[/%&K7.G7$EKHOCJ;43!I2[YY5@U&166-"RAG<2D=0#SDXS6]X-_:G\
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M*75R$EA:=!(A#GY@01D#^\!W%?.?BF(/+]LU*")TE8(E_IS*;=BJX5 % \O
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M&)A<V]O&)!YC2LR(K9P=I(^8^@7)XZ4W6_#]K<ZU>-I-W9O:NS%;=MT+H <
M;),%S_ND]^E13ZC//<6*SZS)J<WFL93&\C,JY)(5W'(ZG &,YK#N9Q+&28D:
M3?N:9G)8DC'KR#U/'7OBO9A[5X>+YK:OIZ>GR_4WI0Q$Y\\I]+)6TWZWLWMI
MM\SH/$?@6]TT6%P+!K6V>%(Y9KB:-8S,,B0JVX@IN'##C@XK)N]0AT0O#I%Q
M([NI26]">7O4C#*@R6"GD$YRP[ 9%7))['4M,M++4%FL);;,5M>R LB*?F,<
MB 9 #LS!ER1N((/:@OA#69C#%%IMQ<[U+1O:PM,)%XY4ID$<C\ZXJ<K659Z_
M@_Q=_P!.O0THRM'EQ4]K^2:Z/5N]O73JMB_X9B.KZ3K%EN,UTL0NK2$'<SR[
MT#[1U)*$D@<G8.PXP;J07,L7E(ZH %!8ELD=?Y]*V="\#>(=:U6"UT_1K^2X
M,@0%8) 4.>I.!MQUS7M6O^'+?P):V>K>(;DZ!+<;U>"W42ZO>RJJ8GV9 M]P
M8,RLP((Z-NJJV*E2JJE#WK]+[.WST=OZZ<6)S*C@JZIQ?/*>JBGK>W97;3M?
M;36^FJO^#)Y_A=\']0U#4K:6Y\3^*/\ 0["SNF,8BL+:1&D5<,&!9VXCXW;<
M8YKR^[_:*^(C7UQ<GQ;?N;EF=HS+O10_4!&R ,8 &#@5U?QL\8PV7BSPG=:;
M!<V^G6FAVD^G6IF+>1O4L06P&8LY8LW?/:O"&? !"J"#Z<UST:,:S]K6@FVN
MJ[]+>6GKYZ'D9+E='&0GC<;1C*55\WO).W112=TK1C%.V[OJSVSPY^T3K6H7
M$-GXB?3[>TD4P?VM9:3;Q7UH2,"9)%0$D'D@<L"PR"01E:GX*^*-MJ37UK/K
M&MO,6DCU'2KU[I9U!;YU9&)*G!P3CTKS.R4/;S%G QR%*;LGM[#TK:T[7+:U
MM!I]U82SE6)C:&[>(QNPQD  ]PI(QSMKOK8;V5-3H16NEK)]7YH].>54\'-S
MP%.,;Z2CR)KU6L;;ZZM/M<Z*]OO'=EI-Q+JTGB*)K>2*23[9+<1-Y0!50"WH
M<?3(_#I[;XE:T]O96=OXD-OIXMR]I%*S0M;S+#D!Y3PY+JOWB06&[:IQ7#Z/
M\0+GP_=O^^N;W3I0\5S9W5X\B7<;(58,,;>YP<9!P1@C-;^F^'/"7B>VEL]$
M\2SP2&9IETK5],9IY<+D+'+$Q#DYVX;;G;GC->-B:4(?Q(V\TKI=[Z.S7?33
M2YP8K#4XJ^+HI1W3C"Z6EG=)2LUO?16;5]S)U3QA\1=)OY;Z[U#6(Y(2!-.T
MLC(-V2%<@E>=QX)JE?\ Q'UO5S';B."[@\N-&@DLHG#2! F[(7=GKCFH[>+2
M;.\W:?K^I6+Q@,@NK-=BD^NR1LJ?EZ ]3QQ5GQ"_B+PKJ=U EY/%:RVWEB:T
MD AFC V_*T>%<9SSU.>0,D5VX>C&I448QC>W9QTZ]'Z[Z'I0I8;GC%4H<UM+
MQ<>VUT]O)Z?B?H9_P1NN=_Q+\?P7%O8QZC'HMLLS6D)C=<7! 5\'83WRHSZG
ML/U?K\A_^"**!/BE\1L*4']BVV W7'VD_G]:_7BO0A%1C9'T5&"IP45_7_ [
M''_&&XBM/A3XOGGSY,6DW3OA=QVB)B>._':OYIO%-XNHZY=W00HEQ,\JC'0,
MQ( _#%?TA?M'ZC)H_P"S_P#$>_A6-Y;7P]?S(LPS&Q6!SAAW4XP?:OYW/&'A
M@)JEE=Z%!<3:'JR+<V(9"WE@Y#PL<=8V#J3QD*&Z&G&,7*3UO9?J>-5<*68^
MTGIS023Z:.3:];.Z\D^QS+0[H[60JVTIMWXSSSQ^@K.S\QS74_V1<SV2BWBB
MF$3,RB!O,&,9/0GV]OQXKF&4Y)QQW-=]9?#*"T_JYWT*D9WLR]#$6C+;U4GY
M?F(QS2K!(93AD8KG.T\_4#O53=@AF!VA<#:>A.<5?_LR^#032Q36P8C$\P,:
M_4$X_2M?;*HO=O=!+W=WN$L/D12X*DO@\'D<_I_^NLQCG(Q^!K0U1)#<.Q(Y
M8X*G*GZ'IZ501<9SP.O-<5:I&I+16+I?#=EE T40G?! ("@^O].U18:X4@#I
MSQQ3KF3#$#T  ZYQZTV.<P$KD$9Z&K@HM+739E).U^I/#:22+)\JJN,?,>E5
M)5:(A3Z9SZULZ?J<43$2H .X5<\U6U9XY)&>*/9$[%T&.GKSZ5Z^)RVC#"1Q
M-&LI.]N7KZ^AC"<N?EDM#*7 <$C<H/(IQ/EG*G'/&#2[%!()X]1TIIQNP><@
M#)X%?.IV=T=FY.9=]J2R@D,,XX[&H3*I4KM!!/'7(J52HLW['>OOV-1NA5%/
M\+^E=V(^&G+O']63&UR6'R3R5+'/ R./KZU^X_\ P2,)/['VGY_Z#6H?^AK7
MX8 @\#C/M7[G_P#!(LY_8^T\_P#4:U#_ -#6N1*VI<59L^U*_);_ (+1*/\
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M[84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXTM(O3\32U1N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2'I2TAZ4 ?S5?M)(1^T3\4(U(W-XKU4X."/^/R
M7BN2M-4FM(Q,5@>",%8[1A\CY #,1VR!U!!ST/%>K?M26UC)\:?B+JUKY,=P
M_B?58;NTC;Y5=+R0*^T9(WCG!.-RM]*\;OI?,E,AGB$OF@[H00@/][&/Y>G2
MKA[.5-RMO^E[I_\ #^ESRU-8E:QZM/U6C_X?MMN/N'2\.VV$HP@,<8(8+R2<
M],=<Y%;'@!%2_O+>Z*BTO--NXI)!( 4Q"9%/?'SH@Y'?UQ3M%\.65[I<FJ:C
M?/:VJ7 M3':0&6:[?:6)C!PH &,Y(^\.#G%2OX@TW0+34;+18;M);R(V\MS>
M,"P@.-ZJJ 8WD$'=G"X P<FO-J5I58SIPOM;T^?EOU.6M5]K">'I)M[7[>=_
M+?2_WG&,N[G;A?4?Y]Z=(KHB[R >N">?7I5B-/.A?[..,@/&3U]".?K]*8EN
M[2>45"DGYF8'Y/4'CM79=/1Z'LJ2^XT-.BDN$O-JXFNW2VC5_P"-G<-U]MH_
M/\_3/BP]MXFTW4[B&WE>Y\,W%GH'V\DYNHT@:-2ZD_*0T$ARH&0XR,C-87AV
MTF@TV]U_[.&T_2+?[-:HT6?/O'4D,!CY]I!D8G.T*@/:NA\1$ZC9:^CF8W6K
MZ/INOEV4#SW3'VAV3. 27D?CLA[&O#J5G[:,H]/\XW7_ (#K_P -=?'8JNI8
MRG..C@[;[7E#F3_[<U?;SM=>26[BRU*.9&CF$#AAN7Y6V\X_''ZUL:UHUSI\
MWGQMNTZ<+-%-SLPZAMF2.2"=IQQE364;"4W#LJLJ1R%7R/E0#U/2M2=[K^P[
M6&2/9$&,L*A2S%6 !);H%)4''KD_7[#"T^:K%*7*VOP[^I])5;YX2B_)_P!=
M_P#,I17#1PM'$@>V8[WRF"Y P,^P)[>M;>G^,;_2[(01"(X(9%DB#';UP?4>
MQ]ZR+'3GN(S<3+)]CB(61P<<D\*N>YQ_6K$L5EL:=HIDQPB9SD8X.< X!]*^
MJP,JN6J=2A)POHVG;>_;^MB9^SD^5J_^?]?@,E9-4\R:5A%-*^&*K\A).?P_
M#CBLTK"LY6)G4 [5;'7WK:\DJ8S)'FV389+>)B,,P.",YY[^W2L<7Q:< HJ?
M-]_!R/UK"I3HS<9UI:RU5U>_X]^Y=-MW4=C7EMI'T@0)$7DW1+N!XR0Y(Q^
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M/Z85Z?B:6D7I^)I:904444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4EU(+<_1P_\ !%3Q \!C;XIZ5U# C0ILY_[_ %02?\$2_$#R;C\5=+^G]AS
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M )JMIO\ X(YO_CU?G-_PD>L8_P"0M?K_ -O<G_Q5-/B;5P?^0M?_ /@7)_\
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M\4M(*6OU4_H(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "D/2EHH _FZ_:*#M^T1\3H)@T2'Q5JA"GC(-Y+S
M7$:M?PO>0P0L@CC !S\O/?-?T;ZK^SC\)]=U&XU#4OAEX/U"_N)&FFNKK0K6
M261V)+,S-&222223U)JD?V5?@N3D_"/P,3US_P (Y9__ !NLG%R:;9PO#<TN
M:3/Y[-$\47WA-;Q]*NKBU>XC,;+%*5P#U((-;'P^^(VM?"G48=5M;Z3[7/&\
M;0RR,0H/(8C."<^M?O\ +^RY\&D^[\)O! ^GAVT_^-TLW[+_ ,'+AMTOPH\$
MR-ZOX>M"?_1=<=3!PJJ49I-2W\^QY];*:.(C.G5BG&?Q76ZMHF?@'XL^/OBO
MQ:MLUWK5\E]#(7:YAN#&'.?EP@P!BL76OBOXB\1- ][JTH\M!&5MI3&7 [O@
M\M[FOZ$_^&5_@O\ ]$D\#?\ A.6?_P ;I!^RM\%P2?\ A4?@;_PG+/\ ^-U4
M,#AX6Y8+3;3N.CDN!PZBJ5&*Y=M%I?MV/YR]5\07FM7$;W$AGDC01K+(V7VC
M.,MU/4\FHGO6NM*6&64*86+1JP]>O-?T=-^RO\%VZ_"3P,?KX<L__C=!_98^
M###!^$G@8CT/ARS_ /C==7LTDDNAZ*PT8I1BK6/YO+:=Q,@4*&###4MRI^U.
M78,<\GM7](2_LL?!A""OPD\#J1W'AVS_ /C=*?V6O@RW7X2^!S_W+MI_\;JD
MFI71I[)\UT?S>W( 1"7!XY /059TS48UF2.Y+K;$;3Y.-WMR:_HW;]E7X+-C
M/PC\#''KX<L__C= _96^"XZ?"/P,/^Y<L_\ XW0XIJS)=!2CRL_G+U M9?NB
MICSSEFR6%9Z_,XPPQV&>]?TC/^RU\&9 -_PE\#MCIN\.VA_]ITP?LJ_!8?\
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MEL9.1QQQ30K+T4_E7]!?_#N[]G7_ *)7H_\ W\N/_CM'_#N[]G7_ *)7H_\
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MK6M7]JD]I?F8?Z#(=W.W/)!P?PKF=-^+GB31M;U2Z.M;I[^/RIYLH68<?EP
M*_HV;P;H+D%M%TYB.,FTC/\ [+33X(\/$Y_L/3<_]><7_P 37##*J7O.M[[D
MM6_+LNB\EI?4X*>0T/>EB/WDI))MJ^VUD[I+1:+2^NY_,E#J+P7BS13(SA]R
MEF!.:_1+X+Z[8^.?#>C:Q/ID ,0C7[6Z*-S*=N1Z]",U^K7_  @_A[_H!:9_
MX!1?_$U;A\.Z7;1B.+3K2)!T5+= !^ %<&=Y%'-Z<(QGRRB][7T>ZW1Y7$O"
MT<_HTX1J>SE![VOH]UHU_70T!2T45]4?>!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444USA&/M0 I8#N/S
MI-Z^H_.OQ/\ VLOVI?C7X:_:B^*GA_PQ\0O$UEI>EZC*UOI]A<,4MX41&;
M^5%!9B>@ S[UYU)^TE^T[IKR7=WXZ^(=OIL=Q):QRR^:/-D3=OB7='AG4*Q9
M>JA22!BLW-+0'I<_?7>O]X?G1O7^\/SK\!;K]IW]J33X$U&3Q;\0K3396B$4
MEX)_*<R+F("0Q@$N.5 ^]D8S4]U^TK^TY)=6^G)XH^)-OK$D<LL<"O<EIDC.
MV1EB,>[",K!B,@$$'&*?-MH/EDFE;\O\_P#,_?/>O]X?G2[E]1^=?A5HOQ8_
M:MUVR\7WEMXL^)*VOA6PAO\ 4_M<\L$L0D*JJ[#&26;?O"X^XC-G S5;P?\
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M3<H/G6J26BW;Z];?+\2'2;VYT^1I[:X^S.@/SY'=2N,'U!(_&E5I[ZY!Y,S
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MSJ:PM(+Q+L_:8K0K$S^7(&P&# !5ZDDYK3O#9Z0D21MYT4A0&6)3D?+ABK$
MDAN.@XX]ZX7+DE97;?3^OZT/+YO9U&HW=^G_  ?ZO:Y%J=O!8W$406.$RVT3
M2/=KAE.P%@H&<<]">O'2LI(HFNHKD3>;%YJ[T<CS.1DX4'D<=?6MB^T57TVT
MN6N/-'E2B!0A5Y%$NP-@\#YFQ@]@?2H(;&'3II;?YX]0B3F51N$<F<%.N/\
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M51S&QX ) /F9!' '.0?CRWT6W^S37LYD-E!EEDV?O9'881<AMN-ZGGJ!DC/
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MR>:TFR2VC,LZ *-O7:,9(&X'UXX%:FL>-M8>TU)[+5+B"VN2HG19@IF'.!(
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MV4FVM;R*N<@N 6\ODM]!ZC/!%=!,;^'4'%CI@BNIY(6:*S4RG>S'9Y+@'"G
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MMH&]/4@<9]L^M:*:@=/M;.X9)FN!GRWWD%(0<;,@=\]>PXK>A.*NJC?D_/\
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M/I7B-E;>=%=,L\4;PPLYCE(7*Y (7/5N<X] ?2O;_P!O#"_MA_%=CR/[<<$
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MM[;1W:X7:VY>B ("".@P.1Z<UQ_CKXF'446RTAYH(0[-/*VP-(V> I7H@&<
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M^#I__B:7.'*C\+P>1WJ281+,0C,\61@D8-?N:/\ @D9^S\#D:?X@S_V&G_\
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MDTQV9^%M2;]B *2&(^8Y[5^YY_X)'_  HJFP\0E5Z#^VI./_ !VF_P##HO\
M9^_Z!_B#_P '3_\ Q-9\X6ON?AS#<Q10'B03=F!X_&I[74-BR%K>.8LI7D9Q
M[U^W_P#PZ*_9^_Z!_B#_ ,'3_P#Q-3Q_\$F/@+#&$CM/$<8&?N:Y(.O7M7H4
M,RQ&'BX0=UV>J^YW,I4DS\-'NK9T -OAO[P-,Q;NP #)]:_<?_AT7^S]_P!
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M]6Q4X3C\<KGH=?D9_P %JY&B^*/PT*\_\2>[R#Z?:%K]<Z\(_:)_8O\ AO\
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MN/C3%<7,XNM-@FM)D\OR\9VCOM)[U^LY_P""1O[/Y.38>(2?^PU)_P#$T?\
M#H[]G\_\N'B'_P '4G_Q-8RG.3YG)_?^1Y4N'\#*7-R_B_PUT/R(7XBZ58WT
M[6NFJBN 8W4#?&0.".P_"N[\)?M6^(=$LA97(^VVQ;(,[LY'ZU^GG_#HW]G\
M?\N'B'_P=2?_ !-.3_@DE\ D((LO$0Q_U&Y/_B:=6K4K04)R;2^_[SGQ/#.7
MXR')7AS>MV?G\?VU]*_LJTMO[)E1U!28JS#/ICFH+[]H?X<:YX;?2?\ A%($
MU2X8QM.;9% #<;E;&0>:_0F3_@DG\ 'Q_P 2_P 0+]-;DY_2FC_@DA\  P;^
MS_$.1W_MN3_"N:&'H.RKQYU>]F_U5G^)X$?#_)X-2I*4'>^DGOY^1^;L?P'T
M7Q;H#1:/?)'J3R_NHY5C!8#K\V.?K7G'Q(^">N?"QF_M*%&B<[%>!MW/OQZ$
M&OV4T;_@F]\(O#^JVNH6'_"1P3VP"Q#^VI"BCTP17;>+?V-_AKXXTN+3M8T^
M\NK2, *GVQE/'N!FHKT;34\,[)ZN+U^Y[_?<5++.(<%BH*%2-6@]9*3:DO1V
MU^9^"FB:RVD:;(9WD\DG9L0XRIZU],_L:?#32]7_ &A_A7XKT.^>5(=<C:>V
MDVAHP%<<X]37W[=?\$HO@'=*ZMINO*K,6VKK4N!GL..E=5\)?^"=_P )/@MX
MOT[Q)X:AUV'4+&=;B);C5Y)8BR@@;D(P1R>*>+ISJ*'U>?+RM/;1W^)?Y,^H
MJ9;74XU\/4Y9<R;71KJGY^9]-)PB_2G4@&!BEK<^E"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#Q0 M%
M?F3\=O\ @I_X]\#:QJWAOPMH6BW_ (ELM?N=,\F2SFN!Y*7$L47R),K-(^Q>
M!Z].17$:3_P4/_;!UO5VTRP^%.CWUZ(VE\FT\.WDK%5V[R-MR<A?,3=C[NY<
MXR*YZ-95DVDU9M:^7Z=CCPN*CBHRG&+5FUJNW5>3Z=S];:*_(?2_^"F_[3NM
M6 NK#P/X9OX9=4&D6LEKH=Y(;F[(?$"(MR6,AV$XZX!K!\1_\%7OVF/!_BE_
M#6N>!O#.D>($D2)M,OM"O(;@,^-@V-<@\Y&/7(K=.YTQDI7L?LM17XHW/_!9
M#X]65Y+:W.@>"K:XB<QR1RZ5=*R,#@@C[3P01C%,?_@LW\<!&NW1?!1?)W$Z
M9<XQVQ_I-!5S]L:*_$L?\%G/CIG_ ) G@<_]PRY_^2:Z;2_^"N/QRE\-WFN7
M>@>#VT]-UO%);Z=/Q<X!574W6=N-QR/05M"G*IL8U:T**3F]W9>KZ'['45^*
M\/\ P66^-4EM<L^B^#?.49C6/2[@J!GDL3<_3I43_P#!9?XYPIB7P_X+#,OR
MDZ;=#OU_X^>1P14.+5S3G3=C]K:*_$U?^"S/QS:,D:+X'W _=_LRZZ>O_'S5
M[2?^"PWQXU2^M;:'P_X,GEEE"&*/3+D$C(Z'[5QU/)&!0HMJX2G&"<I/1'[2
M45^+OB#_ (+%_'#3-;O;1-!\%PI%,R+'+I]P[J >C,MR 3]*KP_\%G_C2;*6
M.3P_X,^UE@T<JV%SM [J5-QSGUSQCH:4DXOEL3&HI04XZIV_$_:JBOQN\'_\
M%<_CEXH?4K<Z/X&@E@LI+M)I+&X1%$?+;@;G+9'''/?!QBL>^_X++?&F.55L
M])\&2KCEI=*N5Y]A]JZ4EK+E6Y$<1"525);K?YG[4T5\G?L#?M/>,_VC])\5
MOXV/A\:CI:6$T<7A^WECCC2X25@LADD<E_W8R.-OOFOK&KG!TY<LMRJ-6%>"
MJ4]F%%<!^T!X\U'X7? _Q[XOTB.WEU30M#O-1M4NT+Q-+%$SJ'4$$KD#(!'U
MK\CA_P %F/CD/OZ+X(&3C_D&7/\ \DU4*<IW:-6['[845^)R_P#!9GXY,#_Q
M)O X/OIES_\ )-6]7_X+&_&W3KA([>S\ ZBAC5FEM]*O JL1ROS7 )QTSC'I
MFIE"4;:;D\ZYE'JS]IJ*_$V+_@LU\<G<!M&\#J#W_LRY_P#DJE/_  66^.P;
M']A^!R1Z:9<G_P!N:J-*<U>*N5='[8T5^+,/_!8CX[S0/*NB^!PJ$!LZ;<@C
M.<<?:LGIVIZ_\%AOCHK?/HW@?'&<:;<__)->M2R;&U;<D-S)U8+J?M'17XQR
M_P#!7_XYQ%_^)3X$8*<$)I]RVWWXN>:JM_P6,^.0C+_V-X(QGC_B67//K_R]
M?2M*N1XZA\<;"5:$MF?M-17XX6?_  5U^-_VA?M6@>$Q;)*%F9-)N58 #+#F
MYP&&#C/I6)<?\%D_CB+IHX-$\%,I;"!M,N<GGC/^D]:,5DF,P6'CB:R2C+;7
MLD_U1,,1"HVH]#]JJ*_$]O\ @LQ\<AN(T;P05' )TNY'/O\ Z54MO_P61^.E
MP,+HG@@OG&/[,N?_ ))KRJ&&JXB7)35V;.22NS]JZ*_%IO\ @L9\<[B[,5IH
M/@N3: ,/IESN8\ X'VGN3P!DU7G_ ."R/QUMT4OHW@4.208O[-N=RD>H^T\?
M0\\5E4INE-TY/5"52+TZG[6T5^*1_P""ROQPCB@D.D>!6WDY0:;<Y4#'7_2L
M\_2OTD_80_:!\2?M+_ *T\:^*K?3;75I=1NK5H]+A>*'9&P"_*[N<\\\UEN6
MFGL?1-%%?%W[7O\ P4*NOV7_ (P6'@:W\%P>(6O-(CU)+J35!;'<[S+L*[#@
M?N?O$_Q5$Y<BO:YE6JJC!S:ND?:-%?EO?_\ !9S6M-57N/A':K&QPLJ^(5:-
MS@'Y6$>#P1TJ0_\ !:*XG$:67PO2[N7@$XA_M8J2,?,!^[))&#QCD<URK%*5
MK1;OZ?YG%]?A9246UWT:^^Y^HE%?EWX?_P""S.I^(;Z*UB^%=K [R",F;7=O
M4@$#,77GIQWYJOKG_!:F^T/6KW39/A5 \UI.\#%=;X)5B.,1$=O4U2Q',VE%
MZ>G^8+'P=1TE%\UKVTV^\_4RBORRTW_@M-J>K7\-I:_":"::52RJ-=P2 "2/
MFB W8'3.2< 9)I+[_@M3J>E7LUI?_" V=S$/FAFU5T<'&0"K0@C_ #UJ?K2Y
MN3E=][:;?>5]=CS<G([VO;2]N]KGZG45^5</_!;2\E=D/PG02 $A%U@ELCJ"
M/*R._P"526/_  6QN+ZY:$?"^VA)X0S:V5!/O^ZX& ?7L.<TWB;7;@_P_P R
MGB[)MPEIZ?YGZH45^53_ /!;2^C+*WPFB$BOL*?VV<@^F/*S5Y?^"T\SZ;!>
M?\*PC$7FF&X?^UF*PMC*\B+G(![#H:UA4E.,I1@W97Z;:>?F3+&*-KPEKZ?Y
MGZCT5^5=I_P6Z:>X"2_#"*WC*D^8=78_-@D @1="<#/;.:Z'4O\ @L>-'^S1
M7WP]CL[N2V:[:*;47P%*!HU5EC.YGSQT7&#NP:YIXR-.2C*$KOR_K^O4BIF$
M:4E"5.5WY7_+^MNZ/TSHK\N5_P""T-X/#]WJ<OPRLX&AN(X$M6UP^;-N#EF4
M>5]U=JY/^V*HR?\ !;B< /'\+8GBX#.=9*E21TQY7MUJUBE*]H/3T_S+CC5)
MM1A+33IY>?F?JI17Y4+_ ,%N;MH7D'PJ@ 3 (;7""<^@\KGI7H_[.?\ P5=N
M_CQ\:O"G@)_AS%HRZY<-#]M&JF4Q 1L^=GEC/W<=>]5]8MO%_A_F:?6K:N#7
MW?YGZ(44@.0#2UUG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME8M<FNUL[9(+L9N TK,N(HK<B$X(+"-MHR_/>?&6SO-'^/EU\0-1UO0]0M_
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MM@^FT>M?H]7C.;FW*6_]?U?J?3X:7/26EK:66VCMIY::>1XY^V/Q^RA\7_\
ML5-2_P#2=Z_G"N5/F-Z5_1[^V."W[*'Q?"@DGPIJ0 '?_1WK^<&Y<;E&,.HP
MU=M*25&<9;77ZF[W1%&V&'&:60A2-N1[YZTJ+N.3E<@X..*D\O*D9! SANU$
M(.<&H^J!M7(E"O\ >;:?7'6E4.N.< CC!I$!0JQR%SP<58@LY#&\CPRI$@RT
MJH<#L,_B1^=<\:G+*[%)I;L2.22%@03GK3YKN29]SN68\TV2X:1UW2M,0H7<
MV>GI]*L75LJK&T3I("@W;,_*?0Y_I7T-"I6J4[4Y/3H8NR:NM1MO<,C [O\
MZU=?X:T!_%-XD=L@21E)W8& V&(49( )V']:Y.WM@BEY<\#=M!P2*N:9K']G
MW4<T<2D(P)7)^8>F:^_R;%QPG+#'-.+U<6KO]+?>NFECAQ4)U(/V+M+HSV"\
M\,1Z'X?E6QU&)K_86)CEVNF-W(((RWS$8.3@GGM7B.H6AMY=I.\\],C!![@]
MZ[G5/%D&J6KW6GO<6M_)<&/[&[B7]V4P"&VC)'3UY]JYB>.:]9]\D322J\[R
M."TA//RDGG)*YX_O=:Z>*<1A,Q4)81.R5OUT/)RNG6PRE*N]6];[_AT[6,]-
M%N[B*V,%M).T^_8L2[F;: 3P,G@<UN^%K:SEL+M;F6(:A\B65O-E/-9G ;+]
M% !W?,0.#SZXYU.33XVAM0;=R<22J3O;J, ]AST[U4!DNKE$4M([D 9.22?K
M[U^>TW# U7*+]]/3LK/\=-.A[=2%2M!QD[+>_P [Z^3V[VOMT;.'-T=K9<MP
MP/ZY_K3)(Y%XF;;NRY8C+$D<?GV^M:-Y9):R3&"Y$L<8QO;Y"V0 P [\DCZ#
M-94S*V&W$MW!Z8[5Y68T>2?M'IS:KYZG33DII-;$;JT;%6!4CL1BOW2_X)%?
M\F>Z=_V&M0_]#6OPN+$D;AD_TK]T?^"17_)GNG?]AK4/_0UKQSI1]JU^,'_!
M7-&?]LOPTJ"!C_PB=J2+D@(0+B\)R3QTK]GZ_'#_ (*O:P-)_;&TM&L8+]+O
MP1!;&.X#%5W7%W\XV\Y&,C'/ISBID[)M*_D<N+<HT)N*N[/0^'K?4-.LO#ME
M;2.[V^HN[3B:U0BT<$@O"P8MP-O!'(SQWK-M+J0:NT$-^U^OF%C<1,("2H(5
MD=Q\O [@''&.:RXIGGD>"UM%GCWLP41[VVD=,\X '.:MO>I<VNGQ/ A^QJVR
M58BIGCW%B"?]DY&?3/-<<:6MGU]/Z[+<X?8<E^O->^W6]GW[+=7WZ'3Z+/:W
M<4^KMI5N+[2+5_/927BO'8MME9,8R PZ$ D*WJ#RL=G=30QZG>6UW-;W,S>9
M>,I;=@C>P8_Q L,D^M=GXWLKKP/X3M-&D%E!=:OMN-0MH(V:6WV-NCC9R2.0
MZL O;;DUQ.IWPNK=5$GEE$$?EHA42!<!6([$C//?%==9.*A36_7=_P!?TO3E
MP+]LG6I_#)V3U?NKMY.5[;JUK:6LVV"6>LI%%?-;V<DHC6]:,@K&6_UA49((
M'. 2>,<U+K+R6VM3O+>2:I"DKQQ7$Q(:>-6(R>25R.<9[U7N$M[:Q2!29;C=
MOFD W(@P-H4@]3DALCJ!CO52* SR\R(@"[RS'@ ?U]JP44WSM^6V_GW_ *V/
M645)\[?2VRU\^_\ 6QOC3H)=&FUBPNY8_),$-U"\H64O(KABO=DR@.>V\ ]B
M;^FR77@W1C,T,=KJ%Y<136&I>5YCH(9&638V["@-M.=ISMZCOC:9+'>VL]JT
MPM9Y5E>25W;$Q #(F,8'*GG_ &ATQ5KQ/'#9-#%'<-(K6\.Z/S1*R/Y2L^#V
M7<QX]CGH*Y:BE4G[.>S=]NBMIIIOY;:/4X)P<Y^PGJF[ZKHK65^NO>]UH[,M
M7-UH)T.[>!9Y?$OVIE:5 ILIK=U(+(I"LKAL$#!^\?2MGX5M-J9\1>$KK;##
MJ5FRXN@5AMIHCN660 @KM^8;B<+N)8$9KE6L7FLX[E=3AFA2+RG!#*RXY$8X
MY)Z ],]2*[3P1HMJ? _BC6=6NXK5)W%A%=2[VE,S@L<[<L5"\D8^8NO]VNS!
MQ49.TGUOU:T=TMO.R\[;'#CO9T\)*-VVVK;MJ7,K65EL];?H<)90>==R::WV
M>)'8)-=+$9O+5#EG4J"<<$DKU'M5VYO+[6]"L+&6YAG6Q$@M[?/[Y5.W()QR
M.X&> #TJ]8^*8+*&_AL[%H;^YMS;R7]Y=[72 1@/'&%"J"P!7)W9!QC)S2&\
MTC4;.*&PLHM+.TH[-NE=V.?O.6QCVP!TXR*X92ES)RAMUT=G;5]]=O\ ([93
MGSJ4Z=K6:>CL[--]U?;OITZTI8+.]TMK\F2W#W:1>5O+1LHC)8DDE]Q;&.WS
M5SYQ%D;59CCJ2<>HKJO%?ANVT!;>+3=1AU"5(T>>2 N/OHK!MI4;5Y('.>A(
M&<5S36L\HC9@#YK<.6&2??FNNC.,HJ47H]K_ /!U.O"U(3ASQE[KVOH_+?7;
MN7;>*Z@TZYNH%B1(ML3NO+KO!P?Q&1G^5>__ /!.A2/VSOA:S#[]_+@G_KA+
MS_.O!]-AMH9(1)JD=HPE(<M$S["HX+* =RG&/QZ=:^B_^">-A:?\-C_#F2.Y
MADGAU-\F)PJ.K6\N-BMAC@YSCIQ]:B;]V?IV9G5J)1FGUZV?IOZ_\-U/W^7[
MH^E+2+]T?2EKN/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I#2TAH _FX_:MM3;_'[XA-YB3^;XDU1C+%T
M!^VS91N.6&1D_0=LGR25F<*-Q=47 /H,YQ^M>W?M&(=)^-_Q,34+.WO8)O%V
MJ2^4TVRXA4W4Q!09X#  DE2/N]*S-,^'NAZY::7#ID\=AK.JDSFVU6<FVL[4
M1NWFM+A5^8C;\W0@<Y)Q.+JTZ"4Y/I]UE^&G^6]CP:F84\'&]5-J[U5FM-6W
M;5)+K:WWJ_D&3G)Z^M*H D +84G!91GBKNLV?V.^FBCGCNH4<HLT&3&<==I/
M.WT]1S4$D4,-PJ^;]HBP"S1 KU'(&1VZ?A3::M='LQFI1374AD(+G P.G Q7
M3?#V-+OQ3%YIG0K!.Z&VD",KK"Y7D_PY R!R1D#K7.V]K+<2JD:DNQXKLOA]
MITD+ZSJ$A6*6VT^:2,3H<2$C:0I[-@MCK7;AJ%2=1<L7T.+'SC##35]6K??H
MC&\,:W_PCE\=1C>*4HRI)87"EDNHF^^C#&".!D'V/.*R;NY$FH37$.^(-*SI
MDC<O.1R .?IBK=O+"MK/;216[/<,KK<-N\R';N^4'I\V1G(/0=*8B[Q#&T:P
MY7;'+D*IR?XF[^GM^%<KH*-64Y:/;Y?+]=?D:QC&-252VKT^7_#W\_E8Z+X=
MV-YK=YJ>G6T33_:;20E1U+ 97L<\]ASC/2N;N9YKPRSW%RTDN\;EE<EV/3(^
M@ '-=;\.+TV?BW2_L5JYO&WP%D^='+*ZY(PV1AAG [?C6IHOP,\3:Y]J$>G/
M'%!<HDUU*RK$B'/S YPP/;!Y[9YQV1I^U;A'Y=]='\M%]YY-7&T<)B:D\3)0
MC:-KV3W:?Y(\_AFD5X<>4\;*RK')RB$C:20>AZ'/TKU;0] TWPM\+8O&.N6D
M^L?;UN-%LK26;R3;RX#I-$PR2JJ3P1@ER*O>*/A'X?\ !^CR277BVRU?Q+;*
MUQJ&FVC+(!&'4*%8D#>,G*\G R.*X;QSXDOO&ZQZE?RMYT<ABVI$(X%3 V[1
MG@CD$ 8 5<5K2PT;1J0G[UWM?2WGIO>Z:?:^FAY[Q4<X]FL-)JGS>\[2BVE>
MR6B=I7OS)[;7OIQB(5Q)@,O4]\?6NY^%_P +=:^)=SJUUIRBWT_2;<W6H7>>
M(8^>@SDDX/ H^&7P^'Q%U>TT*VN"FHW<X"[$9@J#@LP ]2,?EWKK/B;XFL_A
MW9S> /"=Q>6OV:62WUR:1T9+^96P, #A1CE6S@\=LGHC&-%.4K<RV3V?KY=V
MMG9:-HZ,PS"I.K_9^!?[]ZW:NHPOK)]^JC_>M?2Y2^(_Q,'B6S<6]H^F:/LA
M73;:S58K>1X0(Y))(Q_$1T/7USDUY:;IY"V?,EC16X)X4GC/?N:ZK2O$LMKX
M5O=*M=+A&FSRI)>WD\$<MPQV\(DC+^[!VL<#D^M<K;W)BN@8<P.^5^1=^,\8
MY_\ UUP5*U6<93G&UWIZ+1>G:RZ+ILNO+L-#"4Y480LHO36]U9:OL_OOOULO
MUD_X(@ZA//X(^*=H\S/!!J%@\<98D(7CFW$#H,[1T].:_3:OS*_X(I1Q6ND_
M%NWANUO,2Z3+(Z!U"2,ET&3# <C:,D=<CTK]-:X(6Y;H]JC;DO%63N_O=SQW
M]L5MG[*7Q>;)&/"NI'(_Z]WK^;MC\Y)YY[U_2'^V0,_LH?%\>OA34NO_ %[O
M7\WTB[=X8Y8' (Z5O[SAY&O4:S;B3C R2%'04^"5H9$D #;3G!&1^(J/KWZ4
MF3BE";A)-/835U8ORVC7,,MW"G[H, X7 ",<D#'IP?RJ &0QE#(VW^X2<&FK
M*T:@9(QSC_/X58_M&4AMQW$G))ZY^M>Q%86L^:?NOR6G_ ,;26FXDEL^$D\K
M9&_W<'(.,9K16V?3MJ74+0/(@*^:I!P<$/CZ?H:CCU#R=/8+!'E_E,K#+YSG
MC^[_ /7-0/?-=-']H=Y%10@^8DA1T S7T>%EAL$XRIRO)]UHOS.=\\]&M$07
M#LSODYYZD5"I=5W@,%SMW#I]*T;R%3'YZ.'C8X [CZU(EE8W&C7$CZF(+N-D
M>.S\MBD@9MK8;LRX!Q@Y!ZY&*\?,83IU%+FO?U=[FGM%&*NNMMF_R_X9=2K;
MZ@MN[_N5EW  %B<J>Y!&.?KGK6OIQ6^CNKNZU#[,8XRP5LNTSC&Q!Z9]>V*Y
MYT"R$*>.G7K6E8J'M+F/!9R RX]CS^E>EE#K5:LH/>S:]4KK_(SK4URW6CT_
MK4B0[Y=SG<N"S-C)'YTDFUXGE/E[5)4+D!B3SG'>I+V-88(XE4%_O,X/7V_#
MFH'@\N >8Y0OA@HY!'/)YXI8RE4I2<;:K5MVZ^I2:=F6#,(])+&.-Y)&*!F.
M2B]>!V/O[U6L[^Y2TN;*!U\FX :175?X<G@GH?IUZ4V=H2D;HY+DG>A3"KSP
M!R<_I50,%#+M!)[U\UCZCK--N_\ P#2-----=;_UZ#:_=3_@D7_R9YIW_89U
M#_T-:_"QG+!00!@8X&*_=+_@D5_R9[IW_8:U#_T-:\TZC[5K\5O^"QD\=M^U
MGH$PEGBN(_"UDR/#C*XNKH@CWS7[4U^*_P#P6>2W'[36@R&Y+79\,6H%N(_E
M5/M%U\Q;/4G@#'8\TU/D:=KF=2UK/J?&FOPR6\6H6L%LPNXA$TK2VZ1S+ 0"
MN[&/FW,,\9.1DFM31+Z>'P4=6UJ9I;>TN?LNE6CQ($DDP#,&(PQC"E2R C+,
M":S-/F'C7Q3HRWLCW$LBVUG<2R-C9"@5"S8!R!&!SU!4=>E:/QEU73]4UQ+?
MPW,LW@ZQ4Q:0!&T3119.X2!L%I"W5SRV%[  :PO"$<1:TK]-D[+5-W[V/EFG
M.I2P<XZOWI2MHK:63[R>BV?+S6V+'BCQ5+X@LM U*9FFL+>UC2:U0&-3<*S*
M5+C.PE0&!)Y"^N!7+P3IK<NIVUY;VL,\T9NH9RS%H2D;-Y:D$C:P/(8'!4<C
MFGQ7$E_X(BLI(Q.D%]^YD:+'D&53E?,R/O&,'!!'4\'K6\'W9TKQ '\ZYAN2
MC11R6<B=77:RMG(*E2RD=\UYKYGSRNV_7SO?[]VU]Z.JCAXT*-2--6<;VZ=;
MK_@Z>6JWJ:=;'5V@T^SAD^U380(9P$EEW<'D +A3CD^IR.E7I-,_X1OQ!<6T
MLOVAH?,BADM\!)F((!R<?)SSW[<=J;:REU=;KB+RU#Y#6ZJCQCCH0!DX'?BM
M'6M6B\2_9D=GFOWPPO)Y@H+$_/Y@/&2>=^>>_7C*?M.=)KW6G?\ X?M]W^7;
M/VO.DU[C3OUL^]^WEI\]+5/">K)I'B"TOKFSCO[1<P30W .QE="A&1RIP201
MR",CD5;\7VT-O*H>W:WO,9GAF#+)"VT;4^8Y; [X' 'O6GK6F>)+2.QAUO3+
MN/2-*O/(@M)4"0QF0B5D&.I8%3G)X(YQBO5O'O@^_L]'\+?9].34?%^J0P-:
M3R3QDP0.CE%8R-F5B@4"3A5\L\ D56'@L15]MS)12U:=U:^GJ];O\VD>)B<R
MHT,31J77OW6DE:RU3;V22=Y/IHES:7\\^%?PTBUK5!/XFM[NPT5X7$20+_I5
MY-TCCMXR"SL6XR!@<\BJ/Q(\8KJ<T6CZ;IO_  C>AZ7,PL--VGS@#C,MP_5Y
M3MY)''08%=3+KE[I&J:1?RQ:AK%_I9GDU74X9?+-P9 $,*2J-WEJ!][/.YL
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MYE=6;[N/?YM-(_>M?NCZ4M(OW1]*6O6/HPHHHH **** "BBB@ HHHH ****
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M^Y @63/(4#L/PYSVJ:Y:^UW44,<0FN+CA!;Q*A8#C[J\#@?UH3?,I7TU\O\
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MQ/3RV7<P.2<#D#&/?W_]@_P"OA;]J_X.ZM%J]IJD-]J5RB&R))C MI,>8#C
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M3O7\W@;:^< X/0C-,HL7MA+ITBQS[ [(L@"2*_##(SM)P<=CS4,K!WW*BHN
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MFW:4EK;2UGZZWNNR?9(_?]?NCZ4M(OW1]*6M#ZH**** "BBB@ HHHH ****
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MQ P<<G-8$:7?AO3;0+=26NIRG[9#]D8+)$A!4[V&'4D $+GH<]Z_2KQ?X)\
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MQ,,/&.+FI5-;M*RW=K)WZ'C?[9/_ ":?\8/^Q4U+_P!)WK^;L]37](G[9/\
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M(Y[X2VLF2#$BK\^WLQ(3OV/ YKVC_@FUIL]Q^UQX"N+I)"EO?R%7D9LAS;R
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6D-
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M;=>!_P!]4A_8+_:!\L ?";Q'N]1;+_\ %5Y2@KZ[(W/!UN]CIB.-T7&5(X<
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MMNLG==[[WT^7S1]'W/\ P4:_:0MYYXT^+-S,8I"@/]F68WC.-P_<?C5_3O\
M@IY^T%8D+=>/Y+Q5< C^S;3+ =3N$0X/I7(^ _V5=?U70(-7UG7+7PS%>DQQ
MVDH,ES,#U&!]S/3D^GK4WB3X(?#+P1J"K?\ C@ZM#Y165+<I$\4I7*[A\QP"
M#D?A7=2I4L0_9I_>N5.W:3LON9\U4XGRRI5>%A4E4DK_  1D]5OJER[^>YT<
MO_!2#]H^_AN)+3XESQPP<L6T^R#;2< \P_H*CT[_ (*'_M,:Q)Y5M\4+KS5Y
MPUA8C<,XX_<<US>HZ+\"?"?A*0/>:UK^O7('E^6?+CB ;E^@!#*> >1]:O\
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M_&*GL_\ @H]^T[J$HBM?B1J-S*>B0Z59.?R$%?.K36$7A]&0!]3DG;?N'"(
M,$?7)'X54T?6K[0+^*]T^YDM;F,[EDC/3_&N=N<HRY%JMK_UL8\\YPDX+57M
M?9_\ ^DI/^"DO[3$4[0O\3;Y)58J4;3;($$=L>139/\ @I1^TM$Y5_B=>HP.
M"K:;9 C_ ,@5\\:7H^I^*+Z[DM(6OKF-'O)E# ,47YG?GTZFJ%U=R7=RTTG+
M,V[!R0/SJE*\N7JMRHU+RY+JZW\NWWGTI_P\L_:4_P"BH7G_ (+;'_XQ0/\
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M/EBX8.BI8V:CK:[:2?9Z]^W<];_X>6?M*?\ 14+S_P %UC_\8H_X>6?M*?\
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M'FCJ3S*4.:&OH?T0(<JI]J=34^XOTIU6:!1110 4444 %%%% !1110 4444
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M<L(M)UVZMK.Y-S:+(5BG49$BYX./Z5;\-Z&GB,16,6K0:;=238<:C+Y-OMX
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MZYM;@94$?NF]*['Q^9I_V@[O6?#%M#XUAO->T":_\*ZUI<L=RA2*!XM2TB^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cgtx-20231231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "8 K@# 2(  A$! Q$!_\0
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MC=+0KT44&KM;4R"E7[P^M,R34D?WU^M0O>8S^@S_ ()Q_P#)GGP[_P"O-O\
MT,U],5\W?\$[H&M_V0OAZC#!%D?_ $(U](UA>^J&>9?M(:39:[\'-?T_4"JV
M=P(DD+=,>:M?EK^T/^S-X4\*Z8+[13%),PW'R\5^A/\ P4,UVY\-_LB^/-2L
MY#%<P1VS(X[?Z3&/ZU^07@?X_7>OKY&N79E0<8<U^?9]EV8SQ]/,,+5:IQ5I
M1[ZM_J>;7]I@ZCS"D[M)*WS;_4I^'-,2TW6]P-H)Q\U=!J/PST>*R.HQE#-C
M-<9\0?%EK+?A["0*F<Y6LBS^(DX@$,TQ*=,$UI'#8NLE6IR<;[H^IR'*(5Y?
M7L74NJOV7T-:-H]0N&MKC"QJ<<U-=^%]+AA/ENI)%<-XF\1H82]M)MD/I7,V
MGBV^\P+)*6'2O;HY?7J+GA+E78\;B?)'A,9[' 5OW6]EL:'B?0/W[&!2W/&T
M5R\VG7-L1YL#H#W(KUOPG<6UW+%)= %,\DUVGBW0=)\1Z5'#IB(UP/[OK6SS
M26$JQHU(W7?L&3X+$XE.%9.*75E']G7X0VGQ LI7N%!*@]17GOQJ\$)X.\6-
M9PKMBR1P*^T_V/?@UK%AIEQ-)"50@GI7BW[5_A@:?XT>.= '#5\1A,^>(XDK
M8>%7F@EL?G5/&YCA^*)X.M=T.CZ'D'PPT6"/4XI)\*O'6O9/%FB:+J%@H,D>
M<>M>+W[2Z5IJR0$JP'!%<=-XQU:1]K7+8STKZZKE]7,:RQ$:G+8_H'-JF'P>
M'AAJ*NI*[9W6O>&;>%76VPW^[7#IX8O3>Y:TD$6?O%>*]D^$/AJ[\62VZO$9
M%9AN9N]?5/CKX.Z3H?PYDN3:JMPL6XMCO7BXOB6&35XX2I[TI.Q\AQQF^ X7
MPF7SHP]I*JU=+IZGB/[,MY8^#[DRR.B.>2#7&_M3ZZ_B#Q7!<VW[Q4<'*5YY
M9S:O<^(+B#3C)A7( 0UV(MS:6Y_MH9FQ_'6RP4,-F/\ :,I<TVMNNI\7FF6X
M-9I'B'#6]HTER+<]2\'_ +1U]H?PU&E%]I$>W&>>E<M\,=!M?BUXL9-68;'?
M/SUXSX@NVBN&:'(M\]NE>@?!B\N[[5T73&83Y'W:SQ.54L%AJV(PJY)3UOV/
MT;#R_M[*JL*LN6K;W7U1]W^$OA7I'PZM5CTQ0%(ZJ.#6?XL\ Z1XB#F^*+GJ
M6KFM*^)R^#K)+?Q%.5<@ ;S7*_%+QM>:QHD][H\I\H*2"IK\5PV!Q]7&<\ZC
MO)_'T9_#&9Y)FN&SR5.I-Q;=N?HSM_A]^R_X-UG73Y1BE?/(4 FO*OVU/@%9
M^ K)9+2$*A&00*XK]E?X]:GX8^)P;6[QOLQDP0YX'->__MG_ !@\.^/M AAL
M9DE<)V.:^BC3SW*>(Z%&K4E4I-:OH?TKDG#V,RG"J6.K>TF]4^R/S*\HK,4
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M>"Q>%S2O*%#XH_%<_C[+LTPF=8F=.AK4C\5QUKXDMTD8/@_6N?UZ]BO+G=&
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M<@J:^<PV'J8ZA6C?EYUH^QT/'4DYT:*M;JC[=_:7\;Z%X(\,P_\ "*31I.R
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MS8O]T?E4RJ<ZT-Z4Y86=Y1U[,_GCN_V&/CN<[/A1XG/TL3_C6<?V%?C]D_\
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MC8O]T?E2YV%CP3]A7P7KGP^_9>\#Z#XCTJYT76+.U*7%E>)LEC.X\$=J]]I
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M]K;^C5MS\>I/^"8?[1NT[?AV,_\ 89L/_C]5/^'87[2NX_\ %NAC_L-:?_\
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M12"1KDML$(B*^9YF[C9MS7FG[,GQX\2?%#XS_%WPSJM_!?Z-X:O8HM.<:?\
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M:9]O#W2S1VS>7&[(LKKN1"X& Q7G!-'M%M<KZUAKV]I&_JNNQ^&R_P#!,/\
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ML5Z'X[_:"\;^$OVL?A;\+Y-(T:#P[XHM[JYFU!9GFNW,$!9E"858AO*\Y<D
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>cgtx-20231231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &! N@# 2(  A$! Q$!_\0
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MBPUNW>?3KVVOX4D:)I+659%5U.&4E21D'@CM0!<HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHKY:\??MQP?#7]I'2/AKKWA)K30=3O$T
M^'Q4=1'EB=HU;:T.SY1EU&2_<GM0!]2T5\R_M=?MH+^RW-H<<7A%_%(OITAN
M6%^+7[+O)$9YC;?G#<#&,5] WGBS2M&T:UU+6-0L](MYPF)+RX6--[ 84,Q
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ&EHH
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M_=:\&:VNO+,4D:6-L5W)*P/F-(7*K\W!8''ZF7F@Z;J-W'=75A:W%S%C9-+
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M<:0QK&BA$4!551@ #H *=0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU&;Q)8>'(=&BL=1M[>$Z:F$,T8$(PQ+1H-Q8DA1ZFO3?B3XAE\)?#SQ-K<)
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M/%.HWGCJ\MX;1?$X2VMKI8DEWJF!$8U4;G+80EMQ[XQXY_PQ%\0_^CI?B?\
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M)!+:RO#,'MYOD= "ZYV8R 0>.W-7+OXO>#K*[GMI==MQ/# ;ET17;]V%WDC
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M\5?$KPQ:Z=K?A/\ L2V2Y$JW&R5<L 1M^88[U]E?!3_DD_A3_L'Q?RKOX?\
MJO\ :E?ZHVX<B^*]]_/4]+A?ZF\YQ'U%R=/DC\5[WOK\6IVU%%%?HY^M!111
M0 4444 %%%% !1110!\;?\%6_P#DU2[_ .PM9?\ HX5]3?#C_DGGA?\ [!5K
M_P"B5KY9_P""K?\ R:I=_P#86LO_ $<*^IOAQ_R3SPO_ -@JU_\ 1*T =$3@
M9/2O)-7_ &L_A%H.J76G7_C[1;6]M9&AF@DNE#1N#@J1ZBO6V7<I!Z&OBCX[
M?\$[_A/-H?C/QE-%JKZQ.)]09_M(VB4Y;@;>F:^@R:AEF(K.GF4YQ3LH\B3U
M;ZW,JCFE>"/</^&RO@MC_DHVA?\ @6M>I>%O%>D^-=#M=8T._@U/3+I=\-U;
MN&1QZ@BORD_8%_8V^'G[0?A/Q%?>*X;Z2YL[KR8C;3A %R?8\U^HOPM^&FD?
M"+P/IGA30A*-,T^/RX?/8,^,YY( R:]CB7*\JRBK+"82I.56+L^9*UK7T:^1
MG1G.HN:2T.LHHHKX<Z0HHHH **** "BBB@!K.J#+,%'J3BF_:(O^>B?]]"O"
M_P!LRYEM?A&9(97A<7D7S1L5/7VKX+_X2#4_^@C=_P#?]O\ &OB,XXF64XGZ
MLZ7-HG>]M_DS\YS[C!9)C/JCH<^B=^:V]_)GZ9_&65'^&FOA74G[,_1AZ5Y;
M^Q1(B?#.XW2#_7]"PXZU\.2ZUJ$\922^N70]5:9B#^M1VNIWEDA2WNIX%/)6
M.0J/T-?&U.*HSQ\,;['X8M6YN_G8^!J\:QJ9G3S#ZO\ !%QMS;WZWM^A^MWV
MB+_GHG_?0IRR(^=K!L>AS7Y*_P#"0:G_ -!&[_[_ +?XU];_ +"=]<WI\3FX
MN)9R!%CS'+8Z^M?5Y7Q6LRQ<,*J/+S7UYK[*_8^VR?C:.;8ZG@UA^7FOKS7V
M3>UEV/K6BBBOOC]."BO(_CCI_P 2[M[%O 5S%"H&)UDEV9_2OF_5_B3\;=$\
M<VWA&YU4?VW<%1'%'(&4[NGS8KYG'9Y' 5/9U*,VKI)I:-OL[GQ^9<1PRRJZ
M=7#U&KI*22LV]DG<^[**\,^"^F_%RU\2O)XXNHY=+\LA5CF#G=VXQ7N=>S@\
M2\72]HZ<H>4E9GOX#&/'4?:NG*GK:TE9A1117:>B%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'S/^T+^RM\"-=OO%OQ8^+>BIJL=
MK8QRW-W=74T2VMO!'C:BQ.NXMUP<DL0!V%?GEKOQ@_8BDM=0MM,_9_\ &$UP
M=T$$J7$D1+'A6!-RVT\@C*GMD5^O/Q5\$6OQ&^'FN^'KN2WA2\MSY<]W L\4
M$R$/%*\;?*X2148JW!VX/%?&'Q-^#GQ)UWX932#]H#P38^*[V-XO$MZD$$%A
M<VL;AX)HT4$QSQ*&!D4#<NT'[@- 'W3X;CBB\/:8D"S)"MK$$6X&) NP8#?[
M6.OO6E5#07:31-/=[I;UFMXR;E.DIVCYQ]>OXU?H **** "BBB@ KE/BS_R2
M[Q?_ -@B[_\ 1+UU=<I\6?\ DEWB_P#[!%W_ .B7H ^3?^"9G_)@MK_OZI_Z
M$U?CM?\ _'[/_OM_,U^Q/_!,S_DP6U_W]4_]":OQVO\ _C]G_P!]OYFOZ$\*
M?@QGK#_VX\K'?9*]%%%?OAY(5[Q^PM_R=I\,_P#L*I_Z"U>#U[Q^PM_R=I\,
M_P#L*I_Z"U>/G/\ R+,3_P!>Y_\ I+-*?QQ]3]]J***_A<^G"BBB@ HHHH *
MP?'O_(D:_P#]>,W_ * :WJP?'O\ R)&O_P#7C-_Z :QK_P *7H_R.?$_P)^C
M_(_*-_OFDI7^^:2OY:/XQ6P4444#/7OV4?\ DN'A_P#WG_\ 0&K]'!TK\X_V
M4?\ DN'A_P#WG_\ 0&K]'!TK]JX*_P!PG_C?Y1/Z$\//^194_P ;_P#28GQ?
M\9O$%CX6_:XTC5-2N/LMC:_9I)9=I;:H!R<#FO=/^&K/AC_T,8_\!Y?_ (FO
M"_C/X>L?%7[6^DZ5J4!N;&Z^S1RQ!BNY2#D9%>Y?\,H?#+_H7C_X$R_XUE@/
M[2^LXOZCR<OM'?FYKW^1AEG]K_6\=_9WL^7VLK\_->^FUN@[_AJWX8_]#&/_
M  'E_P#B:/\ AJWX8_\ 0QC_ ,!Y?_B:;_PRA\,O^A?/_@3+_C1_PRA\,O\
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M+=5##)4^X.0?<&OF?PVUW\$M6^.FEZK937.HZJEMJ6C1PJ=NIK]BCM1'$?\
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M-4N_^PM9?^CA4?[=?_)@P_Z\-,_E'4G_  5;_P"35+O_ +"UE_Z.%1_MU_\
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M)]8<+XAIM[6/EN(%D\<2J>3PJ1C&ZE[1INZ?2W2PM8/CW_D2-?\ ^O&;_P!
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M^K_^ Z__ !5>)?M*?';P[\78- @T2.]22UG+R?:HP@P>.,$U]4_\*O\ A?\
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MTUO!5]*UI;I"7%Z@#%1C/W:T_P#AYSHO_0C7_P#X')_\37?#.,"H).IT[/\
MR/D<5X;\5U,14G'!.S;?Q0[_ .(^VZP?'O\ R)&O_P#7C-_Z :H_"OQ]'\4/
MA_HOBB*S>PCU*'SEMI'#E.2,9'7I5[Q[_P B1K__ %XS?^@&O5J3C4H.<=FO
MT/R?,:%3"JMAZRM.',FNS5TU]Y^4;_?-)2O]\TE?RZ?Q4M@HHHH&>O?LH_\
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M_P"3!A_UX:9_*.I/^"K?_)JEW_V%K+_T<*C_ &Z_^3!A_P!>&F?RCKZ/AO\
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M^->'[+)?^@"K_P" R_\ DCYSV/#W_0LK?^ 3_P#DB_\ \,(6?_0Y7G_@(O\
M\57DWQZ_9^@^#,6B7$6MS:J;N<H5EA";<<\8)KTK_A,?VEO^@(?_  $@_P :
M\M^..M?%+58M%7X@6'V.W6<FV/DQIEN_W3Z5YF94\KCA9O#X2I">EFXR26JW
MNV>-F]+)HX*H\+@:M.>EI2C)):K=N37X'WGX,_Y%#1/^O*'_ - %;-8W@S_D
M4-$_Z\H?_0!6S7[!1_AQ]$?O5#^##T7Y!1116QN%%%% !1110 4444 %%%%
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M8+:_[^J?^A-7X[7_ /Q^S_[[?S-?L3_P3,_Y,%M?]_5/_0FK\=K_ /X_9_\
M?;^9K^A/"GX,9ZP_]N/*QWV2O1117[X>2%>\?L+?\G:?#/\ ["J?^@M7@]>\
M?L+?\G:?#/\ ["J?^@M7CYS_ ,BS$_\ 7N?_ *2S2G\<?4_?:OS._P""C?\
MR6ZP_P"P3%_Z&]?IC7YG?\%&_P#DMUA_V"8O_0WK_/+B#_<GZH_I/P@_Y*>/
M^"?Z'RE1117YB?W.%*.M)2CK0!^O_P"R5_R;MX'_ .O(_P#H;5Z!X]_Y$C7_
M /KQF_\ 0#7G_P"R5_R;MX'_ .O(_P#H;5Z!X]_Y$C7_ /KQF_\ 0#7[#2_W
M&/\ @_0_S%XK_P"1GF'_ %\J_P#I4C\HW^^:2E?[YI*_F8_A!;!1110,]>_9
M1_Y+AX?_ -Y__0&K]'!TK\X_V4?^2X>'_P#>?_T!J_1P=*_:N"O]PG_C?Y1/
MZ$\//^194_QO_P!)B?%?QN\2V/@_]K+2]8U)Y([*T%M+*T2[F"@'.!WKV3_A
MLCX;?\_FH?\ @&U>0_&'1K'Q!^UYH^GZE;QW=C<&V26&4_*ZD'(-?0?_  SU
M\,/^A5TW_OIO_BJQP$<R>)Q?U*4%'VCOS)WO\CGRR.;RQF._LZ=-1]K*_.I-
MWTVMT.:_X;(^&W_/YJ'_ (!M_C1_PV1\-O\ G\U#_P  V_QKI?\ AGKX8?\
M0JZ;_P!]-_\ %4?\,]?##_H5=-_[Z;_XJO;Y,_\ ^?E+[I'T/L^)_P#G[0^Z
M9\\?M._'WPC\4/!-GIFA7-U+=1WBRLLUN8QM"D=3]:^G?@I_R2?PI_V#XOY5
M\\_M:?"OP=X*\ V-[X?T.TTZZ>]6-I8"=Q7:>.2:^AO@I_R2?PI_V#XOY5P9
M4L4LYKK%N+GR1^&]M_,\W)5C%G^)6.<74]G'X;VM?3?4[:BBBONS]*"BBB@
MHHHH **** "BBB@#XV_X*M_\FJ7?_86LO_1PJ/\ ;K_Y,&'_ %X:9_*.I/\
M@JW_ ,FJ7?\ V%K+_P!'"H_VZ_\ DP8?]>&F?RCKZ/AO_D<X3_KY#\T95?X<
MO0_%\]:2E/6DK^W3YD**** /T3_X(X_\E#\=?]@R/_T8*_5NORD_X(X_\E#\
M=?\ 8,C_ /1@K]6Z_D;Q!_Y*"MZ1_P#24>_A/X2,N]\4:-IMPUO=ZM8VLZC)
MBGN41@/H3FH/^$W\._\ 0?TO_P #(_\ XJOS$_;RX_:-UG''^C0?^@U\\9/J
M:_!,3Q#*A6G2]E?E;6__  #^I<E\'J.;9;A\>\:XNK",K<B=KJ]K\VI]P?M/
MZQI][^UMX N;>_M9K9#;[YHYT9%_>=V!P/QK[B_X3;PZ.NO:8/\ M\C_ /BJ
M_#W-&3ZUY.'SV5"I4FJ=^=WWV_ _0<W\*J6:X3!866,<?J\'"_(GS7=[_%I^
M)^X7_";^'?\ H/Z7_P"!L?\ \56O!/'<PI+#(LL3C<KHP*L/4$=:_"="=XY[
MU^T7P+&/@]X. _Z!D'_H(KZC*\U>8SE%PY;+O<_">.N *?!V'H5X8EU?:2:L
MX\MK*_=GGG[:?_)'S_U^1?SKX!K[^_;3_P"2/G_K\B_G7P#7Y?QC_P C/_MU
M?J?P9Q[_ ,CC_MR/ZA1117PQ^<A7U_\ L$]/%'TB_K7R!7U_^P3T\4?2+^M?
M5\+_ /(VH_/_ -)9]KP;_P CRA_V]_Z2SZ\KX9\8^/+'X;?M7ZAKNHPSSVMN
M_P R6X!<Y0#C) K[FKXNN[72[O\ ;&NXM8CM);$N=ZWH4QG]WWW<5^F\2J;A
MAE3=I>TC9O9/4_8.+U4<,(J4E&7M8V;V3L[-GH'_  W/X-_Z!&L?]\1__%4?
M\-S^#?\ H$:Q_P!\1_\ Q5>H?\(S\+O^?#PM_P!\V]'_  C/PN_Y\/"W_?-O
M5^SSC_H+I_\ @/\ P2_99]_T&TO_  #_ ()Y?_PW/X-_Z!&L?]\1_P#Q5>-?
MM%_'W0_C%!H4&DV5[:O:3EW-TJ@$'CC!-?6O_",_"[_GP\+?]\V]?.O[7VE^
M%-/LO#1\.V^D0NURWF'3A&"1COLKP\ZAF:P%1U\1"4=+I1LWJO,^<XAIYO'+
M*KQ.*ISAI=*-F]5L[GUEX,_Y%#1/^O*'_P! %;-8W@S_ )%#1/\ KRA_] %;
M-?HU'^''T1^LT/X,/1?D%%%%;&X4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!P?QU\*ZOXW^$7BK0]"V/JE[9-%%;RS&%+H9!>W:1>8UE4
M-$7'*AR1TK\Y)T\&>,-8U'X>Z)^P_J&A^/9+8P)=2-]G@T^9@%6X-TJC:B,P
M82*<X&17ZKUYIXX_:3^%WPU\9Z?X4\4>.=&T3Q%?%1#I]Y<A7^8@+O[1@Y&"
MY&>U '>:%:3V&B6%M<OYES#;QQRON+;F"@$Y/)Y!Y-7Z0,& (((/<4M !24M
M(>E 'QK\3_"OCOX+_&V;XD:UI/A+XD_#_6M;M(;HW.C)'K'AZ)BD,$D4[;M\
M4;$,?0DD!=QPO@'59?'7QC_:^.N6*8L;:ST>WCN4W[;1;*8X&X?<<DN5'RDM
MFO;X?A?XU\1R2:7XY\7:;X@\+K??;$M[+1S9W,Z)('A@F?S64HK*I)15+%1R
M 2#F>./@-KUYXT\8:]X-\26'AX>,],ATW78[[3&O&+Q*\<=S"1*@6012,FU@
M4.U3C@Y ,_\ 8-\5ZEXP_9"^&.IZNKB]_LH6S-)N+2)"[11N2W)+(BG/?.1Q
M7D/Q:_X*;_!5-%\9>%6F\1#5$@O-,.-'?R_."O&<-GIN[U]?> _!FF_#KP5H
M7A?2(S%I>CV4-A;(QR1'&@5<GUP*P?BOX=TI?AKXOF&F6?F_V5=MO^SIDGR7
MYSB@#Y>_X)F_\F"VO^_JG_H35^.U_P#\?L_^^W\S7[$_\$S/^3!;7_?U3_T)
MJ_':_P#^/V?_ 'V_F:_H3PI^#&>L/_;CRL=]DKT445^^'DA7O'["W_)VGPS_
M .PJG_H+5X/7O'["W_)VGPS_ .PJG_H+5X^<_P#(LQ/_ %[G_P"DLTI_''U/
MWVK\SO\ @HW_ ,ENL/\ L$Q?^AO7Z8U^9W_!1O\ Y+=8?]@F+_T-Z_SRX@_W
M)^J/Z3\(/^2GC_@G^A\I4445^8G]SA2CK24HZT ?K_\ LE?\F[>!_P#KR/\
MZ&U>@>/?^1(U_P#Z\9O_ $ UY_\ LE?\F[>!_P#KR/\ Z&U>@>/?^1(U_P#Z
M\9O_ $ U^PTO]QC_ (/T/\Q>*_\ D9YA_P!?*O\ Z5(_*-_OFDI7^^:2OYF/
MX06P4444#/7OV4?^2X>'_P#>?_T!J_1P=*_./]E'_DN'A_\ WG_] :OT<'2O
MVK@K_<)_XW^43^A/#S_D65/\;_\ 28GP]^T-X6D\:_M06>BQ7GV"2\2WB6Y
M)\LD'G KK#^Q'K6?^1]D_P"_#_\ Q=<G^T/J>L:/^T_9WF@6OVW5X8[=K:W\
MO?O?!P-O>NG/QE_:!S_R)7_E-;_XJO"C#+I8S%?7*,YOVCMRJ5K?)H^9C#*9
M8_&_VA0G4E[25G!2:MY\K6I+_P ,1ZU_T/LG_?A__BZ/^&(]:_Z'V3_OP_\
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M&?\ )'O!_P#V#(/_ $ 5]GPU_%J>B_,_FGQO_P!PP7^.7_I)YY^VG_R1\_\
M7Y%_.O@&OO[]M/\ Y(^?^OR+^=? -?&\8_\ (S_[=7ZG^6?'O_(X_P"W(_J%
M%%%?#'YR%?7_ .P3T\4?2+^M?(%?7_[!/3Q1](OZU]7PO_R-J/S_ /26?:\&
M_P#(\H?]O?\ I+/KROA3QUX MOB9^U5J6@W5W+90W$G,T*@L,(#WK[KKX/\
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MZX[]H>]UO3OVG[.X\.6_VK6HTMVM8?+#[GP<#'>NI_X6/^TA_P!"Q_Y3E_\
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M4 %%%% !1110 4444 ?&W_!5O_DU2[_["UE_Z.%1_MU_\F##_KPTS^4=2?\
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M1_8W[37_ #_?^1K;_"O&]EEG_0LJ?^ O_P"2/!]CD_\ T)ZO_@#_ /DCH_\
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M_86_Y.T^&?\ V%4_]!:O!Z]X_86_Y.T^&?\ V%4_]!:O'SG_ )%F)_Z]S_\
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MQASNGA/9SY9>UC9O5)V>MO(ZO_AO+2/^A3OO_ E/\*7_ (;RT?\ Z%.__P#
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MX4\LGC\:\=A*E:7M)6<(R:2[.S6I?_X8-T[_ *&^\_\  1?_ (JC_A@W3O\
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MMU_\F##_ *\-,_E'7T?#?_(YPG_7R'YHRJ_PY>A^+YZTE*>M)7]NGS(4444
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M_@F9_P F"VO^_JG_ *$U?CM?_P#'[/\ [[?S-?L3_P $S/\ DP6U_P!_5/\
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MX7?\^?A;\H*/^$=^%W_/GX6_*"O9]GG'_073_P# ?^">_P"RS[_H.I?^ ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^%L^%?\ H*I_WPW^%?N;_P ,^?##_HGGA?\ \%$'_P 31_PSY\,/^B>>%_\
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M_P"PH_X=$? K_GKXK_\ !Q_]A7A_ZC/_ *"/_)?_ +8^<_XAN_\ H+_\D_\
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M 4444 %%%% !1110 4444 %%%% !1110 RBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cgtx-20231231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '= LL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*V7\H(HZ /)%_:I^*JY)U'PO(<< Z#,HS[G[8:WM+_;,\;V3K_:GA+0M5CV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$X%
M %?4=1MM)L;B]O)X[6UMXVEEFE8*B(HR6)/0 5R?A>PN?%.JIXIU>W\E4##1
M[*12&MH6&#,X/2:0=NJ(0O!+YK*X^)^M(T<GF>$=-G(8;?DU*Z1L8S_%#$P^
MCR+Z)\W>@8&* %I.E+7AO[37QTE^&VEP>'/#\@/C'6(7:";:'73H =K7<BGK
M@G;&I^^_^RKD ' _&[]I&Z\*_$7Q3X<\%1PS>)!;V5C>:E,GF6^E@++*7(Z2
MSD7"A(LX&W<^%VJ_C'PO^%?B;XQ:O?/X=WM:SW)DU;QEK&Z:.2;E6VG(-U,N
M,;5*QQX"EEP$K;_9^^ 7_"YI[B:\DO(O MK<2)>7QG;[5KEUN)G03?>*[L^;
M,#EFRB$88C[OT;1K'P]I=IINF6D%AI]I$L%O:VT8CBAC485%4<  #  H \X^
M%G[-_@[X6S)J$%H^M>(\ -KNK[9KH<8(BX"P+R?EB51ZYQ7J84#H*6B@ HHH
MH **** #K7*>/_A;X5^*&E#3_$VBVNJPH=T4DB[9H&_O12KAXV]T(-=710!\
M-?&3]EG7O >GWEQI2S^._![(WVFTGC$FI6L>"3E5 %T@QV E'!Q(>:E_9Q_:
M.'PZN!I7BG5#J7@W5IUFL_$ES,9'T^5@J!+ESRT#;0!,QW(Q(D)'S+]OD9KY
M:_:4_9G>[EO_ !IX'TY)[Z4-)K7AR)!Y>J(1\\L2GY1<8SD?=E'RM\VUJ /J
M56#J"#D'O0RA@01D'M7R'^R/\=5TZ;3?A_K%VUQI-S'CPWJ4\A)  )^P2%N=
MR@'R\\E5:,_-&-WU[UH X+P\Q^'VO1^&YW*Z'>LQT:1B2(7P6>T)/0 9:/\
MV0R_P#/>UF^(M!MO$NCW&G71D6*8#$D+;9(V!RKHW\+*P# ]B!6+X0\1W+7M
MQX=UI\Z[8QA_.V;$OH<X%Q&/KPZC[C<="I(!UE%%% !1110 4444 %%%% !1
M110 4444 %%%<9\6_BQX?^"_@J\\3>([EXK2$K%#;P(9+B\G8XC@@C'+RNV
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ME\P.-/TA3V/G69Q^=]5<I?*?LG_PVK\"?^BK^%?_  8I1_PVK\"?^BK^%?\
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M40HXV4U.I5MY)%.5!*R5SZNC^+WA2#PSI>MZIK=CH=OJ%A'J,<6IW4<$HB=
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MX?\ ["GP6^+.D/>:/XD\3/) RI>Z;?RK'=64I&?+FB*Y1L=.S#E2PYKB[O\
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M\379;P2Y6&RO9S\VCL3A8Y&/_+L2<!CS$< _)]S[55@Z@@@@^E?2G".HHHH
M**** "BBB@ HHI"0!DT ([K&A9B%4#)). *^5KF:;]MCQK=:?;W#I\!M NC#
M>2P,5_X2V^B;YH%8=;*)@-Q'$K# X&:L?$3Q+J7[57CS4/A;X0O9[3X<Z1-Y
M'C?Q+8R;#=/U.D6L@_B8?ZYU/R*=N<G%?2/AOPWIGA#0;#1=%L8-,TFPA6WM
M;.U0)'#&HPJJHZ "@"Y:6D-C;16UM$D%O$@2.*-0JHH& H X  & !4U%% !7
MG'QN^*5W\-=!L8]'L(M4\2:Q<&RTVVN9#' K[&D>:8CYO+C1&<A?F; 4<L#7
MH]>$?M1Z1<6,7AGQI%!-<V6@SSQZDL*%S#9SQA7N-H!.(W2)F(Y""0U4;-JX
MU:^IY'YUNGB<ZOXH\2)K?BV:/R5N[UTA\B)B#Y-O #MAC)5>!EFVC<S8&*^H
M^)?%/P&T'5M?^'WDSV,"-=W?A.]#-93*"7E>V"LIMY<%F(4^6YZKGFN2U_X2
M7/B36KC5;'5+.6POV%RLA)?*L <J5RK+C&"#R*Z+XA^,+'P)X0EL_M"SZH]B
MT=M XW,5"%3<2@9VPI@L[G@ $#+%5/IU*=-0LF=LX04=&='\7=6^/.N? +Q3
M?Z_/\/M/T?4=+'DQZ1#>7%TRSA56,F5UC#?.!N&X9Z URO@K]F3XB?&K]GCP
MCINI_%/3TTNP@7[%I$/AP11Q2PEX0L\BSEI2I5QN&T9YVG&*WX=7UGQOX7\+
MZ#?Q#1_!^BV]F+/29U'V_43;JHAFNQG;$N4200)D@@;WX*#4\.>)/$OPBOKN
M_P##*_VUH5Q+)=WWA>=PI9VY>2SE/^JD8Y8QMF-V)YC+%CYTJ#E#5''*ESQ:
M?4^7OBW\%/BG\.(+;0-?TRUO--G>**UU"TN1]GO7#9%L)6"E'(& L@0MGY23
MQ7?7'[4/@+PAI5OI4EE>^&]91%2#PM?6#V<D / ))7RUA!!!ER<@9P:^K_AG
M\>OA]^U/X:U?1(+2]ADFLM]WH'B&R:UN)+63*B54/^LC+97>A(##&0<5\NZ#
MX-;Q9^RAXL\=2".Z\8^%/$(O[:^O%5S/_9:Q1>6Q8'*R(DW!R-TA8@G.<L/3
MCA[JGU,:-*.'35/J9GP[\'VWQC\/^)/$>O:L-:MM9U";^STLP5L[1(D6".:*
M-Q\TGR$K)*NX#D*F]A6C\1/C#K7AG7'L-2\=:O(R@ R6XL].YVY8*!"^>""3
MP!5[X9:O=P^'[WQA9:7;3^$/$=])JHTWPW92&7P]-*%\RWEA WR@D"1G1 P9
MV(0HRM5G4?%OA4^(?^$AT7QIHNEZV;![*6.ZMDNC-"75MCPL5D4@KC"X8@X(
MZ8RE+"8NFY\D:DXW5I::WUO=.WW'K4[T[<VES<^%,-[X]\9Z# /B)XON?#^N
M:?.]O+;ZA9L\%W"0[*S+!@JT;-QC@QC^_6IXSL?$7AO]HGPKX'TKXB:W;Z'>
M6R_;KV]-I<S)<RK<&W0;H5"[C!T[YXK@?#.M2:WXM%RGPKU2VOHIVMX?%W@F
MTGT:5(RJ?O6BG\LF([B,!I=WEDE,;<]CXA^$=]:+K#:AXOT[4X=9D^U7@\<V
M*M-(P $9\V*6$G8  N% 7 V@'D_.RQ>6*HZ>(HQ@_2,E]\;_ )(MTZTGS0D[
M?/\ 4ZKXT:'X_P#AL/#]U_PG46H^'KRY-E?SZIH=LR6\K@?9R^TH CN#&2>C
M.G09KS+4K[XAKXB73H_"/@&[MBX_TZYT&0+MR/F;$WRD>F,^F:WO"OQ0O_"_
MA^_\):_\7/AOXFT^=C#'I^O)+<O%"PQ]G9WN]TR]<>9N;!QN( KG+&\M? ZW
M%O%\7O -KILA465AJ(ED6SZY2*1KS>R'C:C%MH& <<#6$LEVE3^Z,U^200==
M?%K\U_F>U_#WQ2_C3PA8:M+:K93R[XIK='WK')'(T;A6P,KE#C('&.*X7XJ^
M%=:U>TU+1;6_\+Q:/JNI6NJSKK6I26=PKPQA"B;8W#HVR,Y.-N&&#N!'7_"G
MPR/"/@'2]._ME/$,F)+F;58D5([J661I'D15)"J6<X4$X&!DUX=\0O$5GIGC
M?Q8UQHVG:[=7&H"!)M3MTG6&".TMQY2[@2/WDDIP,#YCUKY_)<//$9C.&#GR
MI7LVKZ771_([:JYJ<5-79[?J/QF\0>#?@3>:/KWAS6=,UJS\.-;0:[I&W4;:
M:X2V*K*#$#(FYE!!:/ SR0!FN8\&SZ7+X-TE]!FBNM)BM(HK9X'#*%5!A21T
M;U!YR3GFN,^'EDNI:/-J/A>XNO!6HQR[7BTR0R64K@ @M;29C8$8!("L.S8K
M0L_#VJZO\.8?B1JGPVBU6:>P>\NK[P-J[:;>2[,B42PF2/>05<C$DF[&>"0*
M^X]IC<!*U:FJB[QT?S3?Y,\WDIQ>]GY_YG">'?B-JL'BR.?5M5\C3Y)BET+I
MPD$*\YZX"8_/CO5[PVWAJ?Q1XXU+3_%?CZVU*_O(+C2O#/@_4[C2Q=.;9#+>
M3(^U! [%1Y\@",48*7/%=Q\(O ,'Q2U"ZU[PIX LK*XLI8X6\1>,]6;52CF-
M)/\ 1T227>0LB$_/$,G&[(-4["S\07^B^)KZ75Y=1\92WESI\]S*JPK$+:YE
M2.&.,<1C8Q<9).9<ECQCLAB:N.JJ+H^S@N[5_N5_Q8ZJIU&DGJ>3>)?@!XNT
M60>,H]>D\9^)T\RXO+2\B =FD.Z1;=UV[NWWU#/MX*\+7/>'O@O\2/V@?#T/
MC3P6]F\VD7[0I9V6HQV]W!-"5=2Z3(1\QP5!(/'.*]Y^%^G>*+&:].NFY6V9
M1Y<=U*';?GDCDX&*-(^'OBJ#X^6UY\+?$,'A+6M3TNZO=8@NK4W&GZAY3QK&
M9X@PVL3*1YB_-GG!Y!>)P--3]I%[>9Y5?!4_:>T6_K^)\\6UMXL>_MKW7/"O
MCR^UB6_2RE32]=MC<B^.,0M;2P J_?!9@1\V2OS5[1X%^%'QEU#7'UO4_"?Q
M'M[^QED.CV]YXITBVCM@5*-*\PCE9I'5B,"/:@)P23FNK^'-KXXC_;A$7Q&L
MM(AUB;3EU"V_L-G>P*K;3PAXS(!(7P2K%QD=!QBOHGX[_%'5?!*:1H/AF*V;
MQ+K1E,5Q> M#8V\87S;ED&#(5+HJID;GD4$@9-5SSFE&[-KRDDKL^)?C!I/Q
M0E\?>%5\:?\ "0Z#9Z&DFOM-%XKM-7N/)BFA5VC*64/E,H8G!#!B!C[IK[3L
M?@O/JEG!>6?Q>\>75K<(LL,\&IV;QR(PRK*PML%2"""."*\,=M,\(W%SJFN:
MW/?ZUJ1 NM6U67?<7.TDJH"@*D:[CA$4(N3QDDF[X4\8R_!%X=;T.\:7P++*
MLFJ:(I\VW@A8X>ZM!UB*9WM&OR,H;"A^3K*C)1N:.FTKGMP^!&H Y_X6M\0#
M['4+7_Y%K&^)'P5UWXG?%+PG->:U?:7X5\,Z;//;7FGWB+>SZG)MA#LK1LFU
M8#-\VT'=+QCFO;U<$9R/SKS+XE?%'Q#X8\<^'?"WAKP[IFM7^K65W?--JNKM
M810I T*D K!*6+&8=AC!KF,3YS3]F[XC>"](T?1]-TN74;;PW<:I9:'KFB>)
M_P"S=82PEDCGMHYR\9@E@W;TDA:,@>5$R@\J;VH_LZ_$_5+6;3-8@T;6'OT\
M)W=[J<5PD$'GZ==*UU$+;9@*4RRD84XQM7.!Z[X2_:GT-_ ^LZ[X\@MO ]SH
M^O2>';FU2]_M*.:Z5$=1;O$FZ;<D@.T(&7:X(&W-5/$7[9?@#3]6T[3-'U.V
MUNYU3P_>:]8W*2.EFZ0<>7),(V$9)$F20=GE,& .T$ XCQ=\"?'DS_$KP?I^
ME:?J6A^.O$4&MGQ3<:B(YM.A*VZRQF H7:2(6V864E<R#.W;S?\ #WPL\2Z)
M;W/A#Q1X6\*-X!L]6UC6+KQ7?7@DGEM[DSN"D6T-#<?Z0R22E@-B-C._ ]#M
M/VK?AI'J.C:-J?BO3+#Q%?QVFZP2229(9+B.-XE:41A5#^8H1GVA\\<Y UU_
M:$^'M_XVN?!=OXDL[OQ#&\ML;(+(4>:--\D EV^4TBKR8PQ8<Y'!H ^8?@I\
M*?&.N? 74/$=H;?Q/XB?6-)M=%:2[-I%=Z+H]\@MF5V#^69DCEESR&+J>^:T
M]"_96\:P>/XK6_@>]T"V\977BV*^NM?/V(>9*\\8%E&BR&<-)Y;%I-A4%LG(
M0?0WPW^.&C^*?@5I'Q*UE;?PGH]S8&^G2YN0T=H@9EP7VKG[O8#K@"J-A^UC
M\)]3\/ZIK-OXTLGLM,DMX+L-%,LT<LY80Q>24$AD?:V$"ECCI0!YO^SG\)?B
M-X$\;Z<-0LO[ \(V.EW%M/I=UK:ZQ MRSQB,::SIY]M;!8V)CDD(Y5=N5W'Z
MDKRF^_:E^%VF>&M-UZY\7V<6G:C)-!:DQ3&666(XEB$(3S/,7NA4-CG&*35O
MVJOA/H>C>']5O/'6DQZ?KUN;RPG5V<20 X:5MJDQHI^5F?:%;@D'B@#U>BO'
M+#]HRPU?QE!I%A:VDFFW%W80V^I37YB%Q%=6<UTLD:&/+$+$/D)&0Q.1MP=#
M2?VH/A?K8UXV?C&PE31+2:_O9")%06T1*RSQLR 31H5(+Q%P..>1D ]3HKA?
MAK\</ _Q>DU&/PCXBMM:DT_RS<)"KH45\[' =5W(VUL.N5.#@U4;]H7X=K\1
M#X&/BJQ'B82_9S9_/M$VPOY)EV^6)=@+>7NWXYQ0!Z+17A?B/]L+X?P^#?&.
ML>%-8LO%VH^&["34)=,MYGA-Q$C["\<C)AX]Q"^8F]02!GD4NF_M;^#[6'Q/
M+XJG3PS_ &3XDN_#MO%F2\EO/L\,4SSB.*,LJA9?FX(7 RW(H ]SHK/T#7]-
M\5:+8ZQH]];ZEI=]"MQ;7EK()(IHV&596'!!%:% !1110 4444 %%%% !111
M0 445Q7Q@^)]A\(_ E_X@O8FNY4VP6=BC;7O+ISMBA4]BS8R?X0&8\"@#S']
MJ'X\7'@JVB\'>%KE$\5ZE%YES=@@G2;,Y'GX_P">KD%8@>,AG.0A!^2-)T*Z
MN[W2O"_AJV7^T[]VCMA(I>.!1\TUS,<Y*(&+L2<NS*N=STZ_U2Y>35=?\0WX
MN]3NW>_U/4&'#,%YVCM&B@(B]D51US7T)^SQ\-9O"^AS>)=9MS%XDUV-&:&0
M?-8V8^:&U'&=W/F2>LC$=$%>;C\6L)2YE\3V_KR-Z-/VDK=#NO /@?3/AKX4
MMM'T]I'BAW37%Y<E?-N9FYDGE88&YL9/8  # 45XU\0/VT_#&C:E_8G@G3[G
MX@Z_(=D4>F;OLQ;_ &756>;'_3%&''WAU'F_[6'Q!\4_&#Q;HOPG\!WD5IIV
MJ:E_9MW>+EWOI5;$R@#@6\!SO9N)'5EQMC8G["^%?P?\*_!SP_!I?AC2X+1E
MA2.XU#RQ]JO650#)-*?F8L1G!.!V KYS#8#VR]M7>_\ 6IZ4I\FB1\TV_@;]
MICXVG?J^M6WPJT.7G[/;9BN=O.!LB9ICT_CFCR#T;I7??#S]A'X;^$+A;_78
M[SQSJQ(9YM:?]PQ'3,*8#C_KH7Z9&#7T8!BEKW*=&G25H*Q@Y-D%G96^G6D-
MK:P16MK"NR*"",1QQKZ*J@!1[ 5/116Q)YY+X)UOP->S7O@>:WGTR5S-/X4U
M&4Q6N\Y+-9S $VK,3DH5:)CD[8R2U7M$^+FA:AJ4>DZH;CPIX@<<:1X@06LS
MG'/E/DQ3CWB=O?%=K5'6M#T[Q'ILFG:M86NIZ?)R]I>PK-$WH2K C/OU%;1J
M-:,RE33V+S*48JP*L.JL,$?A17!)\)(=$4CPIXBUSPF@^[9VUU]KL5YS@6UR
M)%4=<B,QYSUJ5+#XD6.576O"NLHJDA[S2[FTE=L\ ^5,R*/< ULJD68NG)'<
M4A.*X9/^%GW4;;E\%Z:X(QN^W78([]#%C]:3_A O$FKEO[>\?:FT)/\ QZ^'
MK:+2D(R3M,HWS'L-RR(>*'4CW%[.1O\ BKQOH/@>".37=5MM-,IQ##*Q:><]
MEBA4&20GL$4DURSZEXQ^(8$6F6UUX#T!_OZI?QI_:UPG_3"V.Y;;/_/2;+C/
M$0/-=%X6^'?AOP7/)<Z/I$%K?2C$VH/F6[FSUWSN6D;/?+8-='64JK>QK&E;
M<R?#/A;3/!^E+IVDVHM;4.\I!9G>21SEY)'8EI)&/+.Q))ZFM:BBL3<QO%/@
MW0?'&F'3O$6C6&N6!_Y=]1MDG0?0,#M/ Y&*^>/''[ /@C5;IM2\':GJG@;5
MUYB>VF:Y@4C) PS"5%SCA)0!C  KZ@HJ6D]P3:V/BB_UO]H']FHM<>);9?B=
MX+@YDOX7:6>&/^\TH7SH\=<RK*O7,@ R/=_AM\3?"?QZ\$2:CI#)?Z=.K6M]
MIUZB^9"67#0S)D@@J3@@E64Y!(KV $@@@D$=".HKY(_:<\)K^SAK&G?'#P'I
M36Z07L5GXNT2P_=V^I6$S;?-\H#:LR2%2& &2PSDDY\G$9="HG*EI(V55K<X
M?Q[X!G^%_BDZ!<&2]\/WZ22:/=W"[]T8'[RSE8_>>,'@G[\>"<E7KV']E/XT
M-X3OK#X<:_<2R:5.3'X=OYVW>0<9^P.QYP "86/8&/.53=U?B;1- ^/OPNB-
MA?QSV&I0QWVE:O H9K>8<Q3J#T*MD,O<;U/4U\I2V4U];WVE:S;&RU.TF:TO
MK>%RK07$9!W1N.1SLDC<=F1A7HY;C'B(.G4^./\ 7_#G%7I<CNMF?J!UHKQ7
M]F'XRS_$SPG-I>N2JWB[0]D%^P4(+N,Y\F[5<G D"D,.TBR#IC/M5>R<P444
M4 %%%% "=*^7OV@/C=)XU\;0?!/P/XCM= U;49H[/7_%,MRD2Z1'*"1:VY8C
MS+^901'$N64$N0,"NL^.WQBUO_A(+?X5_#)8KSXEZO;&>2\E&^U\/61.UKZY
MQWZB./J[8[#GQ#X]_LQZ5X8\'_!_X>^'9)I-4FU^_P!1&M7A,ES=ZNNE7D\=
MY.V1ND,\<9Y. ,#H* /J;P?I_P /_@1X:T;P1IE[I/AJQL;&2:UT^XO(XY6@
MB&Z:<AF#/C.Z20YY;+'FNZM[J&[ACF@E2:&10Z21L&5E(R"".H(YS7YRS>.[
MSXK>,X?C3%'-87-]X?UK2=*C>,%K6.TTDR3XRO)^VS3J0<@^0I'!KTW2_B%'
MJ/Q"N7\1_%77/#'B33M9T;3=!\+6$JF/4K26UM79GL@N;A9GGN%>?I$$!!7R
MCD ^T=P]102!W%?G]X+\7:\_A/X5R^-_BKXET?PSXSGUJ?6/$%WK*V0MI[25
MTLK.*XVJ($=?,<\[I# !NP2I=;?%?4];TC3AXS^,FO>#?#^G:%J>H^'M>5X]
M/E\1-!?SPP3S.T6V=EMT@;R%7]Z)1)M8$4 ?=-QXOT*TU,:=/K6G0Z@9(H?L
MDEW&LOF2!C&FPG.YPCE1C)"-C.#6J=K@CAAZ5\'_  P\::[=Z[X+UFZOYYM2
MUFV\$R:G<LBO)=%].OY)=Q(ZEAGC!S]:H? ?XZZYXL^+?A>UTOXA.\GC+1]6
ME%KK^OPZL\-RNR2U>6PA2..R==SC[-'*6*HRMRI>@#T+]IGPSI_[.>EKXK\*
MQKI^D:E)-:W&AA2;2*\:"62":!,XAW21A'1<(V\-@,"6Z;XH? _3_AQ^S]JI
MTB";5M6CELM2US5)E\R^U6.">.:?S&')&U7*Q+\J@;5 %>1_MN>%/C#8_!B-
MO$OQ#\*ZQILFJ6J-#9^$I;5U)8_/O-X_ &<C'(SR*^@%\"?']D _X6QX,*XZ
M?\(--_\ +"KYG9%7=D?)VJ>'O$.J>.3?V7FW@NY1=6FJP'= \+'<CJXXV[2.
M._OFO=+BYBL[:6XN)H[>"%#)+/(P5(U R68G@ =<FN"^)G[/?Q/^"_A?7/&F
MF?$OPS9V%E$9YO#]EX2DBT]V9QN=8WO'\H_,6Q$44GJIK*\,_LE_%'X]>$=#
M\7ZI\9=*%GJMFMRF@R>$8[C3X-ZD8,+S%92!GF0-@DXQ7=/%*:5UL=,JW,EH
M=-\.?V6K[QQX/B^)V@>--<\.>,9;NZU/PHTD_F6&GV<LA98?((YAN,>9(,C/
MFCCC!^=]&^.^JZ=^S;X^^$O_  CYN/$&MWUXESJ$,ZFTA64A;DKU8LS))MQ\
MOS @X&VO>=$_84^+7P^\+ZQI>E?M'S:+X=N@\L^GVV@"WM8%(RXA5;@"!3SD
M1[17R9^SM\*/BA\5O#][>>#]&M]=L(9O*:[_ '5C;I@?(@,DGS/MPQ"YP'7U
M!-X6-&HVZ[T7]?TCG5GN?6/B7]I+X7>*/"K>(M!T#Q]%XWTS3D2Z'A?2I$EC
M$:@!+N0));&/@E7E!  .T@\4[]GCQC\0_C!XYN/#5]\1=,F@MM'BU4W^@:3#
M+!.DHA,8CD9SG'FNK$J#N3[HZ5I?LI?$/2OV;-+\2>!OBS _P_\ $$UX^KQ7
M>JNHM-3B,<:,8)ERCLA0 J#G!4@=0)/V0[_P+K'[4GQ:U?P#':IX;U.VCELW
ML(VC@DD5XQ=,JD#;F1ER ,9R>]>-BL#A*M1N5-2[-I._S-(U9P346[%_XI>!
MM0\&?$33M*\0>,O$NJ:#K%HJZ9--J2V2F]1F,UNWV58MQ>,HZ*Q.0D@&<5XU
M\2O@Y:Q:Y'-IOAF"[LGB2-0(/M!1P3G._<023G-?HMXI\):-XWT.YT?7M-MM
M6TRY7;+:W48=&]#@]"#R".0>017R/\0?!5SX"^+_ (<\ :?KNL6WAOQ))";:
MZFF6XN[)%,OVB*&>0,Q&!!@R;V3<V#TV]6$5'"_!32]$BX5VG>6IE^ M!U#6
M;OP3X)M_FU>VU"TU2_2%LG3K2WG6</(1PI;8D: \MO.,A2:]/_;9(31?ANS-
MLC3QCI\LC$]$5BS_ (;0<GTS6C\/_'WAKP1HC6?P[^&GB'4-*>0N=0A6W@_M
M%ON^>9;J=))R<?ZQ\D@>E<1^T9JOC#XP:+X8L;'X9ZY8#3-=M=1NY+N^TXAK
M9"PE10EPQ9BK$ 8 /K7#5S+"RJ/FJQ3]4*5.I4?-RO[CI/"EC%HVK>-=&@^6
M'3_$-T$0#:J"9(KG:H[ &X->7:EX<>PO_$-MK'@[6M=CN=7N+^WN],LUN8VC
MEVE<,'5E90-I7'\.>017JOAR^N-=\1>+=9?2+W1;35=32>WMM2C6.Y.VVAB=
MG120H)B&.<D#/0BO-/BKX:GM_P!E[7?B)!XB\36?B9+Z6>)[77KN&'ROMYB6
M)84D"*GEX484'C.<YKY++I5EF5>>#<>N]VM7TL>C.2A1ASW,[4[GQ.+&QT3P
MA\//$5DEVYCFOY[2WMTL(R/FD5'F_>2?W0<+GEC@8/L6F?$C6O ?@_3_  UI
MO@?3/#NE6%F+*!_$_B:&&8JJ;0Y6"*4.3U)WJ223WK>\!_L^^$=:\#:#<ZI=
M>(-?>ZT^VFG:_P#$=_-'.[1*Q8H9MO)).,8YZ5TY^!_PW\-Z=>W,?@[0H@JF
M9IKBSCD*E5/.Z0$C ]Q7TLUF%9^_4C'TBW^;."52D];-_/\ X!\M?!7Q->_"
M[P/'X2T/XI>&-1"RR7+/X=T2?5[K>=H8,D<LG"A0,[0:NOX8O=5UG4_$,&I?
M$F^N-5E26\&@^%5LHI)539YGEW,.58J%!(QG:,]*]&_X)\0K;_L_K&%,9_M2
MX)B)^X"L94?]\E?SKZ7<#:<C(QWJ?JE9N\\1+Y67Y(7MHQ?NP7X_YGP1I.NZ
M;XKU3^R]&U3XNRZB!,7C71;5RGDR"*7>#;C;M<A2#@Y/ /6O4?V>]-UGP]\6
M+H6_]MZ]:ZC:N-4U#Q!X?DL)K 1@&WBCF*HCJS,_[M%/)9B:9\ WB'[7'QCF
MV#R+S;]B<$,O[DQ)<@>A\QTR/7Z5]55M##3IS4O;3:[-IK\B9U>96Y4?,GBF
M<I^WMX0B"<R>&I=S8_A'VK/Z[:V_VG=-N=%UGPSXW\N271=-@NM.U5XTW?9(
M9C$ZW+8YV)) @<@':KECPIK$UVZM[_\ ;L\.R1W D^Q>'Y+1D /R2NL\NW/<
M[ IQZ$5],R1)-&R.H=&&"K#((KT$W%IF*=G<^$/B3X#O?&5Q8ZAIEQ!(%AV;
M7DPKH3N#JPR",'\1TKG_ !'\*;CQWIFB_#G1_$7B"/Q1(KK+#X<U%K:"W@E(
M\R>]PI_<HN2JL5+L=J@EN/3OV@_ MG\(/$?AN+PC=R>&]%\57G]F75I;X:#3
MY7DC/VFVC8%82(_.RH^3=M;;D'/T]\/_ (=>'OAGH2:5X=T^.SM\[Y9<EYKF
M3O+-(<M+(>[,2:ZYXER@H&\JS<>4\@B_8\ABC5$^,/Q?5%&%4>,I>!V_@KH?
MB'^SOH_Q-\>>#+WQ-IFF^*/#NA:5>6;V^N)]HF>>0V_ER\C!.(GW,2#ENG)K
MV2BN$YCXQOOV.?$O@ZZL[[PJ+>?3M \4ZEJVD^&K#7;G1D^PWMHD30I<0IN@
M>.57<*,H1(P)YQ6[=?LR^,D\.V5K8P:+;3W^B>(M-U& ZK=S):S:B\<J2B69
M7>X(:("0G9N9BP '%?6-% 'S5:?LS:];_#3Q-H1N-)_M35;C0I5N%9]NVR@L
MXW#-LS]ZWE*\'[PZ9..2?]GOXKWWQ+L-4U%K'4+#2_&,^MQW<_B:Y$4ME+YR
MQQP:<D @A>-)5W,VYW96(?+DU]A44 ?)_CKX57WPR_8<TSPMK5_9K?\ AD:?
M=3745M/=VI>WOX[@;U1#((CM 9PAV#<VTA<5Y[H6C?$+XU^,/BGXK\.6^D26
MT^L:%M_L+6Y(8+^*U@N/.AM]4-MN656FBW2QQJ,917SN-?>5)C% 'S%\&/V=
M?%WA'Q7IVIZ\NEQP6&KZSJ"+'J=QJ$Q2]AC"#S9D#LZ%61G8Y8<C .T>.:SI
M>I?LP6>I:!=W7A.?5M7\(7MKLU7[9 ASJ-W-$+65+=Q<L1>*'MEV/D(P)!R/
MT!I,9H ^3?!O[,WBFXTSPE=SW-I8)%;Z.\\$S.+B$0://9RJ1MQO$DZG&<85
MN0:R[K]F?XC>.?"6B^&];L?#6AP^$?!VH^%M.N[:]>Y&JRW%I';),4\E3;1!
M4+,F7)) Z#-?8]% 'F7AKX8ZAHGQ:?Q,TMH--/A>TT188BWF"6*9W)QC&S#
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MC29O"5EK>BZRNB:A>6,5]+:?9A:,;B,1M(AC>-U8;=S*PZ!A7(>'KOQ?\/\
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M'B&.^U7Q5IMGJ]QXDLH+2RD;5K+7[W5-+DFPZO@7J"6VN6P&DA#NH&S[ISD
M^LZ*** "BBB@ HHHH **** "BBB@ HHHH *S_$&H_P!D:'J%^%#FUMY)]I.
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M.RPW<2](BDDI\P+A661F(W*,_0/BGQ/IW@WP[?ZWJ]PMIIUC"TT\I!.U0.<
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M=4;D @^2?"WPS!\=9@]K''8^ ;5K6YNE0;)]2F:..X6W('"1*'C\PY)<Y08
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M9!+HFENEQJ.?NRR?>AMC]2 [?[*@'[]8T-IJ&MZI:Z1I$(N=5O"=F_\ U<*
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M6XWV6*G7E"\7?9:J[O\ H>K6R^HZ48*4;JWVX^G\Q+\#O GQ':T^-5OIMWX
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MPM%%% !1110 445A^+_&^@> -';5?$FL66B:<#M%Q>S",.W]U!U=O]E03[4
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M:UFSGC+(1NZ#A@PXY!KZ#^%'[=4EN_\ 8_C?3+S7!;GRSXDT&SW*2"!BXA&
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M\1ZC /F8@'!EB/<DL30!/)^S3\0/"8!\ _'GQ781*6*Z?XPMX?$%N%('RAY
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M5'7YD!(_A[5V?@?]JSX1?$>?[+H/Q!T.?4,-G3KJY^R7BXQG=;SA)%ZCJHH
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M:H==O7\.P$_8D57U1QGYE892W!!_B'S/_L8'\==/XIUY?#>B3WOE^?/E8K>
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MJ$OKBR@FG51@"1HU+ #ZDUL4V-%C154!57@ = *=7KGA!1110 4444 %%%%
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M"AMS1D<X)!XJ_P#M&>.= _:0_9<\3P_"_6K?QM=SRV($'A^07-U$1>P,VZ(
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MSP'*@KG->T?L1FS;PG\0SIVMW/B73SXWU/[/J]VP>2[C"0!7,@ $O3 D'WP
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M5O\ H>-=_P"_&G__ "+74T4>S7G][#ZW4[1_\ A_\B<M_P (?JW_ $/&N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cgtx-20231231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *3 Q<# 2(  A$! Q$!_\0
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MF. !5>SU.SU!YTM;J&X>W?RYEBD5S&V =K8/!P0<'L:5T.SW+5%%%,04444
M%%%07M];Z;:RW5W/%:VT2EY)IG"(@[DD\ ?6C8:5]$3T5%;7,-[;QSV\J3P2
MJ'22-@RNIY!!'!!]:+JZALK>2>XE2""-2[R2,%55'4DG@"E?J%G>Q+14%E?6
M^I6D5U:3Q75M*H:.:%PZ.#T((X(I5NX6?8)4+9QM##-%T%GL344U'6095@PR
M1D'/(.#^M.IB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^,OQ?U_2O"LNH3ZGI?V72=865 L$(1<+"K<LYP/E&!N4DY& ?8_V6O!M_P"
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M23_&X4445WGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/WH]>HKR'_AK7X2?]#OIWY2?_$4?\-:_"3_H=]._*3_XBCVU/^9?>'US#?\
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MA)_T.^G?E)_\11_PUK\)/^AWT[\I/_B*/;4_YE]X?7,-_P _(_>CUZBO(?\
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M=]._*3_XBCVU/^9?>'US#?\ /R/WH]>HKR'_ (:U^$G_ $.^G?E)_P#$4?\
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MOPD_Z'?3ORD_^(H]M3_F7WA]<PW_ #\C]Z/7J*\A_P"&M?A)_P!#OIWY2?\
MQ%'_  UK\)/^AWT[\I/_ (BCVU/^9?>'US#?\_(_>CUZBO(?^&M?A)_T.^G?
ME)_\11_PUK\)/^AWT[\I/_B*/;4_YE]X?7,-_P _(_>CUZBO(?\ AK7X2?\
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M-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH
M=O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^
M\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SH
MWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH ][_8>8G]I3PO
MDD_N[S_TEEHI/V'?^3E/"_\ USO/_266BOH\N_@OU_1'Z3PY_NDO\3_)'@M:
MOA;Q3JO@KQ#8:YHE[)I^JV,@E@N(NJG&#P>"""00>""0:^[O^';?A?\ Z&[5
MO_ >*C_AVWX7_P"ANU;_ ,!XJ\Q8'$)W2_$^9619A%IJ-FO-'R;+^T3XFAUK
M6M;TFQT/P[K^L$F[UC2;$QW1#??$;.[B+<<%B@!)&<UB^'OC!X@\+>#=2\.Z
M=]AACO[EKJ74VM0VH*[($;9<$[DRH(R/F^=\$;C7V9_P[;\+_P#0W:M_X#Q4
M?\.V_"__ $-VK?\ @/%6GU7%;_J;O*LT;OZ]5UW^\^0M:^/GB[7_  OX:T*\
MGLGM_#Z1Q6=T+1?M1C1D9(GE.2R QQ_*, [%SG%;%U^U3X_NOB99^.OM=C#K
M-K$T*Q0V@6V=60(V]-V6)"KR6R-HQC%?4O\ P[;\+_\ 0W:M_P" \5'_  [;
M\+_]#=JW_@/%3^K8O^GV*_LS-EK?M]I=-NO0^3O$'[27C?Q-X1U/PY?W5E)I
M^H7LE\[)9JDD+."&2$@XC3#,/E&?F;YLDD[=E^V'\1["Y\-3QW>G%]!M3:0;
MK+_7IY>P>>0P+X'( (7=S@D#'TM_P[;\+_\ 0W:M_P" \5'_  [;\+_]#=JW
M_@/%3^K8M.]_Q&LMS=.Z;O\ XNVO<^2-!_:%\7^'-.\46=HVFM%XAECFNA-8
M*XB:,YC\E,[$"G! VD @'KS5;4_CSXNU;X86'@*>YM1H5FS,C); 7+ABQ96E
MSR#N.< $]R><_8'_  [;\+_]#=JW_@/%1_P[;\+_ /0W:M_X#Q5/U7%6M^I'
M]E9K;EZ6M\2V>KZ]SX>U7X@:]K'A'1?"]SJ$G]@Z1YAM;&/Y8][R-(TC@???
M+D GH, 8YSUNG_M#^)[/X>Z;X,NK'0=;T;3':2P.L:8MU+:,22"C,V/EW'&Y
M2,'!R.*^M/\ AVWX7_Z&[5O_  'BH_X=M^%_^ANU;_P'BI+"8I:KTW)CE&9P
M=X]K;K;L? NKZE=:]>W5YJ%Q)=W=T2TTTA^9R1C^7&!P,#%>@:G\?/$FH7FN
M7\-OIFEZMKE@-,U#4M/@DCGGMP$!0YD*@LL:*650Q ZBOKK_ (=M^%_^ANU;
M_P !XJ/^';?A?_H;M6_\!XJ2P>)6R_$4<FS*%^5;^:_KJSY UCX[^*-<\'^%
M_#-T--.E>'@J6JK9*'D161O+E;/S(3&FY1M#8&<UC?$WXFZY\6O%T_B/7Y(6
MU"6*.$+:QF.*-$&%5%).!U/7J2>]?;'_  [;\+_]#=JW_@/%1_P[;\+_ /0W
M:M_X#Q4WA,5)6?YCGE&9U%RRU6G5=-%]Q\H^,/VE/%_CJSLAJ\.BSZM:6XM8
MM>&FK_:(CP00)B2%)R3N5003D%35'2OCMK^A2Z)=Z;8:-8:OHNF_V58:M;V;
M+<Q0[2O)\S8SX9_F9"?F./;Z\_X=M^%_^ANU;_P'BH_X=M^%_P#H;M6_\!XJ
MKZKBF[O\RWE>:N7,]_5'R!HGQPUOP^GAN2TT[1O[2\.QRQZ9JLEH[74)D+LS
MLWF!9&W2.V75ADDXY.>!O+R?4+N>ZN9GN+F>1I99I&W,[L268GN2237W[_P[
M;\+_ /0W:M_X#Q4?\.V_"_\ T-VK?^ \50\'B9*S7XF4\FS*:2DM%YKT_)'Y
M^45^@?\ P[;\+_\ 0W:M_P" \5'_  [;\+_]#=JW_@/%4_4*_;\3+^P<=_*O
MO1^?E%?H'_P[;\+_ /0W:M_X#Q4?\.V_"_\ T-VK?^ \5'U"OV_$/[!QW\J^
M]'Y^45^@?_#MOPO_ -#=JW_@/%1_P[;\+_\ 0W:M_P" \5'U"OV_$/[!QW\J
M^]'Y^45^@?\ P[;\+_\ 0W:M_P" \5'_  [;\+_]#=JW_@/%1]0K]OQ#^P<=
M_*OO1^?E%?H'_P .V_"__0W:M_X#Q4?\.V_"_P#T-VK?^ \5'U"OV_$/[!QW
M\J^]'Y^45^@?_#MOPO\ ]#=JW_@/%1_P[;\+_P#0W:M_X#Q4?4*_;\0_L''?
MRK[T?GY17Z!_\.V_"_\ T-VK?^ \5'_#MOPO_P!#=JW_ (#Q4?4*_;\0_L''
M?RK[T?GY17Z!_P##MOPO_P!#=JW_ (#Q4?\ #MOPO_T-VK?^ \5'U"OV_$/[
M!QW\J^]'Y^45^@?_  [;\+_]#=JW_@/%1_P[;\+_ /0W:M_X#Q4?4*_;\0_L
M''?RK[T?GY17Z!_\.V_"_P#T-VK?^ \5'_#MOPO_ -#=JW_@/%1]0K]OQ#^P
M<=_*OO1^?E%?H'_P[;\+_P#0W:M_X#Q4?\.V_"__ $-VK?\ @/%1]0K]OQ#^
MP<=_*OO1^?E%?H'_ ,.V_"__ $-VK?\ @/%1_P .V_"__0W:M_X#Q4?4*_;\
M0_L''?RK[T?GY17Z!_\ #MOPO_T-VK?^ \5'_#MOPO\ ]#=JW_@/%1]0K]OQ
M#^P<=_*OO1^?E%?H'_P[;\+_ /0W:M_X#Q4?\.V_"_\ T-VK?^ \5'U"OV_$
M/[!QW\J^]'Y^45^@?_#MOPO_ -#=JW_@/%1_P[;\+_\ 0W:M_P" \5'U"OV_
M$/[!QW\J^]'Y^45^@?\ P[;\+_\ 0W:M_P" \5'_  [;\+_]#=JW_@/%1]0K
M]OQ#^P<=_*OO1^?E%?H'_P .V_"__0W:M_X#Q4?\.V_"_P#T-VK?^ \5'U"O
MV_$/[!QW\J^]'Y^45^@?_#MOPO\ ]#=JW_@/%1_P[;\+_P#0W:M_X#Q4?4*_
M;\0_L''?RK[T?GY17Z!_\.V_"_\ T-VK?^ \5'_#MOPO_P!#=JW_ (#Q4?4*
M_;\0_L''?RK[T?GY17Z!_P##MOPO_P!#=JW_ (#Q4?\ #MOPO_T-VK?^ \5'
MU"OV_$/[!QW\J^]'Y^45^@?_  [;\+_]#=JW_@/%1_P[;\+_ /0W:M_X#Q4?
M4*_;\0_L''?RK[T?GY17Z!_\.V_"_P#T-VK?^ \5'_#MOPO_ -#=JW_@/%1]
M0K]OQ#^P<=_*OO1^?E%?H'_P[;\+_P#0W:M_X#Q4?\.V_"__ $-VK?\ @/%1
M]0K]OQ#^P<=_*OO1^?E%?H'_ ,.V_"__ $-VK?\ @/%1_P .V_"__0W:M_X#
MQ4?4*_;\0_L''?RK[T?GY17Z!_\ #MOPO_T-VK?^ \5'_#MOPO\ ]#=JW_@/
M%1]0K]OQ#^P<=_*OO1^?E%?H'_P[;\+_ /0W:M_X#Q4?\.V_"_\ T-VK?^ \
M5'U"OV_$/[!QW\J^]'Y^45^@?_#MOPO_ -#=JW_@/%1_P[;\+_\ 0W:M_P"
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M_0W:M_X#Q4?4*_;\0_L''?RK[T?GY17Z!_\ #MOPO_T-VK?^ \5'_#MOPO\
M]#=JW_@/%1]0K]OQ#^P<=_*OO1^?E%?H'_P[;\+_ /0W:M_X#Q4?\.V_"_\
MT-VK?^ \5'U"OV_$/[!QW\J^]'Y^45^@?_#MOPO_ -#=JW_@/%1_P[;\+_\
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M'(4'JHK*33_VK],\,)J>J3:*_P .)U:SFU*=U9DOX(UEY?(E*,09!\QSR>*
M/H'-!8"OE#X+7>N2ZS>?!;6M4UF]U7P9XBFO[O6+G4)WNK[26(N+!GFW9)=I
MTB9<X*VTHQUQPZ>,)X?%GPS\4Z5XEU26TU3XBWVE7.J:KJS+<:E;#[8)X39A
MC%':PO"BIN^;Y58*F_+ 'U9\-?BHOQ$UWQMI9T>YTB?POJJZ5,MU+&YE8V\4
MX<>6S #;,O&<^N#P)_C'\6=#^"'PZUCQGXA>0:7IJ*SI NZ20LP555>Y)/Y
MGH*X#]GUA_PMCX_KD;AXN@.,\_\ (*LO\#2?%&UO?BM\25\+V.DZ=XAT/P[8
MR3:O9ZA?M:Q/=7<3Q0QDK#+N*6[3N5(&//A;/ H ]A;7HI_#G]L:=#)K$$EL
M+JWCLF0M<J5W+Y99@I+ C&2!SUKQ[0?VN?#NJ:7X$UG4/#NO^'_#GC66.WTC
M6K^.W:V::3'E13&*9VA9^=N]0"5(R*Q/V*?$VHZ3\/\ 6OAEXIF1?$_PWO6T
M:Y+3>8'LMOF6<P8@'882%!('^K[=!P_[.'P-N/BY^SK\#9_$?B>27PQH4%GK
M5MH=A9)#YUQ#DPB><NS.J-N.%"9)YH ]<NOVH+4>*/B'H.G>!O%&MWG@3R3J
MXT];-B5EB,T9A5K@-*3&"=H&[MC/%:'B']IOPEHOP"7XPV<=_KO@\VJ7A;3X
MT$XC+B,G9*Z<JYVE<YR#UQ7R]K=I\09/C7^UI<?#Z^$=S;W.@27VGV]L'OKV
MU^P'SH[24DK%/Y8<(3&^6(X!Q76?&X^"!_P3/UZ/X=DKX1CT&);*.1]TL?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKD888(R#FO [QO%UA^UEH/PU/Q%\2S:!=>#)]9F<FS$[W4=TL0?<+?@%2?E
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M;::S\5Z;I$FK:5;.MC)+]OABN8'GVG@+YB$@A=_R;B?E/K^J?'GPIHW_  L
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M*)U(!['\,/VHM&\;_"30_&^JZ=?Z$NM70M+&QDMG>6ZE>1UBBAP/WK%4Y*\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSD\^AP ;NF:9::+I]M86%M%9V5M&L4-O @1(T P%51P !VJU17'>.?B_X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"B(D=>.^T/\ 9?T'PUXOU/5--U[Q!:Z%J6I'6+GPG'=1_P!EO>,P9I=OE^8
M6 8QAPA(R0>E9/A[1H?C/\<-+\<ZAX%U7PU_PA,5_IEG>:_;+!<7L\KJA>%5
M=MT"HDA#MU,H*]#0!3_X2[XD?$&_^(.C^#/$6C6.K>"9+?285U.S#_VI??9H
MKB26=5;,$+"4(FS)R)"2< 5Q'C;QL/AU^V3XJ\6ZE$)AHOP8DU*>&%B5?RM0
M,C*IP3@D$9QWS7KGBO\ 9ET7Q!\1-3\8:;XB\1>%+W6K5+/7;;0KM(8=6C08
M0R[D9D<+E/,B*. >&!YJQ>?LYZ+??%N?QS+J=\WVCP__ ,(M-HA2(V;Z=DL8
MON>9DN<[MV>W2@#C_A/XV^,.O^*O!.I:GI45YX+U[3I+C5+EUL[=;"9XA+;M
M:F.YDDGB;)CPRA@-KD]0+?[7$]U;?\*?FLK87MXGQ!TXPV[2B(2-]GN^-Y!"
M_7%;OPD_9ITKX1W%FEOXH\3>(-*TO>-&TG7+Y9[?2PP*GRL(K-A/D4R%MBE@
MN-S9UOB]\%3\6]1\,W,OBK5]!3P_J,6KV<.F1VY4W<8<)(YDC<L LC#;D Y]
M: /'?V:%E\<?'3XJ_%+5POAO6$CA\.7GA DO=60MB66>Y( #M(@5HV0%=I(#
M'%1G]HOQ?/\  C2OCK:7%J_ARXU"-[CPQ)9_.-->^-J"DV[<9PI23D;2=R[1
MP:]CU;X%6ES\3++Q[I6O:EX?\1"R73]2>P2'R=7B4@I]IC=""R?-M==K*&(S
MCBLG3_V7_#NFVDFB)J6I2>"'U0ZP/"DAC-DLWFB;RP=GF>0)0)/*+%<\?=^6
M@#RK4?B>?@Y\1_VH_%J6HOIK*X\-100.P56EGM(H(RQ)&%#RJ6Y' /(KU3X8
M:Q\5!\0[JQ\3:3)+X-FTT2P:I?)9V]U%?+)AH?*@N)-\;(=P; (*D'.0:=+^
MS'H.K:[\2KS7]3U#Q!I_C^"*WU;2+M85MPL2;(6B*('5D3 #;B<@'J!6I\(O
M@1;_  J\IYO%OB;QC<6MH+"RE\1WB3&SMP02B!$0$L0N7<,Y"J-V!B@#/\4_
M$#6?$'QQ_P"%::#?IH36GAX>(+S4VMA<.YDN#!#$B,0H V2,Q.3R@&.:\-\:
M>/\ Q1\6/A#H[:KJ,.DZ]X:^*.F^&=2?3[,-;7=S!K-LB7,8D)*C!5]N2,Y4
MG%?27C7X/67BGQKI'C&PU.]\.^*M.M)=/74;!8W\^TD8,T$J2*RN@<!UZ%6'
M!P2#SGB/]FK2]7\&Z5X<T_Q!JVA6UGK*^(9KJT6"2XOM06Y%T)YFDC8$^<-Y
M  !X'08H [;Q#X*@UOX>Z[H.I:@T3ZKITMG?:M BV\S;X3$9<K@!@N,'M@5\
MQ>#_ !3XF^ 4WP_^'?QI\-66K^&=/O+/3O"WQ"T9?]&AG5&BMDN8C\T$A7]W
MO'RD.<\9-?6&J>&(M?\ !UWX>U6YFO(;VQ>PN[@;8Y)5>,H[?*,*Q!)X&!GB
MN!/[/MGJ/_"/6>O^)-9\2Z#H%U#>V.E:D864SP_ZAYI5C$DWEGYAN;D@%MV.
M0#S/]CV]N/%GQ*^/GB37H GB=/&$NC?O%_>6]C;Q(+:%6[)@E\# )8DY/-:7
M[:OAC2M%_9H^-.JV$"6VH:KHR/?&(X\YHR$21A_>VX7=W"*/X:]#UCX$6#^/
M[SQIX;UO5/!^OZC&D6J-I?DM;ZF$4K&UQ#*C*SJ&P)%VM@ $D<51^(7[.UC\
M1_ &M>%M0\1ZO"FO+LUC48A US=H,;8P6C*Q(N.%10!ENY)( ?#2\\=:QX@T
MV/Q5X:TBQT.TTB*YT^\LKQKUS=$>6^6>-#&WE,PP V0S<C&"_P"*GQ*U+3?B
MCX"^'FC3QZ=>^)XM0O)M3DA\XV\%I&C%40D*7=I%&3D!5;C)!'HGA30Y/#7A
MVPTN:_FU1[2(0_:[E$620#@%@@"YQ@< =*X_XO?!'2_B[)X>OIM5U7P[X@\/
M737>E:WHDZQW-LS*%D7YU9&1U #*RD$"@#@[KQ]\1-&\0>"/AUK=[HUMXE\1
M7VK.NOV2>8O]GV:I(A\AL 7,JS1 IDHH$C GA:\[\;?M)_$'P;HGQ4T&.\T>
M\\4> -?T.U?4I=/=8;^RU.:'R?D$F(Y461E<C<#M! &[CVK5OV;="U33/#KG
M5M7C\5:%J#:K:>+/.1]2-TZB.9I&*;&66-1&T>P)L554*$7&?XQ_9;TCQGX/
MU_1+GQ#J]O=>(=3M=6UC6(%@^U7<]MY/D8W1E(U3[/" JJ.%(.<DD Y*\\3?
M%U/C%XM\ KXP\/)&OAV'Q+8ZJN@OYEH#<31&W\DSXD!,?WRX('8DY'-^&?VA
M?B/\2[+X"2:5>Z)H1^(6B:G)>--ISW'V:ZMH%;SD'FKN7<21&<>A8U[/<_ N
M6?XB:AXS'C#54U:]T--!=!;VIB2!2SAE4Q9W>8[N221\V,8 %>&7WP:E^&'Q
M(^ 7@CPUJ/B>?2/"T6LQMKS:8)_L27,*+!')((?*(9MXY&0!R1@&@#F_B?\
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MBSUS5;,^$K*73[*PS%-%-#,%$_GO(C22,^Q26+9SD]2: //OAK\6OBO\15\
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M%VK'2'DOA+OMV$;2>8-A 887&#CGO0![2!BEKR3]I;XZ-\ OAJ_B.WTHZ]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(RQ+I]W$FXG)QDHI9NY&3S7C?B'X6Z]\!OBWX=L/"EI%/\)/%_BFRNI=,B#
M^'M15O,9XE&0+>?RR"O 5R,8R WU\5!Z@'M1B@#R/Q#I/Q#T$^)]=OM?LO%?
MA>&SOIX/".FZ"T-_<)Y3F*W2Y^TL"_W5W>6-Q[+GCYA^ GC"PN?CK\#]5L<V
M^CW7@6[TJ.QTW3YEM=,D0VI^PM,VYIGA\O$CNW!3<0N:^^Z3 - 'P=K*Z+>_
M [P-=ZI!;RV2?&::X=[J'E+:;6;M]V"-RJ\3*>V5//%9WQ;\(V5OH_[2FL>
M[:TL_ FI>%-/TN&WT:V"VVH:N&?<;=8QM9DC9$8QC!9\'+(V/L+XM?"J3XH_
M\(L%U@Z2FA:W:ZZH2V$IGEMV+1HQ+#"9/..3ZBN^CC6- JJ% Z!1@"@#X]^(
M%MHWA;X]>//[*\.#5=#N/@]<JVE:2&@74Y$N)F^SB6(9$K1-@$$N ^1FN!\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYY4A0LJ!G8*"S$!1SW)( ^M<-\:/BYIWP5\'1>(-40?9)+^VL6GF8QV]N9I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN&BFB$T375Q.(B &P[?:6R1PNT !NM?3U% '@'BGX#>)]?U;XX3QWNDQV_Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]U_X+;C_ .(K\NJ*/[1K=E_7S#_6/&=H_<_\S]1?^&ZOA!_T'[K_ ,%MQ_\
M$4?\-U?"#_H/W7_@MN/_ (BORZHH_M&MV7]?,/\ 6/&=H_<_\S]1?^&ZOA!_
MT'[K_P %MQ_\11_PW5\(/^@_=?\ @MN/_B*_+JBC^T:W9?U\P_UCQG:/W/\
MS/U%_P"&ZOA!_P!!^Z_\%MQ_\11_PW5\(/\ H/W7_@MN/_B*_+JBC^T:W9?U
M\P_UCQG:/W/_ #/U%_X;J^$'_0?NO_!;<?\ Q%'_  W5\(/^@_=?^"VX_P#B
M*_+JBC^T:W9?U\P_UCQG:/W/_,_47_ANKX0?]!^Z_P#!;<?_ !%'_#=7P@_Z
M#]U_X+;C_P"(K\NJ*/[1K=E_7S#_ %CQG:/W/_,_47_ANKX0?]!^Z_\ !;<?
M_$4?\-U?"#_H/W7_ (+;C_XBORZHH_M&MV7]?,/]8\9VC]S_ ,S]1?\ ANKX
M0?\ 0?NO_!;<?_$4?\-U?"#_ *#]U_X+;C_XBORZHH_M&MV7]?,/]8\9VC]S
M_P S]1?^&ZOA!_T'[K_P6W'_ ,11_P -U?"#_H/W7_@MN/\ XBORZHH_M&MV
M7]?,/]8\9VC]S_S/U%_X;J^$'_0?NO\ P6W'_P 11_PW5\(/^@_=?^"VX_\
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MU?"#_H/W7_@MN/\ XBORZHH_M&MV7]?,/]8\9VC]S_S/U%_X;J^$'_0?NO\
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M\-U?"#_H/W7_ (+;C_XBORZHH_M&MV7]?,/]8\9VC]S_ ,S]1?\ ANKX0?\
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M# V7C_?#"QD$CY<9*XR2U>5^&OCKKTG@E?A[<W6F:7HFI:JEU=:T]GF>UWL
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M?I\E^!TU<QPTU*T;74K:+K9+\%=^9] OX$\%?LSZUX2M/%)TNZD6R.JZ\UU
MEW=WTCJZPV5M P.R(,I+2$#)4#<,XK-\%#PMH'[.'C;X@Z[X2TJ>/6O$;QZ3
M83P*)3%Y@/V=9-N53.]2R8PJMCD 5Y=XY_:;\1?$"&SGU/1O#YU^WMA:?\)
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M#^N?G#_\31_P[E\#_P#0?US\X?\ XFOK6BCZI0_E#^R<#_SZ1\E?\.Y? _\
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M .@_KGYP_P#Q-'_#N7P/_P!!_7/SA_\ B:^KY;N&":&*25$EG)6)&8 N0"2
M._ )_"H-3UFPT6)9+^\@LXV.U7GD5 3Z9)H^J4/Y0_LG _\ /I'RO_P[E\#_
M /0?US\X?_B:/^'<O@?_ *#^N?G#_P#$U].V?B_1-0\W[-JUE<&*,RR>5<(V
MU!U8X/ Y'-11^._#LLBQIKFGL[' 4749)/IUH^J4/Y0_LG _\^D?,_\ P[E\
M#_\ 0?US\X?_ (FC_AW+X'_Z#^N?G#_\37UK69X;\3:1XQT:WU?0M3M-8TNX
MW>3>V,RS0R;6*MM=20<,I!]P:/JE#^4/[)P/_/I'R[_P[E\#_P#0?US\X?\
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M^M:*/JE#^4/[)P/_ #Z1\E?\.Y? _P#T']<_.'_XFC_AW+X'_P"@_KGYP_\
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MKKFGL[$ *+J,DD].];%U=0V5O)<7$J0P1J6>21@JJ!U))Z4?5*'\H?V3@?\
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M _\ T']<_.'_ .)KZUHH^J4/Y0_LG _\^D?)7_#N7P/_ -!_7/SA_P#B:/\
MAW+X'_Z#^N?G#_\ $U]:T4?5*'\H?V3@?^?2/DK_ (=R^!_^@_KGYP__ !-'
M_#N7P/\ ]!_7/SA_^)KZUHH^J4/Y0_LG _\ /I'R5_P[E\#_ /0?US\X?_B:
M/^'<O@?_ *#^N?G#_P#$U]:T4?5*'\H?V3@?^?2/DK_AW+X'_P"@_KGYP_\
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M^N?G#_\ $T?\.Y? _P#T']<_.'_XFOK6BCZI0_E#^R<#_P ^D?)7_#N7P/\
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M[)%!(##H0":K>,_$TWA+1&U"#1-2\02":*+[%I,2R3D.X4OAF4;5SN;G@ T
M;M%)G\*"0*  C- &*XSX8?%/3OBI::_-I]G?6+:+K-SHES#?Q"-_/@*[B "?
ME.X$$\^PKL\T +129KA)/C#I4?QBG^&_V'4#K<6@?\)$)Q"#!);^>("JMG)?
M<1QC&.] '>45PWP5^+NC_'7X<Z;XST*"[MM+OWGCBCOD"2@Q3/$V0"0/FC..
M>F*[C(]:  C- &*,T9H 6BDR*,T +129'K2T %%)FEH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JVI?\ (/N?^N3?R-6:JZGIL&L:=<V-TKM;W$;12!)&C8J1@X92
M"/J"#0!\&_ Z?5;#_@GU\%;K1]=U'0;K_A(]/M'DT^15,D<^O^3(K@J<C:YX
MXSWR,@]:?#6M7GQ6^./P^;Q]XNCT+2-&L?$-E+'JA%W#=RQ3%]LV-PCW1JWE
M#"=L8X/T-9_L[?#[3O!MEX4M?#ZVWAZRNTO[;3XKNX6.&=7WJZ8DRI#_ #@
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M'B?6_'WA#X_>)7\3:EH?B+P5JNH6>C0V=P8X;"*RMTFA9X =LWG$L6,@8%6
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M^S?H7BFT_9M\6?\ "5-?_P!F:C/J5[X?M-5O#<7MKI,D>ZVBFE#$EP-Q^]D
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MX0^&V@Z=J]NUEX3\72^(TM[N6:98+8K<1QV4+D;BL:7) 9L?<'&#Q]'T4 ?
MOBO63K?Q7\?7VG>)/AJZ_P#"3K')X<\575W9W,SV8CB4O!$_ERDR1,R2/$Y;
MY#R @'T19?#?Q-XOUKQ?XMNTLM&?QAX+LM&&FS&1IK"X1;ASYAP P#7DBG'/
M[M?4X]>F\+Z/<:JNIRZ592:BI#"[>V0R@@8!WD9X^M:E 'S)X4_9D\8>%H/A
MW:KXAT>^L_#GA7_A')(+VVEEBAF$@*WUO&2%\W8H7YL''1@"<Z'@;]G3Q1X5
ML?@5:W.L:3=)\.A<Q3&*&5#<QR6CVJ[,Y^8*Y<DX&< <<U]%T4 ?.?C3]G/Q
M-XK\$?&/0EU;2H)?'.NP:K;3LDI6VCC2UCV.,<MMM$.1QEV]!E/BWX+U+P3X
M\\:_&:]O+%]+A^'LN@OIBVLEPYE65YQ(1C#)N<J5...20,U]&TC*'4JP!!X(
M- 'P]^SI<:CX2\:^$+?3-5^&WC^U2RBTC=X<U6[FU&PMV9?,>*.5Y(TB7;N<
M)Y8(0 ?=5:^X1TK-TGPQI&@R2/INEV6GO( ':UMTB+ = 2H&:TZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4>:2GSR1[@A;@-M!(SF@#[IU+5+31].N=0OKF*ULK:-IIIY6"I&BC+,Q/0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2$X&:6N&^,U_K-MX#N[/P_;WDNKZK)'ID$]E"TC6?G,(WN6P#M
M6)&:3)XRH'>@#S_X0_M$S^/_ (W^-O!M_:)96$5M%JGAF<_>U&Q5VM[B8>H$
M\9(_V76NV\9?M!_#GX?ZGJ&G>(/&&E:7J%@D4ES:SW"B6)9/N%EZC(!/T!->
M'_%_X+:S\)M8^%'CSP7+XA\5W7@Z^CTB71X[:*5VT:=/+N%5885+% B.-Q(R
M#T)YFU/7_#F@_MC>.K[7-/:YCG\"Z4J#^SFGDDS<7>Z+:%)W. JA.K%0.<4
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M!FN0_:6T/46\>>(]:\)W>KZ)XQCT"&UBLY+%[W1_%469F%A)&%_UJEG7*L&
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M,IO!;=@@#U(%<ZWQ[C\-_'7Q+:Z_XGL(_ D7A.PURRE:$1A&FN;J-OGW$O\
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M "UR&G?"_2=,^)VL>.XI;MM:U33[?3)T>4&$0PLS)M7;D'+N2<G.XUUV:,T
M! (KC?B'\*=&^)EWX5N-7DNT?PWK$.N60MI0@-S&&";P0=RX=N..M=EFC-
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MC)( QW6:,T &.<TM)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
M +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC
M- "T4F:,T +129HH _-O]H+]I3XE^$OC/XNTC2?%EW9:;9W[Q06Z11$1J ,
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MO_?F'_XBO(**/;5/YG]X?7,3_P _9?>SU_\ X:W^+G_0[7O_ 'YA_P#B*/\
MAK?XN?\ 0[7O_?F'_P"(KR"BCVU3^9_>'US$_P#/V7WL]?\ ^&M_BY_T.U[_
M -^8?_B*/^&M_BY_T.U[_P!^8?\ XBO(**/;5/YG]X?7,3_S]E][/7_^&M_B
MY_T.U[_WYA_^(H_X:W^+G_0[7O\ WYA_^(KR"BCVU3^9_>'US$_\_9?>SU__
M (:W^+G_ $.U[_WYA_\ B*/^&M_BY_T.U[_WYA_^(KR"BCVU3^9_>'US$_\
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MG_0[7O\ WYA_^(KR"BCVU3^9_>'US$_\_9?>SU__ (:W^+G_ $.U[_WYA_\
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M $*&M_\ @!)_A1_PICQW_P!"AK?_ ( 2?X4<DNP>PJ_R/[CBZ*[3_A3'CO\
MZ%#6_P#P D_PH_X4QX[_ .A0UO\ \ )/\*.278/85?Y']QQ=%=I_PICQW_T*
M&M_^ $G^%'_"F/'?_0H:W_X 2?X4<DNP>PJ_R/[CBZ*[3_A3'CO_ *%#6_\
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M . $G^%')+L'L*O\C^XXNBNT_P"%,>._^A0UO_P D_PH_P"%,>._^A0UO_P
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M_@=HUI!X>UFYN/ 7Q,N=9\0Z5)9RH;BR.I7DX:(%<7&U9X)]JYY0'J!7W,%
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MEQ%I(MW4_+RN_'S#*X(.:^\=H_R:  * /CW]G[4HK3P]X>^%7CKP'JFH^/\
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MW2G'*87.-PIT%I<?%S3?V>;3P]I5QX8\1>"M:M9]<MY;)HFTBUM[.6&ZM2Q
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MB_XC\->&/C?KOA[P/H[Z[X0UO_3+6&Y8'5(%L+><S,ZQY,HBD4;<'_5XSTH
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MH ^@--UJPUAKI;&\@NS:R^1.(9 _E2;0VUL=#M93CT(J[7Q_\,_B=-\']/\
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M0>/_  )X,NK?1M/M?%^KZU=:5J.BRW$F-.-L9?M(=MF=R>6@Y !,B\\C(!]
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M)X&T#5?!?AS1M<O]=L+WQ=JK65OJ&I%='2;[&\DL$D@!+PPEB$C&?WAQT7@
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M/Q'H_COXT?'/2?'EY +*QT*S/AFWGO&A1K%[61Y[F':PRS2NH+CD;5&0*Q/
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M%LUQ(99C#&$,CGJS8')/J>:M44 59M*LKB^@O);2"2\@#+%</&IDC!ZA6QD
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M17+M"I:9 ,!7./F&"1@YJS:6<&GVT5M:PQV]O$H2.*) J(!T  X J:D) [T
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M8X)4D@@$X% &O^R?\;)IOV<?"&H>)M4O/$/B76+_ %2WLXG :[O?)NY\ #
M"1JN2<!1C.*[:/\ :W\ 2:1X>OA<7^=9UB30$MQ8R&6WOXP3+;RKCY'7!X/7
MMFOG_P !_ [XH?#GX;_";7/^$,MM:UKP?J>O&_\ #,MU%YD]EJ$I<21.24,B
M +\I.23BO2_%?PZ\;>++SX2ZO#X%T_P^-*\:_P!N7^EV$\"M:6AMGA+RE2%D
MF+.6.S=Q@9)% &KX_P#VPM*T#X+^(_&6D:+J5QJ6C:I'HEYI-[;-!-8W4DB1
MQF=3RJ?O8V]PP Y->[WFOV>F:!<ZQ?.UE86L#W,\EPA3RHT4LS,#R, $U\I_
M%[X#^.O'?A3]H"PTW1%2Z\2>(M(U;1EGNHE6[BM$LED&0QV$FUDQNQ]Y:^C?
M$3^)M>^%.MG3M/ATSQ;=:5="QLKYTFCBNFC<0K*02I&[9NP2.HR: ,#P/^T-
MX8\;ZP-/B%YIKSZ,/$5E+J$!ACN]-+ ?:4)Z ;DR&PP#KD#-&B?M :#KVLV.
MGV]CJ@.K:;)JNBSO:,(]5@C4,YA/KAT(#8+!P1D<UX6OP*\;>,M8@^W>'+G0
M[;6OA]JWA35=2O-2AFGMKNZ-N?-\M&V^6#$X58P!@CA0!7J/P%U+XG2:1H'A
MSQAX-C\.-X?M(K2\U@W<,T6H-'$(\VZ(<J'PKDD #!7DT 9.G_'32OB7\(/A
MKXGU>ZUSPJ_B?6[&*R32XSF29[@B*WD<J5\ME&&/ .#@\5ZQI'Q8\-ZSXG\7
M>'H+N2/5?"L<,VJPW$#Q"*.5'>-U9@ ZE8W.5R.*^:=!^#_Q'L?@%\'/"5QX
M2V:OX,\5:5>7:+J$#++:VTSO),IW8P5887[V<\5Z?\7/@KK/B3XQ^&O$N@-'
M!I^JV,OAWQ:KMCS=.#?:(F49^_O1X>_RW!Z 4 ;WBW]I7PMX3MTGDM]3NXX]
M$3Q+>^19ONL=,9BOVB53@@?*YV_>PC<<&I7^-?G_ !N\/^"[33+J;3=3\-7&
MOKJ:PEDD"SVT<:KCL!.2Q(P,H*\K_:,^&OQ%^('B3QYIMEX=&L>'M5\&R:5H
MLMI>PVJQWSI,'-UN(=PI=3&O*#G(R21TOAOPCXWT_P"*?PM\37'A9H[>U\&W
M'A[58_MT!-A,]Q9R!CAOW@VVS_<SR10!O^ OBMX5T?P5KOB :]K6I6-QXHNM
M.BCU>,_:1>FX\G[%!'M5MHD!15()Z\U8O?VG/"6B:#XQOM9CU+2;WPC;K=:Q
MI4]FYNH(6W>7*%7.^-@IPZDKUR1@UXM)^S_X[OO EI<_V0+?6O#?Q5NO'%EI
M4MW%C4[1[N654WJQ5'V3G 8_>3'?-7_C%\%?%GQAC^*'BS3]"ETR_P!:\"+X
M3TO2+MXX[BYD:=IFEE.[:BKE5 )R?G/ID ]J\$?M >&O'/CF3PK:QZA9ZD^F
MIJ]FU]:/#'?VI(5I8&(PZHS*I(]1U%=%XV^(^E^";O2=/N!->:SK$DD.G:9:
M)OGNF1"[[1T"JHR6) '&3S7F6G^!?$[?'/X9>(IM#:WTK2O!MWI5_/Y\1\BZ
MF>U81X#98#[.XW $?,*L_&;P-XC3XQ?#CXD:%8MK=KX=@U'3]2TJ$J)WM[J-
M,2Q;B S(\297J03CTH P?C=^U-;:+^S+\0/''A!;@Z[H:R:9+:75LRS:9?DH
MA$Z$?+L\P-S\K?+@X85W_P ,M G\/:;J/B*/5_$>JV>H6<,JZ-JJEW@EC5M[
M1!E#_O,K\IR,J", UX)\4_V<O&/B[X0?M RZ9I;-XD^)6H6DUEHTEQ&AMH8!
M BF1RVT,WER,0"< J.N0/KG0(I8="T])XF@F6WC#Q,02C;!D$@D<'TH ^.O%
M'[3&K?$?X'_"GXD:==:AX4M=2^(-I8W%O$H"2V!OIXBDA*G<?+A&X*>K$<\5
M] Z#^TAX1U:P\83WK7NA3^%+F*WU.QU6T>"YC\X VQ$9&YA,"-F!EB<#GBOF
M[PK^S]\3?#W[.WPQ\ S>%UEU+P=XZM=8FGBOX/+N;6._N+AY4RW V21X!PQ)
M(QQ78_%/X&^._%?C'XVZGHVDVR2:M_PC%_H,E[-&8;ZXTN9IWB<!LH'.U 6
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MDX"@#@"NCHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3XKHLGPO\
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MAMX&\&6OC._%AX0UA-9L9GM(FD>1'+Q(_."JL[GC!.0.W(!Q'C?]HCQ_X7^
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MQS<?#S6%U.Y\/VGB#0/&\GA?4]78&.V>U0)(;B&!FW-*4E11%N)+9YQ73?\
M#*VF6'B'X>:II.O7UB?!D]Y>0+)&LS7MS=[OM<T[D@LTFYCQC!.1Z5D7G[(*
MWBWEQ_PG&K6VK/XK;QA:ZA;VT(:VO7A,,F%.59#&5 !&1MSDYH \_P#%OQ0\
M8_$7X":U=R:U_9%_H?Q'L_#TEQ;Z>T+7ML-4M(E\R)VW1'$X++GG9C(#''I6
MH_&'5_A_\9?%FD^(VL;_ $/0/ '_  E+WMI:%+N3RYI%E4_,>/W+L%'=AS5M
M_P!E.R'@[QKX?C\6ZT(_$6OQ>(TN9!"\EE>1W$5P'3Y<-F2%"=W&!@ 5J)^S
MK#=_$>X\4:QXBO=<AO/#1\*WNG7D,?EW=H=S,9&7!WEW=B0 ,-C'>@#R75O$
M/B[Q[-^S'XSUJZTPZ;X@\1V^HKI]M;LLMB\VDWLD4:RECYB[&8,<+\RJ0"#Q
MT6G_ +0'B/0_#_C5+^TTN;7(?B-!X*TZ6VB:*W5KB.S\N>;)+-M\]BV.3M X
MZUO:%^RDNBV'@O2_^$[U^?1O!NI)?Z):.D&ZW1(984A9]A+A8Y2H)&0,^H(D
MN_V4M.USPMXYT36O$-_>Q^*-:3Q%]J@C2">PU!!$$FA8$_=$$6 ?0\\\ '?>
M #X[M?$?B6Q\5-IM]HL+6[Z-JEF/*FG5H_WR2PY;84D'# _,&Z#%>-?M&_'O
MQG\+9O'5]ID^DI:^'+"RO['3O(:[FO59C]I-P48&U0?*B.P()R>G%>S?#/X<
MWW@>*\FUCQ7JGC#5;H(C7VIB--D:;BJ+'& HY9B3C)SR>!7G_P 0OV3K#Q_K
M'Q"G?Q9K6FZ;XWMH8]4TNU$7E--%''%'*&*[AA(E!3.#SZXH L:]\2?%_C3Q
M_P#$CPCX$N-/L-3\&:?9R@ZC;F5+Z\N8I98XB=Z^7& B MR<N>/EYHR?%WQ/
MX;^,EI9^*+'2;71O^%?WGB6Y6RS+<07%O+:K-$)C@-&/-?&!SP>,5IZU^S6]
MWX[M_%VD^.O$'A_6[C3[?3=;GLO)(U>.$_(\BLA5),%AO4<!N/?3E_9^LF^(
MNG>(DU:==,LO#\OAE-$:%6A-E*4:4%R=VYFBC^;T7&.<T >$^.?$7BGQ]-^S
M%XTUF^L8M-\1>+K/4[?1[:V(>S2:QN9(%,Q;YV$;8?Y1\QXX'/O_ .T-\1M9
M^%O@&#6](L);N,:A;0:A<P6S7+6-FS'SKGREP9-@ X![Y[5P=C^QU!:6'@O2
M7\=^()]"\&ZU%J^AV;K"6M1&'5(3(5)9%5]HST&1SQCV/QYX0OO%EEIB:=KU
MUX?O+"]2\2XMD602!4=#%(C<,C"0Y'L".10!\\^,OV@?$%I\,_ GB;1=8\,^
M,--UCQO9:(VH0VS%3;37"HK!-Q\N= '5@3PW(J;XO_M'>+O#$GQ?N=$ETJVG
M\ 2V*VV@WEN[SZLD\<3F3>&&T,9'C3:&^:)L]:Z;4OV0],N_!UIHEOX@N[%X
M_%I\9SW$-M'B:_#AT CZ)&"%^4=<=:\F\6Z5?WOQM\43ZEK'C7POX@GU$1Z7
M#:>%XM3BG@CB1(YX+DQ.(TD*NWE[AM8MGDF@#T/4?B5\6[_XZV_PXTZ[\.Z8
M]WX+;Q''>W=E-(89A=Q0E&3>,X#$8R/O9S\N#!X6^/GC'QM\+OA5KOVO2-"N
M?$>GW<NHRI;M=S-<QLJ1);6H8/(';>S8/RA0.]==X9^"/B2[\;:)\2-;\3/:
M^-$\*KX>N[:&T1K8 L)7<#=G<9E5NN.-HXYK%\)?L=P>#)?!4^F^.=;M+KPQ
M:7&EQSP10JUQ8S2K*\#Y# '>I.]<'D>E 'G7C3X@7WQ:^&O[)?C/5((;?4]7
M\;:7=3I;Y$:NUO<AMH/(!QT[5H^./VB?'?A"W_:5FLH-!^V_#P:=+9R&U?$Z
M36IE/FG=EF&Y .@^4^M=W:_LC16'@;X;^&;?QEJAMO NIC5=.EGMX79I$W+"
MC 8^1%=QCJ<Y)I?%'[),/BF?XKM/XLOHH_B.+9-5C2UCQ&D">7&(SG@^6 I)
MSG&>* )?"OQ2\?Z?\5[;0O$PTC4M+UKPE/XCT^/2X7CFMI;>2!)(&+$^8&^T
MH0P"X((Q7&>!?VB/'?BS5/@Q+;7&C:E:?$"&[GO[*WM9-^AF!!(Z,X8EMI+0
ML65<.,^U>C:Q\']8\/ZI9>,[77+[7=7\.^&+K1[32H;>*(WJL$D90Y/R2.]O
M" W08Z<FO#/@-X>URPU70H_"WB?Q4^NVDMHNM:9KWA..S@,6\?:4GNO*5G<+
MYN&WL6< _-DT >^?M3>,O&/PW^%\_B_PE<VL::-+%<:K!<V1N6>Q,B+/)& Z
MX:.,O)CH0IK/^('Q"\31>'_BAX@\/:CIMWHWA[0O/LX[JT\R*>Y%L;F3+J_S
MIY1BXP.9#S@5[1JFEVFN:9=:=?VZ75E=PO!/!(,K)&RE64CT()%>:Z7\ --\
M._L_/\*=(U.ZM-.?39-,;4)5$MPT<@(D8Y."Q5F&>@XXP,4 <-XC^+OC,:'X
M+;3+G2=(35?"7]K"1;5KRXGO_*C988[1&#B%0S,SC.!@5ZS\%O&]S\2_A!X*
M\67L$=M>:YHUIJ,T,).Q'EB5V"YYP"QK@HOV84AU;PSJ4/C+6;.[TOP^OAB[
M:T2)!?V".6C1L@^6PSRR<GCIBN^^$_PW'PI^&>B>#K?5[K58=(M%L[:[O$02
M+$@VQKA0!A5"@=SCDT ?)_A^#6/V<+C6?B[H8FO/ NK>)-6A\::'!&7>#;J=
MS%'J4"CNBA%D4=57...+W[1NIZ;XC_8.^,VJZ9/!?:=?ZG=W4%U P9)E.I1E
M'!'7C'/M[5]-_#3X:2^ ] U32+[6'\06M]>W5Z5NK9$"FXEDFF3 )!4O*V >
M@XYK@_$?[)6@:G\!+_X1Z3JEWH7A2]O9[F1+>-'D2.6Z:Y,*$]%#D 'D[1CW
MH Z32M2U#4M0FUSQOX.M=#L?#5J-0T[4VNX[J97,4R7!&S)4"(@?[6\\<5X)
M^V3\9_"'Q>_9)\<W'A?5/[233+[1VN&$+IY9:_A*\$#/"MT]*^O/#^G7FFZ-
M!:ZC??VI=("'N3"(M_)Q\H) P,#\*X7X\_!*V^.?@"?PC<:K-HNG7,\,]P]G
M"C/)Y4BRQ@$],.BG\,4 <?X&\>:_\7?!_BSQC'JUDG@FYAO(M)TM+7_2Q&D3
M(S7$F_Y',@8^7MW*,!L'('RB'\1:S_P37\)6$?A,IHUO8PSW'B=9XY9=+MX[
MHRR7D,2$R;E"'.,$ DYP*^O-&_9TO?#6L>,;W2/&-S80>*F\_4;!;&,V_P!J
M,2QRW$:[OE>3&YN<$_KE:-^R8=.^$^G?#&?QOJLW@:VA:TFL8+>*&:ZMR6)A
M>89.TEN=H!(&,\F@#V[PKJ]GK_AG2=3T^Y^VV%[:0W-O<X(\V-T#*_/J"#^-
M:M4]'TBST#2;+3-/MTM+"R@2VM[>,86.-%"HH]@ !^%7* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 0@'K2T44 %%%% !1110 4AYI:* "BBB@!.M  '2EHH **** "DVC.?Z
MTM% !1110 4444 %%%% !1110 4444 %%%% !2;03FEHH **** "BBB@ I H
M!S2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cgtx-20231231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *, DL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+<D&1U1<;FQQD]: .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)^B*Y91<':2/F<1AJV$J.E7CRR04445)S!1110 4444 %%%% !1110 4444
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MFNZC0GS1GT/N<FR/%JO0QFCA=/?H?/-%%%>N?K9^IO\ P28_Y(MXO_[& _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYT!]68NDGVV]-T"JX(!C1 #ZGY*VJ*3DWN;4\-3I.\0HHHJ#J"BBB@ HHHH
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M/5GA\8U#FU6WFV?0X3 9[PU!XN%/W6O>ZVC%NUXJ[2L]-7:VMCW_ ,9?M/\
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M 4444 %%%% 'S5^U#\5[M+'5?"FD0,;H0':YP3+/M)4*N>0IVMSU*MP=H#?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;[=U99(O.=5WQ<DA58 @D J",+UK;\0WMKXLO=>\4:O/(\ VVEOY ._S0-J
MY;LB,Q^JDG)P+?AWP)%/\+]>\1G6U"NR6\EE>2;8]V[S/,WJ"22=J#NQR,'@
M5PXY47A(SFN6I[L&[/K;W>VE^UBJ=U+5GV!^S=I7A>PU&VTV$6RI;120V*HN
M%F*2LKR]3\S'G\<=JR/VE[:'2M4U-;P?:6O+JWE:)SE7A(8IC)Z@QLA'3"J:
M^<_A!\04\(066G74DL(MV21;UV57W+'N*@L?O;23D#J$SR>?MO7/!^G?'OPU
M9:S PM=4@RL5R4'[R,$E"0">,'<,'C<<<$@_C>881\.YK'&UVW3GN_39_.QQ
MU/W555'L? >I>%]5T[7+Y=/@B#R#S(M-#+<0H2,Y78=N<=>>.>]:_A*;5M/\
M+ZK#J.FBQO+O-NUQ(R@M&,_NT!/"G/)]NU>R_%/X9ZIX)OG$UC'=W,=J;F)[
M=2BS%6&2S9X(!.2,_P (XSD?.Y\1:OXL\4"T7?MGD$$5DH)^?C 4#DMGIQSG
MO7Z9@L72SFBJL6G%I-W?;RO^?S/5C*]-26JM^)R_ANXM/!,MY<ZA#'>1?:%2
MW;;N5">2''?IUKN_&WC"?P1X=B6&SBEO)$3S)HEWQJ&48R._)ZGOVYX[G4O!
MNAPO*$MQ]M@BD'F*ODK(BK@,Z^N0.#SDG/)IFJ:9-<^!DLUTIM6O[Q&MTC2
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MZ]@U%M4$ED&B2$8\IDY4C[QYY!ZU^C6O^!L:#:2SS^4Q7;!.X!3DC:K YR<
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M,H8>A%9^M^'[#Q!IDMA>VT<UM)U1E!Y['ZBOD,NXIQN7TX8>"7LX^6K7K?\
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M10!S7Q&\+/XS\(7FDQQVTLDCPRHMV\J)NCE20'?$RNC IE74_*V#@XP?'?\
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M<%&QSP?O#CU_*O$CG6%E/D39Z[RK$QASZ&O\1/B%#X>AF@C8B16$1;D#>5W
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M92ENCP]?V@]0?5)K^;6)@EP?W5L;:-8N?;D\ _F.2:^@_@U\1-0\7Z \MQ/
MRN#%&L;].Q^AY'&?TKY%\7_!CQ!;SJ^H6I^Q1_<NQC'S<DC)SGKZU[3\'O#
M\/:&-$EG$%](IGGE4E1$F!M!;H&)*_G7P=.K.G+FBS[&=.,XV:.P^-'ABZ\4
MZ%:B$HQ13')$X&XRJ#G&>.JC@^AKY:\5?"37H]05=0L98H8CY<5T%PA&,\$\
MG/TK]'(?!:ZEH!FB5;DS+\ZN<^;\H7<#TYP3[YKSGPWX,\-7VJ7%E;@:M-+"
M+A=/EE&Z!%D*[@OH&!'XUZE;+,1&2?+I(\^EF%"2:OL>7_![PK<V&C6_AR&1
MXM5C47%P86(,7.=N[IG@9Q7JWQ"\(2:SI=UI\JS$[OM431'+2HQY^O._C_&D
M^*4:^"/!5V^B.EIK,\<QADC<,8IDC,@W@<\A",8KUKPC<1^._A[X>U2<*LU[
MI\%QOC&,%D5CCVSVKT\)E#J4JE.;M/0\_$YDJ=2$X*\=3X%\5? =Y;B62VU6
M"Y"AF>RPWFAAG=M7;TQZGZ5WOPD\!OX1M8+/[,_V>^Q+=7$GR);QG)"<]2<8
M/U'O7L&A7]A)\1X=(O=.6P\22&>WCN&52C.AR5R>Y0AU'=<X[U9^-^N6OP[\
M+O%/-:C4+[S8" N/+#12,C>Y+1@#/O7FPRJNXN<E9*_X'?+,:*:BG=NWXD^M
M>!V30&THP$V-S!B)TRN708Z]@<KCV!]*^;/&7P+M+O4A$FHM9WY;'V*XB8F0
MG&W:1QD="0?PK[2^#DDGB#X+>#)M0=KB>XT:U>61S\S,8ER<^M>6>'/$T=Y\
M1Y?#NOVL&G:I!'/+!<SL$4/'-MV!CW,;QNOJ&->KC<EE&4?8N]]#SL)FJDI>
MU6VIX[\*_A9J'A1A)9Z=+]JO6V3>:-@@C! + =2QZUZ1XP^"UW#/%<:;<I:V
M]UO"R20HQ27&?E8C<HP3P#S@UWGQ@U"Y^'_AB26&X5KJ[@NMEP  8MENSAL
M<G<!^=;/P:\0VOQ!^'FGZ5J4K7>NZ/;6D6J%EQMNC"KDY[DYY^IKT\GP^)RZ
M57V55PG)6T?]?\ PQF81J*$E&\;ZGR'XO\)ZY96]D$TF;7I=-G,D+VS+GGC:
MP92<!D4YX/! .",<I\,_"%]:^,;KQ-K8,(25Y[D<EEE8DA5 .<DYZGH.:^IA
MI^E?$GQ&^F,EQ8ZO;VS3NB##;%E:-U)'4!A@CW![UI^+-+T'P/IDVHWEE'IJ
M&&6Y67&XRM&FXM@C).!W]:XLRQN<YKAZ6&Q<G*%+2.GYM+\_\SU*-?!TI-P=
MF_/^OP*_A[3[BTLGN)[B14N!]L@@+?(F$V9QU &[-?+?C_QE?C6YK6_>*]TM
M;<Q&)SAI#P6;=T'S# 'L.M?<$.BMKO@'0M7LH6,TUO'.\4H 8Q2(-R_AD''L
M:^>_B9\(M&DEG>_L[D1NY*36(#-&=V<%2.,YP>HXKSY1QF1UZ.*H2Y9QU3[,
MK#8BCCE./]>I\^>!_B'>ZIXFMM,TVUN=,M9I/WKLZM,055<*5 4#Y < #'.,
M"OHK0/ EYJ.N%3?BX>TGCEGBFC4!LYW,7 !;&,G))X%<_P"&?@-<^&+YK^"S
M\MU4-8S71&5#<EV4#J!CC'K7NV@^&WT[PO:WP(N#&J/>S)]UP<@D>WSECZ 5
MZG^LN?8^M/FKR;DM5MIY+I\M^I5:CA:5--I6_K<\4^,GQUNM'F;2+5IH+F5V
MB0PIEDB0E1CD;=Q'7KQVK@_#/Q]U"+4;:QBUF:9ED"M+J+*<,3@C*G(QQT_$
MFNK^+GPNU76]<NI;.X1[EB98ED(4N<9"\D9SZ^JUX_H7P7U"#Q3%]N1+66,F
M>8E@PV=2?E)!/:OBISG*3<GJ>E",8Q22T/O+PUXIFMK:UOC*+@PA!<M&<L5R
M ^1WP3GVQ[UE?M!>++76/#@TJVF#;W=RR8/ BDP<^_\ *N3\&6"W.F/KGE3Q
M62VTEFL# JS)PIRH^C'/H*XWXO3FW\911!G@B,#!U"_(%$#A57T'S _4FONN
M&<=7AF&%I)Z2G'\_U/$Q6$I2DZO6*_K[BK\'?BG%X+MY;6XN)K8>86!\O,;_
M #MQD'(_ &OJ/P-\0K'Q#9Q21W!>WD/[N20Y_(]Q]:_,WQ_?ZAIWBU(].F,E
MF+6)I$!.-Y+%B0#@X)/6OKCX3^(KZ'P]X?MKFSCG%T$258EV;4/_ "TZ<<XX
M]0:O/,QJX;B'%\K]WVDM/F7/!4\1AES+WK;GU=<745I&9)I%C0=S7.W?Q$T>
MTN1$;@-V9@1P:\6^+GQ=N_"NAV\]Z"(DB+D*<EMI54!([L2#@>O)KYE7]H+4
MK>\>\N-<U%)KH_NXIBJPA>,X3.,=?;(Z'K7)B\^E&?+06BZL\[#9,I0YJSU[
M(_1VPU>WU$#RR58\A7&"1ZCL?PKR+]K*V%W\-[-"VW;?E\_[MK<''Z5Q/P*^
M(U[X@T*.[FOX9"S[8E5L ;3R#Z'D5T?[2/B"'4_AC8>;F&X^VR+(A_A<6]RN
M/Q/(]B/6OL^$\S6,S"@GI)21Y^*P$L)5BXZJZ-7]E&0R?#-23D_:''Y'%>T5
M\F?!KXOZ?X6TQM#M+ZTBDC8/Y<\A0N2H+?PD8SGO7T)X5\?6FO!0+B.0L <+
MU7/OT(]ZK,\RPT\UQ%"]I*<M_5F-; 5XQ]M;1G7T5'/<1VT1DD8*@&<UR>J?
M$>TLRJ0037$C'LA(_,=ZY:V)HX?6K*QQTL/5KZ4XW.PHK T3QA:ZT 54Q'HR
MN<,I]".HK6O]0ATZW,TSA$'<G%5"O3J0]I&5UW(E2J0ER26I9HKQ;QQ\?K#P
MZT$$E_;V;W!^3.XL%S@'A3C/;.,]JT?"GQ>AU=E1M1MIILC"*<JX/0= P/OC
M\#7D_P!M81U.1/Y]#T_[*Q/)SV^1Z=J.HPZ9;--.ZHH!/)Q7DOBWX\:=I-Q!
M:MJEIITL^-F]SO.>G&UL9]\9[9J#XPZ^+O3=0FAF>'R8HTR6X3YE8X[98'@^
MPKX-\2^.-=MM2O\ 499(6NS(1%'&HSM8\ ,1G  !]P:\+-,WJJJZ5!V2ZH]C
M+LMINFJE97;Z,_1#PQ\4TU638;^UN)=VWRU.5;_=8 8_$5R?QJUE;O3-1NXI
MI(3$T2Y9ON@8;8/0G)R1UQ7RW^S7XTFU+Q)<2363F2.+_6!]H&" <@8&.>OK
M7U#!:Q^,M,F>!&>PN8GCE29>(Y4.W=@]00R_]\^]>9]>Q&+H/#R=_P SO^IT
M,-559*Q\*^(?%>NZ?=W]V]^9=0:3 C "C!Y(Z=!QC/ZUZ;^S+XONKK5[N2>S
M#/'%CSI&PR@=<]!@C.,#K7>^*?@CIVIZU%92:-<K>R,RQ7=L_P"Y.>?F^7(P
M>@STK<\%_!#4O#D<4:I'99<27KJ-QE4$80$]!MKQHTYMZ(]1SA;5GJ'ANQM_
M&UN]Q';3>3=6Y9[>48VM&X4D$>H92,?W:Y-/ ">([R7&I_:]$=6WI$@:9"P)
M&&Z^XZUZ/\//&>AC1/%=]:QSNNA3/:W=M%&7E0HOF-A1RV=^>/2O _#/Q0M?
M"_Q4BOK&TFN-"EA*A+I0WVJR4E_,B()!EA);(ZLF>XKZY9;1G1I3JNS>K]._
MI_GT/F7CZL:M2--72V]3MM:\)Z-\--"DU[<?^)9;L\!G0EBL>2ZJ.,L03R!7
MJ?BWPSJ?B_X>6C^%M3;2[J9%O C$A+H,F?+=A\RY!&"#P0*^=OVI=<OO$'BC
M2-.TZX+VFHM?16WEME)5&G[T5<<'>9"?? KZ5^!_B6R\2?!SPEJEK<));MID
M*NP;.QT0*ZGT*LI!^E>OEV%H475C#TO]_P!QYN.Q%:JJ<I>I\CR3W?AGQ->:
M?>7]W::K;V[ZE9RW4WF36DJ+*)8W8_?3=%L)/WEDYS@8Q/%NGRPZO_:6I64U
MGI'BK2H-,U$;<_8VDBVV]R/5&&T'T*XKUS7O"/ARS\4:SXI\82QW=Q<VQA:T
MD)$42M/))M.WEF8,H*@<!>^:FUGQ)X7^+ND36-]?V_V2\LVL%DMV:.2),@KL
MW* =K+D=Q^=>5/'8>FW%R=[VT[7MKZJVODCT882O-*22M;\;?YW^]GJ/P%\?
M:A>_"R%/%%O]CU;0V72[B9>8KPJJB.6(_P 0<%?H217EOB?QAH'P[O+N_L;=
M[S4Y994$X ,Q+RM(<,0=JAF('&3QD'%>NK?JO@G0K%;M=0GA5(FO74+YKB,@
M2D=B2"?J:^(/C9ILG_"2O/);W7V:V9U$9R0H)W,2/?<,GZ5SYOCI/DA2E=6W
M[FV682*YYU(V=]CV_3OC'H^IP):Z[97#17:-%-:77ER*0XVD90#!.2#_ $KU
M2%;'3?#GAK3-,3[%I6GP-:P0;BS1(54QKD]0H3'/MGU/Y[>!CKR^+[)[>1_W
MEPNUE3+#GA3CJ,=?49K[L\)7=YKEV-,N5$MH%1A<KPZ2B1>%[$#.*\3#UZDK
MT+Z2/7KT81M6MK$^:?BK\/=;?6[S4H-.2XEC9E;R%W?*.!@#GC<>/3%<!\-O
MAUJ-MXOLYI3-:0V\@EN#(QC,(!!+\CCGI]:^^_&?PN>\FS 9K&=LA;RT!P?9
ML>P[UGZ3\(M)N98P;.2XGE14FN78,LI7').<=?;M5RRS%1GR<C(CC\.X\W,C
M.^'NCW7B2"0BY?\ LV[B06XQD*ZR9#C/L,GVK7\8?#RYN+@);O)IEZ2=MP@+
M1R=.N, \>O->I^'O#%MH$")"BJ$^XH& G&./PXK5F0OQC(KZRED<)8>,*K][
M^M#YNIFTU6<J:]W^M3P32OA%ID]Q^\BN+B]N(UCN9CRDN,$]^.<9^E>P^%O"
M-KX:M(H((T2*(?NT4?<^E;J1)&H"J%'L,4^O2P>5T<'+G6LNYPXK,*N*CR/1
M%*_TV"^=&EA21E/#$<C\:9;Z!8VT@=8 9 <AW)8C\ZT**]1TX-W:5SSE.25D
MQ ,4M%%:$!1110 4444 %%%% !2$X&32TG6@#B])\::YJ[6.H1>'4;P_>3>5
M'.EX6NUC+$+.T.S:$. >'+!6!(X($'BCXP:-H7A^^U&S8ZC);I'*D.UHEGC:
M9(B\;LN'4%QRN1T]13].\!ZUIMQ:V47BAE\,VLXFAL4M-EWL&"L+7 ?!B#=O
M+#%<*6/)/*#]G:$>'+G1AJ=E'"MO':65S%I86XCB66-_WS^8?-8B)5RHC'4D
M$XQQMUE&T5K\CK2H\WO/3YGHW@GQ2/&6@#4UMS:@W5U;>66W?ZFXDASG'?R\
M^V:J^(/!MM>K<3VT,:SS?-*C?=E..OL>G/L/2K/@?PK_ ,(9X?&E_:OMF+N[
MNO-\O9_KKB2;;C)^[YFW.><9XSBM74[L6&G75TR-*((FD*)C<V!G SQVJYT8
MUZ2A65_\R(U94:G-2=CY\7PGX9T;Q+]CNU3[5>2BS73[R0!%D(#JJCD$D#(%
M;=S;:(/"OB*YTA[.YU+2XA)>6D3AF12,X; _N E?=16)<P>%/VC;O4;.&*]\
M/^)HH8YFMKS'EW4:M^[F4HW)4G D0AEW#Z5Q?PBUNQ^'GQ<U32_$,JG3/%%E
M#I#W3ONCBO[8-$T,I[&1<E6.,].IKYRCEV&ISLU=.]G=6\O.Y[=3'5YQNG9J
MUUK?S^1V7PH^,;^#/@W?+JZ7&JW7A_5I]*>;/ 3/F0O*V#M78ZC=CTKCEU-M
M3U*3QIX56X\-Z]IEP(KC2;QP8Q]H/"*PXDMYGP1W60@C'(KH;GX;>,OAE\2&
MU+PY:#6-*U;9::KI<R[K?48%!5)-W2*94.#N&UL'GGCG]-\(W?CGQ+?:7HMW
M!I&G:?\ 9IY/M&?FB2>[,*<==I\LX]%%>M5E4DE%JS2?R:ZW[:]CSJ:A%N2=
MU=?<^EN^ARWA!XM9\2>++:^N)4DN-*TK4+<OE@T/DS0SR#U*/-EO05[S^R[X
MZ_MCX50^&FA$/BKPK"--N[&8[=Q0$12@_P!QU ((]_2O)O%?PRU#X80:9J_A
MBYD\0ZGX?B-Z).-]Q(7_ -*@V9R8I4;@<X*U],?#_P +^'K.TAU_1M.%G+J=
MI$2SYWK%C<L?/0*6/':IPB7M'RR3Y59VZ]4_7N/$O]VN9-7=U^37^1\N_$[Q
M_J^L^(1=>(="MM#DMIA;RSP[H[S3Y@K-;R,<E9$W@;7'8L.A(JK^TC-<^+?"
MOA+Q+J4;P6\\=AJ5]$%.Y(&A>.60#N(VD#$>C5ZQ\>?"2>-/B)HMM)8K+IT!
ML&U26;B.2 7#R>7_ +1^1AC_ *:>E;OQ(O=#\::3#IL=GY8M&7R)WA;8J\*\
M9&W&QDRIYQT]*Y,14HTU5A5G9M[=^OXWM<ZJ,*M1TY4X75M^W3\-[#?V3O%<
M^L?"JST"_A,>I>&0FER2KEHKF)4'DSQOT973!^H/M7G/[23Z+JGQ+MUCV27%
MJEM:7\>?EN6FE"B%AW81DOGJ,"O3_P!FS2=4\(>%]4\+ZG:K#;:7J$BZ5.K
MBXLFPT9R.ZDLISS@"N>^._PEM[R>&[T'3[>UU2=[J]DU.>0[8;DQ[8V*YZEF
MSP,_)@5U5Y.K@^;FZ7;_ *Z]&<U%*GBN7EZZ+^OO1PGB2VNQ\%_#TES<2ZA:
MVBW20R.2SO:I>1@C/<B!6_ &N^_9%E1-,\>6LQ5M47Q'<3SN#DR12*KP-]-F
M /I5QIM(_P"$-T7PK]A,MAIMM'$2$)DRJ;2RG<.H+9R#D,:QO@GX2U3P1\59
MI8S%-X:O]"BMWNU?DW,,N(0PZY\MV&>GR_2N3#XJA];M3G=-6^>G^7WG37P]
M;ZM><;-._P"?]>A@_'3Q!'X#^,FG:KX=FBM=0C51>SDAHX99P8U61.ZN%0D
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MORL!D8-2?$3XG6&D_!JX\0Z C#[1I]S+,EP,RVS1QX:(C^%@[*#6?^U#\,=
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M%1E3C>4E=WVU5CR<+EU23<:CLHO3Y.YT6D_#V\^$7]EZY92-J%AHNNPWUO\
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MY9 /(89*_0_2O./CQX/O?&+V\EG'%<1-$'A! +[N.3[?.W/4"HO@5XFU/3?
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M!SZU>8Y-4C)2PZNNQ&!S2$DXUW9GQ5\'O ?_  B.LMK-\"+: A!" 6=I?[H
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M<R2*3YGFLVXXQ@=>#_A66,S*O6K2E%\J?1-FF%P%*E22DKOS/T&^#?B#P_\
MV]J^L:8$C>\@@@N1$QV$Q@A3M/W3@]NV*\Q_:!O+J;P[9M:3S6MU=0/AD7)^
M<AG;_>.''MVKE_V>/$VIV7@V>ZFMXI7\XA8PFUI#MSMS[<\^A/I7NVK>%/\
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M."G'5<_A^5=]17SV(PU+%0Y*JNB:->IAY<]-V9X[I7PG@TJ%;2+3/M8C=O\
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M>I-;5% &3XA\+:;XGTN73[^ /;2S13NJ':6>.19$)(_VD6M(6\2J%$2!0"
MHP >HJ2B@"(VL)0(88R@QA=HQQTI_EIG.T9SNSCOC&?RIU% #418UVJH4>@&
M*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<Q\2?"DOC?P5J.C07"VLUQY;)*\>\ I(L@!&1UV8Z]ZZ>BM*=25&<:D'9IW7
MJ@V/)O@1\.=5\ Q:L-3\O-S*&3RQV%>LT45=>O4Q-25:J[R>[_X8J4G)W844
M45@2%<S\1/#%QXN\+3Z?:7*VMSYL4T<CQ[URCJ^",C@[<=>]=-16E.I*E-5(
M.S6J&G9W/./@CX"U'P!X>EL=1:)Y"PVF(8!   [GGBO1Z**=6K.M4E5J.\I.
M[?FQRDY.["BBBLB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9'*DN[8ZOM)4[3
MG!'4'WKQ?]JGX_P? SP"[VCB3Q/J@:#380 ?+./FF<$_=4?7+%1C&2/SP^$?
M[0OC'X.>)9-5TK49+N"ZE\R_T^\<O#=DDDENX?))WCG/J,@\%;&0HS4'KW\C
MP,;G%'!5XT9*_>W3L?KU17D/P)_:9\)_'/3HDLIQIOB%4S<:/=,!*"!EC&?^
M6B<$Y'..H%>O5V0G&HN:+NCV:-:G7@JE)W3"BBBK-@HHHH ***CN+B*SMY)Y
MY4@@C4N\DC!551R22> * )*B2[@EN)8$FC>>( R1*P+(#G!(ZC.#CZ5\:_M"
M_MZVND&YT'X;-'?7FTI)KTB[H8B0?]2A^^PX^9OESV:OFSX"?M%:Y\*_BJ/$
M6I:A=:G8ZFXBUE;B1I&GC)_UA)R2Z=0>N 5Z$UYL\=2A-06O=GS=?/<-2K1I
M1U5]7T7^9^L5%4](U>RU_2K34M.N8[RPNXEG@N(6RDB,,JP/H0:N5Z6Y]&FF
MKH****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5C>,?%VE^ _#&I:_K-REIIN
MGPM/-(Q ) '"J.[$X  Y)( ZULU^<G[</[1?_"P?$9\%:!>+)X;TJ7-U- P*
MWER..HZHG(&#@G)YPN.7$5U0AS=>AYF8XZ. H.H]^B[O^MSP[XU?%C4_C1\0
M=0\2:DS*DA\JSMCC%M;@G9&,>F22>Y)-<+117R<I.3<GN?D=2I*K-SF[MEK2
M]4O-$U"WO]/NIK&]MW$D-Q;N4DC8="K#D&OU9_91\6^-?&_P@T_6/&ZPM=SN
M?L5PB[9;BV  625>FXL&Y&,C!P.I^$/V3/V?IOC?X]66_BQX5TEEFU&0DCSC
M_! N!R6(YZ84'G. ?U/AACMH8XHD6**-0B(@PJ@<  =A7MY=2DKU&]#[?AW"
MU4I8B3:B]$N_G\CC/C5XVOOAQ\*_$OB;3(K>>_TVU,\,=VK-$S;@/F"LI(Y[
M$5\,_P##QWXE?] /PI_X"7/_ ,D5]B_M5?\ )O'CK_L'G_T):_)"C'UJE.:4
M';0>?8W$8:O"-&;2:_5GU5_P\=^)7_0#\*?^ ES_ /)%>_?LB_M/^*?CYX@\
M06/B"PT>SAT^UCGB;3(949F9R#NWROQ@=L5^:]?9/_!-;_D=/&?_ &#X?_1A
MKFPN(JSK1C*6AYN5YCBZV,ITZE1M/_)GW[7YY?M[>/?B+;^-I/"^IR'3_!<\
M:36$5CN$5\@/)F;/S.KCE. ,(<<AC^AM>7_M$?!'3_CG\/;K1YT2+5K?-QIE
MZ1\T,P'3W5A\I!XY!ZJ"/9Q5.56DXP>OYGV>:8:IBL-*G2E9_GY?,_(FBK^O
M:%?^&-9O=)U2UDLM1LI6@GMY1AD=3@@U0KY+;1GY&TT[,^U_V"OVB&LKM/AI
MK]P/LT[%]%N)"<I(<E[<D\;3]Y>F#N'.Y0/N^OP^MKF6SN(KB"1H9XG$D<B'
M#*P.00>Q!K]4_P!E#X^1?''X?*;QE3Q-I06#48AT?KLF'LX'/HP;MBO?P&(Y
ME[*6ZV/T#(,Q]I'ZI5>JV].WR_+T/;J***]D^R"BBB@ HHHH **** "BBB@
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MS4G=[GV/#V*G7=5597>C_3_(Z&BBBO9/LPHHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,@HHHKL/9"O._B]\!?!_P :]*-MXBTU3>(N+?4[?Y+F \XPXZCD_*V5/ID
MCT2BIE&,URR5T9U*<*L7"HKI]S\MOCM^QWXP^#TMQJ%E$_B3PPH+C4+2,^9
MO/$T8Y7 _B&5QW'0>!5^XU?,WQV_8<\*_$H3:IX8\KPIXA8[F$4?^AW![[XQ
M]T_[2^^0<\>)7R^WO4?N/B,?P\U>IA/_  %_H_\ /[S\TJ^C_P!@7Q)_87[0
M%O:LR+'JNG7%D=Y[_+*N/?,0'T)KR'XF?"3Q5\(M<;2_$^E36,F?W5P!N@G&
M <QR#AAR,XY'0@'BK'P,\5IX(^,7@W6I9DM[:UU2#[1+(,JD+.$E;CT1FKS*
M3=*K%RTLSY?"REA<7!S5G%J]_P 3]C:***^P/V,**** "BBB@ HHHH ****
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M>2*^RJY<!2]G3YGNSS,@PGU?#>UDO>G^73_,****],^F"BBB@ HHHH ****
M"BBB@ HJD-:T]IO)%];&7=M\L3+NSZ8SUJ[0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?$O[3/BK1+?\ :[LM$\:?$?QOX)\(IX&BOXX/"FKZ
MA:(]U]NG4O(MJ#D[%QN8=%'/ K[:KS/_ (5)<_\ #23?$[^T8OLA\*IX>_L_
MRSYF];N2?S=V<8PX&,=J /G;X/\ QDM?AC'\1_'5EXE\9^,/V?M)T**_AU[Q
M;/<7=S<:B)&5H]/DN 'FB9<*Q8A%D"A3RY'JOAS]J#5K+QAI6B?$CP-'X"CU
MRVN[G2+J#7(M4\P6T+3S1W"1QJ89!"C/@&13M8;L@9SO&?['\7B6#XL>&;#6
MHM$^'WQ#L1+<Z5:VQ\VPU<,"UW =VS9+M4R1X&YD!!4EBT>A_L\Z[;:K:WVN
M:/X'TC2]/TZ]@O+?P3H44=]K32VS0_ZR5 ;8#?(0D;9)*@OMW*0"M9?M>>+;
MF#P1K\WPBN+7P%XUU?3=-T777UZ%I_)O)56*YN+58R8E*,'50[DY524SD=G8
M_M(_;?@#J'Q,_P"$=V?9-3NM._LO[=G?Y.IO8;_-\OC=L\S&WC.W)^]7R_X7
M\37OC30_@-\,_#GCK0]?M_"_B+299=$@TJ:#6XK"QD5HQ?QNY6U,,41#MC$D
MGEA2 V']HN_V:?B&GP\UCX9Z;XF\/VO@J[UZ;6(=1FM)I-22"2^:^:U90PCR
M9B1YW_/-BH0, ] &OX8^*'B'PWK/QTO(=*USQS=6'BZUT_2=$M)B_E^;866U
M0SDK! ))&>1\;4!=R#SG@_C1^UA\0]$^$/QBLSX0L_!?Q'\+Z##K%J;#Q!!J
ML*V\LIC,V\PKMDCVNWE/'A@%PW/'<_$3]EO5O%ND^/K>UUNS*^)/%NG^(WT^
MZ21;:ZMK>"VBEL+DJ<F.80,&(!&U_NFN:O/V,=3\16'Q%M;B7PIX1T_Q7X37
MPW!I7A736CBL75_,69I#@S$L[@G:ORJ@ R"2 =GJ_P"T?XRM]5L?">E_#6TU
M+XC1Z8FKZYHTOB:."QTJ&221(4-Z8#YLLAB8J@C' )) P3Z;\)/BEIWQ>\')
MKFGP36,T5S/I]_IUR5,UE>02&.:!RI()5E."#A@5(X(KQCQ)^S=XFU_XD6_Q
M(N]*\!ZWXBU'0X-)US0=:M9+BP,T,KM'=6L[(TB$)(RE"F& 7G(W5[!\%OAY
M=_#+P';Z/J-YI]]J+3S75Q+I6EPZ=:JTCDA(H8E "HNU S9=MN6))X .[HHH
MH **** "BBB@ HHHH **** "BBB@""TLK?3XFBM;>*VB:1Y2D*!%+NQ=VP.[
M,S,3W))/)J>BB@-@HHHH **** "BBB@ HHHH **** /S/T#Q/\.?"7PDU[4O
M''[.FI^+TN?%.MV$GC6/3].$$LDNKW4<.^\>=9X%4E(?-95"$  GY<^IW_Q^
MUK]D/X3?!3X<^._%6C:5XMU33[EM0\2ZU'/J-MIMM 08X]D)5[B7$L42G<JG
MRG8L>-WTMX#^"&C^$?A7J?@+49/^$AT;4KK5)[M+F/RQ+'?7<]Q)$0#T'GE,
M@Y.,\&N'L_V7-4TCP[X!73OB+J,7B[P1]HM-+\2W5DEP\^G3%=UG=Q,^V8;8
MX1Y@*.#$I!!+;@#Q[2OV_=0\1_#/4M3THZ/>OHWBN+0]8\96&F7USI%GILL#
MSQZFUL,3*/D$)C9]JR<F3#**D^)GQ<\7_$WX.> -5TSQ1X5NQ-\5-!L+76_#
MCRS6>I6IO(6A:: 3AX6#E?-MG<D&,C(R&'LR_LW^)(O#D3Q_%WQ*?'":\=>;
MQ%+'&\#DQ^4UF;+B/[+Y? C!#!\/O['$O?V.6O\ P-K=@_CJ[@\6ZGXPMO&_
M_"0VNE6T<<&H0-$8MEIC84 A7(9F9F)9F.2" ,C^,GQ2\?7WQ*O/ D'A@Z/X
M"O7T;R-3MIVGUW4+>%)+M%990+1 9 B$K,21D\' S-"_:E\6?%/XD^'--\$V
M.AZ?X6N_!FE^.;Z\UM9I+J.UGGFCGMD2-@IE"HNUB0H9&!W!@5Z77/V7-;>\
M\7?\(Q\3=1\)Z;XS59/$5E:Z7;2B6Z,:17%U:LP_T:69$PW#C)W  C-=/X._
M9PT#P)\28_$FD2M!I4'@ZS\%VVA,A>.*UMI9'1O-9BS$B3:=V2<9)))H ^8O
M!W_!2JP\07WAK4IO%'A">'6M9AL6\%V=E?#4[.TGE\N*8WC?N9)DW1M)'L5=
MH?:Y8 '[XKP+PG^S+X@\(1Z+X>M/BKK1^'.CWZ7=GX=^Q0)<K#&0\5FUZN'-
MND@&%"AB@$98KQ7OM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7$_$+XK:;\.-<\%Z7?VEU
M<S>*M7&CVKVX4K%*8WDW29(^7$9'&3DCBNVKYX_:F_Y*-^SW_P!CS'_Z27%
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M^*D^IPQ1V3_:"/\ A*5(N% 7<1Y'.\?P=]M 'W/1110 4444 %%%% !1110
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M%V[\0^%_#8;[#I=II":?<71"F.$7MPDK"=(XV8;%CC#,$9ONX/N%% !1110
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M#FJRWMG>1PL%EB=988I(F4LG)!#;C@Y4T 7OA7^S0GPR\6> =;'B)M1/A3P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M()!#(5!9-PX;!R,CKBKE% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>cgtx-20231231x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (" SX# 2(  A$! Q$!_\0
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M !1110 445Q/QB^,7A?X%^ M2\6^+=1BT_3+.,L%9AYD[X^6.->K,3P /Y4
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MD$]Z /%[*\_X4[_P4'_::TSPE#%H^FO\/;C5?LELNR(72VUK,LH48&0\LO\
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MX:U"2PU7Q'IVGWD8!:"XN%1QGID&IE.,%>3L1.<::O-V]3J:*X?_ (7A\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^_- 'WW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7Y;?%Y?BZW_!4CQN/@LVBIXM_X12V\TZ[_J/LOEVN_'^UN\O'MFOU)K\M
M?C!^TEX;_9:_X*C^-O&'BG3M8U339_"EMIRPZ'!'-.)'CM7#%9)(QMQ&V3G.
M2.* /TK^'X\0CP'X<'BXVQ\5_P!FVW]KFR_U'VSRE\_R_P#8\S=CVQ6_7/\
MP^\:67Q(\!>&_%NFPW-MIVO:;;:I;0WB*DT<4T2R(LBJ6 8!@" 2,YY-=!0
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MH **** /CKP+\&T^+GQ \8/XDU.:TO;.[;?;Q@>8^YCAN>@&!7HG_#&GA?\
MZ"VH_P#CO^%>2WEEXU^,GQ.U[6/"\+6C6LQB,\4@@"A20H8C[Q./>M__ (5/
M\;O^@M+_ .#"OP_!PP;A*^73K^]+W]?>U>OZ']!8Z>.4X<N:0P_NQO3;7NOE
M6GZGU'X.\+V_@OPQI^B6LCS6]E'Y:/)]XC)//YULUS7PWT[5M(\#:/9ZY(9M
M6AAVW#E]Y+9/?OQBNEK]FPMO84^6/*K+3MIM\MC\(Q?-]9J<T^=\S][OKO\
M/<****ZCD"BBB@ HHHH **** "O@S_@C]_R1;XE_]CW>_P#I-;5]#_M/Z=\=
M-1T30U^!NJ>']+U1;B0ZD_B!=R/#M&P)^[?G=G/2OG#_ ((W"X7X#?$$7A5K
ML>-KH3%/NE_LMKNQ[9S0!]]T444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7P9X*_Y3#^/_\ L18O
MY6-?>=?EM\7F^+J_\%2/&Y^"RZ*_BW_A%+;S1KO^H^R^7:[\?[6[R\>V: /U
M)HK ^'Y\0GP'X</BX6P\5_V;;?VN++_4?;/*7S_+_P!CS-V/;%;] !1110 4
M444 %%%% !1110 5\9_M$VO[1TGQ2U%OA_-JJ>&2B>0+9H0F<?-C=SUK[,KX
MU_:(^(_Q^\/_ !1U&R\#:9=7/AU$0PR1V0D4DCYOF^M>/FCBJ*YG):_9W_X8
M\'.7%8=<[FM?L;]?P/,OL7[8?_/SKO\ WU;_ .%=]':_M+_\*3E5I]7_ .$S
M_M<%6W0^9]E\OGMC&[\:\RU_]H+]IOPOILNH:KIUY9640+23R:8-J =22.@]
MS7UI^R)XT\:?$'X:-KWC*[MKV2[FW6<MMM \K&""!T(;((->%@XTJ]5T8U*J
M;3W?XGS. A1Q-=T(5:R;3^)[+O\ Y'J?@!=57P5H@UPR'6!:1_:S+C=YN/FS
MCC.:WZ**^SBN5)'Z%&/+%1OL%%%%44%%%% !1110!\RZQ^V+=:-J5S:3>$"I
MBD9 9+LJ6 )&<%/:N<UK]JO2?$4+1:G\/K&^0]1/<!O_ &G3OA]XL\*VGQ1\
M5W'Q'@CDU=[HK;S:A'YL405B-H!R%(&,'T'%7?V@?%GPNUKPDT.AQ6,VO;U-
MO/IL C*@'G<R@ C&>#^%?B=7'YC6P=7$O'PLG+W)1AS:.UFK;OHM?4_?:.6Y
M70QU'"QRV=Y*/[R,I\JND[IWV75W7H=!\+?VI/#LMQIOAR7P^_AZT+""V>&8
M2Q(2> 1M!49/7GK7T:#D9'(KXO\ BK)83?#[P!I8TJ.V\87$4<IFMX!$VTG:
MNXCDD_*?UK[*L59+*W5OO"-0<^N*^UX;QN*K.KA<3-3Y%!II<MN97Y6EI>)\
M%Q5@,'05'%X6#A[1S33DY7Y96YDWK:5R>BBBOMS\_"BBB@ HHHH **** "O@
MS_@C]_R1;XE_]CW>_P#I-;5]YU\&?\$?O^2+?$O_ +'N]_\ 2:VH ^\Z***
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MLKX:H0JTL15G5D[)2DFK=6THK\]V=O1117ZZ?FX4444 %%%% !1110 4444
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MSO=;W7+H[Z^C1]R45XA^S=\0?&7Q+CU34]>GA?28"+>$1P*A>;@DY']U<?\
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M_P ,Z-?:_P"/[C3GO+:."V9[>RB&0;B9L8PO7;WQSQ7:_LN6_P ?K>W\1?\
M"];KPY<S%H/[)_X1X8 7$GG>9\H[^7C\:M_M?:59+^SC\4-0%I +]M N(VNO
M+'FE O"[NN/:@#CO@#^TCJ=Y^PW9?&+QU.-1U&UTB\U*]:")8O.,3R;555P
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M****[#A/'_B-^S#X8^)OQK\"_$_4]0U:WUWP>&%C;6DL2VLN6W'S5:-F//\
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MLJ!D8.IZ,IR#7>FGL>:TUN.HHHIB"BBB@ HHHH **** "BBB@ HHHH ****
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MKA=1LU18T1AL.W.,C_@1KO*\>^/?P4U'XG?V?>:%?0Z?J=OF.0W,KI')&?\
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MO_@CI:Q67P,^(MO GEPP^.+N-$!SM46MJ /RK[XKX,_X(_?\D6^)?_8]WO\
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M581J "&SD'FO"O$/_!3.SU#1+ZULO <B74T+QHUW?+)$"01\RA 2/;->E?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!G_!'[_DBWQ+_P"Q[O?_ $FMJ /O.BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O@SP5_RF'\?_P#8BQ?RL:^\Z^#/!7_*8?Q_
M_P!B+%_*QH ^\ZBNKJ&QMIKFYFCM[>%#))-*P5$4#)9B>  .<FI:^+O^"A^@
M_&CQ9X%\2VOA?6-/\+_#2PT26\U:\&6O;]QUMU .0A'4\?\  J /L72=8L->
MT^*_TR^MM1L9@3'<VDJRQN,XX920>?2J5MXT\/WFLRZ1;Z[ID^K1?ZRPCO(V
MG3ZQ@[A^5?$_P$\>ZA\,/^"3L?B?27,6J:=X=OY+64?\LY3-*J/^!(/X5\H>
M)OV?],^$7[$_@7]H[1=7U9?B?)J-O?76I->R8G$D[+L*[L8  R>IR: /V0UO
MQ!I?AFQ:]UC4K/2K-2%-Q?3K#&">@W,0*ETO5K'7+&*]TV]M]0LY1NCN+659
M8W'J&4D&OS:^,UM#^V-^V7\*_AMXNN;Q?!,7A5-;N]-MIFA%U-)$)#DJ<CDH
M,CLG'6NK_8,A;X)_M<?'3X$:;?WEYX2TI8M6TN"[E,GV53Y64!)S]VX1??RP
M3S0!^@M%%% !1110 5\A_%7XQ?"'X0_M$7FO:QIFKR^,X+=(FFM\&#85XPOK
MCO7UY7S=^TWIGP.\$R'Q1\0]#BU+6+["0P0J7N+C;QP,@ #U) KR\P4_9*<'
M%<KO>6R_X)XV:JI[!3IRC%Q:=Y;+_@G.W?\ P44^&=[:S6\ECK'ERHT;8A .
M",'O69\&OCA\(_@A\'[[7/#-IKW]@SZJ+>5;PB27SBF<C@?+@5Y#H/QE_9GU
M#6%MM2^%MUI=B[;1>;A-M'JR @@?3/XU]BZ!\ _A-XD^']K9:3H5C?>%KV1=
M0A6%B8I&*X#CGKCBO&PU3%8N;G"I"3BG;1W5_EL?/X.MC,=-U(5J<I13M9.Z
MOZK8],\,:_;^*O#VG:Q:*ZVU] L\8<88*PR,UIU3TC2;70M+M=.L81;V=M&(
MHHEZ*H& *N5]7&]ES;GV\>;E7-N%%%%44%%%% !116%KOCKP_P"&+E+?5M7M
M=/G==ZI.^TD>HK.I5A2CS5))+NW8UI4JE:7)2BY/LE=_@?(W@/XQ67P:^(/B
MH(DNNZ7?3G][&3&ZLK,?NMC^\0?H*]2_X;0\+?\ 0$UC\HO_ (NL7P+K_P )
M/&M_K)UCPYI&C-!-^[EGF/\ I&2<L.?;]:T_&LOP4\+^'KC4++1]&UFYC*A+
M."8AWR<<<GIUK\AP53,,)A'/"XZDJ2<FD[W6K;T:YM[]S]MQ]++,;C%#&9?6
M=9J*;35F[)*[3Y=K=EW/<?!OBFW\:^%].URTBE@M[V/S4CFQO49(YP2.U;5<
MM\,-0T_5? &B7>E62Z=I\UN&AM%.1$,GC\\UU-?K&$FZF'ISE)-N*=UL]-UY
M,_&<93C2Q-6G&+BE)JSW5GL_-!11174<85P?Q\4O\"OB,J@ECX;U( #J?]%D
MKO*9-#'<PR12QK+%(I1T<95@>""#U% 'P7^P5X%N?B!_P3,U/P@@:"ZURRUW
M34W#:5:9IHP>?]ZOE>U^.\L'[$1_9G_X1#7A\4_[0?2QI[63A"K7!<OOZ#&X
MC'MGI7[*Z;I5EHUJMKI]G!8VRDD0VT2QH">3P !41T#2SJ7]HG3;0ZAT^U^0
MOF_]]XS^M 'YH?'GP?J/[)OQF_9D^*6JZ1J&I^%O"VBKHFKO8Q&5K:4PRHQ(
M'8"8GWV-BNV_9&U*;]I#]NWXF?'32=*OK#P+#I,&CZ;=7\#0O=2B.%20#[)(
MWL&3/)K] ;VQMM2MGMKNWBNK>08>&= Z,/<'@TVPTZTTJU2VLK6&SMT^[#;Q
MA$'T XH _._]M_\ 91_9B\(^-;GXE?%[Q1XTT6]\77S872726$RI&N0J+;.R
MC:!U)K8_X(P+;I^SUXZ6S9GM!XRN1"S_ 'BGV2UVD^^,5[_^V!\7K7X1>'O#
MUW=?!_4/B\MY=21+9Z?8"Z:SP@/F$&-\ ],X'2O!?^"-4XN?@'X_F$!M1)XU
MNG$##!CS:VIVX]NE 'WY1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7XX_MIZ5\(M8_P""BOC"#XTZSK6A^$AH%F\5SH2;IS=>
M3!L4CRI/E*F0GY>H'/K^QU?E)\?/B7;_  J_X*=^-=9N?AE>_%>-_"]K;?V'
M8V8NI(RT=L?/V&-^%V[<X_C'/- 'V9^Q1^S)\-/@)X(G\0_#'4M=U/1?&]G8
MZHDVN3([&'RV>$JJQ1E,K.20P)Z=,5V?[6]M->?LS_$J"WB>>:31+A4CC4LS
M';T ')KM_AEK:>)?AOX5U>/1)?#,=_I5K=+HDT?EOIX>%6%NR8&TQYV$8&-O
M05TM 'Q%^SQ\*=4^)?\ P2[MO L<#V>LZIX?OK6WBNU,6V<RRF,.",@;MN?:
MODW4?&'Q!^+O[./A#]E)?A=X@T[Q=I^HPP:AJ<]OMM(X(YV82!B>P/.>..#S
MBOV/HH _.;]HCPQXB_9-_:;^&_QGL/"FH^+_  A9>'DT#54TA#)/"R1[ P4G
MC.$(R<'#"NI_8(\,^(_B9\?_ (O_ +0NN^&;SPII_BKR[#1K/4%*326Z^7ER
MOTAAR>FXL 3@U]X44 %%%% !1110 5\&_%WP_I'Q1_;IL/#GC69ET&&R3R+:
M24QI*=NX)GC 8YSCKBOO*OF_]JK]EZR^-\EIK.E:O!H?BRP38DTC8691RJL0
M<@@]#7D9G1G6HKD7-RM.W>W0\+.,/4Q&'C[./-RR3Y?YDNAK?%?]F+X0/\.-
M8-SX9TGP_%:V<DD>IVD8@E@94)#;QC=TZ-G-<9_P3DU:^OO@G?VMR[R6MGJ<
MD=L6Y"J55F4>P)S_ ,"->&V_['7QE\6W$.D^)O&MI'H:$*[RZL]PNW(Z1\;N
MG>ONGX._#71/A)X"T_PSH4@GM;4$R7!(+S2GEG;'<_H !VKAPD9U\6JZH^SC
M%->;O_D>;@85,1C8XE4/8QC%KI>5[=%T1VU%%%?2GUX4444 %%%% !7GOQ:^
M#&E?%NVLDOKB6QN+1B4N(%4L5/53GMWKT*JMSJME9R>7<7D$$F,[9)54X^A-
M<F+P]#%T94<3%.#W3.W!8K$8.O&OA).,X[-'RSX3_8WN[J>_'B+4C8Q*^+4V
M3+(77)Y;(X/2NG@_8M\/+*IEU_4I(P?F54C4D?7!Q7O7]OZ7_P!!*T_[_K_C
M1_;^E_\ 02M/^_Z_XU\K1X7R.E%1=-2MU;=_S2/L*W%_$-:;DJKC?HHJWXIO
M\0T+1+3PWH]GI=C'Y5I:QB*-2<D >M7Z9#-'<1+)$ZRQL,JZ'(/T-/K[*$8Q
MBHP5DMCX6<I3DY3=V]_4****L@**** "BBB@ HHHH \2_:B^/'C/X$Z'H=]X
M,^$FL_%JYO[B2&XL]&EE1K-54$2-Y<$W!)QR!TZU\X_\$;;F2\^ WQ!N)8&M
MI9?&UT[P/UC)M;4E3P.1TZ5]/_M$?M2> OV7=(T?4_'EW>VEKJL[VUL;.T:X
M)=5#'(7IP:^8O^".%Y'J/P)^(=U"289_&]W*A(P=K6MJ1^AH ^^:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^FYX.<K"O#KZW&4HW^SO?4\C\5?\$]/B?H&B76H6/B+2]:DMXVE-G!<31RR
M#.$W)M+>Q(^M?1?_  3^L-+A^"LEYIVJW.H375XWVR&Z0*UM,J@% <G<I&"#
MQUKYZU/]HS]I?7["?3ET&XM3<J8O-M=)9)%R,?*22 ?>OIW]B7X1:W\)/A+)
M;^(H3::IJ-VUVUHQ^:%-H"AO]K@DCZ5XF74Z'UQ2PL))6=^;IVL?.932PO\
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M""<[=PSC@X.,5[5_P22_X0.'QCXSTS7=$O;/XYZ<TL=]?:U=F>6>+?MD$2L
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MJB@8"@#@ #C%2US_ ,/O!5C\-O 7AOPEI<EQ-IN@Z;;:7:R7;!IGBAB6-"Y
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M +#>6]YY$AAE\B57\MQU5L'@CT-%GJ]CJ%S=VUK>6]S<6C!+B**56:%B,@.
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MF_#?X/\ A'X2#7!X4TA-)&M7[ZE?A)'?SKA@ 7^8G' ' P*[.B@#C/!7P?\
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M#;PGXQ\;P>/-*^(G@E?%7_'M'$=,N"&?;$R ;HB%VC.,]<#'/W1JG_(,N_\
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M4 >IU\%_\$?44?!GXF-@;CXZO 3[?9[;_$U]Z5\&?\$?O^2+?$O_ +'N]_\
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M_B:@O_\ @K#'I5E/>7OP$^(EG:0(9)KB>U"1QH!DLS%<  =S7WR.@KF/BAX
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M;^!/%O[=WP6\'_ ?1K?3[_P+<_:O%FJZ.A6WA@CDB98Y''!<*DRGU,P4YYP
M?J/1110 4444 %%%% !1110 4444 %<39?&CP7J7Q2N_AU:Z_:W'C*TM#?3Z
M5&V9(H<J-S=A]]>/>IOBYX>\2>+/AWK6D>$=<'AOQ#=P^5:ZJ4W_ &9B1EP.
MYQFOSK_9"^$Q^"G_  4Y\6^%I-<O?$EU#X1EGN=4U!MTUQ-(]J[L?Q)P* /O
MWXN?M%?#GX%+:?\ "<^+-/\ #\MWS!!<R?O9 ."P4<X]ZZ+X>_$GPQ\5O#<&
MO^$M;L]>TB8D)=6<@=<CJ#Z$>AK\W?VV;OPO\+OV_- \8>/-#3XD>']2\.B"
M#PS;'SKJT=%==_DX/R$_,">I9^/EKTW_ ()*:3;'P7\2/$.FW%K::/K.OO-9
M^'H;@R2Z6@W8CD4_=."/KB@#[ZHHHH **** "BBB@ HHHH **** .#^+'QU\
M!_ [3+>_\<^)[#P[!<L4@%W* \Q'4*O4U+\*_C7X'^-NC2ZIX(\26'B*SA?R
MYFLY0S1-C.&7JI^M><_&W]ESX7^/_B/IOQ7^(C&ZA\,V+J;;4K@#3HXE#-O=
M#QP6+9[D#TKY;_8(TG1KK]I;XX?%OP79MX:^"CP_9;$R*8;>=TV-)(BGC:"D
MC>WF >U 'W/\4_C=X)^"MIIMSXSU^UT./49_LUIYYYFD]% Y/4?G7<1R++&K
MJ<JP!!]17XK?MG^(?$7[1%_I7QIN9I[/P-%XEB\/^%[!U($\*-F2Y(_VF'!'
M45^T6G?\@^U_ZY+_ "% %FBBB@ HHHH **** "BBB@ HHI",@B@#R'QQ^UQ\
M(/AQXR7PKXC\>Z1I>O%E5[2:<;HBW0.>BY]Z]#\1>./#_A+PG<^)]8UBST[P
M_;PBXEU*>4+"L9Z-NZ8.17Y\_MP?LS>!/@]\)/'^H:)\/]5\8^)O&%P][<>(
MKDFX_L9B^YI2^"50;CP >/I7&?M6QQ+^QI^S+X"M?$P\1Z!K6JV5I?:E9RL!
M=*@5< GG \UN&Z%1Z4 ?H/\ "7]I;X9_'.ZN[7P/XPT[7[NT7?-;6\O[U5Z;
MMIYQ[UZ=7YO_ !O\ ^&OV</V^?V<I_ &C6_AR+7M^DWUM8C9%+%O2,$CN=LA
MY/H*_2"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ^8?V_/V<_$7[0'PNTB;P9]G;QI
MX6U./6-+AN2%69UP3&&) !.%QDXXYKQGX3_"CX[?M%?M4^!_BA\9O!UGX T#
MP#8M'8Z=%<+*]]=LKC> '8CYF#DG Q&B@-EF'Z"44 %%%% !1110 4444 %%
M%% !1110 4444 ?GK\6?@S\;_P!G/]K?Q9\7O@SX-L?B#H?C>P,&HZ7+,L4E
MG<'9N/+J2"\8D##(^9U8#"L?7_\ @GS^SEXK^ W@'Q1J7CM+>T\7^,-6?5[[
M3[2021VN=VU,@D9^9L@$@<<FOJNB@ HHHH **** "BBB@ HHHH **** "ODC
M_@I/\(_%_P 8_@[X<TGP;H=QKVHVWB&UNY8+<J&2)0VYSN(X&17UO10!\Q_M
MBW_Q>TK]G6RT'X1:!>ZCXMU.**RN+BS*B2QA$8\Q@6( 8_=![<XYP:^>OV1+
M_P".?P&M_#W@VR_9C31]+O;V%=<\3W&J"6[GW.!+=3'JQ +,%Z#&  *_2&B@
M HHHH **** "BBB@ HHHH **** "OC+P3\%_&FF_\%-/&/Q%N= N(?!5[X8-
ME;ZNQ7RI)LVWR 9SGY&[=J^S:* /S^^/OP<^-?PD_;,U3X[?#'P78?$[3=?T
MN+3[G2KJX6.6Q=(8XB%!8':?)1PR[N6D! X)[S]@+X ?$+X<ZG\1/'WQ(L+3
MPYKGC2^%T/#UC('2U4$G+;25!.>F2<=<5]BT4 %%%% !1110 4444 %%%% !
M1110!^>__!1C0?CG\6?'&@^#_"7P^U7Q/\++#R;S5K:RNUM4UF;=N\EY-VX1
MJ !@#J6.<A2O9?"B#XH?'/P!XF^#WCGX+1_!/P+=:%)8VM_I-RLGE$E5"(G0
M'&3D^E?:U% 'Y._M*?\ !+GQ9X0\!^&K#X?>+?%_C^.'4$B;1[IXQ!8P]YD7
M< "/:OTK^"OP[E^$_P +] \)S:W?^(I=-@,;:GJ;;KB8EF;+GU&['T KMZ*
M"BBB@ HHHH **** "BBB@ ILBED958HQ! 8=O>G44 ?G7\2!^VCX=;Q_\/X/
M#-C\3M!\1R2P:7XHFG@A-G;297:R!D (4X.Y>H)!-6?B!_P3Z\8VG[$/@;P3
MX8U"VNOB3X,U'^W[?<P$<UPS,\L$;OA1\Q4J6^4[ #@'(_0NB@#\_OAC\+?C
MK^TC^T_X)^)?QF\$V'@#1/ EJPL[&"<2->79Y+J [$#<%;G@!0 2237Z T44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>cgtx-20231231x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 KT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M))_"O#-*_;3^'FKZKX+L(AK,<GC*_-EH3RZ<RI?*&*F=3NXBW+C<V#R.,'-
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MH **** "BBB@ HHHH **** "BBB@ HKYE_X* ?M$^)_V9O@O8^*?"?\ 9_\
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M/ -4 M%?E!^W/^WS\:/@C^T;X@\)>$O$5E8:':10/#!-I-O.P+)D_.ZDGFO
M/^'J?[1O_0W:;_X(K3_XBE<5S]WJ*_"+_AZG^T;_ -#;IO\ X(K3_P"(K0N_
M^"J'[0DJ6S6_BC3H_DVR9T2U.6]?N\5+E9I$N5FE8_<VBOPD'_!4[]H\]/%N
MFG_N!6G_ ,12P_\ !4W]H^9PH\7:;D_]0*T_^(I\R-$F]$?NU17X;6W_  4V
M_:5DBE8^*-/(4<-_8-K_ /$TC?\ !3?]I.)"\OB[28UZ8;1+3/Y;:R]M"]KF
M;G&,N63LS]RJ*_"^+_@J+^T1+R?&VDH,]#H-KS_XY6E;?\%-/VA;IRJ>.M&
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M\%0?VB8Y/+_X2JR5P?F#Z!:@C\-M$<13EHF7":J*\=3]R**_%>[_ ."CW[1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7;V49CWS.88NF?XOP%6(K^UL6(LH 6Q_KYN3^ [5>U]].5+:XC<W$LR;G4C
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MT;_._P"IX="I*49*7\S^YN_ZGIE%%%>B= 4444 %%%% !1110 4444 %%%%
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M $1Z71117H'8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;;>B6_\ 6W00-ALC]:]W_82Y_:\^%WK_ &S%7@YS@# ^M>\?L)?\G=_"T?\
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M4IJ+;NG*-I>ZVK)O;>[5G>UO,\J+ R9V\$YP*5Y0TVY1QCA6YHE4!V9.(R>
M>2!2;1N')8#]:^FT..[6GF7M'M3J%Y'#N &[(!'6NIMK)RPGBDD64D@%1@;0
M.U4=#LTT^1[ET*EUVPJ_)&1UK6C+6T*NK% #P<]Z]S),-A\94J2JVLDK7VUW
M.BDW%^U2VTNM_D)XI@T_1+)4TI9'GN8U\QY%PRG'S 8[5P<T,D87>A4.-REA
MU'K7M/B;PG#:>%="OI!-+J>HQOY-HAPP&/ED&.HSVKR"^MY(W\MBS-'\I!/0
M]P*^>=7#NO..'E=)[^:T=O*Z.G%83V'[RI'EG/5I;+9J^_1[7NNIGJQ1P0!Q
MTR,BAF;DG')]*<RGK@4A4@ ] :WT/,UM8EMK5IGR?EC_ (I&4E5^M*\9-L2J
M ;6P7SU_"F)/+'&RK(P0\';P#]:C4@LH8D#OBILV[FW-!144M1H!Z=!4VQ(U
M1RPD)SF/D8J.3AFQG;GOUI3)D8ZY[^E4]3.-HWN+#$LTJB23RD)Y8\_I7OO[
M#)V_M=?"Q&R,:Q%MQ^->  L".]>\?L)'/[7GPM/?^V8A_.BVMQ*25DD?T*CH
M*#TH'04'H:V&?C)_P4/TMK[]J3Q4\/++!:[_ &^0U\H>(] 8F$17D?F!-VT-
MG'M7O'_!3+7;W3_VN_%T,$S1QM;VG _ZYFODH7MQ*Y(=R_L:Y:T\35]UR2BM
MM/S.+ZI3UFY.^O:V_P#D=1IMC?6MU!<13J98VR<D$8%=9<Z;%XPM)[_3XHX-
M70;7@! 1U]4'K[5YPMQ+IULV9CY\H&%!Y4>]=+H_B5M/\/NN[$CN,.HPP]P:
M\3$T:CM4@];V7IUOW1-/"QQ$Y5Y:.,7:VEWYKJK_ / ,>_EN9('AFR4M3GRF
MXQZUAD-=2/)C"J,FN[M+JUUP&&]98YY>(KU5P&/H]<GKME)I=W+;$,A0X;/0
M_P"(KMP]2[=-JS.BCB?;4_9/1KI^IE$F5BQ[]JT[/3Q<*#N48(&">366H8?2
MKUA<XE 8A0O<UZ=E=7VZ^AWX?EO:2O<Z"XT8V]J7#!L5FQV!O[A82=FXX\P]
M%^M:-]J9,21N/W9&0P[U:\/64,UU(?.&_8&50./H37L9[/*GB8O*;JFTKW_F
MZFU6G5A1G[6R:\U\MQ^E>&%AN%WKN9.&)/!]Q7L7PST7^V=&U)+B5U-JZLK'
MN#VS7*K827[6R1QL[R?+\@R6(]J]1NK$?"SX;7-Q=2#^TK_&RW!Y4#IGTKX/
MB6E"G0A&C+WY-)+KOJS\ESO'RJ4X48M>TE)*.B[Z]-K'(:KXLM[:>2TMX!>>
M7\I8Y*@^OO6 _B^XMIU:Z\JWM8FSY0X+5GZ/JML;>:6]D>61N?+@(P"?4UQ>
MO:E;I>S0W5DRN#P?-)^E<.78=4*ZE&-W%IW]/N.O!99%QDG3O;2__#V/H7X>
M?&23^U)(K2WB7S('12<G QGUJIH_QOM?$.L/:^(--@N=+)V.8U^91]*\K^'$
M,5YJ#_V6KO(EK(TL;-\W3^'VK%OF73-+$@4QSR%N._6OI.(\=0XBJ*E.ER.*
M2T>M]=?+R.2IPY@75JI+WO=2=W=-WU1] :W\%]"\512WG@;4X;Q6&XZ;)*-X
M/H">0?K7F7B#P'K?A*T22^TZYM)&8@J\1PN._'7ZUYOHOBC4])NHKJV:42QM
MD.A(/YBO;_ 'QU\::GJ6FVMS.MY;!FR+R)6XZG)/-?(J&:Y3"U.HJE-:^]I+
M;NKW^:.A83-,FHS;J1KQ2TYKQDO^WDFG\T<EXOU"SL/"VDV-NKBZ=3-=,_4L
M>E<%/J_FQ-%<0J\;\;P.0/:OH:Z_:-LKJ:9]=\":1JB+*461(@C%1[D'--M/
MB;\(-965]1^'36K,I($,O&?H#7-2S#%T8WK8.4M;WC*+U?S3(RK-LQP:<)8&
M;YKMN,H2NWKU:?IH?+^H06XN=L!98A_>ZFJ*!0YWYVC]:^F=6^'GPL^(6EO>
M^'-4ET*]4X^R7>2#]">PKSCQ;\!M=\/62WBHE]:?PS6WS9'TKZ#"9WA:UJ=2
M\);6DK._Y/Y,^EHY_A9S4:T72F_LS3BWZ='\F>>Z9:Q7<Q)4C'(&:Z/5-2M[
M*S58TVD#''<UF:3:R6KR1RQM&1V88-:3>&#>VK3LX*=AGD5Z%1PE.\WHC]2R
M[VL\*_JD4Y2W?9&# 9+]68@<G@^AKT_PSJ5MXBT-O#>K*#)C-M/GG/;FO.O[
M,&G(6$F03U]*=8-=W%_ + 2/.6Q'M'.?45CBJ,<1#1VMJGV9\YFF!IU\*XUO
M=J+52TT:ZFAXGTJ^L!]@O75?(!V$KRP[8-/T#2KFYTCYP54'*[NPKVC2K32[
MCPG,GB-K>;7(E!B13RH[EC7GNM>'=2OD<V^IQ?9SRJQ_*!^5>/1S'VR=*2Y;
M/?H_-'P]7.)8^E"%;W9+1R=[2M_+Y?<1:/H\=SI6N6=V63=:F6-A_>6OWQ_9
MO4+\!O 0!R!HUMS_ , %?@UX(M-2TB\MS?A9;)G,4XD&\%&&#7[[? ^UALOA
M%X1@MO\ 41Z9 L?.?EV#%>QEU3]_4A>ZT>FW;_(VRNM?$5:=[K1IK;L_GL=Q
M1117T!]*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?"/_  6-_P"37]'/_4S6G_HJ>OQJL;1[^;9'C*Y/+ ?SK]E/
M^"QW_)K^C?\ 8S6G_HJ>OQHG@,#H@=6+J#\ASU[?6L9]EN7!+FYIJ\5OT'&;
MR9I#"2R= 7'./<42I*NQY055EW*2>HZ5);6BC4(K>\<VD9.'?;DK[XIFHPM;
MW+1.X<IP#G(QVK--<UD:N$U2=22LKVM?9[ZK>W;_ (!$\)1@ 06QD$=#48_/
M'7-6 )+0Q2DJQ=25Z-@=.:8EM+,,QQLV,\J">G6J3[G/*FV[)._;[K':?#F2
M5X-1M[#SFU1U5HEB/#(#EP?7C-6/%WA^S\(7\ESI<PU2W>+:YFAV_9Y&7YE*
MGTR0#6%X8\87'AB)C:PPFX,J2K.PRZE3D 'T/>O0_'&O:1XAD_X2"\A>WN]3
MA6241Y\IF489,>IZCTKYRO[:EC.;E]R7;6[TWZVM>WSO>YZ5*AA:5)5:-9+$
M/5)JRT3O%/;FT33=[W235M?'(]A?]Z65>>@R<T^*7RVZ''<&M^?PRVLW&=!C
M:^1SA8%&90?3'>L$PO!,T<J%)$)!5N"I'45[L:D*BT>O;JOD>/&3E351+2^]
MNNFGJOU/N;]C>QU7QE\#OB!H-I;6J626S^?,57>V48C/?MP:^,)Y9[G2[BWD
M9F%J^Y-QSMYP17UG^Q-IZ:AX5^(.G-J,=C=7FE.]J?.VN6Y48Q[G\J^;_"DX
MTZ\U;3=16 V4^ZWN'E7<%8-@,#UR#Z5^=95+V&:YGRZVE3E:UGK'5WZWV^5C
MR\/!?7<2\1S1DW"[;35N5<EHZ<JWWO>][G"*TEO*"I*2)R"#@CWK1TE[DZE#
M,EP\;2. \JL0V"<'Z]:K:I:-;7US&05VN0 ?3/%7=!PT\,/&X2J^X=<9Y%?H
M522=/F\CV:=>5*U3FVUT?7Y'I'Q+\6@^,=+T[1FCO(-*BBMX9O*YF( )#*>N
M"2*SOCQ<W&H>-!+?VYM+_P"R6ZR6ZKA4PG%,\"R[?C+:SO$)DM[PS&.3C(7G
M^E8_COQ7=^-?&>IZQ>3EI+B=B-W9<_*!Z "OG<-A_8XFE&$=(0U?5N37^3;_
M  /HI9A6S'"^TKU7[S7N6]WX;7NW?W=$M?74XPHZ'!R,]/>MS1M!AG5Y]0:6
MUB"%X\1D^:>P'M[UU#S'4M+T^\U".UFAM&,,5O$ )7X^\_JM4H]3N=<U2PM;
MF9_+4"W01#F.,GD**]66)G4BTE:V[O\ EH*>!PU&>E3FB[6O&U[VO?WM$KNS
MOTU2+7A+PSJ'C77[;3-,7?-(V(V8X5%'<GT K=UGX=C0)[*XU+7=.OFGE8+:
M6LQ<*P/\3=!FLG5;U/#MW_8^DW#;T?\ ?7D#8+#TR/;K5SQMX:U:^TJSU/RX
M[#P[+L*NIQ&9<88XZ[CBO*=:M[:#53DA+;35_P##]$M=!THT:^78B$X24H-6
ML_LWU=NRLTW_ 'DR]=P2C6-/N5\0V]I=EGB7S7*QVNT]$/0@CO7(:OKL=AK]
MY#I$HECERLEQ.BEG)^\?0#.<8KG]8NA)=+"LOFPPKY<9'3W(_&J3PQQ*A$N2
M1\W'3VKTJ&#44G-WTVMYW_K_ #.;ZVJE)4Z4.2,9<UN9Z:**M?KW?7LDK%K6
M;2'SHY(948NGSJHP%;N*CMQ;16\INH6D9TVPLAVA3GKCO4#7;6V\*B@D_*Y'
M*_2HTBA:V=WG(F7E(]N<\\\]J]-1:BDW_7R.>$H0FW2BMGH]E_X%N^WG:VHV
M9H\MY88)G S4&-Q'<#I5J65)+2)$1E*<ON;ACZ@=JABN'BCDB#?))C=QGI6R
MO;0Y*BCSZO2W1?ATZZ?YC ,N%]?7M3W1HY&4,&V\94]?I4GE1/*<,S1#&6VX
M;'TIEU;^2R94C<-RD]2.QHYKNQ/LW&+EV+D8LAI4A(9;]7R"Q&PICD8]<U[1
M^PDO_&7?PMQS_P 3F+FO!1R>OXFOH+]AE57]K/X4XF5V&MQ@HH((]\T17*]]
MS64_;Q3LERKI97\_4_H-'04'H:!T%!Z&N@YS\(O^"FX5_P!L3Q8&Z?9[7_T6
M:^7].:.&;<RG !(QZU]2_P#!2^U6Y_;'\6AY1$HM[4DGT\NOE>:8+$\<2X4#
M!;N17)4]YN(2IMQNEN5I&-U</)W8DXJ:YD9(8(R_&"=OI5>WP9 #P,\U)+&]
MTY9 6QP .M-I)KLC%N,7&VEB["\UBBR1,)(FY9",BNB'B,7UN+2_M8[F!1\J
MG"R)_NMW^E4O#/A2]U5RDFVT@ZM+<ML4?GUK0U/PWI5K>RM<:W"V&"[(%+'Z
MUY=6=&53DEJUVO\ H<>.J82;3AOUM=M/Y#K3X>1^(#))HURLYVEOLDIVRK[<
M]?PKC[_3)K"Z:.12C*2"&&#FO3-)_L2V5/*U=R5^ZWED,#]:[*"S\)^(].,F
MM,+B2+(2='\J5_3.>#7T^-K8# Y9"JI.<W;2WO?Y?E\SP7F=;"2O5C*4/1I_
MHG^?J>#V%O<WK"-,LH/>O5/AC\.]2\6:S!86%NTDC'#S' 2->Y)KK-)^%FC^
M*;J.TTJ]N-.1R.&02X'?++TKKO&$VD?"GPY+H/A?7;:75)EVS7>2-GJ,CO7Y
MCCLZ]LUA\*OWDNZ=EYNQXV8\35<4U@L&G[6>B33:BOYI/;3LF=-J=SX*^".F
MLANHM1UA!B1MP)#>@ KYF^*?Q7OO&UTR[O*M\\(ISQ]:IS^#]2U9"YOK.XED
M<L9'NAN)_&FV?PMUF>4[!93!!GYKE!G]:[<%0H89^UQ=?VE1=7^BZ'9E>69=
ME\GB*]95*W63=K/R3T17\,VTKZ7>G)R\9(R.,BN?U)WO+5)6.7C^5B>OM7HV
MA_#[Q%!<00K9%V^;<L<JN"I';!KB[K3)='U2[M;L8R2KH>U>I0Q%.=6;A)-[
MZ?<?4/&8.MB&L)-/1/=;[/8T/@^\@\6*J2&,M$X+ ]!CFM34=9T[78FANX/]
M(B9E29#@$#^\*@^&T+:7XE("[VDB=$VC)Y'%<^[[;JZWC;(I92O3!S2=.%?&
M2F]+*-FOF<D:5.OC)S;Z1M^.OZ%S4+XV<"06KK _3Y$ 5A]>M)X2N+N74KC>
MSLR6[L"3Z#M6;)/%,Z^:6W@ =/E(]Q79^'-";3_"MYJ:-'-'<_N(!G# _P 6
M,^U:8EPH4W'J]/O._&47&BU&.]EHN[2.9M)'_LY&ENG1%RQ .<GTQ3;;5+>Y
M958-;3$\.O*GZBFZGI-S;:?._ER)"K#MT)[5@*-TPW/M*^M=$*<:J<DSK=*G
M6BH0CRRNW?J=<T=Q9RMY<H6-T_Y9#<I!_E6QX>^+OB/PA(L<$TDVG [?LUP=
MZX_I7"W^J2&9)(_W.5 (0X!JS9ZGYTB&Z15CQ@NH_I6%3"0JT[5H*2['+BL'
M+&T_J^(2JQ6UU^5]CVRS\<^$OB$19:A;)I5[)\HGQ\I;ZUQGBWPIKO@]GB^S
MR76G,28KJ)<JR_ATKC[FSAN+=7M65&4\NAX/U':NU\ ?%;5O#-PND7L_VNPF
M(C,<R[MH]B>U>1]4J8-.>$]Z/6$G^3Z>AX=%X[().KE4[QMK3DW\^5ZV]'H<
MD-+U#Q%MAL;269\\[5.!]:ZR>PG^&FA0QPJLFM7BYE=3DVZ^@]S5;QA\1]9^
MU7&G6LL5A;1L<1VZ;21[GJ:XH^(;XR*QF\V0=V.21^-=T:>(Q,8N:2AO:][]
MKO\ 0]25;'9M4IU<5:,'9\JN[]KO3UL6+C4Y8=1:5I9/WG^MWY_'/K4,>O7N
MD22?9I&:$G@'D?A2R>(YIW^>-'&/NR*",U=L9QKDWV9;:U29AE<=,_RKN<>2
M/OPTZGJ8BG[>;@J:=WLMOZ^1<TKQ]=+(4N(\Q,/F7.,\5_0O^S_*)_@IX)D4
MDAM)MR,]?N"OYU+E;A&E%S8VZ! <D#;BOZ(_V<6#_ CP&R\ Z/;8_P"^!73A
M:5.,G."M<X\/A8X>HVH<K:/2****](] **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^%?^"P@A/[,FC><75/\ A);3
MYD&2#Y4^*_&.UF6"4R-&LW8(_3Z\5^S?_!895?\ 9ET0.^Q/^$GM,MC./W4]
M?C!)Y:S/Y99H\_*6&#^-8R5W8TYG%1DK:/Y_=V^1,DSW5Y&T\I/(4N_( %3:
MI?"^U*2Y2"*W#$82'A!@8R,^N*KVQ@$C>?OVA3M"$?>QQGVJ$<\YS6:BN:_8
MOVTU2<&[\SN^]U_P[]>O04MO8L3G)STJ_I>L2:7*A&9(@6S'N*A@PP1D>HK.
M/H1FESA5!& >]5*"FN5[&%&O4H356F[274?O#$[5P.N :[73B_B;P--I\40>
M\L)?/5@<L8\8*X],UP^,]#S71^$S(=2M%M XNGD$115+&13[#^5<F+C>',MX
MNZ^1E["IB'RTK<W3;5[6U_KS*GA^\U/3M5@GTMI8[R-OD,6<@UZ!J'@C5/&%
MF;]=-5-4!5'C@()F8]ROK746NCZ?]O2[D@;1-$($.IQV/[VYC<#YFYY7=C\,
MTR?XQ:?X8\,WG_"&Z9%8XN-@N[[][=LA'WL] 0?2OF*^-KXBI&6$I>_HKO97
MZ-W_  5^Y7U3VDU.KB(TXPE;:4F]KV6BLUU?5'H?['?@;4-&\9WD]VOEO);/
M +5OO Y'!!KQSXN> =;\*Z[KMM<Z=-90"_DE.Y,*1N.TJ>XYJ/PE\>M=\&7L
M&J6)C?4_+:-[B<F0N">I!Z&OL_X0_M+> _BYX6TW2_'6G6(N4E(NEN8/W<A8
M8W;N2HZ=*^4S*MFV28V>:.A[6G-134=URWU2Z_UL?'/+<;0SFKF,8J5*48\R
M3U7+]I*6KLFY2MKH[(^!K066IZ5/'J,OD7, !2=CEF&<;<=_6HKKPZ-,M+?4
M+2\2^@!'G-%QY3$\ @]<]<U]@?%G]B[3-?U7[=X$N9&MYBS&T?:!''M)4H<_
M-SQCJ:^6(? NN:#K9L)K&=7:0QF%XCF0 X/!KZC+,]P6:4W4PM6SW<7HUY>6
MWH?3X;'X#%X55\%.%2+O'26J:LW>.ZM=+56?375=)HVC66J7ZZO:W31ZQ;,K
M36FSY639_K0WY<5QMII\.IK-/>'R_,N<+*SA0.I.X?ES7VUX/_9A2VT"+6Y[
M*6WM;5%MY4C3-Q*K -\P![9P#7G?B?X")>W%_I=Q:1^'HK/?<*;A<331$Y&?
M7:*^=PO%&"G6G",VTK*^FENFF^Z[[ZG7E-.K4JN--1E%)12NU>S?,VW=*WO1
M3?+\/NZ[_-^F:5J'B*:>TTY$FEA.%CC;YGYQ\@[UZ!HVB)\*5>[N+:*_\1H&
MADM&<%K56'WBIX)Q^52>&?#5QX*N[O6=.MC?7;*RV<V[B#'!8CUQTJC#X(N2
M5O-3U&"ZNKB3SY(#)NED4#.!GG/;%>[7Q4:\G!R2I]NLGU6^R^5WY;^Y#'Y;
M2I1KN33A?:26]W&UU>^U]U;6]WH[P_X(%I8Z7XYN,2:<;LYM94&Z9P<[0.^1
MWZ5YWXR\:R>(+^]2!IK?2GG:6"Q:3*Q$GTZ5>^(OBV^U#6FM&MY=,TZW*B+3
ME<A8\#K@]"?ZUP\LB&9G5-L9;A2<X%>W@<+.3^L8C5O;R6Z79OS%B:T:#E3P
M\K+1-+;1)/ENN:TK7:;WMHK(FN$@6" JSFX)/F*RX4#M@]Z=)92"=H7 =PN[
MY&! XS5=YU8$%<D'Y2>U*/W5PC2)E&PV >HKW=4K'!>G)W:TTV^[71ZO>_X=
MFSH/+C<R%BPY]L=*;';LZA^D9.-QZ9J>YFMYKR00QM;VS.-H<[BB_7O4%PJQ
MS21Q2>9&&X<C&X>N.U--M)$5(1C)RNFEIH]WWUUL]]EN6[NR^S0PMO7RI@2"
MISR/4=JSP!GD\5;BNW6WD7>NW;LQC).:JX!4G=AO2B%UI(*[IR:E35M-OS_&
M_P#P2_<0^7'FT$AMY%569NA;J16?OY);)/2KNF.LL@AFF$4)S\SY*J?4@=:J
MO&5Y!W+G /K1'1\K+K)5(QJPV=].WRZ+7001G>HR&)Z &OHG]B"R&F?M;_"@
M%0[3:K$X8\[0<_K7SU;,L,V7^4CL1WKZ3_8XEM&_:P^#HMHFW'5HR\[\&0Y/
M0=A6<I/VD8]&9Q@E'GYDGVZG[ZCH*#T- Z"@]#7:8GX0_P#!3PL?VP/%H7O!
M:9_[]FOF32=#O-5RMO;R2L?[HX'U-?77_!2#Q+:Z1^UYXIW:1:7<Z06I\R<$
MY_=GJ,U\LZCX\U.[C:"$1V%N_6*V78#7F5)UW)QA"WFW^B./VN(4VJ</FWI]
MR_X!JV?A+0]'A$NMZNBR]?LEH/,?\3T%46\90Z9-(NBV,,$6,!Y4#R'WR:Y>
M:5Y9.3D]*T;?P[>I$MS)']GM\C]Y+QG\.]8.A%>]B)\U^CV^[_.YQU,-#F;Q
M,^:_1Z+Y)?K<M7&K7?B(,\UPTER#PF<!A["JE_IT[RJ CB5@"%/4UJ6^G:3%
M());X/*.0EN/O'^E7[K74N8\11_97"[%E<9;/H34>TY&E2CIZ6%2JN,N2C3O
M%)]+6_X!G6FC0Z9!YU[.#)U$*]?QJQ+)=:^UK! NQ'?:J+VK!NK#49)69TD<
MGDG!KUCX&Z"DDMQJ.K)BQM5+J[\;6[$5AC*RPM%XB3YFOZT,,PQ%/!X9XFH^
M:<>WY)'2>*O%,7P=\):?I6C/Y>L74!DN9UZKGWKP^+Q//<O(MS*S^<V7D)R<
M^M=%\2[R?7]<NKN!Q<VI.Q73G"CMCM7 RP/"WSHPQZ\5EE>#ITZ/-/6I+5OK
M?_@'/DV64Z.%5:2O4GK*76^]OELC4N4GM9PR,L\9Z2+TJW>7#VA0VS+,^W+,
M@.!5#2V9 95)9P?E3KD>])>7J7.Y50V[9Y"=*]7D;DD];'U-*C"G3;KQO?9H
MWO#/BF^ACO)5G9'6,[60X.?K4^D_$>5\6^JV<.K1'C,X^<?1NM<\ZOI\=O"G
MWG.YF'?VJOJ4*VUZ?*RN[!YK%X:A5D[QWV^1XOU.C6DY2BK/;OIY[GKFE:18
M^(9(;WPT[I?6K+(]E(P$A&>0A_B^E<9\2M'FT?QG?HD+HLA$NUA@C<,FL_PE
M?W-GK=H(93#([@!LXP<]:](^*WCU=9\5/::Y8IJ*6\:(UR@\N<87LPZ_C7C*
M-?"8V,8^_%Q?JM5]_P"#]3RYTL5@\?"-*+G%QEN_>2NK>3_#YGCF#<2I&H.]
MB !76^,=1-MIVF:-;.2MBN9,#!WGDFM?0_#FF:UK%K/I4XE@AR[07.!*N.><
M<&N,UO4&&LWCK\K.Q#\9QS7IJK'$UHI+X5>S[O3\KGKT:U/'XN$9MKDUM;6[
MNE^OWG2>%]=@;1;Z#4G4PMM"N_)!]*P-=M8(#^Y4H7.0V<@BJ4\!.ELZL&Q(
M#QVJ&TOY(E:-V#HW56YK:%!1G*I![O8^EJ5.6+IN*36EQ)+E+F*.*10K)PIQ
MBDCM'N5(B)]U(Z5+J$'G0B6-<@<%O\:9I.H?9KA$;D9X).,5UJ_+>)Y<W*]X
MLT].MGLD+*QRW%6+E(P\=Y+"6\O =8SC'H:)=4MI\;<12CJHZ,?45F:CJ,MO
M(J8PH'S>K9[&OIL;3P,L!3=+^*]^_F>7*G.<]=S9\:6)O[BSU*"7S!>1C*@8
MVL!C!-<K&?+GVR C'!]17:^&8D\4Z%>Z8&'F1*9X4; ;=W ]:XZXMYW=8RIW
M(<8(^:OC\-+E3H2^S^73_(UR^3B_J^[A]]NGX:?(7452&5%B/R$=:6UU*33)
MTFMG*R#HP[&G/:O=0!4D!9#GRV&#^=(FFW6$80,5/0XXKJO%QY9,]U8F*JRJ
M0?*T[^:-#[=-XB@G-Q,JS*AVLPQN]C7]$W[-8Q\ _ (/_0&MO_0!7\Z:V)LX
MR))$ <'Y5;)/UK^C#]G)M_P)\"$ +G1[;@=OD%70LFU'8PG-RG=N]];GH]%%
M%=A(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!\(_\%C&*_LP:,0<?\5/:?^BIZ_&';@@GZU^SO_!8W_DU_1_^QFM/
M_14]?C7!I\UQ:3W2KF"$JKR9Z$]!^-93:6K'&G.J^6"N]7\DKM_):D4QW(FU
M"(UR V.I[\UI6.DV5QI4MY-J BEC8C[.%)<C'##U&>*HO?W$MFEJ686R,9%B
M[!L8)J#:2OM6+C*2M>QU0JT:53F<.=6V=U9VZ6>R_%=!]S/]H<-L1"% P@P#
MC^M1Y+,OI_*G*F<<9/3%;Z^';C1X'O[^&(1Q%5$#2#<Y897@=L=Z)U(T[)_(
MYG"M5C*JHMVW_/\ 1_<S*T_3)]4N$@MHS)(QZ>E=>WB#4-(U"PL-'L4L]5L$
M:%Y[9-TDQ/4GKR >HK,M-3?6[AOM,B:?I\9#2BVC P!QP.YJ:S\86NA27+Z=
M:,EP59(+PN5D0GC=^7;WKSJRG5=G"]NG2[[O9Z=+,VPF(=*?N2Y7=:IK2WO+
MHVG>UFCH/#OQ N?AJU]Y#)>:EJ,+178N5WH%;[RD'J3ZUG>)-$M@(9],/^AZ
MG;&Y$"\M RGE"/3C(]JX=YWEF>1R7D8EB6.<GUKM? SQ3Z=K$<ES-;W$%H\M
MLT8SN;&"AST!&:PJX:.&OB(?$[<WGT7W=/*YPUL3..%=.HW)IJUW\-WK\M=?
MO.3CM1.8EA?S&<X((QMKK_#%Y::/?S62Q_:;UT,27"/F.-CU;WXS4=KI4":!
M9QPW\%O<WBR23/(WW54<+TR"37.Z5=&P@NI$4>8P"!B.1D\D5O-K$PE'Y?C;
M^D=D98C"2CC*5DFFH]=;6=T]4U?3SU6VGU-\,_VOI_!6I6ND7,,=YH$)C"R*
MN)H2O#8/\6<9Q7WQ\-O#VA?&]X?'=WIMNME=Q%[=E0!N/ER!U'2OQOTW3)=5
MU4QP(2'PW'O7[)_LI:M9Z#\!?##AWDBM+5HRA(^60$EA]#UK\'\1,@C@,)2Q
M^6TW&<Y<CDKVU5_2[L?+XG(L#B,3''5H*$7)-Q6D922:U6[M=WMO=7TV[:\^
M&UC8E7A>X.GL KE&P8VSRQ'<8KQK]H;X7_8]+>]F82V;3[DOW;YV!7E2?2NO
MU'XGZM_:C7JW)%G=-Y+6B]%&>#BO./V^M;U*P_9\T?[#?8D:Z61TC.&:,*<D
M^P-?G>7Y-C\)C\)"59-U))/R[_-?<S:IPI.C"K'+8NBYK1QZ];6>\6M?YHM:
M,^8)FMI/MT]EJD27&FP/(MDJ@N5'WOE]<<\UX-XQ$5QJD-_9WS-).@E@>0G$
MA!Y&>QS6!_PFC75Y-<SB47\FT?:1*1D# (8=\CBNOM/"MOXUT#4HK"6<ZAIT
M1O[&$)E9(A_K%)SP1VK^D</@7E<N>M+1V6RT_P"!=]>ESHP64*@J&%P3YI^_
M=WWW?POK9*]KW5EN8>K>-;3QP3::YIL%IJS2@+J<2[&&%VA77ICOFN:\3?#O
M6O"H26[M"UI(Q6*]B.^"7_=<<&M6RGB\920Q&VABUA%"1X&U;GGHW^U[]Z[Z
M'XA#2%N]%UO3(&LX91 ="E/RI*5QYH'MUZUZSJU<$U##0TZQOT[QU_X'H?4Y
M?AZ>/=:KB92C)6UM[M[-M_@]%=OHMSPIQOV1F( C/(ZFAA$0&R4(.-G7\<UV
M_BGP])X/DB74])0R7 ,\$J,0KQD?*<?6N.:>*9D41 ,3\QW8!KWZ-=5HJ<-N
M]SDJ0G2ERS6K2TM9[+36S'2>5>7T0M[=8%<!1&S9&?7)J#4K"33;R2&90'4X
M.TY'X&G74A!5?+5"O&5.<TB13:A,(DW/(<D*>:VC>-G?0J<HU$XN/OMIZ62\
MU9+OVT\B&U,/GIYZOY0/S!.I^E#JA#,I YP$QSCUI[[?LB@$[PYRNW@#ZTU3
M%Y#*48RD\-GC%:;NYC9*/([;7_#;0BR, 8SWH!4L=V0?6I98&A4AQA^,*1R?
M>H>"!Z]ZI-,Q:<=R5!@;@23G'-?0G[%<R2?M@?"B.(,(XM6@3YO7J:\4\(Z-
M-KVIQVD,B)@-+E\ <#./<\=*]D_8C=Y/VR/AFSYW'7(B01C!Y[5A&495>7JO
MU*E"?*IV?+WZ7[>;[_+N?T&#H*#T- Z"@]*[23\,_P#@I;X>O=1_:_\ %300
M.X:WM</CY?N'O7S%%H%I [C4]1CB,?\ RSA^=C[9Z5]N?\%*/##^(_CQXCO;
M&\2&:T6V@GC>78,&,E37PP=+N+:Y:.>(@C^+J#^->1AZDL;6E1A*S3M;K^/^
M1YT)5:ZE+FY8IM6ZZ/S^3VZEB?5;+3IP^FV*Y XDN#O/UQTK'U'6+O4Y=US.
M\A P,G@#V%:4]J%0CCIWK%DC_>$8KWL3EGU&TGKYET:4$^9+7N]7]XW)C<8.
M:Z!=<6/3T\R!9I%. [_YYK ($>5SN]Q4[#?IYP/F5^3FO,J0C.USLE:'3_@&
MI8>([EI\LS-GH!T%>T>+M8_X1_X1VMO:[1-?XWD#G'>O + -]H3'7->U_$9?
M+\ Z020)553M]!BOGLSHP>(P\;:<WY;'R^;PIU,3@Z<E9<VMEVV_$\?M]5NK
M!F:*5U8_>P>"*LMXFEO"%NH8KB/J0RX)_$568Q^3*P4LI_B/&#5$SJ-ORC([
MXKWE3A-W<=3[*K1A%*+>AK)]AN58QRO9N1@(PROYU7&C7*SIL7S5W?>0Y!IE
ML8[PLKL(^^<5/I9>'5(D68J@;)<= *EWA>S^\YJF&JPIJ5.=X[*XLMRMMJ;"
M>,R1AOF4FK-WIYO(&OH 7AC[XX'H*L:Q>(E]+%(D5Y"3\DJC!Q[&IM-N4FAD
ML[6X:..4?/#*< GZUSN;45-*WY6!_P"QMPQ$7[O;57]2[\/=!?7-;L[E%9E@
MD$DKG[H44SQWK+:CKNJF$@Q-,748'*]*['0X+GPKX)FMK:U=]7U-S%$R#.(^
M^,>M><^(](DTN"VE=\SDLKQE2"I'8UY]"HJ^*E-O1:1_-O[]#2$9XURQ^%7N
MQ7*Y=W?WOT6EWUV(/"?B&7P]K<%Y&3A#\R@_>7N*Z?XEZ/;6VHVNN6$ &F:G
M'YBKG=M?^($^M</"C1Q.^PX?Y1Q7IGPTU#2=3TVZT?Q1,T.A$C9<*,O;RGHP
M'<>M=&,_<36+@KVT:6[7DNZ>QX]7"5_;K&8:+<HI\R76-KO3NMU\UU/.1O$,
MMO@^7)RI]ZS&R#CN.QKNO'_P_NO!%TLD=S'J6ESC=;7UOS'(.WT/M7)W"+/&
M9MGSC[P'\Z]##UZ=:"J4W>+-Z.)AB8*M2ES1?7^MBYHNILD4UFZ+)#*O.>H-
M9951*3&<_P"S5O2U5I&8Y7:I/3-10Q1L'9G*%3G%:*T92:.]^TDDGLMC9LM"
MDOY;=E!9"N]BO\('7-5W>QOVN(YY6B=>(9 .#_O5:L-4DT_399$D,9F!1!GG
M'<FN7<D.?K65.,YR?,]MA2E1G:<(NZTUV^1T7AQWT36K>9VQ&3@NIR"#Z5OZ
MK9)%JC1H9)$+;E<#++GIQWKF?#0^WW<%BZY1Y =P&2M=5KQ;2==N9U8QM;C$
M65ZD5Q5_X]NMOO[''2BGC%T?*]?1[^IA7GA^YLKPO<EO+(+#RSDD?TJH=6N9
M;?R8C(OEDD(.1BB]\6WVH3F6:4M*3G<% S4UGK8AD5KE0"PP)(@ 1GKFNA1J
MJ*=1)LUJP?M)2;YH]_\ @?\ !*<.J.MO-O2-V?KN7D?3TK^C;]G%M_P(\!L
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MBF7AD=N=OT^M3:-IJ:A]JB>Z2W\N)I%\S/SL/X1CN>U9\GS'/8]!WXJ?=DW
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MS_V$K[_X_0H.X<CO<_ [Y@&(&0?EI&4*JY.<]O2OWR_X=I_LUYS_ ,*OM/\
MP97W_P ?H_X=I_LU_P#1,+3_ ,&=]_\ 'Z?*7RGX&H-QP<;??BFE3C(R0:_?
M3_AVG^S7_P!$OM/_  97W_Q^C_AVG^S7_P!$PM/_  9WW_Q^GRA;0_ O9[4%
M3QC]*_?3_AVG^S7_ -$OM/\ P97W_P ?I/\ AVG^S7_T2^T_\&5]_P#'Z.47
M*?@;M)///OZ5=D1I[(MEG,;=2>@^E?O+_P .TOV:O^B7VG_@SOO_ (_4D?\
MP3:_9NB1T7X8V@5Q@_\ $RO3_P"UZB4&]A\O0_ ;'./Y4%3GG.?I7[[?\.T_
MV:_^B7VG_@ROO_C]'_#M/]FO_HE]I_X,K[_X_5V"Q^!GE8CR1@YQBF8(Z CZ
M"OWU/_!-/]FL_P#-+[3_ ,&=]_\ 'Z/^':7[-?\ T2^T_P#!G??_ !^CE#E/
MP*.2< '-*2QXQP/UK]]/^':7[-?_ $2^T_\ !G??_'Z/^':7[-?_ $2^T_\
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M]$8M+4)6=K'X'K=RH 1G\J=A;MOE39)C\#7[WG_@FI^S60 ?A?:8'_42OO\
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MPK*]S2HHHK< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>cgtx-20231231x10k021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20231231x10k021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '; WH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YN
MZ^(WARVU)M/&JPW%ZN=]O:!KATQP0PC#;2,C@XK(U@7/CWQ+=Z%%<2VF@:9L
M74W@?:]Y*ZAEM@PY5 A5G(()WJHP-U=AIFDV6BV4=GI]I#8VL8PD%O&(T7Z
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M+L;YF/HN?]6OHJX KIL4 <]_PGND?WKO_P %]Q_\;H_X3W2/[UW_ ."^X_\
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M_0I>-O\ PF;O_P")H_X7G9?]"EXV_P#"9N__ (F@#TNBO-/^%YV7_0I>-O\
MPF;O_P")H_X7G9?]"EXV_P#"9N__ (F@#TNN<\=?\@JW_P"ON#_T8*Y9_CQI
ML*-)/X8\96T*#<\TWANZ1(U'5F8KP .2:TKWQ;H_COP/I.O>']1@U;1KZX@D
MMKVV;='*OFXRI[C(/Y4 =R*X7PY_R5CQ=_UYV7_M2NZ%<+X<_P"2L>+O^O.R
M_P#:E '=T444 %%%% !1110 44V218D9W8*JC)9C@ 5D?\)CH/\ T&M._P#
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M<%>$?M=_\B_\._\ L=M,_E+7NZ?<% #JCN/]1)_NG^525'<?ZB3_ '3_ "H
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M+(^,7_1'+#_PL8?_ )'KV2B@#QK_ (6/\8L_\D<L/_"QA_\ D>E_X61\8O\
MHCEA_P"%C#_\CU[)10!XW_PLCXQ?]$<L/_"QA_\ D>C_ (61\8O^B.6'_A8P
M_P#R/7LE% 'C?_"R/C%_T1RP_P#"QA_^1Z/^%D?&+_HCEA_X6,/_ ,CU[)10
M!XW_ ,+(^,7_ $1RP_\ "QA_^1Z/^%D?&+_HCEA_X6,/_P CU[)10!XW_P +
M(^,7_1'+#_PL8?\ Y'H_X61\8O\ HCEA_P"%C#_\CU[)10!XW_PLCXQ?]$<L
M/_"QA_\ D>C_ (61\8O^B.6'_A8P_P#R/7LE% 'C?_"R/C%_T1RP_P#"QA_^
M1Z/^%D?&+_HCEA_X6,/_ ,CU[)10!XW_ ,+(^,7_ $1RP_\ "QA_^1Z/^%D?
M&+_HCEA_X6,/_P CU[)10!XW_P +(^,7_1'+#_PL8?\ Y'KH/@_\4=2^(Q\4
M6FM>&_\ A%]9\/:F--NK-+]+U&)@BG5UD55!!69>,<$&O0STKQ[X(?\ )2?C
M=_V-4/\ Z:[.@#V*N#MO^2Y:E_V+MK_Z4SUWE<';?\ERU+_L7;7_ -*9Z .\
MHHHH *0]#2TAZ&@#@/@]_P >OBO_ +&34?\ T;7H%>?_  >_X]?%?_8R:C_Z
M-K@?B=^TMXI\,_$K4O!O@;X0ZY\2+S2;.VN]2NK/4;:QAMO/W^4@,QRY(C8G
M' H ]^HK/\/7]WJN@:;>W^G2:1?7-M'-/I\LBR/:R,H+1,R\,5)*DC@XXK0H
M ***XSXM^,/$7@GP=-?^%?"-QXUUYYH[>VTN&X6W0L[!?,EE8'9&HY9@"<#@
M4 =G17R+9_MN^)=9TC3M(TGX<V]Y\1KG7]4T)M).N*NG9T^%9KF:.\\H[UVN
MJJ-@._(.,&JFL_\ !09IM$TS7O#/@*;6M"M_#EMXH\1S7&I+;RZ;:RSM#Y<2
M;#Y\JM'*2,J"J<')Q0!]3^//^1*U[_KQG_\ 1;5YG^Q;_P FH_"K_L7[7_T&
MNJ\>?$7PNG@W5HIO$6E6L]QIKRQP7-[%%(5>(E#M9@1D$5RO[%O_ ":C\*O^
MQ?M?_0: /:J*** "BBB@ HHHH *\_P#CEX*U+X@?#R^T;21";V9XROGOL7 8
M$\X/I7H%)FN;$X>&+H3P]3X9)I^C.O"8JI@L13Q-+XH--7VNM3YM^ /P%\5?
M#CQV=6UA;$69M9(LV]P7;<<8XP/2OI.DS]?RI:XLLRRAE.'^K8>_+=O5WW._
M-\VQ&=8GZUBK<UDM%9:?>%%%%>L>*%%%% !1110 4444 %%%% !1110!SOQ%
M_P"1!\1_]@ZX_P#1;5X#^R+_ ,F6_"G_ *X0_P#I2]>_?$7_ )$'Q'_V#KC_
M -%M7@/[(O\ R9;\*?\ KA#_ .E+T ?3XKA?#G_)6/%W_7G9?^U*[H5POAS_
M )*QXN_Z\[+_ -J4 =W1110 4444 >+_ +0WPY\2?$#6?AU/H-G:W$.@>(+?
M6+MKF[$),<?5$&TY8YXZ#BN"^(GP8^)/Q?\ B-XMAUW1?"EEX2O]%NM%TO6D
MOYI=4LXY$SQ%Y?EC?(!N.20HP/2OJ6B@#XXA_91MK+X.?$"3XC:/I6L22Z5;
M?9K$LT\=O)96;1+,'^7)8_,!@%>AS7T/^S]_R0[P#_V [/\ ]$K6A\8?^24^
M,/\ L$W7_HIJS_V?O^2'> ?^P'9_^B5H ] HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \&_:[_Y%_P"'?_8[:9_*6O=T^X*\(_:[
M_P"1?^'?_8[:9_*6O=T^X* '5'<?ZB3_ '3_ "J2H[C_ %$G^Z?Y4 8W@?\
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M\_Y$K7O^O&?_ -%M7F?[%O\ R:C\*O\ L7[7_P!!H ]JHHHH **** "BBB@
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MS?\  LL%/YBO2KOX7^#[_47U"Y\+:-<7SOYC7,MA$TA;UW%<YKIE4*    .
M!7E4\$XRG)SEJ[KWGIY=C[_&\3TZ]##T:>&IOV<%&5Z44Y-?:NG>[5D]5M?=
MF?H]QJ4FAVTVIVL,.J&$--;VTF^,28Y56/49[UY)=?';QOH<D_\ ;/P4\3K
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M,D]A6F/C+K_C@;/AWX.N=3M7'RZ]KY;3[#GHR*RF64=<[5'UK\F_^"?GQ/\
M'GQ%_;4\.2^+]6U'Q$+_ .T&\;54,ZLRVY*-AAA6&Q,-P1@<U^X '% &#X*L
M_$=GHV/%.HV6HZM)(TC'3K8PP1*>D:[B68#^\>3Z5OT44 %%%% "'I7CWP0_
MY*3\;O\ L:H?_379U[">E>/?!#_DI/QN_P"QJA_]-=G0![%7!VW_ "7+4O\
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M>?V4?A7_ -B_:_\ H->F>//^1*U[_KQG_P#1;5YG^Q;_ ,FH_"K_ +%^U_\
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MBE0Y5T895A[$$&K% !1110!D>+?#-EXR\-:EHFH1":SOH&@D4^A&*\J_9?\
M@(?@CX=U-;XQS:O?73;YE.?W"DB(9]Q\Q]S[5U_B?4?B3;ZQ<#0M(\-W.E*
M8I;^_GCF/'.56,@?G7(^#_B#\5?&NDMJ%EX>\*1P+<2VY$NIW ;=&Y5CQ%TR
M.* /:Z*@LFN&LX#=+&ER4!E6)BR!L<@$\D9J>@#G?B+_ ,B#XC_[!UQ_Z+:O
M ?V1?^3+?A3_ -<(?_2EZ]^^(O\ R(/B/_L'7'_HMJ\!_9%_Y,M^%/\ UPA_
M]*7H ^GQ7"^'/^2L>+O^O.R_]J5W0KA?#G_)6/%W_7G9?^U* .[KY8_:A^%G
MA2Z\4:7XIE^$^@_$ ^:8]:B@T:ROM7N%V'RD4W$L>Q0>2X+$#^$BOJ8U^<W[
M08\*V/[2'B>WUK5?@YIRW7EW,D/Q4TJ2[D>18]JO$JW"*$P2 Q"DG/WL< 'V
M)\#K?6]"^ VDQ+X3TWP]J<%M*;3PY9RQ1P0+O8Q1,T8V*V"-VW(!SWKY3U;P
MGXO\;?&35+WQ-9>&6\26MQ:7=W867Q.U4#2H2RA5-LEM';L"?X6(Y/)P17V#
M\ VT]_@_X9.ES>&9].^S'R9?!UN8-)9=[<VT99BJ9SQD\YKYW^(/_"N?%O[4
ML&B7NH^.O$&L0S1FZ\.^%K^^N-)@889'U" ((XAD Y63!(&Y>] 'V0OW:6D
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M=#TP>(CJ$GAS7_#SZ=KMQ/'J#7BQQ7,NU)U,QPLR%F,1"#BOOZX\=V'A_P
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MI7PX\9>!M.TVU46X\0:)]@M0BD*(XSO/(';T%>KTBC %+0 444E #)_]2_\
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M]VORD_X)Y_%WX@_$?]M/PXGBSQ#JNMP7;W=S=1W[%XWF6UVK(P(QO CC ;J
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M +36F>+/A;\,?#U_XGB%M)J<NJ:*(=8MKAI=D_VQ9IXI+/;#@I<+#-YAR Q
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M/Q+56W3/H<AQZR_'PG52=*7NSC*_+*#W3LF_-.SLTGT.'_9E^)WB'XO^ O\
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M4FTCN,*J\5UGSYZX\BQJ68A5 R2W %<QK7Q3\'>'5D.I>*='LB@RR2WT8?\
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MR:ZBL3P1X4MO G@O0/#5E)+-9Z-I]OIT$DQ!=HX8UC4M@ 9(49Q6W0 4444
M>'_M/_M*-^SQ8^%Q:Z!;^(M4\07[65O:W>L0:7"@2)I'D>>;Y  % P<9+"N*
M\=_MLWW@#[#%=_#:]O;JRT"'Q+XI2RU:WD31+*64QJ4?I<MPS83'RJ3FNS_:
M:^#/B7XIKX;O/#-KX)U.ZTI[A9-.\<:3]LM9DFCV%D=07B=>OR\-T->%ZG^P
M/XVTCPMI_AOPQXRT:73]4\(P>$/$EQJ]K,95ACN'F\ZS"'&0)9(U1S@*$YXH
M ^L/&WC'0YO!&J_\3>QC:XTV26..6Y1'97B)4[20>017%_L6_P#)J/PJ_P"Q
M?M?_ $&JOQ2_97^$WB30M3UC7? .AZ[K5MI7D+J.H6BRSLL,.V/+>P45:_8M
MY_91^%7_ &+]K_Z#0!I?M8?\FS_%#_L7+[_T2U=7\(O^24>"_P#L"67_ *(2
MN4_:P_Y-G^*'_8N7W_HEJZOX1?\ )*/!?_8$LO\ T0E '6T444 >'>#_ /D[
MGXA_]BSI'_H^ZKW&O#O!_P#R=S\0_P#L6=(_]'W5>XT > :-_P GS^(?^Q$M
M?_2UZ]_KP#1O^3Y_$/\ V(EK_P"EKU[_ $ %>%?MO_\ )K7Q"_[!S?S%>ZUX
M5^V__P FM?$+_L'-_,4 >P>%/^18TC_KSA_]%K7EO[97_)L/Q'_[ \__ *#7
MJ7A3_D6-(_Z\X?\ T6M>6_ME?\FP_$?_ + \_P#Z#0!Z/\/O^1#\.?\ 8-MO
M_12UT%<_\/O^1#\.?]@VV_\ 12UT% !7SI\-_P#D]/XL_P#8 TG_ -#FKZ+K
MYT^&_P#R>G\6?^P!I/\ Z'-0!]%'I7SQX._Y/@^(/_8IZ;_Z/DKZ'/2OGCP=
M_P GP?$'_L4]-_\ 1\E 'T11110!X%^W/_R;1XJ_[8?^CEKW+2/^079_]<4_
M]!%>&_MS_P#)M'BK_MA_Z.6O<M(_Y!=G_P!<4_\ 010!D?$7_D0?$?\ V#KC
M_P!%M7@/[(O_ "9;\*?^N$/_ *4O7OWQ%_Y$'Q'_ -@ZX_\ 1;5X#^R+_P F
M6_"G_KA#_P"E+T ?3XKA?#G_ "5CQ=_UYV7_ +4KNA7"^'/^2L>+O^O.R_\
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MK_Z4ST =Y1110 4AZ&EI#T- ' ?![_CU\5_]C)J/_HVO0*\_^#W_ !Z^*_\
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ME<L>N3[\"J=K\(]%M65A-?R,L@D5I;HN00CH!DCG"R,.<GG)R>:7[^RV*?\
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MRX&T$ ,<Q2?]\D]*CT_X2:!I<UW+:I<0O>7"W5R5E_UTJR^:K-QR0W?T '0
M"KKGPNC;34BT>>6"96B5O,N'C+1H\C@*Z@E6#2$YVL.,$=P?ODDVD-_V;4G*
M,922;TV27KOMK;7;L;J^.M&DT73-5BEGFL]3*K:&*TF=Y25+#"!=P^4$\CH*
MSW^*FA^?;I&TTD;S/#+,(]JVY6'SOW@/S#*$$#&>>0*TK?PG$VF:1;7L\EQ)
MIQWQR(1&2VQDYV@?PNPXQZUCV?P?\/6NG_8I%N[RW.0PN;EG+ P>003P>8\#
MUXSG/-4_:NUK'/366KF]HY=;6MW=NBV5GYOH:UCX[T>_U8:7%.XU#+9MI(F1
M\#J<$<CW&0,C.,BN@Q7)6WPSTV-=)%S>:CJ1TR3S8'O[GSGWC.UMY&X$ D?*
M1D<-D5UU:0Y[>^<.)6'37U=MKK?^O^&[L*2EHK0XPI,4M% "8HQ2T4 %%%%
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M ?1H^)WP>^"D&J::?$7A[PI##J3_ &V![A8E6]F4SL&S_P M'7+XZFJ/BO\
M:C\-Z;=>'['PGINI_$K5-<LWU*SM/"HBF!M$(5IWDD=$5-Q"C+9+< 9KQ_X2
M_LK>+;[X>_"G5/%5U;+XNM->?Q3XD34HLRRS/;-!&@VY =$\H<\ JU:'@?\
M93^(/PA'AC7?!NO^&I/%.GV5_I-_:ZM!.;"YM9[Q[F,HT>'22-F'8AN1QUH
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MHVGAQIMF!N,;,O(&X88\$9K '[:>CIXL^*]C=^%=4T_1/ >A+K;7E]#Y$NI
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MN4 %1W'^HD_W3_*I*CN/]1)_NG^5 &-X'_Y%/3/^N(JM>_\ (_:=_P!>4O\
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M!7IS]*@N_P!DKX:76DW6F+HDEM8W/A\^&9(8+EU!LC+YI7.<[RY+%SR23DT
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M ?+/_!-_0-7\*?LX0:3KVBZGH&J0ZK>R/9ZK836DH5Y2R,%D5201W%?4]%%
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M_P"/7Q7_ -C)J/\ Z-KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/'7_(*M_P#K[@_]
M&"NCKG/'7_(*M_\ K[@_]&"@#HA7"^'/^2L>+O\ KSLO_:E=T*X7PY_R5CQ=
M_P!>=E_[4H [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "H[C_42?[I_E4E1W'^HD_P!T_P J
M ,;P/_R*>F?]<15:]_Y'[3O^O*7_ -"%6? __(IZ9_UQ%5KW_D?M._Z\I?\
MT(4 =-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!VW_)<M2_[%VU_P#2
MF>N\K@[;_DN6I?\ 8NVO_I3/0!WE%%% !2'H:6D/0T <!\'O^/7Q7_V,FH_^
MC:] KS_X/?\ 'KXK_P"QDU'_ -&UM?$Z:6W^''BF6">6VF32[IDF@D:.2-A"
MQ#*RD%2#R"#D4 =-17R_X'U'XB>#+;_A*!!*V@ZO#X>TNTTGQ'KDMW(UU+*8
MKF]#@S>6K">WPF[GR6)52V3VMC\:/%FL"\_L?PQINLG3+N^TK4%AU9(WCOH+
M7S$1$;YF\R4;0I 8)(DG3(H ]KHKP;3OVB-5\4"XMO#FB6M_JK6VHW-M9:A-
M)ITJ-:FV4P7$<ZJT<@:XPY&Y5&Q@6#"E_P"&@->LM:=[_1M..B+K-UHZFTN9
M)+ERFFF_C<#;L^Z#&0"<GYE)'% 'O%%>-'XX:E;0^$GEM-%G_P"$M%G_ &/]
MFU+AC+;2SON+JH(_=A8RI_>%NV.=35OBYJ7A?P'X3U+7M!2R\0:YJ=GHTEA:
MW8NK>TN9YO*):90 44Y.<9SA>#0!Z@3BEKY>\6>.=6^*'C_P;X0U*S@M-)D\
M5:MHFK6*73M%?QP:?)/"X9,,O#1OC(*R(.> :[[XF_&*_P#A@VM6NGZ*FJVV
MA:1:76)KUVNKJ6>=X(8E!!).8B2[,22PXSDT >QT5Y=XG^-ITFVU0Z;X7\1:
MI-I-S%%?;=%ND4Q,^V26W+(/M00 L5B+,0. >E86C_M W5]X@T?2WM-,ND\1
MZ3:W_A^_T^YD>"^E+!;N/YT5@(0R2=-Q0ME04(H ]NHKYKT_]J/Q 7+WGA[3
M/LTT&O\ V=K>]EW"73+AX_GW)]V15!XY4^HKO[CXS3Q>+[?P_P#8;:*6[U"W
ML;>>:=@@+VDERV[Y?O8B*J >2P^E 'JM%?.%Y\4=2\'_ !2U#4-:6T-W/HNB
M6+VEOJ):QBNI[Z>$E9'VC&[ R0"< &M37?BCXHT9KK5-4\+:5:ZYI^C:O<00
MC5GE4B":':&,8*J)$*,0060\<@F@#WNBO-/AK\3M6\477B6VUO3;*SDTN.VN
MHFL+AY%DAGB:10V]5PR[2#C(/!XZ5Y9XW^/$WC;X:&W?3GM;?Q1X1U#7-/O=
M,O)-UMY#*"DCKMP2LL>"I^\&7I@D ^G:6O$;OXH7/A#6-9:+P^MR#JNGV=Q?
M17+E(H98A^^F4_=V\C"#!W*3CDC&TK]HWQ7=Z/J\5[X/@TWQ-INA3:_)IMW<
M/#')"+AXHD61U&"R1ER2,+O3(YH ^AZ*\%C^-_C+4]05=.T30OL<FJIIB-=7
MLZR 2VL<\<A"QD<>9AE!YQD$=*ET3X^>(?$,QTW3_#5C<ZS9V45[?*^HB"WV
M-=R0,8W< D 0NW(X)0'&<T >ZT5X)_PT%K^E:$FMZSH5FFCOJ%W8R76F/->/
M:+!)+&9Y853S#&2D>2@;8&8MP,UT7Q9\90:>?AY?165KK-MJ&KPB&=;R6-8R
MT3,DJ;.)!TX;@@YZXH ]9HKP'X%?M':K\4==T/3]4T2QL!K&BW>K0O97+R&+
M[->"V=&#*,[BP8$=,$$56?\ :9UC3/$-W'J&A:>=&M_$%_H326UV_G@P68NE
MEPRA<$94KG@\@]J /H>BO#H?CYKR3>')KGP]IJZ1K]S81V%[!JJS&6.XB=V;
M8H.-I5<$G#AN,8K,L?VD-=N](&MG0=/728-+O-5NTBN)9+D1VUVT#I&@3#,P
M 89(P<@^M 'T)17SMXE_:4\0:)>:-!%H&FR+JRZ/+!,]X^ E[,L3!E"DY0NA
M!Z,,],5'I7[4.L:EX3EU$>'[ WEI)=P74$=Y(_SV]VMNSA=F5B();<QR#A<'
M.0 ?1M%<'\,-R:MX[C,LLB)K[A1+*TFT&W@.!N)P,D\#@9KO* "N<\=?\@JW
M_P"ON#_T8*Z.N<\=?\@JW_Z^X/\ T8* .B%<+X<_Y*QXN_Z\[+_VI7="N%\.
M?\E8\7?]>=E_[4H [NBN7^)\TMM\//$4L$TMM,EC*R2P2-&Z$*<%64@@^X->
M#:C^TAKWP]BMK*72[/4M+TO1-(OKJ[N+V9KR=;C:C=007!.<LW/.: /J&BO$
M=<^.>N0^ =4\7:58Z!>:?:BZ1('U-_.\V&;R]C;8R,D!B<<KQUJ73/C/XFO=
M6U'3%T#3;BXT:6V74YS?_9HE256??'YHW': .V"<X/% 'M-%>!R_M':S9+?R
MW'A4W$%HEK-*VEM+=.L,H<O*D817F1 H.8UR1N(&!R7OQAN;>\U+5]"T_2=4
MDGATPQW8OIUBGCF+#IM(4J>GRY/(;!H ]\HKP>;X_>(+&**PNM!LCK,DU_:I
M);2S26TDT"AHT ";\OG&"/IFNQU?XE:GX>TSP3;ZAIT$6O>(YEMC$6=(+>4Q
MERK,1NS_  @$9)H ]'HKP_6?CSK>@6.O376C:3<W'AY;-M2M+'4))9&$SD$P
MCRP3@ 8W ;CD<8K)/[2>N:3ON]8T72TTYA?I%]FO)-X:W/WG+( %((R.2,'K
M0!]#45X]K7QDUS1]7L=%33=&U#6-6AEN=+C@U/8D\:0AP&+J,,3GH2-OS>U<
M7%^T[XFC\6W.EWWA[2K2*#5[#1I!%>R3R)-=PEU;(4(RHRD'!^8<@B@#Z5HK
MP3PQ\6_'-W9:)%<P^'KF:?3;G4;N^FEEMD58IG0J$ ( ( Y+<=3FLZV_:&\2
M>)_%46B:=86>FM::GI<5U/<1R.MW!=1L^(@0" -O#X.X<@"@#Z+I:^8_AC\?
M&F_M;0=(\-V]GJRSZQ>;9;Z:2WE-LX!Q(^2K.>J]%'(XK9T_]HGQ->W$%R?#
MNE)IGVC3XYD^WR&=5NHRW!V;"492.N".<B@#Z#HKS+X=_&5/&"Z['J%A+I.I
MZ.A>ZTJ6&07"*-Q#ID;98V !5XR0>G6O//%O[1.N7_P\;5M)TZWLK;6/#M_J
M-A>&Y/GVLT.<*\1&3\O.1T/% 'T>#FEKQ70M6D^&/PJ\,:EI^GP76J>))[$3
MI/?R);B>X0%Y?GW8S@DJH&2:N>#_ (_)KFE?:;[0]326?4KG3[9=/T^XNH\1
M':))I$1EA1B.&<@>] 'KU%>!R_M,3P:/<ZC/I,5@^CWT,>OZ;?-)%<Z?:.2O
MVI?E*2QYVD.A*$$\@@BF^,/V@?$VA7,LEAH6D75BFDIK2F>^D222 W'E;1M1
MER5PP.2.WO0![]17C5]\?IK&W:Z?2(C;I?7-LP%P=VR*'S=P^7&3TQT%<9\;
M?'FN:KX/\&WWVBQL[*_U_2)X)-)U"1I)8I-YD208 *Y&."0V.@H ^F**^?7^
M->K>-_ [ZW%X6LSX7N8EDCDN=5V3EENA&8VCC^<'&&SQ@\$5M:5\8O$DWCB'
M2Y]'TI-&;6)=(\Z*[E-QE4WH^TIMZ<$9]P: /:**0<BEH **** "H[C_ %$G
M^Z?Y5)4=Q_J)/]T_RH QO __ "*>F?\ 7$56O?\ D?M._P"O*7_T(59\#_\
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MWS6[K(EPJR0R1I;R>8'3"2$)DCYC[P#D4 +1110 5P=M_P ERU+_ +%VU_\
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M3RFFSN$@&/E93RI7&W^'%=+=>#]$O?#JZ!/I5I)HJHL:V'D@0HJD%=JC@;2
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MD"4OL0-+TW@8Z4 >YZ5X,\/Z%-;S:;H6FZ?-;PO;PR6MG'$T43OO=%*@85G
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MPPKY:NBYD)8+DXSNQ\HH ^N/$>@Z#=E=4UBWM!]D7<;JZ(5$53N&\D@%0WS
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M-1_]&UV6N:U9>'-'O=4U&<6UA9PO//,P)$<:C+,< G@ GBN-^#W_ !Z^*_\
ML9-1_P#1M:OQ6N/LWPU\3N(YY6.FW"+';0/-(S-&RJ%1 68DD< &@#7T'4=*
M\1Z#I^IZ8T-UI=U$MS:RHF$=&&Y74$#@@Y!QWJ&V\4:'>Z=JEU:7]K=VNFR2
MV]Z;9A+Y$D?,D;JN2&7/*XSR..:\E\/?&JTT'X0Z5%9Z1X@N-8L-"MPUM+X=
MU &.<1QQK&P\D$MO894'(57.<+6!X1MKKX&_%/7M(N8;^ZT#Q-HJ:N][8:;=
M7$<.J0KY5P\ACB*JURFR3'&7A? )84 >RM\2?!P\ ?\ ">G6M/\ ^$4:T%__
M &SN!@,&.)-V,XJAJ'QG\":=X@AT*^UVTM-1_P!'98;F-XQ&9\^1N9E"H7P0
MH)!)&!SQ7S-:>$?$7A;X/^+/"\.AZE_P@HT<:_I2PV<SS+=W5N5.GI;!#*-E
MV);@X4;?-0' !+>B:_X'LOCK\2/&N@WU_K^G^&[_ $?17F1-+D@COA%+/*R"
M>:'Y2/,BW!"&&\]"#@ ]HT+XF>%/$/BC4/#NEZU9W6M6>]I[2,D/\CA)",@!
M]CD*VTG:QP<'BM:RUK2-3U;5-/M+NUN=0LO+6^MXG5I(2ZED60#H2O(!['/0
MUX,OQ.\.>+?B\=9O/"?B^*;PE:ZA'ILTOA348XI2RK]HF24Q"-]PCV1HN6?<
MQQRN*6B1ZI\-_BSX1\83V-W/;^.[&6TU]--L+N98)US<6D\P\K,8CWR6VYMO
M^L3*C!V 'TJUM"P ,2$ Y *C@XQG\J<L2)RJ*O&,@8KRSQI\28O$OP5O/$?A
MRS\27"32"V\BPLYK3482+@0REHG3S4"8<OM7?L5B@)VUQO\ PDWB/3OV7OB=
M//+K]AK>C1ZZMG>ZC#/!<[$>9[>2)Y69W4(4VON/0<\< 'T&L$2JJB- %.0
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MO5/PO-XC?P_INKZS=>.IM-O]3OK;5A'+>QW%JB/+]E9(L"5$.4^:(8(VYX%
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M\/:;<:AJ5Q:Z=86ZF2:YN76..-<\LS'  ]S4EY<V=OITM[,4-I$AN&D"[AM
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MRQ,J1K(Z9 P&".I()S@UXI\9[CX@W/B[Q'8Z*^LVE_Y&G3>$IK(S"QEE$O\
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M\,_$;Q+\#/'>@ZW<:C8>(-1T^>TTZZU"6%[B*=[,+)(IA. GV@R% 3D+CH,
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MX9#Y5TFZ6TNQ'@>81+)."/27I@<>6Z=\)/B.=6BUN3P,()K3PII>E:A:OJD
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M%7?!WP$\40V.EZAJ>CPV_B:V_L#_ (F$E\)I4DMH]EW+N#'.X#GNXX- 'O\
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M\T$-O&K7!.WE8]Q #-TY8 \9-)IOB73]5O[FPBF"ZC:I&]S9M_K(-Z[E#XR
M2.V37S]J7PS\5^(]-\>Z-JW@M)]7F@U1=*\4'5D\JXBN0?*B*;MX90$4AUV+
MMRA-=+\(OA3JG@OXM^.-;OM$M8K;6K?3O(U**2-G+16D44L;#[^2Z,<]#UH
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MF\\)+;^-8K*#2O[>N=51H=:5+Q;@S(%8E0V9'/F*KAV*\@;B ?6$,HFB1U!
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MM<G;?\ERU+_L7;7_ -*9Z .\HHHH *0]#2TAZ&@#@/@]_P >OBO_ +&34?\
MT;7::SK-CX>TJ[U/4[R#3].M(FGN+JYD$<<4:C+,S'@ #O7%_![_ (]?%?\
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M58/^Y"A<<%G)[4 ?0EA\3?"NIO9+::_83B]M?MEJZ3 I-%MW;D;H?E^; .<
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M-R."23DNIY(P!5CQY^SIXI^*-CX6GU?5M&T'6],OC>W5WX?@DB\UQ:20(P)
M+_,X)1_EVC9R"<@'N=SXRT2T\.C79M2MX])90ZW9;Y'!^[M[MGC&.O:LR[^+
M7@O3[2WN;GQ1I,$%Q&DL;R7:#*.X16Z\ L=N3WX[5E^(_#7B_7/A]I%BEYI,
M/B&&2V>]*)(MM,$8&18FP7BW ':P&Y>QXS7G'AC]GGQ)X;\%RZ$+_1[F0Z7J
M5DMPPF&9+F^-RI(P3M53@\DDT =[X\^.&F^#?'7A#PM##'JE_KNIC3YE2XV&
MS!C9P[#:0WW<;<@\YKJM?^('ASPK=06VLZW8Z7-,NY1=SK&,>I)X4=ADC)X'
M->-/\ O%TGCGP_>2:OI4VAZ9XH;Q*7E\XW9+P>6\'3:0IY5\CY< KQFL'XP^
M&4U/XU:B\GAXZO!>Z?81/9SPWL(OW@G:5 DT<4D3;3P58Q_>Y)Z@ ]X;XL>#
M@UVB>)=,GDM8S+-';W*RNB X)*KD]?:K-I\1/#6I)<M9:[I]W]GBCGD,5PK!
M$?\ U;$C/#8.#WP<=*\:U_\ 9WUCQ)H%C)(-&&HV>OW&L+IET9OL=S%-'L:.
M<QX;>JL<,NY<J."*NV'PXT^'XA^&],TS3)-(BT335AUBWTS3'M]*F@R7@AC=
M^'*R+T4L0I8,%W4 >M>%/&$7B674[1X#9ZEIEQ]GNK8MN"DC<C*V!N5EY!P.
M01VIOCK_ )!5O_U]P?\ HP5S'PR\)36GCKQWXMECGMTU^>VBAAN!M)CMT=1)
MM(RNXR-P><*#T(KI_'7_ ""K?_K[@_\ 1@H Z(5POAS_ )*QXN_Z\[+_ -J5
MW0KA?#G_ "5CQ=_UYV7_ +4H [NBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H[C_42?[I_E4E
M1W'^HD_W3_*@#&\#_P#(IZ9_UQ%5KW_D?M._Z\I?_0A5GP/_ ,BGIG_7$56O
M?^1^T[_KRE_]"% '34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 @ ':EHHH **** "F[%W[]HW
M8QNQSBG44 %<';?\ERU+_L7;7_TIGKO*X.V_Y+EJ7_8NVO\ Z4ST =Y1110
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M@<$ &?;_ !Y\/6/A?^U;V^N-3C$=_=F73])G7$%K=_9YF,9+$>6Q )S\P4L
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M]H)0KNK'9,KB>0,C*!@C&,5Z#_PJK3+O2$74A#J6OBQ>Q;7I+2)+C:X(;:%
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M/^2L>+O^O.R_]J4 =W1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY^;CO8T$:*@)(48RQR?Q- #J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4?^_]K_\
M'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#QZ@#H**Y_
M_A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\ X2/4_P#H
M5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\ VO\
M\>H_X2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\ 'J/^$CU/
M_H5]1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4?^_]
MK_\ 'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#QZ@#H
M**Y__A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\ X2/4
M_P#H5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\
MVO\ \>H_X2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\ 'J/^
M$CU/_H5]1_[_ -K_ /'J .@KCO'5ZUUJ.A:):%6N[J[2>1<9V01D,['G@= #
MZD4Z[UOQ;?S/;Z;X=@T]2HQ>ZK>(RJ<\XBA+%B/3<H/K5[PQX2&ARSWUY=OJ
MNM70 GOYE"G:.D:*.$0=E'U))H Z 5Q8:/0OB?(\J"--:M%CCF+'YI8B3LQC
M .UF/7M7:UE^(_#EGXITQ[*]5MA(=)(V*R1.#E71AR&!Y!H U**XN&Z\8^'C
M';SV%MXGM@P5;RVG6VN-OK)&_P A/NK#/H*U/^$CU/\ Z%?4?^_]K_\ 'J .
M@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#QZ@#H**Y__A(]
M3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\ X2/4_P#H5]1_
M[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\ VO\ \>H_
MX2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\ 'J/^$CU/_H5]
M1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4?^_]K_\
M'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#QZ@#H**Y_
M_A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\ X2/4_P#H
M5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\ VO\
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M_P#H5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'_O\
MVO\ \>H_X2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\ 'J/^
M$CU/_H5]1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\ Z%?4
M?^_]K_\ 'J .@HKG_P#A(]3_ .A7U'_O_:__ !ZC_A(]3_Z%?4?^_P#:_P#Q
MZ@#H**Y__A(]3_Z%?4?^_P#:_P#QZC_A(]3_ .A7U'_O_:__ !Z@#H**Y_\
MX2/4_P#H5]1_[_VO_P >H_X2/4_^A7U'_O\ VO\ \>H Z"BN?_X2/4_^A7U'
M_O\ VO\ \>H_X2/4_P#H5]1_[_VO_P >H Z"BN?_ .$CU/\ Z%?4?^_]K_\
M'J/^$CU/_H5]1_[_ -K_ /'J .@HKG_^$CU/_H5]1_[_ -K_ /'J/^$CU/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>30
<FILENAME>cgtx-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2024 2:26:08 PM-->
<!--Modified on: 3/25/2024 2:26:08 PM-->
<xsd:schema targetNamespace="http://www.cogrx.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:cgtx="http://www.cogrx.com/20231231" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails">
        <link:definition>40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40401 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" id="DisclosureCommitmentsAndContingenciesLeasesDetailss">
        <link:definition>40601 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40702 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" id="DisclosureIncomeTaxesNetLossDetails">
        <link:definition>41201 - Disclosure - Income Taxes - Net loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails">
        <link:definition>41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" id="DisclosureDescriptionOfBusinessAndFinancialConditionDetails">
        <link:definition>40101 - Disclosure - Description of Business and Financial Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails">
        <link:definition>40303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" id="DisclosureOtherCurrentLiabilitiesDetails">
        <link:definition>40601 - Disclosure - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" id="DisclosureCommitmentsAndContingenciesLeasesDetails">
        <link:definition>40701 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40801 - Disclosure - Stockholders' Equity - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails" id="DisclosureStockholdersEquitySharesReservedForIssuanceDetails">
        <link:definition>40802 - Disclosure - Stockholders' Equity - Shares reserved for issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" id="DisclosureEquityBasedCompensationDetails">
        <link:definition>40901 - Disclosure - Equity-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" id="DisclosureEquityBasedCompensationFairValueOfOptionsDetails">
        <link:definition>40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" id="DisclosureEquityBasedCompensationAdditionalInformationDetails">
        <link:definition>40904 - Disclosure - Equity-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" id="DisclosureEquityBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>40905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" id="DisclosureEquityBasedCompensationCompensationExpenseDetails">
        <link:definition>40906 - Disclosure - Equity-based Compensation - Compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" id="DisclosureNetLossPerShareAntidilutiveEffectDetails">
        <link:definition>41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41204 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41301 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" id="DisclosureDescriptionOfBusinessAndFinancialCondition">
        <link:definition>10101 - Disclosure - Description of Business and Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" id="DisclosureFinancialInstrumentsAndFairValueMeasurements">
        <link:definition>10301 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10401 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" id="DisclosureOtherCurrentLiabilities">
        <link:definition>10601 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10801 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" id="DisclosureEquityBasedCompensation">
        <link:definition>10901 - Disclosure - Equity-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11001 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>11101 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30403 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30703 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" id="DisclosureEquityBasedCompensationTables">
        <link:definition>30903 - Disclosure - Equity-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31003 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" id="DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails">
        <link:definition>40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails">
        <link:definition>40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" id="DisclosureEquityBasedCompensationActivityForOptionsDetails">
        <link:definition>40903 - Disclosure - Equity-based Compensation - Activity for options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" id="DisclosureRetirementPlanDetails">
        <link:definition>41101 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="GrantIncome" id="cgtx_GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInGrantReceivables" id="cgtx_IncreaseDecreaseInGrantReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredOfferingCostsIncludedInAccountsPayable" id="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrantIncomePolicyPolicyTextBlock" id="cgtx_GrantIncomePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmergingGrowthCompanyPolicyTextBlock" id="cgtx_EmergingGrowthCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceInitialPublicOfferingGross" id="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AllowanceForCreditLossGrantsReceivableCurrent" id="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenses" id="cgtx_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AmendedAndRestatedEquityIncentivePlan2017Member" id="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" id="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OperatingLossCarryForwardsSubjectToExpiration" id="cgtx_OperatingLossCarryForwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryForwardsNotSubjectToExpiration" id="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentTaxCreditCarryForwards" id="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PrepaymentOfInsuranceThroughThirdPartyFinancing" id="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherCurrentLiabilitiesTextBlock" id="cgtx_OtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InsurancePremiumFinancingAgreementMember" id="cgtx_InsurancePremiumFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityIncentivePlan2021Member" id="cgtx_EquityIncentivePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmployeeStockPurchasePlanMember" id="cgtx_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceNewYorkMember" id="cgtx_OfficeSpaceNewYorkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LaboratoryAndOfficeSpacePittsburghPaMember" id="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredGrantIncomeCurrent" id="cgtx_DeferredGrantIncomeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInDeferredGrantIncomeCurrent" id="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseAssets" id="cgtx_OperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OfficeSpaceLocatedInPittsburghPaMember" id="cgtx_OfficeSpaceLocatedInPittsburghPaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FollowOnPublicOfferingMember" id="cgtx_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsOperatingLeaseLiabilities" id="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" id="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LegalReservesProfessionalFeesAndOtherAccrualsCurrent" id="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumAggregateOfferingPrice" id="cgtx_MaximumAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtMarketOfferingMember" id="cgtx_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" id="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityLineFinancingMember" id="cgtx_EquityLineFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LincolnParkCapitalFundLlcMember" id="cgtx_LincolnParkCapitalFundLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseAgreementTerm" id="cgtx_PurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumValueOfStockToBeIssuedUnderAgreement" id="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SharesOfferingAgreementRemainingValueOfStockToBeIssued" id="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" id="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmployeeDirectorMember" id="cgtx_EmployeeDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonEmployeeDirectorMember" id="cgtx_NonEmployeeDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RemainingValueOfStockToBeIssuedUnderAgreement" id="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquityLineFinancingCommitmentSharesMember" id="cgtx_EquityLineFinancingCommitmentSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InsurancePremiumFinancingAgreement2Member" id="cgtx_InsurancePremiumFinancingAgreement2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnderwritingAgreementWithTitanPartnersGroupLlcMember" id="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnderwritersOptionToPurchaseAdditionalShares" id="cgtx_UnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UnderwritingDiscountsCommissionsAndOfferingExpenses" id="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AaronFletcherMember" id="cgtx_AaronFletcherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>31
<FILENAME>cgtx-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2024 2:26:08 PM-->
<!--Modified on: 3/25/2024 2:26:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetailss" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesNetLossDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638469735661709440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638469735661709440" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638469735661709440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638469735661709440" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638469735661709440" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638469735661709440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638469735661709440" xlink:to="us-gaap_GrantsReceivableCurrent_638469735661709440" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638469735661709440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638469735661709440" xlink:to="us-gaap_PrepaidExpenseCurrent_638469735661709440" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638469735661709440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638469735661709440" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638469735661709440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638469735661709440" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638469735661709440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets_638469735661709440" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638469735661719439" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638469735661719439" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735661719439" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638469735661719439" xlink:to="us-gaap_LiabilitiesCurrent_638469735661719439" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638469735661719439" xlink:to="us-gaap_AccountsPayableCurrent_638469735661719439" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638469735661719439" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638469735661719439" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638469735661719439" xlink:to="cgtx_DeferredGrantIncomeCurrent_638469735661719439" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638469735661719439" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638469735661719439" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638469735661719439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638469735661719439" xlink:to="us-gaap_OtherLiabilitiesCurrent_638469735661719439" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638469735661719439" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638469735661729441" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638469735661729441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638469735661729441" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638469735661729441" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638469735661729441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638469735661729441" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638469735661729441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638469735661729441" xlink:to="us-gaap_AdditionalPaidInCapital_638469735661729441" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638469735661729441" xlink:to="us-gaap_CommonStockValue_638469735661729441" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638469735661729441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638469735661729441" xlink:to="us-gaap_PreferredStockValue_638469735661729441" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638469735661739442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638469735661739442" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638469735661739442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638469735661739442" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 3)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638469735661739442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_4" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638469735661739442" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638469735661739442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638469735661739442" xlink:to="cgtx_GrantIncome_638469735661739442" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638469735661739442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638469735661739442" xlink:to="us-gaap_OtherNoncashIncomeExpense_638469735661739442" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638469735661739442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638469735661739442" xlink:to="us-gaap_InterestIncomeExpenseNet_638469735661739442" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_4" xlink:to="us-gaap_OperatingIncomeLoss_638469735661749441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638469735661749441" xlink:to="us-gaap_OperatingExpenses_638469735661749441" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638469735661749441" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638469735661749441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638469735661749441" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638469735661749441" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638469735661749441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735661749441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735661749441" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638469735661749441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735661749441" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638469735661749441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_638469735661749441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735661749441" xlink:to="us-gaap_RepaymentsOfShortTermDebt_638469735661749441" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735661749441" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735661759442" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638469735661759442" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638469735661759442" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638469735661759442" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638469735661759442" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638469735661759442" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638469735661759442" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638469735661759442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638469735661759442" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638469735661769443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638469735661769443" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_638469735661769443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_638469735661769443" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638469735661769443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_ShareBasedCompensation_638469735661769443" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638469735661769443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638469735661769443" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638469735661769443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638469735661769443" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638469735661769443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_NetIncomeLoss_638469735661769443" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638469735661769443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735661759442" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638469735661769443" order="11" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638469735661779441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638469735661779441" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638469735661779441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638469735661779441" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638469735661779441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638469735661779441" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638469735661779441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638469735661779441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638469735661779441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638469735661779441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_638469735661779441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_638469735661779441" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" xlink:type="extended" xlink:title="40601 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735661789441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638469735661789441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset_1" xlink:to="cgtx_OperatingLeaseAssets_638469735661789441" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638469735661789441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638469735661789441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638469735661789441" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638469735661789441" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638469735661789441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638469735661789441" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638469735661799442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638469735661799442" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Net loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638469735661799442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638469735661799442" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638469735661799442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638469735661799442" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638469735661799442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638469735661799442" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638469735661799442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638469735661799442" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638469735661799442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638469735661799442" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638469735661799442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638469735661799442" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638469735661809441" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638469735661809441" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638469735661809441" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638469735661809441" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638469735661809441" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638469735661809441" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638469735661809441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638469735661809441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638469735661809441" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638469735661809441" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsGross_638469735661809441" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638469735661819442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638469735661809441" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638469735661819442" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638469735661819442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsOther_638469735661819442" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638469735661819442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638469735661819442" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638469735661819442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638469735661819442" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638469735661819442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638469735661819442" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638469735661819442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638469735661819442" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638469735661819442" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638469735661809441" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638469735661819442" order="7" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>32
<FILENAME>cgtx-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2024 2:26:08 PM-->
<!--Modified on: 3/25/2024 2:26:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureDescriptionOfBusinessAndFinancialConditionDetails" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureOtherCurrentLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationFairValueOfOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationAdditionalInformationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationCompensationExpenseDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureNetLossPerShareAntidilutiveEffectDetails" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="cgtx-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:title="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_1" xlink:title="us-gaap_ConversionOfStockNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:to="us-gaap_ConversionOfStockNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConversionOfStockByUniqueDescriptionAxis_1 To us-gaap_ConversionOfStockNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AaronFletcherMember" xlink:label="cgtx_AaronFletcherMember" xlink:title="cgtx_AaronFletcherMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="cgtx_AaronFletcherMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To cgtx_AaronFletcherMember" order="1" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingCommitmentSharesMember" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingCommitmentSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business and Financial Condition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_LincolnParkCapitalFundLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_PurchaseAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_GrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_DeferredGrantIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredRentCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AdjustmentForAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_InsurancePremiumFinancingAgreement2Member" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cgtx_InsurancePremiumFinancingAgreement2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_OfficeSpaceNewYorkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_LincolnParkCapitalFundLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_PurchaseAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Equity-based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_EquityIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Equity-based Compensation - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmployeeDirectorMember" xlink:label="cgtx_EmployeeDirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_DirectorMember" xlink:to="cgtx_EmployeeDirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_NonEmployeeDirectorMember" xlink:label="cgtx_NonEmployeeDirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_DirectorMember" xlink:to="cgtx_NonEmployeeDirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Equity-based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_LincolnParkCapitalFundLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>33
<FILENAME>cgtx-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2024 2:26:08 PM-->
<!--Modified on: 3/25/2024 2:26:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets, operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredGrantIncomeCurrent" xlink:to="cgtx_DeferredGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current portion of deferred grant income as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Grant Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income and other liabilities, noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 250,000,000 shares authorized; 32,165,478 and 28,991,548 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_GrantIncome" xlink:to="cgtx_GrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income related to grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss) gain related to foreign currency translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AtMarketOfferingMember" xlink:to="cgtx_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityLineFinancingMember" xlink:to="cgtx_EquityLineFinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityLineFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to equity line financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityLineFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line Financing</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingCommitmentSharesMember" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityLineFinancingCommitmentSharesMember" xlink:to="cgtx_EquityLineFinancingCommitmentSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to commitment shares for equity line financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line Financing Commitment Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain (loss)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_FollowOnPublicOfferingMember" xlink:to="cgtx_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to follow on pubic offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, discounts and offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of adjustments relating to commitment shares issued for equity line financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Stock as Commitment Shares For Equity Line Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock as commitment shares for equity line financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IncreaseDecreaseInGrantReceivables" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase and decrease in grant receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Grant Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in current deferred grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Deferred Grant Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Short-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on loan payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents-end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents-beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of prepayment of insurance through third-party financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment of Insurance Through Third Party Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment of insurance through third-party financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remeasurement of right-of-use asset and operating lease liability</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred offering costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs Included In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs included in Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities.</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OtherCurrentLiabilitiesTextBlock" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OtherCurrentLiabilitiesTextBlock" xlink:to="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entire disclosure of other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_GrantIncomePolicyPolicyTextBlock" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_GrantIncomePolicyPolicyTextBlock" xlink:to="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:to="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for emerging growth company status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Impact of Adoption of ASC 842</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of financial assets and liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of minimum lease commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of options granted using the Black-Scholes option pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity for options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted stock units award activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total equity-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding potentially dilutive common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net loss components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the expected income tax (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald And Co and B Riley Securities Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LincolnParkCapitalFundLlcMember" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Lincoln Park Capital Fund, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park Capital Fund LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price per share</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross cash inflow associated with the amount received from entity's first offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MaximumAggregateOfferingPrice" xlink:to="cgtx_MaximumAggregateOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount of aggregate offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity impact of the value of new stock to be issued under an agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Stock To Be Issued Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value of stock to be issued under agreement</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining value of new stock to be issued under an agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Value Of Stock To Be Issued Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount available to draw under purchase agreement</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PurchaseAgreementTerm" xlink:to="cgtx_PurchaseAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allowance for credit loss on grants receivable, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Credit Loss, Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts on grants receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously Reported</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASU 2016-02</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Priced in Active Markets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Unobservable Inputs (Level 3)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation, benefits, and related accruals</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AccruedResearchAndDevelopmentExpenses" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:to="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal reserves, professional fees and other accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Reserves, Professional Fees and Other Accruals, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees and other accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_InsurancePremiumFinancingAgreementMember" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to insurance premium financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance Premium Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_InsurancePremiumFinancingAgreement2Member" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_InsurancePremiumFinancingAgreement2Member" xlink:to="cgtx_InsurancePremiumFinancingAgreement2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to insurance premium financing agreement 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance Premium Financing Agreement 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Periodic payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:to="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt, Maturing in More than Three Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of short-term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLeaseAssets" xlink:to="cgtx_OperatingLeaseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating lease assets as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OfficeSpaceNewYorkMember" xlink:to="cgtx_OfficeSpaceNewYorkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OfficeSpaceNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to New York office space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OfficeSpaceNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space, New York</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to laboratory and office space in Pittsburgh, PA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory And Office Space, Pittsburgh, PA</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to office space located in Pittsburgh, Pennsylvania.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space located In Pittsburgh, PA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of buyout options in dollars in an operating lease under the lessee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Number of Buyout Options in Dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of option at conclusion of the lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum lease commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows used for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend declared</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:to="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The remaining value of stock to be issued under shares offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Offering Agreement, Remaining Value of Stock to be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining of common stock available for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended and Restated 2017 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityIncentivePlan2021Member" xlink:to="cgtx_EquityIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">.Represents information relating to 2021 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EmployeeStockPurchasePlanMember" xlink:to="cgtx_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of common shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that may be recycled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value - Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life -Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmployeeDirectorMember" xlink:label="cgtx_EmployeeDirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EmployeeDirectorMember" xlink:to="cgtx_EmployeeDirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person serving on board of employee directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Director</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_NonEmployeeDirectorMember" xlink:label="cgtx_NonEmployeeDirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_NonEmployeeDirectorMember" xlink:to="cgtx_NonEmployeeDirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_NonEmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person serving on board of non employee directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_NonEmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employee Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_NonEmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employee Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total fair value of options granted during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total fair value of options exercised during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable for each award under share-based payment arrangement.












ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Issuable for Each Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable for each award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost related to options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which the unrecognized compensation cost is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive common stock equivalents outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of employees' compensation per person per year matched by the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matching contributions to the plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax computed at federal statutory rate (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D Credit (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible stock compensation (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research expenditures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets after valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Operating Lease, Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets, operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating loss carryforwards that are subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry forwards, Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that expire</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating loss carryforwards that are not subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry forwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that do not expire</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:to="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of federal research and development tax credit carry forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Tax Credit Carry Forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:to="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to underwriting agreement with Titan Partners Group LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Agreement With Titan Partners Group LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering price</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters option to purchase additional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters, Option To Purchase Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional shares of common stock</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:to="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of underwriting discounts, commissions and offering expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Discounts, Commissions And Offering Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering expenses payable</label>
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AaronFletcherMember" xlink:label="cgtx_AaronFletcherMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AaronFletcherMember" xlink:to="cgtx_AaronFletcherMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AaronFletcherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information relating to Aaron Fletcher.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AaronFletcherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aaron Fletcher [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AaronFletcherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Aaron Fletcher</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>34
<FILENAME>cgtx-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2024 2:26:08 PM-->
<!--Modified on: 3/25/2024 2:26:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureDescriptionOfBusinessAndFinancialCondition" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurements" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureAccruedExpenses" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureOtherCurrentLiabilities" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureStockholdersEquity" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensation" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureNetLossPerShare" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureRetirementPlan" roleURI="http://www.cogrx.com/role/DisclosureRetirementPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.cogrx.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationTables" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureDescriptionOfBusinessAndFinancialConditionDetails" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureOtherCurrentLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureStockholdersEquitySharesReservedForIssuanceDetails" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationFairValueOfOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationActivityForOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationAdditionalInformationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureEquityBasedCompensationCompensationExpenseDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureNetLossPerShareAntidilutiveEffectDetails" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureRetirementPlanDetails" roleURI="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesNetLossDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638469735662439446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638469735662439446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638469735662439446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638469735662439446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638469735662439446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638469735662439446" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638469735662439446" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638469735662439446" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638469735662439446" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638469735662439446" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638469735662439446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638469735662439446" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638469735662449445" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638469735662449445" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638469735662449445" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638469735662449445" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638469735662449445" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638469735662449445" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638469735662449445" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638469735662449445" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638469735662449445" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638469735662449445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638469735662449445" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638469735662459444" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638469735662459444" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638469735662459444" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638469735662459444" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638469735662459444" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638469735662459444" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638469735662459444" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638469735662459444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638469735662459444" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638469735662469446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638469735662469446" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638469735662469446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638469735662469446" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638469735662469446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638469735662469446" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638469735662469446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638469735662469446" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638469735662469446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638469735662469446" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638469735662469446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638469735662469446" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638469735662469446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638469735662469446" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638469735662479444" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638469735662479444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638469735662479444" xlink:to="us-gaap_AssetsCurrentAbstract_638469735662479444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638469735662479444" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638469735662479444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638469735662479444" xlink:to="us-gaap_GrantsReceivableCurrent_638469735662479444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638469735662479444" xlink:to="us-gaap_PrepaidExpenseCurrent_638469735662479444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638469735662479444" xlink:to="us-gaap_AssetsCurrent_638469735662479444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638469735662479444" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638469735662479444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638469735662479444" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638469735662479444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638469735662479444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638469735662479444" xlink:to="us-gaap_OtherAssets_638469735662479444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638469735662479444" xlink:to="us-gaap_Assets_638469735662489445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" xlink:to="us-gaap_AccountsPayableCurrent_638469735662489445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638469735662489445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" xlink:to="cgtx_DeferredGrantIncomeCurrent_638469735662489445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638469735662489445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" xlink:to="us-gaap_OtherLiabilitiesCurrent_638469735662489445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638469735662489445" xlink:to="us-gaap_LiabilitiesCurrent_638469735662489445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735662489445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735662489445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638469735662499443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" xlink:to="us-gaap_Liabilities_638469735662499443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" xlink:to="us-gaap_CommitmentsAndContingencies_638469735662499443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" xlink:to="us-gaap_StockholdersEquityAbstract_638469735662499443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638469735662499443" xlink:to="us-gaap_PreferredStockValue_638469735662499443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638469735662499443" xlink:to="us-gaap_CommonStockValue_638469735662499443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638469735662499443" xlink:to="us-gaap_AdditionalPaidInCapital_638469735662499443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638469735662499443" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638469735662499443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638469735662499443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638469735662499443" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638469735662499443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638469735662499443" xlink:to="us-gaap_StockholdersEquity_638469735662509443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638469735662489445" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638469735662509443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638469735662509443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesAuthorized_638469735662509443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesIssued_638469735662509443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesOutstanding_638469735662509443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638469735662509443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_638469735662509443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638469735662509443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_638469735662509443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_638469735662519447" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_638469735662519447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638469735662519447" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638469735662519447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638469735662519447" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638469735662519447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638469735662519447" xlink:to="us-gaap_OperatingExpenses_638469735662519447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638469735662519447" xlink:to="us-gaap_OperatingIncomeLoss_638469735662519447" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638469735662519447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638469735662519447" xlink:to="cgtx_GrantIncome_638469735662519447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638469735662519447" xlink:to="us-gaap_OtherNoncashIncomeExpense_638469735662519447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638469735662519447" xlink:to="us-gaap_InterestIncomeExpenseNet_638469735662519447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638469735662519447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638469735662519447" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638469735662519447" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638469735662529444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638469735662529444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638469735662529444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638469735662529444" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638469735662529444" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638469735662529444" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638469735662529444" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638469735662529444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638469735662529444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662529444" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638469735662529444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662529444" xlink:to="cgtx_AtMarketOfferingMember_638469735662539448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662529444" xlink:to="cgtx_EquityLineFinancingMember_638469735662539448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingCommitmentSharesMember" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662529444" xlink:to="cgtx_EquityLineFinancingCommitmentSharesMember_638469735662539448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662529444" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662539448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662529444" xlink:to="us-gaap_StatementEquityComponentsAxis_638469735662539448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638469735662539448" xlink:to="us-gaap_CommonStockMember_638469735662539448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638469735662539448" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638469735662539448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638469735662539448" xlink:to="us-gaap_RetainedEarningsMember_638469735662539448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638469735662539448" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638469735662539448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638469735662539448" xlink:to="us-gaap_EquityComponentDomain_638469735662539448" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662529444" xlink:to="us-gaap_StatementLineItems_638469735662539448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662539448" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638469735662539448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_StockholdersEquity_638469735662539448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_SharesOutstanding_638469735662549476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638469735662549476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638469735662549476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638469735662549476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638469735662549476" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735662549476" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638469735662549476" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_NetIncomeLoss_638469735662549476" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638469735662549476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_StockholdersEquity_638469735662549476" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638469735662539448" xlink:to="us-gaap_SharesOutstanding_638469735662559442" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_StatementTable_638469735662559442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662559442" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638469735662559442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662559442" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662559442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662559442" xlink:to="cgtx_FollowOnPublicOfferingMember_638469735662559442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662559442" xlink:to="cgtx_AtMarketOfferingMember_638469735662559442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662559442" xlink:to="us-gaap_StatementLineItems_638469735662559442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638469735662559442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662559442" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638469735662559442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_638469735662569442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662569442" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638469735662569442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662569442" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662569442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662569442" xlink:to="cgtx_AtMarketOfferingMember_638469735662569442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662569442" xlink:to="cgtx_EquityLineFinancingMember_638469735662569442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662569442" xlink:to="cgtx_FollowOnPublicOfferingMember_638469735662569442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662569442" xlink:to="us-gaap_StatementLineItems_638469735662569442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662569442" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" xlink:to="us-gaap_NetIncomeLoss_638469735662569442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638469735662569442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" xlink:to="us-gaap_ShareBasedCompensation_638469735662569442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638469735662569442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638469735662569442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638469735662579443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638469735662569442" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_638469735662579443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638469735662579443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638469735662579443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638469735662579443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638469735662579443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638469735662579443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638469735662579443" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638469735662579443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638469735662579443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662569442" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638469735662579443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638469735662579443" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638469735662589442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638469735662579443" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638469735662589442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662569442" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638469735662589442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638469735662589442" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735662589442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638469735662589442" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638469735662589442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638469735662589442" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638469735662589442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638469735662589442" xlink:to="us-gaap_RepaymentsOfShortTermDebt_638469735662589442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735662589442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638469735662589442" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638469735662589442" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638469735662599445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662569442" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638469735662599445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638469735662599445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662569442" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638469735662599445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_638469735662599445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662569442" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_638469735662599445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638469735662599445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract_638469735662599445" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638469735662599445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384697356625994451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract_638469735662599445" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384697356625994451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638469735662599445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662569442" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638469735662599445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_638469735662599445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638469735662599445" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_638469735662599445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638469735662609445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638469735662599445" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638469735662609445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_638469735662609445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638469735662599445" xlink:to="cgtx_DeferredOfferingCostsIncludedInAccountsPayable_638469735662609445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" xlink:type="extended" xlink:title="10101 - Disclosure - Description of Business and Financial Condition" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638469735662609445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638469735662609445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638469735662609445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638469735662609445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Financial Instruments and Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638469735662619447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638469735662619447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10401 - Disclosure - Property and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638469735662619447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638469735662619447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638469735662619447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638469735662619447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OtherCurrentLiabilitiesTextBlock" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_638469735662619447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="cgtx_OtherCurrentLiabilitiesTextBlock_638469735662619447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638469735662629444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638469735662629444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10801 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638469735662629444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638469735662629444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - Equity-based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638469735662629444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638469735662629444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11001 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638469735662629444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638469735662629444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureRetirementPlan" xlink:type="extended" xlink:title="11101 - Disclosure - Retirement Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638469735662639444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638469735662639444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638469735662639444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638469735662639444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11301 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638469735662639444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_3" xlink:to="us-gaap_SubsequentEventsTextBlock_638469735662639444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638469735662639444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638469735662639444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638469735662639444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_638469735662639444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638469735662649443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ReceivablesPolicyTextBlock_638469735662649443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_GrantIncomePolicyPolicyTextBlock" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_GrantIncomePolicyPolicyTextBlock_638469735662649443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_638469735662649443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638469735662649443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638469735662649443" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638469735662649443" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638469735662649443" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638469735662649443" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638469735662649443" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638469735662649443" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638469735662649443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638469735662649443" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638469735662659446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638469735662659446" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638469735662659446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638469735662659446" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_638469735662659446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_EmergingGrowthCompanyPolicyTextBlock_638469735662659446" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638469735662659446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638469735662659446" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638469735662659446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638469735662659446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638469735662659446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638469735662659446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30403 - Disclosure - Property and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638469735662669443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638469735662669443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638469735662669443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638469735662669443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638469735662669443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LeaseCostTableTextBlock_638469735662669443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638469735662669443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638469735662669443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Equity-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638469735662679445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638469735662679445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638469735662679445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638469735662679445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638469735662679445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638469735662679445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638469735662679445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638469735662679445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638469735662679445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638469735662679445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638469735662679445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638469735662679445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638469735662679445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638469735662679445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638469735662689446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business and Financial Condition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638469735662689446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638469735662689446" xlink:to="us-gaap_SubsequentEventTypeAxis_638469735662689446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638469735662689446" xlink:to="us-gaap_SubsequentEventTypeDomain_638469735662689446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638469735662689446" xlink:to="us-gaap_SubsequentEventMember_638469735662689446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638469735662689446" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638469735662689446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662689446" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662689446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662689446" xlink:to="cgtx_FollowOnPublicOfferingMember_638469735662689446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662689446" xlink:to="cgtx_AtMarketOfferingMember_638469735662689446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662689446" xlink:to="cgtx_EquityLineFinancingMember_638469735662689446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638469735662689446" xlink:to="srt_CounterpartyNameAxis_638469735662689446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662689446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638469735662689446" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662689446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662689446" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638469735662699444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662689446" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_638469735662699444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638469735662689446" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735662699444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="us-gaap_SharesIssuedPricePerShare_638469735662699444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638469735662699444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638469735662699444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="cgtx_MaximumAggregateOfferingPrice_638469735662699444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638469735662699444" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638469735662699444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638469735662699444" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm_638469735662769448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="cgtx_PurchaseAgreementTerm_638469735662769448" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638469735662769448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638469735662769448" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735662769448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638469735662699444" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735662769448" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662779448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662779448" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662779448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662779448" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662779448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662779448" xlink:to="us-gaap_EquipmentMember_638469735662779448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662779448" xlink:to="us-gaap_FurnitureAndFixturesMember_638469735662779448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662779448" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_638469735662779448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638469735662779448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="cgtx_GrantIncome_638469735662779448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="cgtx_DeferredGrantIncomeCurrent_638469735662779448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638469735662779448" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638469735662779448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="us-gaap_UnrecognizedTaxBenefits_638469735662779448" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638469735662789445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638469735662789445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662779448" xlink:to="us-gaap_NumberOfOperatingSegments_638469735662789445" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662789445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662789445" xlink:to="srt_RestatementAxis_638469735662789445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638469735662789445" xlink:to="srt_RestatementDomain_638469735662789445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638469735662789445" xlink:to="srt_ScenarioPreviouslyReportedMember_638469735662789445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638469735662789445" xlink:to="srt_RestatementAdjustmentMember_638469735662789445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662789445" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638469735662789445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638469735662789445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638469735662789445" xlink:to="us-gaap_TypeOfAdoptionMember_638469735662789445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638469735662789445" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_638469735662799444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662789445" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662799444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662799444" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638469735662799444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662799444" xlink:to="us-gaap_DeferredRentCredit_638469735662799444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662799444" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638469735662799444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662799444" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735662799444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_638469735662799444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638469735662799444" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638469735662799444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638469735662799444" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638469735662799444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638469735662799444" xlink:to="us-gaap_MoneyMarketFundsMember_638469735662799444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638469735662799444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638469735662799444" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638469735662799444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638469735662799444" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638469735662809445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638469735662809445" xlink:to="us-gaap_FairValueInputsLevel1Member_638469735662809445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638469735662809445" xlink:to="us-gaap_FairValueInputsLevel3Member_638469735662809445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638469735662799444" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638469735662809445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638469735662809445" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638469735662809445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638469735662809445" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638469735662809445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638469735662809445" xlink:to="us-gaap_AssetsFairValueDisclosure_638469735662809445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638469735662809445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638469735662809445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662819448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662819448" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662819448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662819448" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662819448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662819448" xlink:to="us-gaap_EquipmentMember_638469735662819448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662819448" xlink:to="us-gaap_FurnitureAndFixturesMember_638469735662819448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638469735662819448" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662819448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662819448" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638469735662819448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662819448" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638469735662819448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662819448" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638469735662819448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662819448" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638469735662819448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization_638469735662819448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638469735662819448" xlink:to="us-gaap_AdjustmentForAmortization_638469735662819448" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638469735662829445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_638469735662829445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent" xlink:label="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent_638469735662829445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638469735662829445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638469735662829445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638469735662829445" xlink:to="us-gaap_DebtInstrumentAxis_638469735662829445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638469735662829445" xlink:to="us-gaap_DebtInstrumentNameDomain_638469735662829445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638469735662829445" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember_638469735662829445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_InsurancePremiumFinancingAgreement2Member" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638469735662829445" xlink:to="cgtx_InsurancePremiumFinancingAgreement2Member_638469735662829445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638469735662829445" xlink:to="us-gaap_BalanceSheetLocationAxis_638469735662829445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638469735662829445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638469735662829445" xlink:to="us-gaap_BalanceSheetLocationDomain_638469735662829445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638469735662829445" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_638469735662839443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638469735662829445" xlink:to="us-gaap_DebtInstrumentLineItems_638469735662839443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638469735662839443" xlink:to="us-gaap_DebtInstrumentFaceAmount_638469735662839443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638469735662839443" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638469735662839443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638469735662839443" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638469735662839443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638469735662839443" xlink:to="us-gaap_ShortTermBorrowings_638469735662839443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638469735662839443" xlink:to="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_638469735662839443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_AssetsAbstract_638469735662839443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638469735662839443" xlink:to="cgtx_OperatingLeaseAssets_638469735662839443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638469735662839443" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638469735662839443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638469735662839443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_LiabilitiesAbstract_638469735662839443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638469735662839443" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638469735662849445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638469735662849445" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638469735662849445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638469735662839443" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638469735662849445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638469735662849445" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638469735662849445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638469735662849445" xlink:to="us-gaap_OperatingLeaseLiability_638469735662849445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638469735662839443" xlink:to="us-gaap_OperatingLeaseExpense_638469735662849445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_LossContingenciesTable_638469735662849445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638469735662849445" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662849445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638469735662849445" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662849445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662849445" xlink:to="cgtx_OfficeSpaceNewYorkMember_638469735662849445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638469735662849445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662849445" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638469735662849445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638469735662849445" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember_638469735662859452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638469735662849445" xlink:to="us-gaap_LossContingenciesLineItems_638469735662859452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638469735662859452" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_638469735662859452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638469735662859452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638469735662859452" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638469735662859452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638469735662859452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638469735662859452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638469735662859452" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638469735662859452" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638469735662859452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638469735662859452" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638469735662869445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638469735662869445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638469735662869445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638469735662869445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638469735662869445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638469735662859452" xlink:to="us-gaap_OperatingLeaseLiability_638469735662869445" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638469735662869445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638469735662859452" xlink:to="us-gaap_AreaOfRealEstateProperty_638469735662869445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638469735662869445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638469735662869445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638469735662869445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638469735662869445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6" xlink:to="us-gaap_OperatingLeasePayments_638469735662879445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638469735662879445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638469735662879445" xlink:to="srt_CounterpartyNameAxis_638469735662879445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638469735662879445" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662879445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662879445" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638469735662879445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638469735662879445" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_638469735662879445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638469735662879445" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638469735662879445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735662879445" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662879445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662879445" xlink:to="cgtx_AtMarketOfferingMember_638469735662879445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735662879445" xlink:to="cgtx_EquityLineFinancingMember_638469735662879445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638469735662879445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638469735662879445" xlink:to="us-gaap_ClassOfStockLineItems_638469735662879445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_CommonStockSharesAuthorized_638469735662889445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638469735662889445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_PreferredStockSharesAuthorized_638469735662889445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638469735662889445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_CommonStockSharesIssued_638469735662889445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_CommonStockSharesOutstanding_638469735662889445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_DividendsCommonStock_638469735662889445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="cgtx_MaximumAggregateOfferingPrice_638469735662889445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638469735662889445" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm_638469735662889445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="cgtx_PurchaseAgreementTerm_638469735662889445" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735662899446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735662899446" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735662899446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735662899446" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638469735662899446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638469735662899446" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_638469735662899446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_638469735662899446" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638469735662899446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638469735662879445" xlink:to="us-gaap_OtherNoncashIncomeExpense_638469735662899446" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders' Equity - Shares reserved for issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638469735662899446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_3" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638469735662899446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Equity-based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662909444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662909444" xlink:to="us-gaap_PlanNameAxis_638469735662909444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638469735662909444" xlink:to="us-gaap_PlanNameDomain_638469735662909444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638469735662909444" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_638469735662909444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638469735662909444" xlink:to="cgtx_EquityIncentivePlan2021Member_638469735662909444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638469735662909444" xlink:to="cgtx_EmployeeStockPurchasePlanMember_638469735662909444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662909444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662909444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662909444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638469735662909444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662909444" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638469735662909444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662909444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638469735662909444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662909444" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_638469735662909444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638469735662909444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662909444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638469735662909444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_StatementTable_638469735662919444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662919444" xlink:to="srt_RangeAxis_638469735662919444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638469735662919444" xlink:to="srt_RangeMember_638469735662919444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638469735662919444" xlink:to="srt_MinimumMember_638469735662919444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638469735662919444" xlink:to="srt_MaximumMember_638469735662919444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638469735662919444" xlink:to="us-gaap_StatementLineItems_638469735662919444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662919444" xlink:to="us-gaap_SharePrice_638469735662919444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662919444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638469735662919444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638469735662919444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662919444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638469735662919444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638469735662929447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662919444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638469735662929447" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638469735662929447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662919444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638469735662929447" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638469735662929447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662919444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638469735662929447" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638469735662929447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638469735662919444" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638469735662929447" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Equity-based Compensation - Activity for options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638469735662929447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638469735662929447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638469735662939443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638469735662939443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638469735662939443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638469735662939443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638469735662939443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638469735662929447" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638469735662939443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638469735662939443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638469735662939443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638469735662939443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638469735662939443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638469735662949445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638469735662949445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638469735662939443" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638469735662949445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638469735662949445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638469735662949445" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638469735662949445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638469735662949445" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638469735662949445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638469735662949445" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638469735662949445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638469735662949445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638469735662949445" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638469735662949445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Equity-based Compensation - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662959448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662959448" xlink:to="us-gaap_AwardTypeAxis_638469735662959448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638469735662959448" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638469735662959448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638469735662959448" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638469735662959448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662959448" xlink:to="us-gaap_GranteeStatusAxis_638469735662959448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638469735662959448" xlink:to="us-gaap_GranteeStatusDomain_638469735662959448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638469735662959448" xlink:to="srt_DirectorMember_638469735662959448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EmployeeDirectorMember" xlink:label="cgtx_EmployeeDirectorMember_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DirectorMember_638469735662959448" xlink:to="cgtx_EmployeeDirectorMember_638469735662959448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_NonEmployeeDirectorMember" xlink:label="cgtx_NonEmployeeDirectorMember_638469735662959448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DirectorMember_638469735662959448" xlink:to="cgtx_NonEmployeeDirectorMember_638469735662959448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662959448" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638469735662969443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638469735662969443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_638469735662969443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638469735662969443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_638469735662969443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638469735662969443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_638469735662969443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638469735662969443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662969443" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638469735662969443" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662979444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662979444" xlink:to="us-gaap_AwardTypeAxis_638469735662979444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638469735662979444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638469735662979444" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638469735662979444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662979444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638469735662979444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638469735662979444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638469735662979444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638469735662979444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638469735662979444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638469735662989445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638469735662989445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638469735662989445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638469735662979444" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638469735662989445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638469735662989445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638469735662989445" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638469735662989445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638469735662989445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638469735662989445" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638469735662989445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638469735662989445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638469735662989445" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638469735662989445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384697356629894451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638469735662989445" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384697356629894451" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Equity-based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638469735662989445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638469735662989445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638469735662989445" xlink:to="us-gaap_IncomeStatementLocationAxis_638469735662999448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638469735662999448" xlink:to="us-gaap_IncomeStatementLocationDomain_638469735662999448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638469735662999448" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638469735662999448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638469735662999448" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638469735662999448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638469735662989445" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638469735662999448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638469735662999448" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638469735662999448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638469735662999448" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638469735662999448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638469735662999448" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638469735662999448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638469735662999448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638469735662999448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638469735662999448" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638469735663009451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638469735663009451" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638469735663009451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638469735663009451" xlink:to="us-gaap_StockOptionMember_638469735663009451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638469735663009451" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638469735663009451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638469735662999448" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638469735663009451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638469735663009451" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638469735663009451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Retirement Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638469735663009451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638469735663009451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638469735663009451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Net loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638469735663019445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638469735663019445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_NetIncomeLoss_638469735663019445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638469735663019445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638469735663019445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638469735663019445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638469735663019445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638469735663019445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638469735663019445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638469735663019445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638469735663019445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638469735663029447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638469735663029447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638469735663029447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638469735663029447" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638469735663029447" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638469735663029447" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsOther_638469735663029447" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsGross_638469735663029447" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638469735663029447" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxAssetsNet_638469735663029447" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638469735663029447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638469735663029447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638469735663029447" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638469735663039448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638469735663029447" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638469735663039448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638469735663029447" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638469735663039448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638469735663039448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638469735663039448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638469735663039448" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638469735663039448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638469735663039448" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638469735663039448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638469735663039448" xlink:to="us-gaap_DomesticCountryMember_638469735663039448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638469735663039448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638469735663039448" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638469735663039448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638469735663039448" xlink:to="us-gaap_ForeignCountryMember_638469735663049447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638469735663039448" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638469735663049447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638469735663049447" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638469735663049447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638469735663049447" xlink:to="us-gaap_ResearchMember_638469735663049447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638469735663039448" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638469735663049447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638469735663049447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638469735663049447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration_638469735663049447" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_638469735663049447" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638469735663049447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="us-gaap_OperatingLossCarryforwards_638469735663049447" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638469735663059447" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_ResearchAndDevelopmentTaxCreditCarryForwards" xlink:label="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="cgtx_ResearchAndDevelopmentTaxCreditCarryForwards_638469735663059447" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638469735663049447" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_638469735663059447" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638469735663059447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638469735663059447" xlink:to="us-gaap_SubsequentEventTypeAxis_638469735663059447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638469735663059447" xlink:to="us-gaap_SubsequentEventTypeDomain_638469735663059447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638469735663059447" xlink:to="us-gaap_SubsequentEventMember_638469735663059447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638469735663059447" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638469735663059447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638469735663059447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638469735663059447" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638469735663059447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735663059447" xlink:to="cgtx_EquityLineFinancingMember_638469735663069453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638469735663059447" xlink:to="cgtx_AtMarketOfferingMember_638469735663069453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638469735663059447" xlink:to="srt_CounterpartyNameAxis_638469735663069453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638469735663069453" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638469735663069453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638469735663069453" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638469735663069453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638469735663069453" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_638469735663069453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638469735663059447" xlink:to="us-gaap_TypeOfArrangementAxis_638469735663069453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638469735663069453" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638469735663069453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638469735663069453" xlink:to="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_638469735663069453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638469735663059447" xlink:to="us-gaap_SubsequentEventLineItems_638469735663069453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638469735663069453" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638469735663069453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638469735663069453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638469735663069453" xlink:to="us-gaap_SaleOfStockPricePerShare_638469735663069453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_638469735663079449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638469735663069453" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares_638469735663079449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735663079449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638469735663069453" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638469735663079449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_638469735663079449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638469735663069453" xlink:to="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_638469735663079449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638469735663079449" xlink:to="cgtx_AaronFletcherMember_638469735663079449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember_638469735663079449" />
    <loc xlink:type="locator" xlink:href="cgtx-20231231.xsd#cgtx_AaronFletcherMember" xlink:label="cgtx_AaronFletcherMember_638469735663079449" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;!IMY0VM]#(N)5??4J4GYXNK3\NKCQ\NSF\N+\"[\X_GGQ:78/G^\O)F"8[
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M-9MRU3.K+!%)(!6$I8C#?& ,[<N1;6E!'O&-P%ILM)&V\L38L^[<1 /#TD1
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M@$;'AD!'I[JJB@@EG560KK]<\OFXU'('?A++GW::3P"EQ%E*<76@B:WCZ.-
MT\#:32*[E_3#V,B<'I^ ED?/45+2/4:P5#5.4[X^3.1N^-"A!:N+\Q,>/N_.
MK]>9Z>SPP:#4!];V,Y*\V:XL:$Z'@L\JVW#N)B?WQ7P3 "S>8>&+^<'P]<DA
M=S5)(S4/'400)U>/*MXN,'ZEKFTG-DHZ>"!]/!+Q!3ETCQ0TH?'Z9'B"D0U)
MM\.#^)4@46C":;\4<\N1S>PJ=L^N/?AY\)P,YT=SXG5D(YY!SX'88[^F\U=]
M6M*\EH3F4,SI^90GVZ?J1S,FFTK;W]]^'CX_<3>':UI##6BE"YSG#8=-<Z"R
MNGEM*V8%]&V./VQ8[ #\$(6UYK,.#'4J'G["TMDZ7Q+>%-NF?IHFV9O*1=,6
M-JE-<F3->0Q5)V:FAH4&(U&!NE19MZE#T\G^/T;B#[O"^=<-Z2.);HZ=9#L/
MY>35@D!*E/<T5+6.934;C,$P@3K^FL%.=3<TCO'L\T2@;,,1%6&.XCA8AD/1
M>?_P^TE.<Z:@#V\I8M"0SKHXDG:\PZN$CL*+]KM<UXQI1*7:C!J=8 :D4WC2
M?BI!@.DDV:>M?X)<T_FS[-KU#76\]46\5"[G[_Y4%'$^B1_'NZ?=3PN7\8OZ
M9GG\70*TR.F86J@,6R>CUX>#V&_;FV K_KZ^L"'8DB^72J*>T@*\SRR<:&Y(
M0?>#R\5_ %!+ P04    "  "@GI8#^Y"_28:   '3@  &    'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;+5<:7/;MM;^*QS?3L>>H15;3I.T:3/CN%LZ;9.)
MF]YY/T(D).&&)%2"M*/^^GN><[!1BY/>]OUB:R& L^_0U_>V?^_66@_%A[;I
MW#<GZV'8?/7HD:O6NE5N9C>ZHV^6MF_50&_[U2.WZ;6J>5';/)I?7#QYU"K3
MG;SXFC][T[_XVHY#8SK]IB_<V+:JW[[4C;W_YN3R)'SPUJS6 SYX].+KC5KI
M6SV\V[SIZ=VCN$MM6MTY8[NBU\MO3JXOOWKY&,_S [\;?>^RUP4P65C['F]>
MU=^<7  @W>AJP Z*_MWI&]TTV(C ^,/O>1*/Q,+\==C]>\:=<%DHIV]L\V]3
M#^MO3IZ=%+5>JK$9WMK['[7'YPOL5]G&\=_B7IY]?'525*,;;.L7$P2MZ>2_
M^N#ID"UX=G%DP=POF#/<<A!#^:T:U(NO>WM?]'B:=L,+1I57$W"F U-NAYZ^
M-;1N>'$KS"CLLK@UJ\XL3:6ZH;BN*CMV@^E6Q1O;F,IH]_6C@<[#JD>5W_NE
M[#T_LO?EO/C%=L/:%=]UM:ZG&SPB0".T\P#MR_F#.WZKJUEQ=5D6\XOYU0/[
M747LKWB_J_\7[&7OQX?WAC9]Y3:JTM^<D+HXW=_IDQ>?_^ORR<7S!R!_'"%_
M_-#N?Q/RA_>>SXI/W[YXJ9QQ>/ -L.P&Q=KVVUJ3QE6VW:ANB^<KVSE:4JM!
MU\72=*JKC&H*1\]K4O+!%6MUIXN%UEU!]-JHGIXS'=;!])AA2YHQK(MWL]M9
ML=*=[E73;'&&WF!+E4#;](8VWS0$W.GG_WHVGU\\_^'Z^@V_O'Q^-BNNNRT,
MBNYU5VD<,JP)]**S RT9;*$V&T).+1I=K$8"F9]R1:M! _J>U^+% "S'86U[
M [P)_G>= 32W0,M].IS*%4OZN/; Y(2FK;I:];4K;FS-C& "!\RN;V\"8@4]
M>'CENPWHGJUY%]<0XW#@]Y$C!S=X:>E?7/_]]>W+1,UW1#K:Y3LWF):Q!N^%
MA0(J??EQ[A]C-3A'!/]C-"1>9/DZ<A58 ?*WZKTN=#P7Z"M'[F6#8XF3:S44
M:KDD!\ X$DBV9QZTP)"%EI[7@RQMC%J8Q@S&;X4EM7%58]V(LP4-$ ;''ULH
M1S&Y/6D_CGLX[1" O;[3W>A!TA_(&3MZ4X\]&)06L3SIWMB:Q+L:1CJ 8";7
MY.C\L:D)DR6$=MG;EI99EQ%N5MPHM^8#^,5W1.P[U3!H\9L*+W3V#= R;H 4
MDZDP#1L+TPVD56XX7VC%$-8$G3,#$^:./K*CRVA@.H)A&(5=.*6UG=X27_OW
M1-P92]*-V! YK]8]/=@TQ9J\+1W9&(((6G-'APHQ670425UO5G100[L-1*UA
M*_SHM<8I\$JV+TCW:,4:-F?LJS6Y]QJ"M=![^,Z*M[K2]&X!??VAARG8_Z3/
M/NEU RF@[2@8<E E$"2PMAXUJ7Q/3YEV,?:.K0WSMR:*>'E3]Z1V!-(*FY..
MD'#3N\66&?\K:Q<A^,I3D27N1ZT:(D!0U5]?_3@Q#V16";6^-Y REE731TD@
M+MN&XR4 XR&=<@$05H/P($?6$RTM+^4X,B8]\&ZV)0[KV9!V%NOM/1M6$*&V
MXV)8CDVPCBYH?%W88)U7NP2>>9J3$;6MGD I=I<M</X(<=^.JW4@)^O"RM[I
MOF.+ H M@"Q..]N=IV_(2O8KU9D_F>*[!QM 6UGRDG^*RY(]_+>G7F?/@FD7
M+<6[^[6IUEZ',R& &U4DC Q/3>K?V W#AQC"5# %(&-7C3T(%(T'XD_P8:.V
M_#C#I1I -2N^A<OJ@R@%X,AVB-,.A-KTMM*Z=I[.2=@"94G;;71]_S JL^)[
M[$V;;&E5H1$T$N"5;A=$SQ#V\5[T8EY.  LLW\&0-.*S^>/RV<47O.XS6C:_
M?%H",@@RH0C)3#:,92+@X,VSMYG'-.Z:S,R*Q)U,[)UQWN'QXZ]^9.E6>"#2
M0O2),?8R1\(6WK(IEQWJ@QQ3;!?VB7)/7WQV63Z]N!0\+W915+#8K815GGW_
M+ QSIC5 F L(E^639T^F8 CN7OV"<4MV4JW(.M?GXX9.KTG[*X'-=/Y-91W8
M023%EHB%R(N.-?PN?591'$O145,,/?D65WJA;-46@#=CS0+K;-?I1EP:Z3)Y
M2(E.:>?2'[!1AFD$;]]3VIC$>&(&HHV]>?O:!2-;IH=WG=LCP(A8@,@[MHAX
M[FQSIV/,)V1A3MU3ELHQH:KRB$35E &2S^TEUF1HF:0N$;67SXM-PY[V V(.
M<GED\E6W2K%64MB@0&PNO-S73&2X;=V0%X4J'^<'S&1!#H1,_K@)LD4IJFG'
MUCL1B(96=&#DFP@4B\"L>-TU6[^9Q&R$A#@(G$QAL>X3A601\4KW@R),,@/>
MZ]78J!1->"4$;RZ?/G>%&RFP9QJ0E&R0P&SY.;9Z%%(![&[DD&'+[JQ1A%8]
M\=.\O,Q"MHFI .1N7/R'0TY*%,CS4W)%.4)M]AT.'43!;,=9E-@8T[(>X/^L
M^/?:--H[/Y@2S^':(E%AX03Z9.T7JGH/',3ZN#(:'P);?%'NY'#BEC&DT!)E
MDTP((J5(4;C@0PY:M((4K1\K"4Q$=UK*D=B!2\"54J9&W;LRYT4IM Y2[&)6
M$8A(,6,;MD7XPPST1C3;.!)A5KRBV*C;AF<F81-8(+F4Q"1CET0)QIC>5.PG
M3$LT(T01N9*P+R?:L(:1 ^WN#9'_SMB&UPBD=*P;29HC0.4^&" P^+30N5IY
M,Y"?Y&4M!CR<7Q)7BR7A@$ +M;8M,A'9@Q3><GY1[@$LYU$P&_&7G+J'[NF<
MUE;HEU'T^K!CV3^$#]@)3%D$B)HL]Q(5>%76'P;-7);(ZQ?"RV]-3CC3%'X.
MXIN%*J^1L< ZW[!IF"0#:D,9-V(;%PU!HU>J*?,$.P5TP]KT]3EY/TH#R!QF
M=D9,&3)TYRPE)> RHV.Z<[8+E"" -5@H>4NW(HD6CQ)RL%=O7K/=COY2C!G
M:$14TEIOHCLN@P[@Y_62F)(^RB*(W8-+;PYD>VR$R),Y001P@ZW>KVV#),EK
M,B BS4.Z2@$*03968?\8ZJ7(R3\$IQ@@L)X'L^(-*\L@%A,IHD1RDX]U_)@-
MX2"[BJ,HBT[SML2@L1U%GVH$H*"ZYWQZ!W\$(S,.,0F #5*(<L]1L4(QU@3O
ML]99$C,ZC5RB,<N8@W.VOI/)Q+H!'LC7B-WX8O*TV$KG;;ZG.:6&HR1JF\-4
M8"]*&YB>WR+1U( 7.?T@0<L:;IE=\F)TA!:)6V5ZHA#,9,7?U*CY:!%9CMO(
MF6]3+BG*+"ABRQ6IVB:K;626B%!LM@P_00&+R"0A5MWC#Z5E_C#;,U89Z/2N
ML=V**'_'@L([9U4(1.SN:,A.4"%"1 Z=)03?9@G!OHJ;:81T-)4 A\G ^>R?
MXVVN-&C)^,EN:N5B.IZ"7XW@KB&A[.]0E'!;-^BV]-Z,]JGH0Y*[Z^9/RI%;
MW4??Z'<L"0J<:92L^5G?DR&WB$8E/%AI2^9Q0X$6J0#)QWI;G/YP?4:Y#[P<
MJJL$2DW_R"6?!^A:59%J4$:LO5JR8KP]AGPR!#[-9"5."=71A;&2E)5Q4(SD
M8B4$.D;*/C1.!L^I!N2ES]C@G"^X:@)=I1T98,%_00@LC>>)IG#!;K7FZ"39
M8G+M $-L<C+74*:0:PF*&??LV!^7!N[R<,2<@YR<OH^HMY'@D1!27R-+G XE
M.J!T8RAS((6M22O*#,BC$?&L^-5V=  <^,-I<&)?]!Q9F8]Y*09'8%U9^%5Y
M'(K(]9%^FDS[R W,OXGI4L3K,*FB)_$U#.$H>F8=F2HR<A.G1+:.\C3G)$4B
MONKP;8SN!^7>NQR X*,_@6]'@>&SU0!,O(2&$#5 !C;<F1H1?)[OY)G@M PZ
MV7!AFH8==%"?,E;,B)>H:Z5<[1-JNDYJX"83,=@F!__7CYSW?D0W9V13V'3E
M9E'5EOL(#];YKV_?G9$0SLCJ7CXYOYB78:?3W^R&^//L\?RL@+L1XVTW7M?(
M(I(U8':V>EC;.E"VY=8# TVF+"3T",Y[2[%EZ6L"/R%](HOF*P(SAC+6_Z1V
M%,+#>R)WBI!]K"#-E294[!G93/1"ZK#CR3UO1#@A2:@"@(IDC*53@'.026RC
M R?I&J2QS'%W3(SQ?4/$8DL7"4M;N#4E[N<(G_E[$%/)*Q],0IW;%BTEYB)S
M8LTAE7\*2PF1R_EN 9H%P&HW2>Q4+$E[_L@Q)A3VR#R3<=E&U>(@6O>50:TQ
M9%8'R8%MB LM;#/.UU*_Y6X* HFL0R4Y<NRAGRZV2(H=,YOS\D8"$<0#9X'0
M3EH_VN,-&V$['1HNJ:S"2HA*Z^YS4_;6&I1#:(0D#0 FW08M GW5D+8F%=8;
M\9W95M&%A^>",?4'Q*J/T%^VY>X RMU>!I<6Z207C7I#"\G_3TQ4-(+3,"X$
MHAGL.)O4[*OB]/(L%<<)07(X1'_6-XGJ8$)CQ0;%$8G6*'_"]JR*_-J7FZ06
M[)X7I_.SO?QM4BNV"\8U;B2]RH0L0A7;$C+)F0?+N0OD<Q:ZTZN/G.@=I8^Y
MH^7>V8PLAX]U=U6J#,$!,4 8=*!O9Y!.]:@\6NFZ\/'G=GF.,T/K+D^?IEY&
MBN(2WP/$Y8BDWI_GZ^MYZL%-$5J?%/VPW'E!19E3MO#%'"[>U*Q]!G459&S0
M($[+0THV3<6)T9+^PD?'U(?DO@\%K@510 2U]_55=#,Y8Y@B$OPC"=^$#+UO
M8H:FWN3\>^XJ<GU!>@Z<-O&1!+$SK4$8&S*4CO6^01C32TLB3]_2\T*Z&V_2
M5/V?,;3U?-B^S\B] HJ4+G7K)//F>-A M(M)V9)=,UM@T (&@Q4IM3YFQ>L=
M2>-"V+3=LR\#8N:!\(%T=5;\3K&SE,F.;3D)X'\[+%Z,I+1QO3/RBN+G"J1'
ML^.."?]:7 PGG9*V''*SG;[?]X$368SF[!-6EJ#&#BA368Y:J [Q%VV%)Y=/
M?'TPU^HC#8R'# 3W**XNI$/Q^-F3XE"#(F(5",9BKM!)AKUO.#&NAJ G2.<D
M7I^$A3$8Y#PB9#22]:.YO"0WXJ3GI6JI>G)+7";MF*C=7R!R'$KYU9+:/IT5
MKSR0R^(ZV^#Z]@;A7]C[)H<X#8'<ID 6QNOBZOD__O]-D-*(7OCF.JH]B_FQ
M#0B9G!+AXYQ:^/[8\A3<A4_VP[X(D?.VB(CT]H K@0/_C)^^G*<3/BL@MM-W
ML;C)D@K_3)]GSYP^.<O>A1UW#5$NT?"XA\Z&E$_?/;!++,[M-@&/[0[5.?SN
M[_X'+=^FOG0>JR<]BC@<<.RSOP_"?!<$Q+QI]BKOC/8^P]@![!\ XNJOT"'C
MY=\_.OQ_Y2<KU(?=)#2,:;"O]<,5_%1JUHGQSN>CMB&II,3&C7Z6;CH^%\;M
M9L6[3]BH3&R@TX^.9$WK"4O??_$Q'1;";%/TH#E05\/0F\4XL)/FH&GI)P71
M^QCNT?[@]?M9_VYEEMV-_F#<$).DHZ-FIL\<$4,E 1+7FQ*SK4\7&6Q"W/A#
M":M[\=+??B))6I*;L>=R.7;6G9+PA5;)Z$R*:&S(G2V^9L*$V9<NJ_YF;67+
M<0KE<SV<?D["4*L,.R]TJ$>'8M8P-(A\@@" !@=EQ#?=9+X/SOH3$)<$5,(?
MP!Z1W1OBF2+H)UTD Y=A LEKF&PQ.>'&I&3HK47"8-YKKCE0D(XX@M<[[!N'
M+/J0;JD#".P420)\)9>X0UDNC5)-D)@=U]BQ\T6#89NAZA68I4%-[ VFYAP:
M2X 3B)T+8N= [)P18T8Z\I"*\V@>X= ?%&75 J0?(^*"$<6GG)"H#WR49R[%
M7K^(2,:R/G+$#%1;D7=RH5-[&$ >T]WI]*RY,Y=R?-]'R=H>Z10CP[@'9VS"
MX)'L0,<<AV/&';)AZXOC-UEQG *^4$#PU53?MP_1V=/+9^5D!9OCR^?>"?MW
MMZB]3S=.:: /[L(4JLQ-I'K?RT95[\]O*X(4.B'A$G&%LX?6UKKAL'2ILY;Z
M5#N.3']Y'LUV3HCCNZ;;C$.698;:E6\$<TDQ#?#F%?Q3<S9-L[CWP$#KX@[=
M>78,)3VX^V2HN['\R>P(/>2?ZHU[?[[$4&C,<CGMY5J&N3M+VW!I67=L8D<9
M5RJ I4P#+-%FY<!I7%#^[D=8P0$5/<Y^%:IMK6_;BJ7RV_FQ^?-82B(C.)".
MH(['[0;4"-!_C'CS00=Z]4QH,X16:@Q?(E;9%EYHLK/R+Y=L$S9QQA^&.#0:
M/<X"-C2(,\N0TY.Y1:V-I(7DLXJ9O(=STED:U$K[=BHZU=,. 9OR)5D9$)KG
M]FNR-^1>N%<G*G\8>+2255/YGG/J;@01AG!@]$9R:#)!D #&82I$23:G!F9T
MWALXY@R7L7RH@X)B./J 6/(L&_/?^J%UUE5QC;%GAAIDK[T)G6Y FJ4:YTN+
M!#$=BWXCVKNK6%W#<#3K/B/A2\-Q/CH40]$VR75E"E<M,L\UXWVIS^@.213R
M'-.MO,[$,_Z_]6SXMVB-8E0[BI!*P]MLR_89=%S3TSB'GS*;E%*"-A=;H\5M
M,'-C3/*G[FUHOTU&;+A_S[6C:!"8I#)_D_*G1G4N5,:XBAV?QFS#,-7^6<J&
MXSB))SCCLG#:M[E4N,@6+,RG&)>#E<,@HK:Q*R,3"#*MG8:Z.,SM5:MQLRX0
M]KK58'0W'8)%R4X$_XT8 ]^?XO&@WW2UEM',-]*/H%T,F>'?\]8B4>".V$51
MQ8_@2(!6_&AQFR3CE4S!*S?U?C>VDYY^V/!&PN.W)(4'B['3:PC]Z.N,83"(
M1,7ZZP ^T(8\IX8Y[/2QRQ%3\X"[D7!S3OA^]$8%9D!4]S[<F4@Q&_O7DN?U
MR4R17T3)4W_ ^([P2-?^FI'I)*9OR/8>B((0JD$%>K:@-0LF4@H=6E].IU,G
M7:F%)H]#4B?!;48;;.&R*V(9K79&+M#F']E_?J\HV_D]%-=3U>E5QH=)\(H9
M0 *$:U?SBS+?((\9?\N'8V+Q_J!V'&-"&4;:TD6#<K>16_H!@.PN0OA(THXR
M$9'47_8(7=_)O($LFF1F") _<!A7+(&EH+'0E<K:)5DO<GJ[A8E\2*Y%%E+2
ML#8D,7VUWH8Y*^9GO"'3P/'Z13O%#U@&'P$>V6[21*!0%X:?-Y1F L4A/I%R
M$\GQQB[#NDV\%5 $K(^!(#T]5U$:#W>/B\=?%9__Z\LG3[]\7OS,@%P>C*FO
M#R>-; O'+E0 R^*/T4*L.?@D=VB<C[FGEID45(:[*"N4N/=!#!ELN\ PA\^P
ML::,38SIH6;G-%^*X38:AXF"BNUW*T,Y%>8'J?#)P&8YE>06'C89EX8Q1N[;
MJSI-C!TD;0@4LX8R3ZE.1N%][X;K3>'U<6)- @XY5AP]>9&[?/PSV\,W\"V&
MT3VQ>1M"?H]R5W^/<F/W .QQ,+&<)D- (HG[P#[UCU'[^VM$T$$FG#L[R3ZX
M_N1BG'!$,& @>[W&#"[)U,\H,^46.'9H/GN<;CA5DS4K[MCQQ8]CCW#U*G,*
M!),F ^"#IFHK\R<R-1X!?GBR,%T&VF_CI#M+OH9Z!& &BSO^D.)&9P4];VF,
MO^_XX,C/K/B5:,ZD>T,@WJ[!:=R.KKBXSJ>0ZR7CK:33'\=;%SX\#/EY?-R'
M_/?\VP*Z/@]Q?3<R%1"#8S-_-S7+)O,;AWY*D^]?A"NBWYJ&3SX$V*2\Q=6U
M4@8O*%=+<U.D'SPO$(=.(%(AT0!@,6#SDCU-)T!W*"A9C)3-CYU)W6AI,/MV
MH[?VN  9!K[R5O=A*DAOK3Z*:OD_$M?X9(\"8Y;2Q3$>9R'\4E7>Z\D\27I<
M]+,4.'F2(X6Z,N<12XYI_,RGE%S^$VA\2Y(KQH,Y#[O-*')>[4=4ATIB)G1.
MO<&4N];(5W16@7:R738S@-/C[#*W1CAI#P/XG+/UT!7SIQ?P7FWTB%K D>D<
M<N5YAZ/6E=RKPX127XHV\C,D>Y40S2(5Q9=A4#N/@B8=5610JU6O5PBQI,8>
M3,UF[!$'<9XE$Z/^XIX=^PI6\CO"A"_S_=#;>_)<@9QHEXY[X\N8S @+5K*@
M"D4/N2S Q/<\_8DL/>EL/Q2OQ[YX&0AZBX_&C<.M;@!&?F9>G&*!OWWVT^N7
MM_@RNY ?6R?AN_((() QI'(UV60_6HAGT#9E'WYG> HU#82EUJB_BXS)(6Z=
MQ/@M5<1]L!J R*]#<+F%)1?TSFX$A3[#1K+!!.=^,A/'_BQ/$G&G0*Z;X,,T
MR>B+/#R&BG%5#C X\/@4/%DUN/\?NAB#MXH0NYJU!5O[&IA<)]N!W6/.U%$]
MI3)]H$T=!_LEL3I59_#?&+5'-G%4@ #VZ>(,OVY@6+;A]:0V2*[TSE8\&DCL
MA"=(UZ2.$L</("5A]#S;'T!R!SM?DUL&<L\T],\2%1A/84&J+QSG <'4V='/
M?H6J_*34N-WEA%S2W_FADNDVUWY^]E5'&D>6#1.RX@C^YY_ "+KP5W]Z(P[H
M7EZ51[)@MHF7ST,MXV?)U?T4[]7\R=E7NTV3Z9-H-QS<.(,GP)"NL$KMC1ZL
MXU@L/?,,(=?EEQQX790Q\A+%Q#[.IR%<N//[AWI8++SY^@!<GS]0.@XB';%3
MD$F-#>$S=\H.;>15\'!!9XVP7^6_ ,(^Q5M_2=RR\F4JCY2QF)=N)98^</'3
MMYJOE-*6_!KA;*7X D!&UEB]0,#[<,D)^A/;LO19RB#R*OGD9Q>$:!PC^:OK
M_',AHN*J\K]7,"FFA %R!G%^<7[Q9'] BP0R- (_/OH-JS-\XJS4@4G<CT;5
MM.G_4;24:>[K:K"(T=(-1>ACU$/![(HP*RG2#;_@@H$H,G/>#M N,9OXV#8D
M\Y.UQ,DT&I&=X []L-.C[,>Y8,SY)\CX5UFZ07ZG*WX:?^7L6G[<*STN/Y'V
MBX(OP!CIDI9>S)Y^<2(#,.'-8#?\4U\+.PRVY9=K3?EWCP?H^Z6EL-V_P0'Q
MM]]>_!=02P,$%     @  H)Z6'%XB#0( P  6@L  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL[5;K3]LP$/]73F%"0T)-FI17:2NU,#2D(3I>^^PF
ME];"L3O;:6%__6SG03:U'0BF\6%?XO,]?G=G7\[76PIYKV:(&AXRQE7?FVD]
M[_J^BF>8$=42<^1&D@J9$6VV<NJKN422.*.,^6$0[/L9H=P;]!QO+ <]D6M&
M.8XEJ#S+B'P<(1/+OM?V*L85G<ZT9?B#WIQ,\1KU[7PLS<ZO41*:(5=4<)"8
M]KUANSOJ6'VG<$=QJ1HTV$PF0MS;S7G2]P(;$#*,M44@9EG@"3)F@4P8WTM,
MKW9I#9MTA7[F<C>Y3(C"$\&^T43/^MZA!PFF)&?Z2BP_8YG/GL6+!5/N"\M"
M=R_P(,Z5%EEI;"+(*"]6\E">0\/@<)U!6!J$+N["D8ORE&@RZ$FQ!&FU#9HE
M7*K.V@1'N;V4:RV-E!H[/3BCG/"8$@;G7&F9F_/6"@A/X(Q0"7>$Y0@72%0N
MT<EZOC9NK;$?ERY&A8MPC8MV"!>"ZYF"3SS!Y%< W\1;!QU608_"C8BG&+<@
M:N]"&(31!KRH/H3(X45_\Q *%YW5+NR_U55S$F/?,S^/0KE ;["]U=X/CC<D
MT*D3Z&Q"?YL$-KN(6O!B+PT+HA26RHR2"6544U20%=H)$ VI!5DX$"*Q;!/T
MAQ%.;._HPO;681A$Q_]L'2H0*9CBPVR"LB[ 5^->TRFG*8T)U\^V^9H+;4YF
M+&EL%LI7@EWJF8FSDMQR,;&%1R8,GY^SZYIP0>2]O;^*??F$=,[G>4/RVW;=
M^O$++I!!>Z>BPIJ*=N!&:%,S0U<S?[YWTUWPT31%&R*D.4^>W'^ \&@W.FHW
M&)9JA\<;.:51$499NF\#^3YK./Q?P^^YAJ.#W<[!T0L+KC1:4\.O@:P8-^9F
M$);VPP64B4-:]WS:>"627%(^!7.9\(A$ MI18$4OM0^$+<A6Y675Z^@WYIT,
MY=1-=0IBD7-=C#XUMQX<A\6\]*1>3)VF**8F3F"8&M.@=;#G@2PFN6*CQ=Q-
M3Q.AS2SFR)D9?E%:!2-/A2GB<F,=U./TX"=02P,$%     @  H)Z6!RW9M#4
M @  /@<  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK55M;]HP$/XK
M5HJJ54(D<0(%"DC0%VW2*J%6VSZ;Y$*L)G9J.PWLU\]V2!HTBE1M7V+?^>ZY
MY^[B\ZSBXD6F  KM\HS)N9,J54Q=5T8IY$0.> %,GR1<Y$1I46Q=60@@L77*
M,Q=[WLC-"67.8F9U:[&8\5)EE,%:(%GF.1'[%62\FCN^TRB>Z#951N$N9@79
MPC.H'\5::,EM46*: Y.4,R0@F3M+?[H*C;TU^$FADIT],IEL.'\QPK=X[GB&
M$&00*8- ]/(&MY!E!DC3>#U@.FU(X]C=-^@/-G>=RX9(N.79+QJK=.Z,'11#
M0LI,/?'J*QSR&1J\B&?2?E%5V^+ 05$I%<\/SII!3EF]DMVA#AV'L?>! SXX
M8,N[#F19WA%%%C/!*R2,M48S&YNJ]=;D*#-->59"GU+MIQ9KH?LKU!X1%J/[
MUY(6NN)JYBJ-;2S<Z("SJG'P!S@^1H^<J52B>Q9#? S@:E(M,]PP6^&SB'<0
M#5#@]Q'V<' &+V@S#2Q>\,^9UCCA:1QS2Z:R(!','7T-)(@W<!:7%_[(NSG#
M,FQ9AN?0/\'R+,YIEN$ G<8_5D.C[B,&^A-Q?0>E@ACQ!*D44,(S?9DIVT[1
MY<48>\'-?UN7T@31O8=\ \+VOSDR_X'YX [OYJR'_+X_"8YD;WB-'DK!J"H%
MV,02NC-[V9KYH?>^QY._V!B8(#B&]<<C]!VDG*)E%)5YF1%3F1ATF2-*[*AI
MS+]H$N'DZEV>#(.K<[7N!,+CL"MU2-QU0\%.CV=I6B)L:_9 A$1@[N!Q%6WU
M3$1;P8I(U)N,K*(W#OIZOLH"[(3,]GU4I31*$6515L:Z7"3G0M'?QQ%UFWJX
M!L"?#'\<;H!.W1NW,]-R$%L[N:7^%TNFZO'6:MO'85G/Q'?S^F5Y)&)+F409
M)-K5&UP/'23J:5T+BA=V0FZXTO/6;E/]P($P!OH\X5PU@@G0/IF+/U!+ P04
M    "  "@GI8.P5LI)4"   R!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6RM5=MNVS ,_17"&_H4Q/(E39HF!I*VP_90(&AW>59L.C8J2YZD-.W?
MCY(3-^O:8,#V8HL4S^&A9-*SG=(/ID*T\-0(:>9!96T[#4.35]AP,U0M2MHI
ME6ZX)5-O0M-JY(4'-2*,&3L/&U[+()MYWTIG,[6UHI:XTF"V3</U\Q*%VLV#
M*#@X[NI-99TCS&8MW^ ]VF_M2I,5]BQ%W: TM9*@L9P'BVBZ3%V\#_A>X\X<
MK<%5LE;JP1E?BGG G" 4F%O'P.GUB%<HA",B&3_WG$&?T@&/UP?V3[YVJF7-
M#5XI\:,N;#4/)@$46/*ML'=J]QGW]8P<7ZZ$\4_8=;'1.(!\:ZQJ]F!2T-2R
M>_.G_3D< 2;L'4"\!\1>=Y?(J[SFEF<SK7:@732QN84OU:-)7"W=I=Q;3;LU
MX6RVR'.]Q0)NGNB:#9I9:(G5[87YGF'9,<3O,$0QW"II*P,WLL#B=X*0Y/2:
MXH.F97R2\1KS(231 &(6)R?XDK[&Q/,E_U!CQY"^S> Z8VI:GN,\H$_?H'[$
M(#O[$)VSRQ/ZTEY?>HK]K_2=9A@-X35)[\#. ;FB3C+6@"K!5@BE$M21M=Q,
MX>S#)&;)Y7][+WP2ND9LUJC]5;X.<5?K'C'<-*U0S^@$-DXI=]TZ@#5*+&MK
M!L!E0>TON*5BN"N*"]/S?(1H$)V/CNS)F,$=W1'7>>6Q!3[2[&EIDEC*X4Z@
M%S$8Q:RW+AB#E58E&C=QN( 2Z1@=@Z+STG_F3L8OX"1.X:NRA'I1D@[8Z%A9
M/& 7Z<%^Z[L)C_JX0;WQT\J0Z*VT74OWWGX@+KHY\!+>3=-;KC>U-""P)"@;
MCD<!Z&Y"=895K9\*:V5IQOAE14,=M0N@_5(I>S!<@OXWD?T"4$L#!!0    (
M  *">EC2DQ#-V0(  &D&   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;)65;4_;,!#'O\HI8WN%DC8MI6)M)5HV;=(8",;VVDTNB84?,MLA]-OO[*19
MD: 2;^K8OOO=_\[V==%J\V@K1 ?/4BB[C"KGZHLDL5F%DME8UZAHI]!&,D=3
M4R:V-LCRX"1%DHY&LT0RKJ+5(JS=FM5"-TYPA;<&;",E,[LU"MTNHW&T7[CC
M9>7\0K):U*S$>W0/]:VA63)0<BY16:X5&"R6T>7X8CWU]L'@-\?6'GR#SV2K
M]:.??,^7T<@+0H&9\P1&PQ-N4 @/(AE_>V8TA/2.A]][^M>0.^6R918W6OSA
MN:N6T3R"' O6"'>GVV_8YW/F>9D6-OQ"V]FFYQ%DC75:]LZD0'+5C>RYK\.!
MPWSTAD/:.Z1!=Q<HJ+QBCJT61K=@O#71_$=(-7B3.*[\H=P[0[N<_-SJQE5H
M8-,8@\K!#\ZV7'#'T2X21WAOE&0]:MVATC=0XQ2NM7*5A2\JQ_PE("%=@[AT
M+VZ='B5>81;#9'P*Z2B='.%-AF0G@3=Y;[+Q:]EVK.GK+/]8+FS-,EQ&]!HL
MFB>,5I\^C&>CST>43@>ETV/T]QW+<=0LAC=I\%W!3>;TEK:IQNDID"5LM*R9
MV@$9H\$<N'(:F*+1-H:I#($REKR14'!%<ZY*8*5!E![?<E<! X%T"4P,#WX(
MV,'D992.06%.YM,QZ (R-(ZZR3Z(!>:(-XOG9Q])A6J8\(I(F75@F,,8?FE'
MBS7;>;KU#%;71C]S>K4H=G!R3IEQE8DF]UH';Z9RBD(;O&;B%)A!R!L$Z6\Q
MN15&2_BIGU#NZT/"C6[*ZK!HDQ@N0TRZK9UE?V/[:E(GM(XB^<A#,&_O-X6F
MNK;,PLEL,@UZ0J6D;GPE:;UF/"?C@D2_^0J2@^<OT92AR5G(/*3K!,/JT$<O
MN_;QW[QKPM?,E'3,='H%N8[B\[,(3-?8NHG3=6@F6^VH-87/BOX+T'@#VB^T
M=ON)#S#\NZS^ 5!+ P04    "  "@GI8'KO4W8,&   L$@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6RM6&UOVS80_BN$FQ4=X-F6_)HV"9"F*]8A
M78.]%?M(2[1%E")5DHKC_?H]1\JV;"=>5NR+95&\N^>>>^%)%RMCO[A"",\>
M2J7=9:?POGK=[[NL$"5W/5,)C2<+8TON<6N7?5=9P?,@5*I^.AA,^B67NG-U
M$=;N[-6%J;V26MQ9YNJRY';]5BBSNNPDG<W"KW)9>%KH7UU4?"E^$_Z/ZL[B
MKK_5DLM2:">-9E8L+CO7R>NW(]H?-OPIQ<JU_C/R9&[,%[KYD%]V!@1(*)%Y
MTL!QN1<W0BE2!!A?&YV=K4D2;/_?:'\??(<O<^[$C5&?9>Z+R\ZLPW*QX+7R
MOYK53Z+Q9TSZ,J-<^&6KN'<(BUGMO"D;8=R74L<K?VAX: G,!D\(I(U &G!'
M0P'E.^[YU84U*V9I-[31G^!JD 8XJ2DHOWF+IQ)R_NK&E*7T8-D[QG7.;HSV
M4B^%SJ1P%WT/$[2QGS7JWD9UZ1/JDI1]A(;"L1]U+O)]!7U@VP),-P#?IB<U
MOA-9CPV3+DL'Z?"$ON'6X6'0-_P6AWN/>1SUC1[71T7SVE4\$Y<=5(43]EYT
MKEZ^2":#-R?0CK9H1Z>T__?PG%8W[;&3&MFG2EA.]^Q6(-<=^[T0)%)QO7[Y
M8I8FTS>.559B=\45$P\BJZFLF%DL9(;]W JF3,:]R)G4[*ZV60%%7?8+"O0O
M%"A;%0)[5@+9;2U@J#4S6597:Y9V9Y,1ZK(F)0OJ2&;1*&:!8E8CJ2SC3!$X
MY@ON :&2X)V,?>1KDD"BG/?:P!E7SD09 *PJ:QXDZEG \J0[F,P.32H^-V#!
MV'5@: ]!VS?IO9O7=EETV9W0VJW5/=>2-R@;>RV0)/1SK44#<M)CGS2[KI>H
M\DV&IUT([("#'I!%UKS9NLV75@@*($-//O G[9[/!B<I?(8#D;QH#,&#8: H
M2=-HS,I8WD1,AE1"WD 9VNNGS)LYW&[\Z+'K/)?4>+E2ZR[M..DIZ;O%CS(V
MAXU<+F30&\B2R%7Q(%U(S ,2W",L#+O3P>21J#84("!DVO&RH8..!Q L'KP
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M7!HJ8)J ;3/_AYJ,R2L,UQO/DK]V!&O)')0D M5G1C9LF5H((H:':1+NU\_
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M$@U/H/&%UF[]P1MTC]+K_P!02P,$%     @  H)Z6/'4.F75#0  '2L  !D
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MHRD^-*:X0U,XJB^M*YPZ?Y Z% !?F@!X8P+ Y,<KG+)P":*")B4(3%4V<']
MJ/[=OTW2?NS4@Q^]Q^_T%E DCR:\<G=>N0G2W8$ZQE?B+*]=.O!D"2!2QN[.
MG<#WLX<4_LU5SS8^S%SC;A@7-U=O%'#GT.:@2/Y++L6>>6^I3@^@>P \:Y#[
M)1L FOC#1/5KGAI\NW=2RX;>9#KW1I-96R<@K,,A_(F\8#:&3)BZG9H:.XEF
MWG0RW],M\H/P;#2T8QS)&ATV\['[74[M,=Q@-O3FP_!RCS3TY[-'2%00)!N$
M@3</#G")_# XRN6H<8=LY$7AT!M!H6V-"P5MV+D,O?%T#D8>-V% T($?GJ3
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M7&GA5A58O :(B4U'*=M2FF9[$6\P[T$_/88LR?I[\/J=Q'[ Z_^_Q 9@\#Z
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M(C!-"VXF3E>A[<VUHR8:S)+^6FB\ ^TOM';;B4_0_0<G?P!02P,$%     @
M H)Z6)RFB@Z\"P  &B,  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
MO5II<]LX$OTK*$]FRJZB99&2+#E.7.4XF5E/9692.79K/T(D)'%"$1P C*S]
M]?NZ 5+4X2.NV?U@BP?0:/3Q^C6D5RMMOMJ%4D[<+8O2OCY:.%>]/#NSZ4(M
MI>WI2I5X,]-F*1UNS?S,5D;)C"<MB[.DWS\_6\J\/+IZQ<\^F*M7NG9%7JH/
M1MAZN91F_485>O7Z*#YJ'GS,YPM'#\ZN7E5RKCXI]Z7Z8'!WUDK)\J4J;:Y+
M8=3L]=%U_/+-D,;S@'_F:F4[UX)V,M7Z*]W<9J^/^J20*E3J2(+$QS=UHXJ"
M!$&-OX+,HW9)FMB];J3_S'O'7J;2JAM=_"O/W.+UT>1(9&HFZ\)]U*M_J+"?
M$<E+=6'YOUCYL?'@2*2U=7H9)D.#95[Z3WD7[-"9,.G?,R$)$Q+6VR_$6KZ5
M3EZ],GHE#(V&-+K@K?)L*)>7Y)1/SN!MCGGNZK9,]5*)S_).V5=G#A+I^5D:
M9K_QLY-[9L>)^$V7;F'%NS)3V;: ,ZC2ZI,T^KQ)'I3X5J4],8@CD?23P0/R
M!NW^!BQO\,S]^=G#P[,I(U[:2J;J]1%"WBKS31U=_?1#?-Z_?$"W8:O;\"'I
MC^KV\.PXZ8FN!/%YH42)-"ZTM2+5R!OKK- SX?!BI@OD7U[.\699Z5*5SKX4
M/_TP2?J#R[_M\]]*&A\* HY4RZDR[,SF/3F5_B7B+?2V+D_;5R_$<3**QN?C
MDZU'<328#$\$,A#Y5;:O\&(S[C@>G(C/VLEB5]IDLB?MHK- \_FV-F09LM,:
M.[!"[6^!59=EQNI'//8&EI3E&MB4:D,32HV4-0:V%=H0-BC<9"+W7G+R3J@[
MH*F%L_!^JDHUR^$B:;?$+7"/*37/)6=BN,4#14]5Y<$,BM"XRNAO.2TMQ:PN
M"O%-%K7T(\C?DF;).;#9.D%+M3J1,A*B@>CBET)/8;O;TLERGD\+)=[KU2D%
M5=9$V#&9*NE?_G+[_O,M7\>7)R+WBJN[5%F.-"F^]#X)NY!&+721*9C2L5\H
M+F?!A\$<^ALL*Z&16F(=HUQM2@'%6R4:]6Y+\:LL:Y0,V#Z>1!" X19!;&%4
MC=N_ZMSDL-)TS=$M2]QX%_U\_>D-U+0UEIC7><8&<0OIO'WL9CQ)XEI![I!4
M+E)=EX[BHM)%GJ[%:J$@TM! A_KG> $V2+ F=E,ID^L,4BV' (92<,S+_#_J
MD.W9CT4NIWF1.U(":Y1496#9+)]AO(+"B,<[Y'+0VRB.HM21)"TD1J5>%[DD
MC<D/7BL8NJBY>M85EU!8W,JBQTC1C3;>MQ?G=^;G=W<4 K<GWO%ZJ*2M4WQR
MA)Q U(B;.NSL5SVUXCIEE>"Z,50@5ZGM>,>JJ:QRA FL%/%$6T\MAB*1BC5M
MRS@RX,>?Y+*Z?-OHXB-H1JKXK$6 46#@.EWX<N^-"BS,:MX@(H=6_E+F=/?)
M2:>\ID'4S"G8_ZG2P'$LDJ^!V"VI/7'-KB]3N-9G9!C6.J\#"\<!"TXX'FMZ
M"\<%2)HI)!)RR$)P[30LWIEIL!C[;6-02L]X? FWMJ[:G9 SZ/B:\#>6@:?#
M_^U&H7;'B+O]K;*Z2=SKBQ^;#S8P3:4D)V"!89N)P8ZBWQMAY'$\ZJ$T_"AN
M%@ 5,L-!@#Q.DMZ0AJ&DT@)-G-T@62%KV,J*:= [A+!;GQ(5S%AYQ**7>#SH
M)2<\M#>FSS\8+H[[7C@^+WC^O5YAQR67&+-]1:;[?,"_3P&4P /V:,#_S^E;
MSN_<@ /LZ__]:OU. 0"0D@S5GOM(8]9(WY4TF>W4__-H,AQW[B=1?#%DQ$J]
MIP]/'$0Q>&YS%T?C9/) $#3CAOW-4@-<_['146'6EI-V]Q0/)_O/QA-QT\)D
MMH$F1D-H7YM#DL!XQO'>XU%T/AEO[#\W$G4CA..>WSIN:S<T&H;H;D<-SS>+
MGH\.^;8C,2(!F^'1>3P0[\$A7A[,SPWI2Z*D/^X2O_-H.!B='%Q- LS-@_+B
M3C20>9^; 5NK=_RZ'\P?#(6J6W.:4BVLT-\ZCV*[8X\G^T3U&)OGOOE4STYK
MVW"DJ)L!%%VV8Z+!1==@X_CD7GT[PX9;5AY#%<JS0X"S2:<&M.Y_LL<[O'=(
M(-Y4VN:,BV2<4LTEWRCBM^2U*<*=-LA<AFDSZ[WV)(NS@L4<1$5FI_?S^9[X
M399RKL@;K!G#)DI*4&T7>1> 5*I.$)K6R[KPJC;-5^ 400XX&!/T1U2(/+T#
M"JTP%)2'(.*K O_!\Q*M1>!_7>:TRD'YZ4VS?\1X@_1M=Q'N#S+_ZY0Z%UBU
M6$</M1"TE2E1(_1L<EKD=D$["GW%\XU.\7!H.2"140RM8/0OT,>-$YZ5J>[S
M!+#19YKV/8T;=0Z^_A9KKT&SVGWT (]9QHK[K7R),"162I+J@BNK+#="MMCL
M/3 =@>?G11.N3UD]>6AU7!,CI7D8O5T,0RRZML@16,QF<)"H)&@U%EJ3-4F5
M1_7>[AS:'K7<*\%8M>D8?__C?=LO[G:Q;F%T/5_L^2ONH27WM)802JY$R@0.
MNJO[VP_?7#2L^6!WP;:XKY^PVUW]BMMP6!<Z2.I'/3Z1<QY-Y2;]:Y=[<\(*
M8HZ,-#*T(7 E M<'+52DS%LWCH$6N3EP:H!\/;QRM'-^D+5\>-\U.R0'XEXD
M%R!&@Y9+?PH'IH-) @A:<E/C6TMNQ@.>80_/6(0ZCQ<@):-^[.%LJN;4E&G:
M(SI#'^Z#$5OP!9K]P3#Q U,DV52QX!S+!]D8#^C)J?.B='ZR?2SW$$]2/$ZB
M_GD?/OTF\X(#@0L.,@YTNJ:\"-*:./&.XQQ'_C!&']QE,OD>AX;#DR>I/!A>
ML &;29LVED$4T*>9>'1@X9#'SB?_"],W4?-,I:+)*'Y*J#[HL$:''0+T!)]=
M],073NJMGGZ7'SSJ)=KS]QM@*=?D"%M/_^0S'PUTHJ,2!_H.)(<@0&+A+>'U
MJ^$CLV6FH/%M"79<8O!'+%S6M 5_DA%?3,Y%YM%7KX!8=I%7#?[Z>%A(P*].
M _I7!A1-UY;PRX2 T761^1'-D8LW/!_F>1PL""7W5H@(7#FL?)'O:!Z%DF?%
MS.BE<.A9K.2WMJF^#?9OI!)! ^$&44&2ZO1K<RH)3:L:1"9%[Z/KRC9J\B!?
M5,&,*FV\&:$),S*F8J/^C\WA)0J84J>$XN&<C"ND50<L1[YCQ^P<U6U[N)MO
M;?'P;BVXEH42$>)X&W)\>=Z(IH4ZL4!GB@I>7WKC,H_2?MM$/-1.,(M\N40,
M2DKO4*[".=/NYCB O<]WHC/+N&)2:&9_UM91>#,Q# >!L-=UN>XJ268*U 8N
MX=1K,TVB!)MNVCT.AN896395A)O!_+PXARV7^*Y]J.TO%$,.'<C+8DW'MBF%
M1A.(/BA"Q#[.>Q(R6NNCS8$S_BFV#&<>$W&YG=0['J%(H#.^1BF[T"NOYY[O
MVCS.N\?L?5] : ][&.O]L6)_;USU8C2YZ)[$/>H;]BTW=&43Z=O\LJZRMC=L
M=W*?Z0;!OVU\-]U4[INI4]],G5(&GQYJIC:GIG363GH=V,'S8+M-C3:C-XG<
M?%_$Y?I04C.HRKOMQB5J$)IINV[/^?TW! >\G.49-XHM)I/)MLT]0T=B_6$D
M?Q?#>4K?>J8FGWHTIM4"(V_[RC]KD]LL;X$XE-"\L9WRW^!PNM+7Z 69PUA&
MFRD=<BN[0[PI7C<8HNXD'-K"<!->_"T!TZXM!:B"4[+(J@*XDQEYD_0$?\'8
MP+-2"VYK*$^98+>+[#8YEO91>HYN?#IN3P@UEH^LE6]',< S>^80):U"H&7"
MF=1VY]*_%)2=0(UH*VZ$= Z6KUU3=E>TC4T3T4+RCC@&"D0P4YB N_1] AV;
M'#9F%"P)<85. RV2M5MHX\^%<G;U6JB<#;!!(<P(7$G4UF.(;,(X%,1#WY.?
M=7ZOL%1FSK_*X#PIG?_I0ONT_>''M?^]PV:X_]7(;]+ Q%84:H:I_=YX="2,
M_R6&OW&ZXE\_3+5S>LF7"R6Q;QJ ]S.M77-#"[0_A[GZ+U!+ P04    "  "
M@GI8K:1CI;$#  "_"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R]
M5E%OVS80_BL'M>B38%FRD[B);2!QNZU BP5QMSW3XMDB0I$L2<7VO^^1M!5G
M38T!!?9BB^)]WWUWQ^-INM7VT36('G:M5&Z6-=Z;ZZ)P=8,M<P-M4-'.6MN6
M>5K:3>&,1<8CJ)5%-1Q>%BT3*IM/X[M[.Y_JSDNA\-Z"Z]J6V?T=2KV=965V
M?/$@-HT/+XKYU+ -+M'_9>XMK8J>A8L6E1-:@<7U++LMK^_&P3X:_"UPZTZ>
M(42RTOHQ+#[Q638,@E!B[0,#H[\G7*"4@8AD?#MP9KW+ #Q]/K+_%F.G6%;,
MX4++?P3WS2R;9,!QS3KI'_3V#SS$<Q'X:BU=_(5MLBW)N.Z<U^T!3 I:H=(_
MVQWR< *8#'\"J Z *NI.CJ+*#\RS^=3J+=A@36SA(88:T21.J%"4I;>T*PCG
MY\MNY?!;A\K#QR?Z==/"$VW8+.H#Q5VBJ'Y"45;P12O?./BH./*7! 7IZ455
M1U%WU5G&#U@/8%3F4 VKT1F^41_D*/*-?B7(1#%^G2+TQK4SK,991H??H7W"
M;/[N37DYO#DC<-P+')]C_V\"SU.4HP'\0 /OWDRJX>@&/BGXPFS=A(R.<_ -
MPD*WAJD]D!U:Y""4U\ 4=%1$N[7""[4!MK&(;2#<"M_ 5^')XIY9K] Z^-WJ
MSL#GSXL<&'#Q)&*KZC7<MFA%3:8+9@@B>TA^L';4T#&/RK/0EBZ@@BJ'3V@)
MT*L(?A1K22!M6Q0J)ZAD41T)#ACA7,=4C:2>@V,28;5_$2)Q7^875V4^KB;@
M&F:3/T$)JG7;DF;JL_J1='D*Q'0K*6HR6%,0Y,50*!CLWY:#JPLP:!,'K) N
M1:0[@'=UTD,^3X6'[)=7-Y0:5^M.^0%\_9<%;"DFV%A&1> A^]K$RXHB,QW5
MB^X;>#^YR*_*,3#.1=BD[#S'\+_K%^Z9>4MU;!G'H#64P!\K<DC\ >]@V:!<
MPP-NA/.6Q0B75/AXLO)8-I:J2DDP5CM#=W;G:%(8(]/QXW$OG>$RW0SC ?QY
M/-;E.'_E:-=2NW1P>LTYX*Z6'3\7[J_4()7X*,!BC72Z.2@:KQ18C<@CA!E:
M[01-%91[*LPP'UU25&Q-.DX*\K;,R]'[ 'C1E<=ZN)BZX)Y:@%2E-3H?B?ES
MH7!'0]R16L/V;/5#@PQ>N\**DZ%"[;R)HS,T##E.\Z5_VT_GVS24GLW3:*<:
M;02ID[@FZ)!.808VC<NT\-K$$;72G@9>?&SH"P-M,*#]M=;^N @.^F^6^7=0
M2P,$%     @  H)Z6&T."-E5&P  *U<  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&ULK5QK<]NVTOXK')],QYZ1'4M.G+1I,^.XMW3:)A,W/?-^A$A(
MP@E%J 1I1_WU[SZ[N%&F%#?IE\22B,7N8N^[X+=WMOW@5EIWQ<=UW;COCE9=
MM_GF\6-7KO1:N3.[T0W]LK#M6G7TL5T^=IM6JXH7K>O'L_/SR\=K99JCE]_R
M=V_;E]_:OJM-H]^VA>O7:]5N7^G:WGUW-#T*7[PSRU6'+QZ__':CEOI&=^\W
M;UOZ]#A"J<Q:-\[8IFCUXKNCJ^DWKV:\@)_XT^@[E_U=@)2YM1_PX77UW=$Y
M,-*U+CN 4/3?K;[6=0U(A,=?'NA1W!,+\[\#]!^9>")FKIR^MO5_3=6MOCMZ
M?E14>J'ZNGMG[W[6GJ"G@%?:VO&_Q9T\^_3)45'VKK-KOY@P6)M&_E<?/2.R
M!<_/]RR8^04SQELV8BR_5YUZ^6UK[XH63Q,T_,&D\FI"SC0XE9NNI5\-K>M>
MWLAI%'91W)AE8Q:F5$U77)6E[9O.-,OBK:U-:;0KCL-?)]\^[FAK 'A<^FU>
MR3:S/=M,9\5OMNE6KOBAJ70U!/"8<(Z(SP+BKV8'(7ZOR[/B8CHI9N>SBP/P
M+B(C+AC>Q1<S8HQZ@?UD'#8TZQNW4:7^[HA4Q^GV5A^]_.H_T\OS%P<P?Q(Q
M?W((^LM7RAD'O-\"=M,IB/L8DI\!IOACI4ES2KO>J&8++I2V<<2(2G6Z*A:F
M44UI5%TX>EZ3MG:N6*E;7<RU;@HB=J-:>LXT6 <;8KHM27BW*MZ?W9P52]WH
M5M7U%GOH#4"JQ/!-:PCXIH;L??6?Y[/9^8N?KJ[>\I_3%R=GQ56SA670K6Y*
MC4VZ%:%>-+:C)9TMU&9#1Z;FM2Z6/:',3[EBK7&R]#NOQ1\=J.R[E6T-Z";\
MWS<&V-R +/=P/)4K%O1UY9')Q8= -95J*U=<VXK%BQD<*+NZN0Z$%?3@^,KW
M&_ ]6_,^KJ&#PX8_QA,9!?#*TG]Q_8]7-Z\B-P](XM,HB4\/BM![8C[A\8/K
MS!I\&Q/"?P:!Y4_$2-A%/WY: O>)&Z2'#OVOWI"(DQ5MR.]@!41@K3[H0L=]
M<03*D:_:8%N2II7J"K58D#-A/A-*MF4Y6(/+K#CTO.YD:6W4W-2F,QX4EE3&
ME;5U/?86,G XV'[?0MF*C]P?[Z=I#[N-(=CJ6]WT'B7]D3R[HP]5WT)(TB*6
M:=T:6Y&*E5U/&Q#.Y.8<[=_7%5&R@.(L6KNF9=9EC#LD1I=1C"X/"L&U<BM&
MD?_X@8[K5M4@;DR>/A-4$7\I\8?.?@&/C>N@UN013,T^P30=F1G7G<ZU8G95
MQ"IG.CZE6_K*]BX[$-,00[I>9 >[K&VCMR1D[0<ZZ3,6ZVLQJK)?I5MZL*Z+
M%841M&5M"".8D5O:5$Z6Y5B1"K1F21O5!*VCH^NV(ARMUM@%/M:V!1DC6K&"
M$>[;<D5Q2P4IG^M[]!XZL6?QQ)X=9/,[76J"1X9V](P.+A[WCAG$XJ<6]OK^
M-VWV3:MKJ F12*&G@[W#(079KWI-=KFEI\QZWK>.70(K0$6GY!52W9%M)#8M
M 9R,"&D_?9IO63-^9_-#3'_M3Y95\F>M:CJ48$]_?_WSP(:3[R-VMZV!&K(R
MFS:J"DF>K3DX!3(>TZ%D ,.R$[G(B?4'F99/9#NR^"WHKK<3;-:RMVLLUML[
M]GY@0F7[>;?HZ^#"7#")56&#"UWN,OBL." FSZ.8/#\H)G)LY"SM6H_)R<-7
M#]@DWIG]=/X(J83MEZMPGFRMEO96MPW;?'#,@DO%<6.;T_0+^=)VJ1KS-Q\Y
M43[8V(!=I:4(\6\); 2&__786]63$ "('<6GNY4I5][*9E((B5>DH8Q/10:Z
MMAO&#XI@2AAKG&-3]BU.*)IW9!L0A(W:\N.,EZJ!U5GQ/0*;-LAR0(ZLNX1V
M@5&;UI9:5\X?=)+VP%DR@38&2/\R*6?%CX!-0+:TJM#("PCQ4J_GQ,\0V3,L
M^F,V&2 6CGR'0E+)1[,GD^?G3WG=(UHVFSZ; #-H$I$(U4B&G64BT. =J/=J
M^U3^BFSODO2-G."M<3XDX<=?_\SJI?! Y(4H-%/L98Z$+7QD9RL0JM$34VR8
M[C/ECGYX-)T\.Y\*G>>[)"JXL;4$W_[X_ET<9LQKH# 3%*:3R^>70S2$=J]^
MP;HF0ZV6Y+*JTWY#NU=D?DK!S33^0VD=CH-8"I"(F"G.Z2M$1O1=2>:!8NBZ
MZ%IRN&[BA7*MMD"\[BL66&>;1M?BYTF7*8:1'(8@3_P&&V681XC'6E5V28P'
M9B :^>MW;URP\I/T\*['?PP<$:T1>_LU8M);6]_JF!D(6_BD[C39=V0.JLQC
M1E51OD^!2"L9"6/++'6)J:U\7VQJ#C\^(BJD.(!\CFJ6*1I."AL4B,V%E_N*
MF8Q81M<46D"5]Y\'S&1!'HQ\3K\)LK56'\VZ7WLO!M'0BC:,YR8"Q2)P5KQI
MZJT')E$U$2$>"CM3\J3;Q"%91&>EVTX1)9D!;_6RKU4*L;P2XFRFSUZXPO64
M_C$/2$HV2-ZW_!Q;/0IZ@7;3<QRU97]:*R*K&@0*O'R2!=4#4P',73__'R<%
ME$Y2Z$$^BS+)RMQW.+01I1L-EU+$QI@UZP'^/RO^NS*U]MX7IL2?<&61SK)P
M@GRR]G-5?@ -8GW<)!H?0EM\4>[DL..6*:3@'T6R3 @BITA1N+Y'$8)H!2E:
MVY<2&8GNK"F3Y@A"HM"46-?JSDWRLY@(KX,4NYA[!B92(+T.8!%_\0%Z(YH!
MCDPX*UY3<-9LPS.#N U'(!FW!$5]DT0)QI@^E.PGS)IX1H0BG"=A7PRT804C
M!][=&6+_K;$UKQ%,:5O7DS1'A";WT0"#<4YSG:N5-P/Y3E[68L3%50@ZU6)!
M-"#20VEUBUQ18)#"6\X )_<0EOTHPH_T2^6EA>[IG-=6^)=Q]&K<L=S?A#?8
MB8Q9!(B;+/<2%7A5UA\[S:<LD==O1)<'34XXTQ1^#N)[*/GX.D:57Q^,"V.P
M\P99*>S[-8S+6(!Y$-!X(K('^C"#4QO3<>SEHJ&J]5+5D[Q,E +.;F7:ZI2\
M,^5N9*XS.RBF%G4FYRQEDI!"9K=I3MEN458'T<%"23:;)6F<>+R0Q;]^^X;]
M2O3G8FR!1BVBG-9Z%])P5;Z#O%TM2&C25UF$L[OQQ)LK 0] B(Q94H@!KK/E
MAY6MD=EZ2P.,R#*@X$$!%&'6EP%^#$539.<?@M,.&%A_!@>SD>EYJGV?'Y2<
MMVP1.G$+* YPN#I:W?X<0,7@:QV_9K?1"8WB5B=%HYE($I=^W8OUJ1"N0P:@
M)Z2KZ1.\-TQRW\6<#19;(2<X!6YH5)C@JU<ZRSE[IY'ZU681:TI<?=I)/&,=
M# _D:\3*/AT\+9[%>0_I)>!6U;WDU9MQ+G#,00!,RQ]1J]# %S6J3D*\%8(8
M#F#FO2.R2/A+TQ*'X%1*_J5"'56+ G&42Z'/-J7^8OJ$1(!<DF':9+6ZS&X3
MB?66\2<LX#^8)714=_B'LFB_F6V9J@QU^E3;9DF<OV6Q9<A950WYC=N;X!!6
MB*</6<)IULV9?J(0DZ5@WV<IV%Z3^$4 !V)@AD'NWFP08D<^RE>U.&7B"IJ6
M2A:Y/JU<+.FD_$4C/J])4]I;%-O<UG5Z/?$!"<$IZ4M2AJOZ[Q6Y8-W&\,9#
MG! 6V-,H6?.KOB-?;)%02(2WU)8\W(9B9=)+$MK5MCC^Z>J$TE<$*F@.$2H5
M_4=1U6G ;JU*TM>68'O+Q=KZ;A_QR5;Z2@';N903[UT8R[59>1)=!^Y*0,MB
MLN.SF^03G*K!7OJ.;?+IG*N!," $D1$6^N=$P,+X,]$4\=FMUAQ@)G=%T1G0
M$+>5/!HT/*3+0F)V>K9O]TL#MV4YZ<E13G&;3XJVD>&1$5+$)F>5-B4^H/QG
M*/DC*U*1JDXR)/<F-6?%[[:A#1"#':YDI..+SC6KI?-9BA447)<6H9$\#NO
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M!(J(9J&5+1OUBG4%69<.C4FGTZZ#GN%<DQ,D19#X/^,-0+CL\G/&JYUI'$R
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MC,@OG_L)<+X)%UZG\+VI>><QQ ;56BX63V2$B5+]-/Y(%H,G;^+X%I0LY*E
M+,;[7M>'V2@$ ":+;&@J!O6-27,=,JKA&_?>_^$N?)C;S(=&QKD@7>IJ+ZF3
MSV2N\;4"RJM87>;[SCC+ !>J]'& 3&:EQ\5B301/GHE*F9),3,4*>IHB]14)
MKF8+-KZYSPV0SIP&: >U(]ULFAZ^VG2CE_NCWX<M_62!V801"._!Y+4HR+9U
MUL]Q BX;_@'Q\5H&]SBYY!1N.G'%H87-,'][_6K51O>H9.T9LZ/8*F]55KJ4
M"]88-6PG8I7X&1+]4L[,HI""'\,=E#PL'8Q&(/]?+EN]1,PK':M@<C=]B\"4
MJP0R=^YO<-N^+0^[K5FZ:S0[?$7H!^(&WPS_B992.!*.!+,3_>@!?Q' W9L9
MF/L*"Y:RH QU1+DJQA+AY?P7B@?(CK5=\:9OBU?AE&_P5;]Q>"L,N$71R*PX
MQ@)_-_J7-Z]N\&-Z15/JCH;?)GL0@=ZA.E*1P_2#RW@&0QD<Z=T:'K!/XZ9I
M\,*_J@-SB=P=C5%^:GKYE"8@D5^&XPHF:S.$(+NO&EJ)&RFP)#SO)^-QJ-CR
MG"(W ^4R)+Y,<]*^;LH3]IC$YS"4P].'T,GZRM-%H5'9>4\!7:A8A0':EY7E
MLO,.[IYRYHYJ*>%M V^J>)%*"@/'Z@11'JXV(>?<*T! ^WA^@K<C&58XA"12
M;J<XY]:6/'A,QPGOF"[Q[F6.'V],PNC/[/YXHQMM;@]N=<E;$$*+/'&!Z90C
M2"6[_6= .#6V]Y.EH?$VJ-YO=T_BH-E(%[IFG[I_A0QG\!JZ 2JCAN/+0,H
M&-'_NB%#0%X UP+$9W_VV\6"BO[3MYK%6PG3B\F>$@[[C^F+4"+\54I@_NK"
MQ>SRY)O==NWP23061P%G^ 0<TGL?I,I.#U;Q+@ ]\QQA^O1K#M;/)S%:%WL!
M.,[GT%RB]_!#Y3N6V'W9#5&*WU!ZBR*TL2>8";,-N1_WZ,< ><LP7B==(6=5
M^8O-V/]Z3RE5AZQ1D:J.DUBV3U?Y)S[&]%<.-+^'@4#RWTB!2L57KC*VQM(;
MDJ3#E5RH=1P(H>]2^IOWPP8O2Q*F<3CKW_?";T$3RZ-*_Y*?024PW)IA%&?G
MI^>7]Z=222##",*G[[O &'8/'! =N7[PB4P,0YS%_U%@FVGNF[*S"*?3M7[H
M8]1#H>R"*)M04A)>3(<I4+*^W@X0E)B!?@H,R?Q@+9UD&LK*=G!C5O%Q]OY2
M^!A^2RN_;*[IY%6F\=OX)M@K>?]I>EQ>(_N;@HO"[/R"EIZ?/7MZ)%-_X4-G
M-_PVU+GM.KOF/U=:49""!^CWA:4,RW_ !O']N"__'U!+ P04    "  "@GI8
M;=OYI_("  #&"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RM5FU/
MVS 0_BM60 @D:!*G=!6TE5K8-#Z@570OG]WDTGHX=F:[E/W[G9TFA-)6FN!+
MX[/OGGONSN?K8*WTHUD"6/)<"&F&P=+:\BH,3;J$@IF.*D'B2:YTP2R*>A&:
M4@/+O%$A0AI%O;!@7 :C@=^;ZM% K:S@$J::F%51,/UW D*MAT$<U!L/?+&T
M;B,<#4JV@!G8'^54HQ0V*!DO0!JN)-&0#X-Q?#7I.GVO\)/#VK36Q$4R5^K1
M"7?9,(@<(1"06H? \/,$-R"$ T(:?S:80>/2&;;7-?H7'SO&,F<&;I3XQ3.[
M' ;]@&20LY6P#VK]%3;Q7#J\5 GC?\FZTKVD 4E7QJIB8XP,"BZK+WO>Y*%E
MT(_V&-"- ?6\*T>>Y2VS;#30:DVTTT8TM_"A>FLDQZ4KRLQJ/.5H9T>SJAA$
MY63&%Y+G/&72DG&:JI6T7"[(5 F><C#D]#N;"S!G@]"B8V<>IALGD\H)W>,D
MIN1>2;LTY+/,('L-$"+CAC:M:4_H0<1;2#LDB<\)C6AR "]ITI!XO.3=:=@5
M?87=W8WMVNK*E"R%88!]8T _03 Z.8I[T?4!YMV&>?<0>IOY78%>K%N-,U7Z
M2^_6LQO2[])=O \CGQSU:91<DX_^3C57FEA%6,VR/AEGO_'&8\M;@L_-7@ ,
M2F*["V#&5:;>9JV@W?D^<V.9S)C.3+-3([T]&1N$=:0@(_[!NE#YQ<H 8<:
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MI"T7HA0V-!@E4\JHIJ@@KWDD0#2DEM[<TEO':'O.W9V3P O/X%^M0V7IFE;
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M6S5HEX#[I5)V%[@#AN:?_0)02P,$%     @  H)Z6+U[&S&? P  W0H  !D
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M6R'#9$%6,@Q$FU",I*Y"V<"<$E94">NIKAGTSUE_O2L!9)L>$L:0,!\$:TC
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MI@MF;$RV<D,3_1H?)%=/J<J3DSNN9@27[X@D(;I^2>E:O2.)3N<@"8W$&;I
MCP]S='IRADX03="/%4N%BA4C6ZKNM8@=Y%W-LJ[<(UUA%]VR1*X$NDY"",L"
MMN(NX-TM_,QM5)Q#<(D\?(Y<Q_5J@*[^/=UMP/&*L?2,GO>AL:P;J$RG4Z^C
MO]RA6), QI;Z- 7P5[ FGS]AW_E29[(EL9+E3F&YTZ1>M@Q;R^=HR9FHG2*9
M7-?(Z27F=8(]3[V[UWU'-4&X[Q=!)=)N0=IM)/T.0@S1- C2.(V(A%!][&I
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M<[0IKM15![@.4,\7C,EM17=07)XF?P!02P,$%     @  H)Z6.+#7222 @
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M<RP)E5EIA>:PP<;38!O1:$CI0:4M7[PC(H@";T_I8="U]X'2J%<:'54ZDZ(
M9?H;Y:0 O$Q&LM ER*.5C0ZDA)?[<@=B@M&PW+B7&Q^5^R@TY4-ZXH-#''G1
M_DD?!@7>];XB=Z<QF4?A%Y4K5BO"H4"8=W&)>-DVVG:B16-[U5)H['QV6.+;
M!-($X'XAA'Z;F/;7OW;I/U!+ P04    "  "@GI8O7QV=2($  !?&P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RMF6MOHS@4AO^*Q8Y6K;13+B&7
M=I-(3:#:D78T43LS^]F%D\0:P%G;:6;^_9I+":3$#=J3#PD&WN?@]X#QB:<'
M+G[(+8 B/],DDS-KJ]3NSK9EM(64RAN^@TP?67.14J6;8F/+G0 :%Z(TL3W'
M&=DI99DUGQ;[5F(^Y7N5L Q6@LA]FE+Q:P$)/\PLUWK=\<@V6Y7OL.?3'=W
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MLPI68M/@C=E]A%[/F><K3>/"E^TZW]F,LW+CT*@>3!$HJ;M5//9Y. "DV0N
MM >DOP"2Z0N K =D06@769"U%"B*W)H=L]Z;V/PFY":@28W4OHJW:.E6$@Z+
MA5%*(I4%'1.Z8@NC4>HUZ%*"8Z?L,U".V%>PBEW2]5*ZTFPTLI,EH)"->Y-'
M2&%XLJCLG[SJGDQ?>'()Y81ER5N6QFDV E_\.3Q]#H](_)"!=,A &OBR?\G
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M-=KC,^_XS+5\Y*PJI)N11BI^/2)J6TF ],T@X[Q",G^':,VO!@A]?QZ$87^
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MU':2S;\_VQ"61,#FJO8EL<W,YV_&'YYAMA?R66T -'KAK%!S;Z-U>>/[*ML
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MNJ,Y%#DZ4&!Y%\'*?]K>]XS:D,4)J4E#:C)(ZK[_A <=;4F\427)8.Z9FJ=
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M970T-"YX;6RU6.UNHS@4?16+':U::1JP^0CI)I&:=%8[TLY,U6YG?KO@)-8
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M/X3>XY=BBR,RL]0F%H3OB37_\P\8.'_UZ7LGL".U7J76,Z'/%V1-LXQF:[#
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M6IHA\+-:QMS)P"=DA!C=<*8*B:Y9#OG? +[VJ7$,'QV;XU[$*\@&:!A^1CC
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M,@AS0.^O.5?'B2%H>GSZ!U!+ P04    "  "@GI84/$K*%T#   H#0  &0
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MLOG+[S)MM4X'M7YWM0UUL!THK-6D L5E1B2:9)_S-"<FA]\E@VM7$](F(3=
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MY[N_H1#4-W@A3V3VBW9YW\!S4+B1BJ=%L&:0QBS_I\_%1!P$X."% %($D&9
M[X4 OPCP,Z$YLTS6G"HZ'0N^0\+TUFCF(IN;+%JKB9EYC0]*Z*>QCE/3CRSD
M*:!'^@P2O4.?J1#43"QZ.P=%XT1>Z=:O#W/T]LT5>H-BAAY7?",IB^3859J
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MT#PU5W+S)ZMN*"QXL4QU^8DVVW-'$P?%N38RJX+M%61<;+_I0R7$3H ?[ G
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M'ZL55SNW8\E("5001A&';>S<^+/%4.>;A!\$&G&T1MK)AK$GO;G+8L?3@J"
M5&H&K#Y[6$!1:"(EXU?+Z70E-?!X?6"_-=Z5EPT6L&#%3Y+)/':F#LI@B^M"
M/K#F"[1^1IHO984POZBQN:.1@]):2%:V8*6@)-1^\7/;AR. /SX!"%I \!8P
M/ $(6T!HC%IEQM822YQ$G#6(ZVS%IA>F-P:MW!"J_\6UY.J4*)Q,5O@%[05:
M 3<W@J: ED2D!1,U!W2-'M=+='EQA2X0H>A[SFJ!:28B5ZK:FL%-VSIS6R<X
M4<</T#VC,A?H,\T@>TW@*M&=\N"@?!Z<95Q".D"A_P$%7A#V"%K\/3PX(R?L
M&AD:OO!?&MG7+TLW[*?3CW<F*IQ"[*C7*8#OP4G>O_/'WJ<^K_^)[)7S8>=\
M>(X]^:9FS1U-60GH\BL3XJK/K:48&0H]6?;)=3":3*>1NS_VT9?FAQ\G79I5
MZ!Y=^!+XSLP!@5)64VEO4!?M1LV->6%OXG,U@NS$^$-CY]<]YCM"!2I@JRB]
MP42)XG8FV(UDE7E6&R;5(S7+7(U1X#I!G6\9DX>-+M -YN0W4$L#!!0    (
M  *">EBYZ]L4^ ,  -,*   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM
M;+56;6_B.!#^*Z.LM&HEEH304MH"$K3=NTK;/=3V[CZ;9$BL3>*L[4#[[V_&
MAI3>T7PX:3\ 'GOF\3-O9B9;I7^8'-'"2UE49AKDUM9786B2'$MA^JK&BD[6
M2I?"DJBST-0:1>J,RB*,HV@4ED)6P6SB]I9Z-E&-+62%2PVF*4NA7Q=8J.TT
M& 3[C4>9Y98WPMFD%AD^H?VS7FJ2PA8EE2561JH*-*ZGP7QPM;AD?:?PE\2M
M.5@#>[)2Z@<+]^DTB)@0%IA81A#TL\$;+ H&(AH_=YA!>R4;'J[WZ%^=[^3+
M2AB\4<7?,K7Y-!@'D.):-(5]5-O?<>?/.>,EJC#N&[9>=TC*26.L*G?&Q*"4
ME?\5+[LX'!B,HP\,XIU!['C[BQS+6V'%;*+5%C1K$QHOG*O.FLC)BI/R9#6=
M2K*SLWL*;XH:GK5(997!7&M194AAMV826KJ!]<)DA[;P:/$':$-X4)7-#=Q5
M*:;O[4-BUM*+]_06<2?@+29]& YZ$$?QL -OV+H[='C##_".N=F#U2O<5ZG<
MR+01Q3&O/>C9<5#NFRM3BP2G 36&0;W!8/;YTV 477=0/FLIGW6ASQZ; F$0
MK<Z_# YIPSQ5M?UWD#W=;D"K&^S@==[R.N^$N=5]F M-G?6U0$N/A3Y&I1/C
M?T9NU#(<_8IDCWX!Y8N6\D5G4!^$12U% <^H2P-J?:PQCY'NAKUM-&/8'.FC
M$:'T;8K<ID!-AN6*'H%]H_6<YEH5]&2S72HU/:)*$R%-G-8R05J?",/O'UV5
M@JS U^E(?!F<K$^9.6/<O20YTX9Y8D]!^))E%'*37C/!DH#/G\9Q'%WO*MV)
MT? :OHL2050I/$M;. A^Q^F90U@6HH)YEFG,6/S>./YTJ<&$?+42#5@%*P2C
MBM2KW[W44HLWC/?%VX/;G9=P,CCUW>54]\&)+WUPX+ AXUX41?R!!Z&3'.*Q
M4SIO?6"L9PI$S0RV%+%]#*@,%_=_/,'=ST;:5U@*;2N*:@^^+?O^Y$;4TE(I
M/(A*^,3S(4CC(ILAJ=-I[0W9]PX\J0RYM)&&D_C;DG:_W?0HME0!EM43J@=-
M^?;$_MO:O:YK&?R-))EZU=)MO:GL[^\Y_#TRJ;URGE(DZY23EHL-I2T7FL2-
MLER 5 0A)2:5IE9&\O\XU&I+QEMI<YH-3$V98UMG9G8%6[QRI<FJE7(LG'_,
M[EBP.%8=33QNFWC<V6U<M\=ZM-NJZRU]1^.RI7'9">BZYAB/;K-]&QQC$!X,
M&B7JS(U3AJJGJ:R?.=K==F*;^T'E3=V/>]0OF:P,%+@FTZA_0?\4VH]07K"J
M=F/+2ED:@MPRIZD3-2O0^5HINQ?X@G:.G?T#4$L#!!0    (  *">ECWZ9Q5
M+P,  .X2   -    >&PO<W1Y;&5S+GAM;-U874_;,!3]*Y$9$T@3:9L1FM%6
MVBHA3=HF)'C8&W(;I[7DV)GCLI9?CZ^=IA_X(L;#5M8*8M_C<^ZQ?8,M!K59
M"78S9\Q$RU+(>DCFQE2?XKB>SEE)ZS-5,6F10NF2&MO5L[BN-*-Y#:12Q+U.
M)XU+RB49#>2BO"I-'4W50IHA.6]#D7]\S8>DFWXDD9<;JYP-R=W)^U\+92[?
M1?YY].'HJ'-W>KD?/W' *8F#HN<O$#WK='!A #'Q]&7BSVECTA>[TF[XL17R
MQ&.,U@_0;)8-$SJ.'#>;,AH42F[V)B$^8-5IR:)[*H9D3 6?: ZL@I9<K'RX
M!X&I$DI'QA:%3=>%2/W@X:[O0;TT.B672KO</H/_/6F&[P'K'ACD0K0&>\0'
M1H.*&L.TO+(=-]@%GT!1T[Y=5=;A3--5MW=.-@3WL$DF2N=,MVFZ9!T:#00K
MP([FLSD\C:IB (U1I6WDG,Z4I,[#FM$TK.R4"7$#+]//8D=[66SM6P=V3;9-
M:ZAI>AG? ?UM-:^]+=M[E6Y4\7MEOBSL=*3K0X&R:\T*OG3]9=$:P-2[N#JM
M*K'Z+/A,ELQ/_L4)1P.ZYD5SI?F#S0:E,K4!IDETS[3AT^W(;TVK6[8TZW):
M%KCGWAOT_'?7><8DTU1LF[:U?\BK_&K'S>GS+SR[/RO[CH,FDXO#]]B<N(=N
M,GT+)M_$=O</WV22':3'N#F_MRX).U>$-AK!56Q(?L#%3FR21I,%%X;+IC?G
M><[DDYN"E3=T8B_S._IV?,X*NA#FM@6'9-/^SG*^*+-VU#4L1#-JT_X&T^NF
M[3W0YN(R9TN6CYNNGDU<,[(-F[7Y &$?N7*?,()Q/!9& ,/R8 XPCF=A>?ZG
M^?31^7@,\]8/(GV4TT<YGA5"QNZ+Y0ES,OL)SS3+DB1-L14=CX,.QMBZI2G\
MA-4P;\# \D"F/UMK?+?Q"GF^#K ]?:Y"L)GBE8C-%%]K0,+K!HPL"^\VE@<8
MV"Y@M0/YPWF@IL*<)(%=Q;QA;S".9!F&0"V&:S1-D=5)X1O>'^PM29(L"R.
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VCM.PT 4A>&M1%X
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @  H)Z6+=_B2[O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M H)Z6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  "@GI84ML*BZ@'   C,@  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M H)Z6*2@/MB_!0  N!@  !@              ("![ \  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    (  *">EC0,RW;W@(  /\)   8
M          " @>$5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  "@GI8#WW9SI<$  !X$   &               @('U&   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @  H)Z6*+,B_:U"   )6,
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M965T.2YX;6Q02P$"% ,4    "  "@GI8<7B(- @#  !:"P  &0
M    @('Z50  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M  *">E@<MV;0U (  #X'   9              " @3E9  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @  H)Z6#L%;*25 @  ,@8  !D
M             ("!1%P  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  "@GI8TI,0S=D"  !I!@  &0              @($07P  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  *">E@>N]3=@P8
M "P2   9              " @2!B  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @  H)Z6,!FRQZ^!0  H X  !D              ("!
MVF@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  "@GI8
M\=0Z9=4-   =*P  &0              @('/;@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    (  *">EBO,'STQ (  &<&   9
M      " @=M\  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @  H)Z6'!GY0 + P  $P<  !D              ("!UG\  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  "@GI8G*:*#KP+   :(P
M&0              @($8@P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    (  *">EBMI&.EL0,  +\(   9              " @0N/  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @  H)Z6&T."-E5
M&P  *U<  !D              ("!\Y(  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    "  "@GI8;=OYI_("  #&"   &0
M@(%_K@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  *"
M>E@+(M&VW@(  (L*   9              " @:BQ  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @  H)Z6&H"6%1\ @  %08  !D
M         ("!O;0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    "  "@GI8=G/YR9$"   (!@  &0              @(%PMP  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  *">EB]>QLQGP,  -T*
M   9              " @3BZ  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @  H)Z6%=JP(<+!0  P@\  !D              ("!#KX
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  "@GI81 Z&
M''T"  "V!0  &0              @(%0PP  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    (  *">EAW ";R9 0  .$,   9
M  " @03&  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M H)Z6'?)=D">!P  ,4H  !D              ("!G\H  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    "  "@GI8O7NP1Q4$  #2$   &0
M            @(%TT@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    (  *">EAEO(-;'00  *T8   9              " @<#6  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @  H)Z6(9+C<(Z P
M+P\  !D              ("!%-L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    "  "@GI8G)7AT3P#  !(#0  &0              @(&%
MW@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  *">ECB
MPUTDD@(  /D&   9              " @?CA  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @  H)Z6+U\=G4B!   7QL  !D
M     ("!P>0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  *">EAF+7TCW08  .LS   9              "
M@??V  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @  H)Z
M6$$>;%/U P  &Q4  !D              ("!"_X  'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    "  "@GI88&3CV7H#  "6#   &0
M        @($W @$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   (  *">EC:H=TLDP0  "05   9              " @>@% 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @  H)Z6&ITT< 9!   ZA$
M !D              ("!L@H! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    "  "@GI87YBZP+4"  #O!P  &0              @($"#P$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  *">EA0\2LH
M70,  "@-   9              " @>X1 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @  H)Z6 3&X-?U @  50L  !D
M ("!@A4! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  "
M@GI8$1>;AY8"  "J!@  &0              @(&N& $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  *">EAK%8"1?0(  +D&   9
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M970U-"YX;6Q02P$"% ,4    "  "@GI8C<M</$H"  "D!0  &0
M    @(%_+P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M  *">EBYZ]L4^ ,  -,*   9              " @0 R 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @  H)Z6/?IG%4O P  [A(   T
M             ( !+S8! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  "@GI8
MEXJ[',     3 @  "P              @ &).0$ 7W)E;',O+G)E;'-02P$"
M% ,4    "  "@GI8==\3\:X$  !R)0  #P              @ %R.@$ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @  H)Z6 P_D/SE 0  ?R$  !H
M         ( !33\! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @  H)Z6(_AMVG3 0  -B$  !,              ( !:D$! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $  0 !W$0  ;D,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>110</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of Business and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition</Role>
      <ShortName>Description of Business and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Equity-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Equity-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureEquityBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of Business and Financial Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails</Role>
      <ShortName>Description of Business and Financial Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impact of Adoption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments and Contingencies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Term And Discount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders' Equity - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Equity-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails</Role>
      <ShortName>Equity-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails</Role>
      <ShortName>Equity-based Compensation - Fair value of options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Equity-based Compensation - Activity for options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails</Role>
      <ShortName>Equity-based Compensation - Activity for options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Equity-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Equity-based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Equity-based Compensation - Compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails</Role>
      <ShortName>Equity-based Compensation - Compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails</Role>
      <ShortName>Net Loss per Share - Antidilutive effect (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureRetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureRetirementPlan</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes - Net loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails</Role>
      <ShortName>Income Taxes - Net loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cgtx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgtx-20231231.xsd</File>
    <File>cgtx-20231231_cal.xml</File>
    <File>cgtx-20231231_def.xml</File>
    <File>cgtx-20231231_lab.xml</File>
    <File>cgtx-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cgtx-20231231x10k.htm">cgtx-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cgtx-20231231x10k001.jpg</File>
    <File>cgtx-20231231x10k002.jpg</File>
    <File>cgtx-20231231x10k003.jpg</File>
    <File>cgtx-20231231x10k004.jpg</File>
    <File>cgtx-20231231x10k005.jpg</File>
    <File>cgtx-20231231x10k006.jpg</File>
    <File>cgtx-20231231x10k007.jpg</File>
    <File>cgtx-20231231x10k008.jpg</File>
    <File>cgtx-20231231x10k009.jpg</File>
    <File>cgtx-20231231x10k010.jpg</File>
    <File>cgtx-20231231x10k011.jpg</File>
    <File>cgtx-20231231x10k012.jpg</File>
    <File>cgtx-20231231x10k013.jpg</File>
    <File>cgtx-20231231x10k014.jpg</File>
    <File>cgtx-20231231x10k015.jpg</File>
    <File>cgtx-20231231x10k016.jpg</File>
    <File>cgtx-20231231x10k017.jpg</File>
    <File>cgtx-20231231x10k018.jpg</File>
    <File>cgtx-20231231x10k019.jpg</File>
    <File>cgtx-20231231x10k020.jpg</File>
    <File>cgtx-20231231x10k021.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="467">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cgtx-20231231x10k.htm": {
   "nsprefix": "cgtx",
   "nsuri": "http://www.cogrx.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cgtx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cgtx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgtx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cgtx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgtx-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cgtx-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 254,
   "keyCustom": 32,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 18,
   "hidden": {
    "total": 23,
    "http://fasb.org/us-gaap/2023": 18,
    "http://xbrl.sec.gov/ecd/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 110,
   "entityCount": 1,
   "segmentCount": 43,
   "elementCount": 525,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 467,
    "http://xbrl.sec.gov/dei/2023": 37,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:GrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition",
     "longName": "10101 - Disclosure - Description of Business and Financial Condition",
     "shortName": "Description of Business and Financial Condition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements",
     "longName": "10301 - Disclosure - Financial Instruments and Fair Value Measurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipment",
     "longName": "10401 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpenses",
     "longName": "10501 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities",
     "longName": "10601 - Disclosure - Other Current Liabilities",
     "shortName": "Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "cgtx:OtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "cgtx:OtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "10701 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cogrx.com/role/DisclosureStockholdersEquity",
     "longName": "10801 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensation",
     "longName": "10901 - Disclosure - Equity-based Compensation",
     "shortName": "Equity-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShare",
     "longName": "11001 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cogrx.com/role/DisclosureRetirementPlan",
     "longName": "11101 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxes",
     "longName": "11201 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cogrx.com/role/DisclosureSubsequentEvents",
     "longName": "11301 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables",
     "longName": "30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables",
     "longName": "30403 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesTables",
     "longName": "30503 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "30703 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables",
     "longName": "30903 - Disclosure - Equity-based Compensation (Tables)",
     "shortName": "Equity-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareTables",
     "longName": "31003 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesTables",
     "longName": "31203 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
     "longName": "40101 - Disclosure - Description of Business and Financial Condition (Details)",
     "shortName": "Description of Business and Financial Condition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_12_23_2022_vzbl8zprq0ijwIokKFM6sA",
      "name": "cgtx:MaximumAggregateOfferingPrice",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "cgtx:AllowanceForCreditLossGrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "cgtx:AllowanceForCreditLossGrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption (Details)",
     "shortName": "Summary of Significant Accounting Policies - Impact of Adoption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails",
     "longName": "40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
     "longName": "40401 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails",
     "longName": "40501 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails",
     "longName": "40601 - Disclosure - Other Current Liabilities (Details)",
     "shortName": "Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_x_Z7jkOkrUCdh_AMcj9ldw",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cgtx:OtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_x_Z7jkOkrUCdh_AMcj9ldw",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cgtx:OtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
     "longName": "40701 - Disclosure - Commitments and Contingencies - Leases (Details)",
     "shortName": "Commitments and Contingencies - Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "cgtx:OperatingLeaseAssets",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "cgtx:OperatingLeaseAssets",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "40702 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails",
     "longName": "40703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)",
     "shortName": "Commitments and Contingencies - Lease Term And Discount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails",
     "longName": "40704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
     "longName": "40801 - Disclosure - Stockholders' Equity - (Details)",
     "shortName": "Stockholders' Equity - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:DividendsCommonStock",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
     "longName": "40901 - Disclosure - Equity-based Compensation (Details)",
     "shortName": "Equity-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_uguCNEEtGkiIZdHpBUsd8w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_uguCNEEtGkiIZdHpBUsd8w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
     "longName": "40902 - Disclosure - Equity-based Compensation - Fair value of options (Details)",
     "shortName": "Equity-based Compensation - Fair value of options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
     "longName": "40903 - Disclosure - Equity-based Compensation - Activity for options (Details)",
     "shortName": "Equity-based Compensation - Activity for options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
     "longName": "40904 - Disclosure - Equity-based Compensation - Additional Information (Details)",
     "shortName": "Equity-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
     "longName": "40905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)",
     "shortName": "Equity-based Compensation - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails",
     "longName": "40906 - Disclosure - Equity-based Compensation - Compensation expense (Details)",
     "shortName": "Equity-based Compensation - Compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails",
     "longName": "41001 - Disclosure - Net Loss per Share - Antidilutive effect (Details)",
     "shortName": "Net Loss per Share - Antidilutive effect (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cogrx.com/role/DisclosureRetirementPlanDetails",
     "longName": "41101 - Disclosure - Retirement Plan (Details)",
     "shortName": "Retirement Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails",
     "longName": "41201 - Disclosure - Income Taxes - Net loss (Details)",
     "shortName": "Income Taxes - Net loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails",
     "longName": "41202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)",
     "shortName": "Income Taxes - Reconciliation of income tax benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "41204 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41301 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_YVGucSObRUi_kS5-NUT2_g",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mUz7VNnd5EuqjwdONSKJpQ",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "cgtx_AaronFletcherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "AaronFletcherMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information relating to Aaron Fletcher.",
        "label": "Aaron Fletcher [Member]",
        "terseLabel": "Dr. Aaron Fletcher"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASU 2016-02",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r602"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "cgtx_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r139",
      "r485"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r85",
      "r145",
      "r481",
      "r500",
      "r504"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10",
      "r30",
      "r399",
      "r402",
      "r457",
      "r495",
      "r496",
      "r709",
      "r710",
      "r711",
      "r719",
      "r720",
      "r721"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r602",
      "r793"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r514",
      "r719",
      "r720",
      "r721",
      "r771",
      "r794"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r173",
      "r174",
      "r175",
      "r176",
      "r187",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r233",
      "r344",
      "r345",
      "r346",
      "r373",
      "r374",
      "r375",
      "r376",
      "r386",
      "r387",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r468",
      "r469",
      "r470",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r307"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance of common stock, discounts and offering costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r103"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r636",
      "r646",
      "r672"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r639",
      "r649",
      "r675"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r640",
      "r650",
      "r667",
      "r676",
      "r680",
      "r688"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total equity-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r351"
     ]
    },
    "cgtx_AllowanceForCreditLossGrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "AllowanceForCreditLossGrantsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on grants receivable, classified as current.",
        "label": "Allowance for Credit Loss, Grants Receivable, Current",
        "terseLabel": "Allowance for doubtful accounts on grants receivable"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_AmendedAndRestatedEquityIncentivePlan2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "AmendedAndRestatedEquityIncentivePlan2017Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan.",
        "label": "Amended and Restated 2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive common stock equivalents outstanding",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r141",
      "r164",
      "r202",
      "r212",
      "r214",
      "r219",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r390",
      "r392",
      "r422",
      "r476",
      "r538",
      "r602",
      "r614",
      "r736",
      "r737",
      "r781"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r147",
      "r164",
      "r219",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r390",
      "r392",
      "r422",
      "r602",
      "r736",
      "r737",
      "r781"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "cgtx_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to at the market offering.",
        "label": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r632"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r632"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r632"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Financial Condition",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r94",
      "r95"
     ]
    },
    "cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "CantorFitzgeraldAndCoAndBRileySecuritiesIncMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc.",
        "label": "Cantor Fitzgerald And Co and B Riley Securities Inc",
        "terseLabel": "Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r137",
      "r579"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents-end of period",
        "periodStartLabel": "Cash and cash equivalents-beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r91",
      "r161"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r91"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "verboseLabel": "Stockholders' Equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r201",
      "r270",
      "r271",
      "r272",
      "r274",
      "r277",
      "r282",
      "r284",
      "r508",
      "r509",
      "r510",
      "r511",
      "r594",
      "r696",
      "r715"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r69",
      "r478",
      "r525"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r235",
      "r236",
      "r576",
      "r733"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r719",
      "r720",
      "r771",
      "r791",
      "r794"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r526"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r79",
      "r526",
      "r544",
      "r794",
      "r795"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 250,000,000 shares authorized; 32,165,478 and 28,991,548 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r480",
      "r602"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r150",
      "r152",
      "r158",
      "r472",
      "r489"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r121"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r255",
      "r272",
      "r458",
      "r581",
      "r583"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r76",
      "r77",
      "r112",
      "r113",
      "r169",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r438",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r716"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r252",
      "r438",
      "r590",
      "r591"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r253"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "verboseLabel": "Other Current Liabilities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r438",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r716"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r169",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r438",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r716"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Periodic payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r71"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r49",
      "r52",
      "r66",
      "r67",
      "r68",
      "r70",
      "r101",
      "r102",
      "r169",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r438",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r716"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "cgtx_DeferredGrantIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "DeferredGrantIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of deferred grant income as at the end of the reporting period.",
        "label": "Deferred Grant Income, Current",
        "terseLabel": "Deferred grant income, current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense (benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r109",
      "r127",
      "r379",
      "r380",
      "r718"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r477"
     ]
    },
    "cgtx_DeferredOfferingCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "DeferredOfferingCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred offering costs included in accounts payable.",
        "label": "Deferred Offering Costs Included In Accounts Payable",
        "terseLabel": "Deferred offering costs included in Accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRentCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r778"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "verboseLabel": "Deferred grant income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r769"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expenditures",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r769"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets after valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "cgtx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities",
        "label": "Deferred tax assets operating lease liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r769"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r769"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r769"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r769"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.",
        "label": "Deferred Tax Liabilities, Operating Lease, Right Of Use Asset",
        "negatedLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment, net",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r769"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Matching contributions to the plan",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum percentage of employees' compensation per person per year matched by the Company",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r203"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r792"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r309",
      "r340",
      "r341",
      "r343",
      "r599"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividend declared",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r103"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r632"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r632",
      "r668"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r193",
      "r194",
      "r195",
      "r199",
      "r415",
      "r416",
      "r473",
      "r490",
      "r584"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r180",
      "r181",
      "r183",
      "r191",
      "r193",
      "r194",
      "r195",
      "r199",
      "r415",
      "r416",
      "r473",
      "r490",
      "r584"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r196",
      "r197",
      "r198"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate (as percentage)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory rate (as percentage)",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r361",
      "r382"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance (as percentage)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r770"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other (as percentage)",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Non-deductible stock compensation (as percentage)",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r767"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit (as percentage)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r770"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "R&amp;D Credit (as percentage)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r770"
     ]
    },
    "cgtx_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for emerging growth company status.",
        "label": "Emerging Growth Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_EmployeeDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "EmployeeDirectorMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of employee directors.",
        "label": "Employee Director [Member]",
        "terseLabel": "Employee Director"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation, benefits, and related accruals",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which the unrecognized compensation cost is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Employee Stock Purchase Plan.",
        "label": "ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r131",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r174",
      "r184",
      "r186",
      "r200",
      "r223",
      "r229",
      "r285",
      "r344",
      "r345",
      "r346",
      "r375",
      "r376",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r414",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r457",
      "r495",
      "r496",
      "r497",
      "r514",
      "r564"
     ]
    },
    "cgtx_EquityIncentivePlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "EquityIncentivePlan2021Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".Represents information relating to 2021 Equity Incentive Plan.",
        "label": "2021 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_EquityLineFinancingCommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "EquityLineFinancingCommitmentSharesMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to commitment shares for equity line financing.",
        "label": "Equity Line Financing Commitment Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_EquityLineFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "EquityLineFinancingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to equity line financing.",
        "label": "Equity Line Financing"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r636",
      "r646",
      "r672"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r633",
      "r643",
      "r669"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Financial Instruments and Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of financial assets and liabilities measured at fair value",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r419",
      "r462",
      "r463",
      "r464",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quoted Priced in Active Markets (Level 1)",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r289",
      "r294",
      "r419",
      "r462",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Unobservable Inputs (Level 3)",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r419",
      "r464",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r462",
      "r463",
      "r464",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r16"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to follow on pubic offering.",
        "label": "Follow-on Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r640",
      "r650",
      "r676"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r548"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "cgtx_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "GrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to grants.",
        "label": "Grant Income",
        "terseLabel": "Grant income",
        "verboseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_GrantIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "GrantIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant income.",
        "label": "Grant Income, Policy [Policy Text Block]",
        "terseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable, Current",
        "terseLabel": "Grant receivables",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r381"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r381"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r234",
      "r549"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r549"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r354",
      "r362",
      "r365",
      "r371",
      "r377",
      "r383",
      "r384",
      "r385",
      "r513"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r128",
      "r185",
      "r186",
      "r204",
      "r360",
      "r378",
      "r491"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r356",
      "r357",
      "r365",
      "r366",
      "r370",
      "r372",
      "r507"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "IncreaseDecreaseInDeferredGrantIncomeCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current deferred grant income.",
        "label": "Increase (Decrease) In Deferred Grant Income, Current",
        "terseLabel": "Deferred grant income and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_IncreaseDecreaseInGrantReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "IncreaseDecreaseInGrantReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase and decrease in grant receivables.",
        "label": "Increase (Decrease) In Grant Receivables",
        "negatedLabel": "Grant receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Shareholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r640",
      "r650",
      "r667",
      "r676",
      "r680",
      "r688"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r692"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r692"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r692"
     ]
    },
    "cgtx_InsurancePremiumFinancingAgreement2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "InsurancePremiumFinancingAgreement2Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to insurance premium financing agreement 2.",
        "label": "Insurance Premium Financing Agreement 2"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_InsurancePremiumFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "InsurancePremiumFinancingAgreementMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to insurance premium financing agreement.",
        "label": "Insurance Premium Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of adjustments relating to commitment shares issued for equity line financing.",
        "label": "Issuance of Common Stock as Commitment Shares For Equity Line Financing",
        "terseLabel": "Issuance of common stock as commitment shares for equity line financing"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_LaboratoryAndOfficeSpacePittsburghPaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "LaboratoryAndOfficeSpacePittsburghPaMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to laboratory and office space in Pittsburgh, PA.",
        "label": "Laboratory And Office Space, Pittsburgh, PA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "LegalReservesProfessionalFeesAndOtherAccrualsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal reserves, professional fees and other accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Legal Reserves, Professional Fees and Other Accruals, Current",
        "verboseLabel": "Professional fees and other accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of minimum lease commitments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of buyout options in dollars in an operating lease under the lessee.",
        "label": "Lessee, Operating Lease, Number of Buyout Options in Dollars",
        "terseLabel": "Number of option at conclusion of the lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r164",
      "r219",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r391",
      "r392",
      "r393",
      "r422",
      "r524",
      "r585",
      "r614",
      "r736",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r114",
      "r483",
      "r602",
      "r717",
      "r729",
      "r773"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r136",
      "r164",
      "r219",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r391",
      "r392",
      "r393",
      "r422",
      "r602",
      "r736",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_LincolnParkCapitalFundLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "LincolnParkCapitalFundLlcMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Lincoln Park Capital Fund, LLC.",
        "label": "Lincoln Park Capital Fund LLC",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r242",
      "r734",
      "r735"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r242",
      "r734",
      "r735"
     ]
    },
    "cgtx_MaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "MaximumAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r304",
      "r466",
      "r492",
      "r516",
      "r517",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r577",
      "r578",
      "r588",
      "r594",
      "r598",
      "r603",
      "r738",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "cgtx_MaximumValueOfStockToBeIssuedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "MaximumValueOfStockToBeIssuedUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum equity impact of the value of new stock to be issued under an agreement.",
        "label": "Maximum Value Of Stock To Be Issued Under Agreement",
        "terseLabel": "Maximum value of stock to be issued under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r304",
      "r466",
      "r492",
      "r516",
      "r517",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r577",
      "r578",
      "r588",
      "r594",
      "r598",
      "r603",
      "r738",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r93",
      "r115",
      "r134",
      "r148",
      "r151",
      "r156",
      "r164",
      "r173",
      "r177",
      "r178",
      "r180",
      "r181",
      "r185",
      "r186",
      "r192",
      "r202",
      "r211",
      "r213",
      "r215",
      "r219",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r416",
      "r422",
      "r487",
      "r546",
      "r562",
      "r563",
      "r586",
      "r612",
      "r736"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_NonEmployeeDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "NonEmployeeDirectorMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of non employee directors.",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non Employee Director"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r640",
      "r650",
      "r667",
      "r676"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "cgtx_OfficeSpaceLocatedInPittsburghPaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "OfficeSpaceLocatedInPittsburghPaMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to office space located in Pittsburgh, Pennsylvania.",
        "label": "Office Space located In Pittsburgh, PA"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_OfficeSpaceNewYorkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "OfficeSpaceNewYorkMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to New York office space.",
        "label": "Office Space, New York"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r211",
      "r213",
      "r215",
      "r586"
     ]
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLossAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss) [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_OperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "OperatingLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating lease assets as at the end of the reporting period.",
        "label": "Operating Lease Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease costs",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Minimum lease commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent",
        "verboseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r448"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases",
        "totalLabel": "Total operating lease assets",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r601"
     ]
    },
    "cgtx_OperatingLossCarryForwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "OperatingLossCarryForwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating loss carryforwards that are not subject to expiration dates.",
        "label": "Operating Loss Carry forwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards that do not expire"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_OperatingLossCarryForwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "OperatingLossCarryForwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating loss carryforwards that are subject to expiration dates.",
        "label": "Operating Loss Carry forwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards that expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Financial Condition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r140",
      "r475",
      "r614"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other comprehensive (loss) gain related to foreign currency translation",
        "verboseLabel": "Unrealized gain (loss) on foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss)",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r15",
      "r149",
      "r152",
      "r157",
      "r428",
      "r429",
      "r434",
      "r471",
      "r488",
      "r709",
      "r710"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_OtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "OtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r602"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Deferred grant income and other liabilities, noncurrent",
        "verboseLabel": "Deferred grant income, noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "terseLabel": "Other expense, net",
        "verboseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r638",
      "r648",
      "r674"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r641",
      "r651",
      "r677"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r641",
      "r651",
      "r677"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Payments for property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r597"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r270"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r526"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r270"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r526",
      "r544",
      "r794",
      "r795"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r479",
      "r602"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r230",
      "r231",
      "r580"
     ]
    },
    "cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "PrepaymentOfInsuranceThroughThirdPartyFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment of insurance through third-party financing.",
        "label": "Prepayment of Insurance Through Third Party Financing",
        "terseLabel": "Prepayment of insurance through third-party financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cgtx_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering, Gross",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r122",
      "r125",
      "r126"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r138",
      "r486"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "verboseLabel": "Property and Equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r474",
      "r486",
      "r602"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r122",
      "r125",
      "r484"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life of property and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_PurchaseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "PurchaseAgreementTerm",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Purchase Agreement, Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r287",
      "r304",
      "r335",
      "r336",
      "r337",
      "r465",
      "r466",
      "r492",
      "r516",
      "r517",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r577",
      "r578",
      "r588",
      "r594",
      "r598",
      "r603",
      "r606",
      "r732",
      "r738",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r287",
      "r304",
      "r335",
      "r336",
      "r337",
      "r465",
      "r466",
      "r492",
      "r516",
      "r517",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r577",
      "r578",
      "r588",
      "r594",
      "r598",
      "r603",
      "r606",
      "r732",
      "r738",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r633",
      "r643",
      "r669"
     ]
    },
    "cgtx_RemainingValueOfStockToBeIssuedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "RemainingValueOfStockToBeIssuedUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining value of new stock to be issued under an agreement.",
        "label": "Remaining Value Of Stock To Be Issued Under Agreement",
        "terseLabel": "Amount available to draw under purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebtMaturingInMoreThanThreeMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt, Maturing in More than Three Months",
        "terseLabel": "Repayment of short-term loan",
        "documentation": "The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months. Includes repayments of short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Payments on loan payable",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r255",
      "r272",
      "r458",
      "r582",
      "r583"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc3": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r353",
      "r789"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "cgtx_ResearchAndDevelopmentTaxCreditCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of federal research and development tax credit carry forwards.",
        "label": "Research and Development Tax Credit Carry Forwards",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r183",
      "r184",
      "r199",
      "r414",
      "r415",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r706",
      "r707"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r199",
      "r224",
      "r225",
      "r376",
      "r410",
      "r414",
      "r415",
      "r416",
      "r443",
      "r456",
      "r457",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r634",
      "r644",
      "r670"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r635",
      "r645",
      "r671"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r642",
      "r652",
      "r678"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r199",
      "r224",
      "r225",
      "r376",
      "r410",
      "r414",
      "r415",
      "r416",
      "r443",
      "r456",
      "r457",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r103",
      "r482",
      "r499",
      "r504",
      "r512",
      "r527",
      "r602"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r170",
      "r171",
      "r172",
      "r174",
      "r184",
      "r186",
      "r223",
      "r229",
      "r344",
      "r345",
      "r346",
      "r375",
      "r376",
      "r397",
      "r400",
      "r401",
      "r404",
      "r414",
      "r495",
      "r497",
      "r514",
      "r794"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Remeasurement of right-of-use asset and operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r601"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r170",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r186",
      "r199",
      "r376",
      "r410",
      "r414",
      "r415",
      "r443",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r702",
      "r704",
      "r705",
      "r706",
      "r722",
      "r730",
      "r731",
      "r772",
      "r779",
      "r780"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding potentially dilutive common stock",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of net loss components",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the expected income tax (benefit)",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of total equity-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Summary of Impact of Adoption of ASC 842",
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r39",
      "r40"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock units award activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of activity for options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of options granted using the Black-Scholes option pricing model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r101",
      "r102",
      "r103",
      "r142",
      "r143",
      "r144",
      "r201",
      "r270",
      "r271",
      "r272",
      "r274",
      "r277",
      "r282",
      "r284",
      "r508",
      "r509",
      "r510",
      "r511",
      "r594",
      "r696",
      "r715"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r216",
      "r587"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSU activity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Equity based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issuable for each award under share-based payment arrangement.\n\n\n\n\n\n\n\n\n\n\n\n\nShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Issuable for Each Award",
        "terseLabel": "Number of shares issuable for each award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of options exercised during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value",
        "terseLabel": "Fair value of options exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options expired (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of options granted during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value",
        "terseLabel": "Fair value of options granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum percentage of common shares issued and outstanding",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number",
        "terseLabel": "Number of shares that may be recycled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r313",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Fair value of common stock (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value - Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life -Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "SharesOfferingAgreementRemainingValueOfStockToBeIssued",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining value of stock to be issued under shares offering agreement.",
        "label": "Shares Offering Agreement, Remaining Value of Stock to be Issued",
        "terseLabel": "Remaining of common stock available for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt",
        "terseLabel": "Short-term loan",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r112",
      "r602",
      "r790"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r162"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r28",
      "r131",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r174",
      "r184",
      "r186",
      "r200",
      "r223",
      "r229",
      "r285",
      "r344",
      "r345",
      "r346",
      "r375",
      "r376",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r414",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r457",
      "r495",
      "r496",
      "r497",
      "r514",
      "r564"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r200",
      "r467",
      "r506",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r607"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r200",
      "r467",
      "r506",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r607"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r637",
      "r647",
      "r673"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r103",
      "r508",
      "r564",
      "r574"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Options exercised (in shares)",
        "verboseLabel": "Exercise of common stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r103",
      "r319"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r103",
      "r514",
      "r564",
      "r574",
      "r613"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r28",
      "r103"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued and outstanding",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r96",
      "r528",
      "r544",
      "r565",
      "r566",
      "r602",
      "r614",
      "r717",
      "r729",
      "r773",
      "r794"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r163",
      "r269",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r285",
      "r405",
      "r567",
      "r568",
      "r575"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r461"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Description of Business and Financial Condition",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r173",
      "r174",
      "r175",
      "r176",
      "r187",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r233",
      "r344",
      "r345",
      "r346",
      "r373",
      "r374",
      "r375",
      "r376",
      "r386",
      "r387",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r468",
      "r469",
      "r470",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "cgtx_UnderwritersOptionToPurchaseAdditionalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "UnderwritersOptionToPurchaseAdditionalShares",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters option to purchase additional shares.",
        "label": "Underwriters, Option To Purchase Additional Shares",
        "terseLabel": "Additional shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "UnderwritingAgreementWithTitanPartnersGroupLlcMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to underwriting agreement with Titan Partners Group LLC.",
        "label": "Underwriting Agreement With Titan Partners Group LLC"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20231231",
     "localname": "UnderwritingDiscountsCommissionsAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of underwriting discounts, commissions and offering expenses.",
        "label": "Underwriting Discounts, Commissions And Offering Expenses",
        "terseLabel": "Offering expenses payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized income tax",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r363"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "terseLabel": "Federal net operating loss carryforwards",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r119",
      "r120",
      "r123",
      "r124"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r195"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-12"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001558370-24-003949-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-003949-xbrl.zip
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MO<6^9% N@]$(Z'F5Z-Q\,;WZYZ?I9#BZFW^/1O_Z?+WXO07U":"6K:Y5I!3
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MJ1/+R\:HF,&(UX]IO K>2-6"5S6FE V<F=@(VKLT:(;-Y2U@90--V4!E$YD
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MBU%O[&)A;W"Z7\M,_6M+M3YBID^*?/PO4$L#!!0    (  "">EC4!$.C8 X
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M6C[ 5E7CR@E8-?7G!4(ZYQRBYD*)D74 @JY41<0=C%!N3TTT.(!U8>E=5<3
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MG>H $@;=!?(2QG9A(1YI,J!V]]Y5E@_-U5J1,Z#5$T[RGR'[]K18C:EMPRO
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M2JB''AQ.[F[?C#'18)^D_<%6^Y'@9"78EE6-R#)/"T6(S.)M/U3C;>FX@\W
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M-H9P-L<\Z-E6?C)CZ$ON5>MT!& V#752 RDXO..7&Z0X;@)BT76"%+?CS88
M$"PTXZ<9>G XRY/#O)QD ?8'NB1,WU#P*H]>U1\.P-:@CI2K=%H/^<.3AW\@
MATS?<$,QR$<!L!#WQ?T<YP-E.@O0ML'V;!P "W>OC,^P/DS6CW$BREPQ'P;
M"M\GXS.D#Y3O_FL;&I\- ^# L5>^IT@?'M^'LQB1EIB_-Q: (\N^)& /\\,3
M@X:<[Y?9@J>Z^V+VP?#W2^CY4?K $?)NWEW:5)I(5W.L/CDO>&V[4\Z+,8<C
M!@+0C4(TZWY9*7C-NBDKA;C!8=:0(&<R>T).<),^TK@]AQ%P2]P<@(ME%CP3
MHV+G,>H8N[\O<$ 1C-CA5[PV2_SYL7J1M3CDOPVR0>G7X#-^=B5;4@RNUJ/
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M<X]643H]A#!B_W(H)<FW)(7]V4/I]!!BAT"D\"NWA=L58'L?E.'<YW)<GA?
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M?$7$F:/TQVLG1GEXJFVIK L%A)056(G2=2D)+&3=&NJ_$!RU;D1E,T'(C#D
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M)?TK*FRH1+I\1MJ[C.]/?\@&^@!$?)_<WX*$4T+/D!_OCMMZ%W(.!(><'G0
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M1=N+Q>I(VUYS )F<1IP2(M)UVD-NH*D9SDI13/'CUOOU/#^;*Q,9Z<JFU1]
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MEF1T[1YXCZWD5M"U%'WQCGJ'.*,VA;(]^AC4:[H7AO+&J".Q0>0>?@J4B6R
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MJZ&J:(HW2IL$[NRMMS</M]=7Y\O'BW/R\,C^\^'BYO&!W%Z2V[N+^^7C%6M
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M9)STHH8\)648W;H&$#QAP18 NY"GC3F5?0-]Y?$LUQ)) 7*[-JP>+%<+E3(
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M&IJ.<8>BC1.11[%@[6'P(0CCG1<.JU[W.$W<V-_F3V2?[A(VS4J2ZM:@$S!
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M/N4[A>+I0I(R:[YYRA#>+GSEK[(Q0RWY-:%EV",3ORVUN8!6)RO)\:H5J3E
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MRL"7/R#1NO.L0U_RA$2[GK,/_J$>DQ@J^LE[;/$_E(6, (!8>8JC6B/@&CA
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M,)$-Q-L!M!K[MA.UC8"QR&OC!S<)5Z/Z=P#'FRC].TU+V'R ,M'924X?4!Z
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MS3(,=W!P4?X1C)6?@+ ?7:H$O6$HXX:\ :U7!;P!R.*%NR&5ZQJBF0RDRH>
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M3A%T[22R"IFO[[[;=-_:I .%!%'\.=MQ2)4#K7T%?+!CM"QQ7"]&PQ?<SN?
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M81O"VK</-W0;0*]D##M:P#5K5YGLH;EG"$)I\V@A@%/6IE0-/G!3X0!8($:
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M_$ IG22,6N;1I E@LR*NMC+,(!-S#>V7,X\,?!!E.1O5.-:ND1K_0L)@"C!
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MFDC-N#ND3<'$#7P\UT[FVT_,3E&S9-&"JW/A%E6S$@Q-T0R%'.RF>C!NYW.
M-Q8[JS%%:S^\%/-MUW-W;EN!5;-PDP:Q31)X4YT1>3HF))=Q&(+DF*5YF()0
M:V4Y?QD\'+$%R=KC[L5#T-4"YP:$-G37Z<+N*@Y='X1)_'(>:GP=^(Z+_WP#
M(LOU^!9 9T<U3Y(4NL(7*?+.TOCE;63SMK_1OV<]*KM(FL"%A?;8B?#19X>!
MYSKYJQ9/!<44;I+/T&\ SWF4E+8'6'C%+R':2N ;.3 ]8?P&HF7@W/NO((P
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MF3+Z)GE &VU_W,!)ESF/X&?R)^()-%?ELA@OD1@OM".)!,0Y<8QY+>H)!C8
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MB] V$]\L\@I&JP7Y2$T>!.N$P)NUAN$1S_42)R*Y]V\R?*C0. Q!%.+,(=M
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M.WXEX\%:A_C!S_7:<VWLVDISF:-?/;@K-Z+FS>N@)_,HVK>PVMZ>&_01+;1
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MWN0B32RZNY(+MOF!<66,5%PUNL@[/*1#[" BMN]4$H']^WT8QL"YB;&?Y0E
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MD?)61.[WC%;2&N1/ABDC5BC19N6(J-,_!A7?BA+2\U%">O? P/-PH$YM M)
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M'@I%>G;1S3T,&Y&SQM&P5913]WO'Z_QN&('5+>5_;EG>+G=U[U+E. JTWX@
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M'L;M&+$P^UYP(YJ^FVU3"VXOQ7BML022VI2'9;NHMK-1O;[R!NO[HS*N$)@
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M'>P#]ZO$/=J/R2=6&:A2Z]MRKK!A5*B)%4&[\3I3>.UF#/.1E"?7%;DAG^J
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M..BSXHTX/>X=2%T)A$),5&5&,"#(;J9ON%DL\ ;L4<_C+W[SE[EO;3-*<*R
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M; T2TNRGT&S>T#%KV/13V(,]ZCAY&E/0DZR^.N9J$]Z@J":5_<,$>4 #=!_
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M9T.S^7W%>%DZC)>%\;+7Q,L"$(IELM%TC$][UW"!,3V:[('L8MH?H\1U!S
M"#F![R-:2&G/A<ER#Z@V#A38N$4+S%D-C-,:@RCR3Q^BEB\DN./-XH[R0-DF
MU\$XKP&.N<:/@4^RF8+-,U)M;KF OH'GX;I-2&%E"!BT1QAW*5>XQT1S.;'G
M\T-ED_ .H<RF[:*U)GF]5XBN&P[CTHK!3R\+FMVNKNO99@'[7V+V_T7NN%(N
MW7IZ,MQVZJ#I!^;@9LW483"4$BE//U5=YR$;8)>"]#DYQK%]: KZ,G,NH'(>
M> <QN.Y)MGM>V]@-!_'@ML+MQ'6T.D"UJFZ@X@<:3U1HK%YR@X/(Q\=;PQ$L
M=8?(**P?%OX0TN'<!%4KUW)<2'$T')*_(OX4>$MK5?>T2T_.>IZIA:0%_7VH
M@LJG;W2[UUQ7)7H$]B?NBV3CZF;[A$?7:ZA#ELY(?"1ZN^V@43[>0JUV#8RU
MN,.&Z!\/XRY' 'VFBJJWCVX>:T;WL*]/KBNZPE^/**!_^VKPPO7NEY9;@2IU
MOYX_Z%5T]!&LRNOBAUUFN%?"B_;Y4,3GG!$Z1QAE )RGAQ^' H_SP U5F9_%
M!UU5\_&YJZ.>8)DRJ!H]>X:NS'@,_IO%Q*$HQJ*#<>^'0#3[OS^..1K\\";)
M@UOS0U7'+8ET-$,>_EI5/WA2ZT('#*22KNLO7E8I5W(2Z7@TGG(S/W?,<QZO
M[WD1%WI- M]^KN3"C2M<+.(*^\16MT5(EMT0+"@>9)5T0C1VR )V\[#!3'>5
M,=:CS8^8LGY41)X'SY]EV12+6&37]=Y%T-&S !$W@YD*!B^,)3-K[L&E6,U?
M%Q>-HA#+1*34W\RK"5H'6\B!&SH QF[97O*NYZAWM1'N,EK$+'Q9'>@K K2Z
M./,VZ#0*!G[1F=!<#6;@&_PN0KN.;*PJ5XM'UJ-?$NQM\;)5//>47]Y/C^6+
M4,5_-.C7J,JVP2(FP+X\E7S9HV5AR&E[,.FO?#-7^)NY44$P@6AS_1AL'KX[
MS8W9N3CEI5EOWPSN\@MXH0-N$8HMF19.#G2W^+H<"]8#D+=&QMSVAUQA+!:/
MF=B]AP\[5\]VR&"*2P[]?>(MKP@J/!;:6''#!KG0(MC![34_GA#H>NSGA07Y
MF.H;J'0EVV/!LGP49'YJ9GYC$ 5S>3C4W7R*USO7\X5ZI'$$2]WJ8 ]XU$$9
M]/SH;&1>!6ACV36HH3I%!(?1#9U!VXT\,$R>7-3+^^IZ;Z)-S3?6CW8&8GUN
MQ.S9L;+H5W119D(79>BB?&5*_SZX#K8!QA5S/WX7SH_VT$/E>A8\]6.1N\*:
M4\0D,>)Y%5=SF=Q4I@V2Z>5RQ6(I!HPS1A:)U4#$W)OYJ/K+4DJN5[79)P60
M+W\N *+ *3 ^Z3T22 /ZZ\+(YT#J+'YD*25UT!R)"0,<L7+1.8BO0AUO8\!0
M 1,"8P#FES0'6W,R,?!7/E>"6XOCJ6'"@AH:I6-6_L!#R<+_S]Z;-K=M;MG"
M?P5U[NFW["I*T6A;2=^N4B0Y<9_845M.I_K]!I*@B#8),  AF?GU=Z\]/ ,(
M2K8D1Y3#JNX32R*!9]SCVFL_.[NXH+__AAA&-NP(HYF!&2:@$_[KW@^<-4_>
MO'E#(S^]V/KM_/3]Q;X;&,WR)T;Q)6^F,S/B<3%9;27/CD]/2+?^].:$]2S]
M^QC 3*F;I8^=ID"._"(8)_GP\2F9U%CB=U!WLWHQ&.<IZV.$OPMF57GV[OS-
M<Y]@=IA-Q4DP:5$+.!?A'<5NOH-^W-^Y03\^0ESG"V5&!TO(3SYV=JRQLXLP
M&7$J,;/U%33D-96AM,&60 1XT YBD7#R5B5:0JCOBM1&ASS@F*6<<LGA3#(^
M_#434%UE;9CPL+%,>LM-PKEK2%XU\W(T:4JZ1 .&*3Y[3;?:6YQI+5@VEY=R
MMU>"!@+39:";^';+F:YQ0QO#K$*P:I4 ?IZ54_K)K%#!7[I.*NS[<H=6=B:.
M3PU(H;3WM0>@X[9(W@L^)ZKQ^]G\&C>K[56RV6I)KO,J\X"A=)Z2&+WD\ (/
M6;-R7>49 X1X)^;UDZ5M#*T^"Z=5P22.\WXC_3/#Y-HF#?@#_X*^DUP#5@8C
M">^(/O>?:=%@2 A;_+"<-\0GC=I-9+\&KZ)LX!I[_*>NBNV-9ZA;0T$W:ZJZ
MD4Q-T3#TEM8ZQ!_Z<CSV!=-IK5XZ0]V:G/SW9J;M87%GF<#8[=H(ID@]KV!6
M5'%-TV"<3?EF88)9G$*_MK(:?2#B:XJ66?$PNKYPN_06S$KQ<SE9@VE( @9M
M*9A?V=Q;#S'2UA5J1,[*F9$/;B?'R8BVQ;7[*+#,@;L<W>\0!AL,GE^^G KU
M$DN<<P<>%(6 2U,'9BEN5,1,OCZGZ76)4L 4,I0$1N$(CVY=+%(TX_(:3 EL
MP7&Z'^)LJ\]E0!X<5I-CW#,Q;I([*OP!:RE7\8W+:58R@M^'$=DP?']^AJ+!
M*9TR85$AI536)7+*PT5M'^U9U)79%^@[DCD>DLX=;R=O!"P[:BJKKO%U P8.
MR3[1 63K/>V#C^'5SK^Y"J>D' P:LGH&2G2/&C8ZIR'T6WP!QXAY_B_K;][*
M7(])-@7-Q4A9:?VI1&$9E8Z/R+#@C<PF:3TE?8K7]#QKMET[89V(.\] =>;"
MN-+>3%]Z6UI:5#&.>1VA]SX@Y0GF\:B(JW46E/*BYE!54M"Z34*TI"MX# IJ
MV]?7Q\Q8K+6ZUW)4<4!*VQ*GZY70O^!#=+E8IVN-<95<'P'UQ0(J;'XBK8.D
M@20W*JGFHW*"H]5')^,"A]2%C&\KZ32+\/-+6>]8VAW7[JJ%:W7-,A,X;148
MU88!>JEM;.9S1\JIVD[-W3HX@>$1!>!)A497G;7XCX Q9!-K<3%2QA<Y&I:'
M^?Z;)O^V8_F8O$<VAL>B/OI<F_0?_W&L%[#SVNCYN;6:NK.T3O*[81;%72&]
M8.:_?XT9WQ2I%6S,;;."FK;\1>!QBE.^:PJC=%[Z4IN;UTUT_\,OVG=<[1.7
MSV1!X5(4R4ENBE^Z)5Y,R4"8LMGBEUOW@>MI7'J,E/($2\)_*DKZ1L;"0"(
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M"X)'/B<6=/TT.QT=;3)7F\S5?4O/=PZW7[[ZRM7GJTV09^-\-BL'Z736 "%
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MS4L% QZY$L@Z-H2:&:ZOF:J]-AIHD$7>OGQ:!%A(=\2]<51.PEK*!HU0N!O
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M&+Y61U(B"2L4V2G32Z-HRST0Y71,P,7M D2LWF!$J=$G^93,A3P-ID=:.HM
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M[9%[^1'9FE2"$T4MM!8>2"\T00)+MF2@C98&2F;=]A* 4!Q#<8ZZ7%-N&#1
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M$NX#1$X8;(L6D8 Y6\XSYCAPS8JX%RNW0)NW&Z\NM6 )@,]PMZ^7U.XE!]"
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MM)$'SFEZI]1#7?[U^S$7M6Q0]M#.;4]5HGRE(J1"_K(T.:L[C=[_'""N(2B
MJ;-11&S#(UZV5_,(%.#NV=I^IF*-TJ"8BTVBF8V21TL#P>&1""[XY+U,._BV
M'<Q5TUX=.Y5<8*Q;."E\:T;L5(I!F_$N.)D*3_],?^JX;6I0!IF6ZK14[U+Z
M\ 5S$*-Y6)DWYYX5(=*G]0V^@+]'KJ7%D;$JGS)XC%T6L%/3NLAF==&\F>6F
MF<$=8T4TX\*EA$/IU7??OWY"GSBAS?!@V@OW8"_0<GR9KXJLK8LE=<UP]\AW
MC,]6;,O+5]]=:#E%EFRC2>K\EWR[BR0C#&)RFP74<5;\\UT3YJ XL@]0KNOC
M[*J=E //#R_L<80=3+&A^SX>%/BELC&BG%2F*@:]!+V030YZK0_K5J"TQ=@R
M*7JYG!6A*O KXNC#^*/G@1 RJ?B"3MMSR2D(*$8;%9SS&![24+#ZF.$;2/TJ
ML2/7+)0=5(MQ,Y=6*XRG12 ,@YM0$X!!GTASLPH6Z@_-9VE[J](]XKYTCU0#
MC-ORY!E0T*8K_KD8 3@*%.YW?PDC?5T$#_W/?RS^$KOKX2CKU+45*96Q'/W+
M_S+Q'/D-;G$?(;I?3Q#=":)[?R"ZNNM6^S*C3NEE^'<(T\.%PS>732^X>,):
M.<%GV@_X%9*PO"@9V!O>\(FPG/I^:JYQ 1X<#%$(P0G<+WA'I8YIH^0J_3@P
M;?Q$9IS?!9W@+%\7+$D&MP6L:G2YQEWOL>22N7BAJ>3HF9*VT@;,'_IO24+3
MOQ\_. M?9G F*^G,9W564#N7%./ _U"7..QQS##IUX)ZX)+"7._$(^"A=%3P
M40>"+>[. $TBHSPQ3ER]1D\?1,02A*0=%CAJJ+6RJNUW=*YAF FHNKEF5L[P
M:.C-9.::L<=WW'2]Q^8&$$S ZWBLQ;,.W#;X,CVU.$!$E!<I-)!/38YADP[/
M>K<[*1SCTT%]%]!#!N,Z-&U,VQW8 .8W*#C7@Z[#7LIKUMNART0&C7@Q:H ?
M*2Y3]DH]58_030(M-)%NG-]IC\ B@KDTX[$U0+]@V4#3(%(!(%-!#$DB&DIK
M*O%,]N>S_F!ET?^E<C1>5[T;XIEHLX+;IPYU<,4>0!U=W$G%*^ML2S4E[:+N
M&H:.NJ8I5SP'SEL-!)J7EW4!.*U\76)/HE@F92:Z?)O/AN51:]UUYBRL^%4>
MFR*D5Y(L47\KV7"L--LZA'P+_A!C[(#P.G1AN/)RA6CC?/:<M=B)H6'>Q^.\
M>/6M>Z:B5<-4J HWQ_0C.U[,1[]MPVC([?%ZW[-V@)&5M#UB86 )&NX-I#:3
M0D 7> Z9SSC_0JHI>72:L%?#-I)"^QUH%/3;8BD9(T_H\-7 _"38_##K*K7%
M[F"2+LD(*RX2G)((MYT5Z:BH-:^19'P9'IUKF'R^YMF&,$Z4^O!$J+TG*LA6
M1#(+T-#3**/I895TRKZF<]4<>1<?L/0$^'>'P"UZMUUJ>9B\J7&=0')ZIIM>
MAW0^>U,2LRM$Q. PR-9SFS$BP9Z]_OY;@RLB6,9*,TF[\%B[JI!&B1#;!/N-
M-PU>S?+-C/]$CLT;B%50LK5<9<:\^<=PAZLPL*-#2<7EF9:BE1\:!QCBQMX$
MR4M@@J32S--K#"JV++3'LJQ<TZ,8]-C3^)/I8F)RDLP!=QEHW)70'%'C3'E9
M)5D$3X9&*3G),??F1Z-"2DXS[:A<^-2$ _XVZONA,7Z_$T<O6D^X:B37+<:Q
M8!6!)G<<@32<FVQ'<[7(E9AP]:=3>NGCT?E+>B%6S_VQS"E&_Q/_R___3U<C
MK(:TEAGXR/T2K58$I9U/V9<C51F;HGW?1QEP^2$E0(1ZK3$?@;*X9*) ZQ[2
MQ8E&8]K HAF8-ZV#M<UGJZJ!"@ZHHH);$PZQ1; G.V&<#3["HMH4S78^).:^
MQ>$*2X03-7P,4,>RZ4EG#9%_P*;@K1RMXZIJ<J>'$W964X!P(SS])9$R@+@M
M> N%:<TD;H42G\.?1X&23/(!*1ZP9.8<7*WS,UK2I*N$YS"*Q%PHBJF[C/HS
MV]$9EX"AK<CDDY4!-Q:R-ZC8$NB6]3)BOHM\4IGWX-:&4S5'LQ6/*E:/K =I
MC7]R+_?.3S?5K]T[<8SDX+8=HRQT,5=[IWV!*1 '4R902-E(3->HJ*JP[BES
MQ[M"^4'98VO"Z;?J-KFJT8C&]-Z6J'6%I4N=.*[C,1;6Y_?*BXTQFCTZ$' [
M:QO9PUS"("KOQ%PO7_%Q! 7>Q^5"Y\H[+YB2/*@,.-R1)4-TLNRXQU7!<SX7
M902$9>3@(<&#C>MI(*/Y<2>^X8-EA>@M6DV$J]&-K71T5.IRB.QU0JO;$.G,
M,(L!1(7Q1(X<V(9 'H"9*Y ";]BATI0:DSAIB5 Y )E/C^DD&"5"WB%BO.")
M(I]@+56^E5B)UOV&:\":Q/@9UO8Q93.?DS@I?^AE4F4=<%S2J=+BF>I\G=>Z
M[!K9@I_';K;!;N:DF!KXH<K;L:GM))+!2>CD$:.02JRO1!X]K[PL2;:X1L#9
M"")6!X+ *:JZPM170KZ!:V"GER)-.3.G*7)?!V'P"@W4OM0H5^L$R,$XTX\M
MF_W:!:E\*H<(-.S'7=;QH=*T+%J6O-M<8UP='6$#T\QC"4X]WQ[=2RB^2]0[
M3"QYO_%M0F%+43J.ID,Y[22E3<F;],TXK&.J*U:/]A %4)%O.&UI*8%>&7#V
MW$0UL73#1:Q%I'<S%C\9&^'Y,-. (*7<[+E3VG8F/=85(LF68W&?NN!D7IBI
M5<Z*B$N375B0&.^RJD6_E$8%R,+&K)S5]'![/FCHQCV=!TKKOOHV,AUBZK)4
MG,)G!)D)]%>FD>YEU?";J6HX50WO4=7P2*I6DK&*5BR7><R_NGT^CZ6F8!*P
MH35O[%@BW1X/Z]GM<DY"A4N&L6K(<)4=.9=2R=,K#DW$X9H 7S'FPD&#V<LV
M^RC%V'_)8\8Y(HE+.:JX,JE/4NW8X62>_ 0ZY'ASF"=%OK=$OH1/#C+0TN22
MIZ[%2):9$^5NI"M!H$0C6[31"K,*Y'AZF(IM?,0F*;)^M4BFT7&WI,"E8GT@
MN4#'$8Z7?N*D*UD,B]C><W89J%*-LT7.__/9<Z(_(6XYI$+&W$K112[?,3?]
M:Y/1,U';0G/'^>Q9KLPU&/H&5?:6B+8A5\Q/0H>VY8\I(<.D#F-G^Y9V 0>.
MM O!XWDXH2URV] K &\*N3SB >,ES+$^X7KILTAFU%.7BH2"<YTGGOO+ NS,
M1F$OP1NJ'+9J$>^U-AX\8J; SN.G)7--2S0CM6KCG\RY>T!2($(,+*0TW&Y&
M M5*8T;:$@B28"/%*&%LY:8"-QLL17W$K7Z=K(6&]UF9,/>O>U4J>H4KCJ>C
M.8L@ ZR)X*!>:<YA!0JLM8L#7"J!FIF6N7&;)#?RP $(7Y"OAU7 DU<*2ZU^
M+^SYEK/M/16Q\]EKG=F8M*>H!?TL;@3=# "1>2 112]5-,NN:88?T<(&R[7
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M!#J'PU413U0X[A)%1,"IPU3NA*6'@FR1?@\&/B>%^*M\PXUGO0LSJ<QV"P
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M:6U#$,/7^TBS]L6#J=H_5?O?LMK_$?1T+'_$7<+J;@;;D'%BFX]-+]AU1(D
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MQ4)[FYZC,&M9[,N0"5)FG;H:SM"YELV6&Z)9NB$@JX>D(9)@#/Y08AJ9]S*
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MZ427H,5@>072-H_\@&D8/]3J. >"M9E<$Q*E$2W#9%JE"W+ M\BT,RU!6$#
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M^X#:^!E5#8^+,-B;NN&&<+Z_99"%36QFP7SOZ9@_P-+SH-6\B5T9.,F16@]
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MTQ5FG^BQ_2DZ(G) PU3M$Q*HJ04R9,OX>Y[MCL_>[,FB78?%'#9=.&AOL2+
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M2T8$L!ZUKG<WN086]:N-<BYI*&SLF99'L ?0NP_']=G@!<Z?O,C9GRC2N1$
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MH7HEOJ*H =QL+F?*F] BE_=S;-1&.+?6++F3T9UR<Z;<IU&-<C'%U#?UUC"
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M)X;UOZ)+&W?5EUAZM1>@!9S;[?',M:M0AD=3M&35U%EN^C.RO-YY] $,J:S
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MXF%&WIZ]#"5NG15.HPK8I<'P/APD:>T@:@C1@=R%P_(T.G6N!AH*8.NR (O
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MN+*!5[3W84]ZATRU)A_&^P^:B[Q+Q?T2Y@5&DV9\_8/8-72*:^Q?6(=0?6=
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M-^J,^CX [KSR\<<9FZ;C8MA#';G3PZIMLYPDSPCCV$2@S0/!/0(>K/8S\S2
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M>HQMS;F<D0H_MGQ/=4S!L,;"0086Y,1MUK<2CU@Y_2/F>4@,T9BWK,_[DFJ
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M#27<$.F5CG7/ON[I#TC;\$>UM!$&"X19"Y<4N&C-^^9G9D0K3)>2IX-WX./
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M; -<$C>*K+Q(25ZF<FCWG967]JYR*#WAT/A&\)&?_3=2.'E!DY?#^&E%HPB
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M\ #ZK$$Q56'R.D;%D3*%#T\L]$_//CW_TM_P+5Z#UZJPJ+S);D=']U(S6)=
M/?J":A^EZS*V% ^,]HV?6+0'I878&+=%RQD9F2,!E.A3.6B2#--P;)/N13L=
M<C+\T6N>)_FN;_!U:,:F@YR&A/A(2YI<HQC)I+ Y9UFQ7A[H;]9L,EI39%#;
M$QDU7OZ):-K$"9I!@&Q.&N!1JR^=?8+V<=9WUW4#3R>I1AEU34F*N4LEF\;>
M/>,DOUB]0H1NNROKO7/CM! \ @@7-5-$_/@E8,2GR;?,PS]X*_@EV'24N1Y[
MA['=*P3&:V8;$(F)GDJ6,NRM1B"+-<6>?66#RT#54"T=JA 2]I_]MZ92!II$
M7&LY$9-:RH9R)2Y:7&,!0PZOP/>DUA GZ'ZQU>0M*X2/C#(_DCD.]44H,XNN
M<RZ40*U5"!BK$<G$S_S1_5)9ZSZY*K#B"]<#BEZU/.D2M*)CGZC:1U_O[K^,
M@7_C+P)O$P7Z=H<V15P&*^8W+ LC(EH5@#:&OIRL[P-'1.FSN&;EB'7>132X
MUG0L4P=E0!-9]?1@7?,,@V4SRY$]=#CTI]@70C6(M4&A:J=$LV<-1L(>Z(&%
M6!!Q7?:62M^+5:_N*(Y)*K8X<&YF%WEY=,ASVH2\SO)D ^XCCNP;'Q'9YO_X
MZ>_IX*S&=N+%5\:0XK8V-*SAN_=^]>G%^=/P56M_@>7?8A,!LRM<2\;%,%@.
M=I[\)%7VLOK1J\"\PU/UCUZ!9",1!WQ<4$X0CN'99\RW?WKZ9;!TJ1IWY>AQ
M!8=P\(DXR1#M^0+7?<Z3!R=V* &:B9==?'F'+7HKRAAOY$\7YU_YQ<#'=8\8
M5*+"#%QR[FY<6>\8T!M(=HUQVVY(U?8\14EH-(K+ZN"K& ;^V1SE$:^Y<YM?
MI=C)@HTM/0ZO^S]T:_Y)/WGO=GQL9"C(LX7EC,;$W"PW.A ?\G/RWJDV%3\L
MU/]PT$==,7(J6Q/%DDKM-GGVY06]^MF7SU1IOJASAS;]?0\%RUVF_Y5[[^E1
M6=6ZW_:<,I*OJ (-C])<\# :'FD=&I:3)4W-D:Y1!P ^%OLG6'-^]H03$5P4
MO:OA%7"QKZ6\;70$S*%XI26X.33UCXQ!K!<GG8O>%-U>FOR,NK5O]LDK=]67
M4A =P@08$*_1((P.E\[6G"DK0W8R^!J'02LA%RZC;MR9'!X0"UM#0AX%5=#1
MNZY@P4K0PWOR_4-6<5>CCPVS ?'$/@R?@,V+U _?V7!I8-#R_F&IG^HF#3),
MPF@NXD12'Y6@H4QP*VCA#%<20H#JY_&$.& MSSB/.>_^Q9)W7_+N)\V[_\9Z
MF$/65=\<4&B3!N7*;;@5S.W5TE ]R:6Y+-_0/0?!NBFH$YA]$A_/;Z^3#7A1
M*C%H@$4\LA4;65@_\E@X=H]R%O@ZI)Q2-FA_X MI<(KK:!7P_[-RWQ;X@AL7
M.M%([?@:UY#TYJSST*RYX/@2G-D6PW.WUX[/P_>/AEFV6:PU1J+\9PR4^46U
MU_4MKW,DS2G3S@'HY&\9F R@M2Z>//G*#^BU[S'&Q.U ]/[IR?GG4S;8O8X$
MR6O\6U\%\P<T4;_+>58O.O^ZD4,G]TQL+SFZ7+HHJ9$2 W1G9?$&[OH,Z]3.
MT-+R710^<C:Q4$GIO:,-Z4G,4VFPS;6$#Q\V::=3B43V-C55O6!>S#(D-C.G
M^'<J'+WTH8S2M_(AB?X,Y/"BER32W^I5RRV,D@+X^<7?+M,IH=<4%"5&VP4>
M@+9JRUY"11$SZC4<$/O3+TC6B8.-Q/4EEW+'E)3ZP/8]KAG/:6;I>0WWU6D3
M$$.WZ%?1WF"_YT7=P/YOBJ:'318@@%]A:]*&7_BM#++7Y,T^.H<7EZ^^U<&_
M&-9R^6&']+T/A[JK2&>H0&,A\5224'9'Y(QA<-,WH=\X\[8=MD7YZG/]O<_K
M>2G1N2T6A3= N?"7%ON:N%X)K\9(390<\%^4Q2M0%)*T R$E+<ITOFK=BD%K
M#T7ZI^ 7M'C5+V"$WV(:(>.7FA=B,Q$G[L?GB[0Q*-'? K6/W8QVPF]/S41V
MBE(VQU_2!>?P[)([6#(G3'U D[KC0CG7:,8ZKI+U#\>>679C+?Y2'_1!PX4O
M@VLLSAU0;(/WG-?@ROLR&1:.WX!5>DL""]QF*>BC[K0&W>Z,(O/DN'/5W#"*
MC,F0 I^SR6Z PU"^J5P#BYC$'[8T@;=ZK7-]X4PRR67.BP0PSGJ,C@&)@*S.
M*6Y?6$36$-;_$+]VQ-0HZKD=Q0<2'9S8@2^O]EAWQ/(.76M,+YHX!UV EEQB
M;SWEE;EGR\@DG91<-_:W2 ;AX*D2 IQY%F#P<#-R>9R7T*;+G24L;/MQTD$K
M&9 //';]=V3L!;EO0>X[!NDJ2]9EUK; \<B^XX2>%!SY."<P^M45U1.A)]2F
M)KK&+#U(I4;B%IMFV2FD(@C2V-H<FL$S?JV;.S.P"R+RPG&/GN.JVJ8C;NI.
M/1#;?1IWG#*/D='=#AD,KIRY9LAI]"S_% QLY=BGZA8N6KCH\7,1)V+ A&N1
MBQKNZ3E8EN+9(0L,0; 3Z!\F-QDPQWJ?)AC$1$>!0Y9<XNJ[PU=[PEYZ"[MO
MA45Q$>.WA<)9J4J/.-,$/C0-3,O@16 5GR"U+.IO8=P_*./>7VK7F2+($<1+
M* <<8KMDW$<4,AQ2_"<EZI+]0<.5V;?V;3R6TT4G^Y:B4*3/[W,,I*8>Z#2L
M!,N $*IO.9(:A\.H5LT-*A'(&(:E(>2F-,#7S<+["^__!_%^V4D_WA'1)N5#
M+F<_!/2R,-#"0'\(!O*3#OPX  LN/ 6C+M4[%\^>;BZ>_#8J.K+ZY/,Y+&,,
M.?^$(><_X.H^/W9Q \*EYAM8VL4<#HYDTQ<7GSV?P3E]]-=G\SB2_Y[#,@Z2
M]#RF.ICJ=FI\83N= *]*-G]I_@KB.U33L2Y2_@BXG++*Y\[]G4,I=YPU$+[
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MK\V2TW?8I-4<O08F+B:E?^%:!UFT\\"JXU&K[OQP=Q*/KC<Y(%W1R/2"&B"
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M%HC&N2^I4K<:P2<=%W46"&,99YS.X #5YAQXY2+5.C+WS_S@PK>0PH+04 %
MUG O: 3:H!9'K)S5G:U3^%[!]'F^&C*\+AKYXP!M:+Y4==4I=4O4X0C4QI24
MP^N3VS6N.PE+>.[4Y7LI2V3+LIO$J:?,R@AD186;L( /*JJ+D&M=@>NT:Q;X
MIP%YGIBA 7,74\+9L@,,$)S4>_6&U"5 IW;$*8ND+9'>8,HEI%^#]66C#0L'
MUG,9D\S4,U$\=Q9HR64Z:%@RJ+XQ$+S8!3EU1Z!5YF27<C#OX*_]W:UZW_@S
MJA:2).#_814&Z8]1& A0O\&49+?/HAC^<NH%0W@9^O.@,8A4L!PIEJ5)Z9>I
M$Y1?XC,^99D.#QV#7..#&7LVQSN3M=!NRI+.DJ?7QM,F$Z7L,_!?@I -KEBP
MZYHRYB2OHPU&FF>E62A9&/TFA[B00DUE^W!)Q=>A8MB0X*@D1Q(NM$6)(G(+
MA"67N@ 5CMB'9U&90XA(OK$83?S "T[!C"PIL*3 :U!@(C9CL*"QP7?, 3@*
M!J6=OW0G< 3'(K;F,Q,.) O,@#;5"EK5A,P )&FW'/XVO9''75)[2>W7H'89
MNI1V*U-\11H-(^'.8A4ID H?ZY$X/%T26$E@UR P?TX)G&SH+!7:0%]SE197
MP3&*YY>69$EX-]+C2J3)NL&8$FY ;D9X.13G+KQ?QCN6*; DMY+<;FDV*I27
MI>B[";Z51,04[:6LRHILO.!""JY61%F*H WN<,X1(^65KR1B^H3VJ&3U<?)D
MG6,IB;TD]FL0.\A,X<\%$"\9AY6DGIT2_0G!IRO([X4N'UW!9*,LF"P+)F]9
M,%D*X5(((Z%1U9%LA(\#+(6".W$C!*GS9"2?2Z&"E/4A9*+.2ML+*YTON."(
MHO@@\[_XE$X^CDNCN"31.\52Q<QFRW;L>CJW' ;86$9*'XMB,, Z,VL^5#6/
M^H+ U#$51:^NZ2&-).UE,1:^SCOG?GQ+5;*,/-N=EB F)95?-X::%&E=7<60
ME-OF5(:9WB!5$8^!R&,2X\*?<'V>*O)"XWH1Q6(J*YPS16M&.5KR3/D0AWO'
M905"' 98Q '7I#H-J.8-"^+@.W=$(RU(1>47/W8]+LN@!CM.KH"FTP7AJ:I*
MZ=^P-Z/T(KDRW'ZFBS/YP$2V#UHE:FR\V"%\1@/!RA)MU+;N.;YVN>G8$<,X
MZ?F(DG(065*<E)?, A24+EVCH?:3=D8F#8)W%*?P7MOS7%PO/(,SJ0Q@"WN'
M>[%#L[\D4JV0;NA09XJ+)8$G7.0GL[2Z[CES*KIDE9P^#-JZ7 QH%KGKJDHB
M01G*B*CZ1=6_&\5""6'K#(0JDZM:[X(+N+"PHAAO#,NB&DKI3^9]F]\DOS#$
M!D35'Y-;>4G70+X=-QW2%?"U&*<=9(]P(GRJZ.0F GN$C>#\'A%.>0G8[^)Y
M58OJ_V#ALJHS&'+M:M[2J82=5JGJS7,69Q(!TX&Y&BYBIYIZV\(J>IYCP-62
M*'>H5M)/E4M64L5A";53':Z6'+I0Z@&K*Z\6 &G"54F%I:M6YZD86,$0X(X5
MIZ:Q"(A;S9YXJOFZ *$23=Q9 M(A36WJ<9H$'JCA2#=HT"/Q/N#?Q!_"X1P<
M/HLH1;:%P6*35RD= RPB@)T1-T+*F<2B1R0$@0S/6UZJAM7MK+F]6'*=56LW
M)9*DP:90%N2Y&#@(&!5*1 ,O\SSPD-82HJ0%J>6/0/WX1-I4MBK%DL+=5.K0
M\'AB^TP@"/P(13;%4TEX*,G(2$@9R8%7A<LYX[Z<G/Z6 &ONP/P+N1/L''P?
M1+NQ]L<)M; T4 22]K>46$UE]*\I7+7T(J8DZ076,9PM>'7GMC<GL2'O"N4#
MG(=9W5)1T6:EN^#H! 'L:T&K2PN"?&=/"MYD#]C-3-2GRZFQL!B(=&R?PY:E
MO)S39G^'K^,G0FRK8X\15RWRZ*IJ;3M -:C^5*FS\?"DFR8E/L-D.:8<Q?<O
MR5&#4%9(<RGU$X9PP0 CA-?APM"K%P'\U3?*-W/J036GHKJ!XW/<*)RK5J2
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M4].]:7RX[TJVET$>,.:!\&'!VI90^Z9(*H;T40RL9NU'5P+1+DL@RA*(6Y9
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M><6A6IA\85UF-%=A,UZ:;^PWJOU+AZ,;4LMX'T9#QUYPH?A$_4S(B"]9,UW
MN5VI$?3?[2'0WCP6KU2"]W[50&[A#G_P^K:0H<VOP,>\/.=;K74>P15<?[?I
MD0_5?GN#NS,J")8W>L4&KQYN<3?>*H@^NT?2O6=+^QJZX-IS8Z]-R@5"L;WQ
M:1R"XW#3P;!$ "9!;WR:D3;9.7,2C-&$F0FR'9(\UALWG-[.H.?'H@UA/-@Z
M$J=NQ-!>AQQJ-7)F^#+#[+>>'^YL'[RV]G>M5N/%=;G,8*F-G_'E<L1<WAC^
M'Y#]/8!A2WY[^*.X!"B:G/G>G?AG0\QBFO>O;0\[RX\G0L31[9@DY2W(YUG\
M0!DQOLS0SCC(-^*-7Y41-DWU_2>B-1*'-A@?*$BD=7"!$<4 \D\>372/6?10
M3(0?82C]0Q!%-_9.[\(T&S_^XO!1\11*H_88%8K)1U2;. $C4X01XQ6MG9_,
M5ZC&7W[5@S+2K\HUFV:1^A/4/CMV-'F#@%5K9Q9\LO4FA855:IE?7<LT'J.6
MP<+-* Y,6L]):=V.@3ZI"M!KI#Y*G?'X=$;S_L<R73]CM42?9FBNK+ZXU^J+
M;EE]459?W*WZHM,4]6:W61NT1:,]:-5[G8'M]%J#1K?5Z3JBYPB[FRH#N$YP
MNB E +<.>#]415L>%1D CUQ0?XP=>=)!U)U1KU5[WZYN[R-:.?6YQOMD(D!K
MB3DHMZ@"VQ\]8*'TY;NZ-)%S,'-].>8 =YEOL@P?<-3?Y7M1@\A4EXT"]Z>J
M3-D FAA@0QE-CCB:?,5]J2[3R'5<+!=Z;L!'O+@R%%U)H7ZGEA&E/*H@'<X;
MI<)Y7A IX/9,A$*! N-7T"<;:Y],V*.)*CZ.+P+IGR7C. B_(]];TS,M],*Y
ME^DYUJ9PU3]!D4J<<QKV01^7!;)7-CG).MD7-#(0ZYP#IK?*-1&Y)4HD]3[B
M3"Z7D)D1]@WV1?7UV( 91[([6S]""6!U+JKUR(XOO<+D-+ 5(]*H(.DKPU^M
M\PY<:C#%NE_"S<*V#8*[2\!@L=I_%F=[-V@B@/>@+1EWD#2O"<D9#TO*G"+)
M%<;3S0>%#X6BB1DVJK-9FR&L_R=*->$?\ P$\_-NQ#/;9@3##]9)D):\\D%Z
MZD?N6C2VHNXTY#8M:E[3[5$)C6#?$BQ$JU_=$B3UL&(+0Q\?8&,"WIO4>,^_
M^*X."T4O9$+ZA0&SGQ2R#PE_3>M]>IOD4-6LIMZ(C PO#1T2T'I=1/=CX1#.
MF]&4X=D72TW*:*Z%<T]V+\,N$6[5;/4_3KZ/G]!=+P@RX481M:3(1]*F"L-'
M7QFJ>TZM=\E5KSJTI)%.;IQW RHNW>NG(*55+QP#W6,S'<,@\.'BJZ@W:BBG
M/]A1X/.<C$A-=+6I:>-B(@BX/BUZ,ZQ#(*&P+BVR\>C51RKZ&0[C08&>P9E/
M..P!%I(&CW*CI<X)M 40=Q\[JA'M ILA3X$+N:V"=U6AV6FT*RG.";*4QXCX
M<1AXW).=[$"W>U!C'L)!J"X=>0^RC\-<B3PM>%5F;M#X^J^SAG"HN$45:943
MKV@F  L.QMW)R@[=HL?(75G)=)/]$GG!/U'97@@MK_R .[#DBQ^R">5R5CDP
MN4,V2,N+EPV.(^%0HQ%/*N-);@Q@&ZVDRZ27:YFJKZ#9BLE1V270J%O2"PX+
M1+Q=6@I"BR#^?_+AI-_[A\T U14>D(!A3)Z+4+$$P2^-D!9/;;HX9F(Y,)>!
M/9-F*P72E+,M5EKR*&TO"HP%2"P4]? \&X0!+\B"-C C]+ J'J4P7!A:LL*(
M4V#-P7\SKP@(Z--3YE]JE$W^XK-3OPQN5>U5MBG+AMH:,:S2PBB WZ/?K;W0
MAWO^MSV=O;*^P8&?6A\^'!9E@<H/PRD<R<RCK U#%X S0'!D"AJ[M<*<\.'$
M]8 DO=G$M=.SCHNRPH\T9ZC1(2^AM>Y5W2[<_*#1Y7*=9;3^;M'Z7AFM+Z/U
M=XO6._V1L.U&9]#OM)N#5K<_'-B-]G@@FN-ARZXU.TZ_N;GX.]9N'+S]M'^R
M?_#).GFW=[1]N/?E9'_GN,+-"?N?=L"F_[1K'7]Y?;R_N[]]],WH/+RLD'>3
M&_IT?/!A?W?[9&_7>KW]8?O3SIYU_&YO[^3XP?H&E\7E99&MYV16!W/LAT6;
M_ <&ZQC73SD#ZB>VRU_HT)>DLG9KW!RV&K5!;5CK Y6-G$&_U>H-ZHUFW6X)
M9]3M]%,YH9/18/=';1&_;AS/:XL/YYUH\.?QN^./IX/&H)']Y/;^X<>=@UG]
M2\V=-?J?_WY_/IIV+P;-Y4]^^O#C[/713O/UGOW7M\;HK_;6WH\0/]G.?O)P
M]TMW$1X%KVM?__?C[.T_/VO_.]J[&+0&M>PG]QJ3CUL?:G\/OWRWS]_^#7OM
M_?2V!^WE3\Z=W<F'77?K")YY=OI3./]\>3_8'G26/_GMZ\\+_VQ\V#O[_N?X
MI'%R\:4Y:9_")Y=V='KVS\#_W^FGQMG!V=MP\?K;QZ WOH!/+N]H<=[=^3-N
M16?SUX=[?WV#132CTT%W^>V=0]&TIY_./M7<M^*-_3%^L_?]Y/.@M_S)-_]X
M?[W^TFG/OGS]LSX_.#T.WM6=TT%_^9-C._IP./RV>W1F?PWKQ[6V_7-R]'E0
MKRU_]/UD-OKKV^'^UIX8[DYJ^_6/0=S='M3KRQ_]U#K9_J=W\:E6L^=[;PY.
MZO7C?[8N@*R6/_KZSS]?__/VR/O[2^?L8,MUS[]^?=_;QH\VLQ^MC\Y_;H5C
MK__E:^V?X/SK_/AC\QR>VEQ^:FOGW+WXL[9]7-NI.X?['X+NUUKM,WYTZ:9V
M/YU,/S5/=]_7WGL76V[CXW!Z[)WB1Y>NZF#?GA_UW/\-SZ:+[]]:Y\??=C\/
M80$YU/?9.SB,WWUWX[VY>_ZC,?S;/_AG!SZ:0WZSG1_.^8_^X:+V_7UK_-?X
M4_SF71<6D$-_B^A][_TGL?MQKW/TS3GMMHY^+!PXK!QB^7,>SH\_MW8.]J;[
M'[SP]']?WO9F\-0<:GDW;K8O_K?7^+KW_>+P[>RXT1^<"5AK#KF\W?G4?'VP
MW=_Y\K[Q_OQ3VPLNAL"HC1QRZ0[Z[R_>SH;?:M-OG6Z_^W4F>M//@T8.N9SN
M#TY&_M;?_MEB=G'\S^O6S#GKP5-SR*6S_>7#\3__Q(NSSKNC2?_L_?#;1SC7
M1@X-[%[X7V=^[W/GBYC]\W$VFA[MA<%G_.@29=FB\=D)WL].OHC=O3?NV:>?
M%Y_?; \:.1<[L'\<A1\_1+/:P>!@]NGX;;/S-8*/YESLZ^ABM/5E>CJO=:+M
M>#I=;$_% CZ:<[%M\>[\0_2YNUU;1"?O#SZ]BX_^]R=L*WNQ0&MM1XS:]8'=
M'_4&(*L%_*M3'W1ZK='8Z7='C:Y]\V]DN.)ZW\F !O1:/;LVMIW!<-P;PW=:
MHT%OU.H.NOU.J]=J#-N=7N/FW\BN[%K?6;K?C__[\?Y[]ZM;_[(8_N_D[.+=
MAS?[;^%X<YAA[M;_[C6FY]V]XYW=PQ]]WW^[> <?S6&&L]T/9^Y!X\WA%U'_
M?-KY\B$\F_J@M7*8X;#^[>U;[_1=\^S[V<_V=_&I^>?/P>=!,X<9#H]^_J_5
MJ3G.WDYTVGNW]7GG^Y_ #,T<9I@$'[?>+!;?=\X.CNS%C]GB^'3^?GO0S&$&
M^^_Z[L#_,&F?[>P=O>_\98?O_CR]P(\N"<1WS1^']L_OHY][T_'GT9MI?WSV
MU]M3_*@2B$\*7B#5(=OM5MN;A!.X0;?W(T<4N*H LU&M-<N+*,!%U*N-?GD1
M!;B(;K57+R^B !?1J-9;Y444X")*T520BRA%TWHOXNKNIIM9K0^WZUY>Y'4M
M.#YW-1@?!KQF]:D\R"%<)1%_B4.X2AK]$H=PE9'R2QQ"R0Y/C!T>KV+LEXIQ
MQ:G<\!!&@8>__.^S]K/;'DBMVNQN% >O?XT#NQH@=FE@3QXR8,DQ1>68ASH#
MS3"-VS),OUJO/VI^P7ZG&P)F;LRNNL9>5V."EM>>N?;&.J3APT*A]&]4!+0=
M1<+HE5V'X"L4",Z=;(6[> V_^BFPV_#PI'\Y)LI*<7<7:;YA_E[;;DK"?6R$
M6SCK?(DX=^8AS46T2<^\?'+6]1.*0Q5JR_<>==J0KGC$BJ&DOR+0W^-S071_
M$\W9 Y6 &"0:$ :;T<]M3\]7*CV0QVG(+4F?WYZF+68U4]UZUG_<'[!F_TUH
MCZC=>^Z[\1$VB2$ R>!8HE@,OASO#II'N_]L=]_L?O[R?LN==[].3FKAY/,S
MPC> %]*WMJ/!P9C:%^H###L-/GT\BIW]</?MEYV/VT=;9_Z7'=N%+SEBY$YM
M+_KOLZWF,XNG;_[WF?LC?NG/ITX0R[\_LWQ["J<QC[9.;7OV$IEOVW?P/WL)
MYVW'.W88(A+57S@U]YF%LV#A6_!D50)],-H]^]M__>/L^_CCY/S/W=>?/I]@
MZTKSV1^-?J6/D9+T2:PO6E:R<\G.3X.=&P/[],^=M\/A_+#V]EMOW#J/S[ZW
M6ML/SL[[7P^\]]VMQ>S+U^%X<=[K;K?.WGX&=NX\^Z-5K[0[E[%SP;W.K+WQ
M-D1,CU",!)S/T!/KLS-^02GT*/V731OSC]QF( :*CC0#R9A.CEC9ZSO3S[6]
MO:]GQ[O^^]YXK_WQY*^+01>MA'JET:O?GY%0\F+)B\7CQ;4K_.OSHG/1KSFC
MDWBR]WXPW9W9A^Z';_XV\"*H^&:ETUV_AB]2D.$P%#/;112RF? C":48$/[9
M*!62+H,.3\E+6;.8RME-<>H9GIB5(3EVCQGV$KFV??3QKY\?QZ^_+.QWGX+C
MT>$LJ)T.>FAC-"LU'--7!B)*%B]9O'C&RW59_$/@!W_/S_Z:U ZBHW?[?N^;
MWSZX !8'TZ51:=6;CS<X\0K'-<0(:GL_5L@O*(\>L?#Y523)VHT%+EM<+4%&
MWX\];_]_H7>V]>70/MG[-NY][WT>],E(:%4:]YFN*%FP9,'BL>#:E?E5+#BL
M?SD\/OEX]/EL\:$UV_X:MEO3Y@6P(*88NI5.J_O$ Q X?D6.OL$BAQFCA_LB
M+D,.I3]29D<?)*3 /'CHV7Z\[3M[B@T_B3R)-?_[_'._?_XS.MOY^GWRZ41\
M>^TB/&*-BAQZK3*P4#)RR<B;"1S<B)$_O*V-PL6'-X,OG:.9=_)U\/?KO\].
MD9$Q@-!\Q.&#K)5QA/>\%8RWYI&0H82*FOOFGUJ>L*.RWJ&@GDWQMOQK>41K
M-S<.%-]]0+8CUCP8?XD$>4HY8FK\<>_3WV=G__M2>]N+_9XWFTQ[_Q B-M@;
MG?9E_E$9HB@9N63D^S(W;LK(^^^^M[X.QN^.S\1DO'O^TYZ]#L^)D<'>Z-U#
MNJ)(@8X#*JHHBRD>O4-4O%-X AE:&BK7>*R]YL4CB9(QG@AC/#:3 +4<ISSR
MZI[?=/S7O=='7_;>#^K[YW]-ZNZD3@-K.ECXW&T^XG8*7;%05BK<66REN+,)
MW.D$<YR%\4#L>5\-71O>5F&DSCV5.>0(G,@]^E1O=\3%EX9S]J/YY]NWTWZ?
MIDYA@4.[4N]<YG24T8.2<TO.?8#JB!S._7L4_6S\N=6W]P[B;S].N^^^M\,^
M3:$#4Z%=J[0:[2<5+GAU!0#=!]<F'G9EC\9Q'(S.)O W$49R(K>%Z9YX48+4
M/7(_ZI?*N+Y:!>!2!@!*PGV4A%M\/U6!S7F)3BD1YXJ9,WNZ9;WW)?A+^BOI
M[Q='CML>C6@0O36S%]C\7GH#I5'U.(RJQQZ'E(QWR'RWNNFCW?KRMO_1O?CX
M14S//K^9__G3___8^[+FQ)&E[?OW5Q!SSHF8B;!\)*$%>LXW$0+$#F(3BV\4
M0BH)(2&!%K9?_U4)<-L&NW$;;#!UT=TV74A5E9E/+I65N6XO4#/Z^'8VEWXK
MN($](RS$6(C/%Y(\5HB[A61R5O.,N@CDICZGIZE"FV@B(8Y+Q] 4=[VGF0=,
M"C\"/^O$8'<1F^O?&%3.81D@^7D2Q7\=5^QNKC#NDO3:5OE>OE$D[5PA W$E
M+@_'W)'L&8T#+(Y8'"]/',^AXX\6QX@7QOT6\'EYQ=:K&E7-==9U 8EC7&:%
M3+]UX?'Z@PDY8 "X-7K"C.O#6J[F3<#=KBX+#BU<L5=R>;MP\][,R0P/S0R7
M/W:R&U?#+,62^P;.==8K=N(&/)E-+D:U97O0FIJF0J4V56EY\HQ5:6^=[['T
M8^D_I9WS?NFO/( @4.9228ZB0B//ER1NH#:1]&]2L\DK3LW>NXKU_.+WTW/P
MTQLV-R7!^ [I-T>H,U\&WSEDJ]>!2LC6G+[I"HH8#09-N;!.>609 E5<LX[B
MSUA]YJ;8&DOR-Y?D,]\&/T*2[5+?+EGDNB].%E-SFIIRGDF82)*1R<&\5:#Z
M^L,JTK,:^T\L$!Q1.;=/]<67/S_Y'!A?=3V7Y8(D^*@(LML>J^M%.D/;/4Z<
M%,)FBS1; IP4,EE8!A?,PQB ,> Z;9ZC,<"8.FE9E(RA2-@/>JINY-=,?X$P
M !H[7/+T9TB??_']G,;,#:+6%4/0K>#)R6V*HZ"DE>0MWQ"235E*/O1R#,G5
M5@*$DK@>'D7>4=P9>_M@0<2">'F">'+%?IP@BL6,Q]2%IEWQZAJ;Z40USQ60
M($*=SM_Q;V9Q?X,0QEO'*'#1.$7D^@^)<>+Z]1@/KP1@ZX^2>.C8EQN13$,Q
M!+&M*^EITIB-G;JI0$!%H0F:Q*$)+,U8FB_H..5-:6XLNY7A@ ]4F4Z7:WFF
MLEBRPR:29A1D.(,Y<EE9J4^:%Y_;%KE%J/K&(=.KB8^>NDXNYF/,QU@9OSO.
M_Z86SEFBS9A!<V!S,YWI2HU>LTM!FSJY2:7D4J>_%_K%9N0F_H^3&/ !)C[
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M+NM/RX5*P8L":',$=PFPU  4E/BN;NQ60\+L?IM L J#O[YX,7O2^G0]S_5
MG*9QI';9"IPVU&G )H%"\GP*"ER*5U0NK2H,;Z1I+<VEDC2U95'UT7])ZVI*
MGFF2G6TUPZGC-0II:Z'$)\;/1V:U=H,MS4J:V'M(-O.]>2[J18)"[X\LZ5Q6
M(3.&*+9=<CWH"A*EB4TEN3\R9XT&RW%7]<GVK%$M5 ?EJ>A![PD96L]'3OQ2
M4BEUS1Q)SW.92K;@38WB0F$4\N5(>[(:=O.U"4."<.TE3<E)CA:"PNZ/U IK
M(L.NG9FLMJITI=V<K,?2 H[<FV<JOWB0P4Q7R4J0:JNM):>V2/3,O7FVDT6W
MDLUPIDQWZ?HT2C.Y)6$JW/[;*^UQ*QJW.U-YM2H^E"IEK\3G%@J_/S)7:O?+
MXZG<EKFUH&EAF=<6RD))[8\<#+,%QA_2K%S(:':I8_&U'-SY]/Y((3MK+P8.
M)X@%KF:7<G.1ZUE-A2+WASY0&=+(5!L]<K7H1PYP-'9:@$.I_:'>>%A>"</J
MQ)8>:-45VNMNR5@@ZWYO*&W23D,)*YYH-:L\JW+)I%P3%"JY/S0E252F.627
M,D=V,]F@5V&K:U.A#A!?+R_34K9OENT(/GT,&D+?D^#0 ]0GQUX[C&QN2%;R
M4,6SDMO.JG"N!TA%3;MTLUYG#7MFML.%RX\T*XJ'[G&*TABN_(=9SK +BUP@
M](1%2:PWT= ]5JG+V4:[( E54LUYI$G4.9\MP:<>X(!5O3%H3,NJ:].IE5.2
M>+)O5.%F'6"!?I=:-%*INBC/TFHA_[#(4@(5#]V;:X4ND<%R;JWE67NJS&E_
MMIA##J12^W/M5[K#1JBL1+&0X\SQI,_W9A/XU .<I4FN.VI5YV5;*J1[ZR1?
M6DY3\="]"31(GO)R^5S-GJ0G*JL$@.B5FVCHW@1*N;Z]KA+YE"SEX4]-VZW9
MD+/H _S*C%--J^NTLZ3DIS(,IPX607F!&HCO#25*^;XVM8DUN6HM^DEE.1VE
MN+BUYVYH[,<]FKT;+QV:O(XZ#<"/W0]/U0*R$K<6(K*5M(V-M0/WV"15H]#;
M?;"Q1^-/GIFM3QS][9A]OR#T=Q/;OI#::)DC@]_4??+-NRU/#, GS_?@,PW'
M6^P4TNYW L4T?FR,_ 7<IU\:UUL]%[]X-U0=0M<N"L%G&-7D/<D>KJ[VY'OO
M"&[]=)4^'.A*O7E="M/EJ^C"8WFY2+J0+*;+!=*%O&??/'C$A,$*!M,% ]G%
MTP4#V5D)\]ZLG5\Y+E^V":G/.PM_&\'/?&)TH7ORMGE^W7NB>0[Z\/_]P?[Q
MNRDC[#W)GW6#4N_?G[>B^WG/1T>^F^.8 5#]A.CJ -6F''X@Y0^#!P8/#!Z_
M"1Y?F!M]8G!YI:8KQI8+QY;WL\'3#GDG;O-X(ZA!_RYJ4-0]^[4794^,&BCI
M^#E$W)RD8*XXQ!7T*13'!32X>;KF;5Z3:R;$Y12X 0A.T=-YP_<7MM3?2ND\
M@>K VQ"'//$V;"*,7[ /;R7^OZD@OBL4G'!UF+6OG;6OR0'DXE>T0 !47QO%
M^:\ZF /'FZ(\Y6NP6"^1>S_%P[NT-;]]#'G^-9_B7MTO#^T^H8$GNC+R?&6G
MOCV7BS97#Q1*V5Z)[7A/+\B6O7&26%;R:;NW:M0BKS.K2XO%!RHL;M!%</7<
M3VS9N@<';M*Q\L(DQRE*(HD\DRQJ1> 525-A%>:/?Y+\'94^2XGUVP0J++37
M*K3T,Z&EE;21U8A!*\^0O>*:S@5,9CA>FY\FM/ITZ!/*J$_(44N1*:-NR/Z@
M"866AT)+WB7IMVKP7'GD8V-$%8 +T,539$.I^L1RK2#TX\R,[^KUX #(I05
MOC \^HD^\JO.X5<O_\)4Q)GMNBW@00TA/(.[UY5$>9VLUP?UC"IFE7Q]&LB^
M,"TL% Y9=E3RCJ4/-5K%V(E! X/&=[$KWP\::W["M,-AJ-@11;-#-V()98)
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M^C&\8ES!N')!N')FH_1H7 $/O8X31-J:+.2S*FF9+9H="@A7D#%*W273;YY
M7%,T<6-ZRJX/X,S60$^8JN4F_D1VZ%\)2&&XN0#..*%%O@]<;94(?=4-G)AL
MV/?&L48<;\#QA@LP&>-X0]:;3'TP FY@S<%/I,]O("R[1; . K#-(@57[_R$
M,T$?1T&(BI5#12$9'75Y0#7,"&58%].-AKU:TNDZ(*8E>@9-SKC' "Y,AN'B
M&\+%MS,$SX86KUJ4H[0AIUO!G+6YG#'-KJ>CII,W$6R@6K3?/M%Q<UBM/=UQ
M'.K$H4X<DMB\XH2];"YQZ9>E6\YLB1Y0*\<H",/AEDR[(0[)[$Q2!H!?)+WT
M0J&XQU F+I:&<0/CQK>U27\3-Y8RU:RTF>E$GN4669ZU.VMW)2#<V(4JOTWB
MX_-3\L04^(E@I/H EUO#<<CKN<7X9<=/-[;HFQ1HS-S7M.@K#^UL+R)DU,#2
ML">" SG8(<,.V3L<LIPUMW00NV.Q&1\H:GW9&9-P0^15WAO9@\9<HJ?"J:,Y
M]#N<,E'U7;B+00/X;33'&.OVW3'RT1T+0QZ,(RW3%:5JLB\ AUC4RJ9"Q37O
MR?O4_@4&',3!F($QXU,QX_V1G+-BQHCP5DQMZD9BI9"64Z85^$9.0)C!(\Q(
M?YN:^5N#,6<Y40AT[.3AJ,T'TD&^,8I_]3HO$+(_U\S;(M1;H,UZ=J]J>:V:
M# C?99G!K)Q-0]!.?X*AAX4?"_\M"?_GVFM'"'_&X[J#V=+LBZO)-!7U::EE
MI&+A/YO%=C'.W>84K@<0;P"=4.'<51.@W*X))/^&R@DO"@-TWHKFA/U;'!K\
M_D7=+^E6V8WM P8'+!7?52JN,+QSVO/ JZ0:#N[@K(6K=_8^<$EPZ^LE&^/L
MF)YQ&1(DP:(=&B6&E$^>G4V^P]?;N2W"QFNI1Y,A\"4C]OL"Z:?3LHO9OW3\
M#'U%<%%=;(OM53:?3PZ5G#03%#IN-I D[T@Z?4>FWFKY@N'PJJ#AO-?\L,3_
M5G3G,R6^7C$T4\T;*5&=+J.N;M2<R%@@B4?YU<D[CB'OJ'3Z^]8F.].AW<6L
M#P=S+@#B\39<9P+'#=F(6P#<4QP'=$9S6<^4 Z93L]69;$A"I52?V$V%IC_+
M2L3BA%$%H\HUV*'O0!6FK/;U/-%JDBO#"X+"B*@KY1A5WF6)_C=4(9U/2D;+
MA?P;_GC._R\9?O,_CP5.D%5YI R<9J;QKXN8"E!N'/TI!VH M9MX8_*;9Z&?
M?U@A_(X&!W1&(*%JJ*:%ZJX@R1*N%\(904(FX!<M^$335YW$5/7#A&<DPA$(
MT#&I&]=U42'1$X;EJJYFP4&0["% M42"^T]8^0N00K0X!%%/O^<B/G<^EV)/
M>8LF[REV'U]?F_I[YZE;P=115TANP-_OF[1CN8 8;7;I@[/^N7[R>.GXKV[-
M__D?_&OW%,T!JH]4P^COYS*71$_=*0;R/V?!\N>21#,[/?BX8(HFGTP[_OO_
MGL[^IZXB-,_Q_!\[A?1D6=O=IF/=9 )BZ /5)E0#OOF'ZBS45;#SI=/WCS&7
M'X\Z+1G3@+Q/LO])//D9[<?>9D[4)?%DR[:JD'" $?Y(_?P]5F'Q!UY@(=3]
MX0-4)F@.T%.?/2^F2.A-?] 44G-_3^"OVP4QT"=DST2C%RR8_$F1_ZF)D8\4
MXK\Z4O9UW-LBP %0@%"(5 H"N2S2KQ#%'AE4/89)GV_QH1U48R6HZ*R>2JM)
M7N$ ;R@,Q:255"J94M(4QQJ 98<DR?RQ>>O7*(VL5*B7.B6IGN@4Q9;0$.5.
M*=N^VT012_7L?4*HYQ)M.=,NY4I":Q!OSF9Q[4<5X!GMT-/L$7P?\ -Q%D$(
M..FJ]A?QMAH?'M((\7:@%=?;4K64$SHB7%@'_E,3ZYUV0LK#WZ1LI2A5<V*K
MC8"+XO].B$VYU('+'IY<49QH/7]:+E357A1 .RRX2X"E!J"DQ&9E0IU 7 J#
MO[YX^J_IZ">Z_7?,K*V,&92>8C1&4ZBAEE28%#F$,D8!A4RFAIS!:JF4JFZY
M47W,AULZ"ZF?KA RYPALGLVE:[HN(,.:?CG4MC.DW'EH\^(J\V#J(P64^CU!
MH17NY4BG$"7IG)49RUQCP>7507%&1M#>/?#0DCZ:,C6JZ=B] 4F;C5HPKN9-
M-)1].;1/=4>]X,$1R4G>'W-VTRBY?E-)*M3+D7-9&\MF?IH5:6$TF>OMLCBT
M!#AR;Z843^F>&9II>V5EP=ID&HUZ>0%'IO?6).3S07G 6?:LDK*]X7"H^U,T
M<G]-"P[XV6(O8F4B$E5'K?8ZN78\=&]-1F::<I:KH"A;Q?XH6Z:3XR1\*K._
M)K//K:>SE-L5(XLDG)18]-1A$XY,OAS)+D(_Q\R"JDWDZL-Y9^P0K;X 1^ZM
MOL.'LJ='>5]<479%"G5UE"),.')O]=F<UYP5Q^VV&%&I;&.6'\ZK#?3V_=47
M/9FLB)EI6LZ6Q[G&(B^G&Q7TT/W5UUE+[9<6HQ8I/2S:3GZ8MA2OJ; *^7)D
M3UQ82IM?T2+P)MR<K8^\HKB (_=6'^6E8-!TNW.[+?EK0G;F788TX<B]U7>I
MX5*7^.%0; >I&=]^$.K+#'K[WNIK8:;AC;P!;6?GM#*5&NFEJ*.W[Z]>Z2A3
M>3*H-^59)FW/HYF1EP3TT .T%ZCAR%JN"9*>#OFA9:>7]-Q4N/W5K]KCQ<1=
ME7MRKR5/FI-6E-8?%G DM3>4&;'%R>I!K\K1E./:88TI*4,!#=W;*4#H"M!;
ME0E9(,:$QDWZO7ESH?#[[W\H9C-M75G;<E1.C]?+B%^Y(1JY_WXY,!6E-)Q&
M8K;L9_QR&/5TT41#]][?G><DL=8%:YFFIY5:/^K+$[C^U/[[L\/)N+[2B[1-
MD.WZVC259FO:A"/WI(0J<NOA$)3K<GM:\C.>K5CD8*'$=SA?C"P55YPNL0,Y
M"[+#TF(^ZDL!&KF_IEFGFM3-=I\A>[FF.C#HVJ U1A/=7Y,BU=*]'LD'-A<:
M[8*1L1>3AZ:2WE\3Y[+E16<T]<1)LB3S3K;7770%.')O3:U^A]3K#T-+KH09
M4Y7 K)F7%TIZ?TUFU:4'SJS3$=4R;=#-<J.YG*&1_,N1R7S-&BT-110C-VLJ
M.:U<KT[BM^]-M.WV6PW'+Y7$['@2A'PUZTP@\2ER?TV-%ABYA9FABQ73+E1G
MYF#<4P4T=&]1F:K4E!;"2A%5=9)L6&-I 2KQT+U5#<>E^LCQND $V8ZAE,VU
MVZ\TT="]98W;8W_=K#\DR5E08/D%8)KE93S7?5+59^WJ?%)R(%-G2T%9-8G,
MH!1W,-];5]"NLU,BKTSLGFUV*&YDC:VAB8;N/54NR&)FG#<LNVVK=.B:TJ",
M&J%1^_@SLR8>7$P?BFJP:IB9>L, 7/S4/0":5F5CQ<K5E"S9V2B3'$[=XKR)
MAAY ($(9)BE[-+3;S;!?SE ]B^S$C]V'((;G>U)K&!#VK!^.HV0Y#_5;W'=S
M;P_J/9,G6M8@)4_8T1KJU-Q\1@MHZ#[+*+FN(\STP526>HV)(E<'LR$3/W:?
M#$7!FQ/%5#VT9Y34L@I-=6Q8<?>H_2FD3&/,"LN1':WT+.^5:P-!VS69>S[4
M=8AT3RD4"W9AG5Q5*LN@F!;BI^[/MJ_S<),:DZ[=2VJV5S/EN01E 8W=FRTU
M6\VEZ8)?V).:)96::UDB/!.U%]@7!G%2J5HF,;8K,XLGYUW#$\1=AY/G0T.F
M9^=43=#M2<K*B_-9QR#*\= # .^ZRWK+S?1%P!%*8^AZ S<9-SC8G^U#+L<:
M2;ZRE&>>&SV0<J;2JBQ0Z=J]Q_K)Q:AL5Q:!/0D&U2QC22SC"VCHGN@Z#D?P
M?#9OV);4K;33MI3C=7-;1_L%(-5(HC30:BN1JV:65:?G/K2(S5/WJ3NF3'4Q
M7V7LMM#CDI+>2@Z7\63W%R9;%"<9*ZLI6O,V4^R8\$O))BJ=MO?8_*)?* &W
M4K>M)5#*G-BPHV4\=&]AU8HS;VKUJ2!..+X3,E)NK"J[0HXO3+STO-'T1E'.
MGI578$VXO55UN=C6;GL^M/! 66*M/LO*TO2!FZ;5QKCEQD/W]P $9K8LA&/>
MSHK--6,/,^.< O?K@$X> UFD6TJ!LJ-VUIE;CC[P4 ,=_H#I."M:'8(E5G:!
MKV1*::'1<N1XZ-ZZ2+/>RKJIH6=S\D0M1=.5_B#'$]A;US1XJ.:X=*U,JO/!
M(M\;6@5NMIG ODF:#&=>W5[.;%7IFU*CR:>)45Q;87]=85,@YEXE(TI"TD\U
M^!'PD+I)[6.M/U(C75[T.1(T\T*WR!%L 9$VM8^URU4Q3W.B:]HJ.R_.I&:0
M;D;Q4_>P%MI:8E=8=)JB*E!*O;8 Q98>SW4?:]/NJB:-5#4GKE)4A<X6&TI4
MB1_[B+5QS/XQ1+8YN]$\QU&G ?BQ^^&I7XDB2]NH$HJO:)NXS,X[C,-7!'E/
MI]))ADF]B&L].?/9!K:>!0[O63Z.2X7^;D+;%U$;]_2X-)=D.HZYO7[,]"18
M].3Y'GRFX7B+G2>[^YU IUX_-H' !=R?7P;BM@YR_.+=4'48>.@XYLP!N-?#
MOM1[P[[;OS]T2)BZIS A+H$0-*;"!5"!NJ??3,''A/@D0G#W/*;#!= !P](E
M4 '#TH40@KOG4I@0%T (C$N70 6,2Q=""(Q+%T((C$N70 6,2Q="B-0]C<-+
MET (C$N70 6,2Q="B-0]R6%"G(X0[[SF_,OSG\];-?>.59_UI.7,V?AO;D)J
M>B#;^5-VY4V]=)M;\BLE<9N[\HL#@=O<E(N6'BPLG[4)OXK^?/4F8.' PH&%
M PO'F?A"\QST85SX^_=V(WW/G->Z2!VQ'V]=3!,T+9I$CAH781IB!L#H>#*O
M].U R.<YXA_&0AR#P#&([P>%. 9Q.;N"8Q#7)CV?;DGRYR[4^V%+$DX'G3>H
M#C8D,5ABOQNC)?:[7T=+*1P!'P/E64A/GQ<>/DKZCA>^U)$WY6$^DICY71)3
MJ7LR];+J/35=)N(BB)]1;/2C/)"-^]IM"GC%9;DP%-RBS=Q0+9VP7$S\6R0^
M#KW?N T(E<#4!R/@!M8<8!:X15OP:4G.;3'+&[8,/W+V<,7&X*9,^U4 P!%+
MW1BU!SI<G4*EI^FKIK00EWK%E#[2>+MB2F?5J;7GYF-2?T=2YX!A:1:6ZF,M
M\BLF==4+L)X^UNR^8CIOJN.?PA+_W&91J2-M\]0]&_]W1G545T/M90+49R$'
M-( :"&V8(DEM.PS0)$V=W%S_5?.HK^27O=91]#WSK-W(+[;U#&VEA$"1C)]]
MI"AEVP%*>6SPL.%9%%/P7-3O05A:P>.H3;PY]C9K,8F5=24_(M)^JB+VBMU:
MH-;+:M%ZUH>J5,^_HQ/5,;VFRE&[H))L1Y*)H>X/H[E?3*_B N1__$/3=S1J
M8I>D#[2:.N$AZ9=V;_L5ZWQB5L'E">![@.O?)\Z]NKS=^ (XDMLY)=G*C04^
MGVO*%<**^-ZH0_JCK\<B(OD>*-KO<[/#HN0C%JUJ[H"H+4NTF%VOPU7U84KF
M"H(2%XJF,09A#/I<#$(I39>W'=\7A'YF*Z(SV)*[C==L 6DR;C:;95K4[-4J
MR#WHZX>FUS\S((FEQ3K'K8.(+$S89O%AM:QW1J@Y#/_'/Q3#WC%L$J,21B6,
M2F^ATA$X].=E 5$+A*KE EU4?1=N5+!%(#&=T52Z%3[(;568<FVI4GX )T8@
MN('P,0>@J : ,Z"7BZ5LI>2(4;IFUZ9C/XW\XY\T<T>2S!X4_86Q"&/1^;!H
M4^_M\K;C6V'1DXRD.#_Y68)*R=6\"=C"4T&E']PQ5UJ1JUFCKX4175TLFI\$
M3Z5E*?*F;DC);2_R1\8X,IJ;/G9):"JE4QB;,#9]+C:AJ\Z7MQW7Y+UQI&B4
M!]:\($OZ<+8NRV/5B\[L<4EM3B[1#XV>6!"#@D2TRW/6B5MG<G_\PU)W-'^$
MQW5Q"5K/!>&Q3SIW#)G%)? U*XB;;FMQF Z.A3N9\*9H]<&I3X&^GP"\XT@G
M%_DJ>A1J:(R$@%8ZWD^1H#\<51V9GLP&XVS1YCPJEP>=>D:U%A\XX4'/+@5!
M!'0X=4BK!MQS3]\<_,3_*6VX9,=%^H$CH!532=5S>HZR"TN6 @N"-.ARW ,6
MJNX[GJ/N6(H[;YSC)I7UC2WZW!?J+UR]?CVTO%];[R-+5W4B\#:P_%3FO::D
M"]H\;XEJ,1N.ESD)V&G4AQJ=YV! P8!RX9?.;PI1WCY]R6M:J;PL5R-RE>-2
M1,HLL\O"UZ)+8ST:$]:B6!<+BW#NS*J"@SJRQRUUJ3L.FRP886X.8>+[2O1U
ME;"X,)K?)*/_JG4+9O3O1_.S,_I[P[^[O/?3QH"OB*D_V3Y,&UF-&+3R#-DK
MKNE<P&2&X_4'X[L?M.G41;U-S,.^0ZYJ3$ Q\A@ZBW$HBML8=?L'22>*_G[E
MI8#W!831%J,; GL!8<N%Q')0BQKXT30:.I8&QQ@ T>(NX8(0?4.W @U=> P2
MD)L2UNY9FA>$\7V#W7;^ZJ3FBUR9:!A8NJ7ZJS;D',F(^2IV8S0S7"KY>/F2
MVX@7+VW7OG5A^(PQJS*=JBT3H**4)Z(\6<Y_G]T%?1P%(7*K@H[WBO/T1"1V
M5,NBC7[)^775]Y6L5>&[<T48B5(C6J[G#%%<%YM__),ZJR?SZM6/[X>;MWH.
M &D2_U=P(/8_)%L.X11[-%FHD(I,:MYPD3$5'L7^V3N2)-$?G./X16?W-[8/
MKUW[^'Y0=(.'!OLH]-/L2]:SQ:!,I2JDU9^FZ?FRKQ0G"XA"#$0AC#X8?3XO
MV(?AY_N?,+P%10U.#BQBTM!):UU2A8GH9SM= 4(1CPPBBD]C.,)PA.'HZZ*T
MF#.PA/SB_@&6D!OG#"PAO\B"OR()^;Z'(F^9H9'>K"^"1321027,9@=IQJ6*
MR R-\^#OJ-3^;;]OG@8?>Q;$4 T *H<UF0(WB EYP_GO^!#\\@_!+W'1UY:)
MC?D<\_E-I._A\-V[3M?1Z69L$&2?V ,M !<10(YH W]N:6!C<+6 YIEN_)38
M]CI@<CG,K!SJ=;I!<AY+^"F66[3RII)"D;_D'<OC&PL8D&X-D+#FQ8R.\XDQ
MHV-&QSG&EQ!.^P*SL-4>48,*-9/(U7 >- M54VCG%M L1)&X(^W"[YZ2'%<F
MBJ-RCZ6)$DY<EQ^GJ>*S'GS6@Y,GL8!@ ?ER <$)-5A"L(1@"<$2@B7DVZ2<
M'2$3IRYI>^)SI:,KW$ZKV6:%KZ=6(I D DS64KK2^?U@PFMO0QWEZB"4C(ZZ
M?*OFK>$R%,?E2TNY8K1!MBKDTPUZH:0W-6]QQ5N,2;>:Y'>!F'3B0.1'L:/<
M4>O:S!J[MJ6;DW >=&EY@QW<<=CQK9+[X(Z=)U[X?8H]XP.J4RF,K^.)2]R4
M3=@0RPF6$RPG1\1&L*!@0<&"<LV"<H&^R4FZDY4[,IOQ!2H4)^LDJ:KCG+/F
M?M_!@2;Y3X_F+4\F^U!JCU;Y"6_/2LF +93Z=%IN*A09=R:CJ;MDFC]S+.3&
M) S#SNN1V8N%':R?;U!0+J,"ZN4*Q07JXA/'"8]6HY.Q;K2%'M605QT*@$JX
MXKK21HUR[U"CUY=I^&L>R*@.JIP9)-2X0FD.:+'%LQ&6)'6W^0%1[Q/R#2]7
MF"Z@;.:+%G(?KT^GM3)5TR#R$[M'KY*CI6=45\^;?K^S3F:\%BD* [0Z2)P#
M)3&EN3#DS7F/$M5&4IP.M4)4Y@6%HE!-3#IUETY3=RQS1"%B?+R'&UJ>/;WS
M]O#H-_M9?@88G;X?)E.MBD/0RP.YTI_6F^*\[ZRK,1BA'EJX&!T&H<\%H5<2
M!#$*G0F%WKYT/V!6=A68M0D)M"Z[E$&6Z=?.C$@K+J>+]9RRL*-.$BRKH1<\
M=&)$0GVW6/8.BB"&)0Q+&)8N+/+Q021ZY=AA+#&ED9.<#^6566/'XWG35*H?
M+-O[$H)>#9KD3*K;(LMYVK;:HTX)6-*LT#!C5XV$8$2Q=PR)$S$Q&GTJ&KV:
M(X[1Z(1VT=%)X[7"4#)5/]\1U5*=5#+.0Y=O-3\)H-K]F5";:CI#$FFRW:FE
M4GHZV,224(YX>M^!P^"$P>FLX/1*LOCE@M/%>7"J6<X6AL.H018&*8.9A_:,
M883S>EW4- GT2M(.[/;8GC_DM>&8 XL82+@__F'(.YHY(ACTK9+&7^V#!]D:
M^ FH%1)J2,!_"/@&&X2)/X5.[:]$ '<V2*BF#V(M\]@8#SW""@+4H3!NC:<Z
MCJ<A_9(P +B@UGC)9P>6R6-;XPEA+=Z%ETWQ"%NN2V//LR6ZWQ1M04PSVIG+
M]KVG*5Z7)#I,B3329(_.R]V!DJ%IU42!AG/&/J^N$O#Y.^"]RG:_&4S_&-M.
MQD-#F72BE%@@J$9]V*IK2U'X@OYYZK!LY_O5;(.4HKK)5KK&H%4VT4:AP\*[
M%)N^(_DC:G7CK!Y<9^P[E6S^*B5XH6CT*3T#F'2UU.@5,BY9T'(&*]3-C#)M
MHFUB_O@GB3$(8]"-5:^]:!!Z^V3O8X DSP&H=MFQ218"WDV5>LM,8?G!F-=O
M %)/GM%FWT\U1:O3:ZCFRBH/&PNT99MF>C0VC# HW1HHX;Q^S.B_?ZR$&?V6
M:'YV1K^,"RI7Q-2W'-S]73.PS_89MC\F*Z3%C^0HS*;K&K&)D6V:V='[-UN^
MP<66$YUFJ,'F:"*.JB<V$5Q$LP2(O8N$8[D@85@N_#)<2^+/NA>"1.J$Q\C?
MH?3VMXV/;YY:A3R0W[% ]I%;-N'K[0--)UO,I<5P*+;[826?C\2&46M^0<B\
MV+9!Y.@#VE8S1;,N,LV@/(%PD$0A<RJ5ODNQ'$X@Q;7S<-'T+S.S,6-@ ?D^
M):&_?QCX>"M@N&;,BF(E\V34S/)^E2CF![W/CPP7]$&3XQN- JGJ'J"D:6XR
MJL<V &JV2.'+M1C>,+QA P!+R)?OPP56O,<2<A&<@27D8NNO7XV)?"JSMAJ,
M9MW*FB)LCNVGINE6DY_D/C\#B_0U>9ZJDQF;UNS%8-C.ALFT$(>VN"/MVMM(
MT?=!?'4K$7IQGO[!4#9.Y[Z)</7N :-I5<KH%9OL/6A]H[XJ:1WZ*S*ZF:4Q
M:MA,=4ZJ-=OH97D+O@6ZIDP<GJ;9.Y(\<WV#&].?-YG-<6WYW#B9 _/Y3:3G
MW62P>!<<ML7)K# 1^C;=99+L:F8Q=?7SK>@N[_$JX+,^"2)O5 3K?FB/%D@#
M\Z@2*M:^&)5N#96P^L6,CI.&,:-C1L>)Q)\<<=V5FNP6(JTM#5NRI=AMEJC+
M'5KY8*G)W[ - U&NZY-L=B("/A.,P-AH F43G>&.- Z_>R;QAH;$4 V CJ*N
M4^ &,6_@E&!\*(@/!7%B*180+"!?O@_?(?/JBF.%8=2M.,I#-)=IT9_+E.>D
M4MSOA_J.JON%CMYBJR3[Q"AIH;/? #))&_AS2P,;.[ %-,]TXZ?$)N$!2W#
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M"M.&6ELHW/[(J9[JF]Z &LK6B%PP^=7X@<\W%7Y_9++9*J[*#K>0B9(=F<Y
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M-3XJVI_KK"<-EVS-)Z-V^<$=-VRM94(2'&"!D.^TN8>5.+?I' 5HIF*6E;$
MO<@#0]-ATU#&0=]NKR-F25:2[=8<#CU 6,,8<38GM),D-RBWW<QB,!6*384^
M0-A>OSYG&$ZB2% I$1F^-JJ5ER8:NL>$Z\S*<X5RNV-GNT$%<HXP7Z_@4P_P
M0$27Y*&>7M+B9))15OK<'%M0!N#0O:?*;I@$Z>DZ:5M$J3/J$L5A6X)##_
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M!CAN<)5Q@Q,7=;XM8F+?]LOY]Y,/H(\T:/.QGI#<1JPE7D:_,L:LRG2JMDR
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M>5$ S9S@#I47!' 2P6BCB'244[W[;1(;$YN[Y1NSH!Y-X-*UDQRR/7?Y,U$
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M+LX:O6FWJ&2S3VVC;\A8\>!.J1WXR@3G\51J$90@UCG>$K9'@&9(6TQ0TC'
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MG84!,]=T0=_LP1'>[WW\@-X0%E3X=WP_>-.F@J1[QL$" (0OSMZ1NT#XT73
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M%!;F@ ?VQG_NWHB!2!(+P,[!VH<=M2#+_MF/RMC^<3"0*,>@RVDHR/[KP1/
M28ET-S@&>@>)C=G!&WI.P#?,E,!UD, G'#$:>-$=Z!#=W>]$N\"=8UA1-K:3
ME)X5.T?*G2U[,6SIKH&>"-T2X;I3B S'U^/W<E#3!%T<WSE7L[<')[SIW)S-
M4ITOD35X,P(5%'@+PNP.N!':!8(P%0PP9,? F4[>*="CN7NM]UT#,):0@1<I
ME#SM@U!.AYF[B)&]A7DL*1:!F"<)I+G:XQ2;0A[S@<:FE8V#H\[E6(#9HNU_
M,BP%(FINB-#TT(]AZ]T>*K0)97=F2H$M:T"CN.8>"X<?!AJ6GZ2H!5M = ,D
MJ.:2GP\3(K<-@OAX!P=G(A_:?C;;1V:K4<.A>Y6*1HQ0:B8)@ ATIHBCW5<%
M0Q(6#/5]5JA8*9=3QW[!^YT[;-_]=6[W?4HC#GKZJ"96(>ET /C)==.OA[U@
M9]4)=CNSE#%OM-<#(;)-?!+'^]X!B3RE 78XX36I*>UGF9J,-0+=HHR(1(+L
M8+MF4!W:SAH &\"6A ;M1RD8E,&0'\!9@$D!GK)O4LT@%H7_;U I?>I+0,X#
M09UB$B,<;A?P)2Z3.Z!B,.VP$)MA/1&M161+XR'"Q"4H"H2":8("9D2R3P@5
MXKQ@-NC$ZI2(K@GY$52-LEW6SEMACY*&##N.KH#7V0[2>V #CS"\O&T'*X8X
MW^@R^NRA!3Z'BT327%.@-LPZ%U_8W?M![$R=#[NU049Y8 5^W7^0+;V7"_K$
MSOS7?:K8&0"&>7!8N L;Q@.<*Z5DDF(#:C.$TF(<>\<\KY-[3NI)4P#MFOD)
M7(%C_[6?1'X+_HN5,NJMA*:-V#HPQN#?])@6H$!3O18$E4<8$OI6L/HYE&UW
MBH0POW%K*SQ+7<T'D[?[Y'OG3/1[H*M['FX0!6:-R8S(1F>7LF$K?B OR?-H
MM(KFP"!L?-%4+K#%2):,9ANG0)]86!I8DR":HJ-3G5#(\ LPBLPQCL#Q-<P+
M!6F):1_K6!I6]&P##^PRT*V(W*?/M_T/3DJ8O7 N0*XM?A[)_E*?,18\,!C+
MF.-A_6[CN1OB7G;@-D*JS1-=+RX #9.O2;*R9L(:\\@M56.@ZPA4O P@ FDG
M:Q&/+]$>\;T=KK34X[6K,9S)!QONF=K18JR[*R3R.-YS'=N)"#Z H5<)KY=W
M[O==KA^^B=V]$;U81XZ&[?43>GVYVL!.]1GJVHPQ-$L7B2# \@<1<G3M$*)X
MT90WDZ3Y='S.[ST27>=BC+92]T[INQU'K3[X[L221E0T"P/-.C/$J,/,!VY$
M)0:OGZQ2OQ4Q!):"K-@@H"JKK(O6#",DV&E7Y:<!\G%3+?<4]F/K]81^<N<D
M!%!F N>^ R.4L! []'UG&Y2[)8;S$<TLO-OI%W-A0Y^!/]'![>&&]TD")_G2
M7@8F))ZMJ87EX00#) HV55+[ Z-J@'A/77\K_9.!_%4^?WWD"\3*H[=8^2U6
M_F&Q\M";8N7AT^]X5J>^*H:Z<Z?LU!'9L%U4B,;BQA S4D"@V%;A0=L0C^/K
MQ./V9)"BK4 *D0<2OR_(7CN_VM@SQ&R'CH=3>I0JNA6ZK9>V0#4)0]3E 4A$
M+!E7OPB.T7Q_AYW03KJ8E2C"W$"_G!_^?0<B<OOS<KN/@*#)1<(F HJPP;K!
MKZ&\1K[FCP?='29%27&_A-NN8+,O_\=_O'_[JW,<U).1'>(3/%-%Q]YSX:-"
MLO_[7_%(-/[O8;7:0;79$3]Y!U/S.694!C2B09&@;W9BPK^H@,1J+%4@7:XA
MZ+"P-' 7V-$)K-/;SK[]R!%:V_Y3B'$0S?-95"?X>Z2MWC&&!=YAX^"E\L';
M[-(A8 HT98$>1=,/RN%M[GM40'>CD1N-'- (YTLCKT9E3_S+VOG'*9Z"VJV:
MU-R62"#Q-.$Y*2U>SSQ^,&CH> 52 -=MYS]#JN><GT^3TEYJ!'TM34D0+7V)
M/+Y5SS/P)S10@'=MDR)Y##[\5=$5>R.KZR8K_N_(RL>CLT-L)TI-B,.3YP<8
MOE.92'A37EC(]@5A:C-!2]<AU\/KZ2#UC8:; O%6F>)OW1#&[UI6EXAUS>8Z
MPN<VL/2DQ<'4J7ZJ^KG#"54IT*P\9DJK7BXJ39>3;:'Q2;SF>Z=ERIIQM4YR
MR,7501C\]SM7C/U]&MC;)HR 0\@'R0#V64W'%ZG2X7H8UW;.YH0JD=\4FC+F
M#E2I(K,V; MKW_*S2F#3V$BQ\(9=S&5^&RM45ZR<^/$[=)SU!?4IQ%,E[B'$
M2)!IGL"Y@<[M 9WKQX<I,?#8S(;8;G[+I8U0<C#9CJX/Z/B+>"N^T$>]Z/I1
MZ?7+K#RL]=J=7,=\TAL_?@=?#7U2\NT)/@[I3NV$#=&.1M#=.5S86Y -WF_I
MI9K!.T_QN;+9C[6Z+;5.8 79(/S,@ :G($\]O&V,TWPNE4RCH>E1Q[7S%XJD
M9@0=,LJ,.M))UN4I_IYH)X5(I"G.IM9TOGB,%.*=6/RS=+>H0BX)W!(^)4..
MR5P3@T\*!KY;&(M)4&F.-TD2;QSWDT62P^U$4B?NX2ZWLZ\I<) 4<%*L,2O
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M%[I]: 5OV:>WMMF3?^T C3@\B:-5API@\"'N(C8'QH% Y;*]18X-L!$ 05'
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M//,(3'RCEZ_KE74@$Q@T^'RH5HK/--CG$9@>-THX_#!F$VPJ.%YSM8'^,'^
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MY,1P/QJ)1ONA$"_VX\.(T ^)0X&-\9A+L>&W?^, <*_[#F]_Y\-:WWB,I^,
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M<9HSW;#5/_7PTL>Y +;2;,,;MGXR; U_3]Y**TUOV/K)L!7<D9<^SL=C*_5
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M$2=Q1?KSCCVML::;;:3/DIJNDTX+1S%&<M/U46+:GS56RC25G4C5]+09S?)
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MIE/%NJV6EL\Q&!!"_?J3P,F+E-6]%WL03\RVQ7A#^I7/\=<J4-^T(.95S_8
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M&\T=@O)=9$>7^K.EVFL,L6Z#P+ED)8]/4]+K9!<)^2.97U#LX#]W2)\^<5B
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M:[RN:J$ZH,I0W3;X,<R?WA)- +=UI[8E8'M^',*Q/5&W58..E/.9AX8C_?P
M5Y"#8$@4NLD-J;*VC1'3),<<\&/35>C=8+:G8W\4#'4SD3X/)*> 0DM,8&]:
M<"['/#!$63M<.IA@Y\MR L-@T!BR%8:J&Z7QY'C1H!OL<!/@Z^UFKVPLD+#P
MH'><[SZ</P;<Q<*UIKD9Y*(LP'%9?:?0=Z[;P<O$K(<B]P7L(-M9C>U8C;$G
M7)]:KLCXF+B1;5!\CE,5=E.0V'#54#J86._5='@_09VW#5[0^V3MI%L4J/Q.
M.J$A.J0!*T.%N ,KX&Q(R'TA\D3NZI$K%.'.X]4MAF"&ZAYNQ%:VSQ489<[&
M%$E44K58KSX =AL9"P.(6^/C%%4'G#.D\R.TB&BQT(MP*(B0,@8!YKFA_5+C
MD.&=&XNK&VWWA>4;6&G]10N;%:W-@+7+9G[,3CJ]3&;YZP^>2 ([S:]U']MH
M/HN>0X'" "ZBZY"$)\R^M-ZR,'Q,MM"!LB_ 7Y #.PWOQ(&T[Q%+[U[K .#0
M.^81X#:"^G%4?.2HV.9/P..\JFLP\098,?I49%8S43-/.S^?%SVK1]E3AEV/
M5:Q!CI(U?@,- =Q_,>M0&J ,'4X1$IW7/H4T$0:-0Y!KHH.PK==QZTQTA9"/
M%"*AS-M<!H?"*KC^I:N3RS2AQZ*9<K?*$.6),J)2BD@]?^)*_Q.B*CR?-85G
MBFZPK6R&5LJ;4:E>@***.*=9O"!. %WY].!]YU"PW$$!0/,7^'_J<KBIK>+M
MN%)+IPL:-:C/*RST&&+^+LI/\*#95SA.6C A=+,EH4/BC+_H@>R/(!MIG*^X
M@]Y@+XS6+<M,X?T$*W;BL8PT[,0IJ>$XAY)^Q#M<#7U[.S<0- L-;NGS$?LU
MA5U\_I5*P7\W5]%K?B&O;NU])1L\UG[?:[]VRL<NN0.=6E#S1&]MPL@+44CK
MIF4BE24%I(O@90W[$T&*PB8JC+/=F<)U^SJ9%Y1)..X6.I U(!]IZ\PXE%:%
MWW':2#+BIHB$AQ!.H7U0!BG3XOW^;D!+N+NW$#![8)C? IPW*J<%,)&DIH5J
MO*5#G2>.5![<,6\$&$QBSZ %-9;Y\4D_6W,_MJAU(CP)?\D8*]1K+P2A/)V<
MZ660'ICW:!C\UC/K0T.1!\R[>WTD5'-\AB;\&F[RT)KC142,$HQY0CKB$NAV
M7IP!]&<0&!Y_TTK L/V5. Z&[0)W&3N.;QO-@Q+%8<ZWN,\8R%D.+&CWH[R=
MU%G;$_Q&M5&-E]#?\C^N#://'-_ZW^B%NX<.?X7O!L)R;@,2&LG;C 3WYW^>
MP NW;X17XD#)XP[BO\#O8 !L2@B$K;5]@;>TO^7%B5]1M-@3S*MLME@GB"ST
M-QB("G3 HAS(J$=C/1B@]T7V('ZX#S=O'Z$-#$?IYT#/$Z<S55^+T+:G5=5]
MK[6>.3:?BULOYQ_II =//>WB:I^0XPI%.[EA;]XJ16,A\Z)W[6&8-ZWG<+*P
M^Y[38A<G!K1V^//+OO6=FP0Q!BI-< BJ/:\;I&C9_(KL"L_ @5,>FD8.4VXI
M! Z [.;:-7QM2(_[ZP'/QK+19JR0TUO/L^4G?!7;$W[_X*)W)F5J[5,":$AP
M501X8 R])=&H,N'7:8O6:7#VLW5#X>7\\U2"<3))*OI$Q?V.#4?.^+ +6^<9
M"[?HS=85ML/@3C !46$X0A#V.0+ @,6G #OM!0=ZH3/[)A6\)UR(!K2E-(<9
MS&W\)S@$ANOK$<?@DZ0A\FG;>N9:%46T:PFY4>M->KE/D,:>*\.UT1U<-UT<
M@,,Q:\,2%I[WXR3J!]'U9- LU!=,J3Q>YD9QK-C(PQRSIV@T"5#O[]_MXAHF
M1,R<5HGP!+MT[:W32O1G<5!NZD,EBVD3K-4G5P*S82>5SH'GF?@*YG0+>G$2
MT.WW\HD0+MV[3U^Q+X0M.3O!.T;>WF#<:M4BQ_V^O>;I7W_\/HJ_D&1%O<D]
M>>NPZ$GOP]W5%2$>=44>=44N6U?DO '\#G/YJE5(7C:Q]E+78-V08]6,<([L
M,ZK94@;*JW<NAT0.52K2 - ,$Q['NEN]")EL,T.&<?2[:!LO$\/5Y[8'_1.T
M,G;%GU38I!A-"FV(KSDT/J_5K3.,6*J,Z(W2"I=:*85E^-A<NI]CP]K$6Z7Z
M<I!1N-B:Z:EE"D],SAP;IX)=7@B-<71T9*CLT9^CDH546+I&X-;>2^7I5!1D
M)]@96GFBDY$APS4[=Z'(1D/&("0U$T!/!>3B(U5DT[OUS-Z3MNCF?O![<'=C
M "P1&.U5/335#1%:(=I/LC(NHTIVDZVU.9IG 96UJ^*L/V%E(@JLB/@3%26?
M\(2?VEZBJI<,P)WY8(W!\2Z]Z'&(N)?MQW&!>V+)^>BZ3SS"(##L;6X7[,#M
MXD8: EIU\X-W+JCM%,Z,[@OJ2'S"K[>A(8[I*ZYF,BQRX8E46.4/9?'R$.PJ
MS-H#7P#$CD39<NTL)Y0$5H<*(?7%N8OT7%&P'*!/*CNR'H 8J!W@+7_#MZ"_
MH.;TCP<MC]D.8IW/677.$>-HG3Z>1>/5M1?ZL .!YR'9M_T!PZYYU0LD/;%V
M&)HIKN -[T]@U%TT_$?.#8<7V"W\$>CA2ILNE!UGP4FFQH9EJIJEAQ,E/$S:
M&;[:W?03RU]_HD\D&7U"!?Y.,_6=%QQ]V0$;3.]Z2YQ9CKZ'4T](ZIQV<9\X
M%%$2$G3:',DKQR._#;3V$B>W3FL8>G=:_#Y!;V_X!7>ODV:YY[\]<H;RHF%Q
MCD/?\X2Z)4;=!3M2)@4W@KR[T%\.%@C !R_&=N?YTS:D&T7JNJYP"[EL35%%
MQP)42C2490\6BU:R'.M3;V%0\'K.7K0$3^?8"S('4'!4Y25:S]9+[M00]2DN
M;C51DQ^+@JWZ[CX<!_U0A%%L)A!P0..332A[(R%VYFI5YT4[A'UH9!O(;>SN
MPY/VWE[V1;>+[D@H2 3]BJ7R&2?R[LR_HB<Y.<"I 9SIS,E!3U'@'ZT)0,U"
MY8M.GB5XW(NYD>QTE6&LG"(7GH7\+,6:0B+XKF5#T.,Q0<PQ,2'?FK99# _#
M<,LSY\??%J= !G)R2'BG6\]+,70[5$.6<;035"-SSVG<<N\%R;^'_^SX94L&
MFE?:Y0R%;1W;.T(ZEJPN/A&+>Q@]HU#ZK^I45#,>:71[KFV47^8LRL^^>WJD
M*T0.=,6GG:;X!+6E,40MTB!-VS#@<N&E*-15@?$&I.4"@AU5%7$ECW-3!4LR
M "L>+-ZI4'RH$!KB694P2&+E_6H XYY+3H7&73170!6!]@=._'-;1.<KTZK7
MGPX]/C RQ54!W'MV<#YMD>\\<%SPW%4D=D<]XI3=)_==NY!"MV(=,,YF,]VP
MH&Q>OQ"F?XH?#U,"8 E=K_47V/CV'3-8)>-,7";GFC/@U]O:&2Z<G))W[NKA
M,/=T,(R\3 E\-L.$<U$AG&BR/:P4^-.!,(%-L3 F&EL;=WM$%D]CRYR$6CT\
M4:2_I\&+]32Y@^*D3@W[\U>1D$B#I?2T=KX*A]D<-@7$YSJX3G R.+R0]@E+
MV,,-/H6<2M+<$$KTPYM4PF&XLWY==)'J>!%><_'NN/Q5_>P#J-GJK+N+8@ %
M[O6YCMS-T /Y/F_S!1,G/L[.W7)OLC2Z6AU+2V:7MS+)U="2;LC.M."DT7JN
MP5<8>V(P4[$3[XS8Z<H4JP3=P76<AM?*;ZA<JMO&40$IY!(.T&W!I[$7[/L"
MLMOG ,BF798HF5UE*E%9K@"# EZ^+WC),O-?"L#,"/7U6P&X+(A0="_PY%T,
MO'HSX!,]IVX*_((T O0.^-JS_FA-7*I>VN@V"L*"TLD&<M1[=JNN<SSLW8+B
MQ)PL<H [\"I8,P.&F#FV_ +E'J*&++!5B5OO;Q>>)L#01WEH(XK_>SD6T;=N
M1C(D(;18SAP_G6";[5O .3(3#6O]#XS:X!T7O[QQ,]J=/9HS5;;@S_!<$(^_
MU V)T[9/3$5#$@TG6$U79<%[$1P=MF?P+UD+ZZ,16H)G>/B)8QN#MU<);ONE
M^Y"[50 %FW<:LCCN#T@B!R_CP3M,=" AFP[=USMGJ0-D059MK]&"J*G@&';C
M2!TJ'(J:.$+EY0"X='CQ#!LJ;+^5X5VTX-A#;I.6/3O(/J'[GKYD0N<:=!,Y
M= P4"PWZ:< $8(6B.#6=J$RWXXX -8F7/4F\RIEG;6+P2A4>] =&XVZ)AUKP
MKMKQUDWEFY77G;<!1D**Q %_SURQ?#C1WKM@L GL4B%/79\=#T@;*@5#'<;,
M?I>F-^0C..41G/+!X!3.Z^Q8'9,;O4;F4EA.T&/U$9_ GJ<-J*G\<F;;CLQU
MVYVY%5T\8VD#O#Y!9C5U0 \(_TAE)=JIE)DG,9$/+Q6^S&1H4P(CH\<C)UU*
MFD_M48*IF70S.^ZN&!J7!N0 .Q[9+<^D;$\8<PI!2SU=,T;UZ88&(WVS:ZW"
M@@RW9T5,'E0[FV323$UR<*1O]OJT4]0(84HKMC9MQ1/Q8B+>: RB_MD5LV;G
M&$E(,.E<BQ<GDU6+4^%(W^Q4UBAN.O&BK:1[79919T5&"M-@I&]VK)\3BCFN
M1&#K#-#N5FJF/"*D >6?'4_V9_2J,QVS4\ ;=)^L8#.P=\H_^W.R)S4V*VK$
MQ!JX8"7Y="W!P7?Z9E<6DWS)3+7GBIB=I:=3(Z:2%=C2UC>[W,\:?*%$%+%6
M.FN;FQJI5PUI$/>/G)'JJ%B=9P5FK92+.":MJ]%F XSTK1-3A(92KSY/%:[6
M25F%<7G>22[!2#^%3 1)G&2Z)69:M5L*J385JD.?HL\$&RV:W#!79^?F$!N5
M-VQ[-6\ JL-]"V6&NL2GDWA#D1>+?'DY;G6ERDD22;5P/M-:23F&:!ACENK-
MV-H0$FC\>&2ETN"Q06Y<5M9LL=;,TG0S7UVB:@C'0TE\.J#8<3V,=>/#(4VE
M&Y7:3#I%(XD!WNYHU&2MR*-F?5EF4NDB!>G.-WVFK0RJ&E%CF-),J%2,$<51
M(GRG?_J:JHU'W0:W88AE0TW4;:(D Y8_04[E=M0JK*49KW1+G4FAM9G3P_%)
M<LI.J>)BW"OQRGK2#@\SZY34S,!W^A8J/ ^IYP0I-+%<SUI&2URV+RN0F/T+
M'67H?A\W,S,EMLZ)N%VF-LT4I%'?0KE5"ASN!EUD8L]<KP;T*D$8+<%(WT)C
M[7$\LXDM#2R]5H"DJ^CD2($C?0O56RP]M_)#G$W/S3:YCG*U; KVO/4O5&XG
M5JM2NU'#8BNS-LYR&[-17YYBD4$K4R@EA.08BZ7+BSC5JN+YD72*\#NM3#:A
MDQU,B;&C=:YI+[KZB 8C?0L=K[FA10JE*CLG8E*IJ;<[&ZD!:,<W.X5/\-FL
MU*"P6!%OS>EV7QI+TB!Y0N#%ZY-YG%'RRK29R^@%:2,DEPTPT@=Z0>-;;7VM
MM-ATJ;38S"Q)PJ@E&$GY>"D](%KK]C*,M<9%KCVC$^-%38+50GS3+TM X-=K
M_0S3FI7+]4PFM:BM -?C_J$=*E=G2N$<IM28PBQ/3<=ID6]  ]LWE%V/:D8\
M$^ZPZ51UWJ,F=,_0)#C4!_TP95O39S/98VKE]"*1,C6CFUO"H3[PRWU=:U+K
MO,*TVHL.I>0X,6: !9PXQ IT*E/D\62'2=<[=L/DYK',8@F'^A9 U+FT,&C;
M#&/KI<*(7,+3&PWU%O#^^%+B7?&EY.VZW'W^0L6Y9*@YH0 !N$%Q+TU&G+S7
M%L>+5/ NW*![V>O8N37G!;?A)QH4LDWOSC^E @4_W.)A&U/3,XJ@@04'3'5@
MD>VBPT8ZO/1#$;NF:4^=:7]_34LY-P+!]=3[@X8@HEP\P<(*CM-IMTJD"?O3
MC=4T4%TUJ]9C8R31#+/33&DRO%;?N8]@^T(=_Y"%OC7ID/T%S3F5FYGB;^^/
M_?5""\BU?J =P#OV@V? (G,+9D)Y7SBV%OKFP"3;[QCBC-G9O G'C+(,;UWN
M?+BS<4O8EG00#91OY<+.V;[[$BH9B0+S;@]F[G0>_/9LF[WW0[\ ;'KN <W[
M'%X:@-@<^Q66BWO5;G1Q@2;VAG)#4U=M2_P*>Q&+8-0Y^>95#G@CG>QY ?[[
M'TMX Q;&LB6&P0MX:(E"Z+F[)B)8[(&7X.$%3T2(!UZ"AY<'OP03+P]^N2I>
M_F,94 6XV'%_,R DW@&$JPJ**U\A7!DF0!>%7Z*"9Q^##YF(1!/>)<-65YZM
M0NCN+^1=7UP1@(GWPV]X,.>A#=J'F6;,0=7-;3,ZM\;F?X9[4'RP5.!8ZOT4
MX2#6_^\%=NN<:-^'/Z 7X9 #'H3P4PF!N(0HW*\WR?.B>%AO\LNE8_; V;<?
M.W$QB@_8CC]2T/,\&*;@255\E16^'@SO(_^O:8 .B^TV8303"B&$GRJR!L/O
MW'C!Q+#/R]:\W\?6\?A&&T^5TJ;ZN;(TA]T?]T,S!;-:C#/=988-/]?L9VZ=
M5)(&K&$=(4Y$9:)P>OS?+^H4?P)03IRB"ZA&.KZ2LD8TR4S3V;)<,8?F:/"Y
MP,J7 =51,I+9']LKII4?9%;59E%>S6$G[T@RZ0/4!5CF9I+C$Z;)0Y9\K2PA
M7I4E4F.V6/=FK283YN9:?1.K);'XM61)O2D3Z8ZBIQ1Y)/"E@47',[!P'!Z)
MGTC>^$I9<A)0![+$:NJMPJI')5C;3O&M"D'P[2)])4 EN&1U^)R=%IF<(B_L
MVC0U+D^!T"4C)PK+W[/E"5MOH!J<"QVZWZ!DN <SX@8:U&?]I#>1_5^<@O'2
M5?:.1Z-?D4@!#0;47&#O_MLC],Z6SIN<);JR^'1:15>VR7RJB&W8$F959I,2
MG0]C0 @D\4C47V?Q+T11^+^NU'0_/3#P&@;.);80SY6A7FRQ928L&G'6[N3J
MT00XKY)$).9O__/7W4BN6VMP#UGFYR3B@).(07*4YL/]9C:*=?,;(F-&4\/)
M86/<H''2.5DFQ?I4/&5T;;:U&9<:5)[)M[(TDF68WSJZC2R[?PR<DV4U<25A
M2G:1Q>:E]6+.1NOQ]3.-9%F</"?+OH4/KRF;2GADB"+*S(*UWT, ^>+#@7=9
MD1UXH_NA#VUE"&2)+."(@LL0K\IPYKD4;<\F2D5)TT.^M9H-HMP,MF*-1/U=
M-Q_JZ$? ?TZ <UDA@4FDMF0X1JDM;%J3)1R6UHO$3R1:W[-DNP_U-/B >>A+
M'Y9UO%YI*F52&K-386;2ZWZ-*,(6?W@D$133^][!?T[6M3>S$I=2=)6Q>[S=
M;YDY/*[04-81?D?QIW756VIJ&:^$PUH65>%N/ A!%,@_2_K>D:KC6:L>K4/V
M]_%]FQ^T&C(335'Y"CO'9*%=S7,&-EPZ>:( MO[KYH?'[<%!/^( ?3,'946R
MF2;Q,#8UE,XZ4VF/.B4W?_HU#OH6?I[M?2*LX13Z&Q:#,O^Y9ULHB&+B7BR?
MCV3#OA8&P$MI4<FE,B(;EO5E;$GE%+:[/) +85/D?PNV 8GOI%08OBX5AN^1
M"FU Z_A^DS8LD>T,^%B2L2D^NUJ.26E:DG[]B47PQ'$OKW.FRX7@=Q!O,FHQ
M9$Z/U[N82(MRH;.J5T21#A;\6K(PZ<>%1E7ITBN&$T=I=LDT(/S(N+\7VOW*
MEOM02H(/F+=SR['*\1JWZ&PR/<].TS);RDRQ^LKH;[!-P*1-(5&ILZMN.<E.
MDP*17*=R=9-:_OI#12CLTM+F#? [D-9*H[6<+K+F#)M*;:716.:P3CY@TH9N
M"^/A)IR?*>G"<JI0E#+/F$LH;:(^^!UI:_]!907^^$9]2;F$0^WD<J42@E*K
M1'ZY4,F>G@FQ">!_0-F$1]FP5(AXH)%NFZ ZG49F8.VZX)1@=,I6'G>71A7Z
M=^] U23WJBBB4N3[I=,%'8 )=CL:<[#-BCT:R;P,ZU:.9?!RIZ B?)T!ON2=
MBOQ>P5.O(LGABKV"K7L]6;REN?5.GHZ>@&U44%< ,!=OJZ@(RJ[>B2E/9VZ?
MEZEHC74A6"7_SV(=W2)#1V;(\V2&FN@6^0S^C=,WS["=B(-GMSX,&VE%0FVO
M.BSR!H9XVUB@DJ9.#Y>02R6'I60@"C>BH8=Y'76'.7P1K+D*F^*$@+RS43L;
M0!RH>R.L*8-:TJ"ZX2M4K49='Q;$]M.C6R__$.5WA,(MXW;V DY?0!\["]D:
M&!.J\9:.>B61J#(Z?MBM );[F1GRPH'?&"+.:4 D[!B1"UD&A\J>.GRX/DXE
M0HP,:[P^'?+@+BX6S2, F*%2Z(8^=3H  9V*D\1]]G98=?N@O.MY<-P%QX35
M>\$3,WNHHI,7;DAVJ<.MI O@#M!@K'="RMLW)"W47-X52^AQ Q6Z 5_ \L)#
MR/:HZ]!"1&U*''$'2]8N8+WF;:.]ET7. ?$Y/5"V<(<EW[U"6/!-#G!.P@[!
MZ\VPVNYY)L+M.42POW4HXN!V9=AS[B1N46G@I>;V9]F3PRX,X!X!']P1YVQO
M*OK.3<5;SCSAX';C'2V4OM M3OC50<V>PN(0X)R^O5</Z8AVNUS'V9%18Z=R
MH=GH%(T>-P$Z(I3[_L0)SO01*Q1$,TYV)9.G(\#.;+P\0QUZ.=1J<;^JN+E7
M-QSH+*+3P@<U]KPCLD79FQTO>]-I7>KTKGF1A.O[K2P*]9HCD@]KOITI8G_4
MN?*$3C?FA#TAA+HD 77I+87GG7-;UF:VY<@T &'.H;Q(*"7RG&VZ73G0<:'I
MGFQW"LEON_(=%GY_82ZXS+U%G0;"<=\<U/X#('RGH+PDSN$NO3,$T=Y>_7 =
M]3:!TARU_[.W'T<<6MM^YSRW$162"M.9#N84==M$J^2<PGRGE@KD,&1[KU$(
M..\,(0S.+W!8;)\,P3Y?,B DTXJ@3D-.6RL?:9S$$SB<#AL 7I" 7,UQ--IN
MS>VPY%1F!Y@'AH9N[)4?K'*FP,W=IDT5AQC*Y;3WLX,IJ%A^(6N?\F^#_WL<
M_^L/#7&.CF]8YM^MLHB:]YAN+<0;5C_</P#VJQ]ZBWZAXN$@W(DW\O1XRA!V
MGN&BFM81EU]8\?!ED_VGES*,DA$J^C-+306LYM?/K<46,$3@>"21>& B )AX
ML$1 $('##BH//-P<#\E(-/Y 1  0\9!, 4'$0S(% P_)"/5#*]8&#!$/R100
M1. P1^V!B<MAXIVQNJ]Z-KYNU]^GINRKD6(7!<*V+G/RHW69J6B$3 :ZW.B_
MK]07=1VL3OW5O0[%GZHY^N"-N^>-*_FV?@04OCI=, !;?L5.^H8[?LU7\J#T
M[XGWGTCIYVWO!Z7_%""\:G/>7)WMHD^B\%!?'_3]4%^#3 K7MNF)C]KT.!:)
M7U>SNY20"]]+AYC (SQQ79WNLPBG)<D0)905<T<(#[B8"[XR0SNY%0]=YD'>
M#UTFR*00Y*,MX+K,21GW0/=WU60*FF7(FBGS=X7P@ NYX&LR37'*H63XAR[S
M(/ @ZC*?)?"JO6MAK(_N2K@%^30+N/+"K$2#E\V']O)#M!>4\GQ7R ZZ8 ^\
MYI(&7\$B #:G.M*]+(\>'IG $?L;T'S-IN..?G+_88#W(ML2QP3^)N1>3"6Y
M8T2C_J@/-+])$[EC-/\M:PYDP#K=\F*P9O/]H/V&PMS12>X9^047^7VW5/?G
MM96;5ND&[TQQ*J?QXE,H(_+BSM0F\2?G#UBY])[+!I\@[@OJ)3>M]HOJBNQ-
M&"(CL5UE&C#E6^N7N9W(R?HD/2'FL10FDN*R98T*48QMO-*)G).*Z=QP:->Q
M7#\QBBXL91Z-'G0:+U2S7]&)P%6T]C(M'-?1<<OR-C^()I^SZ3P7KC#S7)/J
M<YF>VJ:E01RV[B"?8O'D4_1$Q]QOPP4WJ(T-0WMOO>W_NUAL^GVSO5/ ;\"V
M,A[C<]55>X*!S;+KK#Y6^O5%C9C1GV9\XC9L[P5QN1>@GBL1Z><GA$$,BUN&
M.N6[;*O33-9K:H]CM"40!A2L"H[[N\U^&SEPN=/P^[ W=?,:_A<[U2&#D\W,
MA(YG,PVV%);M>'?<QHSQYX_T,'D;UMY><B-_\9:9R2TSCXJ3TO@YR?<9F1C/
MR5HO00H<9.;$KS_$$Y:@'MS\9C,MV%SPB3X,+[7.NG:?A5>/JNUE_IYO');L
MW[7,6A<5FC?X=A)+YPU-$:UJLY""](UC0##$(F<ZO@3=F;ZMJ!E#[W>!Y97M
MOP?ORO7MS2 QX!6,R\^7Q_Y:6S,':=,L:'54)3UGZ*9Y0L&LE9IEJED*AQEB
M\]PHE6G:6DJ-00):FS$B\12/):]W*OT$P_*;[_'+\Z%O8V!>NC;^)UG??!?O
MO]/F'.9*XVRM,N:5=)SJM]<%O9/':" 2@,T)^!;_)O+@L@;FMV?S+TX&/V;S
MF^SZKJGRZC$VUT39'5Y7O6 BB*ZTO9R1\'UL^?NXIW([FGP;_/W0&Y9;Z<8/
M\KY7\?13J39XUPPWU/YN30#?VW/^]3KBS17"D6Z,1/GA-;Z]UQB>?G\_',59
MAR!ML#_/8W3"*[1@UBLC5Z-7K&A'>_+ ZK'I96. 8]!3G""?DJ3?,?3/?9+X
MPU/\\!3_%$_Q">9_I[M8+<F\F3%*8S863?.93#_;*R]H*!BH7W_P2/**L8IW
M>O#]"&9_^(OOC"H?_N* ^(MGLO'P%K_'6WS#G)V'B?$F$X.!1.UTD#YC8D0S
M"W',-,8E+/Q<Z,89PY9:46F X]#$P+&GY(F[Y\N9&+=FE."XY6_-3S?775YP
MV]\:+@_;YGVVS0FI\T[;IJQNC&6CTRYAL6$E86GU0K;.+*%$0K$P./:(V'Y(
MF0M?L]P:+L$TJKX/.[QX#?--$1_T:YI_WY1F3OYT]\"I6C<DH%%!MX>J& 0B
MO4&&.3FH5IJ64# R.39=H9MA16/3G-P(=H8Y66*6SQ.L2+&E"=_/B7*![<QI
MN"M@9T6?")Q\BF)73$;[YB>[H_#<FE&NE5U^ZWW=W CZ@ BXCUQSOJ^T%G(U
MFF/G;7.$&7Q*+E,2W"DP=H#6<L5D\X=$N$^)@$R86^\K0.GI;Q$&@4U/S\CQ
MOA!75VMF/3+S8T$AU)J"U(+$KS_X$Q7_+IF UZT9%G .>$=J^EO=>W>0FMZ.
M5_-V9B(I6(Q>CME-0:98$=&VFYM.73HW_=8."_>TYR =<F9('WV)<7OK77_Y
M;6/ N?TGFL![E/^B"4Q3QA(W>^D,5HJM]"A9F0\V@\8 )YTJ:QA./$635SSO
M;LTG0;UL_!YJ\9ON#^];<GQ+VWE/<KS3=I[VGI.Y'BTU%%'I\5*9*G)9<PGE
M"2K4AGWCB\*'*+E!R;>;;_7;&]V?,%3VQ,BAT8V?L+K3O"2,.MV6R(:[W7@L
M9O2J5AU)#F1U1T^D53Q$Q]5O7P/.4?=KQ+]\Q+YDQ.-;5NG6FQEA,2T)BCRF
M.A-5G-?R' U9!1GQU*L%YOYCP7G_^$9='($3V[3DT?H"U Y6"K$K:S;G\KX@
M+_[\%_SCO8E7 9H@X8_=Z;8T#*?U.AM@?UV%4@^+U!/1O;!F9],X&74V@I:-
M_OV?_=7O.#',ZZIN_/;8;6];8Z?,/8$X3Q+#0T/DE# W C/_YM0EMS;=;<:3
M.T?[[RW'0CB$<"Q"4G^%]OZ&\/ !<\JMPGL@<QD]K(HCZ[?[F/<=8M+ME[HI
M0_S\-D05(&HAPK<?O!=AQM)GOPD<,O._4_#1W5@4C\2I*^'J*-Z<W),A7&AL
M0(GQO^U:^M>I7D'P;\ G0"ZHSFO=?@/N5[_^M)%W21^%(,O"@+PMZ7)_]K#^
M$K$>@OH4!#F/]5>$K#TS5;K*3@LYO+T1=8(M-@8H,AC-MAV)L<_-Q9HNQ;!U
MV=KD"6+%-PL2&!D]'LDFL'6J;*@66WO>] $YK4O+7F- ^-\I&N,*X-?B@K$I
M+;_(VE%A_2R!D;YW2O/*<T\H]D;,NL[@_=EZ75T4&@-R@!V/K US&C\J9EBF
M&YZ(SV-5QFT%CO3-'E]-]/4RFB&84G4UG#7",3PJT&"D;_9&H[F.8A3&*.F!
MVC%&XTRA2L%W4L<CZ[%V=-QDC3(S%>I=@^HLLX68-(CZUUD6IHEUHCP+8S7;
MGL1+#3 _6&?4/SM)KV?E::^2QG*]U7.1&(6-YS$]H/SO;/$ZGA!&\[02SO/I
M1BY&5N5& XST[9UH"/G%1N!G6*L=[VX(P]K0/0F,],U>YA>QTHQ(+!6B5.<,
M>TQ4Y_@2C/3MG<=3C6(F-FLP8K39MR:UYQ([IP<Q_SJ[;)/I&\OI"JNEM1:W
MW%AZ JPSYI\]S.K"G%Y2 T5DPI-*_EDJRJ/&(.Y_YS EYO(K8SA5<N(ZP33F
M23/6I,%(WSOK&#$KII5,'NM2.3+35?I-J@4IF3P>V=[,1[-LC&>8KEG)SO "
M48V.('WZ1R8[]'*PF:?9:6;V3.F3;GI%0)J/'8^DIC@>+ENE"5L2%D,=4\L#
M.2R=HN0VG<FMC%E85TKL@FC137-8YB'5^6;'DFRJIS54B8U5F$RJ@W.-6A*^
MTS?[G-?E-97'.LRT/A^K.34^60,<G:#/SC*97M?J\3 3#I-XZGF4&QB*=(KJ
M^M@*3U1;<1U@DRHVF,Y$JQ4AU?G6.8QFDI3&X%&&R+?2C<;S1A(3<*2WSJ-3
MV7EN."@*FZ@PSG9G"M?MZV1>4";A^'( AY+7.'T]-0-])6M BP"G)!;!*;_@
MQXFMX&^/Q=#2U;W"G*-\.95L0P)GB:$1)QNA!;17H&@W+9U70OIAP=O0DC-#
M__<#0LP_4V<1_9@!$,T"@!Y>NKJ.HRIG&(.YJ4^SY74QSG!-HM.<;>SRH$_#
MU%DJYC/]0L!4_AK O[4N]?T"OF&$8^V&,*QAK4UJDJ[7>W;< 7S"'^H2 O80
MT/I"%F >:!>9(1'PF["]5 N1^%,(4BC"$(384PB ?B;R4)=1UY$08#L#,A[X
MYY$0]H;BQ A'T6ELT=OH@P%KBV)QJL]GJ06Y?+DT\0OBBK, 6D*<)!FBY!=Q
MK_#3N_U3GT?&F]Q5O&2M+HR(MFYQZAGV(?=0LTRE<GI8&":5<'$<;]C+D56H
M /9)GN(>L)DMZYSEG.NSQOL%6S!9XUF3J$RV)>!L:]%MI-G55!H/ /PI(OI$
MQOT7#H%DC?<CXQY8H]JH%DTR+I85L=+D%JL:KHU&0&HEHQ]C#2(2RAP>/V\X
M?:QO==Y VBV8IBT*#B0<I"#\F>C'0_^BZ,LO1HA)Y6KC$K926Q@73@B%G))F
MM5+CUY\3W/)-A-%EX%:RS2Z&MZ<EC*ME"M5GH*<*+%25P"&,/U'X"47U4-IL
MJ^ >:D5/H:5LC0\%T(N6R$\^IK?H^8@X$G!RF**E]8"M32JY>+_"52B:?I'J
M?[+,_Q2<XWG%[&S&\3XPLT;*N+GN\ZG)$G()2?C3:4[8!R'9NRY\R?[>\M&Q
M/?+J@? 6DSVH+'3A^ [Q\% _'QB-,#LIS<K#&9_(8V)X.*[2<XU?B=^.@VX.
MYN?TH-_@REE2Z:K2B$O)Z<9TV8#-T>*DOXS8,0.A&X> ^-A>NDV1 2!D_N V
MQ>W>W!1- !\>JN3H7 Y!4C'W[P(#LC4HIW8',XHL;K98,P0((H1N?4. X"UO
M$'B/(EH[<09_@%3%:6NO03D@]>E4USQ)YSR,SG\P'FD#D1##\6,X#4#Y#& =
MWC6%N)#C@Y7 IQ"ZC0M9.AC BX @;J#SNNPS0*S07L]$>B6;VV]W^$7H1=@%
M&ZH@<3VHU;NI3,]N*.Q4&V&51;'1'BW.-BI&E_2 C9>Z(0!X7.84=.)E:R-'
M/X1Z([SAR^H&A#\:<5(]K(SGP[BD=TB&,]MTO=I,*6M-^O5'U\03BB%\]YM(
MP9Z!/Q< ;@#'$8?(H+$D3F>JOA8!Z<'?@,#5;$Y5UR%] <Z]3T1&? 9_WBBD
M*8@B("_+-M'S$"$#QEUR1@;D:>F&^U19B^4U(JM/&"XA6Z6.$>:6[.E8C",T
M?UI4HW\Z#FP=(8WO(32]V-1)85"OLN&27:@LQ\K<-,!Y9XT-T?5_'@=10,85
M(9<"? #^,TS.6'M81E )004*'8];3(+'PQXV0X(+&Q>MKAP()CZKNO8"2L,T
M!_X;KX09F< +3 E/8O/.Z?:-7XO2>3JVLGK5&) P([F]2&MJ,5%Q>#0,$>K#
MYUD\.NKJ2%=5?8G44!0)8-I3(._!46.>9&XHOZ$46,C6^DT>P=_HW+M\K-,1
MP/FQ*-BJZ(H]'^A/48H#<'<O* RB#1:54L'OO[S;P$6Q-C T2\@Q7*[-K^QV
MP@HK@!1$($%G8'[+ &K0Q>(\=N$D6.1\H-WN2?CC&P.17 2[03M.K!P/T,_-
M3/&W]\?^HF",B[L@&.G!.Q$B7H@2"JCA;$OWOG"B:= W!T$W>^%V[IA=5%/"
M"92Q#&]=[GRXL^<WIVO%J',)B'O1*WOOAX?-"!"_!S3O<Q@&&_YV(I0@@[\:
M&>0&:Z&)O:'<T-15VQ*_(B((4 MU3FU%S[V=3O;BO#X9JGFV",P#*;=!"D%$
MDF?3=1^(>7#+ RG;*/OHV5+?#[S<3HH]$',]Q+P_8_Z\"G8+('BSI,&"AX8,
MWIH7U84(-P%GX#0S[)LF\0Z874_:/Z#U7J7ETQ!+G,N*. W"X<&<A[Y@QPT'
MK.[__F?X()>/DPNP2^&7*#3Q@Z1#1<CK=JVY,.EXH9!A-Q;RD((>@ODAF ,$
M+5<PW[#P[86Y[Z5+O(<4#X(4_SYTMG>A D-20NA*_1*B/@ =<?:!L%?R"P:J
M^N(B+\-5 =OT91@-?X\!=Q$I'JC&LE[*_#Y@+]CJ.N!4\T6%^:.W:9#]/D%Z
MB3HLKL/H'DG\GE1^IQ.:<^=^B0YHWT)C^G)!'C22_NZ17%<*QF3F-B"7@@86
M:Z-N2368$=(><]K)_)831<WF3)$!@+7B3)?,IIOACF*K89CZ3_SZ0T6)IRA^
ME0J)0>+:+SQ(O^VI>5_RY#IIZ]>5*%^2>?U.>?+NG&S8 +*"&RNEW5RQ!*GP
MXHA][F<GL.H#ZK:&Q<](FSLW=QW-!P;O74KQ"<S6[EH7ND>-_[M2S<.H?1BU
M=VO49G5C),H/L_:&HCRX[17],+Y%T_"?8?5N&?&,X6ND&Z-F<;S"E"Z3U@<L
ML5QFGV&%.&#X$M@3$8M>I0]YD/CZ*P_;X##F%Y^\P=GXPW"^O4BR <P^8C5K
MK<JBNXY6I@HW[S)2*IMG5!I6J:1@+;/D-[::L7.7Q-=I<Q1P&^F.U+'[+,%^
MY9L)7VN#S\@_<90J+<DY76%BS].EH+:$TB!VB\9,KTK JJXMD._KQ89-L!MI
MO,PD%TP)GZ<'_65MEA.D01S=11#$$TY=I6%QP-G]MBZ1(/'KS7TF00+&S;2Y
M+Q9?P5#?ML+K(\I;2IDW^_:X%E/F@Z747]1CFM6 A</?>.7QY2TM]HO%G)!5
M+]7 >:.D"DB-F_>7[W&H).P4P-FGL!"S@G^+ =QE>U>C 9;-@0),"%FP5E-(
MW-\.O[\=T=E.2';J<P#-VT+L VM$Z#/1L>9,5.<#/F>(8S <%N11==,,H80X
M-$OHL+ 9'&_LHJ?= C!0(,#NI4ZA"?.KZT%X-3Y:HK&0>?$%$0*6QJ._:J,F
M@**D 0P)CF\IK9N6Z:\,T:J-$ZJ\&FG*O,WVJ";&5.MK^DJ5(=Y-)L?T?]A5
M!M+/CR\:$4O^S.S1H.7QOM([_(&(+T($'B$>B @&(F#7Z@<B;H\([,>6& @8
M)AZ'1$ 0\9!-04$$D$W$ Q.7P\0[K]'.6P]?M^6OR_-^101_PRV_IA%?/:,8
M;0I>?)[.I:8^G$L=C\2"G4O][RO)TWU8<90YJ#AZ=%?\J4SJ!W=? ^$G"-O_
M[P_@VP_70,")2 *_:[YU(C@N4DHCH"1[&2S?.Y*)3XO? %S9;P._FZ()SAM4
M%UT(">)"5/49O"^Y&!7?=+,W"4AP9/1/W#<TH&^][TN$4;C>L6"FGKP[ONM2
MW9*\L(B"QNM3U', W:R6W>O%X] ))%9H3<CLA(I[U^P&4+2)9&.RWI 42\S(
M43>WRIB=2>/#;8'<BTY1.'T/ZLY]W-@'-G$WLZ;:6B:[3 W?C,1$HE1>K]T&
M]K$3G2H?HO$A(CPGU0\7$<>=OBXM(JPYG>V:3;O%U%BBW8K'<P:UN(&(:'4*
MC6Z_2I>5]2;#SI?):.=YL@0B(@[#._V]O^[$.C_2!7.B)AJ<BE1!3IC*FFQ:
M!O*0WH--$PSY=F7S/!B;3-S6B/,#X7+^%>Q>4I_N0@UT)0H0\?2!/#F4\MUX
MMA:>#8L,6\.$> SO2JJ\I+]>RJ]5IC?&ZCF%K36%<0:W2J:<A 6%@")(/L42
M_K3*AUQ\B Q/$WR(C(NHA6\3&7&LWF-(.9G#6E*;T3H9OCBL?+QS[X=%1L9N
M%'O)<FO!EBJ]"BL\#Y+, HJ,.!096/2<R+@WSR$,R3X???VPC!].PTMY!&Z>
ML/2%7L6;[S5(A\>5F[1_6-3G[>ZFAT<519F'1U:-X=5UK24-**@=1I](ZHK:
MX4,L!(=5OM"3>/.]!DDL'.N4R5&:#_>;V2C6S6^(C!E-#2<;Z>O%0BFG,LMY
M?;IAN?+S<A 6F^OZG 9B 6F 5)P(7(KDIUD[(/F!M F3^GPQ4J@U\Y.;*#BR
M8=V2TRF">\E^MILB&^)@2JT96HL6_'HHHL1#)V4N-%SOMXT.+3DS]'\7)GI?
M@G*UTK2$@I')L>D*W0PK&IOFY(\[P-^4,;A-&$;YQ2;2^?=_AUF#5=WJB]8N
MGQ E2+L)Q\=,@OI[/W-69CZMXCB;-D>S<6Y2;)E)&IZ<!.7WGT="[6NC3S;1
MFWCW%8=C8>QPB LMO6Y5G),R#89,.6"3:A)J @__.T.)E) 0N=G,T%< ZI:H
MKC_3&/XEA>=$CW;8G?S+<.SDC&9UP_T*CMMOX5X29MERFQ3+;"UJU:H$KBW6
MHP8L\A/S=6^'"S<CCB0$/T'PR)K-.?*1\V2K8!5*FB&WAVPXR:6G0RTV;68E
M"#4@N/[#[8UDZ]6-F5#&84:45OUF0J<G*VPY(/PC%ZK:8X>B%,:ZW2(F2=1D
MR@\D,#)Z/')9,[ QR5(KMF8K1B^Z+"[+.+P7QHY'UBI)I:R8M;(BL_:T6PXO
MJ?P,>@%\(Z?A%%?)#>@JQDTR"U(MQ$QUM71<C(<C$XD58Y$%(X;5"LMJ)RD6
M4F6M <X5[YW7SC-F. -2N@G0CFC(GR=,D?0T-<O7UU@WN:@:N6%/SE/+*^4)
MOR'-_7W'!]"[P/16J P3OP$;A] N;WG _>ODO#O9Y%"XZ'NEHV8ZS#66.14(
M%T%6;>@3@X)QJL/C&Z:C0[?, @A>S3)#8R"Q@$P3H;CD51L&$X\,?8HD(!#.
MO*TZPA3(+?0R\+L&8*%ZL$!%-:#$04\X0@[\8H@FC)@30H(M0JD)?I2!H 3K
MVBX)**Y J'YU*CR]MX26R-L&D$ZBR;A[SX*M0^EF6VXB_.NT'=-IJRZ-1A66
MZZHY4:KJI2PC73,'_I'P[DOI>7/">QS[L1F^ 6]E'<%^:"V"8.,%)R+QLXUC
M'XAY,,P#+X<,\SAAKH>8=UZ&OGK@WPP("<]6V;=,OBK1[0NB!]_9)O9Z0-IF
M(Y&?R16];;#7A?ON7B-?],%I-^"T"]/%R]E]%TE7=)7)[\-'ETWE?)"*3XWZ
M5J3RN8105[X&("=TOQ^0>Y43DDW3AO<JFK#OC+P87P1FU\X4EXL)=25B(+.#
M@M*]]G,NV]3Z] L.@DGWKB6]I$/>)+-B/+Y1P@S5RDM<MMLD/E%T_I.[H*>
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M9DJZ!%;:4I.X/B[$TE>,T4C'QS4L4017P/3"($"5:0E<6N-%+^.?9,*K,=*
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M+.Z\E35-N0<7PUB;BW%!=<=^Q,?8&UEDZ+W"FQ 2_ERE8+(]A&WBQ+,%J6G
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M%9$,3H9NB$4U,?D 1=U1M3>@[Y1S1.0#DN-4*++PW$5"8,%- W)%4_-%MFE
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MCM>QN%G8/A]1) R6A-C+ZT+L3T7ZV2Z %2'WC4O%^PQ$BH"_"/AO$]^2JF<
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M'D4)R0V\%=.GG",B-Y <5P4!O(CAB-S <C<'JVOK473*X#JQ ,![OND'/I4
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MB%(_P>TT1%OJ7]4MB]K27@YWT?<\W['3ODUC*^V1<*Z2:VC>N7,E#$@:#(@
M-*FW,TD -&DE@9!B88BV8(+"$*7(LVK2;G<D_226172!B1)HBH13E5P;\\Z=
M*F$[$FX[!(Q)O8EY&XQ9UY%ZL0L'B3G$ZE6'G<2.;M$M2MQ= &V]\.81@-/P
M(:LXON51&5#SX8& \O@\0"5??'A&RW_BHV\3_:;K.H%MX)EZCKL;+1:Q:84+
MDCJ8/D-/D7-:(9+X\(2\Z<]P&=*X*G1IEA^'0SHPX%URYYA&2)Q2):=%*]>N
MC&0*!]MVC!'\T_/[UI?_#U!+ P04    "   @GI8([Z[_RVN  #3\@  &
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MNJ^'F -O31. Z&IL%0$PYYK"!RF KQ. IF4\'ZPG! 7^L$0 (GH) *@4FT0
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MG\_=[VIJH]M).-J6F@I2) !!P[AK!" -U A).K C^T_@!^5442R/5^K.8 E
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M8I-DI0775EQY<JTKN0^*\P!&,#C99"KNA08N5>I%C5,B]W.21=C!< '^>]@
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M.GU[D\FH-84.SX-3"1V%'%N27JV-7;W[!%KV;-E\(#PBAVE?_&<E[J((E1?
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M]DR*YBM/OKRS<XI+S9MTC$ML@3WED2RDT-T40FO#KO5V-8S3FN'6^%E7/<6
M!K[CCP[3/I"S3F;&NJ&ZR>9+K0V9X7;9'Z^JQ[*R<)OQD)7P"3JUJN?.P87B
MSVWU.'ZVO3[G ,(&M<BSH..:D,<JGTHDV<PUQQVQ=<NR>:8JJ&PL;TJ7RZ9A
M1Y.8+#V@U&(JC>'S]Z8=\MS*]_QJ'3TQ-38?-]1C$]%YENK\^O,0'E*_?/]G
M N.X\VAPO2G-@.]4.M:TM14M</REDAA_<0-55<3XQBR3<"%:J;[Z2UB.M<$D
M6\F;XO['1FHOC;:/)T86T"X?&[N0OQ6Y;+<9#^W$BHC-=>"L9T'!\KP]Z>A5
MQ,S;.[UEK*L6['(KV3$"&J?=)S[?BAF&"%,J#>AWKY!@BO;JDT_TN#R%-.=G
M&UM56.<MTIE>3;9/5]1C;IZE?B_;>J'MN.=P\5(*L:TTK3%(1!/1+4E9?C@S
M- Y@"G0.J2G0/VI5EWB;Z7T1_25HJ]\B8[31P3Q"P+^L)(9'*SBS1)9\^OI6
MI)8,:(GQQO,J25F6&8,(;W4?1'?1_"B^D !0EF<G.'AG-!E(%IZ*W10T71V]
MS7[#S.]0,4K+H'\3P8K=GBEZM:N?,9-/ $!-I\(RXU7RK2WMJ!]<*FI!Q;"-
M7>0-D!]<CH,=V->)W=BH0L<FB2XL?!X+4I$YQKLBBWMW1%92H4L8@::H9__R
MQM5KBFJD.X\A:(7-%7*<Y((^Z2. \V'6R@G;F]";&>_Z(I#H-MB1=J8SV?P!
MIU.BC&M*N[S"E$\KLS'6&YX5/=.>2IX>[7IZ$7!EG&@:QF2X M*A5T)%SY!8
M9;9GG'S$_/^W-_:+1^J7X(5$*Q44N9R5 :&#)O$?O.@OO(M*]!IN@G(A;<'!
MOB38MS,PT/QVM8NA14"CZB&MVZ\O'.8UCQ7J%K1=?3CW%='I,(K 7^5H)0";
MVV!\<&@-^ER QE-U$VZ\YJ4D;Z6G-R=N+L!0;^0%8#VJ&@2@X0X!P-P C07-
M5.Z3E2%PS"($@,F40MEK2C\-%[SGL#P.QNU!G=:0Z'$($W*>)PN\%WAP1)T
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M^_W G^6)B=%''_XU]8\\AW[OI0?X9?RAT)1<&7R@X:\DK_L?*].//%0=),+
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M9I750V5A)I>L"CO.9W0PE))WRSRX*C9:PP^<20_]>9G#-'#E^Z\(P"<4SH$
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MWPQ!D/=YP.U\&)VB/ZF&"UQN=HK('%[XYR-@7^?FJWU05KL>1L@#%M6VCVA
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MW(%7TKRW]-OX&,3?#3  ^6[!-S[)HTV"W-/$KN$,FPF0PU\ALS: M(YS__4
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M_'E)6[Y4[YVWS,V#&9,7SOI,7U>S'G "/5JQ1'!(VXQU9LGS<QWMX'=J*#C
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M!QXMXS@U$_ZA19%YWGHL:.&0(4HW'TVM!*)QAM(/6J]7>/OY\G@$-Q]O3<9
MBHHF=.XQ'#SVF6SM!9IR7B7?V.J\DX?>$[PLO(1+M,O+X*"UQZ'AO@KC[),/
ME;PF!K4EAEMYR!]<8,;KX.Z98(UJ97=7Q=2R,3:6(Z<J<3P.6.1[R]FP W1X
MU7WNZL=L:QNS(RZR(M^6CDXUVD@T6J?TWF%RY6)%Z[[*%"?MLZC6T :\@3S>
MP<.W/-/,/U <&/2CW%65W\!=F%G/?1 +JL/0(!%[&APRV0,6G111;C%U\'#E
MD,=]H@T1VI)'>B[0CH6;0.;1*#E3+.6H-UUMF%MTLPYJZ"GS0>-:ITF_:Z[\
M&>J#]*?T4S0:+ALI+U46 YXZ_X7_Y_F_Y:(9W'T"/:=4=QC^.?F@[90ZQ]R^
MPH]9QS5VE0->0?W%F>K]4L;3S^7A,:==9(.&92R'9:S'ETJ-B4!K/6(=M7W4
MK&TY$4A^ EL:)0)LTYO9BQ[<?1T$LSG.L9X8M[7\R.HA1R( .@1!-)(^E_UV
M4T<0]=999\8XP9YMUKFMI;FM,2Z[#N1!II!V."RD$?J3!AWO.MQY\"=OLRJ/
M0 FHX8;4 ART@I;8PH/&5#!SR1O8> )! MN^IC<(V5%-,]:E2>KZO9\=.AUG
MTXK'JQ(!"-U.1_"WCEI+7,4DS;9_:"X9_!/--ZH\VJL\X!^(P#=OQR AW#8_
M>"Z;A?/?\:9IQYO\2)\?7:V8(OB<( (P?[PE"2'0_ Q$>"V:"'A(X. ?8#\"
M"/[F.!K6",VJ1A):8U:X]9?6TR!OO>*_^<J-3ON.@&(WV)[PF=3+P.[77NDX
MYY^<!A6FXYMZI+8:SJ"D C<DOJ/SQW#;I-#M6!<0QF:"K#8J>UM.:"P$6<9L
M.<&6VS9YWVKNC*E"&I,=;\4OLG@\IA0#S5&!&FZ[@O@1G1]^!V55C^W8^-63
MQ.\VOOA3&XVVIA%+X!-;WW&S\AGX*72^6!GZ%<,_5?P'+9[;X4A8M5LG1>,/
MHR3_TA&Z0[4Y;#B$L+9L]ST88WX :C:_#/85Q6T+>;U+OC/[2XA]B<6O>G^,
M!M@O>H.^!/<7O7\D 6),\8=\R*H>W4H4G)0M0"PID'PFA7;I'P'P0_#^C]W^
M>C2)/TDH[AUG(18J&] <5UP[;+A:[4>J_H^[J?[0K6/KSQ+D-W)'_VH&:8*\
M9=^:^WE>XOW)W[$?4R3QKQ+)X5\__L8/=:&?9L%M3]2_6 M;1_V0OPV2:O)>
ML9B!)%#'[3DB($/CK?F""+P_VQ49.9'/.Z/?E3Z_\*HIH.X\4^7;YJ>:\M<=
M_AM?GMB^]L^!Q;?GI_ 5@^W#S(E BH W+ZG-:[MM:;LMC0A<,)RMLQ+I> =A
MW.1H8= TC5T]HN-LM#3?<AJS;O%,("7".[9Q(<N(=2%!)^M5=B^IZK.2Z+F(
M+W2TXV%')U8^S7- L*8H1LGC+KU(IO421,H]/WN'[7,Z4_R9:-M[-JP)_,%@
MBT\O<Z#K"G+Y5Z:=! ,1 Z9G2MI!;_#A8H1L\REW7,E64/-&02D6_SEVPP%O
MD&<#L4B,D&1;6JQNO1Y^R:9:*=-W1.23K.V;W")KZ.A&J)JUDM?Q'B?8@0'K
M\[+EF8JN3&E9X+M=_+>BSY96GDWFR;H7?WZ*4F:W^5+"7+\S;T_UR;D>MOR@
MW3%^ L6<?'6"W ,\;.&!LY<M+W]JOWSSY)57Y[1&$CR[$1Q>%WJD05;/P=,5
MNK'9,Q7%#;DY6D-W#AJ5>?KM$N]_73;@1[&2?.=#!=8(&9^=?V@W6CS&R@H)
MYL5=KLE0LE!]377K@,A5'=>3Y_CW&J\W."?QH*0->R)39GH*@]B]3Q ^+PII
M5)N57M>536/=MP?"H6E%V^%:'BX!]5)TST)8Q0GZW5WC:SG-$J_E[BQ'02V5
ML?9PCS!3>,E(M+D\^]-#VG@C= 8GY6A)U!@[)Y?W%>JY9RG6IW@.-%/=-H^1
M%A)@57R_J)=K->NS%V[C)9<U6\T"SUG-7[@%72A9WW0OUSQ]IB%)(.^9]_U=
MN5%2>J'E)[ &MZ5Y1X=V44>+>ZB.Z]V3J;6SSLU9.'R7_N'\O/*T2&>ZE%+V
MU5:XC[A5!7.(K9-%L?OJG FMJJVWUBF)W=1%.5>>;<2&/[*0:<I5MT$S&Q=4
M=3#7R[) E0I[Z&(L!*I3SIB>"F16RF.^^9B?C/72B 3%>HX )<:KM'/AX(!6
M#T_W34^I.6I_H?D(I0QZG@N<35S:]EFAY=+HCE*;:JZYS9#A,"]%I(J);J?2
M"17]A:(5.Y[.QR<CU1IZA37J1W<]',1I%56$XUH^\0F&]%>9LG>(;8'KQ*/C
M= ON+O>I6KPJ^O0F8/ARH+EE6!Z:'6@NVZ5@A4!5.)_SHB"<B%1#C<_.6+8;
MZ<\MB#<FME](K'HPX4L78>\SP[)T]0V6-U=]U.9877]3P/P9T5RV;N2;P"8U
MM]A)X2HK_D_+)2.IEUQ>&B=PH .C!1^=]X4_9*YC7N=B4[EL)';(JH+OT@H5
M)_OZN_=RBU0>J_SJQ7PJ*3#WMH[.ZC-7G(@ 4W5:AN%6:5VM3/,+\-:;X?GW
M+QK#/Q0HW5/8%_5^,#.A4RP_T*/!OTX";9[IO\#E*1J#4U>IAKG=*HX3Y^.Y
MTDQM>\3O[*7Q YY=KF#RNSSEY9TC$1V(FAC#%QXY!"X5U8)81K5QK9Q=:64A
M[ZEKY$*+Q9IJXBV]1)!+=#,2&C.&LF59;?TY^YLMQ(?>G-L@7.^]%BI)F62%
M&Z Y'7)'+@NO"2]*/C"SR=D8.UJI@HNGA+D+%D\]W*UY-.7R[=+F@J&$ZTY+
M)H(A53=<1P6IFR!VI)W'W=G.*OL!J^A"L]98F"_8UN5!9*7=Q01=4""!'3''
M=;8 /F_1=LO36[((4P)W*JE2NZ4W_"S<)3F&6TZO2AG5#V_LC_87#)#/>YYI
M]?J]6L(1\U"5:(U4#==;I_-0S/DM7<A7I^@0>O+42T_BH@C9*;U8L.*;;K7<
M] ]9+^)\<?V[+Y\4IRD M<0TG:MA$>MT$VPX-<9-U_ RR(#_]@I/:5E1U"/1
M0PH3G-2TM%0CH2F/C(]#:Q;L:C<;<J?\BA?.?A[^R%=I+66T)6L03<7K%'9X
MX.R4&9^9](V"4+Y*%-C7#.7R@"FI5-!3.$(E*.@5PZDX*Y8J:)%]2N2[>8 A
MS7-66W+I5;D\@VY&S84Y>?+<(\R+H/&]%D3 ))V@K'UZJPG_@)\(S!7!/ISV
MO:KD5R//H,.V^UJ/F&B[4_S AN:+T![FV'#A\H?!82*-;ME1B4A5<56+NLW$
MQU=?"707A:7)NCS\>(&7LSQ%W89..FBL2W?3.VJQ8%0&+%?:Q<^M61#AOC!A
M]*S;-?RIX^L%R0T_F;G7Q=C(4:.W3#:&(/H91;7[6>H.F/>82^.WCI78TQ4[
M&(+?";!?QM[=E$U.MW(9/A)_Q6COFD!>S8 EW8H0_X'P-K+D*^J'O$[!;<6,
MXH<.SJD7K=PL"*YGJ3D6(+&+(E5"F$L!KL,O#(W)M5@Z1MVE> ]![W7ZD;H
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M&=]1TG6B4=-]\[]YO89D_\O_ U!+ P04    "   @GI8QJD-<7&1  "NG
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M5U-_-';XR2JWZE<(0]Q<2ND(,FGP&.)D<+QPD^7Z-)U]:ZR $E?94Q Q0L[
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M27BOZF757QB&6[(U;^=3+*;'2-9C_HDVY7(?@9R3 CMO$2F[[=!@.O9ZE6%
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MU<8DW\[C0'-P$J$1Z]"<=^ '$BXK:;5:I"A5@^N\0,:"SE<*4331"_MG5@"
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M\^W;MO'?BG+Q@?KB (=>G_TJT-KW1&,X$%A#U]D3]L'8/.Z]I=^ LRR;%]8
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MO\"L/C^(W,M1U(D4"$5_, )X.AV.%)J=LUO%G@V<B%,(TTO;TI^]C9^>\3)
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MM[$>]MY:%[V^1#E!Y["MJ:":S<F_VMQ[GSE9&V\SB2Z'1_!J<] 1C"ZF!-H
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M<%N7S%:ZB^=AJ\RORBIKJMX;6IX/*M:U'GXX=$--<T^YWVO;?OO.]:F1\];
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MU>LJVL\<]@Y]L&:1/VTY7^K>>C5=:+2N/^P25GTI;#M6"=T]AY)2?UGKA.C
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M+ \2B?R$-@B=;8;<P#[N\>J,K7< OSM]50G_<(,6LW#5/6#T>MGCMI^SQ,!
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MD2+N6YVLLN1O:*'-,U-C-]SV-/@^<E7 2E?60P] 2V F[3S,TGT[>P7)>31
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M49]K@1'#FSG=%<?-L+7R<KUHEKT]S(\A/)-,2:'<0Y51>&GUM=.BCA&[C2^
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M,9[XD6;(-U0_Q^,>NK;&@]1WU8AA-DG0'G);T]V0"XTIA$@L/;*PHVX:!'@
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M<R0723!N[(R1RNP85\?AEB#>>WP:4V09;:Z=H<Z@ 4F-7W@JE"ZVFE?9\_-
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MS@T:$6\GNS\B]?G3P13SNS$Q61!9?)\*)*=0YN#192C=F$XM1OC5$A53<(]
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M *6>A2X*?OGY*X"I;0H6(/?[,12IUG-SW6\U7_FBK."P A.61@K92S%BSI0
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MOAD^ U&E*1K<-8Z')419Q7-I/&G+F:AP;&W-L2H[X'Y#HOLV[7,AE\@UZCV
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MWS5>]=G"TP:=7W&!=JG]$-H%T\@S6W1&WSDF,N8 :GHC%O%KV+UJ<=CME6M
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MHD*-%:ZSX@H3@QE1^RML?]&DPCQ1@S)0^KY-DL;(ZW'7*!8UGF<ZGR38<6\
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M]/PW6TR;I7;AV*G5/"C3J>B'45N -:&)A99B6SS_6\V5[;@$"5GW*V#4GLB
MG3=7J]F[05FL06=Y*/##O?%I\=;PQFQ>.?NOE4YF;N4,AU9<O;2<?4B8(2]8
MUWL3:\'-Y[/WJJMT+*39N4LHB7VY%G+0Q=UFBPYU,-NAS:T\C #.WXLIMGLU
MKCA*KN9(C\R!3RU$+N+$6ED*MC"-"GV_5(O2KMUCDDI+2NJ'%DSRY*+K-(X]
MJ4N)8*P\NUYR\7#N4==^.HTY#3Y"3U0)K4[0REMI#?"+#XG\\H%WRS;"05];
M&#VO1Q9HL??CP#6@?D=&Q#J$5^M1XV.JM6&MWHM.VZL)[.A(B5F&4_UC6I+/
M!2 D-S!WNVH'J#7:Q!]2PC>TZ@J:%AC<X7>M_EY]$(2@[(8^(L[YZ%1M4T;/
MQ%#.TF#-7\<?&;O3&(KC].C);R6NNUQEQX=LH]\@B9$9]PY)+*<%A'>48TJB
M27-I# ]H)6:I^OR3M\P"6KX%9=(4S3_N]#-?K7^I=@.(<CU[1"<K,>E]]^#U
M(:J87PKM-12HOJ^3<56[4-*?JJT<R?L._+5%KPC$A[ZOSBPGRB=GFG*>9[&'
M0<HE97ZNB.MN:J@.[1JO^^H.B/9Y4!?<3T]=O\^)K/%Z2\0$38I5! !(U41[
M[3JO"A9Z&8;3VA#-G!?Y\NTS=5'L>]&!8TB3O:V(/L1L[SM,K_&V=:6;DE:Q
MTQ^K&M0,1&0#I'Y9RSG==0,(<S]C\2C+P[!\3J])G]CJV6Q4XW=(;O=<F<^M
M;V0Q',AKJ$P$!V.(*M&NH6Y3![CN=#+O:B,<YM]]G;O2@LFM0S07.>^V42D%
M$PLSKH6_/?Z-8NV "_X1C?HJ1H/U_<,[;5V;!_\J/ %CH[9F0DU:<47"LVIG
M2!3H3U,7)$.C1'4[[WH VM58OU\6M2)"6[7)N[6*K7M_H^(@/FB.P\9S_CJ3
ME4%0\QO(G.3&JW@OV>QRB-K%<!;JS/TD0P6YZ<K@$/)>%,9BIC4-PY31XWX.
M%Z;B$&0O6SCS'FEXJA-F.(0L09YXT9(7ER72<1J]9?+Y!.RJUW-PRCD-T]UM
M*Q0?O]1S(A[8ZOPKZ$3%S?QX>_C37V[+^UU9 =C3HN7$$%4'*_[.2^Y'Y9A]
M2+T^5Q:7OUPXSF,WZ.]]3:-N'JOR-?RG7DY!+:U]4;WAB8E%U%.GHS )>0K/
M?OVRO;2J:/7..>0C53Z'T3</L:;;CNX9U8043]<V3"SH1",,5?^X'F2;HM%+
M;8>.0'XYV,]9IN,^(-&S4[<2J!R9==T>ZW@VAFIJRN0&8-,Z#I&S2I1@.SQL
MEU@S"*CD&)$1F+WP2>R]3ITG@C+F'KKZWOWC: BYA/Y,\%4I*V*H'S@.2^%#
MN^X4@NPQ89$I[V=<UN:"?EU9AN?O]X\U&G.DIRP-=.T9UL>CC@;:+*P:Y00B
MZN_(*-"3FOQ1#Q54BP[':_?>66"I-Z0DK9G'/86YVXNJT1J&&5W<-?N.FW^0
M0'I/RAGB>D&4.5^Y^P[#X%:9A:WA2,\;Q1D4))MF<0%XK><<YZ.Y=<GPH+&J
MZS&(4+/D;[, _E&.E,*Q%'36RN-17D[:(O-]C>3+BO(C+K+/F8I.GRUS^W4I
M#-4N(AH-#C ;J*#V@DS/CE^U, S"9CX(8S).C+3VLJV.,8S%T8MV)--J')E<
ME:KWO@ZS+E#,9:\-L2;T#H],Z#HMF;>/<,B9G%@SW+.KK=@3<:_$R#?Q/:0S
MW?I]E\-M UM+=F_MJ:TY]6#%1;C7\?$:X\+WUY+4FW/,$O/6VF3B3YPW=B0Y
M=O*0=6(E;HO)!Z=+($^)D;8AG0S1I-JL21@J!)BS96./9!2Y#7U?>_\ENOF?
M*EZ2__RMQF5C0$;S!L FW72B<D"]XII=RI95ZK9# X:(68(]/AWKN.#5M<:&
MER0_RM-Z.N0.!6WH5)3Q\-N_J>)]IL/[T5G[Y;MR@X(:"02ZB?$&$"=ESE(8
M_G:A86N_2CN%=P1,(CSZ\D)E_(V1_\!34XVJTT6'^H[)6?U>)XJLFI@[0CA&
MI<W]+PT\CWSH+5->-%1YSDG$8 P>DM7T4VO^6JLS#2Y,0RH?^P05Y8QO) H;
M6TSDCA1_FZ(*9)M=!&DVM>R03?3C+FBI\;/93G,OO_-0_,H=Q!&-CU"?_+1/
ME.HD\U2%%]>F1P7/:2/%&I4+\>VK''TU*<PD&/JL3;L1R#W8,A(;/Y^ZYIK<
M('5:*.B(D%26U84)?.N&/>KK%:"AHQ&M2\A+([[>&P.T7CUC33 (((0(9"OD
M,M+=\H'9UP//^[=_2^)I.9/Z+"/["\=-$BC-%<C=L9E+.G&KPMX8]_+Y;ABC
MR<#A&H OO^*#JBE>^*/MSO-#:FHY),'%&MCA\CY2SKYMT*@V%BT.O 0W_4AM
MZK0XY,KX=6XV[!VJ\2XRY:.>ZWWY!BR ?J7T3K&=E&QB,0;I85^>:IPX3S%^
MQF'^G"Q7"KMND[*K5=I!K(5K'[O-Z?Y)@Y@$(;D E\R: /UH2)ZOJO_DI;?#
MX0RD/O\ 56(0T#(H23RO.INZ?FSO^7FGYVJZRMN,LTF3MQ&T^M;B4G;W&N'A
MXN*4EZWAK) !%2YN=9W$ 1SVCZ94%9QJJV'X^/BVBZT\D4+'?LG/2>_=&Q14
MH5M;E06"U"@X)[?S&X0[[D3W,G25)>FP$W_FBCNDE@>UH*Q_HV>42DKZ]X ;
MGHBNJYR&*;0W!"8-063&P6:O&/I5J@?G2T-X[>\_5>K?N;]NM,*QRS.)Y0P_
MKG0?!+,KO-OKO,,T+Z9=K3*8[N/!H9[Q[D'7M;/*HT[^WD+5SE7_]\[XWEU5
M>Y_%3?H:$.VA%NJAXE/+9-.)($O 5CC.Z;#&^G!*8*CA &1]ZU0,RHHRU,W/
MF6I8*7'/]CN? EX'CPX?=IN]:X<"5RF6,6^^ABI$3ZZ<?8#**^_:1WTW8TP%
MBD8N=)/?-TL>?^7ZRBB-[(W:7#^5R4:M5JKS?K.#FY=]W%52+UZ2(SX+(G\+
M[.840?P\PC7.CQE] Q"QEK1T+#2"J+6939F-'Q[Z4*.9I6['):5O'[>Z,MF]
MDRKPX9>W:_"[?UQ]5DM@KJN#^P(UTD^?YF,- 7%#$':6>#CNGH9G=PL(6S01
M!OI6NI]P@A,864U=[N$'>T.>N#P/].S8ZYI36;9[5#KVK87R[4B<)BH5><RO
M31N8MNO;*UTQ#X_8Q*0\Y;? LW6!".3)I1(95>2YW,?]^%!RDNR5/SPO=[ >
MF&M;Y,P'HQ+]<\<C.IE!)QS0%L+Q>H'Z>Y6CC-JC7D:5A[\DG(+D/IP@SO(Y
MR'<L!",F7/IDG4QXJ*CB%_#<RG\\3>2BF)_C[NH'H4X.+IKNPLM//>8FB'[S
MOQYB-V:+Z_VB(:2:<=&5,\N"KS#F;1!V \!=Q29<M2VUP=>VJ3@V?PB'Q!,#
M9A_0694A/[J0Q]FDI.XK3[5(,BO+DZM;*[!%>9]]?LOOU8'B =$29W<5M(]N
M5DWL\RTX19IN%Y= _SKJL]W8F <\97P6IQZG">.9V:30/ X$F#Z)NVCY<[S
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MKLD'.3#+(]@_ ;:]K D<OU08D^PGR=-<CXM!9KK\:17V8@TW@!:.Z8EIPQL
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M:.2@RB=U:\:86+)GZHMN/_=*:*&-++OBH5N7#S.1J#I(3K]L$"JQ%"@3G?Q
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M7[T; ![>[2]X<*CE1(HEBD/01*UPW*Y*W(??:GS_Y4=CQ7VZU_=X'0E,/UI
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M(*3-ZY??5WT#?=VD++9B.XAB^-L4(>PHH1>B,6L+F0^T""&O?*B-WVD&5.]
M+[.O%[.E[N_[Z>A)@3.!U43#3L-G8::"Q*[B;*@B](I=27,^LCUVLLE,/">^
M9(-52*2,@>IKG4_*F+WK7FZKY9!1M=!OLPTI[ ,IJ*]0ZV1.H+1?M1XS_8]7
MQ=$B%W#CLAX:\\TW0RBF'<L(D].(@?6HEJ1K:.9*B<"^#'&Z*\6;Y AN&/$;
MV8#8\44G+(ISF_$'RWO."3A7F/,^F6$M<>@#3S&?<C'T2^_'<^+8D2QZ-&8\
MM3<_-MXF_OU=K^7D_&\^R>WEP+9B.MU$+R)A9&3Z*W'7LN[U]HBM)%<#^\[!
M+;CXSKVB'82LXTA)"$?K^"@O.?E*#NGL BZQVB,5*AJ24Z"GOW*06-(X V]H
MY"-,#L7C!D27W<1X"".W^VIPI\$W0W#ICQ^^)XSV/IEO=UK9C'2P/HU382*J
MR55]BAC3(3AF<Y=7;_1?=F'JQU[Y&QL+.L:@#T%X=#VUYR1:L$*=ER0U"A0A
M0B<2YHWG,S57Q[[&JH4V67@M#:U9,VI3%<AV@2!:#Q+NX_R P>O*R<H_!QM]
M"WV5Z 8@T:W!IC.JZ#H%O@R)T5=Q"6]BY.E 4M*>XG>$$SUF9\CKD0C5@<GN
M$@/9D.5Z]"1J@23?XVV)WAI)]'%/; KOX??V45(66!P?U@>.=)A"CLU?#V>#
MIX]#A)-HV+GE=PWIC3T&!R#.TAE5]726^;%>Q-$YO;J8^VJ*$,+1M/D]-[?V
MM+U=W_#9OT92[SW]S&!<#UFJ)[UQ::D(?>*D9O*645U%0!XB=3TC16^EKD4@
M&T:3BBN5DOH)$H^%';UVA5RM9;]>":*'*F?':V>43"?!*Z;M%NH?*BYEBR(E
M)3WPNT5+0=".3@IB94Q]4V:&G])\A!IZ L:\[T]@$FP5IZOA+A/$NPW0AEBW
M5*C/\'&$.8IEQNOW@$"<]R@OV-8>,>'S'Q<L3HU#%1H3K@E2#$Q&XP>_VRE6
MX$SF\[&88I#<.CD:",QGGK'U\.ROO#U-#1.0I\E@J9Y94ZV#*CLH1H; &K]B
MH)2A2O;BV;1X6!57?+&>B/A]]I(5\J7EA_OAAM=Y(=2F=?$)#5:GL\-1U*M*
M- (?4[%J\RK6E=A4'RNV%CQA;Q@WW&"-;UBN9F5F)7_<&A>]'SC,/@L%GG'^
M\I8HMJX^@'J&*!Q]S=HJZ@SX&"4'I7@\# 0,? )@E%N&9A NQZJB]I)X@RUD
M>1+LKMUF[AJ*9K5&'A00/D4/RJ<%X\'%0_ROAX?W).J"Z<-G-[EIGD(#,2IR
M(W:4BUQ\&!0=RM P(_9V9_:]B<^HURG\:B=BV<TGZPT4H6*(/'4O^@^#(7R<
M%FI]R5C,&C CS[=SFI:DC:<7UR%GU$$"Z6RJ#88>D<HA>[;:R^MQ-5T:E!>B
M.W3V# Y%4FU4R=<KU;FZ!]=<H&(@PUCK!O/&Y*8S+%[SR)LR=U$_,LP%H:V6
MCD1'1_VAWU/\:KN5+F(KE"YZ(J+D]S/@*%NO!TXIX)6?,#/BI??(L70[T==)
MU;D.]E"X/% FTN4OV\HB;PV/Y%K$5O4_]J!QJ "@'(D<6C<>>J[;OY*!OY+3
M:9AGF!-7ND;76^^-WD(O',(D%AX\3Z((])6A.9\[I.)_S'R@VP!.N3I:7]MO
MW<J &3SBHC8?2KO,-P-]<&<H.T+7)?AZ>B4R:^B?-'Y;## 0YP9,R54!<!5=
MV6:2&53>-$[<=8ZVX2A$%_T4]Q5L2=/C<C6 @*>8H3<W]C[*$<RY3:H-;/\2
MZ%H^'Y[$+9\!#G/_1!U6L5C$3>KCS$.IXG^+G0(XG@&S<D^[3UH,<O_2[<R
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M<PHJN0T#CZ5:TE3A1^OT6(&C'?"1:0'&!_C'N;.KA=!Y7 2S05MY7_#RKW8
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MR0>QR-[H(D1PGC-G-/9X[4O]CP7HCB'"2-\I&G"725%T!D4EHD/#Z@]81OE
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M6>NL^+V2LE9%\TA4F )SGD@.E2W)O*C#(K70V!W-CQ.^-:,_"[C<[G@UV<8
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MP;?1DR@LJC2\'4R-Q7L&E#&KW$BV^7._=.+[;L2MQ!0M0--SKPU,YV%;>HP
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M/:9O>:)9? &2?B;!ZC++(M,"82J;9E77.&A=F.D8A%9P\B@,N)O>!'L+%"*
M<B$SGVHBABES?IHJMZ8C)YX "=2-X@5AK>*RQ\>_(YCS:7(C!L[0(OD[L3]2
MJ[7(\TWR ++M/,KW-8.9+\86B=$5\YN-*\8BV%)2^\)]RJW4]F8P:)H35(7!
M.U;2<E+ZOLFSLQH0S(5-=Z6'Q$?%$D47R#C$[Z)Q]__2Z 0R&O1_ZW3R+S;]
M[\LC],AS38F+\H$Y!7HP!#+-_,0SP91"D96C(DL.B//LQT$2)KR]J90KM7%:
M.1#,\B2RX&_XN06M;BNC+>.D3D!!5<$5T7A?6?<,L)/"L>[@.3T.+P M2%FR
M?FU=$V9(8GV\(E$/I3GG:RWD,R)##&\##;A49S2VF0LBH")J]B##8TTY/+01
M8?:8KYI+:,@.=KF=N<)XZ3$&+POSMYCRC# [.GU:P*WML3JO7)7SQ/><GXY=
M+9K.<#(!"=CR%TGJ_+H,,8YO[;G]N1T4UL 3P-.?+B5/C*"TB;#>/OOP:B4L
M5T?,7%[Q O'QLOM%'%Y/CD;&ID><+IOK^99S_46HM6U<#YXURZ;>Z),A20\]
M.(6^9$4Q-DU-17[)O=QN,_COS:I4[6CC944^5M_RGF*0P:E/N@$#&ZDG$'=X
M-$?)>]7BYW11>.[I14I+D<TR8^:CAMO]2I&^[<0O/Q"8W"B]CZA(I:.E>89.
M72#^QU?8L&/CL/S$L'1%=X;=^,:"R.W3,4PK $S\*<H:#Z1*N\J8(=A_J 0F
M3T<Q#I05]1Z04/8-M*+&W9GS!< \?.?7.,;Z&A 6[1_H9/54^5YU,M$5JLB+
M7T3<[O12U\:&25+]IJGY?.U5\FE:'PI,3Y'=0*8# 9QOSZ8[>0<]OJ,I9L\>
M"/=UUY,75J3J%"3.[7DM#0=[%#?MIHD;2FC 80:M,R\3[4N^")0K$^FF)H]0
M>(;QRJZW8G7WBU"V4.+JS @(&\K4-0$C"1-]TJ& "M^#U[X'&?8B$MQ-!P.?
MUZ1>[9.EQIRX<'!H^VA\R6VO]Q"/?T$/[K_N-OW<J#[+TBUR1_W;J):P(;WL
MCY'U@H-^CRV=7_4'<D\P[<W;'U%4?/Y\==\R[D2*7ILXW<^4E4-;:K\M@WPC
M'GTM9:PO2_YJ+!QOL;S=[[]%]6^^\:F"2PQ7VGA)2? W\9O5F+=EZ?$^. ?$
M\!@41A<<M#34$BP(I31^,QM@>0FEKCW1HC>V0TI%^>:&G(7JHP7G6G0BO0J=
M<_%1IDEC G& CW-6XK?<CL:_F=&84V%0'G2Y/@."T[[K'W10$,U(7-5O<J=G
M\G*, < U@,IFQ0<$710%51#V/'DXMS"B0\&IKF(I9:BN\;RE/OLVF4*&M1,G
M:EO<<XU#J!?Z*N3'O%#"@*-3Q0RWII6Z_DMP%YZ6X^#1T(#>O=BU-T((K3L;
M7:&PAW?4SOQB?'G@JR<LA?Z*L:DSR*C6M^#7!V=7N('IUX[4+:/:)G<MMN_W
M_0;#CEUL(0=C/AADZ!N:I+_]7]I<Q-".SPNP,U*!9Y0;[A0N5PT$'B;8WH3M
MZ,?_<?UKE; ]U_]#Y!)&PI\!A'H>8A^:9BN-S'E81.@"!C[O2AR()M,IXCB[
MR3=):]'G$)8)%I?J<9;@-.;]V1<\)%LY1S^F,UDV^(!\2]:JG9;P_W'V5D%Q
M!>&Z]F !@FMP2""!X.X22/#@P=V"#BZ#NUOPX! @N+N[6W 8=!B< #/HX"=[
M[ZJSS\6N4_]_+GI5=5>M==/R]M?KZ^=M?U\APOT__53^3??_D$CYK^"1(OI@
MR'@T)Q3A'9BT#IDCHV!^%L)0;H 'X6>3"F0G2?)MLV[UD%[O@L7=A7RP ^]#
MQJD>.3")Q)2ZNR\,D!T2C.T39=B*E49_I=<9 TT?,,:R!>,O\F&@I32'MJ]_
M"@0.&R3Q<\,$MFM[657464Y=XC_D&J,KON'8 "\WW6E671J+U/ <.-]Q#ROF
MX78];VS=Y?&!WNR@(*3.I1;<[,9J2"*R?$KT1FL9_&TQ==YQ.H0+H>,$CZ#3
MTE4?0%6&];=HSF#!A_?>JURZJ,L14W89Q"Q%/[#+SV3[ZU])^+JVG#N)OX)5
MYUC"I< '<CU)-YAO]3M\Y-;15%&YR\\UD@9))MS1 ]0?[4 #O:>E=O=Y8-9W
M,:?!N^L&_=SSCEP8U$X8E/(N0WWJW$BH\+]:TZU^^U>_]K.S'8K+&W.**?_6
M6)T=U:P[S8\W6.\M,OR:ZZKJCCY:\[0[_S=CO*07VIN3WP^E+BA1)1JP*E&'
M%M!XN*/;T*6QDZ>'='ER4KKFK(E3(C+*#^?\"@=:N ^7EK1KQ\%\Y7*HM2UG
MJY9T@2,!*1T1DY^1&K>9OQM\]K.QHNZ==:=^=X^5"B(WR7+YN9#](V3R8Y>Q
MLQ:D]:BORZID@B:*;:JI--<JD5$.^-?WO&$"ZR[>(,)#NX\KGX&363/]?<.]
MDK<;B_I>!?%\_87?0U7-?CL/]*-R\<=+R<;EJX1O,..A'J(9.+*2A%I3=\<\
M-+;/';3$@=/8P"EB'F<895#JA$37O+3M&N\YZ!WW^ *@;;)C\5-6_/93MEAO
MR%;+,/[F;)+* 9U<[+[4@6?*%*1^,S<PJ*TGD^5ICEOFB5;8]YL/_BV<J7/1
MSNL#KD++#":Y4^^IH+*=Q@"_-BDM*>O9=5.N$N])2S-1NW2;E==G F[J2G_+
M+U^#,5YS&:=:WE%,..LF\'0RJ_O6U4?[CK5, 'F=]^;;;@4?YT\6.)69YV(7
MMP87,QL\K]N.,\^C.PW+?*G"]3$MHU\ $^B3[.0ZIP,"@GW8*D:",_1\V_<J
MP;Z:<$KYY:JF4V$QF?OWNE5#O:QSQ.BFB7WKX_EE8/G1A]9>^J.M<'_Z /S#
M'A+>B5LEX8NEYQUK*O;#JFT"5N?;A]XO5#7NB7@RE6P".VQ#)R!^.Q&0V\_M
M1=(E2(QC2_MZKJXR,HPP0(!:PC,7Q(>8UF1U4(DOC.]?;BQTN"^:LYL]6IO0
MN/;^.>[^<9IFYK[I_-AW]2G1!R)F9"A^LTE9]?E;6UA1/(M4'-D ZR#_9Q*Z
MMV-"XB&95\:11KBP]+#.-U[LQ?:WZ?>C;LUMB9QU(PV!D]FG$]U" /B(WO4Y
M^4DF1X2HZ4Z.^,68.^4:4]K%(GT@I_5/!^NLIWSBP$\SS$7!,L?MSU'%B"V(
M8U@3M?<2Y5N1JK"I@3#0NPQ7@A^Q>YH; .@93+[W0W?RFR'1S\9OKD<7Y0?2
MUV-L%%,KMII.JS+GSXF9(9FQ%KE=_GHTV@\BH)GAYGN'$&RCCT 5R8:?&9T_
MI<I/G2Q8U[B/50,E#R?U/17N422?2GEI"1!%-OPJQ&O9Y61C+HAI+VIA&K\N
MQ+XH.N0%@'X$CF^"&-)<9^JPXNRZ# L,JO*P%AAR"B-=LV.,(K>RO=E6B1 5
MJUY%C''DX@CONUHZTN\MM+G$E@/0E+4^R8HXJ4@:O7+.V;_+L=YYK\ )["B5
M?M]C.!%&U:UL,'/^))+;!T\>%M:,B.^F,E82OE,UF)Q#AG@X7"R@) &$4%W7
MM6L/VT\3(GFONNI:Y4_7+80YWW5_>OKUB./G4P8^:O94D[OO!#6Z.6]*OY,&
M;F (HMY3+1M"GE"&:' 0GUT=[7PM%]Z&ZA<DV+R>N.2_H<9$3TP<%KDT_+D^
MW46A(ZN>FSNM=,>G_NL%P-&Y>Q]&T?@T=BWOM<%XGZ<TXN/(^UOP(&X7182D
M3_#>_UUG">27J#&E/V,%,@EX7/H6C2Q X6YY6R#2U_,WHGE'3/N4YG,AAF+=
M79Y(#$UAOH,*-;I>PTX-F/ % #D?QO$X(P,DJ.>P%4NK*Y(% G;=:'D\SM"-
M;"\Z+W(,:+C=Z1UT&'^W^RC877]9&+=2ML5/O>OYUP.?3\$L0[X!#U(U(:(8
M[>,Z35,#>1^18ROD)'M'5)&HDKBNRVDQ>VQB B*%^9[FI7+=</9^H:.XW@#,
MQ?Z]?&B7]6"./ETPU=YU6C#TE!&UY[*W<ILYMM2I]AL18-+5>K$ZBD2BR#6C
MC.:;8?E@;/<F@&AG=J_QPOYWZX5F(*,U%:$< [ZR'!G94;*FA#7>*U#)"+@X
MMZW 0)%BA@9AOG+ \+B68A*;.H*3\'67XI+E8-9M;6#X[,G'4^RU+F_*7 V;
M:$*A.+.O63T,/22^"9EREXY@CV!8#F6YVGM[VV(YQ5?HZ5?"T)2 ]KQ7]#?+
MV+N$)&473=S%L7[XB$0"A01>)RXX+Y!QSE?1U>']/&OZ].7JJ][/_O ^J+D]
ML#@"UNR]3 ^Y>Z2%'7/@KA_B4&Z<4#1Z7,I(-3J_:\^8"!-4VPO^%BQ[CH(L
M>1!<;.#/[5S:M2(/]&-K$(:HH(?%YE\G!<#4KCCZ@,@'_?\4@W>*^\+<V1F[
M17K7/,G38'R@[9 ,VV/(XSH54L4-E9OKGG%GY3&@C(G*E",R$\C@:;US<7(:
M$,UUG;)=7E,M^6LCE7F8])!XD6IU:JO@MQ;@I:WX OCAWO+D:KRG\@)(GWT!
M&+P JGC^QU9["Y7_.HY?9=!)S%EA+AUCS"<&',?;0%ND+D;KZ)X93="\GK9&
M C#!=@?R0"D),2?R&%-)AD">>49TE#*JV&A8 CAF1)RS9<'TN4^V?7Y87EK=
M25)$1C5>$/7@C_LI9.?2F_ACV[RM\DV]54WXA)U6::&:2X71P>)M9E=.7,RF
MHC-9BZHRK#<D067T67/ .H_:EZOZQ/%WG\^;C,[AT+&)6D$3) "525Y*+E(-
M)4*[VBY7#.&'FUS&6E%J^)E9KNJ=;U&%&ZK56R>/Z[X:$9C$W]MJA/[P3&7Q
M0Q'_!-W>((CL[N?E*%7V+7TSKJCPZM('!Z("+,8]GX;EXE35!%[;\?.E)>&
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M(;-"TZ=+\NIS')@0O)XX_VN=WS#']ZU.E\,!$CI:PQV+OPY92QZ;%H O==?
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M_I9)_+%_ 7^GQ8W$B[3'%G-9N#.KT&T=%8U5>(YL!O""$NK3FD@[[':_6[\
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MTJN,:H*[:4$U<HEN#_)@L$KM#(IHS0%=NCF:(#W@3/5?I$^.GH@H@6YA/DK
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M.BP-%(ME?T+*-%>IXR3%4KLF7J41)P8.ZTH*7M7PO #"@^<##K7@*L]8Z2^
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M*O],R+DF2^>W[D,%+1&/@:U!^#-@-RML1:;&9"@B=5>"-"4M&D9*K\DJW8V
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M&>Z:W$/UO1WFY<?*4"Y<JZH1)NU7 Y+7/W"MP<F2)>$M6]QW7GZ, /%LBR=
M1.Q26UIT&%+)7RV/,@1=FN"E_Q DW^FT&PZHEWUD,.(U_%(TM&0N?D?KILXE
MQG\Z4S+5D3^,[EAM79-8D01A[N=46/KK0WQIH"0D).!S*XZ&R-JNLL4C/P$;
M5AXN<^H7I7,+C%&6ZER."*IOI=>0;/I/Y9+!TR.NLD:;) 0GZ'DGI4B>5@P
M1>;)"1.Y4)KYW[ZBW0G0WVT[6!URN[/5E:2"10RTFY;<7,L2'Q]/YH&L)G4)
M%@21R^".2]_J7$9*F2[FW+\V\WJ.H"&V9UF%*2&F=@<!Q[.%QW-X0&"G[S_1
M5!JJK#>4OFG,-,$?W:$*+G=J6PO\)-0G?GU*^^81:8>##"'5EYU%B7#]:$TP
MEJC,68+.4(J!RS,M2'*-9:W%YGIPAV1YDLI@!:-5:&*KY,F7?Z?]R84D_!/?
M92+DY".CAE_CXW24E;:S+:7C"P!P9W[CBI#<D<#3&3.M_'I*E<P[]W6<TA.
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MLF^/9HKU>[_SV96HZXEMW.M-AL7VSO^ZHR]?U9\^O,/Z7^V]95A<R[8N/+%
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MUN_-:+$D\^3CC=&K63U.))'0-,$5S>&IKIENM<T.AMU!V?QEU\V)OLO=T=S
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M6Z2,T2BQ9!8=E3TD1.^=?&5M5M9W+)>LW%HT+L[XCF;3'/<CWMX8=E+C;IW
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M."#R^XZ4! [H-,HA_I/3\/\'P8'/_@]02P,$%     @  ()Z6#D#(&29ZP
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M]#C]WL.G>JT/3$N#3]4R^BC+PWC7$RH]V65LURRM5U>U"74>'RT"+YADP30
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MP(G)5U/-GP#E/SJ,_\$^-JC.I23T]M-91!/4&57$!H[WQ3_CK;FOVY:"^I'
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M#730/V=G#[JF;TW&OU+*JLF_B7ZI2WJ .2Q%<5N6)I!5=]OT;T?UI $*D2D
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M?A0.GFQ8#W9V59\/P\ #2*D(;>IF=N?S5'?2T_O2Q!)+4<U)VQ1IQ.U2U#+
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M:5N8ZIQ]><O.#RRU6E]:>^BLQ;1#37Z41Y;O12*7)G$(&P,+^@WU 5HZV(M
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MWK;;.9QK33U:2 \1^K$2Q"?97I?6)5\.-&&?)=1H\[+C2D\?@6&J2TNPHA7
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ME?"=<TRH/3"PVMV@X!A"QDH?+">)"#X#7I^/>=+PP2Q[J."<V1%?;.EF.).
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M^GF&^VNI3Q&?B@N(!V]-7_XHQK'<SYX783I/^2:8-&#)>E19-A4DI?[ ]@S
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MMA;5=[%/%SPU"64"<JH]32V^Q9U@P^KA1DQS&84)CG<G%)-=EMB8]RVHJ$:
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MS/7J@95!,-_? ^PS9X+M>%DYNW^<^Z&KP*A)&/;R*.%E;HV,;=A'UZO'_RV
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M4'?-FM%2=5++/YKO#P%%,V[X,7;V+A'=M+J5_(K"^9 ^Q$"-,Z2#,I@!U=I
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M*&0EME8'0YY>\=V\IN2]H43W$Q5B8?Z(MM_JFXK 3*00#CAS?:*OL0BLWJ,
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MU9;<;K9GA%%I5B26W93ZM>=?NS/^OVZZ+F)#")(29<7I(X<Y TH;?[AO\8_
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M71N:C@PQ.3B>_@E[==):Q:ABJ<Z[I+PH =EZ JVX*"21.>P:9C?5^Y[,PZJ
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MGYA^,4E.2A^U+91=[PP@[,MQ#60*MH)K(=+$?W_C<A/@Q"&G&(6E_;HH))T
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MX=,D,0PXMAE<8FF=A8OK_,N=\>%)/W.Z_<?9MSK]5;3X,8)[D 1^T ^#Z)Z
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ML(M%^PGO&_S@:2B(=1&HV8]\<U0C'-+AW4*%OEV38Z\V4[F#&^?8J ]_W@E
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M3.E!% K0OKRVUX;A!74FX;5.DBXHYD)7E$(C79^I<[9A$G;X3VAKK@#MWE>
M&Z!5[G'0-OOK*T#8#HFUZ G Z0K0J? ]](_$X!6 ;()X]Q]K]-"Y N2_3">1
ME^#-OOS/_O]G]W>6C);]8M>E5WN=)UQ\(FF\SN6_:6+X/_@?_ _^%X"NYOXO
M4$L#!!0    (  "">ECJS1I?^1@!  HE 0 8    8V=T>"TR,#(S,3(S,7@Q
M,&LP,#4N:G!G[+IG5%-1M"ZZZ;U*;Z$*B(#TWE2:2!7I37J1CA!J*-*;@*"
M@ A2I*GTWKN = @]%"D""24$"/#BN>_<.^YX;[QQ[OM]5O;\D[WVWG.NN>8W
MOR_9=PMWZP#E,S5--0 +&P"P,!_@;@EX N!@8_\[, ,7<^ 1XN'AXN(1$Q#@
M$Y(2DY*2$).0D)%34Y*14Y&3D%#245+=HZ&EI26EH&>@HV&@IJ&E^7<3+!S,
M-;AX1'AX1#1D)&0T_\?CK@N@(L2"XM#A8'$"V%18.%18=WT ".,G'M9_#.#_
M'EC8&!_Q"0B)B$DP$^HI 6PL'!QL7)Q_7F/.AF+. [A4>-0<(BKX]_1?$7!Z
MTXA&I!42<CW^T4UK, GG%K/UB20BIJ-G8&3BN<_+Q_] 7$)22EI&]LE3535U
M#<UG+PQ?&AF;F)K9V3LX.CF[N/KZO?$/  <&1;V-CHF-BT](SWB?F?7A8W;.
MEZ+BKR6E9>7??M;6U3<T-C6W]/3V]0\,#@V/3$W/S,[-+RQ"-V";6]L[?W;W
M]A$GIV?GR O4Y=6_N+  '*S_'/^O<5%AXL+&Q<7!)?@7%Q9VP+\)5+AX'"+X
MU"KZ!*^\[W&*1A#2/$XK_-%-Q"5F *>U]9DDIN,6W^!!_ OM/R+[KP46^?\K
MLO\9V/^*"PJ0XF!ADH=#!2@!-R^^)/ !_VW_;?]M_VU?<KE=Q-U9$FJ8(RLK
M10D55&@O>7A[/4G"ACKA!I-?W,)HISS"&-!/&K+FQIGS%'@CY^3J18:9LK&+
M7SD,>>5&=O-9A"Q\IIB[$D#H(I514>L%BYW($83?U5%FL2GJGF7CK(>\5*6K
M)G$Q7<5#&)'@MD, _X-^GB;B7K"7A@=>$,6A,/RZ&X2K9->)M8:*VGCKXKGI
M206BM%;=@%#F">V/[[P21V;= 0I)"0C5USN<K7I<.#_";+MPSJL3T &H=OQW
MD/5B4*W'UZ(]D=VYJ^KLC<1+#NK GW1.-J2UE$Q.A&4QZI<?V<<"K!ON@$-%
MB LDLI-)7)!KHST1%;QQ5.OFP!M?KZT?ML@Z_*G/:G5&N<N^^)OY.,&K.\#-
M 0@KU;=.E_US2(4 K1NC[WU89_T0X8Z7V1G/W?2]=1[6:G)D\RI 3+"-ZYOX
M-]!%[Q&>=.^C5V?'_=9+$X,%.&W:\&,UQ'%WNW"O\";!2?2O6['3PNE/SZC>
M'M,FIN (H*-_4I2)8R&3:1%K_35+'P8ZB>5Y$<S]M2$/)B5TB<%2%JE/W*X]
M&1NS(5P?+Q-$;/S?4P^VR9%2/_X U;8/4;H#(I,/9.^ /HIH,]Z$6PH+E-83
M5#KA[_,X]!/:@UH/HM.E.+UOE]$J#[L.;;JDG@'7'@FH5-@@FF9>&TX?%P+.
M 455R6MMI.)9F>U!2ZJ$XS;KFO)W3"5ES:!Q]BY/0XYLAT23R*57D.K1;:HN
ML#N =(\)F6^QX)KEM6:>;>QVZ</^9NBO5V\",/.E\Y'2>B&HKC2IC>#Z*9BB
MGXD >HBF6F=U%6!>;!N-XVB?X8D;%L<%.FR_-O72/!21G)ZG/;:&&Z3&B8Y=
M$QRLLL/G"A]*!L%<-GA5H=-F%D/9!H1#I,F1TER8%1*DO:2XYG#61ZDC&U$B
MH:R?4;I?7?/)-;YH;="XP;)O0V%<5.E2CD(%!Z;<ZS8>4(HUI4;/@;$7ZP1_
M!V''=,[!TZ9$K,F9?0XJ#5E.5)5--BI0'>_4D7"%VP3TY4WJ'6 _@1VB?Y-Z
M).^P>4@W 2-(#O%V>5-F"8[JHZJ[0#Q:8W%A[:W5B/9W"J+EY9*!"G2%$:/=
M9CL>W/86@#H8T"KI2O=<K7"G[ LTVCH:Q=I$!IY1K"FJ[2X+9WDQD)Z&/\*Z
M)E(-4P5O&OS^V_EJ8E%"7G_C\(GI%,@0Y)2K,9^AF\]<(VO9.J7%/Z?1<,1+
MFOR.("2U,DP(TJWB!%?O2XU;I8&7]LX@S$(4I\Q?SI^3W/A>2]@!_"<;*NXB
M:2GGW9=JNAYU6$@>6@3W'0 WJ)ON=)H@0*O.*++Q--3 #NVN!=1_<R)H7G!5
M*XN-R3XVXYC?%J%;]QZ2V+W%N?DNU&8'HTA4)&V"YR7']EG'_I;X=648]*O6
MY>+'6U)&8;(O/V_6"1_]48C;"5=\_Z53INX.0 D8QY7  V+0=@%P:AB(R"VG
MU;D!&MV8R)ZC*62(/?0N]XVM,M?QZQ<W^^=KD1B?]#@V[X!417Z4Z:9U[#R(
M7"*/;MQM5FP_L4P^GOHRA=4V[J&]ZBDEZ^6EFC80&J@:HEUX!W3KM@E76*,"
M#'-5&NKA^)TPQC8%APHRR^*9R7=DC?=<8&L77LWLV#R.6P[J[ [@HEOBE[#V
M>YM2*8KT+B#L:K0U;(*L+D8NE*"/S:LM'G#RJG*N)E3#Y7R8I*.\[O&9HK6L
M)DD^^ [ (Y^1%T"(6F/MW0'D@D=MNFQ1GA75&14'/_<N GR'<E<'%O'>)W*/
MB(6/YWY7ONPPN[KH-:N$7L2*5^G 1K1E@Y<TJNUK<^76G90')(<('NA0X)2J
M*#,9ZJL"-/_33&Z%X2FIFVNDKF&L"/P"_(HO^WH2];-Y(P2:^K'L49=1"^'J
MG.&2?#4#%)%,4E$=V. +9!R*&?&D-T=[K!@I11^D?3B>MU.K2>E92[C]CLB$
M%7$93)-^G1(\Z[E0.Q $Z4V-M6:\)0=7],ABD+CR(9-'GD,Y5)UG=BOC78&C
M0\K]=-7$^SZ:'))G9L!-08%!74-;0UW./D-U=4 @I7R$E>5G.FCQ]G?"<5G'
MROF=B3Y0; <6BNO:/&R,#<L:6\M%(OHSDU'Y9U3L7WA=+"3_PFC">8)#U(/C
M[<9'JG3%0\UK'E<FX9X[8,D8V3RC^DG6/_;+@ =T;H [WD@\;263?EM/5YH1
MR% &%1L:PYP.+Q%_]&[*PPC!)##[?+S)$)DORV[T+1ZY03D1S;//O0$FF>Y&
M54/!4R#]$>ZG5)B248@+:ALAI7)3V.E8$,L&^C%)'@]Q<O_6ZZGX]2%9V4C#
M480'#]V1C>IE'&&ZAWS& A 6-6G-Z6K="(IK$[[6>0)WZ@=1U"F1KRZ;*:PT
MM/K"RI,S>^*2$BCO *>H?$*>[S3XW%M ($6\$ER_DS%$"!6XKL2P7T @GELE
M-_#!8,G%RP0\,RKPE_UAK"06MK2-\<Z$?(0RZ(V^-6^(T$V3A*#Q9F-\!QU:
M \YM13CK5\6*5F$K*MW?-*AWXU'A$+XN6]1(CMC0Y*9\Z27V1Y8736NG.M?F
MLF&8V)MCF$^)N-]TQ5IDCHIVF!=L:'K:TO2=RE:Z^&&A2H;T\/">,BAX5O^;
MJ60)U+DU?)^?L,E-Y<'E%\[^)^_'_=,KQ9+LJ:"5M7@&OY0!^PQH)W\NLASQ
M(1JR7KC*BJANY5DI[84P5S@'J=;F1K#D@+,+([VQ0@A</GA)+UT/V. [XYP;
M[>PP"[AX"/%H"&X\X4X?Z=:G(<WBA@,L6[/:)'U,U@E^36\4Z UJ9\_V!FS;
MON?QQJC<CI:SW^)W8&/:4/M^P!-=%$^1;? *KSY"C'GLOI3>AU92.:K,.(.P
M !QOP%,^(F<",Q&, J/$D'6H/Z7[=)B&3.XI+)^;*!SK4&AJL)!^($HXTS?Y
MK27\U;OSRQCB=*PK.7V>&5$+3>PQ9ET&/!@I"9\"$:N:V_H_^)D83*5!\Z"$
M-^X "K#ME;; +?5!1:+6]8'3XJ/&9,JZ9PM#%#NOXMC7[:1MR4#0 *0QRAI>
MBB1LGVN3VV"5[.T/8Y[Z*WQV!] L+:E[5I"D/51^?J'W3:YQ?# C:7V3G1+K
MBN!E\8P[1T?,B%:9P8F?"V>C"Y"N:N'A8%5,ULOM-W1>,Y0*U8(IEB.N;XG<
MUI5 X'$2,JT!2G"RWV0ER4MZ,B;FN.&585*8N' C<9\33L(%B/: B10$U[L#
M(K*@=\!;3T<$30O3_;0*4]2G7 W8M?S@KZSAOR?<&_.NNK4[I#Z^RJ#",^,_
M$W&0]?*6]H+P-ET$2!UE[1"ZKG"O#P)/"@Q8Y0QV-X"M%Z;=/YF;TTB33#'^
M94OQ6#4H-;G3O3U $Q4-;]Q(25[7ED;K(*IS6J+'4BIJ(EY]R6#6X,QRYDC;
MLOW1J3%C4\B(&XYU7D6+Z,"T0CP*C&>I2!,$I/]&N,M%X?BMA/#?0S?EIKGG
M?)VRU2@AO-; @@,N:>?IR.7MP$T_"A0_J$_;<Q!"WB9S!Q"S+0K=LN^YE>]*
MEF\2+JY2.W":6BSAJ0HPNG>& ."'C_4(U@R-^PNPE-:_=H!0F? B6$!BB/7&
MZ8;Y!' 8?"# OWKNP>6_2*1V,D]Z$L5&KMQEJRP/PKT#UK_ 0UZBTC:.\2V<
M;QEB#1&.<5<=D2WJ\=R=E..TV7XW3]RKW4M[Q$1Z\7 *N;&QD'FT</4>711_
M09*BI*O_7!@]"J_"%7O>NG'J36LKF?FAEPOR5'*V:62IHH%X9.P]84*<Z>!'
MR2.4^2TQ1P7X#H"MMFZ 2%$4VC/WGB%8F&BR1-U>J%8Q.WX:O%_<X.Y,IZ%G
M%^+& ?YNVO&8# BM5_4MH%+D<+8F;F,N!U?TS?N8[ ;Y5"POJ[H+]K([&5JH
M4]<V_AJ1?C&O@!>B K^X):: KTXC\U'UY6YL\O,.<(GME)06VKH6HW)QD6=I
M&D+/S DUWV8)I.L'G _W V$11O[M,$&!GA;[G)3Z\L7=JQ![@M;.)@U. QU
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M_:N=$>8FGK9Z8J=&S9?%;Q^-'.OY-+,DG9>NKBVY_(ZO/N*L?]ORE#N[AS_
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MX]+[ZMQ*9=-ZD7=#-Q5M&0!+?M%SZ YC7DB2RDE)+%]U,5CE&'BZ,^?<=@2
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M%__44MD/_(RQJ=98]TVZJ)E\ALF" -+[)D'Q00C?C' (5@7Z/LJEPL7;]2#
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M]<?7-C.ZCN>O>!/(Q'AW_J!T+(\!HZ8[D!,M>_MC=XJPNEQ\9]X=;$H'LYB
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MT#$Z'Y:(#K0N2W(GW6EX;C0JZ\[P&[?<!CG)W](M![*'J[A.$(GC1<,<9&=
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M6V9G4 P7[ZANPW1>"S%YFL"?E@A.%!$D0$WL'Z83OM"UL)Z\OY>GT1<PDDI
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M"'66?Z;Q.9&;6=E1CONSQ*DB1_0F:*_/A[**H,!S0Q=.&3;:.WS$7CI/ODG
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MPB4(;[!!D0E?GG/H+7Y,>IH"R!?*-6W3&G>[SJY3WQF5J11@AS<]VOC""_(
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M]UA9T8E5X['M/E-TL -590]IU?G:H;;Q>A#,.[2</JUQ5' _D?^^L"3\X*H
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MT=@J@]:F!G:@J.MX=HR[><IU^NZZ*)"+DQGYNC'6[H<GF"1CE7Z(W'J='<6
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M5]$>QH L=&SWX/'&8!8=!6&.3>'@T28=&L:T>:L\>$'FT6+1TE8K#TN=:_N
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M?4SFC:=^!GPY3K:LF,'>7BCY=44"FC5NC=+NMQ8D>R56K8>>>K/00[P^7$Y
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MP-HPEXCJ%T.HJ?P*\?2#3N>@OXK!5#^]/F2<LBZ.3W>KH^C3>K$.8U9_N P
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MMV4=,=+_6D_Q3_S=497=37624RF[VV'L83KO+#!\<ZZ4.1]+U'W[B9D!4U3
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M^N3.3WG8>3=2Y,$XT'(8RD5F1>692ZG=1]:X?<U\!G=:<0E/C7=&J7GN"*/
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M;I6I;4]P,,I>[ITFCG!,Y+S_E?YR>=<L2=CB,X4^@DS+Y<_6OGVR:8\QX2D
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MSG'4%>E J?':QNB6I[F, -%WM/7C?P"M0].\C!$^A 5?YGNE\*.%+RZDOO\
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M"JI.[[AF=&9[LASWCLW>3SZ8N )05W]R0 MJTA8NE+^T RMQJ>ENSTA?Z2%
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MJ:0 U.:"\>!.7O 9"36U8F.'3IMG8V-[W_4L06)?JTT?;1J.R1)SY)NP;]7
MBF"^31'[K$G_<E:X^A%QLZM,?V$>"NWM2 L@[V&;.M"R%$1-UY2N-Y>)]7G<
M)M-0V?0]V6^S0B7WO[MKJ;&:PT:I21G[$*TG\:WR?8TXGT:+07G*4!$P-/$5
M=GL1![B=(7T17+REP;&3X(=&-;F ?4U@$#PW3(<L ?R\S*@C\392H\"-7\?
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M^3)8,M?R7UO$)Y41,U)M7JZ.+M!R]KI3C_ZO4LYO-+1^_2]IN(D8R6/\-!5
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MTG-&TO')&"2BE*Q*[:4](;DHDWDPG;GWM063*L2&*71ZQREZ5$F$DZ*YJ1L
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M9LYH-/@E@A$M?:,5_UBFXS&()L!+Z:X=@@-\_["9A2(B#CC%(U+&UP):MN,
MDN"GR^"U9335WP')G@%B^3.@ NQ0!UCFSW46\&5@_T.9&2;(FA5VO/-G;@()
M?J/JEY6Y?X,G_A.>X4(MG@';3;QCLB.PGH+_-T!GE1[]GYD[5:1'_P#]22+P
M'Q1B^+M"8+O'L(RPPS();*#(HN!9,[!?>P'^2>#3(Y!E;Q2>.5"5L.5 VZDA
M"SY<@8O^Q']N)0?+=FD)?,)=MX8%M%@&KN'1XQ&I'(;R'D_]=WG^R6]_D8<&
M!PCZ"P,1/\MZ_3<&#K((_KST+_J8_K;$7_0!SGQ>.,LKHE]8^%V2_T*#/'X:
M7/[N!,8_.^&OE0[0VGN_D UJ1I'_D2N5/[FB"7.&!5\J%@('I_]1T-C_<>:N
M_O66-X&#695'03B #8;!3YO"M%\.,P5\-BYH&M#1*4VH3%@@1^=Z 'G(=K,^
M%K:B7<:LKI<BFC&].O"\\,;-^O(/$3RJ9-P?7M TK4,&!*.Q\DCE=TAPIWA-
M)M?X5NGCL5S5I="3NW?OGP< %LDP;,YU@4G'X<@](*+.WQ$'>"0%BI^<=FF4
MU._0U#1_CBU U\=NZN>\S./1=?7_RF+.C,]1<L%.(JQ-HQO[S"L8VD 0S3?(
M!!Z:Q /JM,3RU);9WW+8'RP:PBH=<2# $#@^W7_ $-?=88A/LH_P.Y %GMY@
M9C"J"+1DX]V%#6W$>_#\+1P :=!O$S5\8 +<VPKHEH>=Y74E7I?4$?Q3SA=D
M&(;2=PU+@3\6P O!^!O;_GCCE]5_NG$4_.?["O!/F*G+5">7#P;13/A-I\-0
M)$U$9=P./%A]=.4$B]^,\-\DM-7  Q3I!.Z+X9TDC-]H(HI,%O!!Q:R2,U^'
MJC=7-C(+$F-^R>IQ.AZ;EE.V]V$!!Y@DP1IDW!.[J'):?<210Q7;45>!^0&U
MM$\'H05B7]_ VL)H8T\CM?$E=?%@OJ."\30LA(,1CB <@-[,;HU^QE\490MJ
MOU0VK^$MVDATNSQ PV L*O!1T-76HNO*:Y['^D\NYJ:3'4NU1HNN2!;[ O-'
MBL-+N2YH+HQ'@9BQ^+ULZ ANB68Y*X&?,O(<.!6&*I +!VBIP@'0!L[^MU!W
M\M'&8U?*AP]Z?D >GVI.Y--OO7UD:T7AAS[@66CD<ZD_+_2%A"/--B20U *M
MA'@]@>;P]I"Z9!JL\KG\<V1O,HU+LZF6*N<SMS?-R_9LFXRRHJ9:-TV[UZ.$
M/ZEU:BXX>E6<.2,+SOC'PE=1P\ASX"_'O_5FL,.$8FF3)T="7_L+!L!E(-7?
M^T1!CJ?41D[.5JS-1:;/KS[45W5+B &(U2]33:_BUSEA.\QS+5+A]+5>S;(M
MH(<^OR;A6>P2)=QCP,<AM7WGH-!#J&A2P_)JD=&DG]KZZG,8HNYL;Q_ZO:8N
M^*^,6X3!P=,9LES+.TQVAIG7[$5W*(RGM-T"Z NH1%.>J[#:56POGD](2'C1
M=&!B.;VL/5H->\W.,M9@4C//C6@L7=DU5;&NF_'F'S<2C=_&S*J6Y7*3,'];
MB["8O7"HL8VM3_YNE;P+]FG]@]8P2A,PEB<690ZD!G_W0TI@*?/QCBR.OB$I
M=TM$R?/TLF5OT_+ 23]X#>PG(_B7R\Z,.XPDA\:@\=X,ML<!4$7+=K(4(^[V
M8![B\#+L[.GT],]:KT"K?DC!7VXJI.K\Q7J7P(LS^-HU_E8(=Q0A&UMU7ZGR
MU$(+\<S7CGQ2OK)KB;S@#P- VKKBW5(H)[7,Y2ED_H]3DN!<QF'O1(=,^H;A
M,@]S0=/14B+^]C<$JZ;=(5V)BYG*:LWK+5V"5:W%=M6[,HV9XOU[<A*3M5VQ
MT;]T+OB?S@>1)-BPW[J(%PPYP3N#K,S?A\EP9*M:=-0F6LM"KEN]5^4)GSBA
M=[^O==B/@A,\S :98GMV#OMJ2F>%^LD/U0V5U&UTGE^*^9R%W$*YFA0,25CA
M$0FMHZCX^5D/,G?D>"##81-&7'80RZC2#CQA_P]5H"7WLX>([)UV&$H\"S_/
M95):B%SW*^SVO(4ZN=C>TQA@R236Z^A3Y4^:_]#LW^7ZD%6>ARZ0K[8\7I@?
MZ/NME.;?2RW\6DH\0BY$<.7.01H.,( ]]+1:_H?F%/[87#'HHCS-!@Y 6Q5+
MN[ N9+90$T(GTO\HO_E&7;)$0$D/,X?+?=(K3_;A=1 2_W.C_M;YWF$ZGY!<
MZ,/+%L56>9V.HFZ<HRR91(D"9,^>A;(NVY<9#Y)K5G.6-<3,N'2.J]]/F.S?
ME_R$S(%3XX_/OY?-^XG] OC+[S%B>,?M5,[AC2+RFI%S"22E1;#&JPHL[ QP
MX;2KF!%[V(^96QS?"8,1.#8X+ 90M8ML0FN"#9"TWAZ.6Z(M+E?C)I]_V6IT
MR8C-;]2N;N7>,S8=*ACI4C=+\3H(V#I.CT4+@%];[LNA\ %[?A2?X?K@UC54
M<.PQGAO4T[-O&(PX@ CR$,D)\"U;BPFK2,6A ZOL6?.I.VL9ZGME4R^MR5[*
MVSSV_BYB 8;S@]3+'1A&Q-3$5 7XVRM3M]#A5Q(X1>_5OY;L5"3JOE8=E*VW
M%'$:];3! !CCZ-\/^\<!^X/RGV=XP8\TCG7Z?A/.$E'[,V4/X,Y_3=GKOX6=
M:Y7.CYM@'JK_XJ:7R+]=_]Y%^WV_H)5:0"*H9-+7#=:8$7NV87"<;1CX)YA?
M/(@_G%##_C-2Q=GX)\[F>DB84!NFT,N3<J4T8R#+-YFYHDGDV1ZM5# K4]L1
MD8RVED@^TO PH 9E"S^%D67X'IZ: VU-B03>7JD>8]=C$NZZ\5;5FI902[B+
M\XGAM<(0STI+U_EUJWC'GO75DQ^NX%]3].A_P.M%=2K>+]$.HO-F:+,TA5RR
MN^PP_X5]LK<Z6778PDA7H2.4OI,5<D,*X&;$"+IP-6)T*7UX4Q>$ONXJVB[V
MWK+BI6 29B?]VZ79:C%9OC0UP?I>>)*LNYZ35E__$735ZBRV0_X8VRIGW(#^
MX!F#(7LP2<D-E)[U<G&_I;X&2[0RO%653S3;Q7&"B\+&<P] 'B3R/< A:TR6
MB#*K-8"WDT,W:04V_G&D(QQ*8-@;;09+K;]Q=8P@IK8HJGQDAM?/<2Q<A9GR
MVV'3SL/_-0QB.+),U-</Z6!)K&!C"'IGQ];Z[QQQXS= $@XL+XSV  =X_XOL
MB3D%)V-UHB68\2-Z5DT'2 #F!Z8792\+!5/)\KO*0D1W[3T'=E4[4J?:<^.U
M=36-D6.5IB@9T[0;WGDQO38JRCSZKR2OQ"3I+=F"*-#XO?;A.VT,;;5M%QH%
MM/CU_\.,(5\6D/*VVT8!5E1Q*$5@%S@\T 3<T8;467SND7J6/%YH0>=PR_W[
M#7KX+(J,Q7M>%0<8SQ_2*]Y74LYHHC_B.%1]]'T7XAK0O0U>\D.KXP^M(? L
M-*L9^&Q8#U%)^),S>0<()?GYC(W0#\53HUB#HVM-$)5CQCDO$**QB0L\K(@T
MQ%YT IT%G9^_!G#O/MH 7^Y=+%;@\S.;IM F%%6N)L)DLA/+4&G)9'S]]9,)
M 3X/Y_VOP/MS[:F.+B3Q.7;=/1L!O)F0\APGNU+_N#[+C3'^0>*R=QQ?8/@E
MU;O0B2 Z_*RL+N-3+ ?+"&V'G7!;W,3SW]&%]XREFD5@3Q-=!2IZB>7NZ,=:
MQ&K^(F2KK^)Z7:$+-,LFWNR#[1=N=8(7N0\SO<LX6BW/^U.!$5E+@I$>_-*8
M%20PW'943/4AS/K\-/V[(V,@+T)J4'*MU*T(Y5F6C1+<S&ZO\%8N*USXUH #
M=.]JHRP6:&'?L[V+<0 2"2#: (AHQ'+98M49(V (-]>S4"WROXLB6?I*HF5)
MCWHJ\]5Y:>?UY0%S*J.TQ9*:+T?DK(=N!<!-.I&'Z>[= Y2@PW*4TB+^&<J"
M=])?*A<5Z&VE1SUR -KZ6)>84='0Y"]'X_F)()V=8+U?GV?HG;K00L_E44A(
M(7<GW0Z8TT<%+0C^D\*Q*+P]?C:(-S )([Y!ES%#KXI\=/&V2MZ!+ZB[:1E_
M-@_90?)B(Q@CP A7UU\'?P%NB*$3/*,9?D9SV>4(N6C0BN5SJN)A_"F?;?#?
M%-+Y@=_P>$[?!%C$[@I^_B=+'9T--MY2EBBI,TMMAI;M+,:^=(\-!]**#E(Y
MF(Q=IB]=](B!+Z&KXA_F=M&XM3H_$]AV30L?S;E0*UDJ&[6AFZUU\7E0Y2[+
MSYXM,70@>O!/9T3BG0'YZ0P>O#/ZSYQA;OLZD&(690572@E&:V9O-M%-5),7
MJUZ#BJBX.M:H1?3PZ5D=Q?V8A3;!W9H[#"<#:;W!ZJ@]UT7!+8T^1_DVD_C>
M4X/&W</2RB2"9J;CVF?!8TD=#_/#_)0< V+LQELU[/@AE5.K75W.X2K8IT \
MG6Z_T3E[UIK@KZU%0-11?J?\L;2!P^P\*-O2K_-3XG'.?JX4-4]+.5O%%DA9
M/B5Y\+@MB(4L#P9GLB+.1RZB#O@5#6J0H= GE1;>OI:" Z/717B*-;MZ8YGY
M"@*?+<O:I%2WN7%S%S=Z7GW04EO _7&^WG] XVPX&L ]"G\<R=\EF ,C#;R6
MH6U;EY8,V[5IO#6TZL:<G42+]R[4UN^VJI%&&[%R=P>TGSYN6*V[2F9P+?=#
MZ7>/T3R%$KIE8MMOOXV[ E+[][7_)*]!FX[A+P:(@XQ_QP&NG<:L81EA[9 _
M#NO?#/OY*?>A* Z0A'^L^SU5L+^5$?BM##X"!'^/@+++-?XLN5,.3?S#^UN&
M.N8W[M771["\.^SD7[8AR,J49!VKT_]0!F^"6RM$Z24$C?:PD9P%(7C_EV3Z
MCWMQ@._9J-\&V0_?165&-;0#1H*2,!X]X+^XT&[RJ<6AQ&A>Q<_6YS%'KP;%
MVZZWVGSY'[V9Z'N\H8?^HPUBB$_F2-6QLF_UHVB+>?8(PF%9Y_/P<]'0-VCW
M ;GB&+'RRDJ=A>Z]Y=<M:L5* 7V%;;_- -5O,U#PVSC^[A_#:GO+RJQ7!U31
M@;P(NGF.\6<=T8TEON:CN7?G++0BNN,1 (7^*L<UR3+QTT.OZB&P;:-?YTE9
MMI\S/(/#)%+C\_ #41H%YL.,+X&.:.&MSM$@2I!#B-.$N;37%+W_)?^&HNVO
MC.8QP#.SE,$0Y0V_YO49*PNT^(-Y:RM2"_1#Y.=S5 8.0#&=/;\!H_30E'D
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MW<R'SHU5EW:W.6X0%J.@R_OSHD,7$\!6KDYI25LAVQ7\5;T4G2-SINWEQ12
MWJ(M&$AH.6*U>C#$4!XX*N!!6LTM\ A*D,:]OXE*[;R]] UJH#?X0 S*&"Q*
M'GMIP]'>)HC7DM)T\X$)U\$Q#J"9D1V>R2'8W?]B1)[1_JJ0L)&T]Y/$4K_
M4&1II%?T%GAL VUZ>L\^DP^5 L_P!5/.7P^#FVHP">[OU-S(C#=1C5= :D"9
MOE[>?L :ZORTOP&UN61Y"1\ZMD7>Q2TI=8.OT6J^1\ZBE]_75(?3NYXC-O"J
MNTX'!0G?UU8?0(4CWFD-B\72K]<99AQF #6J)A5N[M6TW5*P@;Y9"R97O^"T
M?+7^\J[ N'OYE&^X.CG431K5H'E3LK\L.^@]X7/7'OPHCTTAC>Y+ _.>H21:
M)P,ED!9Q[XW>"!SP%FP]MOF>-T79]?T6F.S[CWTJ"N^P#N@\RS!\; :^"N>E
M9#AT")GEPS[OM+ [C.*('@" K@-Z!APN)W&<'Y6V'TX<<6B,^;BW#+^S9,F
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MWT\ZO")D"5JT*2LW!JOLX>RGH16]L-_7EW8U7F(./$$"'GJ*'@RLS*?2*QY
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MI+$BC'=#+ACG?OWW[@6+(P"C4O-,+(9-3Z=KB?8ES56R,CLGW 4)H/E9#5E
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MAYJ6%)& <?B*[14-[8V@]!4K[46:J#42X->&"L?;PQ994=B5"8Y_0].:)S_
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M.HXL!4A@C'O8@:6<3I<A"PF*5B("T)I*,Y:7AZ_SGW8S/B28HH'-XS>,W5"
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M^W]NH1@H#??FGBJZX7'MG%_0&J?S%9.3E,FJ-54CHP+<]XZNG@/*7;4ASI
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M&'G8%VU7?Q"F'KABM^$HXEB/+7)1SHP.M+H3$IW%U=-I-<MIG?G#5\8LC"E
MDA7>_37.9]$7'X-BE3\9>,=3\"!LH#'+*L/5L>V18!Q__7";+9A-QKXL!NU=
MV0J94 8^[H2W.&+LDE0#&J@\?#PG+3_&?QZCG$3 KK&;VV?Y./5AW<=H]L&2
M AEU==@"AX(AO*_3/>R+#W_J \J^F5W,Z+5B]"YSV[S70PP>K_V\!W*-RRB#
M5HT:'#4#EV+3Z&BHQBOW'PP5_MRR9057_)1D^/X3/0"6_.!)=R<V^4JQ PUC
M ^)QP58:;=*^\L%\@G'>KP\]8 99/()?A#/I<R_/=40MW\[2H#V6P/!Y02/O
M!G=1'O$T74HG<TW3!2I.\@$?N"8]M7&ZZKJ_5D\Z&54\*AW_^(UQO_6/P-Y%
M0K;"<7$6U_VW32.<*_!!GY(M-LYB^T<6DU$]-*56][-='DK3[XFKUO+BST;?
MV[6I19]Q<25<Z"2AT*P:,8930Q,#1H$54LR^"[8\]-;G&C:@^+N]OO8?%90.
M-(*]R5W]Y.IHR.H/9F$N >;VK#^+9$F2F2;9$8"[+<I(P/-FNFKF)  \! (C
M;1?L6:JQKE=:*I:7@GOM%JF+,WP'/;MDE[?B&\#;NBDJ<XUG.5P*<JPQ8;'5
MN([?H]A89/ZDNR>YTV0>99(N-+\,1J?)I?+K=-V"U16CM]T\F*JG?SCJ5$QR
MU":<J'T<#ANEMW+2"7QDC0L->F[]L^>Y4$EX&P@ZNDL/K:@*&(6)[@3,<W^N
M%7JNU+R:!"B3)%)$TR.^5+$43'+.;9MF2BVNI_)4LVAD2K9_-]GW/EET4N^U
MV<K.T@^#I49EJSE+H<>RQB;.#XJXU0(D:+YDX%,A_)9#:#^Q+3U;\F+M')W2
M@V/&!WDY@BF*BT.526WY1[@SHE^B-_?WOG4E7H_QU$-\=;'-[R)IRM*4SP&[
M3\!K;SK!A(B?>D7VO'YTL'*I2QV\I1@6.ZLMVD=6>E0'4KX55BH_MX1%%(@S
MCIIEWD1WTX?QA)JFQKTX>9)A2^UJ--/N<D,IG%-@I?4AC9\R54AZW["2756V
M$K]&4V:E)@,?!PGPKUBI&C<:2V_7L@[1M3H5 #O;Y^01M+@8C-UMGD?GE0TK
M\CZ;HT^9^O)+G\A3?FD_&+VSFF?K(C"(W1,M;T;>B[CR.TR>R'V'FV-$D:K(
MC/'H,^5'<GHV/50.:OL9B.?Y3A0SWU)<P+>U5WL3JL#WC81RV>4566R]^?OW
M)G2$&LQ?EQNH7-O:K(H',N_+]3B3/0R$,MPI*" K<;?[Q*.S^L ^&' .!UK@
MDVAQ?,MU*T(8*U\J5#5P)AHOG<^O3RE9&/O*RV!TH$4;4"AZEMS%#O7%,@\$
M@DN)+2\B G;YJ55:-2A(@THG)ZD=7Z7N98XUC\VK!RQ-$V"4]Y'=K2=^($$^
MD^Y]</M/ 0$(OS986F[6MI;.A71@'V7/$S22+DM;QMB/BN_/?3KOKA*R98U@
MA91NDK@D66K.6YS!<T[J(SN_D<<U.T?B&:P^G#[+P!>\CN3<W0>:-0&@T'8-
MF3K4^$LH$/^@I<YIH]KR5#AX?E[D73R+L4R6WN=@(OQFU<K? [Q&K/<X[R][
M3_+)\.13.($K5L:%N@+L9V+,KA0[WMY#U&#JWL ?R]VRZC&,[>?:N]*\\*!2
M8KD4?2N)=_O[UL+FF; .76<\X= ]>;ME8-R$MT:?PP<J*IL2VPY],F\Z!3CD
M[8%-G ?X&SC!O6/WOW3WE5%Q;4N#34@@@0#!W37!@KLD! \A>'""-]"X.R&X
MD^"6X-X)-.[N#HU#\" -W6@''<A][[[[WKSO6_.-K#4S:W7]V+5/U:Y=I_KL
MJK/KU/ZHTP$<<#@-37I]H4/2#><A"#2ABB1QIID>/?]\KOP1XK5[ :X$UH,:
M[1R<.%I#P]&TYU'S>5*SK]G@2PFK6,P=?C95U5-VL/6Z;]_EX*9A@*6^ '^T
ME<P,2]1U/T+?VT4+SYLU5^]7:N)G6UM1D2_6WQ85<Q,4S1N:%+57G[9LD8!^
MQ&-D"A%.**X=$$NO^M7L$CU=]=%J%VZNM,[7GYLM^SYEHL\R5*5.-/,JTH19
MT#BG%BR-;%IM"?+#O28; 94AARE%)$$:[.N3;.FHE$.YN_0R@RH?BD6-A.@M
M*>7 BFG=S:03?+KZI">ZF%[;G>:89D:/\$R9N%H7-&X#=2]TTB\XGY5[#LB1
MS5LKKA5S-X 0[( R=[!RP I\:+ON69F):(RU8Q?!5V \-TK'/=?TLVUOY@ME
M]YQ.*E)#O!T!*I)QWIK:B3T.&/N^TM!F%%M-\--4!$9!0A7V4(&@R[!KZND5
M_FI-!TSY+12RR*,S076F(-/85!W$7T]C7,9"[FM/'C60Z3ZL9.W.W-F,CPS+
MT;?R):^?.+%^E._.85H3Z?0,WO<L]J$15VR'(/V<O^#R;,\ &6=D8TF$->0V
MR@.KB9OE*A)8<#]M18V,_)&U2O.ICV]WBD!S^QXLBHCO6!)P]4P'\/>"%G]"
MZ0&N>Z R/#^PT%JX;/S==N(3L:&AP197EE$B<_%65#VF0,3$ZRGPL1S8N4FQ
MXU0'J9:](YS=0R$<P)5"2(RM39&=B$FC*N,5^18]7^4MXZ0CVCR=^$BC1L#\
MR7%^VHRD.8\,X1N21!+TT2-)(LM2]TM)ORHPB!GBI>N.QZ^X;1;1GY(FI(%2
M<Z^6= 'P*YAGR%  [O'24)P+ET(<$8C<(D Q#S=U?$3PG/9SY =AM9^ N^(L
M?T#;]*5U+M))8]QY8. +'[N.&E;"9Q/GB035X9?1KL4?!A<!%*-H)X0C[DX]
M.A+AYE-&WQO4W'(7TA0OM&63V"')"P)%ZVBJI,HRZ'35UZ.!1AQ?6A;[+A:1
M)U\>%1;7""#F<SO-@?12M,&T]2_%DL!BQ9E!X/*:G'=66$"7?+YU8^G*27I<
M/>FXC/(403L52;))=94%AGAA=-7ML\^X<=MQJJ,H=PO%G\ W0Y?( !!BF,8"
M(G+::U)5=XH*N2UA191/782^N,-2[>>?4_H_4+P,N-ZVY9&D7"1\6*NZ@?K4
MGEO&HV<\Y?2G=W[2<$R_ ;@61!VC *B4-ATH3SYI  F^6Y*KE#RZJJ-'FQ/+
MDX%Z7VTNQG+UHI57[3TEC1TBD;37^]8JQI5Z2\&EZW #V/TG)?X&E'\3-OAF
M"OSQ6N+7#8"QX.^O)6P);@">64@_=5^55>:+(&K$=63$"G8=:&4$;VG9<%N
MK#JYWJ73[</0J9YN^X5*?E1]L'Y'W =4*FG/6W\>_<L @KQ]VM7S*T+V8^ZX
MW?YQ\L%A#3^8F"T^6@"P;^_I<MSW:UH1R@D12:R= -NR<9 ^-E?TP.!2FY*G
MC$:35B8.JPJM$N1C.='MG&0?E<7J?],N-Y&5\(X*G3DZ?7K.Q/&\-JS?N6#
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MO3TZ.NEF8TL/-8:H,D*3,S@Q]20_RYHZA,.OJNKIN(9+;5TT>A!=M%@C?8I
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M%RHC8U6D%_F6'?XTE#448=&FC.:^;" ,K<P5&RZ$KHZ59S?7!:0^D7_H742
M&Z_\YO@&$$7UK!$NT9Y%N#OGLUB5<)U5,.!@)[83',2 NL'Q"!!YVCOD\6"K
MZP9 9"GQ9 />F,D/W\PK! Y9N%!&GF:^.H?E;JK> "SD.N)[^>DJ\%HX# &;
ME2"REYS.7ETU01!R,67Y5')R]4G>$OZJ"M^*^?GJUO[<=)BXSKTW'BIZZS<
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MY!UDIF=+,!E/3&\Q^5DK]!(/65GLK8#PS9VFHA^=>[B:P>%-%ZJE/K9/GS5
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M\Z*I_^)%AS=]Q4%F K/^G1MM=#ATDOOE1$*'Q_ C_3G,AD EE>?UO7 >&4M
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MF_T&[<\6I#38<H*P0-W/YI'C"AV@;W=J,L9@&2+]\EMM*)97XI]O)7EXI[F
M9%]FN'C@FNQXEOYX695:G@'[56R=?CMFT'TV?V<&-#%'5GOS6WI-RO9;6F#H
M;VW?O;-@%.OIGYQ_?Y%PKK:\G[KFE1F/?%TY#<]._,0W4RVZ57LWL7OW>)2B
M&8)<LY]Q.'T$X/A^WAM+94/YQ[SO]'!K#^:1H__KR&Q_QJH;@%[5%V%-GYK?
M]EQ7;.LZAI3.#F?E^7*7W/62^R$XW1MT06IY+8#P!8.'5I44YO055LH-2%8C
MB_'0 7'I#DO-,?EK32[O$1K?*IR^<FAZU.ZU8":WJ76U*;';7&2QQLS0OQ3S
MUBKV6TYN:4^Z)J%_>0/X6JE^ VC!]0OR>0/9.;B>&Y38VA6U.]%EN@%\<4'>
M %(.:RZ?RP3= *3,2VX OG0W  R)E0^\G.?D?(87"&*DUA2!RE55LM\(E'JG
M^M:$)'<1-P">#3^D413F=?"0UO6E]#5!%KR-C/@**Q5\A8RX9-U)U9&HKJ3^
M==YQI=G7\I/25V+3^Y;W8]RO?J.SQ3> Y="6]IB_TA.>:!#X@<PECDYB_D%1
M]B>%WQU!?N751V<1D7FO@-4RE4%NAJ^ON8P2C!PFYIIS\C,AF4[)\MI3)GJ<
MG[J*V(3K3VX W-\JJ)=Y?<+\&JUZ88H&RCS[/LR5(<;@F:2+S9COG&<C&YJ%
M.2EGU)4QOW%;ASE[BE='OS2*639].F9[OFO];JJ<,E[_NBR>(G 27]E;FRGY
MW2R\P+L!>%]K6(4+9=F?.NQI_-%6OQVLV>]9E33%2*V7X.FSJ]]-\<Z698D$
MG>QHBP6Q="]"W]]-:F/#@ZS^,A59GGVJ8;'PEM_-?T@5\G^C4&<X%E1=AK^;
MLK]E*U%7&;SX=Z*^_S\F5'!WILZ#W>CC//FU*I8A=GE?:>7OCZ^._B:/%*^&
MDUS,_ZB4_P\I]/\+4<&4A5$=: SAWX3?^GY6!37UJZAHOAR3)@B7N)G];U!+
M P04    "   @GI8]Z.CD-^*  #?E0  &    &-G='@M,C R,S$R,S%X,3!K
M,# W+FIP9]2Z=51;8;<G')QBP5U:M"U6W *4ME@I4FAQ*<7=(4#PXE:@0($6
M:/$BP5V*6X'B$#2!XI(@(4" K^^=]][O?C-W[G=GUOPS.V>OE;7.D[/V+_ML
M^3W[N5NX6P=0OE115P'@X ( .'\_@+LEP', 'B[N/ZZ_@O_W(B F(,#')R A
M(B(D)B,A(R,E(24EIZ"F)*>@HB EI:2GI**AI:.C(P,R,-+3,E+3TM'^XR$X
M>']_@T]PCX#@'BTY*3GM_[+<_010$>,\P6/"P^$$X%+AX%'AW/4!./[:28#S
M+P+XI^#@_K61D(CX'@GIWP4-E !<'#P\7'R\?UC]]V[0W_L ?"H"Z@<B2H0T
MKRV).#UH1<-2OA%S/:OIIM.=1'*+O?<,OT="S\#(Q,S#R_?PT6-Q"4DI:1G9
MYR^45535U%_JO7FK;V!H9&QE;6-K9^_@Z.7MX^L']@^(^! 9%1T3&Y>:]BD]
M(_-S5O;W@L*BXI+2LA^U=?4-C4W-+:T]O7W] X-#PR-3TS.S<_,+BS X8F/S
MS];VSNX>ZN3T[!Q]@;F\^@<N'  >SK_*?XB+ZB\N7'Q\/'RB?^#"P?7[QP(J
M?(('(H342J^)+#UH.$7#B&F?I7RKZ;[')::+I'OO.4E"SRT.YT'] ]J_(/NO
M 0O_WT+V;\#^7UPP !D>SE_GX5$!% $W>M_C'@+^;]=BO=U/@*N'WT-)_O_T
MT2/[_^ )KW[C3BK3 E[_GU9UC:<$M)]L0^GC'N;C_E<U2[M8!V_G>QS@X7^B
M_-M V!T 7>46*IE-% V2*REN0!'U,^!.J]5D<O)PA]IX_;Q/<^$I9J$ZW].%
M?'T<T2DZ"]% +B&@'^H=(*] + $\[5."'^LKF=XMS1ILO1,9PA/'.9!-[@'&
M&UN$^;"Y*6.*RE:QSW-_#34:5X@T)J71#2?)^;"DL=$>2X-.#<XF8 RJ&!GD
M:7>&(IU/&1S5L?6%MZTN:DZC+<.:*4,EB>Y]J6+[4SKH.A36"X<F><OQ?^7O
M:VR-*I.H_GIF<G]J365M(/<IRTG)_01?Z*=@D=%2B,1-JRO6;D/0W0@LIX],
MW&36[-_:^1:9P"=Y'3-PXK\T%ZHP,7L'L <"[$/(*R&!/@@G;8QRU2QYPYE,
MVH2 >VE,?IT,R 5/8788HX<>PEALN+R_ [R<;)#7/=:9GLP] 1[(S3J]*V^.
ME7HA^<6;* W6!<+RK/.OX03W,6M!-TQBVP4%5B6B#7YSS="U9\T,2?HW;S$.
M#:\,5@:]1>9R4.QU<01S0EZ[Q9M3S)%O13U@YHLZ[HNG5<L3G_[R)T:F]QWJ
M*7M9R>U*"+Z/]%GL U1_<[Q>J^03#<&*H7AIZ9--@5"5U8FX/A1?W^AEB+,V
M<$>?@Q)>.^ER9E0E#.%&>S$))TD)3"IFUH2R)V(,MDJ2&RIY+] OD/7ZF9*G
M9H,HZJ.MG1<M'DQIGFWK=@3^^&AHW1'6#[Z_MK2VCLVX6OGR.X^HGF18R."7
MCVYL;I8S*PE@<3)D_;NL5'PP)U9KTJ4P3^MW/;\BG^9,IG)[BUN#9<2P] M>
M<;TD1HITOW6WPR*X!1Z6<MIG(BZ$K@+R5G#V;&YR/]LVV;O:52^%AD-8+E1>
MC0F*=Y,ME/DSCUK1"8Q5YK(74W?S>BR(L<]*;XJTS,W?M&)OT$,+8IR<4*-H
M?$S\NJ'KK,1DJ;8?F4;3>)S2:9_[FK<(FSW>&8W232'D'D*;=N>6O7;&C:*\
MW##$ :8LF>-!W=$HML5@35)P@WCLAA<\:0&\Y<+DGBHAT9V9%^AQU/90RH.L
MC_ ^T=H/G\KVJ[\8C"GB0^A0I B#@XB*/?,'<8%0%E-,@ O-JRBC3R/43PP\
M1RA43F29!VXR?:"X$"M,"+*M)[LXOA(&>8'Q\-\<*S2A;W R^N3BOR5-,MDH
M[R^.<]9T:'.M9!(\QD'@D\<T[-J468-#D%BW*=!$WA/%E<\60G(20@0VV*!H
M0[ZWB).%]I,_!<]M=3<$RI.^:GK^O:]-BIL0MVUS:+T1Z>EEQH"EY5]WB^E4
M"!Z7K8J 6R=M&#9\%48T>$6X<XV_UKZ( 1D(K^?!-KJ#J6\^.[NXG=-.0MQ*
M=NX B_MPC=FULJ :O5&UL59L7YU5T_.G0 S='8" %JF=T'E/<X.#_15$L-1!
M*F01]DO$> SDKKG8J?S^QTK==%&@5)2BHW;4J@C*-@S>P6_AE&AB7L.<D45C
M-![OXZKB5UY+@!7+QB*F[@"V7:Q@?C0 TX)@\U.9<6G70"P-G1--!H_%W@_C
M'C^)V&+U5&(U,$(2#5YQWP&8NFQB%)9?"X >"'Z8'F4IY'"PNBVSYG)2 -_W
M!ND0S>8";QI BAO:L(@^1?+Z72%7[\/'Q(>O4 YIZCF'AUMXG.%4 (#-3_QM
MPK9K*&P4;I/9QV]!L PN?N@SVA95U[3F]K IV^9ZLO :TFCY.W2977:^MZN.
M+).=\J;R#N @#]1M:J^>:W]J$ZU1;V^J+B>3:95 0;.E:Y$_5)6,EIV#W(/N
MM&IW3\0'$ZVAN+JSV__^DW,&LI#3]L"\$%C[3TGH6$*CQT_Y';P#(-/M[!HI
M%@>QB)6I!*>[G+/HQPK!Y!QLPL>*I!.T11^IQ2JN<68.<C2X]0*CV66G( \0
MBM3D8B:S+URL6#/J&*OP;J92(Q]Z34.-L3_G07+E6#DDQZ'2N@7MH&!R(DCY
MQ^)PH8.>FG6>KDK>XW=X"O:#'MD[P7(-$Z&WO,'#S*J)YX9:=?!1#95YS5\Y
MM\/7/Y4^I40R'@4]Q#M[K+BD"L?O9$<1UG;R<]C\%E(8+7OA7,) /RY[%&U[
M4]"&$[9O-KLVX$9L#)&O1=7,45L +5ZD&9LJL0Q=/!AX:Y6HY/=>\0,N&.1A
MD3*G2 F2[*)2=):;FW?^('N3@-HYS0)W"LJQ/@M)YF*E6*CL(H"HQL/O  ?G
MUX+@\2UR#8-)$!>"_*E3?$G!R)S-[1MJBE!X+<X>SJ QX,82XX#2Z.5@:!=C
M[X++Z\L;:#HPT_OHJ\8I2UNG,!*J$/VH)FQM10HOUJDCV29BVUT0=X#HC(!R
M^U7>7/[+<_4MSH&C]3(A%X0S54+H6 +-0+#Q!>P_+7G_IH5%_W'A[ 1APJZU
M]]?H%>TGD6)PG[-L,2.58X0P764>C'D4[\;TL1I.FYMS:"#S-?$9=/S;-\>U
M6J+#700'RW[&!1X\+W'C;[5 <<_]J3PHMDI7M1[O;DMH?(BWHTB#E<1TK+.Y
M=3O A3GV5A\AE[/K52WB30VW.D_</=]_?AR9+#WB,O$-RHLQ0!T;8E ;7>P.
M$8AZ<TI,)/Q&-Y"-IC=!5U[VB(=OU.&;9:NGNU=-&'OZN5UTL SX^<"%;\8M
MS:PERN+KHSCU>M]3>-//8=$A:>UW 6AHO*+#6B0'3K"L:M6^;%@K1@-E.VXT
MM_#J^_C%ZW11+IMDZ2SK^P0^,ENA<GE+IQO /FAH'@&$#Y'(U<?W"J7<ORG)
M_,&W%&J["1T?2A"5V?$RCRXU!J\>OT2:;4= @LH<@Q^<.D,E*JF/#'F,!#;Q
M?LD392:DRF5CRM&_VN?$)Q9,X*H?VGU*AZ62O[>%!U8JH-U$+X:[<9;)ON D
M-5PP''Q%ML'GPHJ>;P"C11<;JJ E)MVE\2PEN5P@>YR?[WUS6YCVG])WN0K3
M8NI^<M0=M2$F")U.[&57$^CAIIS#K&5?1$53)AH@*!0INAR3@N3KS<-M?]':
MQ_YX&NNUR5M>XEB=+,$=E)/-]"DQ_O1FJJ3$W&E1<;W07&RR7>2:'_QC5*_3
MQ*G#6,3)BG!J M1"Y!BV(\/78'"3HD"/94=!>^X >&"HUJ2WH%\?3/\K/HU%
M\MJPD[12B]K[9U+KY #OJ[S#8^3SWJLJ:)&3N62TZFS]AY5 NT 'D%;T?<K\
M_%7/ "%/F5V37,Z;ZEL:L.W@R[9FE.Z*4IGAWS34 PLJG%=V"=FN#Q>W8@YL
MY$>L?6A:I4=)8>FD$"_W1!VRB[-";'@JJUL3;>(<GCZUTOP9_I-P=\<>4U2R
MC&6Z*0V66,:TZ87W*LV#Z$#L+/IZ9.1,C!IJ*@"!#DEH)2#([5HG>.Z6!<.$
MU)\?^.M)X_2!9EVV>Y4%4E2F0PMR2=,7S[[D>BUXF5G=3IF33G6R[ 8+S4*K
M#@6@>INQ9Z.1+2F?;)\U7H.FRH?Y7 '=8\$F6!W,ZPTW_-ON$&*B&&^3?2X7
MA%_7)\V6Q*+Z!#+-^W> C'=)@T5!'*C C:C$=0Y8WOI:WZ'NVIL\^,I@=-&D
M8L,4[+D;[2&?**7JHU"*=1DB4-A3]OGK5Q#?NBZ,/_)4'RG5MZ1-NK0/^U.@
M5![O;QN.7O-E7PI0Z6:K)61A [XR"$0 8<=PMPB041E&SP3%;X1)UFB0\J/7
M-31U X>'3[#37$2P8K/6.5YBUM!?:I <H<'$._SP-YV3]696"/G<.IQ9UWLF
M0[VV)I^Y]EGQY'^>'YLE7B2U"]P!D+JE5=NS%;RUR=T*2LV>[-++CWQU%WJ^
M9O$M_";ZVRV3=_)BK! 7'YRQFG V<W(GY3:BT98(KI1N?;WP"KEP'+H9@X$N
MI$:BE68GAJ'*V&A%20 )CKM5?Q #+S#X5&^=]+.*& VM+?U?H2&%^03__:I"
M+B["C#A @=LWA[E,7@0IJ:$KA9> ^X\N>7\\"<&C'(<RSLJ5"JF7)8]Y$Z2)
M9JS?9C_$&U6T!T;40MXA(W,SW6YR1&I;3+X5.SUA\MY?*<#E_V#QN20D,Y?_
MEP+M;;\Q,*KS_BZ[]"Q6 @XDWP]XJ4'7D1=6R=U0_T41I<61^;=YX=][_! /
M! [4H/K$[)/_S--@Z%6P88E0;(E V</J1FI>R>9(S^;=B*3'Y[0X^F:/Q_U2
M_M2'JWYT\05_RF"/3K*OGQ8XD+K)GB,-N@,$CB0:*)J2-"@#1*53:>\Q/[Z_
M\^/)XX?.@I7;J?:5B"0'!6Q,J%B0VN;L7^@_@/F[M68W96?7^BWCQS+YNI?G
M*PFS5P]QJN(Y:6W("M]%,>&_59ZLH'Q!/[! G+3S,S+X^9[T!K*\7@>?P[+I
MV@ &B>F<3.ST[>YBS]I_MK!4-&HJ0%792\;T#+ 90#-7\CWT\421D>GRH(=$
M(?6RZ@4/.#TK^$-"G,U<?,G:RRE3PR5M+C+Z#+KWJC-Q;<H VY >D0)X".*M
MS<G9'4!%2_'E5V\G_"9[^I$52ZN6 LI2W2"U 3&#A_G$E8??ZR/?AW-'\<!U
M)4@*=@@T_FL<$.=RZ5I_ D5Q!]A =Q!%280D7.7FN;FXY "CU3CK:]Z7Q#);
MI*^T8K^*C 5U(SW<,N%ND0/%$F&EI,3M* 1N\1T@6.84C>J:ISLA.O2!:^J9
M8^I MU3SP6).\SO5_3_L[P! '\/#BK/Z^^EVY'.J3 \"PV8,%A2)VS]A//*5
MR(_*2X.R9^_[-\P18EL3GC0/8NN)C@-_$UDJT^K@*--F_7T]T\3_'4']WE(?
MA::/0W#G\NZE/K11U'$T?HA;F91I5\PO^+60_L<@MQ)S_E]_NXPG6P:ZIRT;
MF4R(!@WSQ!IE[J@-E7_2(9"K9!^X>BTXEM[1%_H.5,-/*2^JK&%GY5+2_\=X
MJ=^%W:N6FUCLC$Z>%L?\6+MA!C<^Q]X5]TMIQA/,E?5KNQ+CW:%A)Q?RVIKE
M43)+'(42W(K73VF_3XIC[&@&K9S3\)K5JDO?!7DE3!^+M\F_^-;:$+YM.7(Y
M67ZHL,CZ]L=#7)9X-=?\)V-DGGU@D:%OGVX)"W)>U34WJ?$T1*G11"9NZ):?
MX;_[Q\*B@10KWY1"M.\IMQ5Q[8L*V@"RI$=Y"P%^V=;7!$V?54C]^5-%DIK/
MRF=T")SD):>UR01=OC627[1_[K';#].W_T_V&&P4LIX"_WW$0S\'*V(=YV])
ML5K3;M\G(8$()Z?FS@F7PAU9;[U=/1GR>G6^JZ$_@DGJI'%7 9W2F&OD/L*U
M_%IC)Y@3N1W5KA14;+34UVL\W?XFVZ=0K6) C;O^_N6OWH0O>.T4(MF J^?K
M$[$09<1$M+'6-\0UBSQ_OU;E35&QT2MN$QD_:DYNFE,"_MS >3>+![>]%A2@
MH/52"?ZO'@J]!7M^L*AR<=L3N:YZ#5#O",%DSG:LE4VP1RJ C^[\#X#VM?+_
MGNK[MD"-,0&3KJ[88X%JI<V?)U]N:&DL^&\G+1K&BVS*N\)O6:0604JXJAZE
M>U=?TX@/4EI>&'[!XU*0/<,#;36+2!](4E"7F7^/BVL[.UL^<\_R%6:3GN[5
M\_3T-8/NUYR/T:U;X"HZCHDA7,-\W"J-EG<[^:>8WLTZ'[H4-<?(F%;$[!2Z
M>)P"_-GZ QN^+ONA:TR5VT;3GU>=/W8/4MH,EFA@U61]IO5IIBIM\BQ0C!GS
M$F,[:R^]V/!CK^G%F0$0I8'XVM5+#%+L4N^:JSKOT!?DG9K7OM?UR\=VN7\!
M\*.T[PMZU_R-HGUYAQYB61\MV1HV7=]!9)CY%GGR NKK5FD3055%P12G.!H1
MT6Z@/A3$H@PY+0I>8B>;R48O'61:P*IAQLO/2TRT"7[5M9_$Z )76JA&>-Y%
MFB:P8^@*$-JP7G6DUC?Z/$0(^5XG8T?SK%:6HT^LR^'A$2!BW&'*-\TR09C-
MSW6#%N>HWF#DRN+0Y =X;4"!8+:=!QY"Z=3)/.?=H7DDOO00;A<>Z-#>,?$@
MZ#//RZHYN5J1[+WUFVIQ06/R9_LOD',ME0L. ;0!Z"(OUYJ']<^Y"GYV?Z$1
M]=?-T!'Y ,I]B+=F#Y7'I*$<YWLX[MF@DK++(!>^O[_RWO,,/T)L."ZI:"./
M_932ID'S#!6WL\S:$1)C!D]GO04]G=8HEA:7,>%7Q&\/O3%\\?Y9A<M2D3*Z
M/T@O2%3%<8YF#%(P;>BD:0@/8NV 'ED2=Z["2=T$<_UT:ES]$9?XH\> _QD4
M#Q5]Z+!AQH%.Z4*ZIOVPAU5D=/+63LYW%VA;M^>..WEP+5<N!H5].I93V_E\
M]!#O,(Y_+)@5?*P[@PW:2+[GY/;7_ LJ,Z//E*>6HK<[+4?74SI!H="7_R0-
M_"P# ?)_V3=?^6ZV;0EO8JD9;)B,^<-+ILJ53Z'K[(7L]GCP9%B\#H9SK5ZE
MR&X#&F,,[5E1%LC/#OS;3H#CME;-7FR3LO6WJKRQ](HBDAX+@B*[;JF:D(31
MPA_L&(+9,F:YZUHHQNT2DKAMW;(^G_.T2""AD8IVVK"\Y^T=U:F]</9J%ZZH
M%9 20EY2H^VK,H/OG*V,<\+I1UE4]O4H')U7OFM^;])%8G.Z8,ZRX46;&2<7
M6_Y'8,Z(WF00 <!;_&^P/?>UI4\+^OR@>6'5,.WH:) )/0;A*X)H8FZ0$QO%
M7XO!!?U74DE"YY8^/J48J9?UI/21[^.,Y?+J<7+="><VTP:<CD:;<P.-OL?I
MX2=%ZNN(ZJ1T#S9 @I!+: ;41*@"IV,P9]I&<?D/0R>#J&WC:9LI3J+7SU/^
M@(KB"6#N(C\/_K8GG;2W<W< &N\6;R CN+PO W84O3%9IEJ\XU02,Y BT6Q%
MSTTD%.W* CHU6SLH0"4CTM?BL"P>**)^)#A> W6;Z5.VM(M:$%#52.633I*R
M:(\,Z4@S&^P-69!30?+%'-FTHWS+H>#W<RREWD#@\B#S8$%\Z(N*)$*S:JU[
MNP9W #OAA=E;?' VV\OK05A3_$%]N8.S-[DL&C].7G15=7D_?3@E^2+I(5[Q
M[!W !?@!AM_D4.K4A Z?S+)+-:/ J+)/AVM<2@]V>I@WP+7I',RED%MY4/O,
MV)#"/:I[AU4ZE+4/=I[>9UX/<32%'NRC*,.5;ON;CV_'=&\^*FXNW+*$+#!S
M_'G*WOO?RNK_1*W \6;MDR\(YY7;YT ]STE5$IROCBRO#'KRZD,&M=D@*JB!
M;_!$R6-]C)T=?#&]SW$DL\D ;TL]#S_";0>GURNMW]_P8((\4S?=]+F#ROSD
M^5)1UL&?2Q5AL7(2:>LO18&.K6Y!KIT;9]1QETMHQYMO(#/4<WA_QVW3>M S
MIWU_X[%S$SS*NAD25B;X:G<C>X?(E_7L*S;&6MPW95S2\LI^NE"2-:),E:9S
MU3P3H&Y4.EV324GCM3S1:W,+E!C"M@L^$6-.CHR.KB]G6>H(YA_>;)T1,N9N
M4J,#DOS0H+=[O83'!VN7ZPFIIR@JPY0@@(F5+ANO7> W3Q+Y7W?8'[[/<K6+
M<JG &7_YM=EL(I)QN'+<ZH"9_\\$T>U"9J<P*F@PLL*;>&O&9K:R_IJT+;*Y
M+DYM,ZS$GSO)?N[%XY1J "[C1HHVJNO0 F$1?34&C?99(S4V 8>;R.W?M'HM
M[^D,L^I>NC\\X;35_WB#^.E\(8YS3D!W4A3=+\QAAEG59C3!V/+;6\#/JVK\
MOSMF1_2XN()VV>#WFHZ=R4^?L$:R-SRYJ3H_-.EEYT7E)L,#F2!<WRUV,XI<
MCXWEAA&M:DR;"Y0_Q$/LGS+P^8$22 !7&7&GB@R8X]?)&\+A[4S%OP2FCN;V
MC;HRU'IC*[\M<J1VK;P_Y7(]>R8W3_4WC\S?4AN!9$#F !2^L5T< 6)'B@Q]
M#>5I5&<KL#E5]+6FJGFF12&S])1#:<K:X./.'8 2I(V2.(+(A2"O!RR A\<N
MA1:'%ZTUY,X+Z]_4K1_<4$S).PW=,NPHB*#L$A0>#L/78H-%9MO%OIM(QA:-
M5IB]")XLYYL0+UU]&<',EA+2SIT/K-JI8EG/3+;&9"+;GLX?^9*KV+^2VF=V
M46Z+3="+9,5^?^$N7V,V!J ="1(-Y?CW;Z\%7C LI.XX(?@^Q/(6-JG :@&>
MZS[;*9#2V-@HJ-!BJF->VBXFEFO;AG5>0B/O ,['B[X6\2'474T;O_7>M-1-
MOZ@9\T=T'2Q 21JI1T?T"6C(CFSWU  Z1%,<M8TQMZPW>5B68G7X,)9'L+)<
MY4IBK+LY=?%#<KHH)>GF:>XEU! J<)-YP#5UBXM1&.=WXN=I:K#OG"AQ="GM
M9J)^\KB)3#V-"+1YF@+KT HE*:IT1,,(4_S+S,5XB@HU014QII&OTR)9<XF4
M#!R(R8CO4P9$/.7 #YZ\ S3^,AYH6(^WP >G8R6^Y<0+:IV^:?D$T_0G2_-_
MOZS$&<4?VC\N_?,<:H3)N7;<LR 7;FC,7&]*:@C"TR#41Q$DZ+#(?"-A&5,1
MNF?*W@QUPD0C0WKR:+VOY10I'3R6>QU\Z):5 2I&7.^&3W&^6'OO.'V^*9]1
MO9; JKR]?/K[Z"E> GE4J)QPY*U"/:8$>?$4Y9)8/Y<1T/_=K)]@ -2GSTHX
MR'1EH&<N=\T1,EP-$;\#5'-SC'3$_4\ZT!\3I3"5?O,M.LL9)@#7>3ZIN-[;
MV1G1CR/^^*P16O_CMEE[],;$ ;P0XAH^=>CV![D=6Q$UZN(Z19>JQ*0HKI78
M%Q.(]WL][CPGOM2%!G)2^.B+:TIXPJT$(A>$Z=]@.68P!P?"5],*M-FS8^9;
M;[O$H_J&UDZ.*:.%IH3UY8FTBK][<\7&%TB?\K4&%#MH4X$$9AT]/3[Y.JDD
MW0'@%CV51.MW@ ^'9VRXA&HZ67PMGXZR]_0NBE):ZVAN<=N83^X D1ST/AS4
MC44%F%[-1N0=(-9[X/6#*'<7X0(NSL#W@Q[/?T?]4>N&:JD:O39CE*T>LI'!
M?WL2J.@YU_2,=45U?.6X<H+MIE"!#0-%T"K@:Q.O#!9;[.9R1>ODZ&9P?S9^
M5OVKDN_3YCT9=\GMSD #0:(##Y>;KQ AB$N%9J5C@%:)9>F^R/=^#P^/ %3;
M<GC))O^?QS^$653XISMEL)H=&'7DDB&*/0>^M$;K2%^MAC0T@A*D,S6IW5 _
MH4T=W)V)@S=T)78*SYG\-!:..!NC@Z@CY(DQX?[G)9D'^LC'@QVTJJ=U&>D>
M2X"M,-:.DH/GM*F-WWZ 5_>V3<TD61X*57@W"WP+-Q321ZRN/_M"KZ_]1>3!
MZ3A_$8KA8+("W*0Y+=P Y5 O!T]KMJ5N3>MW3CW('J!$Q>1*U%C]"=6A\+/S
M&UNM%N^"Q??G48N/.N4!P+KC>RZ*JII.IA%OLN9QXO$;FJS7?^VS--M>/@6P
M:P9$E5T_!_,_PUC![P <C@%IBQ@GD]0Y?J?BR!R@(E44@%H4/%$)\&*./MBN
M*#1FFXM&,>A.2HPIC)L\$BZHC41\Y0TZ?8_30!EQ"^78NW;]P=QUD&;G0I81
M3(GB&8ST/M30,&,Q"X7Q+.U)_FQYSQ8C\G+ (5X-A[O3XV=5M/)-&82N<J^5
M_4M\A;&Y8W;8%*1M3-0P,?UH9=C-*^4ZBRW8AOPB#-^GK.(.X C$60/W:B&7
M#9JB+M[,L+R:.B+_E&<[8ZOLFSF4R6)F=;)H%O;3,@XP?O,=A.-Q!R"[%LJ"
MC_J[;B%ABQ:+AO#"U#_.UDEOHY,TI.-=@S2]I+J(SX'QYM28NO)=V<XO@L'<
M#KX<BY69/HWVA[_<MJCFMQ1[=\TG4%*#C5UDV'L5X-0]^C831M)!!Q:"U"V]
M/O?BD,2%2+R_/M=#IR"%0P^]#UD&<P60%U$0 [2A7?M4AA[S$A/A'T;+=-:+
M09E\<A<+M">2*$XB)\C+#'G '-7!ZEYNGK6E:RR!HX47-D#DB'*"+EH-/EG&
MQ/=*2JTR-"#UZQ# PQ:?4]9!BT2R>/[^YL2*I<SW+98?I ?I#F_Y;KYWLH#%
M^DIZK^83O,?DC-DMKFBGJ/C&<;0BFKDXC$_O %3!TZU)$2B%;759$E-P\))1
M=&\R/LF)8YJ9!O-(D\@+:2<?,KP0R@=)[@_Q[-8W/<'0#6!?,NO2@^07K=="
ML?;C)3<\E9!>[J$59M&I WR_Q/*E\HE@>LBSS+[Y54XDNMR2, 6Z(Q7%5/E.
M6GT]))OE\\P)U8!!'D(5^NS?L@[P4Z=@\%QFR#T%V36'U<>S]6[W,#2JT[=S
MENWUS9DZ\TPSH8(OJR92T%%X?-D7:Q\L*+7[+:*9&>(5:[<GI_6;&$1@IM5"
MI<&[TN>LMQ(G;@/""=GSO18P._W:.9\):O+'FXMC!1C/I1XK@PB=IXQ:-9KA
MEC(_I;EJJH[10IB6$LC+OTFGUB2$SDFV"-O49&"G.OO>YW:BZ;3Q)ZUH,O^?
MC5'\J]]$;BB.OS$P(!R3O0IU*<:JU&*\X'K4@[97*E^$SOG<$'ZIS^@5W[5<
M_.@BA ;?WPWH65@!KVE@VN#67I8*4#=\_<PKGYX@N&@![4?O\2<_T?W@W()K
M>XC7I,2-TZOI6QRG7(GI@^/M\"7CFLB-N"T)3QR L&O6<=P5$/T.=1ROP(7A
MTYD#62)W.YD=M4O5RHI&J=1YDDEC+>Y;IZ7D.0+0LO_,^B HNN0.D.:-B;T#
MO#-)OB$L"Q[B.'$.(>\Z( >>0!5OVK!** ,-S-N_K)RO)X"W!9Z3R+ON) 5+
MO P/?#MH.,T5PB2QPU%+A,WAZ'6[QGN.+<5;L/_/SA_\NA6\';\EP<QZ%2]C
M4@=L6VO<,A#C7OAIRE_JJ45/4%(^BD6^P0]048EPI7NS#8P"^(M4EWV)"_MQ
M2$W5 0[*SL>.\[#D*(B3RWK7/>5'T1JYO9KQ.IFOE7HU^;Z&,:Y\I/4:E'B9
MW'0AZ(X>CWA+6S'_MN5,/[-H<:<UJ",RLEX_PQ<5\RV<CB2EE!& \_OM#Q0P
M4I&-Y\4L1 ;%HC=5T6Y2J,7E5[]<LV+2]40[P=)H/K7@&Z*C@<WZZ8AGH375
M:IJ6T"_UXJID-LPLDGI[@R@)RU:61VFQ8VR>3'!@H*K6%F@RW'Z>0& $4.2E
M/.)XI>=V!["&1F<&<\S4VSL?>R_Q+\GQ"QBNBFOBPE[:A&VXP3_*T0L.\U7R
M';Y&,0RLD=VR:%2 17N&<YDLI;+3ST(K*U3L?T?&E[<1W?=EY$97J2+F^XY9
M0WIL$$O:%/M(3/!@=S!K?!]-/YKQB.6MGQ'+L.<=8.^CO_2(UVF>DIJ=VEK-
M<6AAM$ZJ>L.B3\YB9=6:>=K;CWOW?' _)<%Y;IDD:W2?=K/].#P^@,(?'9XU
MULVT*Q?LTS][&^3W:M:<[1G*QN6DLB\_&"D7VD<UGQ)W<J.QX=9G0;NCP(.)
M^+8WE\T1B66A:UNU7[-27WIK$\O;H2W2:5\-;91DI1F&FF$B4;L@RDZBJ(E>
MV<R8!@Z&+,[I@P,C'"-]H,2+A$'B#^X6W\]!.G@@C6L1C' ?K"K+7PI=^47?
M5V0WU<C($<C6<5[H;':_V?Q5#&-:N)*,C 1?C*)M'A$XON_$<?H.8+^TN*Q!
MUX^.=/*UFI:X5P#CRD  GART<0URW1BC^CU;&0Y='$HQ\9KU,Y!'004[%^Z.
M#\[]71$I#]JJ35>6/L]OR1&_8W7'(.JQ.->OA!,A;O )"E.PXMO)+CCG=)7$
M5V&=7+755<0PJ",Y75$@B1N_+]B:+> W87025J+,"!N("4$LR3UJ8.&R"\PW
M*R2] [#'2PYGP),OE)KN)1L1V.Z&U,ZE.,"UHQ4XVF>K)-@4>\C]6W@B#:Z5
MA#@SI-2?!.O@#Z9OAYFI)BL\V)/UZPLA O,_3[HG06XX&A3"?<EA-_T-H,YM
M5R"3 M<LJ:NY9?X#>7#]'HPWD!UG9,3;AG\AF2F5[;<D'ON-^<?3OE>"]S@Z
M;6!:LYMAV8"==K:_[:(LQJN"W*ZGDZEATN=3)#SN1(;G8[YEQ$G=1\>2*,@#
MKVL%"/7,H6#5,<BH_.E\YJU[_<V?V94^*"^^R+9C%O< D=*8"3+Z\![\F,D1
MT4,NW!=@><+=[/350CEW:H6*P8L^Y>?KP4KW-?*_SCBFA!C,*O J6\+AED4[
M[H->\.M/;I(;^J%E"O;/3R(_EIU,^+RSQYN\Q073;\/G>]R ._-[5K/XVGXA
M[.L]<F4KQ5FT2205J4\8#P@"R+T4R=O]+5%2/V%2L?7'J6NOFXQ>\?2*4WNG
M\G(E#L%3.F;F-9\2B.:]RB?Z=^>P<#2, G?.<@:GN>)<E"V]W%@/]"73B.S?
MRY)M2%SFH)+1@9A!5.:@ ?-%\BT=5GBV_5F&1HLB7+ CLJ#I6; EM=J3]ER/
MN!M%*#&F">F'(.Q Y(P9_,WG,5AA.'_.]6LGC_*U'953O4A//W\Q!CQ7D9BA
M 4][O/R;]+,L;\7%.T"W+XV]Y"I3*JEH],NZKR51P%4IXH.^:GE/==!\^3P'
M,@V^K$BBP&:?2Q=^N_&&V9O'_&J?W?I$C,%/>MTF*XE(*_W$K\^-.7C>G 03
MB8@1WUAW"L&MA.>\FH>H&%E1J75;A64KO"G;,P3@_"G%.V+FW\Y;I #&U2YA
MIM]BRKU*S!V9T[%BAMK?5OROG)9B0N\ JIOKUJQ7V5?,H20G%K#16\TFA.)-
MF%#(&9YA'E.G(A@*EXJ%ZZVK"6'OV]8UNOAN&R6M_,GPEW2.POW08GYOTP[T
MU@TVC;"+V,"0H[A4T_JS60.J)X_>7^/MZ<1>'$B;Y339+3'EDT\L7-]J1L!+
M;L+NW[X]>+O157.!S2'JU;[&5<*6+_SK!"SJQ.A^0[;:=[&1&*/W1 1#K&37
MOXED4#1][%S(U7 WD!C\,U8/4GEJ-%I:]/'>2E-M]<8T71^$&#.*F$B0U/CA
M: &<[H&QQM^/.MCW,)<;2M(I2Z2T^N@_]@9Y/+!&A8'V9:YRM"#)YSZ[I$0>
M]JZI(!;HY-0!7GF..6C5.T#J@Z*0^;&UV^0  -KX7^D/\I@=2X/T+4 1*:=N
MJ M=54QW+)YNLEN2$.^ L?S+3OV= A ;I'!XL "81F6^W:#(P;CRUU2%OI\4
M22WU".YF"$4@_8 ]WGQ]I>B2\K1+A2#72:7+;U5FZZ\_9,FRFS15C6C_4BD5
M)3;BDO]AAX<PN"[?H9.SP<1%=V!-ITF?@K,Y03:*C0(8\)>UT$/^LO1>**7Y
M'@=%/;FPV6\)2>H)>&.+F4QEE?9:<]+["F((^9"*5S@%_PX)*H\Q>"&$&(*'
M^*K:&W"1P#5]WB$?;F;4D#A:;WTBJB]*+!\C+5$DHR7:+L7ID5#@<,!!$4R^
MO&=@T,F-B2_>-<A>00CHMSJ^J!LL,O$YH=<5>R"88?L3_PQ@4&ULK&3I1-=0
MKXY/]?!%DDCD6S8 >_IV"*FB_7%T"'.#_',MI$7,M$G[](:1T'<-(\3)V\XC
MQ$X!WW1EP-M77[[D9&S$J?.P)7"P8SRU&<$<?;)D>I45V<5?/=[7U1Y197%9
MDZE"7,?Y1X^#29RN\%<)YB RI88K3JNLOUEZ:Y5+N4@=$#[)HHDECT=0_%:@
M*OA,A'G!AB++3AZPGJDA,?A&_)HXAF"DKHYF\C4MO2]:1]-F/X\!RP2?(%G$
MI+U&T:5WQ@<V'<R;C-ZKNYDUK1G4"SL)51\@5U>-PVBCG5 E/6L4-\D]YES3
MF:]G(+*MDB5^\G4NU\9U_@8Q'_(RQ/UI1H_3N5%F1PU(W%7M: L@Y$'!:E%B
M\H=S,\F;5Z@LR,ZA"8\LTH0O[8O!6RC6!FD093EI.P-2M6)E[GU8D\UW:I6N
MK2[%^VSP#J#)0B(JZE1K8/!TI/M30CB0,!3$8GJ3#95(IM\SKIFW3"*=8#$$
M5_3<=^GA#Q1Q_>U*?I'#$H&& C%>)9BH.P""H5<X^LKVFT/Y;BX)2A!=$N+J
M+1?/WR&[0!H9H\V?QO3>EG$I[?YE\U;G7D$< +4&ZU)KG0FF6#$S&;#1Y+P=
M-&I1QF]I:FA)\O=]R&2WD!AYY,X_VGD?C&>.2DJY?K&VV\G6VJY-ZV!L.<G8
MTW8L8O_\L=V7LON4'A$6.IB\/EF[#^UR94[&8R-&N[)!;<LKRVKW#!'* K\\
M%@".N>D;@IS[ZI.NA<W1+\T,']8T=*1PINJ.MKPV -68^R9\T2$B*H?PHFP;
M*HSV?"VH?4* 1@*2ZSN-5RZ?:H3Z=$8[U;)NG5E/!\!0BK]>T69R['S87)O3
MZ]>:V>?O,S,C?AR#KKW)G9O0I,;EM!O7J; LD%RW'%[+=3IH125:H4N1 [$H
M;HS6_LNY#-I9SDD[%$Z3\O2[]E01SA<GF?C41?Y+"=5,6Z%<& L.]-HA*4J[
M3]+&9FHCJE?90?9):ZC:":\\[AB'POEA^CA&M<^<8[[*9^%,,JRX>H9Y^C5E
M?W7\Q[A?+&'-A];;NV9T_S:["@X.G@^A.AL%)AHG92*$X_+HVB4(&NIY)S21
M]''*[4IAJU/:]9<)6K)6KOP':^''-E[(MEX&28;LW"(WP0^O,F$S@<(EINZG
M"7CM%]#D.X#3&G/P[[D0NH9R"]R]5:Z_F2!:?$R!?RBD!B+'AI5Z<KH]-%4S
M\;G$WO#G\%B0$Q+/<%[B.+R38@:B<B&Z/R_KK+LJ?Z#P:NP!:^8K\L(KJS@
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M['G9]QKQ9(;=JX9>8S?)UG"RCJ\_%^]? ,[9-R),O/\_YQM'L4I3D+<5]F7
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M[]^Q!1<*\D, >!3;<;62X*F(9J$$CW):DZ^4PS3.%UF^\8;R7N96M)WZHY?
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M[6V_X=#O./J]#V6TMCV++7")-HA:>1^JQM5Y1LN*GIMF!;K&08#\.NJP$2.
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M*#PO<"4S..9B1XQ@DGZM%MODM:D'(><Q 9-_$=?O<*C$']G9-R< TMF&O_Q
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MG=88QAK#J^ZJ7C.H^SQ?NJW"HWNJU =)M2>  J\A-*$\-HEL T?6'7,61YX
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MB(W+T/6QUUX_Y$\T=$NB,\,XPR<WK=IJ&L=/>)YYG883ZOF^;-[_X.$YGC8
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M<819=3//08_*+NC>HI)^1HV'%8DIX'K4?V 1;SQQ$IDP<P>\_/R8X1+B7NK
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MDUC-MI[AV>V))X;9W/[)CL2_FMAHT_\&4$L#!!0    (  "">EAJ/-;#;%
M ');   8    8V=T>"TR,#(S,3(S,7@Q,&LP,#DN:G!GO+H'5%/MMBX<1 6E
M(TT$0A6DBC2I49 F(M([48HT 9%>HR"]@X#42)<:>NA(!Z5([RU(KZ$&",F-
M7W5_Y^QS]KUC_/\B&6.M9+WO;,]\YIQA82>P"P#RQPK*"@"\2P  'NX/@)T&
MR 'P+UWZ^<(=EW&O*X17KER^?.4Z <%50N+KQ,1$UXF(2$@IR4E(*4B)B,AI
MR"EN4%%34Q.3T=+14-%14E%3_=P$#Q^WYO*5:U>N7*,B(2*A^K\^L%\ %(2
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M4& Q\&&A@8JUK7!A'$F/\:!$>M>;;2S@G4Y48,,MCG$_=(8E5=U.<WZ$1-<
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MRY&MCL:OG44<T4IFT=3B@'=?$7E(4&NU8<V6L\OPDB&)S!R.5I[5C!#JW"M
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MCR0?#.)G&5ZD3[[0#!Z]44T+C'^27.T77^2BI2YO_I+: ?.\"],$.7Z<KTN
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MZO+,U[]_;UY"8@$SF"KHSP;/%X1K\%+=Z&<Z1X[6GH_8FXKV]I:3ZX$,"K&
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MSF7AE"1?P3  WL:]?/0=S?,']N+K'%$<U[1%#-4TC,K6+'B6,DPX1KD852]
MG=2/)UCD0:[DMF7G]>-JT*6*!AT-ERP_A5=?;F0<4XHOR7;O!"G'^K51PM6'
M(/ \2X2Y?C $:>-!0K&P*FGVW1>I=A['!8+DQ>[MIVA_=>S2ZNH7F0M,83K@
M],)_$&2@T)%"3QG_>(Q""<5DFSOOD ND1BS*S=0<']RW?&'''J9;K#;.>[6-
M5%_+#Z,!%C.FO!6;.^RRJ"M3545RR[VX[E,ZS@_(C5D)W 8?W80W]N?:F;Y9
M^@R_P1RA5HK44N_5\S2LW5<5I@$:;T"NMS:,XF\B>OUN[H]R'&:QMI9+]?&
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MFORIMZ,?,JR-  Q%TX_D*!GF*_<^X$9+9%TW"7U* P"C#^8V"W=Z>U#_5;L
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M]+L =R$VO6MF5KJOW?F.'?D+M)MVWW?%/3>D,PGZ7[5A']@D]S(%W()(T&&
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M/@QB!%!LD9+K7"^^(G=/AC\&2W_R?G/5L6T^AEHG#HSVC+J*_S':[2!LV$!
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M/%N\5%X-S+"8<#!9UL\-@@T*?"/\\[C*PZE3R&9;+T*2G&+PDYNU%/(FM5%
M6V#9TLVG%$Y%KKCVR>-S?-Q[TRW/_4?UR4ULRXV(\%@T/O+OL*>__-$F.>!M
MC(RYA))U7&98J08(C+7JB*PX//)AX$ZR]6SC^-5WZJ^\_&MX@[@-& V';\.3
M0DTLD2UQQ>#G>S=A:XOB*ZY[B_K\A71_[I^ X)-\N$M<-%C'C!4G]ELRLPH\
MG\'.ABVHLKAX!0-7N#I4O2-5O;GMHRRIL!:'2MJC$2U;#=7O_N9Q([4RF@#<
M';GZXDO[U_;N&9ZEFF97*]RR@4'15# 6;V!^9,98/Y.%[-;2Q ;)32*&VPQ
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MZLW!"&E9LNAJT9;Q_Q-\(7M_RKT;>34D0@*T#E "U1I+33=Z@VG$SZ7D+6+
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M+-J0,\;/\_$Y%^GI4@KO@\5818H8\\"Q'*JW3?,%C:C,,7&_X,8%(?6^LAM
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MPW\1:'8R,1 487T#Z,5H]C<S+V/MN"5KF=IC66A9GVI/X.D332:2$]_))!J
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MLQ[&E&?AOA]3\EUY#%ZN2;QQ_977;:S(-(.3"$(HT1QD,\](JA?M,T@EW?N
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MH.IWDNR]_(O,BX3]:09<*-+<9W@^L*4]!-SOO$/D=4F_[W>=@BI[K?L2'*)
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MJ28T;IKS;U6%+C\F$0LLQWKK^BT-^#%.Y;70"P8HP'L8LE^#$SPV!>MH$E2
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M.ZNK7A24+9&]H_EW&/%_A3RIA-H(:;N?+:F]YIY/;032_K)<!E\H1PN"7M?
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MG?F'\*X'+.;!G\^2)RU>6?F6>G];Z],N=WTT)8;WWM]6#3<7:J9<5V&'.@5
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M_C%#.AN.X[8-+A0=]".IP]DEQM&5 B1ZJG+^!)PW>"1&U>07K]['&D[+1W<
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M:19=!+5/&LY,FQ=4$3A<T>Z15H%M9-\!R/<E1:WV&"/:TC/28;B>RZH<:5^
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MD2)-*H)>Q7CXEVD[!;-&0^33Z_8E87X! W$2;;3SDN_D_J"/,9Q_L-+BW49
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M]UFX[P"?W6ZG I\_^6>>9Y>U9YMF!&8O_/SEQQ9@N_';HE.C%:RFEU0%/24
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M+6 W41V,IH[RW!,_PG5A$Q=+ZI5%T^LMQH6-D?>;K*7' )<\+\3DV^<'#X@
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MCS#?@T0A?,@[0!Q7@R9QZ^^MR-,I2<$O%KT"W1Z,HMUV)@5?"(X!<@=Y,W<
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MZ"Q#[)@[2(NMHCB:'(9O4VH;??P?;U)UZ^I2P"9]$&>2C(<#'6S1'+PC?7F
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M)E^BZ\*\V=,CUY(GEY:DJ6TMOGQ]0$[O<C&T)A"]%-@G+PWZIAF&?B*GV'6
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MK5R,+NLP&@FS+W!@?C &J7$4%W N,=E*5(/@<;$7.17KPLQ--2CQ>AV M]N
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MG*[WRK1!CTY.RWPY16OJ]:L/P^0:D$RK2(Y.)YNYW>8@.=V])3)/EE,X["8
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M6??TPRG!R\VF6:O)7OU$Q\@B$E&2IO@K7MPEU[LXR! A3M&.,,Z ?7%;?"J
M:OL ._,5,;]!,&LTF@I>$8.FX?Z6<6'G.NE$/UX!H]AB24<80)\KNI5"FV,J
ML0_>CC@Q_R#8V7'VF6.^LC,',TTZJHKS( YE_?>?_LVTX!?[B $A<WJ^:+1
MQ)J2:K6GA$+CU3T;/Z.6JOF-5B$0R=43S9%;0!O(%DQI(NH$N4%GB5YID_3V
M-49UO^*%WMW+^L+KYT&+Y9*W@"+VJ^S/&!/_GVCK@V=PWRU@(6FP>/YNS-B
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MNZCG/^QN/7=B;@&V#KB>..L#68@KC<89!OT.'^N-E)5E?8"E74D*%XFA5>1
MA:VK1K*<14V([6DU4J.,DPU^(A;;YC.X6L_^R8\6K#'9=K_48#^NW)9M28:[
MO05"L"/R9JD_\-<<8*X:FRCS@=,<60\J=<TCL.W#!HT$&4B<KJ%S#DXH2[-
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M7[*XY7?)/.4CT(28.!RZA^[QX-YYJ<3D;&VY(2S_)$R;-1<T<>_ =CX0G9.
M )U+!(6T<X/@8+[MY>>1RV<"_0T_T<_WWI=>VR.YAB+@:;(_*#/=L&W?OZZ+
MWI^M/8YOG6G51.L;M])^L1[,53^=^FYD/OPV>=,]8>;[4VK)&XXL*+5G8D['
M4;C7: C=%?);8"(HW'#:8QU["TL[ :GG3?W6Y.;<6TBG97U;9\X=X#OHO?U=
MSV&4='LI[:7L7H:3EQ=!0U,Z0XJ.I4)";-CCS5&L2=EOI^.QR%T\X)(T)Z[$
M:6DT5CSM(?I\;Z]N.YRC,L<YG&A36&=I5A3TR,*6H/XC/ R),9)(7 8IR\E:
M[I.:0_TX+9;5,R\W3DV:+/5THQ.*_+WW3NB.^,[;J0$&@E.^'5K61!U"02#U
M#W7];]-(I+N2)U/PM/;*&RZJ*9FX!7<5^-[^40"O-L6Z:/6;6#D8B2ZOYZ<R
MJFXID6O"W&$Y#: XA"A,<Z)5NO1R!$G32F[ODU*[G7GTIMI"K9HUU,_YW;5N
M=XZCFP@89JSOG*FL9_D8N'(+]:?K"$[5-!D,"?X5D:I<.8O\I!9XH,HZZC*A
MI3+RZS;WGUN*,Q=A.Y!#]Q\^,@0CT-^7FE]"MM$+>. >[U6'?:Z0_GJ)"YAE
MR*^[OJ.C!/\P)8$5:6PP31\Z*7:)#HO"/D 6V4 ]EC:FJ<0[=M._;2B%LWYP
M,GU=\&+IO@J'N^07*X[4Y3%5#M(^2%@PQT5N,(<K%S561G3:E#*URXN)J*&1
M-FMLB/7R(/L'&1\7>27S<<I%8NN-,STSJ*NUI=%4JQ+:DZJ??[Q5\_/]:FM5
MU;,H[RJ'14;,[?;<^6\4)">9MP@'#I/F)G3C4!+1,%(T-RTNJ;<*%SELR6E@
M-K/_9F9"Z^<CURK#$@;)>4;HEC]'*LK?%J.W3^1V287QCVK5Q5+T-4\AW[Q/
MX+AHF+ZS^_0W:[<>]]R<SB!EK>.E(:$P$+[S[19A3^O+,Y&?X"N%#F/&1FYV
M(_@FSHU0>D9.CNZ.LO#9@N@/L#$^;\NO II98[$U62U^:8Y4EGB ,QC N1V'
M8HX_%F_7+/_*.-4_5RQ*K?A%5RX_[SYYGY4_8LZ,L)=,6$NEG7>\)!=$C='>
MV2R B>+"5T%Q\VF7M:LCT:\J/W"V#4UT>+)*JG$1F:1C2X7K7O.2!DKR:[&J
M/3\'83(>X5 KR'#)@=S+*1LZ3%X7YX_)8!!6K/#3_)I4#)\ ^6J*D-/ON4CE
M*M::64,HX^F$)@"+<SR[[<I=G_$ZF SZ>U6K&&U >:Z.J2^UK?Q0*%98[O7C
M@_W;09F'EOV=VC2J%BH=C[\0T.PQ[N"!NJ2==93G?!*J#"?8T\B6593I@4;H
M)=Q$V64KV/<3,9FJDSTCDJK:Y"6ZIO(@%OB3>O\B5)FB$&:$\>^^TVJ^^K75
M%-6B6<-\HKB?)?"9K4Q \%E\35ABOPD]W0J&8*!B2/I8#K.7BM5#>W:3*=NB
MN^!7YN#!Q_N3C8,.=@TQQT1ROXYMV&02C"@R_KQL4N*<VC\T)!U4U#ZG[VI_
MQ;RS6@FCJ\.:QDUT-$\791:NUO>D6M=^B7GS5,,M-&(E)I'9[Q%[J"@5/#JD
MBCDL6.!<%.>UHN+48R/.9AL:^4-@;RF0[^L+P*R[>*>0_:EP2:>X>MA"#-^%
M@B8 31O9*<YSY:Z+C,-6GO1DWVK%/D@M2A!8&MBHTR-T7V^ND7'QJ/17KKD7
M'()8M%-5VZTS4B5F^"]0@'9\, $\.EBT#RNHC<V)AHF@H8?O?=PS QK3>]%+
M0D4?'D(%8D["?G]*<WC!\-R!+W7K"G."V3G_.((9%]YCR]*JZ5L&W>P3RA_@
M:#2R#!N=4Z^0F*T[NXMZ7/6TM&?MV<L/U%N_06&&4/GC8MP4*F<>I#OZ;*+2
M)X<*D:%D]:U\^7FZ_@"Y$1X0XWGS]5DO:!YM^)(^XG0\%L#@@23N&NT(/. <
M$LU%@'6*D5VFF;>""JS9N)BP.32,+;"VSJX[I<) O!ZWNPM( :*5:V:97&P7
M\<J\*&12MC2N05D-?24*--#FX=4'4Z(>Q0V6\O49@UP/R7;'[UZ_$2U"+G\>
M+MJ=$G09"^"&03A^TTX'G&4)E&2U.UL9,;HG2W:DYYAC:7!(D49\_VUW5;2>
ME/0-%]Z7D4KWLMVZ0MPA1%THVP7"8],Q6XMIOHE#/"! ?JX6]$I_'@\448[P
MK1&;#(BU/[9A-#8DYBZ>-"2-@@E=I/F,1-FR*.MB#4RQ)E]7DSBW_<J*P<7E
M8G5ZGLX?Y30Y3+!:L5X<@>\!ELH7Y,\G<?)GK#BE%=ND5N,K27$+YDL<Z<YX
MN+2$\P@L>?!A X&YGM=90U,F&EMZ('7>_O9[Z>#^.T/2;U17?LHZYCHNQ CC
MPW82+89@W0+SVC+\P('E0S7X9^>5/T/2-L6J[VI*[O\X"*L1&@XB7/7<B5L9
M263+Z&I[L'=BBNDM6V&O:QF54(:(TGY\6D$O_'XCUFQ.0XT6*,80C+X-0ES)
M6)?-Q9M64.6YXRA"  ]TZJ[J*W5G/LMARKHQX0NOK3C@>6+A]/BWQIWG\N^P
MX?&AY$]A2>C]G<]74=2<]+$V;L(3LW'2)]\P_Z,U0]+%Y$1]76;SF?X^W<W>
M!3E-MM84F<3JOHX-?3S@.Z;*_5[>1N2B ,$)?:D3UP&I6PX%B]C.#K@XVJVT
M,7WKW=HV5.T/$^VC376V1=[P[8Q\YMMA=ZP_LA..BD/.OUI>K4/<Q+)#FY<(
MW:@R/CJ+TM%3J-O/'8?<3JCL$U"?4_$*59F^ A3>$8(QP ,D4!#*O]L3^(60
MQ*;^S%;V$OC"WWTLH?S<8)]2[%B5^;MM6B-).ZMUQ9 QEOF<OKB=Z]9%UKD$
MQN:L!WP;3(W9*Q8H<QA;-!>;R;STFC\(RB F:'K_NHX[)T75$/PE+Q0<C,LX
M8\$YH8MCP:S0)!.L4VS%$3QJ '1L_>-3@^ZF+CTO>;%6O:.3@"P?C^9V!&,^
M"C(GT@6FNRA4UL,B(#30.$.L'_+YM+_)3,I"4,2-!;J;?%[MB7)\M,(I:V^_
M/KWBZLZKT&83CGL*IX#O*DGT.6"=XFYBXRL1CC4&ST1M:.DZ>20O/GH9B#T.
MNEAT\@N ?W;.O19[Z]\0]:N^RWO4]7C@20OH@MW?FNKE-.3 T!=^1CP;\G.A
M^:<S839V\SSN(1Z8Z6F\?*=]U>$?LS/_;L[_%^B_<?WOX!(91@C]M%&>.;)F
MDJ#"(28ZN%@B%3:GZV4:$E<-G[902G8*:$70<[GXO] A4$_4 T":>0AI3.,N
M:#6)[1<>H#X'.:+5F*K1R_1N%M9)28_TWL3M\MZ/^;340_Y=P/Q2M9*AYV26
MA\4BU1BWC67N:K3(Z%S>W9B"F2# X^?<H/BEWB6%_+K6B>'<&8'%6Q&%B7?6
MXV&?=>?]/M&H@OOS6B7:;>GW85?ZBQLJB":-2[6(ZE*T1D9/=,]'U,EIROR9
M?S+H;;_ ]3.3]$\: \-"SGNZP/VH$'88 =9;K_^<<963N<? @;'25+=-+YSL
M^:Y8W2<GTH-<ZOG_7R]#ZTFI>31 F1)HFF49/+9\?5_92"**!Q>'BO&=?2WQ
MI+E<P+B="-LR&@L<NM[*"[W^GY%((BX)Z]\90EXA)JYL4,I.Z[?.$\ONXO$L
ME5#TKI<(>%2QX;84B;>J"CBC=&X[T[WA<_$/S4#[ERSI[-$<BCIO'*22.T@*
M[XD_$-J*>Y$2^]%")4>?XK$IYZI$?# I+K!$-BD&]JCPIW^<LR])Y.FZO=US
MEB_OP\<(B)A^2IH>0J)M.+#R,?5)(!>+-L3GLI_'QQFFT\=K56$BR3<:G[:[
M*W4_4"7Z!.@0O,OD^5F25Z-LB1X2;,]FG6Q5@]L49>7_JE(9FIH,369PE7K
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M#9-<2YI=0=DOEAZ'-Y G:AX14VM=3_V]O'N&)6VW 7#NQ<@XF#5:@G";+=7
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M8)4KM< %D\+%?,8Q=[^:&LJ(E2U\72Z:-^XI;F(G,T1IGG[+0O9[=!=E%\M
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M]J/<&*'-PYZU X5XRT&Q\A="@\TE?2$\U/W#'MM@<9C>:8&B,(X$W,>6)U;
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MH8(151K3/M^STUWAY>>!(!<IFSC8 )Z8'SPQF*TI C[87BYX>NZ#U<O%M]'
M\)EY^%E<R'4I/,6#L?E$AE-QXHM:^!$*WHD0S*4A 7C-@[;C"S,D8"F,!%Q2
M08'&2, &AST)"+Y*$+[WEQIR_M3PIX8_-?RIX8_54.([]7FF9ZV#QETS$Q-[
M+[[O">*?L[D_Y?])H23-_ ]02P,$%     @  ()Z6#M.1EPCG@  U:8  !@
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M]2HUY8A5L3KO9DFQ\:"3DW7$2BI%N706GE!MYH*5U!5Q;YCLM*:P4A=_1QL
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MZZ3=M84^5D8PS2MV1V% I9DRI@BY3 ?=LD EIWJ+2?E1R>9W&$=8!PYF%FN
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M62!TZB'@W(:J*>NXX<2P7W\;.<NBV:<" +6+0+$82SK3Y^3?Q<8=+GXCFEY
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M/\@Q'L[65V+!06*?R+](<_7]Z@(V;^&KL+ZH7K94*36IMLO;N,C/A=F4O;B
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M@LAA,CB3R47(ZDJX#K^*+ZS.=VJV[V4'125+FK_')Z6_EU!@+8CWXK?5IA)
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MD N S>^\03-/XMZL9)N_$-,'>($-OPFYW"_?;& !RX?\^/I]F9 +@",BY@)
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ME>Y6;BO;[[%96ICIEJA![=:MYA9P/S,';#5:8LDGZZX8Q/_MJ#*M5,"N=P>
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M$<IE;,DA8>.P^<Q_QMULB9O ]!FCR[9G/ W=^=,J/BXAU;/X*T0V5W7J<P)
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M_K)<5#E^]\-*>]B.)R/FKMSOZ^0-]U,:.Z!7Y^&<%X P"-,7>:+8=H+=$7V
M7/*/U]H0!<3GR4R?-ZTWHP%HI 5>IK--EAA02!0T'5_YCE_+.H+6FA>LC(G[
M4K"TPRHY</]LRUHE<02C' Y'(# QBVY=.E^RJ)=%\PK!/L][5H9+7SR\CH)U
M*@O9^IM8JP/>F<]T+=/ 0OM.*./$RE?3NN4Y)%2MWXG:O8CC9WEK<XNV-K[\
M!F<)-]$$4X:(,N%2U+FGC+G[O=I26J?6XYX:P+7SL5T#>2;&8\_2BX&L'V:!
MT0R'LV+WZ&%?M+[YN]IWO].4+E!X.<C].=&[Y/I/(]GM;$,P(SZFZP( ],R
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M<]#0,='1,0EQL' (_Z_IL1N _^)9XK-$5!1:P#-\%%1\E,=^ ,V3G.@H_R+
M?Q#*LR<9GV.\P'R)]32A\17@&0HJZC,TU'^D?AKU?QH'H.&C$[SEEG[^6L,<
M@]:%D.=K8L$+NO=U/42:4W!Z7@O78,R7Q"2D9.0,C$S,+*Q\_ *"0L(B,A]D
MY>05%)6TM'5T]?0-#"VMK&UL[>P=W+ZX>WAZ>?N$A'X+"X^(C$I*3DE-2_^>
MD5E85 PN*2TK_U'? &EL:FYI;>OMZQ\8'/HY/#(],SLWO_![$;:QN;6]L[OW
M9_\ <79^<7GU%WE]\P\N%  JRG^A_RTN_"=<S]#04-$P_L&%\LSSGPGX:.AO
MN9\32&M@F+N\IN7Y^H+P?6)!70\F':\FG,C"=>HE,3W?!@/B'VC_0O9_!BSX
MWT+V7X']-UPP #8JRI/R4/$!DH![K<(H9L#_/WXO=> BA24K*_Y+MXS<7I.!
M"24G..;&34W> -] P=H\0?HG;1"5K( B,;VMQXLH'H,X '7)]W3UX0:KLJ4>
MMC ,9RJ70RF"*5E"@,;_<_9>&Y2,>R!"O@;EKR";C):4J6S557BP?K*OVEFV
M!+;4MR%('9V-4'<D4E#^I.@^!V^Q<? .P+C"J2E:G2[U'3EI[=YP$6KT-?@J
M;86B_8SBG:TE2D5P;>Z%!Q"4AIGU:TTXYKZ=/^Z0_#2YU-%>PRGHK;0D/X([
M<TZ-#O!(T6-!T&VJ)L,;^B*K@-QF8S8+S@;?9BJW6]/]ZE],'DFI\GB+?W,W
M^OJ@#8#H8<)#MB3#N@21 8\ ?7A_LZ;A;P?>?3TV;X>K,WDWW#7NE[43Z$$3
MJEVI*Y,HLH3J_R,3;7D&0O9". *8C/[@;$[@5:? M/^Z+O/_7DW'%%.HV_,
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MNDC1**42X5N]:!YFNFW\ FIKQ,)5QBQ$+2S@'=*=)N+D+:()C$#5GK\<?4J
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M%+9NGMZ1*\K?"9P.06_8<CF?@D=QWI8I;3=JSQB3SX$HWGP@DCYP:"("2O)
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MS2VPPB-%\O/7/5NTNG;TF(XMLP8697E43ZXK$M)I[O"\96?@Z(??%:M)/?W
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M]OTEV4#K#+MU\,8Z!-Z2\YL[Z,HABS<H.TV\=J&RO&;)$[]@GZ44M7)4ONE
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M4@2\7W=ZB,;R]&H:O$<U./':88;2,V2&,3G,CP/@_#T:8(Z219-40F/UPA1
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M9//IL:KH \ W31WQIEU\*[0^ZN8?Y=L[H^Q--+;QAT(EB7UY!Q$]/>7ER./
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M1[?(+SO_[@W6HSE_ WT =/XW:,EUYID'P"[;__8SE[YQUD&CP7NR1W_@\'\
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M\@SXFR#J-5$OGJ(D2=V*[Z.]$A_=QYBYAPM)']B\1A!!38P0 Q.Y'PQ>&!O
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M^/L?R?11(5\,.MS1][[7)P>02$/#,3\02=N[HERY9T'R*Y:=3]K5UJ^[HBI
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M&?E#GBG7U]4O<WP!]#TI;[O6;?6+R.6*=Q@34+5@T0$'D(6@O#9UP**,K'C
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M;.C1=EX_WUY_-,4],-U]VBO"9F>]F&DT?5LNZS^ZU]&<#2WP\B*HHW*[YDA
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M9Y%8$;A(+:MJWXE>_+[>ZOMX)6\GHWS40X)S,UJT02F%@Q_$_/FZ-!@K/D(
MV\G#/"3]%*=]G.\PB.;S]BZN8KI(3.#%-8 *NVAOMMR_QP&RDOWYF9BQJ-0K
M;-XB)[S7YWD'#,?J9"V:$!KY1FI\=Y*,A=F'-H,5[#\YK#A\><G.C4C'0[MX
M7NJ[NCB.#KA5JUC8V6RX;JHR]"TQ?'WKTU _OECQS,[!^.N#!_C; A+TF;,,
M"%A$N(9<]02]-1/QB'1YY<N8[ <IVX%6 'HECHGV7__4<:3#->DUKK@2@D0#
ME5/M^*\XDDF[#L2BX[X1/")"KUY0(63DQ+[V2#KG<+;+58\'&*"&"D-SE#5<
M')0^0R\F<ZZ73J4S$]4=;,7L_ZP0"_;[W#V1OP<$>\F7Z3C2F,04HH'W@*XL
MND+4TU%=MN_@OC#QR'#'<[3P9$.=:V/;WSW)$X4M(Z!7QW.%ID.[<VE,C=0I
M_<7BTNL/HWU!%2307SBVSG1(&;.B]_++-Q(HT\?57T'.< ;!G?D"8E&0N0HI
M?FE-ZK]KP@^@=1YE38-0@B523#"FK+LU -.A>Z'8&,^%$U_U&YQ8=5ZYPPX,
MI-3W]YI$I"+^OOLHX$1AOK+>(?MIYPALJBWW,TG];2K%SIIIR42BL[].?VS
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MEVMK0G:3.*QR!0/D%^I0<K1 '&%E*$W@+Q:\:,^*_I5P# =_@I"B3(_=&T+
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MS=WFB2>*;&@%'-.J5^X5];%RUD!S^LAJBB^=UVC\<?6O"0G"AJ"F.(I$# M
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M3PY:P^20G98!$@+ $_9C<=D;"TSRSCK=!D83/C]I4&M4/-A'81?EQ.@5-$S
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M ,] D$=V1&,.E2_8?/\F._6FTN$QYY@1VWQ\6#Y9C%Z"6TTJ(1TF,0$\&?P
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M?BK_8J+0B')+?!7(Y13QX?LJDZNK#%)M7V:I=AK7K<"X*<%W!W"\V$",%!@
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M,6Q"(-N]@AAS(-*%DF/E#NFJY>2EJC$?X.#>QD$@6B\K[^D_JJ&L3?^H*F3
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ML$),E)=#RG,KC53T>$)C[5 ZI ^L=.XW;V]F+Z5X1_[N&8T64QXQ.D_JZUN
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M.4]3S;N4=R<'U*LW"=NF9IB&UC%_P9MXR^$SE6^UX$LC^P951A2C8/5'GRC
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M3N)(?6+INDZ)B7)+;*4[)? ,<#.!^LM]7M81ZT.)NC?K(E;GUG2U1VSG^GR
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MAYJ2++XMV3,NJR=D:^/F*U5E9F&;J'@FC<,8]G$BW(/0.E1_;=YUX%S\(H%
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M=/_A1X'16V'<NP5DR'Z&9?FX'N/"!T7%:5WG^8-B^#_> J[Y%%#W;P'O,CM
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MG#E/[D!G $/%6']W3?M"R',.2K)#8GRN& +'9/"/GBQLW0)(&^4*U'8^Q2O
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M.CK*#(;&$MF>IP14P)(^P/DC+ U^_\S+4!L5[+:[X2O4RBON3W$Z0(" )MB
MIYUF'(/1;&JY33!/6/HKQU>.]#5^,PY6F%RL7)->UBW@72KD*MJT?[_DJF'[
MIV+\'XO0V/T,/[TSHI67K'7#PB_-W[)6&2D7_YB(> .@O#XWQ;:9,N2&<DPM
M.T=8"0IF<G#K5P% /\:D2ZJ)Q\U>+#J/(SVU]*16ES-_- *7FYQ5 VS>QAPO
MB!MLIJ?_$$ADEE_XC1=R\'$07G;GU>V?);G(TM>X-3PFMEC7".":3D(S83"Y
MC(=__+7\Z*9%I6[L53H6*[N[RP+W"9]C>%:D95XRZS]Y*;31"DBH/1G?J(A6
M>--0HMK0:["#*FCP63P48_D6Q:_6:#X;7^VX57I0'> \EB-UCW"IWZ?2J:>%
MZ50H6 Q[K%2!'J)$ 0_;08R(K7CODKL(B5*XYEOL/KADS>"Z!;3ZZ?VI/(R'
MZG/XEUW07Z<GK_PP/ZZ](Y5OAPWA@/O/:\D)89X77%>2WNE*'&CO#1+)1S(V
M,U/T(,[3/[< <T8D_A-E?_8C<_)Y!RJ0H3[(7!U).G_>?5C86=G\8 [,2RHM
M)MRWJ[G =S6+10C25$"X_#A8ISQ $PQ,L%'Y;I*:8U(:2/=R0X30#*2]A2?G
M4^D 9TB\X-<F5=^#:[Z#_SU,G>JKA_Z@VBK[H,/4CKA2L3<%PQ%T\3Y$:9EM
M<(_#2%&-J2DL55%1B:'N!:A52F)TD#J/\_QQYW>>)#$ZXM5=]>8$=8.P&5WU
MESEKXIMBFV<0\UM *"WFY@X5"9VFF%=VZA@S2.SBJ9*4SET811>>8=HQ[BO-
M>M?]:,<^5'5WN7/I NLQCU0R/JY_9XC+5,;% *MO1? *M?EWBNZ08-Q[[0A@
M7U,8ELIF]?SFB3HE:*GI;H)"J?^/'H:NM!\EYJ"V&+J>5H\?$>[3>')WLXXK
M2._. Y=# X&@$=8C/2P1,N1.5 *E Y]@(/\6R\31L+J,7;RAVC)^A.&9:37H
M4([L0E2=^A8P/<6.C9O5V^B^YAOZSSQQ_F<Y=R#73^R7V:.:R?R)CW035TU)
M=F2HQYW\Y<\U9NTT?J>OB,!VZ'!G72N&*DM# Q"F48N'>C"56&2)2DW&FY^9
M#Y B(@D)Z))FZ1*T-8(=M%1D6EW8:1H)JH'%EF,86RX7PT^G&X7M[>XHF0UF
M2W3BU<\6W\$M FH:3TL9OZ>TTDU1SU6WSMB^_#T95A,2.7=]K?Y-[P7/BZ6Y
M#>0.EHL##1DB=&N_CV7K%E_-X 1%F1*L8UQ6C>9Y^U94%=2B?RJX]X;2_N(C
M)7@;+^<'+6PA0]J_#;87OQ.WF&N?B.?RR$!,KA7!S[Y )X1R;L"53."8;W(\
MB<*R0@2$QS+9,E$^3=:QB:\=F>/^I;9XN$.K?%M^0)E4JM](LDMY2%5+U>,B
MDUW)!F00K216;RML?^"9XN=,KV<#2EZ2>8:17D%0F>C/;M<;U3;:/J7.?RXV
MV#G74;D$ .;;?T;@>0A-\ "76>/<26B4(F6R7;"EQ3?'89AP-"0/.O3=M,9A
M$O?]L,P#3*SB6/QC.J.]](UO9^:0AJ+NCVXF%F787M,:1,3UMXEF.@P2^T!P
M74ZZ-";NGNN;(C'&[Q2Z#(GK!O5),VQ]8+0C;-;/UFI*UU9N\S?L!L)#!;SR
MM0_P6F]&.N8NK/@;CF )_8&P<7<$\<>=P.<3G?6_G2H@3JRLEN >L=F$EEV4
M_J4HBA_B;;I,(4,_@N)Q&%6)L*A+UH$KE^)T?R056ZE'$&*[@-3/*Q$U$\VD
MF%*IRA6NH +!_ZN][XIJ HJV#(+T8@&1+AVITGL7 B)5J:&HH8<  H$  12D
M2"\""M(%I$9*Z(+TWA$TU(0F/4$(H3J\66O6FIDU7V^]F:_YV!_G\YZ[S][[
M?-QU\TZ4UEPB4J8YCW.J0KN7V78QV4;35W>)M?L,LL[,9F[K^J?>SX7X8*I!
M>-MO(S6/8KNF;6/%E(N=CU"G5Q)IF06]0)X"!2!%TF;U*K^X>^)6?56(:/WU
M L,Q&RJP?5:5]VO5J:9NR:ZHT?GFF/K[]WQS4G-S#+,N?;YO^EF0T/]M7GRO
MNO.X\I!=QHQ))9^[2N03=D^6[2Z#\\! .B!]LYLF'[Q[YRP^)6;I#)/\Z$6)
M=OPJ8+8O!2_8HZ3:U!!GEF5@-[+TM-):T\.3=UJ!::L#UZW^OXC@_SPU.J(Z
M'LIF1?+W4!90ZXOPDGN15H=C5,C',$Z2RS+,A H+P1"DW0B!70Z$CW%TN+\<
M=/']+*\:]!,:3$C!&;#=ES&^T>WEQ8;J'6S6&Q[GWK45WVM:1=J[%R-WM<^U
M;5T#[CG@*MJ>9*3HB;=]$O6O:Y>[^#[8[U[@>TZ/",QX-7'Q &\K2=!^-7HV
M.^,K^EAXZ,NIX_Y23<2BYP%;8_7^52L7%^?MH5P>V/=LPX;%8KZ&[6K4W-@B
M06F<DMBZ<H4L6W;/:H@@"!U;.3:"K&U;;!1)(;R.+@7;"DA5/%?GGC80_S1
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M-/V!-:ZW7DTVZJ_]A$ 'KAI5/,PQQ!A+$6<V)?&&^H["4%N*GO\&R^'S&@O
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MI4$W9>K^K*R;HQO[FT<TTG>L\(-\:4NE_XD7P_\?_S7X]_N_ 5!+ P04
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M.?-:<E;2VQ9X @'X,JHR?FS8+_0QVXK(B#-MY(A6T<HN%5@P\,,+)Q/MA]>
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M_2095W,);WC2KE%HEO51NFLSG;-QU-$BG?;!\$\W4W 85@P3VG'^;*QTC1_
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M/R9_YLLP^Z<B3#ODZ\I_RP3_0R;H7U2";]3\A<\WOXW]*/*^ZRCWWX',^J]
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M'C@:=*S6A24K 6&N H=D+U0N@5"Z7/"]SH*S('.'TXK,\#=+?-_R]PY]:7\
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MQM__@@!!F$M#3^;8XK-W+;WW2BM/+D8PWBT'*J 9?9!H>\LE[+<8MZ#6Q]<
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M)2$SUL'0Z7/.]?V><S[G+S@_W+\]UW5?]_T\[_?[]?3[.NT[9W"Y35DFZFX
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MW<K):M-J'+"Y'_?CS?ZD,_]O2_CW^'\ 4$L#!!0    (  "">EBWA-IW/HH
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M92P[TZWOQ7<3=!VF #T5NO_7IL\1GAH-8*ZO*[%WYC$N: 5442#EY;(+HX]
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M^HG&YC:HGH\1,!X_L2G6$1SYI$SW;NCOX[(2MB1_4LSF=6X+ZW?(6Q"QHG3
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MEEG7P\I?)3MW_L1QO;!$^^IY$B9R+9%_+[AM]^(G,\#F,9!#59&;)?=%W[C
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M[C*472XMM-A5[=W3K+UR6EA:&"2G>7*#% I3JFKC<;8.(+86^DKS7[65/W"
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M,YEGK:8&E&2QS?I(8:]8X:6DM9=;6WFW6@8F8V_(Y?J].^$V]*C^0=/5'LV
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MCEU>'>K2Q+8=< ?6A$+2ON)54YY<_(CWK_I8^.Y>]I=G;TEN,ZX!I7SLF%+
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M"_88)>_O;^'M*PU:%RSK:;EOL;KV^I%]:"48RR3%()*P^Y/>0WFI',M>;+G
MS3XW;+AS^*OJ>\;PH]3MYJLGBO#'WDL%+-NXN/,:>4'+159;%8;&&7NX.6JM
MF[%J]]X']/S&*Z\,UH9W7K=,0&_63F)S N4Y;177S=,X0Y4TC[M&VPKH5RS]
MM97;.^LBUOF<?0RW'H^L3GU@O?7D]07K!GWZ>G:7^/9A%=RZI47'BH7?F_UR
ML\MK[\0.DD*Q!8MZ8]G*YZ<7'=_I?O;HQ(D8F7T@;I^ERXTZ;A?<)RN,^A5^
M+$&JUWQKNBIZ&F+U5<OKEALVU^/[/0'JN"$2'DSK73A%'^M7K.4M*R5KM_>9
M03IU$JRGN_VN3N%P/K*E21[EI,67'>6;U':X^!D_V+WF"W6CZ$@UXAF)4@Z)
MT;4Y4(E#/O?J-)?2;NM.&1^)PR<.&3R73:3T/*;\'_/XGV >S/D):8:+D1O_
MZ.GA]XX!P985!1%7]VG4;%2]IO4&\UXUC\A%7Q"B1"=.5[9I\ ^.^E41^-CV
M[LMK*.XMC)BN[&RXA$\7%_/P&ZFOPM'$,=/JT( >H 3,%*G"4]]LVS3K/&A[
MKV?:T3<1'M_;^=B)1:&MUCCNV&1S[;AK-S[;%00O*;-LJ(&O(>! R#8"Y[RQ
M&Q+>CIDJ!R'LECR\#4R*W$D!>],* !! =F@-?Q_0$ \@IAT=MK[)-XI";K\6
M #30S?G!;!,L:.6_!D"1C+\E>.8!Q*U=V\E"UEZW9>I?[NQK_-"W[NDTM8G\
MY:<6@2JB,AYBF56JRN?GLXCAT(?<ED\R\0'W*Q-+/W_5R'<;IP03I\UA\)6S
M'$J"]S5>N=FNM^_N>X9O:+(E(W[)!$GJ,N6AY>].#BR];F;N.$\NRJ\3/9C2
M6-\:_&_'KY7I8"[C5KC1Y75@=(^.Q&7RMO=-&C$=I[[C*I=W8)W6ET*S#O<F
MY0[W.VFH9>Q:,#EK&S5&04]A"HK]W1A=8OQ+U-(UF=O2KUW:TMRYDQO6NECB
M^IBJ0GS5:;/K9ND<_4J:,P&OE<J),OTH;V>3>271JXG0:Z:HJ')WV.S\4L#N
MA:B?CV1($10"PRX-%_BX$*L-XQ&)W&6"!U-+Q<6L/]2C9W^<A IP\*/M((1+
MZW+-<&;ET/2>,JCM2^#E:A)S8#A0)SGW07JV.G25N%,4J@,!Z_M+G8!K+D0M
M\@0X'=Y'XB\!T):R.#"[;5K_+F!$-K,$)(X +8,W!IY$NJ%IST*JP*\4P& 2
MMYM\5U ,KJWO%H$W%P+XC]Y,":1U"3-U"ZH VRS0Z9GB:EQ#SXVB>182FB^+
M^\;%->BX[,!&/'#Q..,>H&F6[ <S2< .6#+%3O"2HPAVVQ],SI8*$0$4&Z\'
MVR5'S6"2\, )KI5",3B>^1#QI\0!&?FYUL J_E>&P76F4J8- $M2XP&5BI,*
MO"XW!V++JN9*]&%*-OXV#H>4&AL=FXWBM;4P*7!T!@R(W\, TA(0=J;#!26B
MH#-6S3E!=43E<Q[SK5WMI%LZ\X]VFG]KR-BZ/6B>5"@J/-TE]#X2HERMK(J5
MBN; ZT^+-B,+B"54"X%&Y ,59<-,>4V^Z<T"UWK3T<""JM=/7H1:GQU"NZVM
M=*7E%#I>F9WBG)T00\*BS1 X#<TLI8D+I)4( J[%%[['!*#P)GT(-S]E@I)+
MA_D$_B"M&'?Q =102$+$=)##W*ESL5##JP)D 7@!V%.83 -F^/)W:*K:]C[2
M@,Z9?,8\KRW32[4N_&XW??U>3M5K>656Y"R4CS1#,Y.8J2>NT_4QNK#U0VUY
M9,UJ?^V*H?$?*V2?4#K9<R0=W?2'U&7Z!Q<??YJ;^]3.TGJP?JU!V@.JV#'&
MA]$'Z7_/&6"L",4PV+<-8<"R'(\"BUJ8[[:VE#BM>9DX-R"+!&E=HN!28 .>
MVGPDNC3\)0Q<+3NZ[!\<1O*7PTG4.%&]V B,3/$)S-U=@DTZ*CX2AU/D#;<]
M4X@ZU1P9,FBUY)1ZTXK@\WLOU'=JS[L-6$$]I+OD79ST"F0]QR$=WL":#S%R
M\FN3I]5'[VH?;,W]I&BMVM46IGIL4>H5N0?GL*B30E3^_(1\KTXX4:&W@<+P
M=L2O:UZ?$V9O::^SF)PM2*&H#[A\[9A^]V.%W]FA>,<VL+^A;<0U1HL94*3=
M[E?( DYFQLA[[(ULEU;MQ>3,JE43[&UFS]9N4]"ZSYKDGCD?9$S_;"*GND1T
MV&RCK\G+75D*5\AM-SO2GM3L*_K!>WJI($N_'*+1?RAYL^=_@*N![_ ]V)Y0
M#O<'%P8&N/O;D.*0BIO%O^4H!TQ^?OJ^S?9,>B61J]X-M,<[4SH2X8?BZB/+
M'@M1FR3=$"13B'JA%[@7)T11QX6HJ8(9/3X U$7?_MUN .0.,[VGR@]$]:M&
M;[S;M1I-Y?B,_E!_ZC@@N1HNS'JD#,SY/,_'^*]#W'HX:@=F;A+B6>Y*9U&_
M"]BD;U,<33K\<$R6OZ@27$I)X*.V06]XM0=B>2M<$'P>_'HWI7[;.B'J>F &
M$L\,02Q\ (1 +Z83@,<^(G8R+ R;CL?D+N"!8*$.?2WR02/%!"2L95CUI\JY
M(_0?O8M[UR1$>1(XF(-P92^%JSB(GILF(0EJT]$(-S4-(KMH<1\AR^U%J:IZ
M1\$#J/^C#R0 Z-^@1#$3MX#[_C(DR JF=&H@^MS?P'+-(*8)F"JP%X^(JV%/
MEG%B".0JT#W]72JX[IN]Y>8([]T-,M?VMKT5HLI=8$.$+4K]$04)OLZ5@FW4
MTP+233=CB^ZU68K1'RREJ9T7A]:U-1"9:61YJ"$/"'VZ%J(7LW!/5$4ODFYP
MR*21_GCW'^F!2Q]$Z8'1 SO8'RB&[G2K-YYT)@V2H92\!@"B(41=-(-W$\M)
M4ZX4SC(AJMT61$4)>X:W0-(.+9BF])G!FSU"Z;/:EZ'Y:B$JVO_,XRD829L_
MS$,[5U!F$ ((+S,F'H)7T&6L!/XDTR$Y\47>2&',Q*5SGDLJ:0M4K@>XC6+^
M#+=X+M\>;\ST" U$_^CR@<R:KUQ-FCN6EHO:XY >(VO!D_US:F#/\8HW@X65
M7_=,FYT:_B,U<+Z/V&NS^]@#P=-;D2YVO*M>WX^9!K3SCOZ]M'CO0.;&'IG4
M-JH0M1:ORQSKW93WPJ><H=X:@:E\IEOAQ1[Q9;3WK2)K'/-6H5'G[YL5%SPR
MH#I2QY5>7'SNDN3>/^^5="LMNX7*&^FY?:Q_"*.[()[3(%[]T&13'D>C5X>V
MG?,X]%E=YLVDJ@2Q=S;?S_OKA=I(]7V+_W8OT_3K(E(&Z9P@"9;,Y.BSKS&Q
M8;="W52.TP_%:-TAK'_AM3AR>HFB]UE^B./C@)<NM&>U>94#H7G?V=GD9<ZA
M#B\]K#=>Q*J8.CR7_2I*<+.WQO=02HOJUU J"4J<#,BUXW;JF'[RQ?2I36,%
MQH=\>+9-?\?T=X&/X91,S']$"'@F0 _'UJU"R =G#EE#X3H'6?BYU#1C%RW^
M3>Y]439E%OL/2@O5V+^D0&*+ 1C'!1>D0K,/_#E8AMIT.AO ;'QT*V:L55:P
MJ*UN;M9L OB QMHW4-L;-&\9Z=D8UWZ'$.6?A6APB2.0./1U+Y"[)( "36#G
MY(;09_>8\ 1N[*@>9SAV2ER(^K%35H"R[1T-F..)<@OU7+5N65$/ YJ'(N4P
M2+W?9W&/X>8^B!\F"5\'LV"-_DDG0?2_E0UJ3/X[6@G*R/JLN?1R+"WG6!O)
M_55104'\8.1",>7GRLZ1_-?D;47NFS%7W'+>/-EQKGB*[T77$N 4NRH#GU1T
M3BIX.&^S%643[$<#2ZLDKB:O.!YWK^3-E>[,O<:X%T 1E7O[."&A72<0_M\.
M)IYD4@62A>F">32G#8 -PV,>WLSM:!R"M1& ,YB]?L;);H!6 9WSV98;_J&.
M,NR$%:)0N$%?#5C?.PPS[-""F?HH1%45^[/O")[?)-YK&+;A>3WQ/L^^D7CC
M>O5^\9@=.$=?T0%F% :V3G2"&"F5F=+NXXRL:&VL$:05UX_3=0RH 0F]0T>_
MK5F8DAUYKR^M*=)JM+"3V[TN/6GKAZP*IW/'E1RW;-9_/79C3&<)].7%2ZCM
M 8:'RDZJ8CK#D4H: M^#(A+73FH<%J)D3.X*KH8SSPU3UKV,U'*Z]I\X16%A
M&COA8N8CJX&G\I?D5_[F'(&K\6Q,5 N9W-)F8?>G3Q:/!S;0I0D5>1R\D5L*
M43%GM9+!)U7/:Y*K9[M1&I>\_:U)D4 AB#,MJJIFJ(Z:[YBU>;/9TKF)=2<M
M>B[<#O*30$UF/?BUW][>496UA-A;(HEMO?DDM:19I\?RB=NC4LFM5W>^V;F@
M=)%2Y?_*#OT6[C,A:C%P_;@N(#K//J+,ZI.:E?Z!-N8.5* GL2WHIL#ET%<L
MFHF=-3D.=F9F%?_I9C,[BV.M01@ DQ=(7'T/,>!50!(TT$K$ ''>"&YJKD\?
M"7*K_R?OLY5PDR *B ]#CXIM ?DV*D?(UL!Y4__4OZ:++I/\;^E?8PA1-/DR
M(O-IX/?==FA:=&+'\6ZTT;;>Q^)/+Q7)<L[9 );1"L&+ =$?BQ&\F+I5LI=-
MS/G('*#0\C*:NK+/39=/XI6EO-^F(VLP$^N%J -4Y,0?K642VVL&[E4&W) U
M)#QKKS1/)5NA=95\3[(X;82R[UDZ+EH&FW<E.E_*VPJ52Q0(9(!5] #.Y6P&
M;\^"&L8PHHX>]BW[O\\*5$PIB&"LDU 959"*&3Z%X6S#(5L* QX"?;7/&F*"
M[9TV<W[/J.?) \7\V1GLFFH JX]]!;,4K^WVFKC"_#6W8 -:O>?'DOU[ZOI&
M<.=_ZF3KP\4X;N44O/5QI*%5+M,!5'Z2BA/<-WV\_=K.91-)?*T_X:U#)T9Y
MUPV+,<DC1X$6-D^G/+DRZ^-H<'C((#0X;<NU_I@XJ[UTAPYG=]/5ML-#8_]_
M]+*A$S %1/CIU?= =KR#AC>1O4DO,1X8KD&7$U)R%IBI%7X*5]U.X'?A6!C
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MRQ+#^"1J/=P7@$,X!)$0 LAQQYOA#7,Y]M/!!(Y9H#Q43PRE:&JULWVI@L5
M+'V&>I*%J _UE&'#1 2PYD5<-W:D(-4(P[I1MB;))O$<Y.XIU_3-;N#H-I3:
M>Y.\.<*?T:-8C%W85+S6B<FKA#$>+RMO>CS8T5SA>*DKG5_<"T+2GPMJOA8D
MY=["BMHC9V);M+3KE&,,'@UQ$J(RTC'.*N??%(S_(4P8_R=,_G<+D\!U/MQ
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MKR10)-$AEQ0B+EF/G=\R//I)_^JT>U' 4/\JI($H:[G2Z#?B?"^6^4J(*C^
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M_I/9_S=B$?^_F/TW8O\7KS4 $>:3?\G#) <  0\&I?&\@/^-_XW_C?_5,($
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M$A[4*:T@M^#U"/@8\0BX=/5G60>1_OV+!%Y*W558;J?=_%O5COZ^.SY+AD=
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M#D;8"P!? /]XKSAZGH%T4 T]%2VV2THS'J'1*FNBW.J@@[5"\3[VX\ZEDMT
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MK^GZZ044]_U3!MS#'P%XK2!*360'5+?):2UQUUG;$>)FO3"1+LX]5\"U3I3
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M\(X3*P2XA?*+.)UTI RS\[;--F6#QQITKF#3%=.S4<^WD+>C 428NSP)YT'
M1L<_WWO:[Z+RY6@_I9[53^$0M+IL6$?2H1^<0#-CPY:,#Z5!_#O!_+O<'>XE
M6V;"ZQ!W[8H?$UY\&XS>C"5OOB4RR1[%[P2)-6@V(%O-JP:_ZZ_=/5O;8J$%
M<<\',[Q-K VY+BV:XN;H3,0!^V5KOG:=M=YE^>RWG% O6;+[(&L08Y(!,XH<
MD^1;T.A_0O_G8S:%+P #JFA.7,RL.S-%F\V77,B>^/Z!@^MV]!&0+KC0P#.-
M+QOT"#"H1<Z5(!\!T";XPPJ*1\])@;FG2]+HSTD>4PM73R/NZA2,%T,VDIZG
M[(4W/41T$=++!HD%ZZ0,*CSYUBX$7&CTIL> C?_-IPPJ#[!6R&VX($"]Z8/W
MQ5R@N" H<Z3[KJN"[_.QJM,)P:D10J+@@H+SV]??/0[=7)ZZL1(<";@+!I%T
MT"""+.'$C?EL>K8?JN-LS!2Z-,J=I\]BDJI'VL/#//J7*29\LX#=8E;I2K@6
M0::HE;^%*_\*%.$]73QCI_FUALS+BWAG[^#3IVGC<YV&_9,')**X=+N=5O&]
MU,MM@=I:JFU]\!Y3A;H:TY.6QK8:3?M/$*(/!-R_-EY(CL_H2$*C27;4K>!5
M0QS_2,U?7< R$40YZ8>NAIQODT],;!R97[[CY,OVBL+:>6^S$A.DC* NS-T+
MI9$83:IR[C!B" OG7H3-^T3CP03',K^%<]RFO_KT7,%ZN3>4:VB6/&>&3N:R
M(E 24K&B?BGKU.CD86!DWW$"I.]1VMD.E\I3^ Z=MG^]7(^27O[IW*VVJ;;F
M_+F=[VLDF2CWX1LE![C8!,"N*P5GMF)J9Y/KBKZT>_YC:SR_??@0[SNE*$YO
M]S?^$S*'G;,QV5HU#G^<%&@[N^&&94^_60J*JG!E-@)8VUISD\+IL,+J927Y
ME6>'UAHA\$.6.(:J(8<VDZJFP*FZ"TPG6.665@N[G@"WQFWJN_'A=+=1$"?!
M?8IC4O^KI9K:A![O4/'M_5FI]"^6-R&AAY\*F9!)M0.[XT=+;58<NND?P<K'
M@TH$?PH[\5-FDZ\#AURA-2B]O20M78152D,;__VXD#B$" DTZ)P?6<BW$=UZ
MG=*&13*B7L2*-T+WS&O$CP6O!Q-W1%#YU!)>%290WRA0D4R#H$V\MEMZ)9/$
M^0A0?YENL2\0JSM+-C%Z%OGV3 "E%%J*S+NSL+10']7?,C_^LS%91S LV&BK
M 4T6&;:VIJ7G/#3/EK/^2I?7>5(KE-(2<;Z$/@@=2:ZMTBLOK,H @7=P$UI-
M<!/+5LH117$+/SI[6GMB<>U2S]-<-WW/8;>+8K ="*'Y;4PO(4KCH3A(GC1)
MCN;&73(MY&=%0789T_<-2N5WB]VO/P>-82NQ(F;XMT)HC[=XF_.N3BL/7'/5
MP4R+)>LA_AP9X?'B*3&]?)%[!VU'@]MD U!!9X/Y<XA/K%"#]FA1M;\NPZA]
M[/.UX4GUG#Y)_X%]VKC^!8.;M$#_PG=!U$!'& VZ+^[/2%M' C-Z[=8<#DD1
M;HMSGY]\.W^];NTIG"Q":*8%X'N FX2S2+Y"+<&8L9%Z"/";%1:S110/@GD+
M/6I"DN+NOUO OB;[_FW9JS]X!W9I2[']*4X8GS1E&B'0:4@RQT/G2ROR^M98
MG[C6@T7!OJ;5K?[:=5T\T(\P#2NL.EIZ)EPZ2&F(+$IO*8@B3RT2FM.0/]P]
MESGB 2)4L7:GLY(\2'T__K:;KU+M*$V)U6;):\91[6SM,OW5&1*\AY.!4+9B
M ;T+<GP$X)-$VI>4Y]UKT\;#) )3N)^5&#E,FJ@<B$;S8#W_B*-P#&D]"R&<
MK349\+='!(Z!#3OPO@[),13DC[$_G_S:U#Z@C\>:C <A\EV0X_#PJG7.V[B]
M6RY7[%YJ,_';,(=QUH85\ZE]2R:G8M]'I&M^@^K23<%5H<M7LJ/@_J^37YWR
MV(LDM_",H><-N,;Q]H%J?1R\+KPA.E_+N!CS7KCR%VXH8#D!CM T'<.89SZ$
M5FC5>O<X%FR?[;AMJAX>B<.VX JDT= +ES_KEHZWL1TM)YZNGV7YU2;:WHL%
MK2MM"M,=?O]N3OXE9:9G:M=HA(4,:3VFP 3OB.Z1K70VNFO+VORC77L"^T#U
M#%.Y'*/IE7%SCB_=0*,UY9'X0WXO!TA88^XJ6$H+K-<.WQRML2TYS>.)>P2T
M^'QNRM8X:D_V1.1P1?I>I=,DAA^\G"3E<W<"MD"&'_277<6,(]66F1_D>/P"
M:T8^I2H=':^\6M$C=,TA,! H_Z CTN85?MI+\5!S)057:&E$7A*Z8V[\OKLJ
M9.IJT]J&\1YVOU77<T-P'W=PAL'PZ'T[65VGWR)H8> =8J#A0NLTBT'[\KF/
M+NF6\[+4,XZ*_/*G_IZO.3[0<VJF*ZT>/']/\E-1.H4V"!^Q/XO@'[@+R:HZ
M,65)[E'%:0\R\*B./5PHX7?[.OJ>UZ(\ULR.1M](E BV/OT(( T20 C%N7M!
M2:E 9H-).XSR9L;+0CU&P2#.0K/ #-F(-%=BXK$[%<[T;,R/DF)]F#]A0*?M
MZ+23%Y))-4C(ZR8$-<HWOYY"DUO#IC-9*LY4C^X=Z2&O6G#)GS$93(M0!]V8
M#K1D%]RB+T[@'*7"..7B$C&N=Y@D-0$ NV?.\UU:$QE[I0T4D^:$$ 0]0R1W
MP6G?()A*.A# V"+C>5=OP_2S-56_TM^WXX*Y%I%_[6R23;S&/YX$'K9>":^:
MC3:!T/QF2.9;Q79$UDK"Q][NE=E?,;G\LW0T>J7C]L0\V2/EO][23(PK74D-
MA28S .-#L!U9*-JR.N"%*5[OW:NT\E/GUECMS&G7NNZ_AYV&\27%P*SA109P
M=$W].G)^XJQU0G#G&S'5E+CGC+$*;?H;#9O@AL\$QGO_RMF^LR,X>%<J7,Z]
MBEAYZAYS4/*%Q4CKG<5R>_<PH><L7:)C_?'1NAEV4ERR)MZ!D9N1QUUZ3^7]
M3072HA+DK+W2&&1E3U-0/2%.4SXBDFWR43J;#4]7[(?E[[>2,J//)-S7ZJ *
M,66@T'<]B.4,YB*(6?X4_M+J<"IF=%9[C4AI45;N390;/FX\X#J ?TP Z#!%
M;#7ZQI&&ICW=L8/6EVS]Q, J)VK8R-#+0B"M)$5 >5A!64V%,JT#5T7SH5J!
M]M3:4C)$I"E+7$L3<F'#KJKD2LXO@&AAI52+TA F_R1]E)9*:E#::17=]U2.
M%!&@K0;$0\:OFV;H7DX/*C=&4?]I[O>Q&%\W(^DRB(Q\QW@3A?3M(R<-3XFO
M5X_[W&<O&:HP)SF(U@2[9W/](O0/[-C[\@:W=,Z2=A>X3@A%*1 CDINAVA^G
M1M92HL\X%[D6! ]!VL,:]X1C'-S,\L/".?F+%#C^5-WN,/>=>^,@7>'X*EVB
M1X -,OUBJ!UAIS7AKC!+9""W*UTF4$MCE1]!BRDX7DSJ5=IR11RJC3!,L*YW
MN%V^RP8'$VR869J.<\8[_/K/)PKJ$D5L*KW_&XRH$9&[P3&#0 PK9,0-][<L
MR0'[CTEM%T)?8/'4\@F2HJ&?<:S[BTE%'JI#Y,Q!?&O"N"#3 \J1@$Q+V^E?
MK 7</_;]_XFWPD8EX_ ]MB_[;+C[23S*W=^^S_<(0^MLT0M]OLF_-"KVPM6G
M)7Z,R?"&)S3S"/VH*YC5Z5L2LM0VLD(0([\MGF]>7,LKQ1 -^*_)JL5CL-^H
MZJU(7/&<(>#+[H2_O4!@DPX14(9%$GU):M"RI/5A]*)'P<;?](#Q86\E2S<@
M35-F%WCX!MV3]'OA)KU#I1M.&GXU&]U+U3YW=9.V&^.]0@OF"EK/S<_ER8K&
M.1S5?0_ ?*(*6ADF7=<=8I"L>(C;*5 XVB7I8UNE"K"[:*%Y!-@NF1R./8BH
M/0V&+OKWP3X@<$> =')FI2@>.-.^89YO34VHW>:6D,5%A>'P)&#'K-_K>WX<
MDXE'NR3/F7!4*"Z*'^XU!'<,H9O?:;6-XNA<E&N^J5M^!Y@0KSK\.&R/M>.+
MT>M%''8SM6X4^ @P+<RLFBA5GY9$XSQ4*D@6W/6VN<+K5,!%+>MV_ 4].RYQ
M>=8+R,,4UBNWK.T@N8?/(8Q(9:C[]:\+.:\Z"OK#Y:);(O77@SDDP-.2D%PZ
MB:OW=!40SP(&[ZSB^O?[J]@%6;T%CL0-]>2F:X/?V"/PACU&>^-K 7IGV+JJ
MU,T\A5H[!>[]*RV62&9G_ZL)\VE@E 3]:\-O,UH27_HIG7[HO*)VR-F'):8O
M!;Y$=I4X,60&Z%2[R3W;Q7WJR,RJY"SVQ>M X;5!"JC@.\*B06^Y55YV., E
MS[?A@W/-\:7G#;BI?DZJA*\_\?Z:NM5)HDPT2_Q&6#3S8SU!TTG]<W6HZB=-
M>#H3N0:\*K9M%K_XOMUWQ<JYV=(KW-63\QV3)X?(D;S3VR9DFG66A?-@]R1?
M.O,?K:[6K'4YS(/7XV4;F&9\:79"7](V]"GCH1EHFN!%UZX@VLI.#L;>35^\
MBY\C*<L9:#)A"J>#OHZ>X)K6?XIN#!+34#J?FIC1.BGU(Y!XBIV9UX=CPW)&
M[1$0W^->C&3&VU_Q,7,5G_0@$FUV/)+/YGU+S\G3I,JY(G '3@QA"Z?)=?79
MD7^"1M>$,H0ZF_,\/&^7S5X'_IEWZ9PEQYSVMJ1!^D'[L&>Y9E+*E9R#>8?7
M(@_-NEI6@LY-U6:#VHF]?3)K.YKK'<V\>(84:!;D6"J$"LK7$LS>7#S#SMW2
M?'JPG_8K.UU-KJ69L["RK;JT64JDQV!G$W>,X<-"CVJ9L7,V+MKBFM&F /?G
M<UE=S+3XOWMC+$VD$1)FE8L]3#4GA3A+*SF%:W9=X1H3F$2#;\WW/F<^203P
MGQ#PF>I^TFY(B1>^[EO#O7$2]-@ULT46['3*I*-I'>VC@1?_"M;?B!71^KH5
M48"H_#:T8W@;'Q4 ?YF7G#H16J73X!Q<95GZ-S7;7%R,6X.U1IHURU8&*_X&
MH,$:H<2$=\*_G[+F->A\+^W,X#=&^N18VRW5<L1^%T8Q=.M[E_5YNF/Z,FRM
MA3-*XSV.%M%^1A$/.5BYU+.B/"G+L$,ZE!F)$QJ%?O8">R#]=NCVF#-/?G/P
M8I..I:<E*V4+-+!3U,>,/V$$^?"0B1:7^GQ1K_#4^99BHD+G=0A37T&'/R[]
M/6;S$0#C@_4ONC]9VIM6<:W:F'L7@[^3HE!>OYS>C 57.,%Y[3IRO*A.2)4;
M4J<VW T65R;U5[6#W8,KG"5'IPQ:<QN$&Z">#=C#-DQSG?M>7S4V?&T^6":;
M)8)B7_@H2#\"K.!'U 'FR:=V(<4^I3U&-Q^04\#A6?SIBM/T.M WE57L>VP\
MH3V92[<EST^<!"HD\P*1E6*P=V=?!E2IWCSY!PQO"+C/@31I'K0R^C.($@Z,
MA7D3F^GER<J'CHANE&N5J_-RFJYG<_SHRU4B'^ZRQ>K"Q.B>3=ZF:^M#:@BB
MJ5&BQA %KI.;47]A+D98D+R-SG)OUUA(J?3=-^NFHV$%>?2/ *-H.19X*/0B
MQB9/6]\UY!&@Q[ $%37?/#FML-1EVH>E=:O(>13J /I_\V*>N.,>_Q-$:"R0
MLQI<+3>P'.DT.CJJV>!]GS"^EU4<ZY;G21^I(-:M2>+OTGSXK2ZPV@V:[,"E
M69*F4I[69&O+P1KQ(D)F.L1S>N_;;/R66,S>:[WI#U[!T =GS?DRT("S,4P\
M@Q,Y>1FR+GZB-*Z@G#8 T9Y'LZE7HY2[0LE1[U;D1':U94WF6C=Q!Y<I:E+T
M6[.7EU8+QX7<:.P+H98A:5A8U)?)B@IS&_*J6.$;1D>W$2@+"/ SFGIJ+S2^
MEVL.);8G<UUSG4)F<<IO(UC5FC4_.<.?5,NJ;B4R*UO^_,DWK!J?CI%@7;-Y
M<>@>,#'O-C((6.5@6E@&A?E;RBM8D8O3_AG"^B.KVNYKYAW>$V6U%?<RWYA<
MD<5[ ]2GW+HX6J#05J523<\><Y9N,?KU;SJ.2.6@5]>@C%YB:E+BSG+-VDXR
M78#1P". 2,ZQ<?.TEW#9#7*4_T\<]U!R5WF.0[CF@E^@-?TH7F33[^$"34O@
M+'N-7;NS"2&T;?\60G9B3Y#%,-/T] [UHF7(\QMGF[\+F\;>5Y^-O;.Y2>-:
MT0X^RS!YPIM<^$S1O<RQ\VX?P6AW2%J-ID3#:#15O@:$ =\FPH%2.L8[[;.W
M.8<[<5A_]G$O;Q#I OIIR.Q:S3QKON%26?:4_HJ$)OA'[Y)U!.BPZ,>'"<9W
MD\-]?.%MBM3[H>U'40K/?Z'HDGJT$*2#W:/YW#5.2<1%GRO:?+A29GNV@ ![
MCJ>)E_R_L>$\8S>*0*@+Z'GCB]!!8JE'@ #?WX(T(U_UB;6JF!Z56M#^]JI_
M1\2YGH]C;;^?(KQY([E1>KTU6?;^\/O\[B&_K*.;$'?R%MZ;"8'+YV^3%"?L
M>,)PS?-V>KE#9D,IT81(*W-$92Y">$C2ET:/_A#^ /Y<GJ#K:\]88!TX=IGR
MPXR<2C^@IAY"A)X(I0J1!ZFK($)J$.!7- $->1N5D3R?K3L7=K;*WP_^H<X,
M+[0ACM 1L5@8>5;AT[S MS'AX+U-$FI;=_$4I" <MX:;)#%+ AHU^]:@.YC$
MB;:-+K(7B,IF84W^T#F6RSH^FR>]AWL4S+C76U<5,MVK@-1Z!.#][43@= 2#
MP"\^B]6T1MFRN;VZ_OAC@GLCJ.\YZXXKQ'\.^$$WP8JT1[C>,< (QB*9 %TO
MOIRM6G? V%K&YA!B>]>)@2VWK]YJ-%'4TC&8$L]"W0,,]-]Y8-BV:(IV?];X
M"/"Q=LMA8<?D+!*##9%U]?M<8VW1B#M)GGZGO7[@*# Y#[;>M5K3@OK%R_%M
ML?_T)F51W0L6TWG9S4P[7ZYI35[]1&@?GZLY)>+= 1: 9)Z4ZF)U;Q1(AGX.
M.MP;,MHF]YXH;I_;7=)&AY</"5"6EU+2):MY??%OK'\5V:7P^]C4ZBMX6)[_
MQF4>I;GCGO <./0((-,&W?48!=15MR[NBHPFOL_U3!Y_@U%\A*W!I)AQH]('
M%VJ^UP\R74)A,M6"W W:D\VDFI+*(C2I]VA?URJNY])[ D8] U>2XONA?(MN
M;Q>_26;T_9B7L,=:-&L.W06'MY'B!+U<:(60@::&NRLCZTWYCC.T:P33\Q?M
MQ,PZ5@T%1_9X?]?K*&O@>%A*(/AW#NI-][T<>^DCSB=V-1;Q%'[J#<C,/ Q3
MZ'A9E6X]@V<G[063'*FOM*Z[FKWNLOBZMJG&Q/ASYXKU$F^?68GZ$CC,@FV.
M)-Q]!,3(/:DZ[1[IB$9I<G*OG3AF[YY/4$W=Q)84*OY0PZ(3=;?9^"4O>?V!
M^JGP@+;PRX0HWX*#&O".(.Z;93<4Y4Y^:+Y1^Z*@A-95U%?O4RW_Y4^7Y(/9
MO]**Y=K_)$9Q?P?>K+*)6T6?37\51R07"23JOC04> 1$__0,%C,%DJ*"H1 L
MAR1[^ 6T*M:'^-F^D ^>X18IC.:^US_[Q#O=TP/=?*G!G#4<,I<'251X[M!+
MU]R,M&\T)A:S:%MTV__6NQ#K;"/ I8K_:22GC@P'H- V9"0Z.%EV6$?U\*9"
MIT)]>A*]5PZO2#25;-BS8"#-9@(.2RF1$==&V,0?.27W,T9:6M2 /,Z$42JN
M]2!9TQ7KKJ5S8=CYU91$5U(9V-'\N8^M+::C>2B)/Y91+=+S;L\"09O@ YX7
M]C;3-C+0A,':>)=E,]K7Z H*J%*+<Z)E)C#E\2#BR#IH#>R?C(;Y[7(RLR,D
MBN+2[TQV RT"SNF"(!TYV5Q1G'@U!U U*F:Q+X>]6D)9MKE&A<1CC;?.1O-C
M93*\>C'R/V Z1\.[HV,OX3%#L^0F7.LYAWV%\UN; AP<AVEZAP_[19NXA(7&
M.^_O:7(1'*9PELBK1P"Q8R_N@IQLA;%) B_+,)H[FCZ^UI7$$*^"1%??KX8S
M8ZNC!_=> :EN"I>,]*JU $5:!38HK#FN/0*&_?ZHR[:^&HFG;[_4E!Z5.;:0
M0;+ MX<"?& _0DA^EA)4VN7MSL@09!G,'#_AP-PPFI^VHR[JTQ>Y2@C-E^;2
MSUB>1CT"=E@$@Z@1$A>#%YAC4$'277"T!-G7"<]9Z"9%L.6I_QJ=J+K %]XW
M8JT,W6BZ[TL^!;K#SYVL*-P;)4STS0:*D>]<2M/?:1?:@[U(WL5'827:.\R^
MNG)'\@SSN]\#ZS^\MK_7W\F)NP^KMU5_N#3Z ZG8(*[BX& Z":DQ^39++IP%
MWH^"E=&>#X0 #X/(RT^[W>.O=<^^,[Y%?A,JQ1K9LZ!9FO07Q:O8(NY<;QO7
M)R'1!5Q#]!X*KS;MA[9IA*+Z;K:^.U>O=2Y)D)*!0K3PZ['>,X+*<FHYZL2
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M^>QD:<B!N0#Z 63UX*KB#F"]URI:ODFI@>6=&U1=,W42<D^4ZL_R];PV"W@
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M5?Z(_;T#Y.FX8\_EY+8H%-?,1".+1@T:R@H,^-ISEQFDCC:L"RQ5#XD3#NX
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MA[#4/WD&7WC1&5YTS;NO<ZM:R;)^BUC!N\E!D)6 LT21"&Y7698 :X4(42;
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MP;OUXO J\-1>J,TLK@"6[T0TLFVJE=GA=$XG;X?DM/X+1 K6/SL^#POD$-B
MS&%6GK*3Y GFV6&\PT?\4ZA+/P#O7W#H!' 85SMF.M")E*F62F:U.E)UC_#,
M1KXN9Z8T)%SA5-?E]N*F>-6L_##.K=N<#,Z'NN(_>CT-%B]P,G+9[4*M#VM7
M1X&*OP)NQ\44B /*GK*!:/W[NOQYOYW&VQ48&,EGE=8TV LEDM)MN.V_(US3
M2@EZV_=+&E5?DD/.>[0<@:A400E$=Q" ++=!*=3/[$;W%A+? X*ITP$ P#%
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M\\;HKW@/?PKBZD-"]\H7R(GWA.;F-( 4L6J:'EP#*8D9RO=NJ7XGGX_LI%W
ML> !GVT4&+#^[$3<&)#KXOSNE(<I5\'H9\N*&J+S3^%DK?)'9JJ8'4VL'1Y
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M7+/@E.)/NZ<^::+W3IKA#UN^CVGFFK9EFZUV'@K:;@B(/]RS([H#XDIRRNK
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MYSF]M&Q-$^T<C@,+0Y7B;-!GRLV7"K#"PH5N?R5'WVO3GE:AUF326C\[_SL
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M[R->_28#,[C,W8*[+2>7J%.$R?FY<K73T(W"E6QO/_99]N F&T[VB.]P_<A
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MT1K3>.N26Y6+[IJ>R"N])Y<T9_"A_@1F.;BPC3_V*7 9A A;7:E:MC,8-N"
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M:^SLM'%]7N;@9F+^)OF:T$,)G8*""-C0D$ 85P'RJD\= MQ'>B#)^Z)B5AV
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M;I&FLE^/W75>+?Q\19MGK6*T75O7V?(U::?H["7#[VQ$6_QS"69F2YK+R8A
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ME>';FI,:""=\%;_%ODO1C4>Z28HIREZ<H8[XED_^188%K8:*@&HOZL+R^N+
MFLW8V=0_& VH:I;AS/L4>^=UJBLDVWTF=V45"<Y_SD'#&;9R\"X3;])EM,A[
M;^PW!A?=QS[@LP(3S=9>*1V3KA0 ?@J5\2J6L9$F15_>.?J[@,(!T"53WBU
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MF( '6_SHXN8KE"TKO<M46:#0Q4-GIL3#;>790]NAHOV8EA(2F'QI#'-\ (1
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MKN#871:X5U2^Q'F98C);ZC>_;;2RU"WY)YBC$BEK#X/]&!B^GP?/G$) 1O?
MIQ[KN#\NUE@52!#))LGF<^N**:?,32;V'^BLA.4TQP7F4C5\ZU#@8G'O$&6W
M.@7X9N>;!:A+>0;:H8L>;]8B,/#@X5\[TM^,C.[5^)^%"2=ZO_P^5! C,@@G
M/W8378';MWR#PYLDN;C;W%.?$WVNRQ%AC CBFQ%Q3J1YEU*\:GIH+@71:UC
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MC '/&$(!UZC:K"/^"<YF/\X.JK)FRL"+Z:@8)L(*PV8C]F'Z #X]0WAM1#X
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M.U8%J("R23,F.SH&R0SF:_Q_:/NJL"BC[M^ANZ536NGNEA(!$>D8I<,A!&2
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M>+3%7:D'E&?CMC&3J>RCVAI/WD&:L4J0,HBMQ![!^WD5JEJ1:_<\$0*-KZM
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M5'W,.53HV%6LW(=\;O^4$ 0E^QT_'$CN P.O[8PD7WDF]K+6^Z:26+O#0V%
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MM>J-O>=;O.IV?[&H^.0!0"3TY8:.S&4Y!>J.TZ>6/IGP+$$C@X(@X7?"9;?
MML5W='<%YED;RJFVTNTF5^0&"YHKX C-6FU+;Z03[9],J#&G6F 8"BS[?WX+
M];^+M<KP%IV[,C;:"%%/\_/E#^NMG[F^?PO30ZRUGVHPZQQ]W*/^IJHDL1RF
MD" 0B>2#/>M$RL2TB-"Z66KE?SO^Z[481:6_SY>]3P1\DPX5U?3,Z? N$+!E
MCP^A:4O4SQ*A/J+6KGK^IM&O)RXQ!PM0ZNP__5ZU;^P@3-Y2 ,<4]3NFF;Y;
M7P^X(,@T,7&KT]Z9(D&0DY]WJ;6Q*CMC[6T0.V++VK:T]3S19J%T,8.]62IW
M8]B1"D365>X#=260'2:4Q.K43>@'LH-=3Z]N&^I=RU=>?EZ#OQ#>_>'-^^%4
MHY/TQRX.G^24!D(FNCG;KQO%]LEES/M&BV9S.-JI3]EB(OB4ZO)Z[R6!IJ8=
M.G&XAQV9FGX'K77]JUV@DWBVHDOQ64L"ZLUX+&!JU?:VQ3V'YQGTM;AD31__
M2W&#0'N6@S">K^W5GO&V--WTO%NPCA<(^*JM_O[6LTUK@M+DF!UR[4EPM;2M
M+/*F[&M/@VN=ZXK\:\_][BLSG=EJ!U)Z L!>>-+O1UCMFF_[=PO)UT<\N2W/
M\SFMIWBZ!+.-TKGCB'QM QP!&01<W2H:J*Q(A(VPC:'N\CLI)7E>QXSC^7V>
M>$)&CL8,?*RQ(K)< 0(#U$7,=;#T[Y>-*\UKG<P\0CX^>.N>+ #2C%-R^I2
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MQR8?=L Q/4LOQ^\U693Q8:DSE 7]X7QS'BPU)6_NR4-I-9KM_2E7O3.BBN!
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M"=B^!A#4@OYV'_-?V6L5_I9WKEIK=PE'_DL";\A-V&5>2#L^!!XG,,W^Z\#
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M%P CJ$W&!MP(M:U#%="W",+2?\G]98H;,,/*(_-86-11#K4^ FL$2F2J!>J
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M<<*SL/*#:K%CDKVDU3%GD<Y=^NHG\'<)]MV]X]LY>X7S';S1@)-LRS4;QEL
MVX$\IS+$JE'&8\G1S^7!R,+:5_BW_L^C%I^N_;\-O3XYC@75Y\9 ><8P,K/@
M!#532KH)6W=K?W\'?D0C]=(_BG,5:=(?#;V6F]N"_>$\7'M^S_!'/@N%MU[7
M#FE,L.TQ+D+F+RR88),;(<O<AG_?-V=X<HXKZ-JYQVZ34GK&R%STF4X\A!C
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M@-)K^W$<AEWS$&76$X<8VT_LL@F/)$?Q&0!TNB3C,K$?.\VQ4>NR790W<[<
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M?/@4K?BGV7L]'K[P,7820(<734SXGSQ^Q(2IR6(?@P#"BDR%=U=RG6A157L
M/AT5Q=T]P(KYV=A_$F[^IPE#\KW_EOCOK@$^UR [(PS3%":>2[D*G#)V;/0T
M^B/7=O^KVF,ZYZ+0T' @*H$8;#'38T$_A0-937?$I]A1Q+5DAX+2F G,^_&2
MPUA1\+]W'UKD2T+S] GP(>\DH'),PFG8%O.T]BG<3[#X00%RBNJ@-U;P]R3
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M.:+;@A>CFEO]>V_^AG&647,6%6SN_?.UX(>/@%?Y6?=496A$I LLEB6^Y>1
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MNT$*T#2-KI:H>MEAJU@"P=*&J]K3>LP#&)O_1$[9#6"=!+9AHL"*MMRL(#^
M^Q6NXL[4\M1DOI?T3(>6D2Q(+VRR!)M^GY5N;/3T/+BV\^AGC#@O+ZI>-1M7
MFP8GKK#U(E/UV #7,#]1J&K*4=',[ZND'/MZEYBJD6,-3\!6T(L"5!*V@J#
M]4)!"-D6<\5DCZ6;_GV@6^[05++J (>^,-DD&MU6?8WSJ<?Y75* -",W42?J
M.!,EVV_B!,LGO^/ )!+VZT]A8^V4^-6]3Y3#8JD)?QBY4S@\=#M.L@3^5A#X
M4V?N!H#$UT86?]YJ7>C7-#U9CI@KH2F>#K97Z;>=76F?GKCBQZBA=6X [!A1
MQ'M45K)D7"[Z _SG>49DMPTG)G]@-V;;[*YEBV3EDXX*=K0ORE0#2= U'H7E
MK4/=+5N+:]'R/#?E7ZD;KQP_X=6W;N#PRN>H(^-ZY8UH,<32C/]'"'G_9T3?
MW?>EW)G!:]\K7?O?V@C;/!\W3UHIL=RJ4_@\W\8#X16AAY(AN=EX*C,Z5EE#
M95<L+J65E22F[@Q592E=;_F$R[U7](M!%O61$RY O= 5J*<'/2F>\Y*7CKTY
MO1RB&6G/-U[QO"4.,4IP4>-5C@549/AOO$"?84-(P3< P+L; !%PXP7D/VWY
M6LVUU+++\ZJKX(.&+!L1F^JFR3T;FPOPOH]GN-_#/0KL>!LATAN=)5"FW6O2
M.0.U<@4+[]V/U: 9J!@4.*TJEZ&D9!68!&ZX0.5:KRO$CUPL*?=N<XVSNR2I
M8S*?(X*;#-$^#<#<4;=O7\2U(Y C3_+_KQ" _Q7B\UI]L&>]7U"L%"T=K'HI
M->\*N//;S[8!G=3G1SH)M#FA_FFB%@5R9Z=Q;#I,VI]6S=?R"7V/_^0R/.HA
MP!37_OV^HFP6$&78W6K=MX9;P]!B6#BX/D[:2P WX%T-WR=6GWX$$-Z)Y/FM
M8)T438+9OKVD=3_L%[^C/QJ7#WV[<A#9_F_SU7FMY-;16EXCT*1' FQ3D%OG
MP^??>^PKFPT%([_ZUVCW:E-I(I@EVV;<C(7$M727U4#,V? $P4_6W(*V_KBR
M8?+:21;H,S7D>,<P>8B,01'(\SLD3#?RHJ=IZ(?DQ)V].IYXW^M G6HR?&:\
M^=L-M2L-M7M-]&\)H/'O^O(?5H%!:6KW&FHY#5$IIN4C_Z<)6'.,O:Y8N(PS
M1_>NPRC\IK X4[ > U&,.-(F<=CQXYA<A-,<=4U*WSW+>+)%@[Y[%:D*8I!T
M$4:H'DJAD10]@VAO]4K9UDTPAA#12,F^!F1_I:)Q5L,\B/L/,?AKLMX _E];
M[Y7[0X$GOQNS>-OXJ.D9E3U]88X\/U/ZZ54\8,A".<\;P-/0^AM  )5_"/M_
MV:ZGFI6[/D3M ]C-J-QF;;0>F^SMLJ=L>@/HN ?LBOLO.U;#@]S*\ _[LK.;
MH?V_0/+_%RHX_P;I/\U!X<[#AS< KJM8X<BCOQ0_^5]\XOY?E/]/6YIG03[$
M<LO?N7?2O.@_D\/[KV3_VMS-!#]*,'''3YH$:FX (:*;[9<T$NT80!*&_[_,
MK=0WY[3^"=?_7PK!DGC(UE5Q"FQ _"R?OE6(V!O OR7BSK\5X_^P$\V#%_2Q
M:A<LYK3POX18^S<A-/Y-C_]MN6C^^*>V_]3VG]K^4]M_:OO_2VW_=]YQBZS9
MDS6OYOABH):%$-PNF?X(B;3>NN0"$TT?UP>['^P*8@E<^P#'ZK3G14>A<Y.J
MDQ82R"5+=!)*MM,$'!VSFKK1X&[GMV*5;;8@-\73'#!1>A:ARII*LJ1SN!*7
M 987"?3CAUL(!VY44.^;O(>A.#>U(H^O%$.M=OJVU;[HWENV)HUG"I#'M<NS
MJ^!'61Y)K0.)]]N8?\BLU&X>F.3#38;Q O/J$QE6=LZ8<X\6ZPF^ULDR[;M7
M1&61((\+W8ZT>YIL0O:_S.9D;;_.26(S^I!%_,Y:WE61U>,V5K.=:A1S-QO;
MK)[63.TPL\#YZ4!]NHWA]>:'.*ZZG77O]--Q(NC[UBF_QU#':3G[<OLZ"UID
MT;GLPHH&0[TZ5U.D(:>AH(LGGAF2C !7'.=X2859Q<5DM[<='^WXO':F]G9$
MG*.CUV5$-#1DZC.)SI[Z?_*4%PA&:?=D>H^?1Z.ML_<N0[YBR5"2,=\MJE3(
M=KV$YNC4J(X[G_+B 63=I==QX1Z1DI%;>HB3H.UY2Q5M:ON8[]^'UM[1"^Q0
M4HPT,.Z^N5K8,VHG:[=CQ\<\1SKE('QE]4-)>?OV?;RVFZS8.EE.GY9W_"*S
MYG$=Q-,AR ?1@&C[E5!QG?0R=)6E19%N%8>M+('?5I@+[MFIXWGEPY(X@L>_
ME321]U00H?,LFB?%813VE[$5]D3+VC;@CQ6"SDD!VTICR_%B!XJLO'\K>!*)
MY41;=E0;=R-8_;4G;5J,+59$RNFX^"-($FD'=QWN]$\0#3:BMY'8L:FN?3#]
M3Q1\39EUM&;G2%*#.O';^BZS41#.L1UN YP?+A S[R<&8>Z62@\I+$&T\G8=
M:(<("V]D'=&NQPP2'8O%WR/ N]2K.8GVPY]M4;;.,894JS?-B>12PQ>5(3&"
M/W74&6G8OWRXWW"HE$W6?<N8<H,#1,4GP99GZ318KNF<6;CSA[JXCSDC/>_4
MHJ\1TDMSC4 X\>9=6#<LK$U QC^\IE6L=\Y;[C(DIO6<>_BA+._/"]PP_M<L
MOW_W\>/.UMU"<7I""+6;%%\+4;@WUV*+("85TYUU$]!2]6A,>+ML@>?%O;2H
M++J;77I"@5&? [7;580IL/Z8 ?$AB\+=M/1TW6(IS+/6#K&F@LWA#Y]MK9-U
M)Z4#SH5R8W);QCO;J<4=28E\KEW[+]DJ0/X(X@Q6A5,"=6N2:=K($=8>\>(+
M<A<5MS9&=,X&.Z/)OJ<,>_BO%8.U%T]:$^>VS4%8\S5I@NT_7KOUXCC31[=
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M+)-"I>VV%93PT5P-N@J^WO!: 7WL.%CJ<-,XU/E)UQ9'G?%+;(8G&;HB]P8
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MZ<-4>L&YNHBBEF+7!^[F(\3/[I!F)V[^[>!L\16';B/'@LJ6H$/X\-;+^_'
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M;P F98^#V;5;QUG53/[8KH-[I(&V)\289VC3L@@1=W* 5GOWQ%::A+SDW@T
M8<EDFXBU#I?'61IU!N*T4-/!O*X,30Z"6%WU-4<O/#UU!4-V?.5&>5>Z/U$E
MU7@0M7W&.3^*;2W<3V0X/#DJS\?EL4HVVD1*@,HY-:;H$IZ5%R3?^_.%Y%W@
M4<*?2#3QNF'WD6:O'^%UJKLE =KD1+5]\AF]R4GX'*4]S24D_$]\]1T2K#4M
MG-#IT[;KN!(J#['E3=_72HWH\>-0F6SAJO#OXG//]\HC+WR!YSE?X(VI5]!A
MP#)_]-8A6!;7-QT\QH<)UNGVNSK_J%$_J679## E %S.C[!179>V6'V'\D[Y
M<1PH4$S].J(V3F25TM;T5=78]7UJBK*+_,DY$'72MI'RQ[F>-T"A.+?M [#6
MH'9CA;WW#!W5>4&I4;1J/R?#LVPO2-?4<U'*&2MAGV#\7/TEEI#HL=A4$SLC
MQ@EEV^6+VVL2%]4B9C=W3O R2J-EVBD-,>,DO$/A)6N,6QPSE-(!3JC"D=,A
M:-2U%(24G)>C8,$M7"AB_48D'SP7.0:C*P(5BS;45K5$9U;U-AD%W]/]X1&@
M1"#-$KG8?IT-]<^&7&DC*\+E> KL21'FG%<ZR/,<LNP+T8BR^.=(LV_1(##_
M\5 *(P/>[VSRO&\5:5AJC"O*?+P+%EQWF6[L@!5''<4WU7QISG] 9%+6<_;2
M ZFZGJ/#DFKV\1[E[;I6-8=AST=CAZZZ)?70]9TF=:F.OC9W4:=.'TYV8H2.
M[[ND+4-':-X\4AKL%\?YM4T[#-'41=FLAGS30LCSO9S^_:PA#214"C:!;'VR
M'A+<IG>DCE<EDS_HDI.X,H1\/]A8+=X<!7=>^J:&"3I5B,?7P3,TG9V_J?F>
MJW/%D+RA21A@CAC@0$6_P]TG$M@!:9ZGHPJ#\R'8G=U.32_VL!91D? R=W'3
M$A_&$=GH\_+3K@(;HIP9@"?N$@%]P76VG"]]#XP0_4J;T/Y1?72-3XRF:EJM
MJH+R4TY[NEW*^$>)3M>+T*_DKP *4;EM?A- >W--,V1%2(Z,T&<%\7FHUC>(
MN:#*DD2IJ[%$1P-L!,Z8=^_#"/YRXI#L+#LM]N\- BMAO:3"(D3V\VVB2/GD
MMAHAJM^];<6%0XE2:<0?EKGU:")?ES]NH8ZWP_UY^6Z:IT5;L+RR+Z!:E@5
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M0.46:YS$X<C.Y&2C8KUN$C<N"80_ Y2Q",.J_2GK;@U*OCWTUQ$5\[5^[0V
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M31]B$<O!BBKOMR+=)MBMWL 5,J*9/^1J/?%^19^I&A5^=/86L2DY:2C[<7U
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M;$&YB@R?M]C^0 $7*X.6NQVNU5 _<4Y0ZY+<X>IP@E%G-MX!HO18FD$@$S:
MN(62/F^RVCT0RM2>%Q@-Y;?/)[C0T8L?C?Q81-FDUV 6_RF0O9=-R/G:8Z$W
MF@(M P;T.4KY=]]DIOJ??$Y?!#?WW+LNCE DQ X&GW,8#MG062_Q+)M+O/?V
MK.7/Y%;8(,FD]N[1NT?*0#XV)C1+OM9H,T A #*23OUI)UV4*P^3]\5 KUSQ
MQ6<Q8"90B*H%052O6]^G=8K+-,_+63HKZV44-;LF:3K%5#CH4LVC+72OUS#^
M(NUZ,B]O)8)CP;6]/;<-V-CRQ?E;AI]Y=OAWTEFW_\5KT/\WL2-!9(8J_ 4,
MDMNTXUJSU.LW0__\*)-!VEHT_.(Q%)$/'BJZ@=O,$#^JN0*5['>>LLR'S(Y\
M0I4?<IZNE4;WU:S-S]Y2#H!0_/22<&ILR\8N"&R8)>D/9,76;XF.<)E\D:L6
M%WLJ=L37S*CKDOF(HR18S?R?2/ +J7[QG%S^\Y4<#MX5&1G^B>"JV].]R&<%
MZ4I)N;>AG_AFQ^AK:F,,.?EL*&50"VZKOT=P,>#PVF0@W[0LK)(_?1I[,*W,
MLZ[;]T((5O;53$<+X.Q.9)H+*'43:T[A?.26QHW,\DS:KCJHBCZ)7:-M(2M#
M1])Y7-SLY/Z94&GC-I_MM+#3HAV=I"ST4;JP<(\;XE,A:0G8_1G!!;4\?MPX
M5X$[>XMZF7AC?M;RPXBWQOY;TNV_@"AL\Q9N-Y?)](YP@4N6N>./Q'H^%@(;
MC_G(V B70[.[[!3 ;@8M26L#30O\$Z!*(5_:=JU6LSAULF<OGIK=H222521M
MMC,K-[:#R#90609)"MZQ[GI8/OEV>$7I3SP%>MLTCHF$N:59P13_Z":(^LZ]
M)^GRE)]*[ #D #J]/7ED')$>+]S&T_09ZJJW*._6^[*[HTFGP&V8Q$%&AS0V
M:RB0Z?DMY=,PJAP/E\:V-ZCWRSM8D^U"Q_M9)X6^0PX3N)E^V?4-&Q FC4>_
M8.)-=_N['P*2<OOG=QW;[L8KB>3O/YH2!_BC(@<VJ?=5UCJ'X+&5* ^_KM'S
MYZN?NU2S;<9(CQ6>657-6 ;%_KM)J.U/[*'NG)C<V$]6SPQW[X9M5R7T*XKM
MZ,5?5J?/R7A*_WO@&[SAE.>/%VJ;S::/U"&Z*-)LT/6&PF^ATP./[LV!2$KP
M]POO7'],MW"XK$&N2V-3]K@L35/5>+-[ZGUV8(;E][$A<8##(W0QG97EFI56
MZ?[<ZIJ-_.F<>'F84[LC/#=>RKHHF ?BH)MMCE)\_KVWRI3]9O!-DZ;D?ZD,
MB(RWO8,CIGW:5W&-#TC3T%_4YYP0A=R;YWP_0+/+Q^:9KGQDXLY+=R5;(N?U
MD1"F7^]6HY4LWU+HF]MV,XN>+WPR.^AT>^61%L#/4K$??),0="&Z+MFO(OP^
MF%%W;@92.<19FAFS3=_!_J#C@O);1O\%T!3>6E5A<;>E_ ,$:KI^0Y-/F38E
M5=2I2 >X7,%$$BT9!9173!'$/\DGRR<*IFO<E7=IU@RHBI$2&D9+Z1[.8IN/
M E(XV26<VIK:HG]:P8Z8]#Z:_G8@GPR?LKK)\Z:9Y!U=O%P8U(L_1:\Q6511
MQDK JL3<?!O^D'P\!)@:6*U@:5.4_ZNEHIQERI<?[DAM3YT>VF3G9UBU6V/T
MD-EE_DNM9 D"/D\AR4?=8 WT<$KE*;5B!YP/O8RD^CX#D6]R-S7PD=MT@S-Z
MQO%8[X51V[4^_),A7Z4%\+]H&_@+H#Y$_2RN\;#E79#\':Y!5).L]1+,=M-8
M\Y-Y($D/D\<5)__6#11W'0@UK?ZDR3C O;13Z#>>U9D;2#V@Q)>ITU&;66@\
M2^;<%A^0(NCB==IUCR:_T8KM: X6YX-@)-TA;V>;<MG_"Z !WBV?H(;;LL^+
M"\7O'SM"/1VT09NJ%3<E:?W\UB$5'Z*D<GJ+N-(WS:(#N.7MEN_*>DA3Z9YM
M* -8WCC2ZI+"IW3L<><#'&9QV[CUXH3F+C#=Z)>ZBB%WCE4E'P2UG9?R<98-
M0+FBA-9_()(6>!]]F='L9LLY'Q!RE=OVR].S+"X5\KXJ%X!VPA^;0*M[-[CQ
M2]W-/ *SIT=!5.Y/</]#?ERQA#=22NJ_N[0 =H2"W@A.?$5N2Q'R'T$N530E
M\<<0YX1UOP8\8*/7H)SS8C0,\=R&<+IDCS*W^C/L K1O:V;DI2N-, =ETH=R
MS=Z"J$G,&&9C]:UTQ<O;(V5<DN5-!/\"0A*YBOW-+^H&D%2'^173%9\(P?H]
MBQ)>!F_.S11\Q\0RN7:%'61,<D:>04I%F)I)I@Z0-%?W:]?=VU0RXIM3_IPN
MGOPH[VA(UVZU=O1TJAN7_NIK%G!\^WNHBL7=] Q[EU;=N56J,"=#?L.73^G>
M\* #:T*?SI))E*(SZ#PZU39R0DKW5U2<5YOS6/Q0VK/C4TOOI&/^0>FS-4P&
ME[N<8%^FC^D6;ZZF(_QJ8DD4:#U/>]C/ZQMK(\_'=RI'4N"#>2^PO#%\NWE"
M"=.@6F-D]YQ/O6KD'TXS+*L"T1JT&X0T^3^G^A0MY;=O7:Y6%6PK&Q:PJX*4
M9I[BD]?_T=#SG,<+SOD_S>I;0GSHM?R.*.'O +UF_[$DFW*U OR5^]F<E>4
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M?=;Y8.NNV#IU<UG16#=KV-5DO/+8T>=5+ZU!6/<NTO6C&ZO*T*^6W+@O=/[
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MV!7I8,]CKHRJB/-@FBL;>XQ%X P=-%A_2?SGAC*:>G[]=LPM$!=CAEAV^!!
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MPHD> 3?+6M-ZQ:UNK> 41[$^3 9@_E3<]$4Q\LY/H-$7:/*Y=?RO 9W^ML[
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MH7/[__=F_4]_^H,9_C3U,U!+ P04    "   @GI8&T66<LKJ  #)^   &
M &-G='@M,C R,S$R,S%X,3!K,#$X+FIP9^R[=SB<W]LO.J+WZ+WWWOL@(EI$
M$+U'=**WP2 (H@=!B"!!$&6B=Z-W$9U19_0^@S")P?9]S_L[>Y]]WG-=^YS]
MOO^=-<_GCYGUK.=:]UK/?=^?SUIK[A;O-@ /GVKJ: *P'@  6/<?P-TR0!V
M_>#!/]=]P;F_< EP<7%P<(GP\?$(2(A(2(B)B(E)R2@?DI)1D!$3/Z1]2$%%
M34-#0T).1T]+34])34/]ST.PL._;X. 2XN(24I,2DU+_ORYWW0 *@@?)#W2Q
ML3@!#RBPL"FP[OH!;/?]Q,7ZMP+X]X+UX+Z/>/@$A$3$]S<T/@0\P,+&?H"#
M_4^O[VO#[^L!.!2XE!P2:GA4AO;XG+[4DE'I7PBX'M?VT+R80G)+O?*+)B2B
MI:-G8.3AY>,7$)26D9635U!4?Z*AJ:6M\]3(V,34S-S"TL'1R=G%U<W=/R P
M*!@4$AKS-C8N_EU"8D;FAZSLG(^Y>5^+2TJ_E957?*^K;VAL:FYI;>OMZQ\8
M'!H>&9V>F9V;7UA<@L$1FUO;.[M[^P>HL_.+WY=7Z#]__[$+"X"-]:_R']I%
M<6_7 QP<;!S\?^S">A#\SPT4.+@<$GB4:H;X]KY4G))1!-2/T[_4]A!R2;U
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MJ^?(['C[$!=?WQ!/7X]O?<SO]16/"XR=#$RV#+!_;+_IX:WL0\9W9Z]QM"[
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MM-[.F=)[RWEWU@*0?I'S1<R>?.Q8#:@&=.&QT;7Z@6I#Y(#21*CG+]?L]NJ
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M!NNY:F9^5Q3X4_S*$M^KSX/.>O/S@50WS5\:Z^8!-H YV @=C! C=/<=XBF
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MY5I?=W,96,:WB"^;.G%Q";]6L:587IYM<4I-:%WNJ/XG+6E:[9L[\ 2(KW)
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M_>ZS'5Z\Y[EX F":Y7K1>)9Y5+74"_2:]U*17<!6D'#A*TBO9-ZW4?6_[D^
MMTL3E23+,!?!/P+\#4\ :*CXU;C_ +ZZ@::*4\!S.[(=>JW^QVF)C[<-=Q:A
MGG&_5,=Q;]@7>_D8<F ,O^VW#N:%*6:Q,N1^*2M*E6I\3FSWV62 W@I#T+0T
MKXKK)[?X36HUUL@VXW]W[W   @UO7?[ZTZFKZG;,I@P.;E#W)^.]>5_<#3[/
M]5V[/E%MI*GBL.4Q_:E&K/&IW2Q9:5VFJ+JG<%?/+=F#-52X.>%K:)THW1.@
M 8R^K&D:9"0T,YGB*6X/E:Q@D:]MZ<G#%DE:K@^!LZ3PZ[73%^W^AYHE$=$\
MW7>>G7\.O=Q,$&\-@ZF0> ] N)1?<<X3 ,=L$:1)GC[2&S@I5?P\'@9,G7?!
M@ 1AIHV21J;]MKEE$.$3B'^Y)V^Z R-ZG)SSO1R;WC-2&(ASF6S<!@Z+<?E\
M"<:X;X-7>LOVVJ_SO)^W.Q_ IP0K696!'!%)0R"NXMNZ17BU[3TWRL&4J1U%
M4;!!E&1B4&1F%!6LP]-LK(Q[O+M6:5'/>6(JN%$0!>\BZ@3N9;-F;*RL:J+8
M0Y,5XSRKOK=/PM&-P;@G(6J$:6]&<O>EZ1LOGP"A$@NI=JZALT')5U>990HE
M"\7$;Z@ +8S]\X "&+E3#/!D2DM/:5#D?U(,?OU("-H@$<K'0'$Q9WI.\[[3
MI6:]41_P/U_;O9C$0LL:S0J9V*\?=;8P1"A4G/*%)PN;R5Y;$6<>D63-YG+]
MN*HP[\,O_M99^BOIV+_>!]E%R9MCM1&OII4R.DB!H(SZGBVA@"=OZY_H-&P)
MT+:<CVZG[Q\B];ZA):]#0AB\,WL"7]?6A@UX9;HMKMIJ43EWPDB78-)CYNMQ
M:@1[^J/I$1=GZ2)>7/T/] H4> 4B!XQD4FJ.Z_8/\NHHX=GK:$"RQRNJ/12K
MKVJ\X@N3,QU_13$CDU(YIB1,WI=E4DIQT/B@04]1\,KH X2\,VRC$B19:;%S
M$K4X3Z[#I4"C[)5%)O#LA;%EK=WMM<&<@Y1TJ?&^4<E19T[9XNL4O[86O3>_
MM&:S?@3CM-2XG2,)@R\.7O'>'@QV,C3^F<40H22U2V+U^D)4W#]0BV;%C%O+
MMZ&Q#KZW01?5V*U@S_@+DIV RXV7O$MAG^MCIOGHBS^MYC"AS5+=2EKD>Y*>
M*9YDM^:9;9AVX0PPUAH>Z).4+4*.BJ=SAIC?%-4U9PAN5K$K,%BZ)K,,B>X
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MB=EKI^.^T50+E(EDD8GVV#BA@@4X.DS/&PQ5L!4=V^H2-YX B,J"?RPG& .
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MROID7Y@9H0</^A'S;[^G[[3091@:I)"_$Q\6W_<EL-__6K9G1N*O>&O!-I
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MH&RSA)[HF4P\5&STS9 ^+7-$+%NGW\W?Z];,^ADK-KN5^P9Q4B6T;+&:R^U
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M-D8<'9?OOQUL?F_(?CYP9[<F20T64Y&\0=%?(9HTPFQ$&>H2-A;%\ EG=AX
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MU 6<9M?V$SW[Z043N#"Z?Q(S8A7NZKJ4^JF%YP9A&KK68;UO0AVCRM0.<5Z
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M$V:%:8]O7.OZRX(O&0F4R0B5RO>R! Y,M\=5%G+%BL LH4IA#J^G)&<9/1\
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M!0  PF2+ZK+^YE]_I>K #IV_V?3)X [2J]]J!PZV>Q_>=^T^ &0,,(F0V0?
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MOP-_^YI81C]13M3=GMWO65BPDL?2Z^'S;J($,XX$30K;OOT%=<>LLQ]TSB?
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MU+JL=7XZ#\]F[!\]UXOXH?DG^XP64[$:%T6DVXZ='U0PLOB^PQ9RVO!7ZA(
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M\*WB6X (9/FX/9Q(Y4QDQ)M4X6D-LXA,/%Q&G7."7;IO"8TB@?.^OW08 <?
MH*=16<D8M[CFBUP9/;[!7A(K1;18*7M2-R,N24]\J-U8Q^MH>X9UV2F0664A
M]B<*:".T.E1V0]<#@-T7QEW,*FEA)HQFCTM+5WI3T!TMRG8CQC<=3GYD.'T<
M(YL ?D0,,@N=DM^5#:T6O/M4,C$+[30\P4[0P\NOTIL\Q6K%> PA6:6Y:*T\
M!]-$$,'95=TQQ2X?F.-BHK*/W N^4DA*2G*$2!+'B?Q)@QE*8>S0)U"O/.Q\
M_I#1*%??^NB&S+LF-*CI%$K53\?+ &\<ZKE(-?]GV.!R%'[G#P/;#NQ!&Q9.
MX)?M?-GBW5^I.L719FYGJWK;,M;1\979V_5(P!>B)-0(>_)WJ'J"5 T558JG
M.3GVY'O>5E Q[T\+,=)M,393;5&UIXJN&<K(ZN_[/@EW!;-!G^.S4.-R_;(*
MP"*4&YS"!2;?VXU N(B5MA8&E18N,,G2.%Q]10DTG!P\_1'6N997OFWOQ@82
M^'B9_:]"H5?J9=:0L7&G54N)1>E-#6]_U^^@J?)WS/2#R05]I%)6H"BX$SU9
M7Q&3'?9NAK!:N=KJ+NC:DO/3F+5$Q*(9#]>XH\A0@FS!@B G?Z8SV:8X95C_
MDQHEM5!4[1-/%L@CB'^M(Q<;QJH@&S.[MR^8.Y9H!T%^SK1?YM(!#EL5XS[;
MD)RCNVD'PIK%XY5N Y-0NP:)G5-XWU)D^7)1'&R8U+)&(AUKUKJ#&N_4IF 1
M>A6N:5K/>M#R'U-<F;&TZ+9\S)HEQCHWS,7?5RZQU;MTL:?#J/&)79"<3J:*
MI:86ISQ?XG[U5MIB/O&)W-[?2X#=][ S'6]5(-&?2TTH;?_!:4Q;]!&%[W::
M.1;)0YPY<XJ$NJ#'KT&5JUPG(0::>D[FL^X.$7;M.FS&J0):7H>*08(?^GY)
M!J^MI;'@&0:_GC^ (50>WE2NQ,;F8QG .:.6AY> Z7V@\+I$BY%_<E4 GX?"
M_$>H)28UCC+M"F=%]97OC"AKBE.Z^ @L+E5FFYMZ$*:Y.*_AZ@XLZ8X_,+1I
MUCHWJ/.W,ZIM?O WL[S7SVN>Y]8A.N_7K,5T,M9!=E(?WWMOATB'91BZ!,3C
MS$?>K>K2:^E-M^S+_.GVYAFI"JD4R=F]+QI;6/<Y_AT-;*.]^U-?<HST07@A
MQQ110A?#V UV8TBL-1BDWG0+U=,8DAS#)3UF4FBX_>Y% _GQKY46$EQW(!O8
MF53^UM&Z59^PV";E^[,,?>)DZQ$3J&6PA[AS&B7XWDOE _'EZ0*&MR^/(N5<
M&#:Q(M,\<SMNN!ER9- 6ZDSJD4S_Z:NS[1'#'= M*AQ9B]#(O><H4,SMBS3_
M,,ZKMZ FF+B%3\I&\(]9651A35OM8Q\%/HYERWA2#'AG_W"L\19O2;I5OU_-
MY#CWMPKR$50XX5-.,5I946^ZOI73 QWB)@1$!R0,LFJ09X6'DM0GPD2U4!/A
M,"G\W^M)*#/*F"44,2,D"'5!&B1]G*,>Z/O:8?DZG=JKT;>[$SDI[]&?(1:#
M1@1_3'MLBXX*KY5:'430?.:/7SVI64O.T7Z[SJM(ES&6]U%<DO<TO%BR_C:J
M\OH10/B44J@VAB)FC4?,#IA2LZ@5XCIOJG6X_FRLPRFVGSN@+GZYKZ'FH_.0
MWE_+CD58+!S42V,%5>S !YV+@>+7I_)1AQ!'G&*4?+Q+4CW5WB5@[2CPS]"2
MQL@ 4O9 #O%)#Y5V'4^@I]5N/_?L5SQ(5K"WYFU_A/[A/)(ON+06%7CWU[+(
M-Q;8[Y1^%7TALF-9V@XQM0?CW!_\A?K6#BM*:^(Y.20STOO6&<&,A,#I7-Q+
M;.LO,/VQLW07*/$F"Y!IIJ5'13J1*]1=T%34\25(Z&)XO>:%NZ4Y]_L&&9Q@
M)%38:15,\=N::R9=R[;T9[^M1ZF2%HMKTFS6E-9S5:X7_U6P8=U0,-GG1.V;
MK*5L#7+L'60]BW#2/I'DD\VR5&=MF5FZ1V>IG;'<-^H3KL[-I%8W@0:EOE;A
MA) -68O.,1!TCRVHZS>YVOZ83K9-AC GPV0P*Q6KXBF%@(LB/_&$7!P0&'8#
M$F8*8FIU7LOQFS6=Z-1[-%LJGO/!0E=$0XU?!*+_:)(2>>3*UK9G;/'VE8UW
M7#I97K!5/_\XC1[7$WCP@[Z&LT2\%A@3%ZDB"LG"U6$+$-D.:))+ -5PS(]L
M_R".;!O-*?(Q?M5UOLP;?[@)5VFZ%<J.XG)G& 0WYR9VR]FRMJ<J::%HF\,^
M:65X5QF()8OI='@?:>L-5*^O1[VWD_XG0-H.OT^6#QE(;DE41P[R^ B'8\1'
MW,+BO;;_*NA'5"F_.4-4E5A:?L'<7^AYTSQTV"'I89^I35/7-WY495/*#P5C
MPO0P)XAW&+=ST' O[71W0&=V<=:YHF9'UM"AI1ABU@:^(*'X7J1:ZFDY&?3B
MI38"D]![<Z+_$K#W_1+@$C8PBD_"6=JI>&;5O-X=71DU!YQO>+JOK/:U,TJO
MU=B.H/#^Y><.\(*-(.QI-R%_Y(\"%EQD37=5N?M<.0)&PT##18'?[+T]-5*_
MGND_!V=G#'.G+4#V,NZSDZHB[_;'G#Y*1$Y+U].XJ+!>5*O<<BMD!=_853!(
M:@T%<G68%7?'?K/0E<0*?(,=4JG_TN5K\BDN\W F^R,P)[+,;]\9@Y 1V;"G
M=.:9D!DG2..+2Z O\('%^!GM[)*IUB3[SG:Y$,,Y#@?UY/3:9._"$ZQXE'01
MPS)L#DQ]W",! UK^;E]A0_A=/-?#"#1FSGZ(I- 6JQ!T[]LQ?"(LQIUQE.Q5
M1+LTZ(2:V%NB78&H&V""?^?J5*K 7SM,QR5$+NY9]#.7)!7=>F(RH:BIX/E3
ME7*'W*@,6Y/1^25E*GV==Z0(#"*.MLG*6G-CJZ9:+\0M)\NQ+.,NP A;T;I<
MQ\</:AK-/1U-DK_PC&D&' 11/G/[3?/?!ZE,'!<MDJ':NM86"*P5$*1Z#_:%
M&%8E]QI:NO<5$_!V5-2=;/<OU Z+/A3T >8;Y>/$A$KSA5^AF7]"@OABUXA!
M\D:L<%(U@O &*-):: 8*PNRB/ >JZV/-6WJ5)SU$]P_VZUJ"[%IG/%[1M=_L
MZ);@X(69OSQ<?C?>9ZWB\P'XMP(*PWM60X@&Y&;XI<>?L:^D-/TJ#VY\FQ82
M*+7VFA8R%@G/(=&Y93.?[P)N&6FNA*1ISA1I-YH>]/+O6%,'&D-K>UI;9\<>
M;%W8RNXPO)9 ]^IA#"(('DAZ BUF["56?(CV$L"X'3R>MMC-R1XMZEXKXA"+
M=0B![_NZ?U<'.N5E26=2RS:<%GDV04(&\G[!Y##=]:7(,D."[[SG\N)<GX53
MXRSK74%NS>$WE+]UZ8#.9,N7 .>#5#BF>+\7N/)=&G^,O 'IG%&=%9>1[ZZL
MV2^/16OE!ZA>@V;\[>B7F86 UCS#H:$H'JUA!<JDEA2MP467=/#./;]JUL+A
M7T3OUT$02[GQM#=1DYO=<-P 9@.9(*Y"/NI9/OY)S0VK^*2S2[OV^QB+L"?D
MI@Z _#ZIB0B$/,T<<PE89$;))7>[K,$7E95D/KH"+0?[S=.RW>PSPUS57_\U
M\.<6?G!8X?\LV<Z]/_%^>B! 506.#\0.]O&RQ5P""+=7Q*:['R$H+^Z)U+TL
M9,PD:SKYZ>6%7_3RTA=6["]JB1NXPN.5N_F#*VS8E;AZ-\,1>PL+KN'T;Q_L
MW[Z%-H7+"]#:]4"K406*P]:"V)5F=*VP"=9@^+-TV+6= %&&!"B?YP=S2\YH
M1V69=/-!@1&<%9[SY>&7+^)1)JCO9S@X5FN5?@M7$=]JQ:737> AK4V@OT@H
M@]CW9OC36)1*6[O!L @9H%LE;8Y2U2U@#\I@R5>GHQ<O5P9)7!DTF.N]U5M6
MMQVT,6J+"P(^5-$D__QNSE!3:[RK#E"7A)+;#UTMXMR14^'%,B0J*1?C!XE,
MRL_5VZ9@B]4B14Z]F2L =:! MB''[?Y72*$[W7Q]B]95J\L&."V$OQ6#:9S!
MC ?!P#:4W]S^B$O'8TR@(=N05K,..=(GQ,D?,6Z%Y8WP-\#;B[,O#:+.)_8_
MXJM4*N@,%T"+5%?TN%R[XQF[-U!+<103N*3*ZSOU'^S$)_>K\8=3\A?.<0<^
M^[9DY+S<PQHALU744C9M0?P1QBJ0L'CO^4!>-5_QX#TVGW2U/;?5)#@S1,X,
MS[P*NK:-)%<"HR82B")3HJ^[Y=#G\>XM8RXGX.;;NO5MY3]]RK%B""-[;A;Y
M.^$@_<45P7=WG3/*51]]><'V+'@55R6\CDQ$MDGSTO4*6!% '5B#*"71T.+?
MB'FYX+@DIP[/?=K/+][$LL235I(R\]?H .U##'M?ORS"H=R?]X/HH1J><G$$
MP5+(QQ&<;CWC;B'TS*'UI/LKY<^YM:7O:5NL&6_I&YG(GE'.OS$9#P#SPO@A
MA><HBH3RW_\H'TH.Y:YYL140?^8J,U/1_+Y(;>!RVX^FH+Z(;CNO:TT5\KOG
MIOB\/T?Z&)Z*.+]!K/7:"+L*<R9G'8_?;.K*K/48K()K$=0L;:\9T!C QR]F
M2K:CW_+%)G5%@MNPQC U/A' &UZ?0Q2$S16*X.51O(D-;IW K$H(O#]@T;K4
M$5?/;VQ>6[#_I=UD45=)/[F)PK+A/%KB*QG8"O\7RX5")G:KHWK"!F^"$TXJ
M">S^Z.7[,P-$[R#[2.?BS*D<??!FH61=AP@9(=&+BG)*\\>O87Y-JN]&3#]B
M*!""57R]KL](PP%]/(#Z7!@W<=YG5X$A@: 35@U1'^[EGH3*^-:#OZ*$*U)Q
M R%^1W=;<Z97$YYDHP06);_USUV7^DZ0N.C9ZS99"XL[4YZ(5V)%<RJ!O40<
MIJ$2WE[SBTH'S#I<\NG7"F]OO D FAG[+=9(J?*J[X31U)T@DQ:UDEL-F*V6
M78)O:I\9Q!FM/%QMZ\QDB[6(2X<>9G%U?FJG[4F3YSB^_U^&)K:5B2WI=[+1
MTX Y\O?VO<I+F&SVQ4C(Z[S3J1[^$2(=9\7R#GBFAK%<97X#'&RJ92F4?=A:
M"'N<&X!%NK&S,\;;)2[J1HE,Y+IPOTY_[P\@B1H/0++"7=+8H>)6QO1N+_'^
MJ'$[O9G]1:1V[ZQ]QV?$P5.N#5.^E.AT5?N+7YYWV-UKG@CUVS!4EG].I$BQ
MS^9SN3Y+U\>F$H7(%*YT=#3=3-4TOO^H@9]Q-E0#JH>5W;7&EZ_)0[W=V1*H
M&O$V*[>F,HG4&_E/,PU[-N)K$DM6I6U$BGT^ 3C&G,17+P%)QZ#P,#H8V6YP
M;JR(AU,7/K 6/W+^8H:N<1F495MAH*@@G>]4Z'"?<_V 8ZF%28CL@.E1I$X?
M=Z8S'4TL.2N?/(_PQB6 &[^$QI5C0LQG9> ,OQE0M8']YJTGPXBDP#L&Q6.X
MNYGDGM)17KR*@7>JC+>X-/7%]S+.54'#H&@%XXSBQ44D/K!_A6JFUK_G$6X[
MY\^NH2S5B% )[X.$1QTNO\(//C]7L9 !A+IS/SA-4;@3E$GRCH6N@4?^P&C^
MZR6 KO<AI'U( LJ#D8N0%F=PSG #T^]W&Q_N-/_ZI65+\\^YPK,\A^DS0R2!
ME"0)_*L\5T\[O?( >U$1T4+/KCDE0O"N0>[*YE4OCXODL$FX!%(L[D!4:8XH
MLDNHRHIO'RZI\@-"[]]*<71Y["Q@P_I>Z)?J;^J*3 #_>Y)=:PV,(+HBL3L(
M+1Y/!&)CTSZZ*+1'RT#\QA>?'HC(Z0B4R=$^$".Q&GN@&%SGI7,K:VL%A.]9
M0\9W4H[\)#"6.Y>J8FP[)QVLG@09_37LTGV1MSXR=JA:F?7A4?_?IO=[E.$,
M'VM78U=NI6MF:,R*N)(>_8!4?DS]@5@TE.RG[\JT7V$U3-A]C_$%L_>?._PD
M*+1@&"(<L: 8Z!T$C&K:7WC98GA",?^=8P2TTB95R:,O)>G+^,CQ0*%O&AH>
M/TV<*^2_R!'O'2^SA%@,Y7WLS(M-"N#O;.SJ:&K[K.4C66+:KCK!Z$_N8!;W
M\@-#%WJA020D0/P;Z3''_A.KE]FZ@/%)9D3O,WP8MLLPUUJ%"F,2)[W,9SZO
MY(;^8GUXYO)']':<?A>MM\\8/"C'I/!.XSWM$?"U1^'^K6 @I(/P$B]?!IGO
M#]8O0N\NVPVQ&=_,[BT6:?N4OCVMP_/+L#2YIOJ08Y,KET[S^HPJK]X4^!J!
M^J),Z25F%_<8+U,+R3>;F69@T@WV['9"4]75V32H'BKD?S3^=:0KMF$LDI1Z
M'DY_4M0'YW6%,_7RJM7N,CJC47_J;J<>#)Y%6O^T'LIL*L-\J=$V!CCP7J_A
MN"&A"HSZ%[4\*&6P4OVE:/'!-%;\T^4");=.O94<CR&84\;6 -9S(:/+@[#&
M]W!'. XKM[=6@I_ !4VKL+FQ9S[-,W[GX.)0.W@C%8W804B;>MXA+TBMB6C,
MZK^O0[XU[_R!@7:NEPQ_.&]UA;Q) R 66\Q!_(GR':0!ENXO#&BQ:Z6)IL)I
M!-%1^,D>TD_;>V:8<O13.NK5.JT&IKR:AMZCC"4*@RVL78RE3%T-T'HR,B&A
M+@[]+H)QWY.8*,BKC 'WA".%%RL_,*1PX9RP6H/B\9< LF,0B=M\ ._/1:<$
M03B6O_-6QPQQQE?F?2U+SI<OZ<-\0;V6NG>RJ1Z,MR8<LURDK;5A+E+VZY/K
M18E"YOC(,-:P 7><T-+WV;M1>T<4K:(M%M(DKPY91UC9MY9S0!J&JKPR^"X<
MJ <?MRJ><#,L4<G/GY<#LKJ-M=K%;#_B"M%U4XR09L.8!XVWJDG:O].5R/(6
M!)A\@&RMFF+;A^:Q@03^W#.I]NCZ;A'FI\"70V#GCO:B?8F)K@T_V=5KB[Y=
M\FN4<T(?& I>A]DO(5DA34=#(!8"V&$MZ;1;RA_U,E1\$/M[7Z!V<LEGIG.,
M[\FP*I5D%=#RT\:X.Q2$9U]#TN_T<B8-@=@]".JH,/K8\^NY+F5WB[S]'KU%
ML;=3"U-//UR('4Y]\)TQ_\_J><Q_*V5(CNH'BQ9 SS#*?P>9@]8B:ER0#/[*
M3[:TVXA?;FB[B]5LM.FZ\#/SC//FC6_NC]F0EM::(^".R@%K(V F\1:#>! F
M[3?O#:"\3+6IM.GZ;*FP:]MWT?JG;U.>W'FO),DJD)@MFG=&F@C *C/C/+/T
M,*LS'M G8A]5*,#7>@9,@VQ6'YQK@Q^L'8153WCVF,$Q7V]:X2(P</6YDXI9
MOR)*R/U+0+_),]'Z-_[:8ONB[F597NEO]9>, E*0NPHIGU42PK"R$X.%][#\
MP-MS?O2\@V<O6]]$_EDS>E$H5ZB93#W5P&<<FAA=]#93\24<<$6*0<-VE6D4
M^'9-K-I,&>-RREV<8A3)Z_WEEO<4BS^5K\]$>CF3?7EUD:MD]PD?"@6A/9/F
MSWJC[$I6G,^LLG/>M-U*V%]9%NB]=X_=4>B7^[,[5F,=R8BBV$N @[ !Y<1J
MTC@76/9F3AKJ,2:VW9LG?J%^4<OU3L2&WB6 /^-+B<;K1IH?<;<BFZ .^*]K
M2 :H/29W$ YPMN:>/5'V?-(]!]P:ROW+UC"4KN3Z@N-5>B:TGZ#<.:O"B3]8
M<V='7SN(@/'A31Y/GVQ..LT?CQU<=VU:65C1HKV6(VAFFZC]3E>0_\92ZO47
MD]<.8L*:'T$EL4[A_HWHN[,&,4J 0HH;7.+"^VH.;5G[%MV#S43EQHW5BTM
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M3YRU\,Q>BV#+)2 R&@P>K&B1E82*1[)UIO(TMI2^R*(QI6.C8D_M(&L-Y=(
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M:JJ_1GU^U._\.(":E8;M^MV'%R[KO:&]X<HNY1_[_:+ H[)FCA=#>$%I2[<
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M2_*%#,G#$94S=>J(#%.@;FOZ]3?R%B4P3E&+]0B(>O98<35&RWLAIIJLX$R
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M0__Q.$:'.,H.L)C9#H<$=]O"XJY9!AE5#RMZ(&7QJ(U=8&"#^KL"NQFQ<?B
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MI8G'!=$3;41,R><A!M<8LW^]MP?+,UR0W+N _K\H?\)+HSADY.V/>D97O,:
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M&7PUT&8HFNNSMYQL64NL(8BQM4VNUYA/KIL_K!A 6@*)M@,(N7XB7H7K(;C
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MFC-;DXZ%!L0$$$A1@201;Z4(H0B"&%^(:AFU1::<O.D)8\P;IQ]K2=,)1K>
M4&E[1R+Z&0]'.ML!1S_$([_7 7@VZK.%&&H3$N-X*D7C22=F!0!/B.E4@/DP
M!LH2J0W?>H<X3Q)H: UWB[+SXBGEWJBN#VP*45!3H-29F_?6[,6H@Z0)GL/]
M0Q$JYT>O1S&E<5JMP$)*7TNY*"J7[(BY[Q^9>O*M6Z1+Q/NJX2PL/W#+(MH.
MP$.)6L%NM*$0$N8TH7R0%ENB!W46P$U- 6/FT2[/NO5';O,WX7JS@:<,5)=*
MY_XW%2CCM:/(%BHX, Z%:[>J#P*NCL(""(UL+GK6!>O[C@NP9/ON%TG_Q);Q
MTRT.^,5WA*YK10=98QR?G#L@K [4K[4AT5!Z A"P:N1CM;*IL?BOY@J"P;BO
MC[7<VN\W,YX[W.2U\'GQG'<W(3$0=@;C$N;'<]7G#3\SJ$I>OY6UX/I$^+N)
MU.%5.PY-5LK=G9E]8G*3TX2/\-2'UW9)>K:C&<<%&S]__%CJ8,(A7G0__+YQ
M] -6<4^\M>#@:%UH0#M3ZRI&>(\4_[C@(O'Y\%KF][%>/S^P\;>-3*YK<R(.
M@)G%AW <5YK@NJ"7@%/(W0,,&MX=$'%',-V'VX8_X9I]*+)1:C1 D&63G093
M+&&_ N"WF=]7V(FU2T:&(W+/LV["SK@(NP*>N,<PP@(ZHZZKJYHSAY;[TT;G
M6<M&=$/%%9@5*!AHK,C/C1!"&7!']",E1.I+1&B'=6H+H^O--^;96=KVQ28L
ML_:%@C@C>L736P"2([SK"%\/_5O32V)79UJ*"4&0:UM#!>*FT]'+UZ=3SHW_
M :@_<Q(?P9F7HD#0AD=+B.;O-6C!MMY-')@UU7S%<XR5P2N@K7O6\F1$P%C:
MY"XF:?4ZG]<LKYFP[PV$.9,N<+!CW_^%$89IE33<[ >\YO%RN 5TT%?5=H+I
MM2)^3'"Y*6EELEZ/5D03%RQ8X>P [_^EE./Y'THYVYK_4LK1_0NEW"X7M%I(
M9]1POBO>L"M(!!;QNIB-XA%@!2#2K?37@"XL/930GP%=S/E]SD+I?Q49E*9^
MI+**I$@1X'X)J-"F9+CW'<[QXU]D!F#^ST$6\-3VP:?NA"2[%3.<WX[?TPN,
M$\T^=K%;'R:[NT9YR.$A4U2["5;*+L IU2>J@NL6\'&-_EK0>^9[)WX("&H%
ML5]>\=9K&L<) D$+(!8EUPD7RJ27LQ_N&,M#9)6=U(U<NYC6^?)"6/_FW0%;
MHLIO..9:2.X._4J"?$V\[O2(1']PY4#AL_$TX:8AV>G)BT=WU/W3U;0@YQJ.
M@5'3E+_M,IQ C!)]O^F+Z*7A81K*0ZHH)Z>F/O)\Z?E*@F60-D'BT_YRR0>"
M7+YR(_]C\*7R*D^(,/HA,J(4J+?\=HET<DRNOMR]DS/\IV2]X.H<I%TU8N[-
M(E)3-M-N^)'1T.\XFMVG[*HZAP2\\2(EF2Q9/:W5Y!$@A9NDPBA"_.W]-CDF
M,(V7T;EZBFNMQ"FJZ+57(OWL0(?_LU&>=X2YBPM&*F@;_0=\#=$>[_E<'N[L
M :-A6\$]SSN2J1+RL41EU9/K4P6T)K2S&L%H8\)%N!L"2?DZ_Z.,J';A3H?Z
M%\<!;GTQ!V7!HQW[AC.I##A.F/0J'MPR(8=28JKRD^SPKD_61-HV1P;2&Z:#
MB L2L+>8X$Q-V6/\]$+83;I0<%1W[ZNJQ9F/?^_*ALYI358@\B?_W(TEI!9Y
MF24,/D.]_C-]*_H?AB$$G,<VWWRO5B94JT3ZP@@_<Q49*6 8(OU9$@XZ"NV/
M0C]B?']TV8E^L.CFB,8 O:KG%<!VI#:6-PUH^@:%BDBM"5XL@BCOG+O_+2"1
M"\&#[FU<OF&I^9-**DY)@R;?=$\V@]?)G\R5*WW.B>=_VV6.#4 5T*R,8H,M
MW/V<+?#7B9<,0_D-\S[U/9849A.E/$@#U,IH&1OTG0F/IQQC3Q _Y3=XB)-6
MD?1IPS6C?DV2S=Z@3Y!I?.X8J]6-#UP4[UT:7((U)'_Q ]=-6^',CL/PVHX2
MPA!YOLX;-+M^7^%U=(4V*RM&F9BZ=XG>S@59N;')*WO)\4LG.<YB,(>9N-:3
M$QH/DGL.D44!)3,[L@LF2X9SU!&8+R(VM$Z8)$E=O%E'U(MVS\6XRNLF>+CV
MWW-71#A8Z$U4B& PK3'!L0"&.<6[!OF9<987GA=.^@8_A56=&6+()? J5C26
M;'72_$)JIW75YO7?ANES,\=S6G\=@O5^DMR^/T@*O'X]O7__XN#%373O9E3,
MVL!L].'B.,660$I:S,]L,]H#\&]A,A?6KZE$\E1"0+7.H+_VTE6>_ A-ISCZ
MR+W27!5/G$IV_)#Q/0$!!0W=J[QQ=SM:2^S,CF/<&>TYH<0E[80WSSN?,YSA
M%/ZY-\K2NA633;> \B7#)6]B"HMC9MWC!7>=]I6X-S*9$+-"H\5Y@R7#A06#
M%W= )>MGF_)A?'+)BW6ROK](JH%OTK.+AO50#W@[VK?=@55L_IDN] M-]/48
M-\3T*G<GRM=A+O(MJ^\K]LL22A$"35'<3/YH-:Q^]MS=<]Y=]9U!;X>&D,\6
M2IKL$?HX.KC?XR6MLW0KH!-<I99-M9'GVW=8;:@S9<OJ%2<EQ2)W7I)M%Z>F
M-<=F.-MA36XT5T^K;LSW"A2#^?_"B_Z#;/8=5E)R\XY<^ZA+3%[OXV+O6!_V
M]6/5'W_]4U6=BE%[__%"$\.9^4.MDSN\QEUIV/H8S#,!^1/N2I)T0TJ-UW6<
M8+/KDP5Y(O+=WL"79(7%TS[)^:$AJ=/":O.S=]Y@88!!;Y(WHSL.8-;,ODL&
M?L\C\UOV=P\S^;W>%$W*Q<:?O$/6][M)#88UJB<^FC5#&\(VAV264A__^D^T
M=@06=0;T*V./.PYQ]Q3X*WV],3_/B(B\=_+&_L2EKBVP:-*K'[@Y?L1UE*U
MQ?('+>V)U2_Q/L$3ZA]*]&U; F8@#(W'3+Q*Z_+T \Z3ACA!DOA_5IN!;8WN
MA;#'^72\D9&!R%]&];K+' >PH2+:GH-OT+]Y!>NG_L7<5 L8=$A\GOC"ATS-
MA?_HSQV-*M&7^GGELO1R+DB6Q??5LS]0X>F* C+YW^Q.J>_R[AQXWU_^%?86
MRG>/@V&WW341!_SGA*K%LP;+AK/*WIBZJ4^CA8X8B!7)C^PU7)R724QL:PQ
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M$V#XXOH([B@RB&=!CVDM.>;7D2=)QQ>B9Q Z9/"U)HK_)@OUP755#MXY;VS
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M+H#"B,X!"E0"*^E&:3Z;=%,U<M(SMRUQ\K/K?!HX]=Z)/K)%Y[5,FZ!+(/Z
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MR'K6Y4(W/E;:\:6$/M^-AOJ[#JT YU'+M8JU*F>WTK+]9A=)0)/U*/]N@E8
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M_)<R/P_RP."1Y0F@4Y8$Y"&6MSS ,*#)/S3^<C]\Y?G3;@/;C7<F^&%C4^!
MJ/_9"39XOS;VS;8Z=BN[7:L#7^[J_>T)F?[>[WE2TAWCP8_Z2X5Z ?.DII#5
M0'2BG7MP=Y-_OK>3,%)]@N'&[, !1M#)Y8"]6(M]CT&N=+@HSD5POBM.M,#X
M[ZM=_^?>-M:F]>D[ADWA"PZ>:LFR.M?)M/QAB\]7VD5AED3E7J(Z>0%>_3;
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MYTJOY*D<*'Q-O-'K[QGP <:*6ZAT3>'*":9/]S4'L.:_O$!/P^/WX^]I@Z)
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MO&EIF)X?\(5CSNK]B<N^TQ=U\>6;<%8O4>J=Q7ADC7DW\KF^RPF 83B>DO[
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MS-R9[YN'OO>E7WJ?LUZVK?7OI?M\YVG^:1WP4DE.40Z ] ( 0'I^ $]+ !D
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M7*8_^=!BP_0E@JAG\= G?4U]9E@YL'!%A#2)<"6?><_UQG*UQ4=0L/-V-@*
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MC?%'J>*7"$9-Q>7\4S_3D"#"0].7O.-H <H([PU_"1QIT;?^&^BP^M+?\>\
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MY3^_5G_?$N9BWW,GLVP@:UT_H*_8JD2Z)T2VE*-T6JBWV,5'.)GIL8/9V21
MS5$!P7\=$5U (W6 J^;MYT+!S_4G4;V)NN/TLKP4@F&O#F2,#^F@]V)[T1'W
M\[U0V=Z4530-"WNAXO3V?2N2*I^=VJKJ=A>X<0O3]O+R2 :U2]YY8*(T1910
MC:1X_4&*UX4 N-*6*/SC1_(9TPXPYC*%O68/J\")FFNV?#_T*"_[G.KW?/'R
M]$R4C:K&Z6W&.V-'QES=K*9?<QR1H/0YDVL.'V@O#P)B&'^S=::'].D+U8]I
M$,95&8:^;--UM3AWBY]60!_C%F-Z#77(E!W4^,8_-SK)X'PB.U/W9PBSE%9$
MM2%#7@4#0>JGMS^R=@1\!1 -1;-W*;DD96YC1Z\UIYC9^\U7P;:G-!FE2Z.^
M@"2"X%I-,([P^;'!CQTA3:FK8MZI5RN[KQR1XI>WIBHT=EO]>(1)MJ35?Z>T
MD09%!_8^J#ZNWNDU-?-WTB=%ON/B?W'[J0:("]W9C#.UL/2DWA^]1AJXB76N
MW2)!B><N-]$/5RJX=FK( SX!@!XO^2D9+L'>#R%-#V!Q4K\G@&.O"9[[E_?B
M=:>TE2GW66M=STE&([54V_U2(M?\N>:C0)>2^NL@'=N%CV"9L+@S1]1R2J&"
M'R/!:7PD/K61VA;QVU6/29<V]\3C2G%/  <PB0+(JWII,<GZ-.38E.60D\J%
MRO30D!>9&E#!HJB4IYS;*R2DRN($&E8;&8AYX^;3W[1O:&CW(P$ENLWT)[YU
MV?6[97BLU(1F]]M$&4X<?)*R.>ZJVMSQ5VFM*24<T;Q,7HJ45I(/#L)]G@:)
ME2OCTCSI+6[JAKVBML@U <L78@>C1>%4JE C@21'-#B=Q*_K"MXMXM/IQ2S?
MZ0CW2?;0.0]_2D_=B ,AQI]L(5\(T?QB?Y<U7BB'+)Z4$@K(_=R*+;1CNK-'
M.G8T_V"&S=8N4'D:K,^TEZU>-K8G"#A7C?^=P@;R)7'EZ5$]8,5E\[M)AS&E
MWE"O[LNC(W^]*-F=[4LCCM.7JV*[+TP],3<@7?L[5,6P_35YT8^BD'R]1'#\
MO%1;^V'?/L9'*Y')/_XF9CM^V_*,Q_"5;KP10+M2QW%]VL\YBWTDCQXI+@?@
M'\BV5B9.88@048(6-O8T%XY\4J1/\XFB"::I&XWH[8K*5W%@<?R\FWK@&T!7
M"%>V]$6IK^[]#33JZ5$BHXK5,"G</-81!6XH\,677B$RI;R)90"_R=!I+I?_
M2N![@$EKHZ\$CRI>1Q>@O?12D&^P,'J^(3L[!G"5F!3V5AM)L?JJ$+G79%.>
M@W_V;C%HYM6:BDGTBJ></^#'/ 'TF72$>1-VOU>(0??/G]>)+DK@1J)3C/VB
MP-8&R#BK+C"*=T-7_QP&O6^?SF=>!0)3YQE9_4"MZ*9])0$?6Z<+X.P;;8T\
M(?2?S*^]KA9%=/F_Q=NG1%*6./U*H#N,/3254@H3$]QDX[VX:Y,8N2TC81Z+
MG66KL.,KK(\M!@GDWT<VORFFFB5:,GZ;XGA_I,=*'E:G: L;]'6@G0^MJQ[@
M[HPQS=ZM<397W&'^K<DKP1HQV?!]$TA?*?I535)83WN+Q)>=PU,WW?G,1:7.
M2VZM%]?21 7%#/.8](3>I=EU?E9V.L[6!.,;75F"O:J)5(O$ZPO:+,.VR6U(
M[=<7!,QF6+-JT3;U*?I<OSTCB/6_T:H+503PT@^KAG@90I+78B ,Y-JWVR72
M*BTNI7[RLBT7#;E?I@Q^?'EUVB*:]6"GX]3%QDN(G!WD7$?9D'9-8(%]+Y.@
M[GL&T.:Z/US>@=P+'?YQ9GT"E/(9LCG<)2TR-H3JH32.L93:LS-%;R19?A)<
MYE*TVRO,:.&X$,6Y^I,@3 *PC+O591$Y*\Y=8>5C.=-QFW.7V^L^_T+F)/+H
MN&VF"TJL^FT5Y\W2@9R0_F:E7FS\F_S'2>N!!I27EB@TB-T*T2'AEE!3/V]#
M=MQHPX73<O,V]L>?O]ZE.0=&<V-;,*4VJJMTHCZ7Y\O:IVZ<'LJ0M%4=G7=
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M*'&+[?8S#^UA/D\K_UDQ5>,E_KB9VRDFSI$:6FK7]$<N60<-@Z3-_EC[:[O
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MS-$ 1?_-)C*'$H@6ZXA#QXVR<IO=Q7_UZ1[P$/*\9,]%^"QA[OK03&EJLKW
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MNJ3KZ9AEC/.+'J=Y[FKPWS(R88&]:*:]1CENW38WYW@[M]KF@\B&YJT;\E3
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M#(?U_-"\PL'@DIHS]\O&B*U70$R*?O&>E%^IH-<*\NC@2';.3!-S0>M5^'9
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M;B%^UNN)3$YKCC:=J<6.VI^K-!7;%TX/5CZW>;;LKY'C5AO5BMSQ5X1R*+N
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M&E<90.^:Q;O6M6U*.<3:Z$+CI'Z&E2DZD+!GC)3A*X:9.2I"XFXYF*7:54.
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MZ:G2JBH4YQ:CR%_O<,_G!L49:^@F" 2_-U@,NG,%(,L[NY6>E7//:[=;VOS
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M_W2 B4=<"2.!_RW:7R3[CPD6_)^2[%\$^U>YQ@$6:BK*QZ/F ,# \:VLR+/
M_^VI^-$J5C5,MD)RJ*.0M7UE,: A QIV_?$5AE8/,;&7D5TCM'U(N+%/IMX3
MV;P7>0_M368#4+[2!<Z5+)<L&&Z_#V:<_G1!U>I>GIN*C>R;YWX!.2HJ)='B
M//CP@<"@)SK\(%S:,FBZC@PT!W22 <%LTJDIL:-1!$&^F@S,>?=CH\WHM<@
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MZ=2_Q+TE"QS@FKC&[*RQ95X'D2$YI3H5=@\7B2PELR]+YH8M)"XJ3*U/QZ8
MC!=#WQ*5BWL)ZUB%5%24I6PLWC$^Q[,\)Y/Y8^Z^+H/1H^E$"B5HZ2)0%.'J
MTU8RP,R'.!!!CDLJ1X)#NR(Y>-LK[YZ/!C0_5J,<A<]2=X(Q3O#[%"M_Z1X9
M"(D&$Y$&1!ED-&3'0 :,*PFC6/G5L;,9[(*4PCA\%"E\(8S$0]'F+2T0KE3[
M(F4]?*&\K -$,D Y4?R1)XG'H$/^4"P)1+A#>777#N+/ VF(CP3P:((UB ^]
M%'L'@7%D)P-B Y1"L3G>8XX>=J(,91SS?GO7SE)3D,9_:&P"E$(D/@J\]2_9
MRX@_-W3HU@-@,W]JO?1W0OE+<%'-(?XD6?:?A-I=>V-&'_,/YOA/4HV6FNN(
MJ/Z=:'\WX?\;C6U)FYUH/MPH!N*R@3I0OODKB#5N+T]IHE );3Q\_VZDMW?<
M;5W:!PX7F^D:6'90(H0S%!XJ->=S'&-&!I:+OP=I159K>![(V20?1U6B#V]I
M^20V3R"ZGPZCU^PIN&#PW1)U_6]FFZ/%*GMFR94ZB*!%!D0:I2EZGD"!FP,5
M2]R+9( >/3?:CMA3< <?JE2#(F;*JR+ABGCIFSC/%XTG5],YY952-: -UU;Z
MS"M+0B?Z9A9.*PK5B*I("3$!^RO2X-;1?;_B%WG3,\N#;KRC*@.]VNDR46+C
M75^9KWZKOWCS6KR:&K;\-\.>TY8EM+8Y,.*>C9*X<3&=,=Z+*1K^'G*"(567
MOS?#NYWO/M?/3KK+V#1K1N^B!X]R.7I$2+8>5%H7,R)X>?KB!18A/Y0D!V]4
M%^:[F(8\J$G1Z#N[:5_\*?NNQA;;!?>\,C) 2^=6;J+H@.L+RALIET:PV<*R
MV[SLW(T]Y5*A,NOLR9P/M>&?!KX:?@W^V-S=#@28SO4=<%9L'N(IME2OPC=]
MS98,2&;C"DGM1Y!CNEJ4"%P/5PM3M8STY'"S+)MT0\D\MIMNYPIQ$#5;?T#C
MQ&&'^F.+(*U/?QN"J2<#<\G!%?+A(';Y<@_QRYX/8%\/-DL>\YWZSI[K1RL)
M33T5%BKW"K>KS2^9GJV.>_OIK8R>IHE\)*MR0'&%M@>!&L?;#F'3?.[M<>^A
MWKN*>)F)25Z/3KXYZL'&A)R^T:W<8IDRF<PW&%)1&%IVXL>,%UJUMX1_1&KU
M3J&7M2QW4CK,7(][5>2L^=]RK7]*5-^)>I2%3]^&V&.CL(@!#P?J(U$RT)U$
M/$<&BD]2UI?Q*!K^[U7IIQ_"_H>I'A66#)2KMJ9SPG5& H5-,\;&)Z]DP()G
M[M1!4TL8+W;^..EQR3%-G4TZF!"!<\2:4E0J?%HVS'X ?LX9(WW,LZHWN)N#
M3K&_^?W2*4V]A0-'>-"C2^(4V(;ZZ)K!'GOF^(W'YT8VN$X"5@69"^4TSK4-
M2&DK,Q6N3[+TX/P&6NAVW*8*LLKL#6 _ B.ZV7#LQT%K%#A];22L W0@\:^H
MJ>\X'3T?!J,G-3U''$JX4O?_4^SFWT\XS_%-$F7*PA![&F[I7VWVGQT%UXOM
MU5$F$8&9.8X==]E*:IC2GLV@_QN7&I]-F5MSJ:/\ S,ZU7\8XSK?]Q\(?5&W
MD0$WDQO3%,* \7@3V_)KM;VR@YNA3?C+-UL9.GKSX>@]%%18NA/M.O@$-^^"
M)!@7J9&!REM67V+? .5_A:3_5K+2FFOPOXT;#9-39A74(TW7O>)1"5WV:#9C
M=&PH5:/.O0OG(2 +B;=P(>AP97F6JM!UE)C1.@?JYGR/(,O\.K6;2&B0UM^&
M*&FTI#L;&1#=1H0I"D.S !]"RU#W_CXO@_U^,=L$R3B) BGNKZ-(;_KL%_Y(
M X'-W[-_COV*,87X ;/:?Z!X<.<C1]A-D" <AG^4F>.F[N5 N-)J61M:Y55$
MZ#@R]*_35U30=1&NH^7;FGP'DFYXXU@<V/MG0XF?67]"^^4XNWB#>"4#+HW_
MGLSVSNG9L49GH%S%X$;Y@46778[3(]><K_&E=#=[XF+U@( R7,IAYRV"U>Q$
MKP)SH8?*G'Y9RHC@LHUQ.-;U9%;7>H_:32JI^*?0PL\0VI6G4&VV_@K&K+)@
MVSH&*5CYZ@NM4D7]SY;G *I^%Z:FN]$BNX5[;Z,[0!<U^Q7+'D\A[;PS&*'?
MR(!K.@UA!JO:,F7<VDB%5T:]\J[;^M)8Z'6J)I*:],7@2W!Q:U!KAA2?FM@0
MQ7>_ED4X]458.G#AKE:*2.$LP[";M';3>MDQBKKOGJ&_V-N&/X@UO%XW;C^6
M\&VJ)V!M/N7K#_1L>FU#Z(M\F$_+M'KEE_Y==A9;F%7;C.?0]:$I7:[-2RD_
MPTZ<X^LYCZDZRZ(1>723@CCZ(LA 67XKJT_K865A(8&^M;:CD.[M/=OC*R:1
MOGOMC'>VUFK4@/L9QU&^QV\"N1$_T13VGC&:!]LF72WR)]6[_,7:N!SQ4*Q-
M ?$\Y3,$4E"6;@:[^Q\"MNP=)%I<;MO0JM_N^E3DZT_;"&B?!\.:FA63=#U*
M\3@+?NDCK!#S/#O?3>4F9+H+SQTL\^BTFA2JPO?=AR3.7-,'>=A4H\*IW,PU
M9S93X6LIGY8_5O"*KSM-U[ZW:D$SP50[5)(O]!8Y.*P8^SX5"Y7UFT.\+KXL
MG'5#_V*O_X^8]WX![WGZ-[<R=04VGZX'75 P%3]*.9#?NXT30>=0S)!%_:!+
MU= @XWK*0M.X!,V)!K]Y#HC]:%C+MC>.HTC]_/O*\=[<T5\![+RM/Q_(O9*N
M_3+CGS.];#UVA[*<#[<QP9&81BFBW9 V#^*^@7_>RGC#K[+G#S\_W/$WUQS\
MRI'.)Y.IS[5E2%W#?1,42^).P&C-M%V2J*OL]Q!+++[I_\#VK8C4.7%3D(OE
MS1P7_LU85^J!L\57,.BV5$B$C<5^Y>$-5#:?G9CMREZ+Y.D"9Z=G+K%ZIX_G
MGPO'LG./]E/I<44_#S;5U6'6\S5X!7;S9( -M;]V53&'\FQ-VDV.V4(<EN-;
MW;R>4'FJ\/VZ%WJ7&YD)S*;4H8B!N+XPHA]<'.>^?_A*E*<^]<:04TUPVS7#
M\&]+C&9M(CJG':5.!&F=IY@ -A^L/#%<6XQB>KT[25'N.- 8+^EZ%<;T^#$%
MEEUS:#CZM\N#M-/_M$UA]4PZ!+=(3$3R(D8_)).&,]@V(J7[ L_"G^!F6C2F
M1"<<3(Q2;SV_0QG40AU'R%'?Z6C.<'J)KJ8-BJ$O0%TB^./G6B&G-N F(B]%
MLKW87CX=*9TZCHM6O9[!L\7O]8NJFBUH,:-3>7&?# AIRTM%3X_W8$22Y5[R
MW[RYVK[7OX(2!,7K>GSYY%*J.)^FP H$L.K=&O0&K=LKC*]-V%GSO[Y456<2
MW^%?R.8KTH:\K&?;I[:I(^)[=/G.2@JRV9.O-<?]8[;#!X79J/QRVPPN?6-V
MV;?4<7'O\>^'T\OVB:\W 3+PDZV/ C>+((06+UQ^!Q]%=_[BN#+_Z-?ZZ3/,
MC:I="HC+KO^L,U_Q*ID?EU.N5JG?2!4I@KT5';=%E05K?#BR!25*'MP>RU53
M3S"+W:PS"MCHAO?:2,<3?+%%GNWCD(E=^Q.RG/QT=SEFHN+GQ(4PO)ZF?JON
M]R34/LJ^RQ-]A?OAK)];D[3GAFI009_,BCS__?$_V&*A;D9#T0>\) K5_;F>
MAS@'G1K:8,(A_]YI!@F;3R(*$HZ'B)^N_96&ZO!-TU,<J>EU"O80+72@H._C
M?,3H&_3AR4+M_TY!!EM*O2G6=-TD%W:JG5=;:) H. <66K4,$BR *V=U:UH>
M++(J>ER?*TUP&(.(!DY<A/58_-"\)/7J@;U?CXFGPF9KI?;Y*/WW=F&6L=8^
M'+\ZRQ7>B'OW*5%M@AD;55QG>#V*2>UYJRD\V0]T:@>)NGG&SEYL?DX7QIL.
M/RI/NM=&^^F_\PDX;RQN.:#Y[76FS]V,>&X#<7S3IH/MD?P=0EH/1BL.[[%E
M[SYDJD2ZML)<('C51>*N*G-;"%6'GM\" *_("AP?@CJ<&-U=Q'F,Q!7H8N_4
M*^8MV[Q/LQ@T.7=")?WE C[IM-.L8Y$>>#WU4U^>[1VWZ9/!"+ZV\<QA&8G&
M"4_..T+7'1,>W4'C3FA75!0'=JL*5"+GU(;:XJY\=&^41K:G.+?:\!H;S9W.
M>2JY.2UO]MC 09IN<>_BZ)FAAQ6LJAV6EM,7$RMT/T&,\Q3'OR<O*C)@MZDN
MHYN,0?!^>FN\1H?*S$E-;IQ7V_,2K8;&0JPT<WGH9=73,$DUM0WI_L9S<'\<
M?;/$4%^LIJD;9@!1;1OPT>Z@[DF=H,5.UZJ#%EYQ%AG2"#+ /?TU>B-TSGZP
MH@%\#6D=AQ@4X J^%ZS;P:9UWG-"<4\E8:\TK-4U[;R(@(#NF_=C =F],\B]
M4;YVO[';,MQPIW._N(7.:4P5V0S=0!;5<JA*"#;;IPW,0J(#F0B)&&\\*)1H
MX/QQZ8'70_G$;T\.WG5\JQ9:1/H-CL+]LUQ55!6[ SR]-"_T*E@W:P;"I\TD
M?G"_/='JQM>U6$R!3"Z;8]KL+T%4J$!!"!0]43)IHK1:((&*']"XX.1MW[LM
M1GO7ZX>>MU4ZC=PC5.KS.NZ1]"=.9VK"S(9N8LV?EFA"O5A"*&"O[9+,A;%+
MIV-ZTY8Q6P78\_K<$WDY!X_2&[BA#ZO\=B#2RXS?OZ[>*AYH%%^:/E,UZ#*T
M(4KI9++&MD"1^A/=V=5?3E_H7V>&=ZH)#=&W';,233RS.\'OI4J2S>POGQ.#
MWC:<%/L8,,;"*%RR.5Y=AQ[[WH$=-!3],5_Q@)ZSW8W/V=$IJ0843+>_/)A\
MF\#_$6IF/64'BQUG?3K>WR+W<">3B_UL3:QW8I8"IV\XG6#CPX373RP+G.6,
M]WNE%J2+UO9&QN724I8<\AV'7/#:2(^\UH*>3]:=]R[>CEPN/JEW1NM$Y6.O
M=6M+,,<SZ+N*LQOY]F=_S@AK5A!+.LJ,RA7>?I][W1RJ^'*%UBM-GF""P*;3
MW%GB6.41,+_Z[E%.Z>"K)]><(OI+]<6_P6L>TE^:%WIIH8P,ZOXX/7-#^=T)
MR/C4F%U+O]P0=YNY?ON-I\+PUQ84.J'[G>[24G^/'<+?UBH0::RE[FVU,W2O
M2CM\)T+3**=]+^;P0];Q!Y8$:G72NN[I,J^FKW$)DQSF4X1\DPJD":)"?,[\
MC9[;_ 6$6J)LHECPB6"OH1/U@XM[_B=MI/8@X0_*&JOB\BK3L#]<S*7&8YJV
MN;[(:=_/?VUJ%PJ,[*#9%@<_PT_+.);%[1A7)MV1*8K_SFO-$7]%"/JZ6KY:
M[H:.9L*(1&B3]%/+1I2Q\L!$@/)SV_WU)]/VYC_0T<_XBHKE0#9#(\Q/L]Q,
M!CVBOWS=N-34=8G_$^DBOB-Q%L'@+B(^+,F:;VVKU7W1,#7W]LV)6U[ -YU9
MEY1M6<&]AZ;L*S9TF6Y81@</$>8[G(Q%M[K?ZG'A57;I"4E/84L6WC21_2.-
M5,?9&%(8)D#5/FE<2_YZS>"K_3C!ES)>NO-)X MGDD.%XG[X"<4B"YW-BVA*
M6#M62*LVUC.Y^T802-11;>^B1VR/&>%#AEL*M7O9]/DL/9J^A_SPG5,*GVV3
MP7+63=UJ^^VV0_70_"F=&-AR3J]$=[FQ?\];U?*7!/W.>PG#+(L_K=)<R0 @
M)^.15U:/I^'=<^^1R,DWBO&4[:Z.Q%IL[\<[NH3?T^&C<:H<L'D*%ZJMQ,/]
MIM.+KP@]G>R57?BP\3Z94=Q3])J*<%-.)#X8%-=W_MI'IF<*Y>_%;.WMUV4_
M?ZY<V0P0J748+]U>>Z::SJVIE=\P[*/Z46CD=53AVZ2KKUL?.;N^ZBT)GZ@1
M;-1GTVGNM!6*.B^=R?)9@6%#NEM>FZX7>@]K,501,+AJ<[56US;*6?ID$M;W
M^OL+WP>>SGD&9$\WW+I1)A 0TO"IQ#E4.?K4<-!%.[6O,#4]39F#BF/>9/]]
M.3F(:YD>E]6;.[]Y[I84D6MSCC=:FXGTO1^JS?QC1F]XP]OUX4)-K,3S"Z6&
MUH%W=;[3*_]"X PA,0Y*!-0LA/\G 66??*>B/Z^L<B@[20E2UF&^E5' +\16
MLPSQ@)M%DA#TTU?R8$]!7 [7\I1*TERQ#A8Q$SDT3U*P:!=3=EAJ"YBIJ-P$
MTJ*BS3M2?J2V/H"MB73=F+=H>GXQ2(<>6$P!]LY+=P1RPE:QX,AZ7VR 5%M2
MH\!+D_Y'2=_=E#K>]TB7GSLKC0[2A@L=6I7]R\&-$R*)<S,TX/D<XB,*#/\$
M.E8>&_V2]G=Y_?0E5G\^)E&\]<?H%.#SYC>/#,O,S=%B!1Z#_C;PU'CMN$IY
MU9F07 ![\*MU-F_=ZK(;[6;4FMR&<A3,\AQ+F>*54S17F;Z]NWNC-39Q%_6'
MDS(Q9 #:QSH#2]T+;XQJXDGGD/=.A0J>(^JG<0_)//)(?F9E-L$AT?/1Z+JB
MG7Q/8C,]/Q?5GO[+V9 ?C?2N@122\2IE=TY=(O<=GBY,K2K-^8X9/^8Q6^^L
M$T>_*O?!'#2;*)B,K=@-(MPL&3= Z6;K8L_,06<(AL[/&_WYY:X=U+V*NF#)
ML?@$*=^$ZO^@T6K3BVX* %W&670VJY<+2.06IQY7/*R*R7\8P>V8<J%)XWQ,
M/FMT]&B[@Q NVYH('=3T_40@ TV\XW.P>MBCN;:31$684[J93J.3L?>O1,N[
MUT7AH/2%[WI X O8E=;L%@>!H9TG']T%:L<Z%V0W"L'IWF=I9KLEZ>9B%7S5
M%E-^Y@B?UTA]^WE]H;HZ\4RPA+QX_(7;>M3B\7Z 1C]-N=7[542Y52N8E7#*
M&)^7/Q<@T-.2DA,J*.L ?2V[(<1#(^9S1)E1>(IQ^K@&)N"- U_\8F<M:RWL
M/=W MZJN]$>TE2]%3,5\^)?3U/OI;_V;(;0&Q<[T+0GHS.X<F(+>M\$_JT@F
M!ABKXZ@]]"$KX'_[;[9V&6Y(TW=,*P[!Z3&K,8Z6;C<[.#/'ST;%);QHVE?>
M]FEC#SGTZ4!,,-_LU]3]1(ADE>QL'MG_,N%ZN#Z=%NSX?.E.N)/=^R>];H3T
M/5%<;VB<S#3_C_JKRH\-$H\;L$67-T;Y#ZKTQ&-SYM2Z9D=Y5+P_8CZ9LJ&4
M/B3[>+!?D<^_7"R7J'FK0E4\YTAZA32'.DXGG2<@(*HIK.^K6 N,?'S\/O4K
MH-X,.@E/*0:KH3PFM<C >4(/!KE6T*B:Y@8W^-@K@N0JLTWLWX6F"J)45";2
M%40_WT+Q+\:>1ZTK'DD33#&0IDT>0F'K^&+,>L4'A?Y)6V/Y:.]SM^TX@LWS
M3A^SPMZK6G';RKUL[TPRUEL>V-5^&;DTN_0@(98)/N#7V+A792NV'BDMW[(Q
M2/"\YG-_8^1U_+>G1C\O259(K[ CU<B  %P]K,-!#)=4)+&3A,(<+388QE$S
M]ES&>]SW8]&&[10;&!-8_;,(ZD>M*@X7ZRL&-P7-DB!R7T_)?_"ZE&BG2,>'
ME*EC.-/\J\&/0N(1+V?*VF>:?Q:#RS1O1GI6,&S*KS\LA\G*.,6<1"6SE@I_
MX>EZX+T0+D3E\#O =\O>YYRPPL4;64&:4*/C#Q0KD(7KC,-**;K:M)-07$A7
MAKB-J]6751^?ZEV=\7PX D*"G=<-L*#('0\?"WQ(=7V9,4)ACY53;1,;K]*C
MG#M8#>.Y$1WS2SY/>IQHCFT0:_;3K"VN*=#-71XX*5Y3[5'P3HU?J^8SA)[H
M@'-![C(^A%_"FH"MZR(T1R._VZ\5OG<Z9 *F^F4J- 2M$RR&LX=_N<W#%F)_
MZG"*!EX5>])MWK%!"BY?R@JZ-!..WCI-0)*:1T&'LH5-""?(@<),"'BW!71\
MSF]_\]\J!0[A5LR8O@-I$3DR@-*0/_YHW_^G'> @C=H#]KUC0A1FYH0U[,K1
M(P_.YF(Y28X9]\/*DOM<--U(DD1<>;RTC]6!EEZ +T20]*.V(BRDWMS+QP>?
MVCXM4,XPZF.I+3!2OK11="U/+%3:U^"MY66O_NU@0PJ-9MZ[CYMY2>3'W00+
M$:QN&)=\MNGY:,KSPCO R_/IT=NJL?A-3M9V':I$4\"1#_5!&7D*BN;0OMB*
MFH K$7Y@9.7O)$UKW>B'R5\/<;GM[;SMV:S*S'>:DPU+]R1Z]">(1GFB.O"$
MJWIEIF39Y\G<J._KOMYTV04WJ"_:;]F2-HR89N^IT<=FC/:D:>%EUV<Z>#TD
M6[&@L!W9IX<M1[<33 BN)/C:B<18>[/O-.XUK8%+B0>A)D  ^Y$^;+M-F_$'
MB;<Y<X7=D:X$F^JA3E(. ?55P3>NE\8WJ!>SPN>PJ/$^+&^8I@%VRF'ZTB]#
M91-'XS"C1$7N<LO*-*>;ZQ/#X&]W=NF%I==G3L$$=?'9;LBB9<O#5+<J8_\'
MH\P)-#W[3A!]D0KS1EZ84<5JD2O!YX9Z;M=KDV<>P_6I0XX)&SU;"<.Q[!2?
M[1D:J$R8,2-<P4M^WS8<T0P<.=1Z\W6O=+Q3$P0M\7W@X^84<]U]BONISBPU
MQ(341R2R_FL$&1%-I,;,4!'/X.M%0 /K2F^+E>K"$CVR)^H_RQ0F+-$#SZAS
M70,II'WK2CTU&;BK 3[F+*?:1K7;J\Y=.,Z5J5?&H$3<>038OH0>,CJ/XVVR
M$)\O9YS049L3NX2RMD6,@TSB<E01[-Z%L,Z3OE9)@[UDX$0/+?@MZEH= 3)[
M=*RWRYS.[#K*^YWD:-=S[Y2A[>@3NU^USF89 $ =1.MK@;NA\/[]0F'M?EJ:
M/1+=@==2W[FPXX;YB':AY7=X<RL!XKX\O6ZM93DZ]>Y0JR-7,LQ#)1_*HI[Y
M2FED;] SVBCV]IU=_DT'(V_\1,>A4 (9>$CDPJLW29RC29']49GE!!S_NNU\
M+JY/>?W-6_H*'XO\2Q+=*D7+J*+1!<>%+V^_*?.;C+;J9R7[*/>01*SEB>\,
M\7R43MB!GUUB>$YH(SO\%1F(V(MZ<F)SHR[X2]<AMJ+>VVMV9EP,DU>5L=0H
M.>2M7_,BA5_IJ,TG4H_?LN5]-.C1[DJ9;><308/S,G%?FJT$7X"N.%C/(<=\
M,.C8H8#.T/7RPO[F9+.!U]:3YT#K&:""8ILW>#DVV0ZWG3)(+#IN W/15^8B
MUVJ+\N/M*!.C:\J<T-L;%29D8/Y;TS%2FU.UI2_D"7-WXT#ARDWE]J$PF6R:
M3P7=:_2K#NL.U*!FSW RP'(;@IEI8_2VUY9H(?AW,.Z]->R[6GU=W6<M8(44
M=63<G@EISR::XHY'6WNM)WIB5^8/QCUZ$$,:B8+Z 8(@FS[VFWPV3[)ORO$,
MV3<>-QXIEJDUWR];<W[8PVBC%J8R/_PH+]GSP6""D7>8TLT5_P#NUB6*F:\7
M1JU>7+8)+)3H);ZBC7CXB)Y^([Y#DU8-$]&\6SRCO'SY<0&*+CT3?R=:3HQ1
M0DA/E6YW/\$&WOX[,&/VOSXHTRAV7$P2)I[';;:OT[<%7L+1O2$)CLANL!5A
MK94T8JZYU $R'*IO$,\O)G5#4OE05=)8,C#>TRKP6>32EU+<PDQ[.@=4O2:)
ML!S(B==J3'7S$%B_R?C6$76&7C-!1Z3HB'-"T#,HQ1#",@%SF,K_4+2^+N/0
M+17V34-R2R@)Z3<[.]I@%1_8,_ZH*A<N^:4*3YL>L>9]1B8$@W^.XLD/I-M0
M->7]:I A3.LW]9>]#]CFNB 94)HC=:R:'G,K^S,L.YP[NN:VK)V)JUSK?8ST
MP$X\+C$X=R?]F2)U@[K*Q0X_+X<1=;,3 W^_[_9WZ:9(HI7%CX<[)MK^ZY=7
M!*6EG\G+MK>^,ASVED "5J_@%H0>+/H4405/0=>M)A>+RH^TY'YYXQ]\0@I=
MS;GNY49'DR"BYE6A?M(V%W"#";;[J083/?%1MT8K-.Q%FY5_<DTZ7!.[.7,_
MC$GQ!_*N@ND]&\<Y.?3<BS+,S,MB;PTKD%P#*FEH[=)2U^<\:P.[=?-=5#>:
M(+781@9$X'K'%9J7Y*-V/0S:+I.!=3I\A85BH<)$?$PHGZ7@*=9F/J'1#4#(
MC(X]^#/1P"7;L5T])BF[T$C,L/-&Y85FSK2X8JQU$ D_?VAY_/\IG:BOPX+6
M#G#;<XB.HL"%>J\Y6;&.E.>I+G29CIC>YU#:R+%O,53G"T-9KH9=THS]L0+^
M Q<1/R[/P^G-K)_QI7#GMU*4CW,GN^Z',DC WK7HM,JH#P_^BM"-[*^]9=)?
MGU(;9O.O4.T_JI"@?)[TT*\I;,@"V-=]H[+0Z?'F32[[:0^F=VXYIWD[OUG7
MOO9/(=RKE\ *>B)+W'RT&?'?1&A%Y 1J">Z>?&[,N44]=@?!F]U2ZR+F7HOA
MBOO(1NFU&&;(#_HU? 94A!JWOQ>:*?G"^4FN:\KWC/OW!?B^ZBFWTFD$O^>Y
M)![K-]I",4=$A4J$D',I'MQB&J*>'B..O]-8/RROZ2G\'75/HNV7Z]SX+7E1
M8-J&->>5>97F:_8A7;OT=C#@FGY*D_VCJ\B9+^IYB>KT23W?GEE'"G\M^A+<
M\UJA@?TR [:VV5@'E,K3R%Q3>IP =G$972/Z9N2%R64JE<%<6O$S?8X:2LOL
MZ1[G-4(\YL]Q7!"LF7@-?8^O"FT4A1 >'6MZX(ZLAC7OS2'#G@N(Q!\&1M1J
M^!,VG3WBPYN-]7_BOHV-9X1V2D<>&[7S9;"G-TH1%0AE/AD0.S<0GQAN(X'M
M=4EW#HC%UN'#,IV$MG^U8W6PWY.4G_^\?T2Q7/^9#23J)B7/ VW$24KSB-^G
M1U'V!NL:GEY>N*A;L2/G\MYV\_#0/O!LU)!7_N4@AY?M>TD&W,F \*IE7*=L
M;W)K@62,Y/<6O;G=3K6/@?RDX</-**)'OIM 45J"X[W'=XP>Y_87<\7UJ*C'
M[F[5C#B^S"<#C&\CJK^6ECYO/ 0YOW:&K2"/(*RT9\V2%4W&&B%^,T^Z KLM
MK0;@-]P>5-4:/W%12(Y79:P3$Q-W!!?Y]:VC*<RJ#,],:NXEMOONMYD*F&83
MQ1\,5(R4-7B>G.(YXIX>8^(7HKSEN[I5'"RA?7PT NP"B>98J>W=*(ASS8Q[
M5"Q@EO]-*#I-^I<:XF)FDD5N@OC\XJ:7F[.W?R#]*%[%.KQWV;(O9UC,=&KA
M1Y4+=,9D(^ 88WK HX0\W ZC$+PB]Q&K$/#\G4'PZG?0,4]%(:0@'4G+944Q
M%I7RZP>>1QIP;X+/;(]DK+^UG.5B6S55BH;!5U&D?K<\&0!$RJGVVKD=6@Y9
M;W1,;XW<KJZLCG&.M+ADI<]O*=)VTKW]+\;6"59%H2<*N)'<+'<.QL^;&:[B
MMY;TI;^BG<E 4-@L,LQ;N?%B;^&,O<K!F\5])L-PETEXY^21%00;8( U:2QY
MK"0KUNJC?C/H?A*)!/NEZ95XIPOTX:DV.^$EWJJCUMB=QT$$E_-8MJURWOCC
M)-V48*)CF[V"VN\K"QFET-"RH"D9MZ=F_):2,B]*NFBV]-W]@,5 48H'>XD%
M']';(98J453'<8CYGD N,C#*@-C)79UI_#?+EZB7\7\\!>IS^8^G)H"-U07D
M>!C&)42NWCR7D =Y=<C>1OWK[6Y!QL!G5(5_R$]XSJTG,OY<(L;!;>P8T<8\
MY8/>(UTDTT_2H(A4U4@%Y&7*TRE?'X4K^%O7XC<,XAS'49Q%+6>O<U*?S'E_
MO/:8:D^J:37 \S*!-:>M\=007.MCL\>Y<MS"^Q(#&N:&:'-%?17INS$33ZGZ
M_ Y,+7'IE*6,3[!HP"LGA]JV)57Q)/L\YX&<JC!3*C ^>UNEVT.X[@0B)'Q^
MZ[%>P$L<:_D^ 8Q)R.W%O-O9+ -)0NAMWRHEV:_WECN__>2BZ;2=<C"#92=*
MI_.0AK^X)M<B8^MU/U]1>K#:VLB#;JP>O'LOU&#X-(-8N!-U8@+-BQK_?OHQ
MYGTW-Z I-X-=_3B3>#L'IC&+BJZ0]30+N_[%7@&K4ETM?O9!]*=8JA5#;OFU
M8S(@KM$$WJ,NH^B]M"5):>**#RZY@Z./RTO_66IVJ04+>B6U!/LIL&_F#P!\
MZ6\/.'!_0!'\K^-O)#S)<]_C.4Q*5U]/&E^YL#0W*3"05[MYN48Z+CHV*\&H
M4 %SZ5;\>^&4L:(!'(4U", -":KXB;9-C&3]*%PYR]?*Y3+2'#:^,K9=JF0W
M6\J",14N+">4'%DO743<<U?WC(0[9DO,,13+*$UI=YB6E<:+Q^J]8_[<-!<]
MNX?*>H8*>5YK&NDR.C>R6^-9K,+8-NH^\+7PPZ>>LHR^AU:AI.%TZC7O8\0-
MO$$(4<P',2<M_;;XK>WX@^\'%HL/.T\_XCMJ3;<;_7:[9;2E/_G+\Y&]@YW*
MNF>D](T[0OOG^[;=0>/]-]V9-)<EGF>[K'-M"EYRSX<6CN4U@G(T!9_OD[@'
MBQV,EVV@SQ("<^)R6YV<^'DN<*E^P59"@PA:>*_KA,*,^M?-DLF??U:-[<H*
M+'FD?;WWPSI B_VR-!J5G:LVG)?+^RQ0&=DZTH+]9(YB,Y+<J M,6AN)<2]G
M.IM5H8G[7XL]T9IDP)/2.1E@UY2>.Q9L$V@,R5W>AIKNQ1BTC1]/'=E^T;=0
MZ<^1XY!TDBA]?$%C=,D9GGWT<*5T>3]-**JU=C/J/GZRI/LX%7-,;6!BV6?&
MO^I#D_V5@5VPYQP_-D@#_//M,A(G=2. U]!$RA#ZKC<SU&A:XVW5AS*I]\9!
MK>\%]FNWT4%6T]K#@;S+I^#7!LJGZ-MM+VHEO1F+X J85KA<J5X@3CW8P!ET
M%IJR\0%3)!=@;-E8-?3YM&!N3>UK P&V]PGM]V?@MW#/WV5:0ZT"SP[*EJ>.
MC'GXR\Y#N3H'[KP'+3OX']G!+$&GX#*5\="Q-71I192L"<MS!8=.,3W)R[U<
MB(OAB_'J=T5^X"<#64?+;67!;2+2N(7VS3!O!J)94IRUFT(WD_&SL:H)JIL#
MC."PQ\0"ZC74N*CKAB@!*G.C5)\D4^;\[!(+RZV[+QVZU*VZ;-)"YHJHFQ%4
M,A5NS^H".$?-A\Y4EZ2,0];%:WBV%A4.TAP&ELNT=W>7EG68__O7!,?$[V2[
M/&>(5/C6";#?TF'+*GU&!GA<4RKZ*TM&E(YZ@AFWBC:RXPBK3>(CV;4=T=\N
M?XJ.OP%P 2L8HC?^1E^+3_]2;4!.HRC>>7"CLG_MK6\(8C'G<^ =1^$I-&!R
MUX%P9$/XX*N=@-N[6CF8[<B]&/7+!)>YU.T:%I$#F@&+IF^*T#O.>H:E@%N/
MSF&'[L<;%^9O>RHSU[!463U%!%JSRR!T?S(!\^6H5\EI,L.RN^@(WCAH58E:
MTNCEJJ[!-5/S5^#5242?D08RT;)!IR/-&NDZ%E/WI$/KHFF!_(;(8 <6MCY?
M&W]V;(3A2>-ENLO%AOQ:=(9<5/,0.J4>#4@$&> 5$30\XSPR>]L5>_MT0*R(
M&O=:XBR"1AG-!6[K$^PM)*KAI4+7-'7AR2/[XV^2/(3<D_ =M]MNU=')A/'1
MQV(;MH(H>O:7=/(?G!EM>/7_QD%27-_Z*C9 \!9AM<":D&I7VK^ :PSQ0&"Z
M''$*T+Z"*</!LBN:?8*^T!JQMKLA9Z).Q4&>$D&G;6"?$UY0 ,L_W<[Y%BA*
MFD8PU?-^DHO)GIJ!Z^"%JL[=8TO&2%_Q;UR8>/CX'2'$.C6:MZ\"\ &7)7?*
M\LZA6_UE;8UK>7GW'C=#/WVV5!QOYUZ,CSE_55+O@8Y1,S4?*HHH@9MH5=]<
MOX3()0,M X//M"[ PE<X85X0W/;R^'H;?H455M+N)3?\X7HGLP*/(P>#&@I=
MK.ES#T-!+!.$_'8=V(W1M2^3#NT(T5_=DW*.<<FG$Q\P&<YI27=IBN'H,0:1
M< A%AHY<K" JXG!8(&?KYQ0LS%IUY/#ALB(U=U'C57/?1W7Z7%_&+TD&:8=R
ME?^.=[_+5J(*^1\*G7,CY]BY[\ $6VJKPKT-7'?6%4:,ZT)UX\7T9'X*?Z>%
M>^/$2$QA&-,HR"GV4.4&@*#2L83^J6P[I2N@8,')\_!3>#=U,"-_TSXJLX>
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M#@VD>AE]R*MVBQB;G3>YPJE6)2N8LNN/V-X48 JO<20M:TCU_T)CK D&I)
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M9HD-=2.;:[:=:]DXU#^3!/E.U^QF]24FM2_I0H@A%932<11B?OA?KE3TTV?
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M):F"7XW_C;GWCFMRZ]9%@U2E]RH1Z=*D=V*CB0@B$#HJ(DU !"1 ("+2FX"
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M<5]9YCP%.;['U-41%SJE[TH^<O;?ZQ+)B3.2X:QU\[<?FE-N2JGV7('0))
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M]>62/M:-:?V7WZ7I6E-:48PF,C(*X](14[!5,;AZTY=SIZ:K.L=N:IHU>W2
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M)Z]EK0"H*6EYI:5B,8L[52%+S-^Z M (+'9SX%I49[.DD8S-PJU1Z<*WW87
MPH%G@Z][^C_];@ A/):&8T(EX9%[6HH>2]EWMVX'1Z3>Q72G8@>L4URQ7/JF
M#N(.+7*,(],1F[!OH(3J)'HW(C^Z)[[:S8]PO_TJY&9G!E]3:;=%I&94UE 5
MG<\;T11E?;4+[#D2E%O,_)">FUEM?'"\\;:31X**H5.B[5M]9TC,_>HW@51@
M[K\FX7QMX6AQAKU>$!FIT7:R1S-%E6]9(L!OZA/S72N'!A@TG0:"J3D]L#+D
MV8BS()L  4X,O\;G6!.%SP)U,9]QR[4<&H'!Z#BBH?XK$F#[O#.93[+],$%T
M$(US45&$N(S%4]&2$IPN"2!2T ;#4E62 */GKUWT)&-$P8M+),")9FXT#"N]
M 3S5V6SJ;M1L(P'V T!D_KQM/08Z#)D,3@#\;QV-7:/^/SP86VVI!>.SF#MA
M9Y3#?V0K?8'<)^HF"!,;D>0:>CC8GCG#^K[A]<FXF<S_3QD!0:".O1,6/!D!
M/)CU)G#4C(!!Z#/B+1 3[)?*+ F@*^/' 0 /Y3*2$> A49I<-4I#,E/^#?^X
MM68226Y4$(P+MDWQB8S;?$UI1_4+H9BEO1,=YF@05G*CY53G]JG (3Q'BPP3
MQ=LPM,0N;5420+_O&O#6/\*/'.M ^"S]V):=*&*BS;',O]$P!_XS7_* 5D-*
MB+]@ZZOPYV.@%6X7$L#N/GEL.2B2,=S$6T!6<FTTEO\(:X4P;\>1N\0674S\
M?I/<<W(.A/_J/ZX!36*14'*S19VZ%H_6R.-;(U7_]]MH'!5"?VG HN'^2507
MSS=:GSLYT!=98)E0:M+8KA)CI>XZHU8'[0\&:@>#Q_T/@#OYSI\=]9$B:&P:
MRF.1D_Z]2,6/D4OCHEQG8%]%F"NSI&WBA8<$)L5K@@WH?GO]CD7:PQ_^FC 6
M=[Z$LJS&;^[CMO:;*=^D7S3,YHJN:%%\6RZ&3O>1 *S.&*8*3(YJ!3J@*T&\
MPV9N"ES?E/,>:2S_X/M;3ZDU=T!6A/F2!OY7&Z7 ],1B57>87)0.\SI7A@IB
ML'!9)-6N"SYW4WL];>6)K_"-.]8BJ=%$4[HN:!G&(I27&>%D]AVCU^#O\=7&
MWC9;W,1V7JEE-GO4QBA8K0?!9]]X_LGZ#\2U/.9&#FC+LH.'_YDJ5+-Y>L\_
M.)?INH]/H/0T6Y=4PS7G=+DKUE2W=ACZVBX%)P;"C1S>5E,LGY( [3 &O"S.
M<+D3?12'R!J\?$\K9>A 4]IR.UG,[L,5.0#X^I_UY";A"1GI6" =WDGY)\;V
MEE+6F\?OVR7$Q"A3NRS^3R13#_82'.FG4=X1MRQ30\([-?Q>'1A.<%.4[7+O
M'H3OY[P.X,Q%PY9U,Q*T%$:WJF;7FR7&152"RG-])1(*LH.^S<>7A"SIEP4E
M0(// J#,L0?7LU"",2(O^ H_B@1E[M#N7-WEM\U%W4_,U@V$]&@I0+[>QMJ4
M;[5\Q3?K+SS;OOIC;F/%.N*NKF3H[HL6Z1R,QXD+[O:PB_!6@^:6IQYUSA1*
MZIWMIS??_4'1J&*X"B&[K+K$.WR!WQYHD613Z_%@+Q@H^#@JH[<5<7V9AZ<K
MR#A@++?Z]9/3@A6?7_ZONRPZNFKSQ6HL@S3=<Q;"=#DLB\__OQW+Y\A#G)]R
MX)W4\EGB#]Y1-)^H@4379_)[>LG(CFZ;^0WGC)USGA6R9,T;YMUP= 'WY*)-
M>P^CE1AIR+-X0NO\9VO;JDJ<?K>EMW3FI^R(TC>Y&NJ:T+POO8. H.GMC.!\
M1[SD@9]4\*]'Q)%ZZP7BAM=*^D.A!>+S>#7Q_(LE" _RO' >9A&/T;D >;$I
M!S!&#\W=7.U";A2<7[FTQ,E#);FI0+&6>42VAE)'+EP6D55;9#%;SFRR]5FN
MRUC>0=%:\UPBK6_F?C!L5A@YV?.Z#'I-;%*W;&):7I<6Z_M^QG-(5I1.\=TR
M47QC(Q.0A'V+;D[U1<E%U./K_1LS)XMC9<IV]F84E>XI^7+I>K5^> RNAS%"
MDGIDO'HZ,T'M36#C[T9-.@==7/?;M%Q6D_EXHX71<'L,4[26[L>YC=^GQW?9
MRQ>K-\8#%8NU+=#/7"D'R0W:.Q$U_$#N\+MD]$Z ]CG4.02BBY=RTM"A_-%*
M"2Z.S=7OJD*R+"9L?BL]>?2SGXY')#7S4.-OQA^[46CK=H>N\B[+N]%9]RJG
MER8/<XY0+1>4@#$V?Z11<FP)"J.Q$0\_;57J*AHZE6CMMSM%Z]&,LX5_</G<
M%1SRGR>3_S>%N G0_OEF,CCH;TKB?Q:7#O]_D-K@%CH%W']*[@G0METS^=TR
M]H[M<B>B@O1DQRB:08R^O0KR8#Y1@<4"L;*.L/7T<CB2&Y^21$UV*&QDUW!+
M%.#_AYXQ)""<[!AW0X7(Y56?8.MG7X_YT'NT9-<U]\=>=H6+ ?G=QQ:[2A1+
M?*KX7% T;/O6'WTQ#8?!_[;C#>!$.M:2*7SF=*?<&:WJ >=NS9\+."BV!3E(
M@&0G\EOA:K!#F^ETXHSC_E,0V<]M,X.(X0Z%?\JC#?3>22-W20<&2&P]('MH
M)8IU$H"Y9>4F>HT0[MER:#9]W8Z\-/S9_YM2.&I R5XZ=1Q712YD%"<!;F8V
MQ\&S=?C)S=K 6Y-[B":5!,@?O ;4%4P[Z EO6<'I7")W0'$1^1LG4NN^8\T0
M=  ^E[83>,9QN$@ B@)"6'4Y3&G#0N?(B,%3D(S2:H&GZAYSU4DGU#,DP#2Y
M42.Z$.\=,F(1&T7!S\C\O2"]:8#<S#?VN00?$P*5*8W^?W\L_]G9?3P%AKO[
MI%&5$ =\M19G'/@X78[/C?'K-2/9$3.&B'GBZ,H+>-[G/"9-)&TX7(L"/7T=
M33AU'5VPNO8H64O[(9:?)4">\)-7Q^9@7/MY\'2ZNPVP<P>\C)[P2SKOJK+
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MZC\N!FQ\_I^;72DOM>YCWR9BX$2N1L7V="/4+*SZ%H8KQ61NL,K)A3[\PXK
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M7('MVVH]94XS>"#ZJ#P7*\FUNS^W<O7'#Q=I!L'K5.C ),KI^#6M29#[CH?
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M/RY-"!]K\([.I1?"I:*CS-&RQ5_L-#;YO'^)3$33F,T"#@S6;85]./OQXNB
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MQ(1F4=5B@[H^!/ATJ%$LSRE85,P))+77ES)?OR;(7!PZ;K-;]G6SWK.X+4G
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M?\A5&P3QV=P<&?D?M+U55%S1MBU:! T$#^X6(#C!78(%" 27(,$)P:UP=X<
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MR('T;.K&6U-WM<CD!TN#N8I:/#*$P$<?>NB?D D ?4+_(+3C;MQN6WP4I-D
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M692>):;/ (>A@>68@]_O7@FNXF,.HQ=W[<;?)+1^^[R:3ZP8:ZA*0DXNGVQ
MJ_02Y2 .OMEW6&9D]BK,/%,OA9-@)!F=@_(\;AB-?0<UAU;Q]1R2M;^ZPUAV
M3GF\E,XJ*8G7XOWFD(BSZ9\+W228=*4"M)O(F,;V?>=LY65AF9*K^TO7OTXM
MH11DGZ4^Z.(SC'Y)& 9 V^F(_7T73ZW;.J8%<:CN*<<,,R9W+[]S[;2KNM3]
M=:O4:B6FY_3^8OW%K6V(#76^"(D+/W5^883TTD _J+=K;KC_A</:H)6BFG/V
M\1R_%3;\;M,,!6G-PL\3Y9'"FDO2ZVI)ZK\\Q.0/NQT1T9['^U9#C]1%. ^
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MC W/QGL@10#8:Y\?^(X@.%UHI_K5F.BE"2UBNSUR;X\Y4O)8P@[M_:W/&C'
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M)ZWO-&:Y^A8,8[N_ZH=*H0$-;MJ8F/=*LC%LTK6!G/IBKD9@#!_=3NRS(99
M'._B^]E597A4*NNG2!=8QIH2>D/:VM)O(QX8%P)58]:QB>HXF\MLO&XIK/<^
MS[+_\/K#0 M=Q]JPF[AX&9I_/MMQKFI^0IY4YQ.G]]H8'I*B;&]>=/)$)2WX
M.2#X+$7)IH'Q3?W;B(65AB8Q #[]-&:1O]9]KK_T=H#7F&9WP*LEU5 P!];)
MJ0?B&R E^E9BE-.1F*B?SB\9BZ9BIA)$!?S\>_=4,<E!<#R6U+ D7OR=UQ?N
ME:TV[4:0,&$OL_[8C=E0$C'RHG^Z%RH^(7X"CHJZDX9:)8.Q4H=\F@BIV%A
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MMM'#2"-EWDNJ$%J*V.IY9@\6_0AF:UEZ@N?EC/"JW)98)\$#5'D_=Z>,:Y3
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MI?^;#+C2Y/0T4V2P!.E_3SILD=9<:0)Q5VV?$Z7M@T=\%02>/^=0I8NO9W@
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MTL:XJ4T(R@R*I5I6:6^=O(2JJM6TAT_L\&A()VU2Z>,$4Y@"@_N4&)M%L"Z
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M\$I3#:CPV=&K!G+S"5YE'P=?CBP:WF)/[P'V)%*WN5M/4 &D41MUL[BN[1<
M%IT55J+X$AW]8*BIYGH<0G.K[&*\ M^!MO<LCSB<]5>!]P8RR%D8*V')R9,;
MR0/ZEGYHZA^(J%A_LX*5/GOB\6R2K""PW-<#+$>;1W&P2YP]+KC_UI9QRDP_
M0BX2#I6],:NK;YA\79*6"0T;<Y2I,N=X/@9T$W%VW06K$\8_W-;!0XA[U5J9
M:;@(I\4:<!\0T.)8GTE6Y#Z$\*I@?#;+Y4@Q@1,W<FKU1"P-%,#0YZ/&P18Q
M!^J':QV.Z1M<L2)6V =4#9:4]2WS<&)[HS2-$;.?>I#CW7-H_7OMY.!S0(\S
M3XJ!^A/OKG4LH"YQ0GJ)DR]0[/YIP_V//X"8\/1N1ST-ARN+D2:A\0W)DZTP
M>:8_@));^1F/"6:'>[(TZ;0Y40WU4VO/>)KPCY])F^N[1JIPB97$NW,)5B"A
MYZ:I+QO!*JC(IE3^.B/L!RJ)TH3! %+H(LV8_X(-R@5)4ECJ$+3,Q-P:^NOU
ME"A84'>APN58#[14E,W$DS=D$PG(KOI&] 1HG9LGB[\O=1^#NI^>Z?7R,C2-
M'7D!KHL;)HG?^;SV?+1V<&GDF9".>C\> #L/=1HJPOS(P:M%++70=,DQK=A#
M;###X,.>MR3'WM<<D LE3 >7*6(CF[#'M*JRU#'3ELK[=\5WT')TU[IT2+"Z
M;%@-LO$?>ZC_<I3^Y^$_T2UQ8W__%TY?(X]_+KQ^(SGY;ZJSNK&FW%A"&O_0
MA]6;DB=0YJ<$?/H7'=K_H?T7<6#IN9H'#/1ID<B1[[?(="($]]I;,WLG0$P_
MK7-8T]5IDL,N\ J]\)*M^##V5VZSX$O&5P/ZJ)R<WV_6>.9$'1G?QXVT-'R5
M2WE$1*&R(5:S1<OX$! @R%1R!M);#+)?X]#]\3?J&)!)<B3R,2XW$MG>-G4Q
M9';X&HU>R>$ M>WL()P:(T__!A<;[9J$K5?-L:#/K8U-*9IEHUX2.OJG'WO8
M6LQ.L3#-0?;MTBKW8[#F!7Z.4+^Q9V/W8XP7CMP^;(H6X7;!X]-];F(I6(.
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M^[7F.=V\^<^"5!NC(<:?B3,8KF.K&&//<)%8E^'",=]5=>3?)F?VH9DR-O\
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MR-NG;H&._P'4(^1_4?@XF31\3Y/ +OT!-!H90Q7W3X&\#%NJPZM$JPD.>()
M=^G%(%V$&/3C;UAZK>5UWN<&$3!%*I5M_ ^ "HG7;]*!1'Q(NM6"2%P<,>$]
M13O./EU5EFMA9:^N"+41.5N7Q\L**N5'G.$)95Q\PL+<V#.WQ%N$S-%,!)-
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M&  %I.16'^VM,@V40XZ,L9V,F,WZ2X,XY\9STJ5)R!A[/AJ>5#0#@G^$A9(
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MB'N%POPS#H4"0MFUH;->I1B\Z0.3PV@FYV6]FO?H3]HG;*6+F$ P#IRZ?OH
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M+7W%"1S3\*GRAM*'JU7ICU5*KO9Q:M3I6_$,W^ PE!*'C0O)DSETPBA=MOX
M:!U_I_Y /(DH2O4L$*VL"#W97N,XWOGT7CKK%TO\LXW'R?V@E@9,8;Y3+@D'
MNNI3HV]52HV&5"&\E6!]Y+V1/#2L25AXX]>3W7O>NR^<:,$8^ 095[SS$3QN
MXFC_PTE:/P\Q["I4I^I@P'88Z8/-SDW#3M/G2WK[K%+X5$UY-EPJK8//L@^^
MS\^F :W"!^?)/^H4ZDX0&I!QP&9B1M!W[]O9R>8QE1;"KCZN:Z;3^1>8##QK
M9<V8?9(H:P90[Y)6-7Q"O'?,N]%*S!:@XB,J$COMF->>>"/@=F6IH\_[ZL%M
MV?>7TG7N33; ^=>%-^*DY#]-UZ!5D."U_=]I4+O"1+8NMA0"L#?-R9.X&O[F
M&(21"S;Z?>L-T&E-$ 7/24:2,JX<<(*KP%7;6D\1-+L4)8\.'T&3!\-MQ6AN
MQR5PK+%?CUPE30IX=C[>/W/\7<"\V.BZQ)ZEU__;,&ZL%\"<A:]PY)KS+#>^
MTR%;2H;Y52OJTV&INKNKW=[U_&/@1V5@ZX-A!7VB*%+HCXW2P8I5T)5%RKGN
MK*C,BWXC7\-BT;N&4K#XE6=[MX(KPX,US?Q01HYXZ](N6@YQ32>GH/K+N_M*
MT6',^#&_2]K0);U*37C%S++L3@K06KF-HN(;>;P-SOM@F22&6"%Y&DK8_\>J
M8O\A?9]_H](I^+>D\0T6="/HFO)BXC?R&?ST-A'A?>>C\0>0]ZC^WQ\&[)?\
M)\26_DEXZ3_1A&W62=;F4^C_ A68C]1R4DW4KC/@8[<8/QHOB<Z?R_ZL ADA
M0M9TD 8-5,?^ 1S9S@9=@#UE^5$YJ5O5Q$Y2N*UV3/D%3F3P]C%8>/#/ 'R6
M4D:E!_@L9 J 23S:\MM_R/@$]1IFBA5O0O6&D:@#W'G5M-44#WBH9'Q<# 'B
M9EA 7CJY#M E*UH>.$.W&MFZ14IFS)=.)^U@2=0\(Y*U&FS:4>[G2I2P[%MC
M&,?NRMP*()]OSSG?X(J$\S-KUK8WSY_:U:29Z.OD&C>!AH"+;:7DNZO-R:F/
MC"2NWUS2EG#<904R#WU?=;17_6JVLKB?Z1$O> *<X-+^7%B']6O'E.M=5\C0
M%D<P-[;</9VT5KJ>'V$ H6[FX0U(?W)*,ZD,=N55[3:6<LM>]D3/!^?V!XE3
MFQ6L$I9LUMM!BG[27^E>U%?14V"\7+DZL5AH:UP0Q)/!_OZI]N>L>Q,YF1=M
M<O83N(E/$LD",F^.RWT$OB43J[@Z-U(LW^68O%1H.($,$:EMI_A^G6M7VDB,
M.#VYE?-(7E]<<6@ %77Q)^0#!46_+-]#)0U'IW8H-\_<2/!7E@"I/]:I/7*C
MZ>[;"_9K!QNE.*;-+ NFV49PRGG[GVSR[W)[*K!)6E3$XTL.,N"L4P"52Q=_
MYG# 0C%W]7U&IF^D^&&UW#F(E57%UHSQJ7;D.:$MV8-XU["#3*N>8V9U-!_B
MUG5,K)*S%<$_UCO&/H"ML0M[I2TM?H8U/A5ASOV@QB,HS/?]Y^*1HHH%\B6E
MRK&J_5,7Z0'^BG/I(>YQ-3M!OF(\W@:M M=!/(*2^\D@:_TM@B/1.#!33\_O
MBE]KS)\4ZPO'"H^>JZ\[6OO_* Z<+B"?;VDWN@J=NNBD</(EF/8$51HNZ(!E
M>?VD@V2JC$TXESP(4BCY8MN"O<F7,U=:,"\V"<?8P,)@WH"O\]12'Y(SMJ\W
MFY+495^?6*PJ4<N)^8RY+S#7"X8)&.QX+\C!37_+:(((*U<)9YO59"=V^?+.
M"O.N:4AH;%@VK!_<1Z ?G6WU=S#4Y72?]+Q&BT$%BHFK2CHLCJ&][]GFSU3'
M"=1]:*]-A257!PH6L+Q198SZEJ#RN,,1,VDPYX4?3EU[QM-821,Z$\WFU5WF
M9\]I&()I]G:WVJ$X#B4$K"K" UQH$<#!?U3"[+_@C,^_L7[]S]A_I:C%?^ T
MT7_$/GJMGYG#!6^HP4$71;ZG_QKJ)O%\_D_1<DJ8#A[Q!D>4 IHY%O9TV%ST
MYF#*!3A"W$_P]L>F+04KMD3WWNFC$Q!VGR5%7&\YR)6Q-].K\MWHE6DX@#HB
MN@N'B9$>(,R$CYT'B#^TL._[[3&U?"#UL*'DZ^ZO5ZUO\&BZA#3?E )1C,&7
MWTBZ8_?^ #;99_^":Z/9H-.[ZK_X)_^>0D;[/B) ]?X/X"\J1Q\ ?G)7!?WK
MH-R_W/6-)/1_^_K_DR_>!/3<H863%%6,@T'52=6T#S7M$H[MB]J]D$GL V6I
M4S,T^';"I0CC12SS*M[RH#%ZN!B(Y-:@8I]Q"SLT:A/:9,T;D;G<63YHF9M\
MX'?]B0<AI1(K\9+Q4X#ZTV I+'-CAPO!F#-@";N6TY1-PKN!W32VUZ,V@./W
M,GY&()- =M1.;JS'0%V[X:*:1XH8+\=K$H.I*-:0;3K [/>F)N<VF\TMQK8K
MJC6N!J(G+OS%9B!H1YW*'P"K[$&/;"C\?XDI_-^^_E?W50NTJ^**:A,-@(SB
M?!=.JL9IJ^SF9AQZ)U%FU,&QT,VV!'F]JVY2H_5_[.K7/1Z+KTPMMY^PPN0^
M5U;5LN5\*Q]5K]!+VY[[;5?N#/O4;7FS/]TWZ>]_I,!X@XOAQH=Y\\VF/MQK
M=NUI\QU7IC4M>O=GRWR,^<_0F[_TP_NN/=9K3AZ;%ODF;P[_US2?RIQ:\0+E
M5X=V5ZVO3\Y?>?-L9CE73+1/JTJ7X]146T<11@O%!N6ENH4"&75J']K?;8F>
M75ON&?^US&K.6I$/Z^Q>^8DV\QVP>OYWU<7-'\VVJN[:>KUE_8(9?Y_TO;OF
M*N_VF:U>"]B ']*Q-&K6$#2K[?.16U?*SEV[)[1O7H%=Q+UW5QGMWCZ;4Q?"
M>&F>=M.'FI6/ZCODE#_*[N1??I@'V-9_<=/SEGKYS/9->V8;\8?D>TUZ[_PQ
MO*>Q.6Q7\^%=)LW?M\T*.:MZYY2[UG6)0(GS[*>#"B\>RUY_:<MJ7V&_[1LV
M;.^[=.XN2Z&CT-N0P N,#F(OJ-1E'<4#A__?! !02P,$%     @  ()Z6/44
M>3<5!   JQ8  !@   !C9W1X+3(P,C,Q,C,Q>&5X,C%D,2YH=&WE6&UOVS80
M_BN<@S8M4+W:3AS9,; Z&;8A:8-.P="/E$A)1"E1H&@K[J_?42]^$9+:63S,
M6X+ LH_D\9[CP[O337XRC.LLP5E("?K5O[U!1(3SE&8*A9)B!=*2J03Y(L]Q
MAFZIE(QS]%$R$E.$'-L<FH[KFK9A3">@:]8L$IF'^I8[M%S;'2#;]=RAUQ^A
MNUOT[MZ?O:]F7WV>^5_OKNMM[^X_WOPV0SW#LO[LSRSKRK^J!P:F[2!?XJQ@
MBHD,<\NZ_M1#O42IW+.LLBS-LF\*&5O^%RM1*1]87(B"FD21WG2B)?!),9E.
M4JHP"A,L"ZHN>_?^+\8(9BBF.)U.K/99SPT$64XGA"U0H9:<7O92+&.6&4KD
M7M_.U1A66C#<F?-@E(RHQ'-L^\TXQX2P+#8XC11(3/=B+9,L3M9"48/S).58
ML075VC?TAIQBZ05")>/N%H^MS-MUD<B4$>&4\:5WZK.4%N@3+=$7D>+L]$,M
M@6=!)8M.Q]7L@GVGH!H *OJ@#,Q9#,JUL>/: UX#/MC:I*05GD!P H/7#PD+
MF'I[XIS98]<QG8D5@+OR?\"T$*A*Y3-LNV&%0B)"?\R#@A&&):/% <US]S!/
M3]_::(ULP0KP'&=JZ26,$)K!_+<G(]?NCR>6GEO;J;E1;7#9T^32+,8!IZW2
M0$A"I1$*SG%>4*_]LFGH&>R6U)[1G IA!&P=;W!+:Y6MRF:J4R-0I)4OJ%0L
MQ+S!FX+1G#9:^A<0&]YL@F_8[]GF^;#6M,'RC2T$J(VX*%LGM+^-4N+<"R#(
M?#-* +GSYJS&<5 (/E=TK"_P$- I'5(B(5.O^@:KZ3O[@P%#[SM.J*]Y\ZG(
MONA=TQF]6O#.P!SU7RUZR(?#5PM^X)C_1]Y;2NIX>,C8=]A@<N#;>5BZ'Y8_
MFP?2(=)H1X*"(DJ)=/N0FG19#P$5'Q#0AA%T8E=_C]MR=I$KM'IHR]#:P!?7
M$1H&9QDUVOMANN?/*')6Q<UR5=K\^ 2VW%*3[2FO5#<GQU)7"\?BF1T55UV(
M/M<-S2WI^,$$E4?*CY>4Q9_+C,HB83G*J=2K<4S_'G=T+'C:9\?(G@-PI0Y:
MKX,JO\\E*P@+=8K5;U(L"X7,A<2U0,)_C#/VO?J]S:''8[9C[PC:D+X[$1N'
MWV(IYAGQ3L(HLJ/PW_!L9?>/V303<5;5(LA/*)0Q= ZX"G3G?T4W_M4>+%M#
M;Z+R?P7YWO=HC; -N$<,<<>]T=7C,P^U"I='C/BEA]I$QB-&N.-,?YX7D+0X
MPYTP9E4ME_8=X3"=HZ?[1'LVAC9?6Y)5G%U[7_>$A/3:=+316-P>:/SC=OS5
M)K"MEF8CVNIH=KNE.9031OT*AR-PL8<7@I&&(N<7YL!99<]:9E=U?MV%K=JZ
MT[\ 4$L#!!0    (  "">EA"S!N@L 0  &(<   8    8V=T>"TR,#(S,3(S
M,7AE>#(S9#$N:'1M[5E[3R,W$/\JTZ#"(67?(83=$(D+H)X*-.*"3O>G=W>2
MM?#:6]LAI)^^WD<@H=S!M5"!+I&RB>WQO#R_F63<_\6R3GA&>((I_#8^/X-4
M)+,<N89$(M%F=DYU!F-1%(3#.4I)&8./DJ93!/!<>\_V?-]V+6O0-[R&S2;!
M0P@<?\_Q7;\#KA_Z>V'0@]$Y?+@:#W<KZN,_AN.OHY-:[.CJX]FG(;0LQ_D2
M#!WG>'Q<+W1LUX.Q)%Q1304GS'%.+EK0RK0N0L>9S^?V/+"%G#KC2R?3.>LX
M3 B%=JK3UJ!?SI@GDG30SU$32#(B%>K#UM7XU.H9"DTUPT'?67[6M+%(%X-^
M2F] Z07#PU9.Y)1R2XLB#-Q"1V:G8Y8?T-Q:<YKJ+/1<]]>H(&E*^=1B.-%F
MQO8/[N<DG6;WDZ(V+I3(B*8W6')?X9LP)#*,A<ZBAR(>VUDL]TT$U]:$Y)0M
MPITQS5'!!<[A4N2$[[3K&?.I4-+)3E11*_H7&M;&0(VWVB*,3@WS4MFH]D#8
M&!^O"9EC94\L6&H63VXS&E.]O>5UW<@/;*_OQ,9=Q2NHEIA01?D#N@T%5V5X
MBPE\XBD6:!YF>(E3J@PG$[NC6<QH D=)(F9<F\."4RKS%S3!?X8))?F:H'OK
M;Z@RWF54+\*,ID9[0[^]U?/=(.H[)>U+NGI-JR\(2>,^+4!G")0G0A9"DC((
M(5Z Q(EQHDDG9JFBJ!W;$'S6)CN4V46%\(+.?&G7:1(SA%C(%.5ARVU!@HPU
MR+T;JX(DRW$CK=YA)8(Q4B@,EU^B%[#.,O#7(@_O#Z7*114<2G4M1A9BIL,)
MO<4T6DD1M5)+YVAIWNE2X8:LU^0SG:XN_J>XN4&I:4)8$^-5N!M]HWE&-5JE
M[S#D8BY)$:THT?BX4=:S'ZJTOO[/D_ZWVM;#DI%12N:$1:N9HYEJ#1Z/9?AP
M:@C@L]6#"V%#$ 26WW6[O>XN%,8+A/(RAS2 &8HIKS(VC#,TUN/,N$FU32Y*
M;#C*RVR4 N&IP8W252GU77<?3OZ<F: MJ8Q D^9AQ AO/\W1=[UO;B9J*?!9
MC'SO<4:5ML_<GQ=,+!"-[T1R;1*M--58+?59(O#_/M5^;##QTK(;B%:E?V5<
ME_WGIJ(R^)T2L4X%\4UB>B.)R7_'B2DXZ/9^.#%]&_WM#6HWJ'T?J W>+VKW
MW?U>9X/:#6I_/M1VWAEJ@Y5:VSLX\'?+3L/W8+K!X@:+[P2+>^\7B_O=P.L^
MB<7OA.#;[%2]0I//N$C,)$@LA-205CV(<V+^J8/?;9>_*3KM^DY HBHPN6L%
MEIU!P6B]84(YX0DE#-1=R^\IYU>-!#6+%4TID8NRM\AF93NDZB12!4><SPS'
MRUJS^I ]U_K]R6.%B9"5C@LD$NH>RS$FF,<H(? JJP+[+7<D7^&<'>7 B>1*
MPS;)BPB^BIGY77EV-OJYW##**",ILB*CI TCY%PMV WAE+R6Q'4P55+JFZ3Z
MF<F[ZD62ZZDTQY*6%4S(<,NM7M'*?=#Z0E;GQ]+UC'*TFK&[5I:;2Z>URKP^
M=W?)59 I6K%$<FV1B39%B]P(NBQF^P=VQUN6L^92RJW*5GUY5MW&#?X&4$L#
M!!0    (  "">ECS??89@PD  (-#   8    8V=T>"TR,#(S,3(S,7AE>#,Q
M9#$N:'1M[5QK;]LZ$OTK7!?W-@4L2[:3II73 &V28H/;1Y#K8K$?:8FRN*%%
M+4G9\?[ZG2$I6W+26Z?;A[-U@#@1-:2&HSE'9RC))W\+@HLBIT7"4O+W\?MW
M))5)-6.%(8EBU$#K@IN<C&59TH*\9TIQ(<@;Q=,I(Z0?]8YZ_<&@%P7!Z0F,
M=>8[R2(FPW!P% ZBP2&)!O'@*!Z^(%?OR<&G\=DS:WW^\6S\SZL+=]BK3V_>
M79Z13A"&_QB>A>'Y^-SM..Q%?3)6M-#<<%E0$887'SJDDQM3QF&X6"QZBV%/
MJFDXO@YS,Q.'H9!2LUYJTL[I";; )Z/IZ<F,&4J2G"K-S*O.I_';X 58&&X$
M.ST)Z[_.=B+3Y>E)RN=$FZ5@KSHSJJ:\"(PLXV%4FA'T#&'WALUML."IR>-^
M%/TV*FF:\F(:")89:.D-7J[;%)_FZT;I)A<K)JCA<X:C-\9-!*,JGDB3CS8/
M<5_/LNZ7R<($&9UQL8R?COF,:?*!+<BUG-'B:=>UP%_-%,^>CJRUYO]A,#1,
M4#!CF IT21-P. ZB7O\(FWG!@IPY]WO]E^U9#I^#B6&W)J""3\$MM',-O$@A
MK>+ FKAHQCZ0DY;#"S?X1(H4=E[<YGS"#1G"P4[""42]?(0SQ"/7/L^YAAD)
M;I9QSE/H @:_/WDQB(:CDQ -=VZ."4R+J2]-\NSB>GSY]O+L]?CRXX<_=VT.
MNWZ>-B?3]#3:]/.R2]YQ3<DU3Q).5<J[)&'*\&Q)3$Y-_(T<&SS8L58 -Z;H
M&11HS,B9&WS+$!LZ$8Q,I$J9>M6).C!9(?S97FW[]+#;W@'7(TBD$+34+*[_
M&7W;B+0GUI@J7BQPT_H?"+J4E8DS?LO248/#G9=U (V"W_2;Y-0<4R*APB/
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MY73?89% +;M8XG#<YXNL>TM$J_=N_:3*2I5 7MK6>TD"^6>=L(LU4U9 %2>
MPV /*Y$<T:0JC.,I(%%>@N3:,]6>J1X14R6[QE07<RHJJST0LRS+6((/'Q1,
MW[-:LJKRMM!2;O/^!11+3- 1=!#R$AA/X$1_WH-MU!Y=63-<ALJ^O,9+)O7Z
MEN5:YB(!_HQP\#VO['GE\?!*NFN\<NX@>Q?Z>#O)KYO8/??RRP-T#Y9@,DDJ
MA0!OU#OWC#J3VD [/@,#8VF(.?EW!>42#'WPF2X9,!6HD0UK[W@"_&'OA!7M
MV];/G%<YU:OB$'6,93:66I%GX^$%V)((?L.$ORVV8=_]GT.T"VRV7V/Z-5>M
MC_X_5JWM<RIIS6C=M7! '=-DE;6&0%YX0-UW9YEHY1JM4FZDTJM2RS; D+,9
M-X:QOU!I;R04<[C_G(-_.,A^K?F7Y($=%R\[M];\6@B""RD<2 !OU>!-GX0S
M0*TO;%9KO@M&;[!2<8L8ME:Q2S#V:9CZ/O2#N, OS[H;9?<H!)I"1\U6 N&S
MO.$7;J +@!^2H^O*)0VUDJYFD%L0%7?CVRNS>V_:[X)Z>-%[<8<U7-N^'MI3
MRN-8$7X-94^FX-K=!8 S*S> (NQC:IY+NJYJX,5<BCG#TJ&@4_^TG?(*A<U*
M(9<,]BYRZ60);3$5,,LWJ:MZ/Q?RAU'O:!/RONUG0]Z^*>1POQ68G0_HH9\M
MOO>#X8=)M7R@E9%U@WNGR+:TXA*M,]W;8$L#LAUB4?.JXU[TL+"M_:RC[>&\
M0L8FX&0-K,.7O>/GOS6EV0:(&B\V-0;'G,+'K>HPUML!8C:>P%7M)EA S+[X
MLM1J/YUH*2K#1C5O-6?\?=_;<#'Y5Z6Q,MA.I6Z?2^ZU,__9IJO/GI2CJ#<8
M[D_*#SPIEOW:5[^OA\QW"DN+)8Y[@]+<%ZD6GSJK!IT.CE%3U:R*:WAP98K)
M[T_ZSZ/1>ZI E0Z>=PF^!^H"];",]3194W!Y2^QS#^1)9']^?,S^,I7N1B/4
MX<:K6F0=AL>0(P^<;PM)K>O2 ZZ67Y<CR"B/+T':R;'/C6^<&[L>D[.<LXQ<
MW+*DPLLF^>B6$+OD2C'-D7-ML5VOQ>WSXQ?+CQ/>EB6V9.0&!DBP8KURC[1
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M4$(*&3A%25/((B(ZE[Q.\I^_[!T-5KN#*^O;=-[]G@3[BQ=._P!02P,$%
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MC*E55@(DT53YY%JRN(+WVP.[W5P$X;+/+:XCRX?UXJ6^]Q]02P,$%     @
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M2P$"% ,4    "   @GI8U 1#HV .  "0U0  %0              @ $7$
M8V=T>"TR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @  ()Z6/LL%97=*P
M8;@" !4              ( !JAX  &-G='@M,C R,S$R,S%?9&5F+GAM;%!+
M 0(4 Q0    (  "">EALK^5A.&4  /O(!@ 5              "  ;I*  !C
M9W1X+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    "   @GI8NIJ7K"M%   *
M-@4 %0              @ $EL   8V=T>"TR,#(S,3(S,5]P<F4N>&UL4$L!
M A0#%     @  ()Z6(-$PNIP_@, MO0B !4              ( !@_4  &-G
M='@M,C R,S$R,S%X,3!K+FAT;5!+ 0(4 Q0    (  "">E@COKO_+:X  -/R
M   8              "  2;T! !C9W1X+3(P,C,Q,C,Q>#$P:S P,2YJ<&=0
M2P$"% ,4    "   @GI8QJD-<7&1  "NG   &               @ &)H@4
M8V=T>"TR,#(S,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @  ()Z6):WIE2^
M/@$ S5@! !@              ( !,#0& &-G='@M,C R,S$R,S%X,3!K,# S
M+FIP9U!+ 0(4 Q0    (  "">E@Y R!DF>L  ,'W   8              "
M 21S!P!C9W1X+3(P,C,Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4    "   @GI8
MZLT:7_D8 0 *)0$ &               @ 'S7@@ 8V=T>"TR,#(S,3(S,7@Q
M,&LP,#4N:G!G4$L! A0#%     @  ()Z6 ^CP@4+O@  G]H  !@
M     ( !(G@) &-G='@M,C R,S$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0    (
M  "">ECWHZ.0WXH  -^5   8              "  6,V"@!C9W1X+3(P,C,Q
M,C,Q>#$P:S P-RYJ<&=02P$"% ,4    "   @GI8;XZ8;A(Q  #>-@  &
M            @ %XP0H 8V=T>"TR,#(S,3(S,7@Q,&LP,#@N:G!G4$L! A0#
M%     @  ()Z6&H\UL-L4   <EL  !@              ( !P/(* &-G='@M
M,C R,S$R,S%X,3!K,# Y+FIP9U!+ 0(4 Q0    (  "">EC%!5-35CH! !)D
M 0 8              "  6)#"P!C9W1X+3(P,C,Q,C,Q>#$P:S Q,"YJ<&=0
M2P$"% ,4    "   @GI8..2RD6M@   R>P  &               @ 'N?0P
M8V=T>"TR,#(S,3(S,7@Q,&LP,3$N:G!G4$L! A0#%     @  ()Z6#M.1EPC
MG@  U:8  !@              ( !C]X, &-G='@M,C R,S$R,S%X,3!K,#$R
M+FIP9U!+ 0(4 Q0    (  "">ECNH^\N2JD! %FX 0 8              "
M >A\#0!C9W1X+3(P,C,Q,C,Q>#$P:S Q,RYJ<&=02P$"% ,4    "   @GI8
MU'P+!W=4  "/60  &               @ %H)@\ 8V=T>"TR,#(S,3(S,7@Q
M,&LP,30N:G!G4$L! A0#%     @  ()Z6+>$VG<^B@  $*D  !@
M     ( !%7L/ &-G='@M,C R,S$R,S%X,3!K,#$U+FIP9U!+ 0(4 Q0    (
M  "">E@?4?BDX?\  +H0 0 8              "  8D%$ !C9W1X+3(P,C,Q
M,C,Q>#$P:S Q-BYJ<&=02P$"% ,4    "   @GI8WT]Q-N&+ 0#_R $ &
M            @ &@!1$ 8V=T>"TR,#(S,3(S,7@Q,&LP,3<N:G!G4$L! A0#
M%     @  ()Z6!M%EG+*Z@  R?@  !@              ( !MY$2 &-G='@M
M,C R,S$R,S%X,3!K,#$X+FIP9U!+ 0(4 Q0    (  "">EBI2UVQZ\0  -':
M   8              "  ;=\$P!C9W1X+3(P,C,Q,C,Q>#$P:S Q.2YJ<&=0
M2P$"% ,4    "   @GI8IK^''W&K   VLP  &               @ '8010
M8V=T>"TR,#(S,3(S,7@Q,&LP,C N:G!G4$L! A0#%     @  ()Z6*1R.M01
M" $ X#4! !@              ( !?^T4 &-G='@M,C R,S$R,S%X,3!K,#(Q
M+FIP9U!+ 0(4 Q0    (  "">ECU%'DW%00  *L6   8              "
M <;U%0!C9W1X+3(P,C,Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4    "   @GI8
M0LP;H+ $  !B'   &               @ $1^A4 8V=T>"TR,#(S,3(S,7AE
M>#(S9#$N:'1M4$L! A0#%     @  ()Z6/-]]AF#"0  @T,  !@
M     ( !]_X5 &-G='@M,C R,S$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    (
M  "">EB7><V9-@D  $U"   8              "  ; (%@!C9W1X+3(P,C,Q
M,C,Q>&5X,S%D,BYH=&U02P$"% ,4    "   @GI8RKK2H2\&  "E'@  &
M            @ $<$A8 8V=T>"TR,#(S,3(S,7AE>#,R9#$N:'1M4$L! A0#
M%     @  ()Z6!+>F$DW!@  ?B   !@              ( !@1@6 &-G='@M
M,C R,S$R,S%X97@S,F0R+FAT;5!+ 0(4 Q0    (  "">EC<#Z!>1!,  'QU
M   8              "  >X>%@!C9W1X+3(P,C,Q,C,Q>&5X.3=D,2YH=&U0
52P4&     "( (@ V"0  :#(6

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>cgtx-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgtx="http://www.cogrx.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgtx-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_XUZrCkEwDEyMKEMstcPgZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__0_YbKxmOU2r78jXkEEzlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_bkEmqGmAXk2V435yqi4NaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_bz4gK_i3F0uQC7rL-HFYWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_UveeLV5jg0Gs7n8IWxBGxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_LshqVKz1-k65X8p9RQ7mDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_uhpLOBdKk0WZcXfNyIcT2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_glCHD9EtbESXtKFFuEPfMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_mjbf_mTu8EG-1PNbRNcxEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fxo-cpkpfUGMsbMoJHuOAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_6UVH8Rgk6cL-CiQ1IpeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_X48c3Sa37UK9EHex0j44hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jO4Ihl3vbUygM5jjvQg_Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y4ykLegMm0ecV5xUeC4XMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MGbOgarFTEaIN0_BlZV7RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9Bca2RtZUSaAp6SOKJZeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mjQQQJ2EckyysDZdzZQoXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ga2Znj6Iy0yqPXctu2LwwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_RHH5Gs9baU-2LKRDJ3NO3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_x_Z7jkOkrUCdh_AMcj9ldw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_onxTRXE0sU2j9FuXL78qkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cRBLgf-FmkW2y3hxofLyXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ygnTJ3cZlkyoT6PpTTP3JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-15</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_8bYcitqYY0y77znhmkKzNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_QC7xgFr49EmCFLiMsbsf_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_gQpvyXpSRE-aqnPz6O907Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_tRoSIxX58UuuBcSM22cTJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_yDEeKMfAzkS-KSBkUEc6qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_LRobkF0nj0SY3xdEzUjMVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_rrHi5dcFDE-G4d-8RUX0Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_uguCNEEtGkiIZdHpBUsd8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:AmendedAndRestatedEquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_WLXjwrWnP0CgsWctD9xbtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_fSE3Go7PW0eAeiIVxPMeeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_cgCekGBDeU-iow6w5GkUWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_oU9CqFmCiUKDm0PxrYz0zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kQSwmvFsp0mgTkQQwG0VHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_efBKw3qAME6ZmwdlSdK_6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_-Aambe7M-Ei21IEK190qVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cgtx:NonEmployeeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_EmployeeDirectorMember_Ln6Hn2FojEa8itKVr-awUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cgtx:EmployeeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_nrintSTwQECLB58C0p_EaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_EgdiPbStcUqDXdhNU2tjcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JA-tMjbxgkOcxeZ-D5dbbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VVVdi6pD1kGcMpi2IuK05A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-558bBZDIUKyf-5W-hEnOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_d7jEg2zHjU29ZRjFt5YiYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_Cb1fCNb9LEq93fXulA-3xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_lCt9u7t8z0W44yS58i4_kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_YVGucSObRUi_kS5-NUT2_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HMKbTdzF40CY46TtwizjkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pLCQK7N8yEeOO-emzO9KTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_7LajySWg40OL9NM2rgbwrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_q3DH0WMQa0CmwYFvp51zwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QXLq1_nOvk2P7yx3QDOUOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTU5BrA1tEmz30aajDlz6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_c7z7ZQ_fFUeLePhaNsuU1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OdAlZTCHTkKTcjg6k-b-og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_ZB35Xclq7k6gaWDy5dCb0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_YK8t0UGtpEeESc004CPSVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_YqDdVDtS20ecG70OxtdrqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_vQQHg-kY3kaNtOqhbYQgyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_ecCutZaSMkeuO8iQOXjXGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_60EfJYivGUOdbqzJUjaoug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Ao_-LDEYrUuIE9YczdQENA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_cRq6e-5OZ0Ke_a61Ul0DuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LxxS8eZ15U26cdY_7vD36w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_zimJT2kt9UiSyyAiSWSK6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XYSO_78oUkSochkQvqlMkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_ENLs-VXh8kmNzn1_ZzoFlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VWGUaJ66V0y4SA962FOAsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_9tl_WCDNBE6HpfXJYxxGQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_S_oPesVvSUGLXTpCrxhISg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_zQZdkP6aak6WFLzryRsnUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_iifjj9nFxUWWEEoGkB7y3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Tcs3Fe77zk-E5SHgaFWR2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pRPh5Rg4yk2qvio_UPRCJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_MrwJ0AbrfEahvl8J7zIwLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T29Qjyz35U2p3fWGxDsVjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W7FO-pbJEUO0d761WgliwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tqAFWsRuSEOU2TS77Gr5vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_70PXE3i9G0SgTEnVDcJbMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tuVKl_ZuvU2ErvU1ol886A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_GoVENcIHxUC0xotmdahUqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">cgtx:AaronFletcherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_JlzDcywjoU2rtXry2sZxig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_22_2024_Z7oTilaLYUqLKorj8N32wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2024-03-22</instant>
        </period>
    </context>
    <context id="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mUz7VNnd5EuqjwdONSKJpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_fYz-UjM3pkmim-rRGGRZzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-15</startDate>
            <endDate>2022-11-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_V21-ck426EKj_jaNHfEcpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_CljcQCdgAUmy0i-o6OBaKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="As_Of_12_23_2022_vzbl8zprq0ijwIokKFM6sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_JzSuP6-isUqGYxI89s2DJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_lease_pZh55Gbcxkm9kdN4Koe6yQ">
        <measure>cgtx:lease</measure>
    </unit>
    <unit id="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_segment_5qxERgMtAE2JatGJwvNkAQ">
        <measure>cgtx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      id="Hidden_e7x5gOaUTkO7iSYDksxQhQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      id="Hidden_u5U8is6XH0uIv9RGk6BAnw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_bvYulE0s_k6M5tHg_TPnUg_2_1">0001455365</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_Cjcx_bcnp0SBp6Yu-feEWQ_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_uis9W9wjnEev87DmC6EBtw_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_RmTfk1QR-0SQTGvWnWpfyQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Hidden_fCMcc30VrEuBtpYtIUMoog"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Hidden_g32P2O2i-kWhjcBmZYKsXA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Hidden_3dmFxBspikeQpVonqzl1-A"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Hidden_LPJj1PySJE23Xx8l-XIWEQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VWGUaJ66V0y4SA962FOAsA"
      decimals="-3"
      id="Hidden_FMlYcx_LLUigdn_0wCQu8A"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XYSO_78oUkSochkQvqlMkA"
      decimals="-3"
      id="Hidden_68HRszMgH0iikEmClqgPAg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Hidden_uaCaWxtaRUyygHCR2IjWgw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Hidden_DpqAOV6-W0KIuqygKL-oAw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      id="Hidden_bNPKjeMogkiRwabi4DnToA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      id="Hidden_x_0-tty1qkCdgZ8MygWwoA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Hidden_crfbz-8nX0uPcYlZLZkBoA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">32165478</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Hidden_z0-6MhzaqEi07JiIaYImxA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">28991548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VVVdi6pD1kGcMpi2IuK05A"
      id="Hidden_mQJYQs2rZkWuRg8O_Rotqw">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RepaymentsOfDebtMaturingInMoreThanThreeMonths
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_EgdiPbStcUqDXdhNU2tjcQ"
      decimals="-3"
      id="Hidden__XyZb69CXEGjsKwFBnsFpA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">634000</us-gaap:RepaymentsOfDebtMaturingInMoreThanThreeMonths>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Hidden_ePTF4GwkoU2wTSik52QcmQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">28991548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Hidden_Qj7kaN5TikGnEe3obL6iig"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">32165478</us-gaap:CommonStockSharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_GoVENcIHxUC0xotmdahUqw"
      id="Hidden_EhWfKhNhJ0mxDKk9K-W3pw">true</ecd:Rule10b51ArrAdoptedFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_5JWUffvmYEWUYBSqKIB03Q">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_oAc1CkJNNUqJ3UOR6b2GRw">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_29cybrsRkUmEHjUyY2FohQ">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_44tc0W4bDEiClQnyrxKjQA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_9QVtmySu5U-brjaIERJctQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_EisK1kYjHku6RtMJ8oMqjw">001-40886</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_wFcRdo-CW0aGDdQyhnVXpQ">COGNITION THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_gixG949HjEKve9CtMfIxZQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_Yd7OMcnjM0C7klfvr2Kulw_1_1">13-4365359</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_dCW03ZOvw0yfKu0_jhQR1A_4_0">2500 Westchester Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_AWssRxUS7Uqt_QDyXeiEUQ">Purchase</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_2FJvCDOow0KTtj6BRVBnuQ">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_zdEwLRxD8UiAjR-h4n1-JA_5_1">10577</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_LQeYhIpyXEuHT6_pQzY9YQ">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_AX3lyVT3vUerFnTxNqwYLQ">481-2210</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_zFi0jcVjdEe5NFGnji4OXw_3_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_hlu-lYKR_0W-bbr25rWWkQ_3_2">CGTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_6quRf6ZFjkO19wbJhLt2Jw_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_sfnTavekaEuE4D8pjjDkOA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_T6WMLRz8zUa_dj0FUVmDtg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_5T-kAMZzekmz_ZyonreCCg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_47LrTjoh60q-lRtwLHEwrw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr__5m0RGpwvUqKUJdVSnZaRA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_qulyBhyOwUKdZdmzEbhQlA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_Xn4nd4vCwUy6_1I135RDpw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_UgRRCwblZk23tMvKp5rTfQ">false</dei:EntityExTransitionPeriod>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_fw4YROLLl0GwSOlD8V8ExA">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_V6-SGj6C5USjfPCc-rNt1A">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_JlzDcywjoU2rtXry2sZxig"
      decimals="0"
      id="Narr_eYrSw5rPBkSYIzJNb0dEwg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">43124364</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_22_2024_Z7oTilaLYUqLKorj8N32wg"
      decimals="INF"
      id="Narr_G0RWPU8nZk6i5Rg3RlWBHw"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">39000152</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_Szyx76JM7U2L-y-OWZSX8A_1_1">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_9-yJft1UAky0hGeD7m3pKg_1_3">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_qumr7aEcMkydz5LyzrjSEQ_1_5">Philadelphia, PA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_MOcDkXnBxkqfMhvJDBNQTg_6_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29922000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_IWOlK7-ypUWbfyv87A4kGQ_6_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">41562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_E9dmQ0EEWkSDnK8fE5MTVw_7_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1281000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_dw90dcTthEK_mDpaPiLYnA_7_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3672000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_dARMVzMfBUyaHNoScPpo0g_8_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3019000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_LonoXukVh0OsRHIn8Yn5Ow_8_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2413000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_cqSllIZrlk-UPaTEYf8q8Q_9_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">34222000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_b1UPSTMRQkyL4pAWr54m3w_9_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">47647000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_uXvQ99vzskCWqhNTeYBidA_10_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">284000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_LG0cryLF_U6RplTW_XBXkg_10_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">233000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_fMENXkkZU0G8tn8lphm8jA_11_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">657000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_IHq4W_fHSkehfDvzapBrvA_11_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">813000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_EF6nB8BRUEK_1IvVh1ih1w_12_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1732000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_siRN156ewU2dkx3JGGm99g_13_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">35163000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_Xcsz2J-9aEOtYxg7Hq5r9w_13_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">50425000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_54UG9MiwMUemkQFuJznzSw_16_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3695000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_VG33qMofNEeUQdv2p8GS-Q_16_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3216000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_kVDGjV02zka7WFPH0kDGBQ_17_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4055000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_u7AjXRer7Uy5NLc1LDTzNA_17_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2094000</us-gaap:AccruedLiabilitiesCurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_uTzy5mns70C3whMxSYRpgg_18_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1701000</cgtx:DeferredGrantIncomeCurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_KZess_vOIUuuGPF7IO6YaQ_18_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1702000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_ACMlXgnA_EuYYQUGz8o0JQ_19_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">174000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_kIXkIi0zXEmwpgp8p6og-g_19_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">149000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_nSjazw9B2kW6EmGtQR0gRA_20_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">544000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_fpl9UEOfbE-kZd8NfFz4Xw_20_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">634000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_R37irfA3QUO3ZWD406MyAw_21_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">10169000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_REHBo4NAQkKoNc5BTuMonA_21_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">7795000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_K6h04P_fAESd_9p3fqjlNg_22_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">520000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_PxVKbY7saU29JMF4Kwx5bQ_22_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">695000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_DiEk4gsQYk6qd4VOPWQV1g_23_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1686000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_xYw2CKaC5kil-puoe_8ZhA_24_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">10689000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_Gni-uHJQCEaQiIldLoZH1A_24_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">10176000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Narr_tV_uk0LW4EqTfCgSy3AXIA"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_R7Q4kBy1O0yJSaklxHLXkg"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Narr_VJh_hDPTb0uzTVMzUZj1ug"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_IDluKXgQ5EaH2aWjd5a2Ag"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Narr_0SBDRX_atEGLrSA2qH0JmA"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_tBBoEXIKk0Gnhg6bn-A5Ew"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Narr_kJ3c7pJMTkKfbZ1MUwWOyQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_tO5kEOr0zkeyJ7tQuMdCZg"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_NrrQ2BzquEypUnJnfcf-jQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">32165478</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Narr_heGMF26E2k2f7mpxmkAjoQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">28991548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_JA7gicFC3UqJ1utnWEg6tw_28_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">32000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_NA--BCdb0E2pr08GYMY5MQ_28_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_impE8gmj5UWtZrQ55NDidA_29_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">165826000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_Gy30Ahk_jU6I1C6erql5wA_29_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">155820000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_mpSeZ5BxFkqYPanELEEQgA_30_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-141189000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_cBTwBWEpOE2DLHKQP787lw_30_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-115401000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_IIk3kWQFkESyS9KrhmfJpw_31_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-195000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_dXuOM9_gqEWaQ9JBQeAxhw_31_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-199000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_OfNub9GHYEqjcab0E4gSfg_32_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">24474000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_wd4JmzjkQkSMJA4fm6ssFQ_32_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">40249000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_XkwUxpBSXUSyr4W4MVKuQw_33_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">35163000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_DGIbykuXkU-Z54ovQ7DLHg_33_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">50425000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_5Uwg0j81O0-F43HcHeoH0g_5_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">37196000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_dpbr-_hX-UuR_U1fNfUrYQ_5_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">30324000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_Jz3NNYNBaEC_FNpsUrApGw_6_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">13528000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_z7m4Stbt_ku125bnu5-_mw_6_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">13227000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_u4EOaW11CEyFw5_99k8lyw_7_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">50724000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_ShpadbYV5E240hpJR1q6yg_7_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">43551000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_X1q-IrAfMUaTYtO6K7UhIg_8_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-50724000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_CYOVA9tYVEqrd4dImVaYzg_8_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-43551000</us-gaap:OperatingIncomeLoss>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_6ZTsdvGRfEG2FV3b7FUFAQ_10_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">24805000</cgtx:GrantIncome>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_LA-ZHOM-E0SqFPf7AhgGdQ_10_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">22217000</cgtx:GrantIncome>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc__WlRBoRwpU2vpopLr9HUtg_11_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">158000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_CgRZ2DkQAU6j4LDqLCATqA_11_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-35000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_ccGIXjmcRUuYMORyHrxqOQ_12_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-27000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_SxRWsrBgT0OnSSieKNnOrw_12_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-28000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_hJJSNCX6e0CTy2W381zRmw_13_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">24936000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_-rIbUBhFuEmcKnBhEDUcug_13_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">22154000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_ToJDp1mYL06FLOyQ18QiLQ_14_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_eZWTlsucz0GFCa0igR25bA_14_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_q-_bNE9PPkyx29Ne-pI2qQ_15_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_h9fU9Rsv5k6DfpCzphQlFg_15_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_fl6x4SPEb0CqO_Ye7w3o9w_16_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-25784000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_xU1QKS4pmUqDwC75kTznyA_16_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21398000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Tc_tt7ejucBVEOL3XAel-wMJg_18_4"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="2"
      id="Tc_h-oy4MpnuEKG9U8gisrfDA_18_7"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Tc_5okWLioRMUe-rn54YqJC9A_19_4"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="2"
      id="Tc_Bo6VYqxgXEymp8uX2ORf8A_19_7"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="0"
      id="Tc_fdy-6uNESESyCFF3b_DOqA_21_4"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">30029087</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="0"
      id="Tc_NKfcgaFf8EapxuVdfMlufw_21_7"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">23640199</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="0"
      id="Tc_QxNBJs4TMkaqUfOAKINmkQ_22_4"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">30029087</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="0"
      id="Tc_4JaXdF-RQ0yfossGh-N_JQ_22_7"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">23640199</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig"
      decimals="INF"
      id="Tc_JuSGa05TOU-bdrbuvrH9yQ_5_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">22230032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zKFh-9r8KEWHVMsaNJaHig"
      decimals="-3"
      id="Tc_yMnY-MxI2ECzztyLZp0DGA_5_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mjQQQJ2EckyysDZdzZQoXg"
      decimals="-3"
      id="Tc_EIwzD6zsu0Gm5QHZyxNThg_5_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">145453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9Bca2RtZUSaAp6SOKJZeg"
      decimals="-3"
      id="Tc_MeelY2xwxUi8Uu4_VgVk2Q_5_10"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-94004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ga2Znj6Iy0yqPXctu2LwwQ"
      decimals="-3"
      id="Tc_IxIuopnt1USourhfjufQAQ_5_13"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_60EfJYivGUOdbqzJUjaoug"
      decimals="-3"
      id="Tc_OS6UI2ZPWEGEsGO-SJv5lw_5_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">51273000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw"
      decimals="INF"
      id="Tc_y4K8NDdD1kGx51ew-0f2JA_6_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">1761516</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw"
      decimals="-3"
      id="Tc_WQOdAcvFiEaHCtjxDOek9w_6_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw"
      decimals="-3"
      id="Tc_Pzhj-iwHNEGwtvlqLAlOsw_6_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1616000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_awNS-vtXl0yM4s14Uj6_4A_6_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1618000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg"
      decimals="-3"
      id="Narr_CiK7Vv_AhEOPuxzv4-HzHQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">816000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw"
      decimals="INF"
      id="Tc_b0Rl-lHW20GK0_U0cobwBg_7_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hgoU5sjCHk6o1DFeTNBaiw"
      decimals="-3"
      id="Tc_3NCHsJ18K0iXp92vxX_Hmw_7_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw"
      decimals="-3"
      id="Tc_P6Usi-mPd0izIaAmErCTVA_7_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5179000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_udQNwswumUeKtCCY94n1HA_7_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5184000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FccIJxJLu0yD68-8gJ5xGw"
      decimals="-3"
      id="Tc_l4qJtdN2P06o5-r856wRFg_8_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3572000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_RSh1YK1qO0ybvsQGLgASDw_8_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3572000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pLCQK7N8yEeOO-emzO9KTg"
      decimals="-3"
      id="Tc_fn4166FIxUKfSeCLAF9P2w_9_13"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_JTaNcqijnkidgmtvsV2U2w_9_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTU5BrA1tEmz30aajDlz6g"
      decimals="-3"
      id="Tc_CZIShyFm7kqI3s5GIX29UQ_10_10"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_mjdfSAW1PUyT1eeKty6VOQ_10_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cRBLgf-FmkW2y3hxofLyXg"
      decimals="INF"
      id="Tc_OvAb7gvW1EaP3EpbcGuJ7A_11_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">28991548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cRBLgf-FmkW2y3hxofLyXg"
      decimals="-3"
      id="Tc_4LLEbeWFeUKXpNQEvXlzLA_11_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y4ykLegMm0ecV5xUeC4XMg"
      decimals="-3"
      id="Tc_y6DdEND_wkuT3exLtosZTA_11_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">155820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jO4Ihl3vbUygM5jjvQg_Lw"
      decimals="-3"
      id="Tc_Dg1VR0JF2kiShTIeiOqGPg_11_10"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-115401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MGbOgarFTEaIN0_BlZV7RQ"
      decimals="-3"
      id="Tc_SXqAMpcd40-90STM88d9sA_11_13"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_1p3edK3kskSjkvZFcbj6ew_11_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">40249000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw"
      decimals="-3"
      id="Narr_V0-T4I0f90W2FUVY_B22ag"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">159000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_mjbf_mTu8EG-1PNbRNcxEA"
      decimals="INF"
      id="Tc_abJkFXLCP0OuNg5KVfYRJg_12_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">2859074</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_mjbf_mTu8EG-1PNbRNcxEA"
      decimals="-3"
      id="Tc_49LIPWGBn0GcDf5ANgB_pQ_12_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_UveeLV5jg0Gs7n8IWxBGxQ"
      decimals="-3"
      id="Tc_WUq2gXr8QEiTWPagyiJbPw_12_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5124000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw"
      decimals="-3"
      id="Tc_X5X45Xj0K0i7hUutC9Nc-g_12_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5127000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_glCHD9EtbESXtKFFuEPfMQ"
      decimals="INF"
      id="Tc_HSkeuldY2kaBHgNE4QsJmg_13_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">189856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_bz4gK_i3F0uQC7rL-HFYWQ"
      decimals="-3"
      id="Tc_GdYQ67PPG0adoe1OpDmhNg_13_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">318000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_LshqVKz1-k65X8p9RQ7mDA"
      decimals="-3"
      id="Tc_0rcUv8N0Bk2ckwYbSCt39A_13_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">318000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_uhpLOBdKk0WZcXfNyIcT2A"
      decimals="INF"
      id="Tc_4xfhPk4Lv0aMkfWC7imdog_14_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_bkEmqGmAXk2V435yqi4NaA"
      decimals="-3"
      id="Tc_V7o7ae7Cr0euohHezXtkhw_14_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">210000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_YVGucSObRUi_kS5-NUT2_g"
      decimals="-3"
      id="Tc_sEUNdmCCmEe7BshejfQe_g_14_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">210000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tuVKl_ZuvU2ErvU1ol886A"
      decimals="-3"
      id="Tc_Y5AJixYYN0yLqUieVUaGGA_15_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_kHCO7bR21EyBjTp5HZeA6w_15_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HMKbTdzF40CY46TtwizjkQ"
      decimals="-3"
      id="Tc_eggd28qfaEqi-duWzbUw0A_16_13"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_cak_Bh0uTUC6MPd7Of3c0g_16_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QXLq1_nOvk2P7yx3QDOUOA"
      decimals="-3"
      id="Tc_beRgeWh5Q0aianNvSeokjw_17_10"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_iQoRlvRx1ECgrabO5i9XWQ_17_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_onxTRXE0sU2j9FuXL78qkA"
      decimals="INF"
      id="Tc_MwROsHeBYEu0vdJnELMniw_18_1"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">32165478</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_onxTRXE0sU2j9FuXL78qkA"
      decimals="-3"
      id="Tc_-IAbb7Vw50io_UjzMwX_3Q_18_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_6UVH8Rgk6cL-CiQ1IpeA"
      decimals="-3"
      id="Tc_kA4Kg-EgcUeFn3Tqz-U_Vw_18_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">165826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fxo-cpkpfUGMsbMoJHuOAA"
      decimals="-3"
      id="Tc_PUP3nrr7zkeJtYrCp1U9ug_18_10"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-141189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_X48c3Sa37UK9EHex0j44hQ"
      decimals="-3"
      id="Tc_qz19R5rWIEaDo3H0CIvpOQ_18_13"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_7OwUeE0pxkWUmHBS1se8TQ_18_16"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">24474000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_Q2N2qMFxp02RpBCEJ_Goww_4_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_fXKNlAiJIkucZmVSvH0b2g_4_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_JgW_uHvslEiwU49TGoLBoA_6_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">96000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_e9vJ5myMckqSRNVqp-5qpA_6_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">83000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_yfIG5ux3zEKLQBkq6GNbDw_7_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4354000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_abrRsm2tY0ubXEEu4Aes7Q_7_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3572000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_c1VP1-d8N0CMLIcfhORFaw_8_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">156000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_C1RvbWdmgUubKdXzjGieow_8_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">152000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <cgtx:IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_6wUezDz9l0CEOXAXVg51sw_9_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">318000</cgtx:IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing>
    <cgtx:IncreaseDecreaseInGrantReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_hM2g4rQRCEmSMSXMOAvT0A_11_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-2391000</cgtx:IncreaseDecreaseInGrantReceivables>
    <cgtx:IncreaseDecreaseInGrantReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_RFaktXF_xkOr7nu5jkbjRg_11_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1873000</cgtx:IncreaseDecreaseInGrantReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_jhBIN1_qqkmRwlKseVIpdQ_12_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-1852000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_ba6q--EtsEqVanTqbHVFtw_12_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1302000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_LHbVC6d7-EmlHLgdHdffig_13_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-467000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc__D6DtQpnU0aRNvHnJttoTQ_14_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2440000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_8ykt_abAFUuY52eJJwSJlA_14_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-749000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_CSy6NTamMEuXrvQDIYuW3Q_15_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-1687000</cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent>
    <cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_r3SiB8d_e0ueC3SP54GTSA_15_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2635000</cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_P6Y9o1I8YUuan2-UoYKDSg_16_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-150000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc__mxGN6s_b0yGHsoeXOfMnw_16_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-121000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_rRn1OpHemEa_ZkdaFt_8OA_17_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-16018000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_mMCqNkQj_ke5_ZUOEigJuA_17_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-18533000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_ASyqXYmXFUSwDOdfdPKHBg_19_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">147000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_gXJy9HQ0F0ChwR-IRW-kww_19_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">171000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_abFJJs6H-kq_oOUzrQQ5KQ_20_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-147000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_ubsmFnOv7UerhHHiv_3z_g_20_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-171000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw"
      decimals="-3"
      id="Tc_dUGZ1aBTQUCOFY1duEo02A_22_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5127000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_YVGucSObRUi_kS5-NUT2_g"
      decimals="-3"
      id="Tc_r6Sfol9bF0qZI4N7KtGpHg_23_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">205000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_7BfqL4TLkU-eK_JmEUmxvg"
      decimals="-3"
      id="Tc_x4Y607WBOUmNXRkBvpFKIg_24_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5324000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_8m6RmWZ7xUym940GPf90-Q_25_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1618000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_likratsYfkO8kBaA8j2KgQ_26_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">811000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_wNvo150mYEGFNfT_IIKzrA_26_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1396000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_iqCe-AbTC0iKoDNyuM1RMQ_27_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4521000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_FW0r_VRaS0iVgLUpHfCFhA_27_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5546000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_3VLDUEaSqkKtCKyYYGuwzg_28_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc__nXDgW5aA06mYSyxHsJrrg_28_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_ay1Kose620iSW1UvALMe7Q_29_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-11640000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_Rr4aFg_J2UK2vdAPms7R9g_29_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-13159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_0ooJLVmuO0OoRozOHB7Sag_31_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">41562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_60EfJYivGUOdbqzJUjaoug"
      decimals="-3"
      id="Tc_ovGOepxS-kqijUmxZL0ulA_31_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">54721000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_DjESLnFDVk-zE4WSJOYU5g_32_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_RQoCXwJ8iUam7iHaAb7Inw_32_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">41562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_u6DLmE9yTEiW04aNqgFR1w_34_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">721000</cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing>
    <cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_UlCmxpNvDUmssqEv3Ihtjg_34_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">838000</cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_c3J9trJ70Umh1uIGPil9zA_35_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">349000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cgtx:DeferredOfferingCostsIncludedInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_El2H_e2al0a3Fn6LUo_c4w_36_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">140000</cgtx:DeferredOfferingCostsIncludedInAccountsPayable>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_Jkns-F2hD02Q8rPHUWfhPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;1. Description of Business and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cognition Therapeutics, Inc. (the &#x201c;Company&#x201d;) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease-modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (&#x201c;CNS&#x201d;) and retina. The Company&#x2019;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 14, 2015, the Company formed Cognition Therapeutics PTY LTD, as its wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;), primarily for the purpose of conducting research and development efforts at facilities located in Australia. Assets and liabilities of the Subsidiary, which uses the Australian dollar as its local functional currency, are translated to United States (U.S.) dollars at year-end exchange rates. Income statement accounts are translated using the average exchange rates prevailing during the month in which income and expenses are generated. Translation adjustments are recorded to accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) within stockholders&#x2019; equity. Gains and losses from foreign currency transactions are included in net loss as a part of other income, net. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 15, 2022, the Company closed its follow-on public offering of 5,000,000 shares of the Company&#x2019;s common stock at a public offering price of $1.20 per share (&#x201c;November 2022 Offering&#x201d;). The gross proceeds from the November 2022 Offering were $6,000 and the net proceeds were approximately $5,184, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#x201c;Shelf&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp;amp; Co. and B. Riley Securities, Inc. (the &#x201c;Sales Agents&#x201d;) providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf (the &#x201c;ATM&#x201d;). During the year ended December 31, 2023, the Company sold 2,859,074 shares of its common stock pursuant to the ATM for net proceeds of approximately $5,127. Please refer to Note 8 for further details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) for an equity line financing (the &#x201c;Purchase Agreement&#x201d;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$35,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;of shares of common stock in the Company&#x2019;s sole discretion, over a&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;36-month&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;189,856&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of its common stock as consideration for Lincoln Park&#x2019;s commitment to purchase shares of common stock under the Purchase Agreement. During the year ended December 31, 2023, the Company sold&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;125,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;shares of common stock to Lincoln Park for proceeds of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$205&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, as part of the equity line financing arrangement. As of December 31, 2023, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$34,795&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;was available to draw pursuant to the Purchase Agreement. Please refer to Note 8 for further details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The Company held cash and cash equivalents of $29,922 at December 31, 2023, and received net proceeds from a follow on public offering of common stock of $10,363 in March of 2024 (Note 13). The Company expects that its cash and cash equivalents, including the net proceeds from its IPO, its follow-on public offerings, and its ATM will enable it to fund its operating expenses and capital expenditure requirements through at least the one year period subsequent to the filing date of this Annual Report on Form 10-K. However, additional funding will be necessary to fund future preclinical &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;and clinical activities. The Company expects to finance its future cash needs through a combination of grant awards, equity or debt financings, collaboration agreements, strategic alliances, and licensing arrangements. Please refer to Note 13 for further details. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg"
      decimals="INF"
      id="Narr_gwx2-sVA70-hKsPrEr4SgA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ygnTJ3cZlkyoT6PpTTP3JA"
      decimals="2"
      id="Narr_Nep-z7KtuEWgXGeyloUuzQ"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.20</us-gaap:SharesIssuedPricePerShare>
    <cgtx:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg"
      decimals="-3"
      id="Narr_PnGAyHbiE0K--npcbGpPEw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">6000000</cgtx:ProceedsFromIssuanceInitialPublicOfferingGross>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_11_15_2022_To_11_15_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ne_C5_Rn_0G18WJToGBXlg"
      decimals="-3"
      id="Narr_dTJ_q7LloUGAuGmLDcybjg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5184000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <cgtx:MaximumAggregateOfferingPrice
      contextRef="As_Of_12_23_2022_vzbl8zprq0ijwIokKFM6sA"
      decimals="-3"
      id="Narr_9cck9cmQXkWJlFFZTs_siA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">200000000</cgtx:MaximumAggregateOfferingPrice>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_V21-ck426EKj_jaNHfEcpQ"
      decimals="-3"
      id="Narr_2pFFVlxzgEaCxOPqscGtrA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">40000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw"
      decimals="INF"
      id="Narr_zpBErroONk-5VAXD1yo9jw"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">2859074</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_7-kUNOjookO2XQEkAE94cw"
      decimals="-3"
      id="Narr_1P3NpSFKyEyHrDfN1K3yyw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5127000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"
      decimals="-3"
      id="Narr_9V862H9a40S32sFVbIZRJQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">35000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <cgtx:PurchaseAgreementTerm
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"
      id="Narr_XNFoqh75dUCYX7xo8DuJJQ">P36M</cgtx:PurchaseAgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"
      decimals="INF"
      id="Narr_MGpDgmMJK0WujMumG22DeA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">189856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA"
      decimals="INF"
      id="Narr_Her4KWZ5Okab6Hwi8TmttA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA"
      decimals="-3"
      id="Narr_b1KXo4r2XU6PN1ZmNheGbQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">205000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cgtx:RemainingValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA"
      decimals="-3"
      id="Narr_eDPIJjXb3EG9yBvOxTWfIg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">34795000</cgtx:RemainingValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Narr_iwzAGfTy_E6-cOajw0zcpg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29922000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_Cb1fCNb9LEq93fXulA-3xg"
      decimals="-3"
      id="Narr_qEUe9pcvS0e-cTTwOwbzcw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">10363000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_p_cQVa88oEyjcgbAg6-BTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Grant Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#x201c;NIH&#x201d;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2023 and 2022, the Company generated grant income of $24,805 and $22,217, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2023 was $1,701 and $0, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2022 of $1,702 and $1,686, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#x201c;CROs&#x201d;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#x2019;s performance, cost structures and compliance &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2023, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Offering Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#x2019; deficit as a reduction of proceeds generated as a result of the offering. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be &lt;span style="-sec-ix-hidden:Hidden_mQJYQs2rZkWuRg8O_Rotqw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt; and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2023 or 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#x2019;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement is a lease at contract inception. The Company&#x2019;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$616&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and corresponding current and noncurrent operating lease liabilities of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$130&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$486&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Impact of Adoption of ASC 842 on the Consolidated Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prior to adoption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of new leasing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;adoption of new&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;leasing standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(1) Represents recognition of operating lease right-of-use assets.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(2) Represents reclassification of deferred rent to operating lease.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(3) Represents recognition of operating lease liabilities.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2023 and 2022 that met the recognition threshold.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Following the provisions of ASC 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;&lt;i style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/i&gt;, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of the Company&#x2019;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $4 in other comprehensive gain and $1 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2023 and 2022, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;(&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements&lt;/i&gt; (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt; (&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_iqpurcQAv0aWQF1pjBKaYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_aiQw-GO67U-ZDzHsfp9EjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_5uPg20GEjUe8YXlNtBNCqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_TupW2OW2dE-vmK43-cqB4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Grant Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#x201c;NIH&#x201d;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. &lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <cgtx:AllowanceForCreditLossGrantsReceivableCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Narr_gk5mU1iqxUyfAnLWndiRig"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</cgtx:AllowanceForCreditLossGrantsReceivableCurrent>
    <cgtx:GrantIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_5bswnzyv2kONB0vm0wlX8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2023 and 2022, the Company generated grant income of $24,805 and $22,217, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2023 was $1,701 and $0, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2022 of $1,702 and $1,686, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#x201c;CROs&#x201d;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#x2019;s performance, cost structures and compliance &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2023, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.&lt;/p&gt;</cgtx:GrantIncomePolicyPolicyTextBlock>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_v1hm5MNco0mObpPLpbFt_w"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">24805000</cgtx:GrantIncome>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_HDGzxBFe3UWR7rR0W-OQPA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">22217000</cgtx:GrantIncome>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Narr_5Y8yH03cqkq1HaeW4mURoQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1701000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Narr_9RA1iPuGBkmGc0eTSjPl6Q"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:OtherLiabilitiesNoncurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Narr_TN0YCOZacECXeNQCKV9i9A"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1702000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Narr_WCtl7YrBLE-8l1JL2hiWow"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1686000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_8OIeXhtMU0aNt2Ub7pexkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Offering Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#x2019; deficit as a reduction of proceeds generated as a result of the offering. &lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_HvLtL5DtBES-ELSeuxITaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be &lt;span style="-sec-ix-hidden:Hidden_mQJYQs2rZkWuRg8O_Rotqw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt; and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2023 or 2022.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JA-tMjbxgkOcxeZ-D5dbbw"
      id="Narr_V6AXHsECHEmN9OPqeIirOQ">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_gI1YWgjC90yXzrjGnp76mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#x2019;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_VXRoCZZ-AEmR8prB3_ZRyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement is a lease at contract inception. The Company&#x2019;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$616&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and corresponding current and noncurrent operating lease liabilities of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$130&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$486&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Impact of Adoption of ASC 842 on the Consolidated Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prior to adoption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of new leasing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;adoption of new&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;leasing standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(1) Represents recognition of operating lease right-of-use assets.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(2) Represents reclassification of deferred rent to operating lease.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(3) Represents recognition of operating lease liabilities.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA"
      decimals="-3"
      id="Narr_RixqnmmuOkSMnlbasrFeHw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">616000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA"
      decimals="-3"
      id="Narr_R56Wh79QXEeYHc2tXheO8w"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">130000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_jmnoErn6Vk-C3mU3SDSJKA"
      decimals="-3"
      id="Narr_gmCPIrIlEEC3xJzD19vRRw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_SSSQwjvtyUWafdevGOuhLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prior to adoption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of new leasing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;adoption of new&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;leasing standards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(1) Represents recognition of operating lease right-of-use assets.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(2) Represents reclassification of deferred rent to operating lease.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(3) Represents recognition of operating lease liabilities.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA"
      decimals="-3"
      id="Tc_1s8FOlKuwU6NANTyjtzPOw_4_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">616000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ"
      decimals="-3"
      id="Tc_0QnhszhLB0-vVvA5ovgnLw_4_8"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">616000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentCredit
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OdAlZTCHTkKTcjg6k-b-og"
      decimals="-3"
      id="Tc_in9m0JJLLEiH4n2U90xmvg_5_2"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">6000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA"
      decimals="-3"
      id="Tc_v6oPQLtH40GYAm4gwwRJ4w_5_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-6000</us-gaap:DeferredRentCredit>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA"
      decimals="-3"
      id="Tc_FihJ5lsDT0eOXsRHRANqYg_6_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">130000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ"
      decimals="-3"
      id="Tc_mSsnJjkhh0-BYHmr1ZIwmQ_6_8"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">130000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_yXF1TVkgGEuZOkwkdgkgtA"
      decimals="-3"
      id="Tc_ZIIsrs-hRkGasBsX87FTRQ_7_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_RVpwudlD-EqHA1Ms92FWmQ"
      decimals="-3"
      id="Tc_S7civEQvxEadJ2g8AFG2Gg_7_8"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_EMnPNq-KSkuwePj_99MMSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2023 and 2022 that met the recognition threshold.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Narr_9cD8KYWEA06NTzxtEdQnXA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Narr_JR9TGs4VpUCBlEeyc-lekg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_r8GE4JExgkOcMJITST9ojw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Following the provisions of ASC 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;&lt;i style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/i&gt;, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Narr_6pjLU3LyN0KpX0ApnsXWJQ"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_xfX1UwU1WUmCspQTxba6zA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_npfWObElV0a3x_ViurXG1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of the Company&#x2019;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_U2aNd-RMYEKwXG7dkvjzIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $4 in other comprehensive gain and $1 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2023 and 2022, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_M-yQyd85y0qpi3z8INw0iA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_eX7xYlX_L0ifOXTUGUtZrQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_ATBa66RcmkukpqY6I9U89g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_Q0QpPzh2xEC7IF7w6epi8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Narr_KAeI9f4IfECu3IId9_57VQ"
      unitRef="Unit_Standard_segment_5qxERgMtAE2JatGJwvNkAQ">1</us-gaap:NumberOfOperatingSegments>
    <cgtx:EmergingGrowthCompanyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_xlRmcrMcuE2zus2uHly22Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;</cgtx:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_tJUGHDxSzkiBM4Cn2zsLoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;(&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements&lt;/i&gt; (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt; (&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_MtLgR3W_gEGc8IrAqzV2qw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;3. Financial Instruments and Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Financial assets and liabilities measured at fair value are summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;There were no Level 3 financial instruments during the year ended December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_AYkqJd_1i0udIFZ7G8Q28w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Ao_-LDEYrUuIE9YczdQENA"
      decimals="-3"
      id="Tc_-AC-omu4CU-GZ9cmCK-CvQ_7_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29391000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_cRq6e-5OZ0Ke_a61Ul0DuA"
      decimals="-3"
      id="Tc_ZBY8ypBPKE6YVMX5-UFMvw_7_12"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29391000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_ENLs-VXh8kmNzn1_ZzoFlA"
      decimals="-3"
      id="Tc_NSrLKKAb2k-qaagduyMJxQ_8_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29391000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_9VXbVQBkpUSKW-Z92UtMuw_8_12"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29391000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LxxS8eZ15U26cdY_7vD36w"
      decimals="-3"
      id="Tc_QPkje6MqvUCxetjSfRmLaw_7_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">37479000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_zimJT2kt9UiSyyAiSWSK6w"
      decimals="-3"
      id="Tc_KzNjJt09CkOgB_Zwe_PUxA_7_12"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">37479000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_9tl_WCDNBE6HpfXJYxxGQw"
      decimals="-3"
      id="Tc_qqfsFeJvsUy5feutZn4h-g_8_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">37479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_WYYmep5vFkughzsuOxnpCA_8_12"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">37479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_anp_eYq1VESHXuMvSlOFlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;4. Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Property and equipment, net, consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,049)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (953)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Depreciation expense for the&#160;years ended December&#160;31, 2023 and 2022 was $96 and $83, respectively, which includes amortization expense of $2 and $2 for the&#160;years ended December&#160;31, 2023 and 2022, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_njYsLHeh-0eY04SRfRmO8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,049)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (953)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VVVdi6pD1kGcMpi2IuK05A"
      decimals="-3"
      id="Tc_aQkVLZcWqU-j6E8AjVQtlA_3_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1193000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_d7jEg2zHjU29ZRjFt5YiYQ"
      decimals="-3"
      id="Tc_b9pWCzAewkK0Po4Ib2Ko-A_3_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1057000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JA-tMjbxgkOcxeZ-D5dbbw"
      decimals="-3"
      id="Tc_O8ChhQikhUSeh12OUMJ7GQ_4_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-558bBZDIUKyf-5W-hEnOA"
      decimals="-3"
      id="Tc_GPp8nrEo3k69OJysBqxTyg_4_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_2YF4u85SuEGY9WiMvygtFQ_5_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1333000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_sBg8kB_45kuxMhwKNRPowg_5_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1186000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_cai3e1SbAkGcBs4N35L1DA_6_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1049000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_HoI_EN0JuUi8IWJQ0QX-ng_6_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">953000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_gK6QmaiookyIxRQIbbmRIg_7_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">284000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_CSmYeOaz2k-3abdYYOow9A_7_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">233000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_rhrTqAHeEUyjYvP9MvBDAg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">96000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_3Ne4GUpd7EeytWy9GbVUZQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">83000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_URZz0zoZXk2U65ep12aB1g"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_ccCD494NwkSsUw1koZi-RA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_ELKTzSZUskmdhnrBEs4NIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;5. Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Accrued expense consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee compensation, benefits, and related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees and other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_ks0jtr5QmkiaPwVbjhxv1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee compensation, benefits, and related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees and other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_EHOC1FnUr0yvCoHEMUNjxA_3_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1165000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_KxXqZnewjEGSni9cpVuRbw_3_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">870000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cgtx:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_x2kHTS7qLECTEF-LfiqQLQ_4_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2520000</cgtx:AccruedResearchAndDevelopmentExpenses>
    <cgtx:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_mJLJFCExY0Khj7_IRplcYA_4_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">900000</cgtx:AccruedResearchAndDevelopmentExpenses>
    <cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_BIakJ9o5KkSAIdblZRJ_Hw_5_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">370000</cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent>
    <cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_HmlQCVNPfUCtpQXOMsbRVw_5_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">324000</cgtx:LegalReservesProfessionalFeesAndOtherAccrualsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_pkkUWTk3H0S2m-3egAD81w_6_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4055000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_EqdF7IW-9kaWBkDEegd3Xg_6_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2094000</us-gaap:AccruedLiabilitiesCurrent>
    <cgtx:OtherCurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_VtxdrzrLek23KUMIQst7zg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;6. Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;In October 2022, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $841 of certain premiums at a 6.85% annual interest rate. Total payments of approximately $72, including interest and principal, are due monthly from November 2022 through October 2023. As of December 31, 2022, the outstanding principal of the loan was $634 and the amount was paid off in &lt;span style="-sec-ix-hidden:Hidden__XyZb69CXEGjsKwFBnsFpA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2023&lt;/span&gt;&lt;/span&gt;. In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through October 2024. As of December 31, 2023, the outstanding principal of the loan was $544.&lt;/p&gt;</cgtx:OtherCurrentLiabilitiesTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_vQQHg-kY3kaNtOqhbYQgyg"
      decimals="-3"
      id="Narr_MqugpkDn9kWt5-Rpha6v6w"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">841000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_vQQHg-kY3kaNtOqhbYQgyg"
      decimals="INF"
      id="Narr_vZGm38_UCEuH-Cyj63lW1g"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0685</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_YK8t0UGtpEeESc004CPSVg"
      decimals="-3"
      id="Narr_Yuq_XG4J3EiFHuVn1dSpBw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">72000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_x_Z7jkOkrUCdh_AMcj9ldw"
      decimals="-3"
      id="Narr_PgAk_mQwlkCFjdNDkR7F3g"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">634000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_YqDdVDtS20ecG70OxtdrqA"
      decimals="-3"
      id="Narr_wJH75imWJEqs4S3xjEuhNw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">721000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_YqDdVDtS20ecG70OxtdrqA"
      decimals="INF"
      id="Narr_vL7-_sfTJ0m4OCvx7qMSyg"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0865</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_ZB35Xclq7k6gaWDy5dCb0A"
      decimals="-3"
      id="Narr_7_MmvnV0SkS7DNo0hwXfig"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">62000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_RHH5Gs9baU-2LKRDJ3NO3g"
      decimals="-3"
      id="Narr_7It1_ZgulkqAOG_5QlHhMQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">544000</us-gaap:ShortTermBorrowings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_lUSEPBEQJkW6HbDhTau80A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;7. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. The Company also leases approximately 6,068 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 31, 2022, the Company entered into a lease agreement for approximately 2,980 square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified one of its existing lease agreements for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2023 and 2022 were as follows, in thousands:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease costs for the year ended December 31, 2023 and 2022 was $215 and $203, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2023 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the lease term and discount rate as of December 31, 2023 and 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating cash flows used for operating leases for the year ended December 31, 2023 and 2022 was $209 and $172, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Litigation and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;As of December&#160;31, 2023 and 2022, there was no litigation or contingency with at least a reasonable possibility of a material loss.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_S_oPesVvSUGLXTpCrxhISg"
      decimals="INF"
      id="Narr_3Sq05Jq4YUyIEfUlIN8hnA"
      unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg">2864</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_zQZdkP6aak6WFLzryRsnUw"
      decimals="INF"
      id="Narr_sAiF3IsgVESA6stWZ4SSSg"
      unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg">6068</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_iifjj9nFxUWWEEoGkB7y3Q"
      decimals="INF"
      id="Narr_PhVTRRRShkalOjUYEDrcCQ"
      unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg">2980</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_c7z7ZQ_fFUeLePhaNsuU1w"
      id="Narr_q5AMWSvJLkusv7PgGt0DPA">P45M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_JzSuP6-isUqGYxI89s2DJA"
      decimals="INF"
      id="Narr_2AQaGVj30Um38sLxMqTxuA"
      unitRef="Unit_Standard_lease_pZh55Gbcxkm9kdN4Koe6yQ">1</cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_JzSuP6-isUqGYxI89s2DJA"
      decimals="INF"
      id="Narr_syiz1maXmEqc_6rBobd78w"
      unitRef="Unit_Standard_sqft_Q757Lwdw7kC4gob8yjaoGg">3706</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Group_HOKUznt9bEyYW3XjmAUP5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the lease term and discount rate as of December 31, 2023 and 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <cgtx:OperatingLeaseAssets
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_pOq-GBzPekGr27RmZeqbaw_4_2"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">657000</cgtx:OperatingLeaseAssets>
    <cgtx:OperatingLeaseAssets
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_edXoWiNNIkiABJPulKwZ6A_4_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">813000</cgtx:OperatingLeaseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_Js-khG4nMU2lwR7Xu47QMg_5_2"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">657000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_Z0D44kfuq06H8xjbRD2ubA_5_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">813000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_ZNw_FuoCZ0aBXs2wvTbdfg_8_2"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">174000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_cF6wNDqkVUCkMqzE_ixIcQ_8_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">149000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_apuVRwxrvkatv8YJa5iTTQ_10_2"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">520000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_L8xixJTJOEqUcLqdxVCvhw_10_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">695000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_VSoce4qdBEWOQ6YuHDw4rg_11_2"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">694000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_-itJ-xWdS0GYgdRzm5uhew_11_5"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">844000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_AXkyTSE7hkSp5vd2bisTRw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">215000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_FZhLo3CaFk6oCzs_g0TATw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">203000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_tyG0w-hPv0iGu9i8VTN8Ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2023 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_Z9Iu-QfCYEajfYLzEeoDvQ_2_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">221000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_1xlMO9jcukecLLP4Oh8ZTw_3_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">222000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_dnTXfIWhtkG68xhi9zzsgw_4_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">155000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_lEeIxHsPS0SEMVyP8qLN2A_5_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">87000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_LAUUc3b5BEusE_6i0T7LSA_6_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">88000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_9IWyobFkY0KQ8VG-sd2npw_7_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">37000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_cSArPD9vwUe22jj4-vJBIg_8_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">810000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_ysWtITW5AEyYh-tkpjvgOw_9_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">116000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_7mViDVx34UmcLIfOVFgu_A_10_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">694000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      id="Tc_K2cAzOCeb0mL76ddZslLBw_4_1">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      id="Tc_ESsZiKRku0ivQgkpGTBuVw_4_3">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="3"
      id="Tc_PLyCCfzTJUKiPBWTx5b4qg_6_1"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="3"
      id="Tc_mUbmT12Sfkq-caatSawsUQ_6_3"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_7rjfD7AffEyZHvtsMdPB2w"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">209000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_fWHu8dDpHUC9hal41oG2uQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">172000</us-gaap:OperatingLeasePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_rWCi4C4fFkS3Kf3nHtH6Iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;8. Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common and Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2023 and 2022, there were 32,165,478 and 28,991,548 shares of common stock &lt;span style="-sec-ix-hidden:Hidden_ePTF4GwkoU2wTSik52QcmQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_Qj7kaN5TikGnEe3obL6iig;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Common stockholders are entitled to dividends if and when declared by the Company&#x2019;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2023, no dividends on common stock had been declared by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;ATM&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000&#160;in aggregate (the &#x201c;Shelf&#x201d;). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000&#160;of its common stock from time to time in ATM offerings under the Shelf. &#160;The Company sold&#160;2,859,074&#160;shares of common stock pursuant to the ATM during the year ended December 31, 2023 for gross proceeds of approximately $5,286. As of December 31, 2023, there was $34,714&#160;remaining of common stock available for sale under the ATM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Lincoln Park Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000&#160;of shares of common stock in the Company&#x2019;s sole discretion, over a&#160;36-month&#160;period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued&#160;189,856&#160;shares of its common stock as consideration for Lincoln Park&#x2019;s commitment to purchase shares of common stock under the Purchase Agreement (the &#x201c;Commitment Shares&#x201d;). The Company recorded $318&#160;to other expense, net in connection with the issuance of the Commitment Shares. During the year ended December 31, 2023, the Company sold&#160;125,000&#160;shares of common stock to Lincoln Park for proceeds of $205, as part of the equity line financing arrangement. As of December 31, 2023, $34,795&#160;was available to draw pursuant to the Purchase Agreement.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_1PR33-7VA0-z6p6UYzsQOA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_zNZrS7M6A0eGeC04DHU2zw"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_T0TWRmD_F0G56M2Rd2QSLQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_AKYpwlXQb0WQ21a9MH1mBg"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Narr_c0k-F3jjZk2qDPnSItzQJQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">32165478</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Narr_tUqJAS3ETUqiJmDQiHcmdA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">28991548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_DuJ5rhNKHUqrguipAXIQew"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:DividendsCommonStock>
    <cgtx:MaximumAggregateOfferingPrice
      contextRef="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_CljcQCdgAUmy0i-o6OBaKQ"
      decimals="-3"
      id="Narr_5wDfm78JEE-PmAs7DqECRw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">200000000</cgtx:MaximumAggregateOfferingPrice>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_V21-ck426EKj_jaNHfEcpQ"
      decimals="-3"
      id="Narr_GCH0Kw4aekuBHVzu--qO7A"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">40000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_lCt9u7t8z0W44yS58i4_kQ"
      decimals="INF"
      id="Narr_o2cGyANHG0-zKAjZIGtfRQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">2859074</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_lCt9u7t8z0W44yS58i4_kQ"
      decimals="-3"
      id="Narr_ABAkIHi4G0qIjb6GgR0bKg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5286000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cgtx:SharesOfferingAgreementRemainingValueOfStockToBeIssued
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_fYz-UjM3pkmim-rRGGRZzg"
      decimals="-3"
      id="Narr_scETmmzTQ0Sz4vVwe0NGdg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">34714000</cgtx:SharesOfferingAgreementRemainingValueOfStockToBeIssued>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"
      decimals="-3"
      id="Narr_JZ75MUzIgU-NrkV0ePXOoQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">35000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <cgtx:PurchaseAgreementTerm
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"
      id="Narr_eSFYaIEkqU6kgekBO6XP_A">P36M</cgtx:PurchaseAgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"
      decimals="INF"
      id="Narr_YvS0pJtz_UuLsHhUjVXDDw"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">189856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U_FVxhu6OEujaY5wx37h2Q"
      decimals="-3"
      id="Narr_ZvXtX5umEUyhl0Q3f9Oczg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">318000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA"
      decimals="INF"
      id="Narr_-qpRdZ5AQUSFDAkLzfKPIw"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA"
      decimals="-3"
      id="Narr_Pi-Rnx7T7kOCCIn5_PqMUQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">205000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cgtx:RemainingValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_m8o64DLWNE2Ljkf5Bke5ZA"
      decimals="-3"
      id="Narr_fyStsB1Y8UeV76DgbV75gQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">34795000</cgtx:RemainingValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_Jdz4dhFWpkaWYo3Hdkj-7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;9. Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 7, 2021, the date upon which the Company&#x2019;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;As of December 31, 2023, the aggregate number of shares of common stock of the Company that may be issued under the Plan is 2,954,570. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2023 pursuant to an evergreen provision therein by 1,449,577 shares, representing 5% of total common shares &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;outstanding at December 31, 2022. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company&#x2019;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#x2019;s board of directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the &#x201c;2007 Plan&#x201d; and collectively with the 2017 Plan, the &#x201c;Prior Plans&#x201d;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 15, 2017, the Company&#x2019;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#x2019;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#x2019;s common stock at a discounted purchase price. As of December 31, 2023, a total of 209,532 shares of common stock was authorized and reserved for issuance under the ESPP. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of our common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.20 &#x2013; $2.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.72 &#x2013; $3.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.47%&#x2009;&#x2013;&#x2009;92.68%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.09%&#x2009;&#x2013;&#x2009;92.73%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.46%&#x2009;&#x2013;&#x2009;4.71%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.87%&#x2009;&#x2013;&#x2009;4.22%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.18&#x2009;&#x2013;&#x2009;6.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.50&#x2009;&#x2013;&#x2009;6.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2009;&#x2014;&#x2009;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2009;&#x2014;&#x2009;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#x2019; expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#x2009;&#x2014;&#x2009;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividend Yield&lt;/i&gt;&#x2009;&#x2014;&#x2009;The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value of Common Stock&lt;/i&gt;&#x2009;&#x2014;&#x2009;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Activity for options was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;000&#x2019;s)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In&#160;Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 628,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83,931)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,012,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of stock options granted was $1.56 and $1.83 during the years ended December 31, 2023 and 2022, respectively. There were 628,769 stock options granted at an aggregate fair value of $983 for the year ended December 31, 2023 and 524,370 stock options granted at an aggregate fair value of $943 for the year ended December 31, 2022. During the year ended December 31, 2023 and 2022, there were 0 and 1,761,516 stock options exercised, respectively, with an aggregate grant date fair value of $0 and $1,325, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2023 and 2022 was $0 and $2,738, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair values of RSUs are based on the fair market value of the Company&#x2019;s common stock on the date of grant. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon vesting. RSUs for employees vest annually over three years on each anniversary of the Grant Date and RSUs for non-employee directors vest on the one-year anniversary of the Grant Date. The following table summarizes the Company&#x2019;s RSU activity for the year ended December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted Stock Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 542,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,264)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Equity-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,572&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, total future compensation expense related to unvested awards yet to be recognized by the Company was $4,258. Total future compensation expense related to unvested awards yet to be recognized by the Company is expected to be recognized over a weighted-average remaining vesting period of approximately 1.6 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw"
      decimals="INF"
      id="Narr_MjcyCtAoAkaWUPrkciHZmg"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">2954570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_ecCutZaSMkeuO8iQOXjXGw"
      decimals="INF"
      id="Narr__4yj_RIPvEKLhwGf70JQHQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">1449577</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_LRobkF0nj0SY3xdEzUjMVQ"
      decimals="2"
      id="Narr_iFj1VrHuz0axxS3hYYuycA"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_yDEeKMfAzkS-KSBkUEc6qg"
      decimals="2"
      id="Narr_tz7SKPw_Dka6yEXlL518jA"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw"
      decimals="INF"
      id="Narr_W9SysfqFDkaTNepYjUi24g"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">7543185</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_cObAhYy_cU6F4R6IGoSZpw"
      decimals="INF"
      id="Narr_0bL5NFAbjk-b9uDcNWzY8w"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">4334131</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_uguCNEEtGkiIZdHpBUsd8w"
      decimals="INF"
      id="Narr_Mrdo76deGE6dHSmTU01-zg"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">4334131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_rrHi5dcFDE-G4d-8RUX0Kw"
      decimals="INF"
      id="Narr_2s9uDvrjnUOhWX2F1C0wGg"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">209532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_WLXjwrWnP0CgsWctD9xbtg"
      decimals="INF"
      id="Narr_jrEmeV7VfUmxseN2AV1o1A"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_WLXjwrWnP0CgsWctD9xbtg"
      decimals="2"
      id="Narr_3WYaxQtmWU2KsWkmg5FaIQ"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_lCc_NntOXU632R-UmDKjbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.20 &#x2013; $2.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.72 &#x2013; $3.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.47%&#x2009;&#x2013;&#x2009;92.68%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.09%&#x2009;&#x2013;&#x2009;92.73%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.46%&#x2009;&#x2013;&#x2009;4.71%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.87%&#x2009;&#x2013;&#x2009;4.22%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.18&#x2009;&#x2013;&#x2009;6.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.50&#x2009;&#x2013;&#x2009;6.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_8bYcitqYY0y77znhmkKzNQ"
      decimals="2"
      id="Narr_dsNJ7EWwDU-ZOuZay9k9rw"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.20</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_QC7xgFr49EmCFLiMsbsf_g"
      decimals="2"
      id="Narr_VkDgsYhuxESH_DxNRJixqA"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">2.99</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_gQpvyXpSRE-aqnPz6O907Q"
      decimals="2"
      id="Narr_PRi2CVkoBkifdcK_tA7Dmg"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.72</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_tRoSIxX58UuuBcSM22cTJA"
      decimals="2"
      id="Narr_8a9NbZFmJEGkivuOmBhLmw"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">3.05</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="4"
      id="Narr_Wiu3HBJ0zUK0tMpjKAH-0w"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.9147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="4"
      id="Narr_2ZMboJSULE-er7UuVGP48g"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.9268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="4"
      id="Narr_g6Y57BrWuUSzhKQ5HEHSFA"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.9109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="4"
      id="Narr_Oexg0kFvF0qKyvqU4P7yZA"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.9273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="4"
      id="Narr_EZK4TpjkMkCAbcSxp_4apA"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="4"
      id="Narr_aFd80g3nwEaEkOvuAnig1w"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="4"
      id="Narr_coMRkL3ghUmdpsAyYO2JgQ"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="4"
      id="Narr_TzpKaBkolEuXcuYSsG17kA"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="4"
      id="Tc_SQiE4B5HMUq0idTNHar0bw_6_2"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="4"
      id="Tc_SFe3RC31-0mrkVyDMTfVKw_6_4"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_cgCekGBDeU-iow6w5GkUWw"
      id="Narr__08FV_c69Eu5cFxwh3gmKg">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_fSE3Go7PW0eAeiIVxPMeeA"
      id="Narr_SidjY7dQNkWAxEaefCUwEQ">P6Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_oU9CqFmCiUKDm0PxrYz0zw"
      id="Narr_I8MPUxWL9Um9d29yBGPs5w">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kQSwmvFsp0mgTkQQwG0VHA"
      id="Narr_ATdhbz-HpkCIwmk55kqDsw">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Narr_uTLP1UfrOUmiIRQVJrXajw"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb__-V7QHAhmE2uHEa4nnVeww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;000&#x2019;s)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In&#160;Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 628,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83,931)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,012,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="INF"
      id="Tc_49ZFCHa-MEqGR5YaDXlTAg_7_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">3679468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="2"
      id="Tc_607trlmcWUSVR9POlXaEnw_7_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_fJjKhZ9cYEi2hq3OX83daw_7_8"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2085000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      id="Tc_yJkAcrcT90CHrnketNRIBw_7_10">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Tc_OKRL5RK--E2zZQKLAAtwgQ_8_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">628769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Tc_bGKhFOMhckC75YTyIoVH0A_8_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">2.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Tc_vEyxrGOAxUeu4Xi_tXUCwQ_10_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">83931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Tc_lKicsDrKhU64CcDDYFXLvA_10_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Tc_4DvehEQhK0-ZIW7ErugS4g_11_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">10901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Tc_LlzrwQVTK06bM8tnPIFPEw_11_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">2.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Tc_3KEwZj0J5UKjcYGeiIUVqA_12_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">4213405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="2"
      id="Tc_cYkSviN4GUqTsf0rcBiL5g_12_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">4.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_Di7Yd7lxyEyfsHhdk2lOkA_12_8"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1579000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_T7NHuDjgk06AwhUzIi5UeA_12_10">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="INF"
      id="Tc_A5rw1sXCD0K6xo43Mq_z_Q_13_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">3012499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="2"
      id="Tc_mXZ9GXAgQkekXcgL5JaFsw_13_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_CcgdfVWSeU-WW766rXNtPw_13_8"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1431000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tc_WPRDdvmKdkih5VjleqOHaA_13_10">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Narr_qsomFLyJ7EaR2VRpzuL_YA"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="2"
      id="Narr_Qr-6TQdbO0SzBjCPPXu7YA"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Narr_4m6vXzo__UueeJmoqpBv3w"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">628769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_wBBGo-db9k-Jh7QuwftIMA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">983000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="INF"
      id="Narr_Zng5DFSd1USvWQCUxmgh_A"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">524370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_NQNJs37eLkeMRavxO1nffw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">943000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Narr_BGOhK0xlS0a-8dIGkCUnKQ"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="INF"
      id="Narr_KusW01TmK0aODINZ2VRdUA"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">1761516</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_d13bBAgy_UOjMG7YMaM5AA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_7HksVzh7YUyFfkhRyYcBjw"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1325000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_jKpLbpc8H0e-bhNAqncxeA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_ZC_YQaLF3kWlgfaBiCQmwQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA"
      decimals="INF"
      id="Narr_Mhqb7goV3EasTAPNRBkyng"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">1</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_EmployeeDirectorMember_Ln6Hn2FojEa8itKVr-awUw"
      id="Narr_CvzP3d_PNU-KuIMwhkqsrA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_-Aambe7M-Ei21IEK190qVg"
      id="Narr_qC6xtXN6kUmfiTvCnlJ8Mg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_vJO_rntdGEaGTcxuT8t-kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted Stock Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 542,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,264)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA"
      decimals="INF"
      id="Tc_qEJErd_t7EW3FCR-Vkul-Q_4_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">542419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA"
      decimals="2"
      id="Tc_4M1rxkTRxU23kcefUZYFjA_4_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA"
      decimals="INF"
      id="Tc_rCQfRJhx0kWECo_U2wwFZA_6_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">20264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OPWBDXuQkUmnf0MvJQTfvA"
      decimals="2"
      id="Tc_nSMvWy4MmkaqWEgBFHElAQ_6_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_efBKw3qAME6ZmwdlSdK_6Q"
      decimals="INF"
      id="Tc_rcBi7LE9vEK1qC_YwOpGdg_7_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">522155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_efBKw3qAME6ZmwdlSdK_6Q"
      decimals="2"
      id="Tc_BkqRYuhO6kq_wgYvP6ntQQ_7_5"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_SOh8lixfnkqTUX5R0ENPyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,572&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T29Qjyz35U2p3fWGxDsVjQ"
      decimals="-3"
      id="Tc_2sFslSw9WEO1zfe88KLyyA_3_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tqAFWsRuSEOU2TS77Gr5vQ"
      decimals="-3"
      id="Tc_SVIQWYNALkyzDUqw94VZjw_3_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W7FO-pbJEUO0d761WgliwA"
      decimals="-3"
      id="Tc_ylEXh0PGkUORdhD1tKsi9Q_4_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3684000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_70PXE3i9G0SgTEnVDcJbMw"
      decimals="-3"
      id="Tc_DuQJX9LSvUKMXMUdZ_9EvQ_4_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3044000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_HuWzX14kkkq-ftOEclyOSg_5_4"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4354000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_KGlEwqPmzUaLZw_-eRyPqA_5_7"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3572000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Narr_ZatDqmN11UCsfphGjJSs9A"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">4258000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Narr_KdpFLT3eLUO4tON21nvyfQ">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_53AmBpHPy0W9vNrGbXiH5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;10. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Restricted stock units issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,735,560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_6oAtPgffMUaWlGegNoKFEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Restricted stock units issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,735,560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,679,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Tcs3Fe77zk-E5SHgaFWR2Q"
      decimals="INF"
      id="Tc_sW3P_Qk13k6K4AOi16Qfrw_3_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">4213405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_MrwJ0AbrfEahvl8J7zIwLQ"
      decimals="INF"
      id="Tc_a9IivEU32UeyrveDjtR-_A_3_4"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">3679468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pRPh5Rg4yk2qvio_UPRCJw"
      decimals="INF"
      id="Tc_Qf2gFWZLI0-XiACEY6dMnQ_4_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">522155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="INF"
      id="Tc_Bs1SHCj0nUWSYrmDEdDc1Q_5_2"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">4735560</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="INF"
      id="Tc_iUYBP8IQvUiw8ayy2IBhzw_5_4"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">3679468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_Vj42ovN4KkO01c9psGPBdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;11. Retirement Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of 6% of the employees&#x2019; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $199 and $156 for the&#160;year ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="2"
      id="Narr_gAsVVV23AEe1d5nUNNFK-w"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_Vk7a0LByN0ORcV80NcuqyQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">199000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_53n8F3Zh8kC2FDhdQSq-Qg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">156000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_QGZ2yMwYX06_G2oZwz0Epg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;12. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;The net loss consists of the following components:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,767)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,384)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,788)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2023 and 2022, the Company recorded no current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) is the excess of a U.S shareholders total net foreign income over a deemed return on tangible assets. In January 2018, in response to inquiries by companies, the FASB issued guidance that allows companies to elect as an accounting policy whether to treat the GILTI tax as a period cost or to recognize deferred tax assets and liabilities when basis differences exist that are expected to affect the amount of GILTI inclusion upon reversal. The Company has elected to treat GILTI as a period expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;amp;D expense over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside of the United States. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D Credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 407&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,435)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (147)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (178)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2023 and 2022. Management has considered the Company&#x2019;s history of cumulative net losses and has concluded as of December 31, 2023 and 2022, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2023 and 2022. The valuation allowance increased by $5,772 and decreased by $2,610 for the years ended December 31, 2023 and 2022, respectively. The increase in valuation allowance in 2023 was primarily a result of an increase to capitalized research expenditures, while the decrease in valuation allowance in 2022 was primarily a result of a reduction in operating losses and tax credits, offset partially by the capitalized research expenditures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred net operating losses (&#x201c;NOL&#x201d;) since inception through December 31, 2021. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;amp;D expenses, the Company was in a taxable position as of December 31, 2023 and 2022, and has utilized NOL generated in prior years to fully offset their income tax expense. As of December 31, 2023, the Company had federal net operating loss carryforwards of $29,843, net of Section 382 limited amounts. Included in federal net operating loss carryforwards of $29,843 is $11,501 that begin to expire in 2035 and $18,342 that can be carried forward indefinitely. As of December 31, 2023, the Company had state net operating loss carryforwards of $12,060, available to reduce future state taxable income, which will begin to expire in 2028. As of December 31, 2023, the Company had foreign net operating loss carryforwards of $349 and foreign research and development tax credit carryforwards of $268 that can be carried forward indefinitely. As of December 31, 2023, the Company had federal research and development tax credit carryforwards of $2,851, net of Section 382 limited amounts, available to reduce future federal tax liabilities, which will begin to expire in 2029.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Utilization of the Company&#x2019;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The amount of the limitation is determined based on the value of the Company immediately prior to the ownership change and could be subject to additional adjustments as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. In 2023 the Company completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $589 of federal net operating loss carryforwards expiring unutilized. &#160;The Company updated the analysis through December 31, 2023 and determined that it is more-likely-than-not that the Company&#x2019;s existing net operating loss and research and development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively, due to the conclusion that an ownership change did not occur in 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue for tax years beginning on or after January 1, 2020; however, carryforward attributes that were generated prior to January 1, 2020 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_VUTNk6oW0ECcGZieKVnLbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,767)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,384)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,788)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21,397)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_JW_MkLDbeU-yFGxMZfN6iQ_3_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-25767000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_9o4mZqSAfkmlpJh-5j71iw_3_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21384000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_rm2iFqqnlEKNLv8eFfd4Kg_4_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_kweX1_9NukmE0_mVLwMgrw_4_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-13000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Tc_VKSxQP7oykKXE86_w59gXQ_5_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Tc_Lz085U7Bh0GxxTkchzXelA_5_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-21397000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_ZhTk3OYq0ku8piZMu8bDDg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_8grkNmBg0kW4l7O9027i_Q"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_LE6zMQ4QPUGUuRoXO3tW4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D Credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="3"
      id="Tc_YMWXOlAXO0-HQ2BUj5Jctg_3_2"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="3"
      id="Tc_HK_u68IwMECzCS_17Mm6Xg_3_4"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="3"
      id="Tc_1titDZdpCEO6fthGTIzijA_4_2"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="3"
      id="Tc_7_t2JEXNREivplzBuUp1kg_4_4"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">-0.153</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="3"
      id="Tc_81X1DVa-J0CAN07Wg9mewA_5_2"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">-0.224</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="3"
      id="Tc_y-0cWRywsEKHecNRA-l0hA_5_4"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.120</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="3"
      id="Tc_D364VKehuUmgy9VqphlsIA_6_2"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="3"
      id="Tc_W8StB5ptxE6s5vccSq4TvQ_6_4"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">-0.151</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="3"
      id="Tc_bf8Jyec7wUiREFjOOArnJw_7_2"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="3"
      id="Tc__6a4AspilEOE6UqyjUYFqQ_7_4"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="3"
      id="Tc_bmQtAKukpUmJ2d8Hn14t7Q_8_2"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="3"
      id="Tc_yo95y-600kCvRF579y0Xmg_8_4"
      unitRef="Unit_Standard_pure_XC2fhz502kGU4hRxQtuTEw">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_nrXNmUhPfESqWWU_lGkqzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 407&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,435)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (171)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (147)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (178)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_JtcbNRX33kygrFD0EaaFNg_4_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">6847000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_0Y_gykuKL0KrkemQdPCxKg_4_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">8194000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_Dz249aUTDkqfem9h3q35-w_5_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">3112000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_5cH_McsMAkuow0z22rwUMA_5_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1728000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_e3xAO_0HyUalyJiLlqigwQ_6_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">407000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_W9UpSXGuV0OTbieji3TV4w_6_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">307000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cgtx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_SGUMa9vsSUydl6yNwTQlNg_7_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">148000</cgtx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <cgtx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_A9ka3CiI0k-C8wyBu06F0Q_7_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">178000</cgtx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_u_oK3NHbjE2gv3jviH3V5g_8_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">11371000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_-w1VlLax0keqqSNAkyziDQ_8_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5687000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_QU3OMbPzaEqds8yeja5sgA_9_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">223000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_ojpA7UobAU-6vBuh0B7rpQ_9_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">354000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_D2yDPNRm6E2Yz7mEwg2Z1w_10_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">246000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_UNtOdPI36UOSIhSqMANmYQ_10_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">165000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_CQsDAsXXYk-EeRyT7ZQ5pA_11_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">22354000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_k7t6ElvOTU6n2FiW3MAlkA_11_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">16613000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_ovGji26-60iRk1JZNy0aug_12_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">22207000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_cbQbNyA5t0KWYbzwu740IA_12_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">16435000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_Z1vZEWzFPE2PegHPWjfXDg_13_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">147000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_Pf1iKT_anEyaWl-0rZMTQQ_13_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">178000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_O5BOQM-RkUu_2IOJcBOvzA_16_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">8000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_7pwxauSfxkGSi3e6g7rB_w_16_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">7000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_OCQROXhbvEmsIUO6b_ZdFA_17_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">139000</cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc__xUXYSZnokuJDzaIQonMfQ_17_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">171000</cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2023_NMRtdIrDGUCMAR-knUCaiQ"
      decimals="-3"
      id="Tc_KdmHyoCtYkGF3GwBYWMQ9w_18_3"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">147000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2022_agJCGbbuP0GY8f4vtkq44A"
      decimals="-3"
      id="Tc_2OrxfUmglUqATTmeyhxLPA_18_6"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">178000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      decimals="-3"
      id="Narr_eC1pUsoftEWXM4Tyrae3oA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">5772000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_9fCc-YRF40WHz2Ds4Bbjzg"
      decimals="-3"
      id="Narr_sk_cb8VwhEmiNmv4pv59SQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">-2610000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ"
      decimals="-3"
      id="Narr_huPDgo3JRUCGo3dkA69tCg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29843000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ"
      decimals="-3"
      id="Narr_GoGOptgaDE6_M-lvMqRENg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">29843000</us-gaap:OperatingLossCarryforwards>
    <cgtx:OperatingLossCarryForwardsSubjectToExpiration
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ"
      decimals="-3"
      id="Narr_IwgbhB0ebUm5EL0xBmO_Tg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">11501000</cgtx:OperatingLossCarryForwardsSubjectToExpiration>
    <cgtx:OperatingLossCarryForwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ"
      decimals="-3"
      id="Narr_ERCogLQ-iU2-7K_6WSpnjQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">18342000</cgtx:OperatingLossCarryForwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_7LajySWg40OL9NM2rgbwrw"
      decimals="-3"
      id="Narr_jY3T5h3Bd0aBBp1b19lk_w"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">12060000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_q3DH0WMQa0CmwYFvp51zwQ"
      decimals="-3"
      id="Narr_kIsJb0NiakyN9ShR_b-Qog"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">349000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__0_YbKxmOU2r78jXkEEzlQ"
      decimals="-3"
      id="Narr_VZ0sLAzYnEOc0a5ycfOPrg"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">268000</us-gaap:TaxCreditCarryforwardAmount>
    <cgtx:ResearchAndDevelopmentTaxCreditCarryForwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_uj89_hjTpkWxeoi9eBW6OQ"
      decimals="-3"
      id="Narr_1xZymyxE10KcNPa1ghrsOA"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">2851000</cgtx:ResearchAndDevelopmentTaxCreditCarryForwards>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_XUZrCkEwDEyMKEMstcPgZA"
      decimals="-3"
      id="Narr_fEY-QTOJg06DVDHm9gXT0Q"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">589000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Joj3-xKF9kWyPMuoTqNOww"
      id="Tb_tabj-x9Bi02BZuX6xPKdvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;13. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale by the Company of 6,571,428 shares of its common stock, at a public offering price of $1.75 per share before deducting the underwriters&#x2019; discount. The underwriters were granted an option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share before deducting the underwriters&#x2019; discount. This offering was made pursuant to the Company&#x2019;s Shelf Registration Statement, and a related prospectus supplement dated March 11, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 14, 2024, the Company closed the offering, excluding the underwriters&#x2019; option to purchase 985,714 additional shares of common stock. The Company received net proceeds of approximately $10,361, after deducting $1,139 of underwriting discounts and commissions and estimated offering expenses payable by the Company.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mUz7VNnd5EuqjwdONSKJpQ"
      decimals="INF"
      id="Narr_ZbtK4NLsoUuHBGiMQE8i0w"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">6571428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_nrintSTwQECLB58C0p_EaA"
      decimals="2"
      id="Narr_Fi7QNIrvLky5VbPlFzvniQ"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.75</us-gaap:SaleOfStockPricePerShare>
    <cgtx:UnderwritersOptionToPurchaseAdditionalShares
      contextRef="Duration_3_1_2024_To_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mUz7VNnd5EuqjwdONSKJpQ"
      decimals="INF"
      id="Narr_rA_NjmvUL0SAOBfk0SPDTw"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">985714</cgtx:UnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_3_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_nrintSTwQECLB58C0p_EaA"
      decimals="2"
      id="Narr_b0OKv_3JoUSgmEqNyIdzfA"
      unitRef="Unit_Divide_USD_shares_aNxTj0aceUyFohkYPvO2pA">1.75</us-gaap:SaleOfStockPricePerShare>
    <cgtx:UnderwritersOptionToPurchaseAdditionalShares
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ"
      decimals="INF"
      id="Narr_bZi5oi_TiUmm9kmhYvBv0Q"
      unitRef="Unit_Standard_shares_3PjCj2q6B0e3ewStfI40UQ">985714</cgtx:UnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ"
      decimals="-3"
      id="Narr_6MAQvDB-PUW0vEavRnXsMQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">10361000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cgtx:UnderwritingDiscountsCommissionsAndOfferingExpenses
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_x31NNz3CbEub0vkTvYBwBQ"
      decimals="-3"
      id="Narr_HTmoFMSys020LLwcxg6CLQ"
      unitRef="Unit_Standard_USD_3RDjA7FDQUK-iu7WhT0rhQ">1139000</cgtx:UnderwritingDiscountsCommissionsAndOfferingExpenses>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw"
      id="Tb_slyfpVK_VEW68Boop4OX0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;During the three months ended December 31, 2023, the following directors or officers (as defined in Rule&#160;16a-1(f)&#160;of the&#160;Exchange Act) adopted&#160;or terminated a &#x201c;Rule &lt;span style="-sec-ix-hidden:Hidden_EhWfKhNhJ0mxDKk9K-W3pw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10&lt;/span&gt;&lt;/span&gt;b5-1 trading arrangement&#x201d; or &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as each term is defined in Item&#160;408(c)&#160;of&#160;Regulation S-K:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100.09%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:19.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:13.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:12.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:13.81%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:22.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:19.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Name and Title&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:13.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Action&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:13.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:22.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Aggregate Number of securities to be sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Plan Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:19.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Aaron Fletcher, Director&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:13.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Adoption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December 29, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:13.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Rule 10b5-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:22.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 28, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;(1) The plan was adopted by BIOS Equity Partners, LP. BIOS Capital Management, LP is the general partner of BIOS Equity Partners, LP. &lt;span style="letter-spacing:0.2pt;"&gt;Bios Advisors GP, LLC, an entity controlled by Dr. Aaron Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to shares directly or indirectly held by the&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;BIOS Equity Partners LP.&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw"
      id="Narr_oYW6j5bUnEG_KH5QuF_k6Q">Aaron Fletcher</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_cgtx_AaronFletcherMember_chjc6FFkBEOev7KuqfZyYw"
      id="Narr_t9NOD0pxQk6c52VQknRFRg">Director</ecd:TrdArrIndTitle>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970200400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 22, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COGNITION THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4365359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2500 Westchester Ave.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Purchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-2210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,124,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001455365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643969835840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 29,922<span></span>
</td>
<td class="nump">$ 41,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivables</a></td>
<td class="nump">1,281<span></span>
</td>
<td class="nump">3,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,019<span></span>
</td>
<td class="nump">2,413<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">34,222<span></span>
</td>
<td class="nump">47,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">35,163<span></span>
</td>
<td class="nump">50,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,695<span></span>
</td>
<td class="nump">3,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_DeferredGrantIncomeCurrent', window );">Deferred grant income, current</a></td>
<td class="nump">1,701<span></span>
</td>
<td class="nump">1,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,169<span></span>
</td>
<td class="nump">7,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Deferred grant income and other liabilities, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,689<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 250,000,000 shares authorized; 32,165,478 and 28,991,548 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">165,826<span></span>
</td>
<td class="nump">155,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(141,189)<span></span>
</td>
<td class="num">(115,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">24,474<span></span>
</td>
<td class="nump">40,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 35,163<span></span>
</td>
<td class="nump">$ 50,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of deferred grant income as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970175072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">32,165,478<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">32,165,478<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970317920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 37,196<span></span>
</td>
<td class="nump">$ 30,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,528<span></span>
</td>
<td class="nump">13,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">50,724<span></span>
</td>
<td class="nump">43,551<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(50,724)<span></span>
</td>
<td class="num">(43,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_GrantIncome', window );">Grant income</a></td>
<td class="nump">24,805<span></span>
</td>
<td class="nump">22,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">158<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">24,936<span></span>
</td>
<td class="nump">22,154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(25,788)<span></span>
</td>
<td class="num">(21,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Unrealized gain (loss) on foreign currency translation</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (25,784)<span></span>
</td>
<td class="num">$ (21,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">30,029,087<span></span>
</td>
<td class="nump">23,640,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">30,029,087<span></span>
</td>
<td class="nump">23,640,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970496032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>At The Market Offering </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>At The Market Offering </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>At The Market Offering</div></th>
<th class="th">
<div>Equity Line Financing </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Equity Line Financing </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>Equity Line Financing</div></th>
<th class="th">
<div>Equity Line Financing Commitment Shares </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Equity Line Financing Commitment Shares </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>Equity Line Financing Commitment Shares</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 145,453<span></span>
</td>
<td class="num">$ (94,004)<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
<td class="nump">$ 51,273<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,230,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,761,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,761,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">5,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,397)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">155,820<span></span>
</td>
<td class="num">(115,401)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="nump">$ 40,249<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5,124<span></span>
</td>
<td class="nump">$ 5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">2,859,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,788)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 165,826<span></span>
</td>
<td class="num">$ (141,189)<span></span>
</td>
<td class="num">$ (195)<span></span>
</td>
<td class="nump">$ 24,474<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971935888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, discounts and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, discounts and offering costs</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970497136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,788)<span></span>
</td>
<td class="num">$ (21,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">4,354<span></span>
</td>
<td class="nump">3,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing', window );">Issuance of common stock as commitment shares for equity line financing</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_IncreaseDecreaseInGrantReceivables', window );">Grant receivables</a></td>
<td class="nump">2,391<span></span>
</td>
<td class="num">(1,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="num">(1,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,440<span></span>
</td>
<td class="num">(749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent', window );">Deferred grant income and other liabilities</a></td>
<td class="num">(1,687)<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,018)<span></span>
</td>
<td class="num">(18,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments for property and equipment</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments on loan payable</a></td>
<td class="num">(811)<span></span>
</td>
<td class="num">(1,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,521<span></span>
</td>
<td class="nump">5,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(11,640)<span></span>
</td>
<td class="num">(13,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents-beginning of period</a></td>
<td class="nump">41,562<span></span>
</td>
<td class="nump">54,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents-end of period</a></td>
<td class="nump">29,922<span></span>
</td>
<td class="nump">41,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing', window );">Prepayment of insurance through third-party financing</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Remeasurement of right-of-use asset and operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_DeferredOfferingCostsIncludedInAccountsPayable', window );">Deferred offering costs included in Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current deferred grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IncreaseDecreaseInGrantReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase and decrease in grant receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IncreaseDecreaseInGrantReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustments relating to commitment shares issued for equity line financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment of insurance through third-party financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971452400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Financial Condition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">1. Description of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease-modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. The Company&#8217;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2015, the Company formed Cognition Therapeutics PTY LTD, as its wholly owned subsidiary (the &#8220;Subsidiary&#8221;), primarily for the purpose of conducting research and development efforts at facilities located in Australia. Assets and liabilities of the Subsidiary, which uses the Australian dollar as its local functional currency, are translated to United States (U.S.) dollars at year-end exchange rates. Income statement accounts are translated using the average exchange rates prevailing during the month in which income and expenses are generated. Translation adjustments are recorded to accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) within stockholders&#8217; equity. Gains and losses from foreign currency transactions are included in net loss as a part of other income, net. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On November 15, 2022, the Company closed its follow-on public offering of 5,000,000 shares of the Company&#8217;s common stock at a public offering price of $1.20 per share (&#8220;November 2022 Offering&#8221;). The gross proceeds from the November 2022 Offering were $6,000 and the net proceeds were approximately $5,184, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (the &#8220;Sales Agents&#8221;) providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). During the year ended December 31, 2023, the Company sold 2,859,074 shares of its common stock pursuant to the ATM for net proceeds of approximately $5,127. Please refer to Note 8 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Purchase Agreement&#8221;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to </span><span style="background:#ffffff;">$35,000</span><span style="background:#ffffff;">&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;</span><span style="background:#ffffff;">36-month</span><span style="background:#ffffff;">&#160;period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued </span><span style="background:#ffffff;">189,856</span><span style="background:#ffffff;"> shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement. During the year ended December 31, 2023, the Company sold&#160;</span><span style="background:#ffffff;">125,000</span><span style="background:#ffffff;">&#160;shares of common stock to Lincoln Park for proceeds of </span><span style="background:#ffffff;">$205</span><span style="background:#ffffff;">, as part of the equity line financing arrangement. As of December 31, 2023, </span><span style="background:#ffffff;">$34,795</span><span style="background:#ffffff;">&#160;was available to draw pursuant to the Purchase Agreement. Please refer to Note 8 for further details.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company held cash and cash equivalents of $29,922 at December 31, 2023, and received net proceeds from a follow on public offering of common stock of $10,363 in March of 2024 (Note 13). The Company expects that its cash and cash equivalents, including the net proceeds from its IPO, its follow-on public offerings, and its ATM will enable it to fund its operating expenses and capital expenditure requirements through at least the one year period subsequent to the filing date of this Annual Report on Form 10-K. However, additional funding will be necessary to fund future preclinical </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">and clinical activities. The Company expects to finance its future cash needs through a combination of grant awards, equity or debt financings, collaboration agreements, strategic alliances, and licensing arrangements. Please refer to Note 13 for further details. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971388992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2023 and 2022, the Company generated grant income of $24,805 and $22,217, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2023 was $1,701 and $0, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2022 of $1,702 and $1,686, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2023, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of proceeds generated as a result of the offering. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be <span style="-sec-ix-hidden:Hidden_mQJYQs2rZkWuRg8O_Rotqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2023 or 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#8217;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of </span><span style="font-style:normal;font-weight:normal;">$616</span><span style="font-style:normal;font-weight:normal;"> and corresponding current and noncurrent operating lease liabilities of </span><span style="font-style:normal;font-weight:normal;">$130</span><span style="font-style:normal;font-weight:normal;"> and </span><span style="font-style:normal;font-weight:normal;">$486</span><span style="font-style:normal;font-weight:normal;">, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impact of Adoption of ASC 842 on the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2023 and 2022 that met the recognition threshold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;<i style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</i>, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $4 in other comprehensive gain and $1 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2023 and 2022, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Not Yet Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements</i> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971395200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">3. Financial Instruments and Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Financial assets and liabilities measured at fair value are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There were no Level 3 financial instruments during the year ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971396128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Property and equipment, net, consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,057</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 129</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,186</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,049)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (953)</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 233</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2023 and 2022 was $96 and $83, respectively, which includes amortization expense of $2 and $2 for the&#160;years ended December&#160;31, 2023 and 2022, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971388992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Accrued expense consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 870</p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 900</p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 324</p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,094</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971564000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Current Liabilities.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_OtherCurrentLiabilitiesTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">6. Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In October 2022, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $841 of certain premiums at a 6.85% annual interest rate. Total payments of approximately $72, including interest and principal, are due monthly from November 2022 through October 2023. As of December 31, 2022, the outstanding principal of the loan was $634 and the amount was paid off in <span style="-sec-ix-hidden:Hidden__XyZb69CXEGjsKwFBnsFpA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023</span></span>. In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through October 2024. As of December 31, 2023, the outstanding principal of the loan was $544.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971527200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">7. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. The Company also leases approximately 6,068 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, the Company entered into a lease agreement for approximately 2,980 square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified one of its existing lease agreements for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2023 and 2022 were as follows, in thousands:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease costs for the year ended December 31, 2023 and 2022 was $215 and $203, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 810</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (116)</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 694</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2023 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.0</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating cash flows used for operating leases for the year ended December 31, 2023 and 2022 was $209 and $172, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of December&#160;31, 2023 and 2022, there was no litigation or contingency with at least a reasonable possibility of a material loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971551280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">8. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common and Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2023 and 2022, there were 32,165,478 and 28,991,548 shares of common stock <span style="-sec-ix-hidden:Hidden_ePTF4GwkoU2wTSik52QcmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_Qj7kaN5TikGnEe3obL6iig;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2023, no dividends on common stock had been declared by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">ATM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000&#160;in aggregate (the &#8220;Shelf&#8221;). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000&#160;of its common stock from time to time in ATM offerings under the Shelf. &#160;The Company sold&#160;2,859,074&#160;shares of common stock pursuant to the ATM during the year ended December 31, 2023 for gross proceeds of approximately $5,286. As of December 31, 2023, there was $34,714&#160;remaining of common stock available for sale under the ATM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lincoln Park Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;36-month&#160;period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued&#160;189,856&#160;shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement (the &#8220;Commitment Shares&#8221;). The Company recorded $318&#160;to other expense, net in connection with the issuance of the Commitment Shares. During the year ended December 31, 2023, the Company sold&#160;125,000&#160;shares of common stock to Lincoln Park for proceeds of $205, as part of the equity line financing arrangement. As of December 31, 2023, $34,795&#160;was available to draw pursuant to the Purchase Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971402560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">9. Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 7, 2021, the date upon which the Company&#8217;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of December 31, 2023, the aggregate number of shares of common stock of the Company that may be issued under the Plan is 2,954,570. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2023 pursuant to an evergreen provision therein by 1,449,577 shares, representing 5% of total common shares </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">outstanding at December 31, 2022. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company&#8217;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#8217;s board of directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the &#8220;2007 Plan&#8221; and collectively with the 2017 Plan, the &#8220;Prior Plans&#8221;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2017, the Company&#8217;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#8217;s common stock at a discounted purchase price. As of December 31, 2023, a total of 209,532 shares of common stock was authorized and reserved for issuance under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of our common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.20 &#8211; $2.99</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.72 &#8211; $3.05</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.47%&#8201;&#8211;&#8201;92.68%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.09%&#8201;&#8211;&#8201;92.73%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.46%&#8201;&#8211;&#8201;4.71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.87%&#8201;&#8211;&#8201;4.22%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.18&#8201;&#8211;&#8201;6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.50&#8201;&#8211;&#8201;6.40</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8201;&#8212;&#8201;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8201;&#8212;&#8201;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8201;&#8212;&#8201;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividend Yield</i>&#8201;&#8212;&#8201;The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Common Stock</i>&#8201;&#8212;&#8201;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Activity for options was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.7</p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 628,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83,931)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,213,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.5</p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,012,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock options granted was $1.56 and $1.83 during the years ended December 31, 2023 and 2022, respectively. There were 628,769 stock options granted at an aggregate fair value of $983 for the year ended December 31, 2023 and 524,370 stock options granted at an aggregate fair value of $943 for the year ended December 31, 2022. During the year ended December 31, 2023 and 2022, there were 0 and 1,761,516 stock options exercised, respectively, with an aggregate grant date fair value of $0 and $1,325, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2023 and 2022 was $0 and $2,738, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The fair values of RSUs are based on the fair market value of the Company&#8217;s common stock on the date of grant. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock upon vesting. RSUs for employees vest annually over three years on each anniversary of the Grant Date and RSUs for non-employee directors vest on the one-year anniversary of the Grant Date. The following table summarizes the Company&#8217;s RSU activity for the year ended December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 542,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.07</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.97</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.07</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity-based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 528</p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,044</p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,572</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, total future compensation expense related to unvested awards yet to be recognized by the Company was $4,258. Total future compensation expense related to unvested awards yet to be recognized by the Company is expected to be recognized over a weighted-average remaining vesting period of approximately 1.6 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971436912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">10. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,213,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,679,468</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,735,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,679,468</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971459056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">11. Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of 6% of the employees&#8217; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $199 and $156 for the&#160;year ended December&#160;31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971374048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The net loss consists of the following components:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,767)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,384)</p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,788)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,397)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2023 and 2022, the Company recorded no current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) is the excess of a U.S shareholders total net foreign income over a deemed return on tangible assets. In January 2018, in response to inquiries by companies, the FASB issued guidance that allows companies to elect as an accounting policy whether to treat the GILTI tax as a period cost or to recognize deferred tax assets and liabilities when basis differences exist that are expected to affect the amount of GILTI inclusion upon reversal. The Company has elected to treat GILTI as a period expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;D expense over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside of the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The Company&#8217;s deferred tax assets and liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,194</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,728</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 307</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,687</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 354</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 165</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,613</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,435)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (178)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2023 and 2022. Management has considered the Company&#8217;s history of cumulative net losses and has concluded as of December 31, 2023 and 2022, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2023 and 2022. The valuation allowance increased by $5,772 and decreased by $2,610 for the years ended December 31, 2023 and 2022, respectively. The increase in valuation allowance in 2023 was primarily a result of an increase to capitalized research expenditures, while the decrease in valuation allowance in 2022 was primarily a result of a reduction in operating losses and tax credits, offset partially by the capitalized research expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company incurred net operating losses (&#8220;NOL&#8221;) since inception through December 31, 2021. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;D expenses, the Company was in a taxable position as of December 31, 2023 and 2022, and has utilized NOL generated in prior years to fully offset their income tax expense. As of December 31, 2023, the Company had federal net operating loss carryforwards of $29,843, net of Section 382 limited amounts. Included in federal net operating loss carryforwards of $29,843 is $11,501 that begin to expire in 2035 and $18,342 that can be carried forward indefinitely. As of December 31, 2023, the Company had state net operating loss carryforwards of $12,060, available to reduce future state taxable income, which will begin to expire in 2028. As of December 31, 2023, the Company had foreign net operating loss carryforwards of $349 and foreign research and development tax credit carryforwards of $268 that can be carried forward indefinitely. As of December 31, 2023, the Company had federal research and development tax credit carryforwards of $2,851, net of Section 382 limited amounts, available to reduce future federal tax liabilities, which will begin to expire in 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Utilization of the Company&#8217;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The amount of the limitation is determined based on the value of the Company immediately prior to the ownership change and could be subject to additional adjustments as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. In 2023 the Company completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $589 of federal net operating loss carryforwards expiring unutilized. &#160;The Company updated the analysis through December 31, 2023 and determined that it is more-likely-than-not that the Company&#8217;s existing net operating loss and research and development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively, due to the conclusion that an ownership change did not occur in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue for tax years beginning on or after January 1, 2020; however, carryforward attributes that were generated prior to January 1, 2020 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971397024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">13. Subsequent Events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale by the Company of 6,571,428 shares of its common stock, at a public offering price of $1.75 per share before deducting the underwriters&#8217; discount. The underwriters were granted an option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share before deducting the underwriters&#8217; discount. This offering was made pursuant to the Company&#8217;s Shelf Registration Statement, and a related prospectus supplement dated March 11, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On March 14, 2024, the Company closed the offering, excluding the underwriters&#8217; option to purchase 985,714 additional shares of common stock. The Company received net proceeds of approximately $10,361, after deducting $1,139 of underwriting discounts and commissions and estimated offering expenses payable by the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970703536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_GrantIncomePolicyPolicyTextBlock', window );">Grant income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2023 and 2022, the Company generated grant income of $24,805 and $22,217, respectively, primarily from reimbursements from the National Institute of Aging, a division of the NIH for aging research. The current and noncurrent portion of deferred grant income as of December 31, 2023 was $1,701 and $0, respectively, as compared to the current and noncurrent portion of deferred grant income as of December 31, 2022 of $1,702 and $1,686, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2023, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings, including the IPO, as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of proceeds generated as a result of the offering. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be <span style="-sec-ix-hidden:Hidden_mQJYQs2rZkWuRg8O_Rotqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2023 or 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#8217;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) using the optional transition method of the modified retrospective approach, as of January 1, 2022. Accordingly, prior periods will not be restated to reflect the adoption of the standard. The Company elected the practical expedient to not apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred. The expected lease term for those leases commencing prior to January 1, 2022 did not change with the adoption of the new leasing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of the adoption of the new leasing standard, on January 1, 2022, the Company recorded a right-of-use asset of </span><span style="font-style:normal;font-weight:normal;">$616</span><span style="font-style:normal;font-weight:normal;"> and corresponding current and noncurrent operating lease liabilities of </span><span style="font-style:normal;font-weight:normal;">$130</span><span style="font-style:normal;font-weight:normal;"> and </span><span style="font-style:normal;font-weight:normal;">$486</span><span style="font-style:normal;font-weight:normal;">, respectively. The adoption did not have a material impact on the condensed consolidated statement of operations or cash flows. For additional information on the adoption of the new leasing standard, refer to Note 7. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impact of Adoption of ASC 842 on the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2023 and 2022 that met the recognition threshold.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid,&#160;<i style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</i>, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $4 in other comprehensive gain and $1 in other comprehensive loss related to foreign currency translation for the&#160;years ended December&#160;31, 2023 and 2022, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Not Yet Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements</i> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971402816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Impact of Adoption of ASC 842</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prior to adoption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of new leasing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adoption of new</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">leasing standards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rent (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1) Represents recognition of operating lease right-of-use assets.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2) Represents reclassification of deferred rent to operating lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3) Represents recognition of operating lease liabilities.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-12<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971395200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of financial assets and liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,391</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,479</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971396128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,057</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 129</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,186</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,049)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (953)</p></td></tr><tr><td style="vertical-align:bottom;width:76.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 233</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971473824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 870</p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 900</p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 324</p></td></tr><tr><td style="vertical-align:bottom;width:76.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,094</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971474112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2023 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.0</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum lease commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 810</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (116)</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 694</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643972375728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of options granted using the Black-Scholes option pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.20 &#8211; $2.99</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.72 &#8211; $3.05</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.47%&#8201;&#8211;&#8201;92.68%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.09%&#8201;&#8211;&#8201;92.73%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.46%&#8201;&#8211;&#8201;4.71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.87%&#8201;&#8211;&#8201;4.22%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.18&#8201;&#8211;&#8201;6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.50&#8201;&#8211;&#8201;6.40</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of activity for options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,679,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.7</p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 628,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83,931)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,213,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.5</p></td></tr><tr><td style="vertical-align:bottom;width:43.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,012,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.7</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock units award activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 542,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.07</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.97</p></td></tr><tr><td style="vertical-align:bottom;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.07</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of total equity-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 528</p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,044</p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,572</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971395200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding potentially dilutive common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,213,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,679,468</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,735,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,679,468</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971721200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of net loss components</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,767)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,384)</p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,788)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,397)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the expected income tax (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,194</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,728</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 307</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,687</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 354</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 165</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,613</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,435)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (171)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (178)</p></td></tr><tr><td style="vertical-align:bottom;width:57.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643968460032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Financial Condition (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Nov. 15, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,922<span></span>
</td>
<td class="nump">$ 41,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering | Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing | Lincoln Park Capital Fund LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement', window );">Amount available to draw under purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_PurchaseAgreementTerm', window );">Term of agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum equity impact of the value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_RemainingValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643969337856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_AllowanceForCreditLossGrantsReceivableCurrent', window );">Allowance for doubtful accounts on grants receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_GrantIncome', window );">Grant income</a></td>
<td class="nump">24,805<span></span>
</td>
<td class="nump">$ 22,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_DeferredGrantIncomeCurrent', window );">Deferred grant income, current</a></td>
<td class="nump">1,701<span></span>
</td>
<td class="nump">1,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Deferred grant income, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized income tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) gain related to foreign currency translation</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property and equipment</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_AllowanceForCreditLossGrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on grants receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_AllowanceForCreditLossGrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of deferred grant income as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643968932512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impact of Adoption (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 657<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported | ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment | ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479341/842-30-25-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643969350608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 29,391<span></span>
</td>
<td class="nump">$ 37,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">29,391<span></span>
</td>
<td class="nump">37,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">29,391<span></span>
</td>
<td class="nump">37,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 29,391<span></span>
</td>
<td class="nump">$ 37,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970278096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">$ 1,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,049)<span></span>
</td>
<td class="num">(953)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643969997200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation, benefits, and related accruals</a></td>
<td class="nump">$ 1,165<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_AccruedResearchAndDevelopmentExpenses', window );">Research and development costs</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent', window );">Professional fees and other accruals</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 4,055<span></span>
</td>
<td class="nump">$ 2,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal reserves, professional fees and other accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_LegalReservesProfessionalFeesAndOtherAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970633376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember', window );">Insurance Premium Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths', window );">Repayment of short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreement2Member', window );">Insurance Premium Financing Agreement 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months. Includes repayments of short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreement2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreement2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970257296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_OperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 657<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease assets</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease costs</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease assets as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643972399248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 694<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember', window );">Office Space, New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember', window );">Laboratory And Office Space, Pittsburgh, PA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars', window );">Number of option at conclusion of the lease term | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">6,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember', window );">Office Space located In Pittsburgh, PA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of buyout options in dollars in an operating lease under the lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971482192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Term And Discount (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971546176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643968433008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividend declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember', window );">Cantor Fitzgerald And Co and B Riley Securities Inc | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued', window );">Remaining of common stock available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember', window );">Lincoln Park Capital Fund LLC | Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_PurchaseAgreementTerm', window );">Term of agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement', window );">Amount available to draw under purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum equity impact of the value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_RemainingValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining value of stock to be issued under shares offering agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970180672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 15, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member', window );">Amended and Restated 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,954,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">1,449,577<span></span>
</td>
<td class="nump">7,543,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of common shares issued and outstanding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber', window );">Number of shares that may be recycled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970327760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Fair value of options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">91.47%<span></span>
</td>
<td class="nump">91.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">92.68%<span></span>
</td>
<td class="nump">92.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.46%<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.71%<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 4 months 13 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970088640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Activity for options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">3,679,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">628,769<span></span>
</td>
<td class="nump">524,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,761,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(83,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (in shares)</a></td>
<td class="num">(10,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">4,213,405<span></span>
</td>
<td class="nump">3,679,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">3,012,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired (in dollars per share)</a></td>
<td class="nump">2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">4.73<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,579<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value - Exercisable</a></td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life -Exercisable</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643969366352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">628,769<span></span>
</td>
<td class="nump">524,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue', window );">Fair value of options granted</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,761,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue', window );">Fair value of options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward', window );">Number of shares issuable for each award</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Non Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for each award under share-based payment arrangement.












ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=cgtx_EmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=cgtx_EmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=cgtx_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=cgtx_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970053008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSU activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">542,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(20,264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance | shares</a></td>
<td class="nump">522,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Equity based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">1.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance | $ / shares</a></td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643969335488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 4,354<span></span>
</td>
<td class="nump">$ 3,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to options</a></td>
<td class="nump">$ 4,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which the unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 670<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 3,684<span></span>
</td>
<td class="nump">$ 3,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643972452096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Antidilutive effect (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">4,735,560<span></span>
</td>
<td class="nump">3,679,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">4,213,405<span></span>
</td>
<td class="nump">3,679,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">522,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643972490272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage of employees' compensation per person per year matched by the Company</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Matching contributions to the plan</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971431392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (25,767)<span></span>
</td>
<td class="num">$ (21,384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (25,788)<span></span>
</td>
<td class="num">$ (21,397)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643970665088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax benefit (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate (as percentage)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit (as percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(15.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as percentage)</a></td>
<td class="num">(22.40%)<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">R&amp;D Credit (as percentage)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="num">(15.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Non-deductible stock compensation (as percentage)</a></td>
<td class="num">(3.20%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other (as percentage)</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643972606144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 6,847<span></span>
</td>
<td class="nump">$ 8,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">3,112<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenditures</a></td>
<td class="nump">11,371<span></span>
</td>
<td class="nump">5,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred grant income</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">22,354<span></span>
</td>
<td class="nump">16,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(22,207)<span></span>
</td>
<td class="num">(16,435)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets after valuation allowance</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">$ (147)<span></span>
</td>
<td class="num">$ (178)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643972010672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">5,772<span></span>
</td>
<td class="num">$ (2,610)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_OperatingLossCarryForwardsSubjectToExpiration', window );">Operating loss carryforwards that expire</a></td>
<td class="nump">11,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_OperatingLossCarryForwardsNotSubjectToExpiration', window );">Operating loss carryforwards that do not expire</a></td>
<td class="nump">18,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">29,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_ResearchAndDevelopmentTaxCreditCarryForwards', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">2,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">12,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLossCarryForwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLossCarryForwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLossCarryForwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLossCarryForwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ResearchAndDevelopmentTaxCreditCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of federal research and development tax credit carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ResearchAndDevelopmentTaxCreditCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643972147040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering | Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Underwriting Agreement With Titan Partners Group LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_UnderwritersOptionToPurchaseAdditionalShares', window );">Additional shares of common stock</a></td>
<td class="nump">985,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 10,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses', window );">Offering expenses payable</a></td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of underwriting discounts, commissions and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643971594416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (25,788)<span></span>
</td>
<td class="num">$ (21,397)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139643969301456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=cgtx_AaronFletcherMember', window );">Dr. Aaron Fletcher</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">During the three months ended December 31, 2023, the following directors or officers (as defined in Rule&#160;16a-1(f)&#160;of the&#160;Exchange Act) adopted&#160;or terminated a &#8220;Rule <span style="-sec-ix-hidden:Hidden_EhWfKhNhJ0mxDKk9K-W3pw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span>b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item&#160;408(c)&#160;of&#160;Regulation S-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100.09%;"><tr style="height:1pt;"><td style="vertical-align:top;width:19.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.81%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:19.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name and Title</p></td><td style="vertical-align:middle;width:13.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Action</p></td><td style="vertical-align:middle;width:12.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td><td style="vertical-align:middle;width:13.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan</p></td><td style="vertical-align:middle;width:22.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aggregate Number of securities to be sold</p></td><td style="vertical-align:middle;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan Expiration Date</p></td></tr><tr><td style="vertical-align:middle;width:19.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aaron Fletcher, Director<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:middle;width:13.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;width:12.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 29, 2023</p></td><td style="vertical-align:middle;width:13.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;width:22.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2,000,000</p></td><td style="vertical-align:middle;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 28, 2025</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(1) The plan was adopted by BIOS Equity Partners, LP. BIOS Capital Management, LP is the general partner of BIOS Equity Partners, LP. <span style="letter-spacing:0.2pt;">Bios Advisors GP, LLC, an entity controlled by Dr. Aaron Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to shares directly or indirectly held by the</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">BIOS Equity Partners LP.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Aaron Fletcher<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=cgtx_AaronFletcherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=cgtx_AaronFletcherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
